{"doc_id": "10048291_2", "wnd_id": "10048291_2_1", "text": "Unaccountable severe hypercalcemia in a patient treated for hypoparathyroidism with dihydrotachysterol .", "tokens": ["Unaccountable", "severe", "hypercalcemia", "in", "a", "patient", "treated", "for", "hypoparathyroidism", "with", "dihydrotachysterol", "."], "event_mentions": [{"id": "10048291_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 6, "end": 7}, "arguments": [{"entity_id": "10048291_2_Ent1", "role": "Effect", "text": "Unaccountable severe hypercalcemia", "start": 0, "end": 3}, {"entity_id": "10048291_2_Ent0", "role": "Subject", "text": "patient", "start": 5, "end": 6}, {"entity_id": "10048291_2_Ent3", "role": "Treatment_Disorder", "text": "hypoparathyroidism", "start": 8, "end": 9}, {"entity_id": "10048291_2_Ent2", "role": "Treatment", "text": "dihydrotachysterol", "start": 10, "end": 11}, {"entity_id": "10048291_2_Ent4", "role": "Treatment_Drug", "text": "dihydrotachysterol", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "10048291_2_Ent1", "text": "Unaccountable severe hypercalcemia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "10048291_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10048291_2_Ent3", "text": "hypoparathyroidism", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10048291_2_Ent2", "text": "dihydrotachysterol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10048291_2_Ent4", "text": "dihydrotachysterol", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "10099659_3", "wnd_id": "10099659_3_1", "text": "Stomatitis , diarrhea , dermatitis , and myelosuppression are the main toxicities of 5 - FU .", "tokens": ["Stomatitis", ",", "diarrhea", ",", "dermatitis", ",", "and", "myelosuppression", "are", "the", "main", "toxicities", "of", "5", "-", "FU", "."], "event_mentions": [{"id": "10099659_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicities", "start": 11, "end": 12}, "arguments": [{"entity_id": "10099659_3_Ent3", "role": "Effect", "text": "Stomatitis", "start": 0, "end": 1}, {"entity_id": "10099659_3_Ent0", "role": "Effect", "text": "diarrhea", "start": 2, "end": 3}, {"entity_id": "10099659_3_Ent1", "role": "Effect", "text": "dermatitis", "start": 4, "end": 5}, {"entity_id": "10099659_3_Ent2", "role": "Effect", "text": "myelosuppression", "start": 7, "end": 8}, {"entity_id": "10099659_3_Ent4", "role": "Treatment", "text": "5 - FU", "start": 13, "end": 16}, {"entity_id": "10099659_3_Ent5", "role": "Treatment_Drug", "text": "5 - FU", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "10099659_3_Ent3", "text": "Stomatitis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10099659_3_Ent0", "text": "diarrhea", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10099659_3_Ent1", "text": "dermatitis", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10099659_3_Ent2", "text": "myelosuppression", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10099659_3_Ent4", "text": "5 - FU", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "10099659_3_Ent5", "text": "5 - FU", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "10102531_2", "wnd_id": "10102531_2_1", "text": "We report a case of reversible encephalopathy syndrome in a 16 - year - old girl with acute myelogenous leukemia ( AML ) , who is undergoing during consolidation chemotherapy composed of BH - AC ( N4 - behenoyl - 1 - beta - D - arabinofuranosyl cytosine ) and idarubicin .", "tokens": ["We", "report", "a", "case", "of", "reversible", "encephalopathy", "syndrome", "in", "a", "16", "-", "year", "-", "old", "girl", "with", "acute", "myelogenous", "leukemia", "(", "AML", ")", ",", "who", "is", "undergoing", "during", "consolidation", "chemotherapy", "composed", "of", "BH", "-", "AC", "(", "N4", "-", "behenoyl", "-", "1", "-", "beta", "-", "D", "-", "arabinofuranosyl", "cytosine", ")", "and", "idarubicin", "."], "event_mentions": [{"id": "10102531_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "undergoing", "start": 26, "end": 27}, "arguments": [{"entity_id": "10102531_2_Ent3", "role": "Effect", "text": "reversible encephalopathy syndrome", "start": 5, "end": 8}, {"entity_id": "10102531_2_Ent0", "role": "Subject", "text": "a 16 - year - old girl with acute myelogenous leukemia ( AML )", "start": 9, "end": 23}, {"entity_id": "10102531_2_Ent1", "role": "Subject_Age", "text": "16 - year - old", "start": 10, "end": 15}, {"entity_id": "10102531_2_Ent2", "role": "Subject_Gender", "text": "girl", "start": 15, "end": 16}, {"entity_id": "10102531_2_Ent5", "role": "Treatment_Disorder", "text": "acute myelogenous leukemia", "start": 17, "end": 20}, {"entity_id": "10102531_2_Ent4", "role": "Treatment", "text": "consolidation chemotherapy composed of BH - AC ( N4 - behenoyl - 1 - beta - D - arabinofuranosyl cytosine ) and idarubicin", "start": 28, "end": 51}, {"entity_id": "10102531_2_Ent7", "role": "Treatment_Drug", "text": "BH - AC", "start": 32, "end": 35}, {"entity_id": "10102531_2_Ent9", "role": "Combination_Drug", "text": "BH - AC", "start": 32, "end": 35}, {"entity_id": "10102531_2_Ent6", "role": "Treatment_Drug", "text": "idarubicin", "start": 50, "end": 51}, {"entity_id": "10102531_2_Ent8", "role": "Combination_Drug", "text": "idarubicin", "start": 50, "end": 51}]}], "entity_mentions": [{"id": "10102531_2_Ent3", "text": "reversible encephalopathy syndrome", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "10102531_2_Ent0", "text": "a 16 - year - old girl with acute myelogenous leukemia ( AML )", "entity_type": "Entity", "start": 9, "end": 23}, {"id": "10102531_2_Ent1", "text": "16 - year - old", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "10102531_2_Ent2", "text": "girl", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10102531_2_Ent5", "text": "acute myelogenous leukemia", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "10102531_2_Ent4", "text": "consolidation chemotherapy composed of BH - AC ( N4 - behenoyl - 1 - beta - D - arabinofuranosyl cytosine ) and idarubicin", "entity_type": "Entity", "start": 28, "end": 51}, {"id": "10102531_2_Ent7", "text": "BH - AC", "entity_type": "Entity", "start": 32, "end": 35}, {"id": "10102531_2_Ent9", "text": "BH - AC", "entity_type": "Entity", "start": 32, "end": 35}, {"id": "10102531_2_Ent6", "text": "idarubicin", "entity_type": "Entity", "start": 50, "end": 51}, {"id": "10102531_2_Ent8", "text": "idarubicin", "entity_type": "Entity", "start": 50, "end": 51}], "lang": "en"}
{"doc_id": "10212021_1", "wnd_id": "10212021_1_1", "text": "Methadone withdrawal when starting an antiretroviral regimen including nevirapine .", "tokens": ["Methadone", "withdrawal", "when", "starting", "an", "antiretroviral", "regimen", "including", "nevirapine", "."], "event_mentions": [{"id": "10212021_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "starting", "start": 3, "end": 4}, "arguments": [{"entity_id": "10212021_1_Ent0", "role": "Effect", "text": "Methadone withdrawal", "start": 0, "end": 2}, {"entity_id": "10212021_1_Ent1", "role": "Treatment", "text": "an antiretroviral regimen including nevirapine", "start": 4, "end": 9}, {"entity_id": "10212021_1_Ent2", "role": "Treatment_Drug", "text": "nevirapine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "10212021_1_Ent0", "text": "Methadone withdrawal", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10212021_1_Ent1", "text": "an antiretroviral regimen including nevirapine", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10212021_1_Ent2", "text": "nevirapine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "10212021_4", "wnd_id": "10212021_4_1", "text": "Methadone has two roles in human immunodeficiency viral infection : pain management and treatment of opioid abuse .", "tokens": ["Methadone", "has", "two", "roles", "in", "human", "immunodeficiency", "viral", "infection", ":", "pain", "management", "and", "treatment", "of", "opioid", "abuse", "."], "event_mentions": [{"id": "10212021_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "has two roles", "start": 1, "end": 4}, "arguments": [{"entity_id": "10212021_4_Ent1", "role": "Treatment", "text": "Methadone", "start": 0, "end": 1}, {"entity_id": "10212021_4_Ent3", "role": "Treatment_Drug", "text": "Methadone", "start": 0, "end": 1}, {"entity_id": "10212021_4_Ent2", "role": "Treatment_Disorder", "text": "human immunodeficiency viral infection", "start": 5, "end": 9}, {"entity_id": "10212021_4_Ent0", "role": "Effect", "text": "pain management and treatment of opioid abuse", "start": 10, "end": 17}]}], "entity_mentions": [{"id": "10212021_4_Ent1", "text": "Methadone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10212021_4_Ent3", "text": "Methadone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10212021_4_Ent2", "text": "human immunodeficiency viral infection", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "10212021_4_Ent0", "text": "pain management and treatment of opioid abuse", "entity_type": "Entity", "start": 10, "end": 17}], "lang": "en"}
{"doc_id": "10225085_2", "wnd_id": "10225085_2_1", "text": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field .", "tokens": ["Methemoglobinemia", "after", "axillary", "block", "with", "bupivacaine", "and", "additional", "injection", "of", "lidocaine", "in", "the", "operative", "field", "."], "event_mentions": [{"id": "10225085_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 1, "end": 2}, "arguments": [{"entity_id": "10225085_2_Ent0", "role": "Effect", "text": "Methemoglobinemia", "start": 0, "end": 1}, {"entity_id": "10225085_2_Ent1", "role": "Treatment", "text": "axillary block with bupivacaine and additional injection of lidocaine in the operative field", "start": 2, "end": 15}, {"entity_id": "10225085_2_Ent3", "role": "Treatment_Drug", "text": "bupivacaine", "start": 5, "end": 6}, {"entity_id": "10225085_2_Ent6", "role": "Combination_Drug", "text": "bupivacaine", "start": 5, "end": 6}, {"entity_id": "10225085_2_Ent2", "role": "Treatment_Route", "text": "injection", "start": 8, "end": 9}, {"entity_id": "10225085_2_Ent4", "role": "Treatment_Drug", "text": "lidocaine", "start": 10, "end": 11}, {"entity_id": "10225085_2_Ent5", "role": "Combination_Drug", "text": "lidocaine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "10225085_2_Ent0", "text": "Methemoglobinemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10225085_2_Ent1", "text": "axillary block with bupivacaine and additional injection of lidocaine in the operative field", "entity_type": "Entity", "start": 2, "end": 15}, {"id": "10225085_2_Ent3", "text": "bupivacaine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10225085_2_Ent6", "text": "bupivacaine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10225085_2_Ent2", "text": "injection", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10225085_2_Ent4", "text": "lidocaine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10225085_2_Ent5", "text": "lidocaine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "10229976_1", "wnd_id": "10229976_1_1", "text": "Detection of activated eosinophils in nasal polyps of an aspirin - induced asthma patient .", "tokens": ["Detection", "of", "activated", "eosinophils", "in", "nasal", "polyps", "of", "an", "aspirin", "-", "induced", "asthma", "patient", "."], "event_mentions": [{"id": "10229976_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "10229976_1_Ent1", "role": "Treatment", "text": "aspirin", "start": 9, "end": 10}, {"entity_id": "10229976_1_Ent2", "role": "Treatment_Drug", "text": "aspirin", "start": 9, "end": 10}, {"entity_id": "10229976_1_Ent0", "role": "Effect", "text": "asthma", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "10229976_1_Ent1", "text": "aspirin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10229976_1_Ent2", "text": "aspirin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10229976_1_Ent0", "text": "asthma", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "10357715_2", "wnd_id": "10357715_2_1", "text": "Calcipotriol ( Daivonex R ; Leo Pharmaceuticals , Zurich , Switzerland ) may cause irritation of the skin , whereas allergic reactions are less common .", "tokens": ["Calcipotriol", "(", "Daivonex", "R", ";", "Leo", "Pharmaceuticals", ",", "Zurich", ",", "Switzerland", ")", "may", "cause", "irritation", "of", "the", "skin", ",", "whereas", "allergic", "reactions", "are", "less", "common", "."], "event_mentions": [{"id": "10357715_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 13, "end": 14}, "arguments": [{"entity_id": "10357715_2_Ent1", "role": "Treatment", "text": "Calcipotriol", "start": 0, "end": 1}, {"entity_id": "10357715_2_Ent2", "role": "Treatment_Drug", "text": "Calcipotriol", "start": 0, "end": 1}, {"entity_id": "10357715_2_Ent0", "role": "Effect", "text": "irritation of the skin", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "10357715_2_Ent1", "text": "Calcipotriol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10357715_2_Ent2", "text": "Calcipotriol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10357715_2_Ent0", "text": "irritation of the skin", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "10367184_3", "wnd_id": "10367184_3_1", "text": "This case suggests that sarcoidosis and pravastatin , two entities not frequently associated with myotonia , may interact in a synergistic manner to produce severe clinical myotonia in humans .", "tokens": ["This", "case", "suggests", "that", "sarcoidosis", "and", "pravastatin", ",", "two", "entities", "not", "frequently", "associated", "with", "myotonia", ",", "may", "interact", "in", "a", "synergistic", "manner", "to", "produce", "severe", "clinical", "myotonia", "in", "humans", "."], "event_mentions": [{"id": "10367184_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "interact", "start": 17, "end": 18}, "arguments": [{"entity_id": "10367184_3_Ent2", "role": "Treatment", "text": "pravastatin", "start": 6, "end": 7}, {"entity_id": "10367184_3_Ent3", "role": "Treatment_Drug", "text": "pravastatin", "start": 6, "end": 7}, {"entity_id": "10367184_3_Ent1", "role": "Effect", "text": "severe clinical myotonia", "start": 24, "end": 27}, {"entity_id": "10367184_3_Ent0", "role": "Subject", "text": "humans .", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "10367184_3_Ent2", "text": "pravastatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10367184_3_Ent3", "text": "pravastatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10367184_3_Ent1", "text": "severe clinical myotonia", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "10367184_3_Ent0", "text": "humans .", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "10414481_2", "wnd_id": "10414481_2_1", "text": "This patient , who had a history of osteoarthritis , had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints .", "tokens": ["This", "patient", ",", "who", "had", "a", "history", "of", "osteoarthritis", ",", "had", "severe", "hepatitis", "5", "weeks", "after", "being", "started", "on", "diclofenac", "for", "increasing", "pain", "in", "the", "joints", "."], "event_mentions": [{"id": "10414481_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 10, "end": 11}, "arguments": [{"entity_id": "10414481_2_Ent0", "role": "Subject", "text": "This patient , who had a history of osteoarthritis", "start": 0, "end": 9}, {"entity_id": "10414481_2_Ent1", "role": "Effect", "text": "hepatitis", "start": 12, "end": 13}, {"entity_id": "10414481_2_Ent5", "role": "Treatment_Time_elapsed", "text": "5 weeks", "start": 13, "end": 15}, {"entity_id": "10414481_2_Ent2", "role": "Treatment", "text": "5 weeks after being started on diclofenac", "start": 13, "end": 20}, {"entity_id": "10414481_2_Ent3", "role": "Treatment_Drug", "text": "diclofenac", "start": 19, "end": 20}, {"entity_id": "10414481_2_Ent4", "role": "Treatment_Disorder", "text": "increasing pain in the joints", "start": 21, "end": 26}]}], "entity_mentions": [{"id": "10414481_2_Ent0", "text": "This patient , who had a history of osteoarthritis", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "10414481_2_Ent1", "text": "hepatitis", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10414481_2_Ent5", "text": "5 weeks", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "10414481_2_Ent2", "text": "5 weeks after being started on diclofenac", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "10414481_2_Ent3", "text": "diclofenac", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "10414481_2_Ent4", "text": "increasing pain in the joints", "entity_type": "Entity", "start": 21, "end": 26}], "lang": "en"}
{"doc_id": "10431414_1", "wnd_id": "10431414_1_1", "text": "One case of priapism occurred during heparin therapy for a previous surgical operation to the knee is reported .", "tokens": ["One", "case", "of", "priapism", "occurred", "during", "heparin", "therapy", "for", "a", "previous", "surgical", "operation", "to", "the", "knee", "is", "reported", "."], "event_mentions": [{"id": "10431414_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 4, "end": 5}, "arguments": [{"entity_id": "10431414_1_Ent0", "role": "Subject", "text": "One case", "start": 0, "end": 2}, {"entity_id": "10431414_1_Ent1", "role": "Effect", "text": "priapism", "start": 3, "end": 4}, {"entity_id": "10431414_1_Ent2", "role": "Treatment", "text": "during heparin therapy", "start": 5, "end": 8}, {"entity_id": "10431414_1_Ent3", "role": "Treatment_Drug", "text": "heparin", "start": 6, "end": 7}, {"entity_id": "10431414_1_Ent4", "role": "Treatment_Disorder", "text": "surgical operation to the knee", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "10431414_1_Ent0", "text": "One case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10431414_1_Ent1", "text": "priapism", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10431414_1_Ent2", "text": "during heparin therapy", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "10431414_1_Ent3", "text": "heparin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10431414_1_Ent4", "text": "surgical operation to the knee", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "10431414_2", "wnd_id": "10431414_2_1", "text": "Priapism as a complication of heparin therapy .", "tokens": ["Priapism", "as", "a", "complication", "of", "heparin", "therapy", "."], "event_mentions": [{"id": "10431414_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 3, "end": 4}, "arguments": [{"entity_id": "10431414_2_Ent0", "role": "Effect", "text": "Priapism", "start": 0, "end": 1}, {"entity_id": "10431414_2_Ent1", "role": "Treatment", "text": "heparin", "start": 5, "end": 6}, {"entity_id": "10431414_2_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "10431414_2_Ent0", "text": "Priapism", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10431414_2_Ent1", "text": "heparin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10431414_2_Ent2", "text": "heparin", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "10456689_2", "wnd_id": "10456689_2_1", "text": "1 . \n Artelinic acid ( AL ) , a water - soluble artemisinin analogue for treatment of multidrug resistant malaria , is metabolized to the active metabolite dihydroqinghaosu ( DQHS ) solely by   CYP3A4/5 .", "tokens": ["1", ".", "\n", "Artelinic", "acid", "(", "AL", ")", ",", "a", "water", "-", "soluble", "artemisinin", "analogue", "for", "treatment", "of", "multidrug", "resistant", "malaria", ",", "is", "metabolized", "to", "the", "active", "metabolite", "dihydroqinghaosu", "(", "DQHS", ")", "solely", "by", " ", "CYP3A4/5", "."], "event_mentions": [{"id": "10456689_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 16, "end": 17}, "arguments": [{"entity_id": "10456689_2_Ent2", "role": "Treatment_Drug", "text": "Artelinic acid", "start": 3, "end": 5}, {"entity_id": "10456689_2_Ent0", "role": "Treatment", "text": "Artelinic acid ( AL ) , a water - soluble artemisinin analogue", "start": 3, "end": 15}, {"entity_id": "10456689_2_Ent1", "role": "Treatment_Disorder", "text": "multidrug resistant malaria", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "10456689_2_Ent2", "text": "Artelinic acid", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10456689_2_Ent0", "text": "Artelinic acid ( AL ) , a water - soluble artemisinin analogue", "entity_type": "Entity", "start": 3, "end": 15}, {"id": "10456689_2_Ent1", "text": "multidrug resistant malaria", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "10465148_4", "wnd_id": "10465148_4_1", "text": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery .", "tokens": ["Reported", "are", "three", "children", "who", "developed", "progressive", "paraparesis", "after", "intrathecal", "methotrexate", "administration", "followed", "by", "complete", "or", "partial", "recovery", "."], "event_mentions": [{"id": "10465148_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "10465148_4_Ent1", "role": "Subject_Population", "text": "three", "start": 2, "end": 3}, {"entity_id": "10465148_4_Ent0", "role": "Subject", "text": "three children", "start": 2, "end": 4}, {"entity_id": "10465148_4_Ent2", "role": "Subject_Age", "text": "children", "start": 3, "end": 4}, {"entity_id": "10465148_4_Ent3", "role": "Effect", "text": "paraparesis", "start": 7, "end": 8}, {"entity_id": "10465148_4_Ent6", "role": "Treatment_Route", "text": "intrathecal", "start": 9, "end": 10}, {"entity_id": "10465148_4_Ent4", "role": "Treatment", "text": "intrathecal methotrexate", "start": 9, "end": 11}, {"entity_id": "10465148_4_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "10465148_4_Ent1", "text": "three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10465148_4_Ent0", "text": "three children", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "10465148_4_Ent2", "text": "children", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10465148_4_Ent3", "text": "paraparesis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10465148_4_Ent6", "text": "intrathecal", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10465148_4_Ent4", "text": "intrathecal methotrexate", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10465148_4_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "10466445_3", "wnd_id": "10466445_3_1", "text": "In the present study , arsenic trioxide was given intravenously for 42 days to a 56 - year - old female patient suffering from chemotherapy / ATRA - resistant APL , with 43 % APL blasts in the bone marrow and elevated D - dimers .", "tokens": ["In", "the", "present", "study", ",", "arsenic", "trioxide", "was", "given", "intravenously", "for", "42", "days", "to", "a", "56", "-", "year", "-", "old", "female", "patient", "suffering", "from", "chemotherapy", "/", "ATRA", "-", "resistant", "APL", ",", "with", "43", "%", "APL", "blasts", "in", "the", "bone", "marrow", "and", "elevated", "D", "-", "dimers", "."], "event_mentions": [{"id": "10466445_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "given", "start": 8, "end": 9}, "arguments": [{"entity_id": "10466445_3_Ent3", "role": "Treatment", "text": "arsenic trioxide", "start": 5, "end": 7}, {"entity_id": "10466445_3_Ent4", "role": "Treatment_Drug", "text": "arsenic trioxide", "start": 5, "end": 7}, {"entity_id": "10466445_3_Ent6", "role": "Treatment_Duration", "text": "42 days", "start": 11, "end": 13}, {"entity_id": "10466445_3_Ent1", "role": "Subject_Age", "text": "56 - year - old", "start": 15, "end": 20}, {"entity_id": "10466445_3_Ent0", "role": "Subject", "text": "56 - year - old female patient", "start": 15, "end": 22}, {"entity_id": "10466445_3_Ent2", "role": "Subject_Gender", "text": "female", "start": 20, "end": 21}, {"entity_id": "10466445_3_Ent5", "role": "Treatment_Disorder", "text": "chemotherapy / ATRA - resistant APL", "start": 24, "end": 30}]}], "entity_mentions": [{"id": "10466445_3_Ent3", "text": "arsenic trioxide", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10466445_3_Ent4", "text": "arsenic trioxide", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10466445_3_Ent6", "text": "42 days", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "10466445_3_Ent1", "text": "56 - year - old", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "10466445_3_Ent0", "text": "56 - year - old female patient", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "10466445_3_Ent2", "text": "female", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10466445_3_Ent5", "text": "chemotherapy / ATRA - resistant APL", "entity_type": "Entity", "start": 24, "end": 30}], "lang": "en"}
{"doc_id": "10473079_2", "wnd_id": "10473079_2_1", "text": "We now report the first known cancer patient who developed life - threatening complications after treatment with topical 5 - FU and was shown subsequently to have profound DPD deficiency .", "tokens": ["We", "now", "report", "the", "first", "known", "cancer", "patient", "who", "developed", "life", "-", "threatening", "complications", "after", "treatment", "with", "topical", "5", "-", "FU", "and", "was", "shown", "subsequently", "to", "have", "profound", "DPD", "deficiency", "."], "event_mentions": [{"id": "10473079_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "10473079_2_Ent4", "role": "Treatment_Disorder", "text": "cancer", "start": 6, "end": 7}, {"entity_id": "10473079_2_Ent0", "role": "Subject", "text": "cancer patient", "start": 6, "end": 8}, {"entity_id": "10473079_2_Ent1", "role": "Effect", "text": "life - threatening complications", "start": 10, "end": 14}, {"entity_id": "10473079_2_Ent6", "role": "Treatment_Route", "text": "topical", "start": 17, "end": 18}, {"entity_id": "10473079_2_Ent3", "role": "Treatment", "text": "topical 5 - FU", "start": 17, "end": 21}, {"entity_id": "10473079_2_Ent5", "role": "Treatment_Drug", "text": "5 - FU", "start": 18, "end": 21}, {"entity_id": "10473079_2_Ent2", "role": "Effect", "text": "have profound DPD deficiency", "start": 26, "end": 30}]}], "entity_mentions": [{"id": "10473079_2_Ent4", "text": "cancer", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10473079_2_Ent0", "text": "cancer patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10473079_2_Ent1", "text": "life - threatening complications", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "10473079_2_Ent6", "text": "topical", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10473079_2_Ent3", "text": "topical 5 - FU", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "10473079_2_Ent5", "text": "5 - FU", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "10473079_2_Ent2", "text": "have profound DPD deficiency", "entity_type": "Entity", "start": 26, "end": 30}], "lang": "en"}
{"doc_id": "10487084_2", "wnd_id": "10487084_2_1", "text": "Paradoxical seizures in phenytoin toxicity .", "tokens": ["Paradoxical", "seizures", "in", "phenytoin", "toxicity", "."], "event_mentions": [{"id": "10487084_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "seizures", "start": 1, "end": 2}, "arguments": [{"entity_id": "10487084_2_Ent0", "role": "Effect", "text": "Paradoxical seizures", "start": 0, "end": 2}, {"entity_id": "10487084_2_Ent2", "role": "Treatment_Drug", "text": "phenytoin", "start": 3, "end": 4}, {"entity_id": "10487084_2_Ent1", "role": "Treatment", "text": "phenytoin toxicity", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "10487084_2_Ent0", "text": "Paradoxical seizures", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10487084_2_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10487084_2_Ent1", "text": "phenytoin toxicity", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "10510156_2", "wnd_id": "10510156_2_1", "text": "AIMS : To identify the   human cytochrome P450 enzyme ( s ) involved in the in vitro metabolism of rosiglitazone , a potential oral antidiabetic agent for the treatment of type 2 diabetes - mellitus .", "tokens": ["AIMS", ":", "To", "identify", "the", " ", "human", "cytochrome", "P450", "enzyme", "(", "s", ")", "involved", "in", "the", "in", "vitro", "metabolism", "of", "rosiglitazone", ",", "a", "potential", "oral", "antidiabetic", "agent", "for", "the", "treatment", "of", "type", "2", "diabetes", "-", "mellitus", "."], "event_mentions": [{"id": "10510156_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "potential oral", "start": 23, "end": 25}, "arguments": [{"entity_id": "10510156_2_Ent0", "role": "Treatment", "text": "rosiglitazone", "start": 20, "end": 21}, {"entity_id": "10510156_2_Ent1", "role": "Treatment_Drug", "text": "rosiglitazone", "start": 20, "end": 21}, {"entity_id": "10510156_2_Ent3", "role": "Treatment_Route", "text": "oral", "start": 24, "end": 25}, {"entity_id": "10510156_2_Ent2", "role": "Treatment_Disorder", "text": "type 2 diabetes - mellitus .", "start": 31, "end": 37}]}], "entity_mentions": [{"id": "10510156_2_Ent0", "text": "rosiglitazone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10510156_2_Ent1", "text": "rosiglitazone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10510156_2_Ent3", "text": "oral", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "10510156_2_Ent2", "text": "type 2 diabetes - mellitus .", "entity_type": "Entity", "start": 31, "end": 37}], "lang": "en"}
{"doc_id": "10516999_1", "wnd_id": "10516999_1_1", "text": "Acute hyperphosphatemia caused by sodium phosphate enema in a patient with liver dysfunction and chronic renal failure .", "tokens": ["Acute", "hyperphosphatemia", "caused", "by", "sodium", "phosphate", "enema", "in", "a", "patient", "with", "liver", "dysfunction", "and", "chronic", "renal", "failure", "."], "event_mentions": [{"id": "10516999_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 2, "end": 3}, "arguments": [{"entity_id": "10516999_1_Ent2", "role": "Effect", "text": "Acute hyperphosphatemia", "start": 0, "end": 2}, {"entity_id": "10516999_1_Ent4", "role": "Treatment_Drug", "text": "sodium phosphate", "start": 4, "end": 6}, {"entity_id": "10516999_1_Ent3", "role": "Treatment", "text": "sodium phosphate enema", "start": 4, "end": 7}, {"entity_id": "10516999_1_Ent5", "role": "Treatment_Route", "text": "enema", "start": 6, "end": 7}, {"entity_id": "10516999_1_Ent0", "role": "Subject", "text": "a patient with liver dysfunction and chronic renal failure", "start": 8, "end": 17}, {"entity_id": "10516999_1_Ent1", "role": "Subject_Disorder", "text": "liver dysfunction and chronic renal failure", "start": 11, "end": 17}]}], "entity_mentions": [{"id": "10516999_1_Ent2", "text": "Acute hyperphosphatemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10516999_1_Ent4", "text": "sodium phosphate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "10516999_1_Ent3", "text": "sodium phosphate enema", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "10516999_1_Ent5", "text": "enema", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10516999_1_Ent0", "text": "a patient with liver dysfunction and chronic renal failure", "entity_type": "Entity", "start": 8, "end": 17}, {"id": "10516999_1_Ent1", "text": "liver dysfunction and chronic renal failure", "entity_type": "Entity", "start": 11, "end": 17}], "lang": "en"}
{"doc_id": "10524732_2", "wnd_id": "10524732_2_1", "text": "We report a case of recurrent torsades de pointes following treatment with pentavalent antimonial drugs and amiodarone .", "tokens": ["We", "report", "a", "case", "of", "recurrent", "torsades", "de", "pointes", "following", "treatment", "with", "pentavalent", "antimonial", "drugs", "and", "amiodarone", "."], "event_mentions": [{"id": "10524732_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment with", "start": 10, "end": 12}, "arguments": [{"entity_id": "10524732_2_Ent0", "role": "Effect", "text": "recurrent torsades de pointes", "start": 5, "end": 9}, {"entity_id": "10524732_2_Ent3", "role": "Treatment_Drug", "text": "pentavalent antimonial drugs", "start": 12, "end": 15}, {"entity_id": "10524732_2_Ent4", "role": "Combination_Drug", "text": "pentavalent antimonial drugs", "start": 12, "end": 15}, {"entity_id": "10524732_2_Ent1", "role": "Treatment", "text": "pentavalent antimonial drugs and amiodarone", "start": 12, "end": 17}, {"entity_id": "10524732_2_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 16, "end": 17}, {"entity_id": "10524732_2_Ent5", "role": "Combination_Drug", "text": "amiodarone", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "10524732_2_Ent0", "text": "recurrent torsades de pointes", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "10524732_2_Ent3", "text": "pentavalent antimonial drugs", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10524732_2_Ent4", "text": "pentavalent antimonial drugs", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10524732_2_Ent1", "text": "pentavalent antimonial drugs and amiodarone", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "10524732_2_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10524732_2_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "10566542_1", "wnd_id": "10566542_1_1", "text": "Postoperative hypocalcemic tetany caused by fleet phospho - soda preparation in a patient taking alendronate sodium : report of a case .", "tokens": ["Postoperative", "hypocalcemic", "tetany", "caused", "by", "fleet", "phospho", "-", "soda", "preparation", "in", "a", "patient", "taking", "alendronate", "sodium", ":", "report", "of", "a", "case", "."], "event_mentions": [{"id": "10566542_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 3, "end": 4}, "arguments": [{"entity_id": "10566542_1_Ent1", "role": "Effect", "text": "hypocalcemic tetany", "start": 1, "end": 3}, {"entity_id": "10566542_1_Ent2", "role": "Treatment", "text": "fleet phospho - soda", "start": 5, "end": 9}, {"entity_id": "10566542_1_Ent4", "role": "Treatment_Drug", "text": "fleet phospho - soda", "start": 5, "end": 9}, {"entity_id": "10566542_1_Ent0", "role": "Subject", "text": "patient", "start": 12, "end": 13}, {"entity_id": "10566542_1_Ent3", "role": "Treatment", "text": "alendronate sodium", "start": 14, "end": 16}, {"entity_id": "10566542_1_Ent5", "role": "Treatment_Drug", "text": "alendronate sodium", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "10566542_1_Ent1", "text": "hypocalcemic tetany", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10566542_1_Ent2", "text": "fleet phospho - soda", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "10566542_1_Ent4", "text": "fleet phospho - soda", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "10566542_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10566542_1_Ent3", "text": "alendronate sodium", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "10566542_1_Ent5", "text": "alendronate sodium", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "10566542_2", "wnd_id": "10566542_2_1", "text": "This case report describes a patient who was previously prescribed alendronate ( Fosamax ) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho - Soda .", "tokens": ["This", "case", "report", "describes", "a", "patient", "who", "was", "previously", "prescribed", "alendronate", "(", "Fosamax", ")", "and", "presented", "with", "postoperative", "hypophosphatemia", "and", "hypocalcemic", "tetany", "after", "bowel", "preparation", "with", "Fleet", "Phospho", "-", "Soda", "."], "event_mentions": [{"id": "10566542_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 15, "end": 16}, "arguments": [{"entity_id": "10566542_2_Ent0", "role": "Subject", "text": "patient", "start": 5, "end": 6}, {"entity_id": "10566542_2_Ent4", "role": "Treatment_Drug", "text": "alendronate", "start": 10, "end": 11}, {"entity_id": "10566542_2_Ent6", "role": "Combination_Drug", "text": "alendronate", "start": 10, "end": 11}, {"entity_id": "10566542_2_Ent2", "role": "Treatment", "text": "alendronate ( Fosamax )", "start": 10, "end": 14}, {"entity_id": "10566542_2_Ent1", "role": "Effect", "text": "postoperative hypophosphatemia and hypocalcemic tetany", "start": 17, "end": 22}, {"entity_id": "10566542_2_Ent3", "role": "Treatment", "text": "after bowel preparation with Fleet Phospho - Soda", "start": 22, "end": 30}, {"entity_id": "10566542_2_Ent5", "role": "Treatment_Drug", "text": "Fleet Phospho - Soda", "start": 26, "end": 30}, {"entity_id": "10566542_2_Ent7", "role": "Combination_Drug", "text": "Fleet Phospho - Soda", "start": 26, "end": 30}]}], "entity_mentions": [{"id": "10566542_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10566542_2_Ent4", "text": "alendronate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10566542_2_Ent6", "text": "alendronate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10566542_2_Ent2", "text": "alendronate ( Fosamax )", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "10566542_2_Ent1", "text": "postoperative hypophosphatemia and hypocalcemic tetany", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "10566542_2_Ent3", "text": "after bowel preparation with Fleet Phospho - Soda", "entity_type": "Entity", "start": 22, "end": 30}, {"id": "10566542_2_Ent5", "text": "Fleet Phospho - Soda", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "10566542_2_Ent7", "text": "Fleet Phospho - Soda", "entity_type": "Entity", "start": 26, "end": 30}], "lang": "en"}
{"doc_id": "10573314_14", "wnd_id": "10573314_14_1", "text": "Until further data are available , clinicians should be vigilant for a possible drug interaction when tolterodine therapy is initiated in a patient maintained on warfarin therapy .", "tokens": ["Until", "further", "data", "are", "available", ",", "clinicians", "should", "be", "vigilant", "for", "a", "possible", "drug", "interaction", "when", "tolterodine", "therapy", "is", "initiated", "in", "a", "patient", "maintained", "on", "warfarin", "therapy", "."], "event_mentions": [{"id": "10573314_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "initiated", "start": 19, "end": 20}, "arguments": [{"entity_id": "10573314_14_Ent1", "role": "Effect", "text": "possible drug interaction", "start": 12, "end": 15}, {"entity_id": "10573314_14_Ent3", "role": "Treatment_Drug", "text": "tolterodine", "start": 16, "end": 17}, {"entity_id": "10573314_14_Ent5", "role": "Combination_Drug", "text": "tolterodine", "start": 16, "end": 17}, {"entity_id": "10573314_14_Ent2", "role": "Treatment", "text": "tolterodine therapy", "start": 16, "end": 18}, {"entity_id": "10573314_14_Ent0", "role": "Subject", "text": "a patient", "start": 21, "end": 23}, {"entity_id": "10573314_14_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 25, "end": 26}, {"entity_id": "10573314_14_Ent6", "role": "Combination_Drug", "text": "warfarin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "10573314_14_Ent1", "text": "possible drug interaction", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10573314_14_Ent3", "text": "tolterodine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10573314_14_Ent5", "text": "tolterodine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10573314_14_Ent2", "text": "tolterodine therapy", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "10573314_14_Ent0", "text": "a patient", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "10573314_14_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "10573314_14_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "10575189_2", "wnd_id": "10575189_2_1", "text": "Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy .", "tokens": ["Thrombotic", "microangiopathy", "with", "renal", "failure", "in", "two", "patients", "undergoing", "gemcitabine", "chemotherapy", "."], "event_mentions": [{"id": "10575189_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "undergoing", "start": 8, "end": 9}, "arguments": [{"entity_id": "10575189_2_Ent2", "role": "Effect", "text": "Thrombotic microangiopathy with renal failure", "start": 0, "end": 5}, {"entity_id": "10575189_2_Ent1", "role": "Subject_Population", "text": "two", "start": 6, "end": 7}, {"entity_id": "10575189_2_Ent0", "role": "Subject", "text": "two patients", "start": 6, "end": 8}, {"entity_id": "10575189_2_Ent4", "role": "Treatment_Drug", "text": "gemcitabine", "start": 9, "end": 10}, {"entity_id": "10575189_2_Ent3", "role": "Treatment", "text": "gemcitabine chemotherapy", "start": 9, "end": 11}, {"entity_id": "10575189_2_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "10575189_2_Ent2", "text": "Thrombotic microangiopathy with renal failure", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "10575189_2_Ent1", "text": "two", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10575189_2_Ent0", "text": "two patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10575189_2_Ent4", "text": "gemcitabine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10575189_2_Ent3", "text": "gemcitabine chemotherapy", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10575189_2_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "10579985_4", "wnd_id": "10579985_4_1", "text": "We describe the clinical course of 2 patients with Crohn 's disease ( CD ) in whom lymphoma was diagnosed after treatment with infliximab .", "tokens": ["We", "describe", "the", "clinical", "course", "of", "2", "patients", "with", "Crohn", "'s", "disease", "(", "CD", ")", "in", "whom", "lymphoma", "was", "diagnosed", "after", "treatment", "with", "infliximab", "."], "event_mentions": [{"id": "10579985_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 19, "end": 20}, "arguments": [{"entity_id": "10579985_4_Ent1", "role": "Subject_Population", "text": "2", "start": 6, "end": 7}, {"entity_id": "10579985_4_Ent0", "role": "Subject", "text": "2 patients with Crohn 's disease ( CD )", "start": 6, "end": 15}, {"entity_id": "10579985_4_Ent4", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 9, "end": 12}, {"entity_id": "10579985_4_Ent2", "role": "Effect", "text": "lymphoma", "start": 17, "end": 18}, {"entity_id": "10579985_4_Ent3", "role": "Treatment", "text": "treatment with infliximab", "start": 21, "end": 24}, {"entity_id": "10579985_4_Ent5", "role": "Treatment_Drug", "text": "infliximab", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "10579985_4_Ent1", "text": "2", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10579985_4_Ent0", "text": "2 patients with Crohn 's disease ( CD )", "entity_type": "Entity", "start": 6, "end": 15}, {"id": "10579985_4_Ent4", "text": "Crohn 's disease", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "10579985_4_Ent2", "text": "lymphoma", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10579985_4_Ent3", "text": "treatment with infliximab", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "10579985_4_Ent5", "text": "infliximab", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "10610018_1", "wnd_id": "10610018_1_1", "text": "Elevated serum triglycerides with clozapine resolved with risperidone in four patients .", "tokens": ["Elevated", "serum", "triglycerides", "with", "clozapine", "resolved", "with", "risperidone", "in", "four", "patients", "."], "event_mentions": [{"id": "10610018_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 3, "end": 4}, "arguments": [{"entity_id": "10610018_1_Ent5", "role": "Effect", "text": "Elevated serum triglycerides", "start": 0, "end": 3}, {"entity_id": "10610018_1_Ent6", "role": "Treatment", "text": "clozapine", "start": 4, "end": 5}, {"entity_id": "10610018_1_Ent7", "role": "Treatment_Drug", "text": "clozapine", "start": 4, "end": 5}]}, {"id": "10610018_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 5, "end": 6}, "arguments": [{"entity_id": "10610018_1_Ent3", "role": "Treatment_Disorder", "text": "Elevated serum triglycerides with clozapine", "start": 0, "end": 5}, {"entity_id": "10610018_1_Ent2", "role": "Treatment", "text": "risperidone", "start": 7, "end": 8}, {"entity_id": "10610018_1_Ent4", "role": "Treatment_Drug", "text": "risperidone", "start": 7, "end": 8}, {"entity_id": "10610018_1_Ent1", "role": "Subject_Population", "text": "four", "start": 9, "end": 10}, {"entity_id": "10610018_1_Ent0", "role": "Subject", "text": "four patients", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "10610018_1_Ent5", "text": "Elevated serum triglycerides", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "10610018_1_Ent3", "text": "Elevated serum triglycerides with clozapine", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "10610018_1_Ent6", "text": "clozapine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10610018_1_Ent7", "text": "clozapine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10610018_1_Ent2", "text": "risperidone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10610018_1_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10610018_1_Ent1", "text": "four", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10610018_1_Ent0", "text": "four patients", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "10610018_3", "wnd_id": "10610018_3_1", "text": "This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine - treated patients .", "tokens": ["This", "increase", "when", "clozapine", "was", "switched", "to", "risperidone", "and", "vice", "versa", "is", "consistent", "with", "our", "previous", "report", "of", "elevated", "serum", "triglyceride", "levels", "in", "clozapine", "-", "treated", "patients", "."], "event_mentions": [{"id": "10610018_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "consistent", "start": 12, "end": 13}, "arguments": [{"entity_id": "10610018_3_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 3, "end": 4}, {"entity_id": "10610018_3_Ent1", "role": "Treatment", "text": "clozapine was switched to risperidone and vice versa", "start": 3, "end": 11}, {"entity_id": "10610018_3_Ent4", "role": "Treatment_Drug", "text": "risperidone", "start": 7, "end": 8}, {"entity_id": "10610018_3_Ent2", "role": "Treatment_Disorder", "text": "elevated serum triglyceride levels", "start": 18, "end": 22}, {"entity_id": "10610018_3_Ent0", "role": "Subject", "text": "patients", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "10610018_3_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10610018_3_Ent1", "text": "clozapine was switched to risperidone and vice versa", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "10610018_3_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10610018_3_Ent2", "text": "elevated serum triglyceride levels", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "10610018_3_Ent0", "text": "patients", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "10614572_3", "wnd_id": "10614572_3_1", "text": "We report a case of severe hypotension associated with intravenous valproate used to treat status epilepticus in an 11 - year - old girl .", "tokens": ["We", "report", "a", "case", "of", "severe", "hypotension", "associated", "with", "intravenous", "valproate", "used", "to", "treat", "status", "epilepticus", "in", "an", "11", "-", "year", "-", "old", "girl", "."], "event_mentions": [{"id": "10614572_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "10614572_3_Ent3", "role": "Effect", "text": "hypotension", "start": 6, "end": 7}, {"entity_id": "10614572_3_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 9, "end": 10}, {"entity_id": "10614572_3_Ent4", "role": "Treatment", "text": "intravenous valproate", "start": 9, "end": 11}, {"entity_id": "10614572_3_Ent7", "role": "Treatment_Drug", "text": "valproate", "start": 10, "end": 11}, {"entity_id": "10614572_3_Ent5", "role": "Treatment_Disorder", "text": "status epilepticus", "start": 14, "end": 16}, {"entity_id": "10614572_3_Ent0", "role": "Subject", "text": "an 11 - year - old girl", "start": 17, "end": 24}, {"entity_id": "10614572_3_Ent1", "role": "Subject_Age", "text": "11 - year - old", "start": 18, "end": 23}, {"entity_id": "10614572_3_Ent2", "role": "Subject_Gender", "text": "girl", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "10614572_3_Ent3", "text": "hypotension", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10614572_3_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10614572_3_Ent4", "text": "intravenous valproate", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10614572_3_Ent7", "text": "valproate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10614572_3_Ent5", "text": "status epilepticus", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "10614572_3_Ent0", "text": "an 11 - year - old girl", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "10614572_3_Ent1", "text": "11 - year - old", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "10614572_3_Ent2", "text": "girl", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "10633877_3", "wnd_id": "10633877_3_1", "text": "Theophylline intoxication mimicking diabetic ketoacidosis in a child .", "tokens": ["Theophylline", "intoxication", "mimicking", "diabetic", "ketoacidosis", "in", "a", "child", "."], "event_mentions": [{"id": "10633877_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "10633877_3_Ent3", "role": "Treatment", "text": "Theophylline", "start": 0, "end": 1}, {"entity_id": "10633877_3_Ent4", "role": "Treatment_Drug", "text": "Theophylline", "start": 0, "end": 1}, {"entity_id": "10633877_3_Ent2", "role": "Effect", "text": "Theophylline intoxication", "start": 0, "end": 2}, {"entity_id": "10633877_3_Ent0", "role": "Subject", "text": "a child", "start": 6, "end": 8}, {"entity_id": "10633877_3_Ent1", "role": "Subject_Age", "text": "child", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "10633877_3_Ent3", "text": "Theophylline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10633877_3_Ent4", "text": "Theophylline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10633877_3_Ent2", "text": "Theophylline intoxication", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10633877_3_Ent0", "text": "a child", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10633877_3_Ent1", "text": "child", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "10646879_3", "wnd_id": "10646879_3_1", "text": "We conclude that MB is an effective treatment for ifosfamide - induced encephalopathy .", "tokens": ["We", "conclude", "that", "MB", "is", "an", "effective", "treatment", "for", "ifosfamide", "-", "induced", "encephalopathy", "."], "event_mentions": [{"id": "10646879_3_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 7, "end": 8}, "arguments": [{"entity_id": "10646879_3_Ent3", "role": "Treatment", "text": "MB", "start": 3, "end": 4}, {"entity_id": "10646879_3_Ent5", "role": "Treatment_Drug", "text": "MB", "start": 3, "end": 4}, {"entity_id": "10646879_3_Ent4", "role": "Treatment_Disorder", "text": "ifosfamide - induced encephalopathy", "start": 9, "end": 13}]}, {"id": "10646879_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "10646879_3_Ent1", "role": "Treatment", "text": "ifosfamide", "start": 9, "end": 10}, {"entity_id": "10646879_3_Ent2", "role": "Treatment_Drug", "text": "ifosfamide", "start": 9, "end": 10}, {"entity_id": "10646879_3_Ent0", "role": "Effect", "text": "encephalopathy", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "10646879_3_Ent3", "text": "MB", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10646879_3_Ent5", "text": "MB", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10646879_3_Ent1", "text": "ifosfamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10646879_3_Ent2", "text": "ifosfamide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10646879_3_Ent4", "text": "ifosfamide - induced encephalopathy", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "10646879_3_Ent0", "text": "encephalopathy", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "10660641_8", "wnd_id": "10660641_8_1", "text": "Since renal insufficiency was induced by AMPH and the other antifungal drugs were ineffective , daily administration of 200 mg of ITCZ was initiated , and the inflammatory signs and symptoms gradually subsided .", "tokens": ["Since", "renal", "insufficiency", "was", "induced", "by", "AMPH", "and", "the", "other", "antifungal", "drugs", "were", "ineffective", ",", "daily", "administration", "of", "200", "mg", "of", "ITCZ", "was", "initiated", ",", "and", "the", "inflammatory", "signs", "and", "symptoms", "gradually", "subsided", "."], "event_mentions": [{"id": "10660641_8_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "10660641_8_Ent6", "role": "Effect", "text": "renal insufficiency", "start": 1, "end": 3}, {"entity_id": "10660641_8_Ent7", "role": "Treatment", "text": "AMPH", "start": 6, "end": 7}, {"entity_id": "10660641_8_Ent8", "role": "Treatment_Drug", "text": "AMPH", "start": 6, "end": 7}]}, {"id": "10660641_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "initiated", "start": 23, "end": 24}, "arguments": [{"entity_id": "10660641_8_Ent2", "role": "Treatment_Disorder", "text": "renal insufficiency", "start": 1, "end": 3}, {"entity_id": "10660641_8_Ent4", "role": "Treatment_Freq", "text": "daily administration", "start": 15, "end": 17}, {"entity_id": "10660641_8_Ent1", "role": "Treatment", "text": "daily administration of 200 mg of ITCZ", "start": 15, "end": 22}, {"entity_id": "10660641_8_Ent3", "role": "Treatment_Dosage", "text": "200 mg", "start": 18, "end": 20}, {"entity_id": "10660641_8_Ent5", "role": "Treatment_Drug", "text": "ITCZ", "start": 21, "end": 22}, {"entity_id": "10660641_8_Ent0", "role": "Effect", "text": "the inflammatory signs and symptoms gradually subsided .", "start": 26, "end": 34}]}], "entity_mentions": [{"id": "10660641_8_Ent2", "text": "renal insufficiency", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10660641_8_Ent6", "text": "renal insufficiency", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10660641_8_Ent7", "text": "AMPH", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10660641_8_Ent8", "text": "AMPH", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10660641_8_Ent4", "text": "daily administration", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "10660641_8_Ent1", "text": "daily administration of 200 mg of ITCZ", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "10660641_8_Ent3", "text": "200 mg", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "10660641_8_Ent5", "text": "ITCZ", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10660641_8_Ent0", "text": "the inflammatory signs and symptoms gradually subsided .", "entity_type": "Entity", "start": 26, "end": 34}], "lang": "en"}
{"doc_id": "10667036_1", "wnd_id": "10667036_1_1", "text": "Caution is , therefore , needed to prevent undesired accumulation of TCA that may lead to protracted Cushing 's syndrome .", "tokens": ["Caution", "is", ",", "therefore", ",", "needed", "to", "prevent", "undesired", "accumulation", "of", "TCA", "that", "may", "lead", "to", "protracted", "Cushing", "'s", "syndrome", "."], "event_mentions": [{"id": "10667036_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead to", "start": 14, "end": 16}, "arguments": [{"entity_id": "10667036_1_Ent1", "role": "Treatment", "text": "TCA", "start": 11, "end": 12}, {"entity_id": "10667036_1_Ent2", "role": "Treatment_Drug", "text": "TCA", "start": 11, "end": 12}, {"entity_id": "10667036_1_Ent0", "role": "Effect", "text": "protracted Cushing 's syndrome", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "10667036_1_Ent1", "text": "TCA", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10667036_1_Ent2", "text": "TCA", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10667036_1_Ent0", "text": "protracted Cushing 's syndrome", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "10679548_2", "wnd_id": "10679548_2_1", "text": "Bronchiolitis obliterans organising pneumonia associated with the use of nitrofurantoin .", "tokens": ["Bronchiolitis", "obliterans", "organising", "pneumonia", "associated", "with", "the", "use", "of", "nitrofurantoin", "."], "event_mentions": [{"id": "10679548_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 4, "end": 6}, "arguments": [{"entity_id": "10679548_2_Ent0", "role": "Effect", "text": "Bronchiolitis obliterans organising pneumonia", "start": 0, "end": 4}, {"entity_id": "10679548_2_Ent1", "role": "Treatment", "text": "use of nitrofurantoin", "start": 7, "end": 10}, {"entity_id": "10679548_2_Ent2", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "10679548_2_Ent0", "text": "Bronchiolitis obliterans organising pneumonia", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10679548_2_Ent1", "text": "use of nitrofurantoin", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "10679548_2_Ent2", "text": "nitrofurantoin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "10682234_8", "wnd_id": "10682234_8_1", "text": "He became completely premorbid 2 weeks after administration of levodopa .", "tokens": ["He", "became", "completely", "premorbid", "2", "weeks", "after", "administration", "of", "levodopa", "."], "event_mentions": [{"id": "10682234_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "10682234_8_Ent0", "role": "Subject", "text": "He", "start": 0, "end": 1}, {"entity_id": "10682234_8_Ent1", "role": "Subject_Gender", "text": "He", "start": 0, "end": 1}, {"entity_id": "10682234_8_Ent2", "role": "Effect", "text": "premorbid", "start": 3, "end": 4}, {"entity_id": "10682234_8_Ent5", "role": "Treatment_Time_elapsed", "text": "2 weeks", "start": 4, "end": 6}, {"entity_id": "10682234_8_Ent3", "role": "Treatment", "text": "levodopa", "start": 9, "end": 10}, {"entity_id": "10682234_8_Ent4", "role": "Treatment_Drug", "text": "levodopa", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "10682234_8_Ent0", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10682234_8_Ent1", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10682234_8_Ent2", "text": "premorbid", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10682234_8_Ent5", "text": "2 weeks", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "10682234_8_Ent3", "text": "levodopa", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10682234_8_Ent4", "text": "levodopa", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "10688731_3", "wnd_id": "10688731_3_1", "text": "We report a case of a scleroderma - like reaction induced by long - term administration of UFT .", "tokens": ["We", "report", "a", "case", "of", "a", "scleroderma", "-", "like", "reaction", "induced", "by", "long", "-", "term", "administration", "of", "UFT", "."], "event_mentions": [{"id": "10688731_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "10688731_3_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "10688731_3_Ent1", "role": "Effect", "text": "a scleroderma - like reaction", "start": 5, "end": 10}, {"entity_id": "10688731_3_Ent3", "role": "Treatment_Duration", "text": "long - term", "start": 12, "end": 15}, {"entity_id": "10688731_3_Ent2", "role": "Treatment", "text": "long - term administration of UFT", "start": 12, "end": 18}, {"entity_id": "10688731_3_Ent4", "role": "Treatment_Drug", "text": "UFT", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "10688731_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "10688731_3_Ent1", "text": "a scleroderma - like reaction", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "10688731_3_Ent3", "text": "long - term", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10688731_3_Ent2", "text": "long - term administration of UFT", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "10688731_3_Ent4", "text": "UFT", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "10698143_2", "wnd_id": "10698143_2_1", "text": "Ibuprofen overdose is usually characterized by GI upset , dizziness , and mild sedation .", "tokens": ["Ibuprofen", "overdose", "is", "usually", "characterized", "by", "GI", "upset", ",", "dizziness", ",", "and", "mild", "sedation", "."], "event_mentions": [{"id": "10698143_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "characterized", "start": 4, "end": 5}, "arguments": [{"entity_id": "10698143_2_Ent2", "role": "Treatment_Drug", "text": "Ibuprofen", "start": 0, "end": 1}, {"entity_id": "10698143_2_Ent1", "role": "Treatment", "text": "Ibuprofen overdose", "start": 0, "end": 2}, {"entity_id": "10698143_2_Ent3", "role": "Treatment_Dosage", "text": "overdose", "start": 1, "end": 2}, {"entity_id": "10698143_2_Ent0", "role": "Effect", "text": "GI upset , dizziness , and mild sedation", "start": 6, "end": 14}]}], "entity_mentions": [{"id": "10698143_2_Ent2", "text": "Ibuprofen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10698143_2_Ent1", "text": "Ibuprofen overdose", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10698143_2_Ent3", "text": "overdose", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10698143_2_Ent0", "text": "GI upset , dizziness , and mild sedation", "entity_type": "Entity", "start": 6, "end": 14}], "lang": "en"}
{"doc_id": "10698143_4", "wnd_id": "10698143_4_1", "text": "We report the case of an 11 - month - old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone .", "tokens": ["We", "report", "the", "case", "of", "an", "11", "-", "month", "-", "old", "female", "infant", "with", "a", "depressed", "level", "of", "consciousness", "after", "ingestion", "of", "ibuprofen", "whose", "mental", "status", "markedly", "improved", "with", "administration", "of", "naloxone", "."], "event_mentions": [{"id": "10698143_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 19, "end": 20}, "arguments": [{"entity_id": "10698143_4_Ent0", "role": "Subject", "text": "an 11 - month - old female infant", "start": 5, "end": 13}, {"entity_id": "10698143_4_Ent1", "role": "Subject_Age", "text": "11 - month - old", "start": 6, "end": 11}, {"entity_id": "10698143_4_Ent3", "role": "Subject_Gender", "text": "female", "start": 11, "end": 12}, {"entity_id": "10698143_4_Ent2", "role": "Subject_Age", "text": "infant", "start": 12, "end": 13}, {"entity_id": "10698143_4_Ent4", "role": "Effect", "text": "a depressed level of consciousness", "start": 14, "end": 19}, {"entity_id": "10698143_4_Ent7", "role": "Treatment_Route", "text": "ingestion", "start": 20, "end": 21}, {"entity_id": "10698143_4_Ent5", "role": "Treatment", "text": "ingestion of ibuprofen", "start": 20, "end": 23}, {"entity_id": "10698143_4_Ent6", "role": "Treatment_Drug", "text": "ibuprofen", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "10698143_4_Ent0", "text": "an 11 - month - old female infant", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "10698143_4_Ent1", "text": "11 - month - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "10698143_4_Ent3", "text": "female", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10698143_4_Ent2", "text": "infant", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10698143_4_Ent4", "text": "a depressed level of consciousness", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "10698143_4_Ent7", "text": "ingestion", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10698143_4_Ent5", "text": "ingestion of ibuprofen", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "10698143_4_Ent6", "text": "ibuprofen", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "10715308_12", "wnd_id": "10715308_12_1", "text": "The CATAPULT I study shows that tirapazamine enhances the activity of cisplatin in patients with advanced NSCLC and confirms that hypoxia is an exploitable therapeutic target in human malignancies .", "tokens": ["The", "CATAPULT", "I", "study", "shows", "that", "tirapazamine", "enhances", "the", "activity", "of", "cisplatin", "in", "patients", "with", "advanced", "NSCLC", "and", "confirms", "that", "hypoxia", "is", "an", "exploitable", "therapeutic", "target", "in", "human", "malignancies", "."], "event_mentions": [{"id": "10715308_12_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "enhances", "start": 7, "end": 8}, "arguments": [{"entity_id": "10715308_12_Ent2", "role": "Treatment", "text": "tirapazamine", "start": 6, "end": 7}, {"entity_id": "10715308_12_Ent3", "role": "Treatment_Drug", "text": "tirapazamine", "start": 6, "end": 7}, {"entity_id": "10715308_12_Ent1", "role": "Effect", "text": "enhances the activity of cisplatin", "start": 7, "end": 12}, {"entity_id": "10715308_12_Ent0", "role": "Subject", "text": "patients with advanced NSCLC", "start": 13, "end": 17}, {"entity_id": "10715308_12_Ent4", "role": "Treatment_Disorder", "text": "advanced NSCLC", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "10715308_12_Ent2", "text": "tirapazamine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10715308_12_Ent3", "text": "tirapazamine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10715308_12_Ent1", "text": "enhances the activity of cisplatin", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "10715308_12_Ent0", "text": "patients with advanced NSCLC", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "10715308_12_Ent4", "text": "advanced NSCLC", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "10732843_5", "wnd_id": "10732843_5_1", "text": "In this case , it was suspected that a combination of cigarette smoking , pulmonary fibrosis , and low - dose methotrexate therapy might have promoted the development of lung cancer .", "tokens": ["In", "this", "case", ",", "it", "was", "suspected", "that", "a", "combination", "of", "cigarette", "smoking", ",", "pulmonary", "fibrosis", ",", "and", "low", "-", "dose", "methotrexate", "therapy", "might", "have", "promoted", "the", "development", "of", "lung", "cancer", "."], "event_mentions": [{"id": "10732843_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "promoted", "start": 25, "end": 26}, "arguments": [{"entity_id": "10732843_5_Ent0", "role": "Subject", "text": "pulmonary fibrosis", "start": 14, "end": 16}, {"entity_id": "10732843_5_Ent1", "role": "Subject_Disorder", "text": "pulmonary fibrosis", "start": 14, "end": 16}, {"entity_id": "10732843_5_Ent4", "role": "Treatment_Dosage", "text": "low - dose", "start": 18, "end": 21}, {"entity_id": "10732843_5_Ent3", "role": "Treatment", "text": "low - dose methotrexate therapy", "start": 18, "end": 23}, {"entity_id": "10732843_5_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 21, "end": 22}, {"entity_id": "10732843_5_Ent2", "role": "Effect", "text": "the development of lung cancer", "start": 26, "end": 31}]}], "entity_mentions": [{"id": "10732843_5_Ent0", "text": "pulmonary fibrosis", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "10732843_5_Ent1", "text": "pulmonary fibrosis", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "10732843_5_Ent4", "text": "low - dose", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "10732843_5_Ent3", "text": "low - dose methotrexate therapy", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "10732843_5_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10732843_5_Ent2", "text": "the development of lung cancer", "entity_type": "Entity", "start": 26, "end": 31}], "lang": "en"}
{"doc_id": "10749332_2", "wnd_id": "10749332_2_1", "text": "It remains to be seen whether the hepatotoxicity associated with troglitazone is a drug - class effect or specific to troglitazone .", "tokens": ["It", "remains", "to", "be", "seen", "whether", "the", "hepatotoxicity", "associated", "with", "troglitazone", "is", "a", "drug", "-", "class", "effect", "or", "specific", "to", "troglitazone", "."], "event_mentions": [{"id": "10749332_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "10749332_2_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 7, "end": 8}, {"entity_id": "10749332_2_Ent1", "role": "Treatment", "text": "troglitazone", "start": 10, "end": 11}, {"entity_id": "10749332_2_Ent2", "role": "Treatment_Drug", "text": "troglitazone", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "10749332_2_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10749332_2_Ent1", "text": "troglitazone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10749332_2_Ent2", "text": "troglitazone", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "10749332_4", "wnd_id": "10749332_4_1", "text": "The three reported cases demonstrate that troglitazone is an idiosyncratic hepatotoxin that can lead to irreversible liver injury .", "tokens": ["The", "three", "reported", "cases", "demonstrate", "that", "troglitazone", "is", "an", "idiosyncratic", "hepatotoxin", "that", "can", "lead", "to", "irreversible", "liver", "injury", "."], "event_mentions": [{"id": "10749332_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 13, "end": 14}, "arguments": [{"entity_id": "10749332_4_Ent1", "role": "Subject_Population", "text": "three", "start": 1, "end": 2}, {"entity_id": "10749332_4_Ent0", "role": "Subject", "text": "three reported cases", "start": 1, "end": 4}, {"entity_id": "10749332_4_Ent3", "role": "Treatment", "text": "troglitazone", "start": 6, "end": 7}, {"entity_id": "10749332_4_Ent4", "role": "Treatment_Drug", "text": "troglitazone", "start": 6, "end": 7}, {"entity_id": "10749332_4_Ent2", "role": "Effect", "text": "irreversible liver injury", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "10749332_4_Ent1", "text": "three", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10749332_4_Ent0", "text": "three reported cases", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "10749332_4_Ent3", "text": "troglitazone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10749332_4_Ent4", "text": "troglitazone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10749332_4_Ent2", "text": "irreversible liver injury", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "10755579_3", "wnd_id": "10755579_3_1", "text": "This is the first report of a fluoxetine - related death in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism .", "tokens": ["This", "is", "the", "first", "report", "of", "a", "fluoxetine", "-", "related", "death", "in", "a", "child", "with", "a", "confirmed", "genetic", "polymorphism", "of", "the", "CYP2D6", "gene", "that", "results", "in", "impaired", "drug", "metabolism", "."], "event_mentions": [{"id": "10755579_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 9, "end": 10}, "arguments": [{"entity_id": "10755579_3_Ent4", "role": "Treatment", "text": "fluoxetine", "start": 7, "end": 8}, {"entity_id": "10755579_3_Ent5", "role": "Treatment_Drug", "text": "fluoxetine", "start": 7, "end": 8}, {"entity_id": "10755579_3_Ent3", "role": "Effect", "text": "death", "start": 10, "end": 11}, {"entity_id": "10755579_3_Ent0", "role": "Subject", "text": "a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism", "start": 12, "end": 29}, {"entity_id": "10755579_3_Ent1", "role": "Subject_Age", "text": "child", "start": 13, "end": 14}, {"entity_id": "10755579_3_Ent2", "role": "Subject_Disorder", "text": "genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism", "start": 17, "end": 29}]}], "entity_mentions": [{"id": "10755579_3_Ent4", "text": "fluoxetine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10755579_3_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10755579_3_Ent3", "text": "death", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10755579_3_Ent0", "text": "a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism", "entity_type": "Entity", "start": 12, "end": 29}, {"id": "10755579_3_Ent1", "text": "child", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10755579_3_Ent2", "text": "genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism", "entity_type": "Entity", "start": 17, "end": 29}], "lang": "en"}
{"doc_id": "10759907_1", "wnd_id": "10759907_1_1", "text": "A 50 - year - old woman with a history of migraine without aura , predominantly occurring around her menstrual periods , developed a spinal cord lesion following the use of zolmitriptan .", "tokens": ["A", "50", "-", "year", "-", "old", "woman", "with", "a", "history", "of", "migraine", "without", "aura", ",", "predominantly", "occurring", "around", "her", "menstrual", "periods", ",", "developed", "a", "spinal", "cord", "lesion", "following", "the", "use", "of", "zolmitriptan", "."], "event_mentions": [{"id": "10759907_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 22, "end": 23}, "arguments": [{"entity_id": "10759907_1_Ent0", "role": "Subject", "text": "A 50 - year - old woman with a history of migraine without aura , predominantly occurring around her menstrual periods", "start": 0, "end": 21}, {"entity_id": "10759907_1_Ent1", "role": "Subject_Age", "text": "50 - year - old", "start": 1, "end": 6}, {"entity_id": "10759907_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "10759907_1_Ent6", "role": "Treatment_Disorder", "text": "migraine without aura", "start": 11, "end": 14}, {"entity_id": "10759907_1_Ent3", "role": "Effect", "text": "a spinal cord lesion", "start": 23, "end": 27}, {"entity_id": "10759907_1_Ent4", "role": "Treatment", "text": "zolmitriptan", "start": 31, "end": 32}, {"entity_id": "10759907_1_Ent5", "role": "Treatment_Drug", "text": "zolmitriptan", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "10759907_1_Ent0", "text": "A 50 - year - old woman with a history of migraine without aura , predominantly occurring around her menstrual periods", "entity_type": "Entity", "start": 0, "end": 21}, {"id": "10759907_1_Ent1", "text": "50 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10759907_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10759907_1_Ent6", "text": "migraine without aura", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "10759907_1_Ent3", "text": "a spinal cord lesion", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "10759907_1_Ent4", "text": "zolmitriptan", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "10759907_1_Ent5", "text": "zolmitriptan", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "10759907_3", "wnd_id": "10759907_3_1", "text": "The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan .", "tokens": ["The", "temporal", "relationship", "suggests", "that", "the", "spinal", "cord", "infarction", "may", "be", "related", "to", "the", "use", "of", "zolmitriptan", "."], "event_mentions": [{"id": "10759907_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 11, "end": 12}, "arguments": [{"entity_id": "10759907_3_Ent0", "role": "Effect", "text": "spinal cord infarction", "start": 6, "end": 9}, {"entity_id": "10759907_3_Ent1", "role": "Treatment", "text": "zolmitriptan", "start": 16, "end": 17}, {"entity_id": "10759907_3_Ent2", "role": "Treatment_Drug", "text": "zolmitriptan", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "10759907_3_Ent0", "text": "spinal cord infarction", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "10759907_3_Ent1", "text": "zolmitriptan", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10759907_3_Ent2", "text": "zolmitriptan", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "10779995_2", "wnd_id": "10779995_2_1", "text": "Secondary leukemia in a child with neuroblastoma while on oral etoposide : what is the cause ?", "tokens": ["Secondary", "leukemia", "in", "a", "child", "with", "neuroblastoma", "while", "on", "oral", "etoposide", ":", "what", "is", "the", "cause", "?"], "event_mentions": [{"id": "10779995_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "10779995_2_Ent2", "role": "Effect", "text": "Secondary leukemia", "start": 0, "end": 2}, {"entity_id": "10779995_2_Ent0", "role": "Subject", "text": "a child with neuroblastoma", "start": 3, "end": 7}, {"entity_id": "10779995_2_Ent1", "role": "Subject_Age", "text": "child", "start": 4, "end": 5}, {"entity_id": "10779995_2_Ent4", "role": "Treatment_Disorder", "text": "neuroblastoma", "start": 6, "end": 7}, {"entity_id": "10779995_2_Ent5", "role": "Treatment_Route", "text": "oral", "start": 9, "end": 10}, {"entity_id": "10779995_2_Ent3", "role": "Treatment", "text": "oral etoposide", "start": 9, "end": 11}, {"entity_id": "10779995_2_Ent6", "role": "Treatment_Drug", "text": "etoposide", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "10779995_2_Ent2", "text": "Secondary leukemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10779995_2_Ent0", "text": "a child with neuroblastoma", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "10779995_2_Ent1", "text": "child", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10779995_2_Ent4", "text": "neuroblastoma", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10779995_2_Ent5", "text": "oral", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10779995_2_Ent3", "text": "oral etoposide", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10779995_2_Ent6", "text": "etoposide", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "10803790_1", "wnd_id": "10803790_1_1", "text": "BACKGROUND : Cyanamide , an aversive agent widely used in Japan , is known to induce various degrees of hepatic lesion with ground - glass inclusion bodies .", "tokens": ["BACKGROUND", ":", "Cyanamide", ",", "an", "aversive", "agent", "widely", "used", "in", "Japan", ",", "is", "known", "to", "induce", "various", "degrees", "of", "hepatic", "lesion", "with", "ground", "-", "glass", "inclusion", "bodies", "."], "event_mentions": [{"id": "10803790_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 15, "end": 16}, "arguments": [{"entity_id": "10803790_1_Ent1", "role": "Treatment", "text": "Cyanamide", "start": 2, "end": 3}, {"entity_id": "10803790_1_Ent2", "role": "Treatment_Drug", "text": "Cyanamide", "start": 2, "end": 3}, {"entity_id": "10803790_1_Ent0", "role": "Effect", "text": "various degrees of hepatic lesion with ground - glass inclusion bodies", "start": 16, "end": 27}]}], "entity_mentions": [{"id": "10803790_1_Ent1", "text": "Cyanamide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10803790_1_Ent2", "text": "Cyanamide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10803790_1_Ent0", "text": "various degrees of hepatic lesion with ground - glass inclusion bodies", "entity_type": "Entity", "start": 16, "end": 27}], "lang": "en"}
{"doc_id": "10803790_7", "wnd_id": "10803790_7_1", "text": "When cyanamide - treated alcoholics relapse into drinking , more severe inflammation develops in the liver .", "tokens": ["When", "cyanamide", "-", "treated", "alcoholics", "relapse", "into", "drinking", ",", "more", "severe", "inflammation", "develops", "in", "the", "liver", "."], "event_mentions": [{"id": "10803790_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develops", "start": 12, "end": 13}, "arguments": [{"entity_id": "10803790_7_Ent2", "role": "Treatment", "text": "cyanamide", "start": 1, "end": 2}, {"entity_id": "10803790_7_Ent3", "role": "Treatment_Drug", "text": "cyanamide", "start": 1, "end": 2}, {"entity_id": "10803790_7_Ent0", "role": "Subject", "text": "cyanamide - treated alcoholics", "start": 1, "end": 5}, {"entity_id": "10803790_7_Ent4", "role": "Treatment_Disorder", "text": "alcoholics", "start": 4, "end": 5}, {"entity_id": "10803790_7_Ent1", "role": "Effect", "text": "inflammation", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "10803790_7_Ent2", "text": "cyanamide", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10803790_7_Ent3", "text": "cyanamide", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10803790_7_Ent0", "text": "cyanamide - treated alcoholics", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "10803790_7_Ent4", "text": "alcoholics", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10803790_7_Ent1", "text": "inflammation", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "10885900_1", "wnd_id": "10885900_1_1", "text": "HUS has been reported after several anticancer chemotherapies and most often after mitomycin C - based chemotherapy regimens .", "tokens": ["HUS", "has", "been", "reported", "after", "several", "anticancer", "chemotherapies", "and", "most", "often", "after", "mitomycin", "C", "-", "based", "chemotherapy", "regimens", "."], "event_mentions": [{"id": "10885900_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 3, "end": 4}, "arguments": [{"entity_id": "10885900_1_Ent0", "role": "Effect", "text": "HUS", "start": 0, "end": 1}, {"entity_id": "10885900_1_Ent1", "role": "Treatment", "text": "several anticancer chemotherapies and most often after mitomycin C - based chemotherapy regimens", "start": 5, "end": 18}, {"entity_id": "10885900_1_Ent2", "role": "Treatment_Drug", "text": "mitomycin C", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "10885900_1_Ent0", "text": "HUS", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10885900_1_Ent1", "text": "several anticancer chemotherapies and most often after mitomycin C - based chemotherapy regimens", "entity_type": "Entity", "start": 5, "end": 18}, {"id": "10885900_1_Ent2", "text": "mitomycin C", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "10885900_2", "wnd_id": "10885900_2_1", "text": "Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine .", "tokens": ["Severe", "hemolytic", "uremic", "syndrome", "in", "an", "advanced", "ovarian", "cancer", "patient", "treated", "with", "carboplatin", "and", "gemcitabine", "."], "event_mentions": [{"id": "10885900_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 4, "end": 5}, "arguments": [{"entity_id": "10885900_2_Ent1", "role": "Effect", "text": "Severe hemolytic uremic syndrome", "start": 0, "end": 4}, {"entity_id": "10885900_2_Ent0", "role": "Subject", "text": "an advanced ovarian cancer patient", "start": 5, "end": 10}, {"entity_id": "10885900_2_Ent3", "role": "Treatment_Disorder", "text": "ovarian cancer", "start": 7, "end": 9}, {"entity_id": "10885900_2_Ent4", "role": "Treatment_Drug", "text": "carboplatin", "start": 12, "end": 13}, {"entity_id": "10885900_2_Ent6", "role": "Combination_Drug", "text": "carboplatin", "start": 12, "end": 13}, {"entity_id": "10885900_2_Ent2", "role": "Treatment", "text": "carboplatin and gemcitabine", "start": 12, "end": 15}, {"entity_id": "10885900_2_Ent5", "role": "Treatment_Drug", "text": "gemcitabine", "start": 14, "end": 15}, {"entity_id": "10885900_2_Ent7", "role": "Combination_Drug", "text": "gemcitabine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "10885900_2_Ent1", "text": "Severe hemolytic uremic syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10885900_2_Ent0", "text": "an advanced ovarian cancer patient", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "10885900_2_Ent3", "text": "ovarian cancer", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "10885900_2_Ent4", "text": "carboplatin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10885900_2_Ent6", "text": "carboplatin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10885900_2_Ent2", "text": "carboplatin and gemcitabine", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10885900_2_Ent5", "text": "gemcitabine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "10885900_2_Ent7", "text": "gemcitabine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "10904571_2", "wnd_id": "10904571_2_1", "text": "Colchicine - induced myopathy in renal failure .", "tokens": ["Colchicine", "-", "induced", "myopathy", "in", "renal", "failure", "."], "event_mentions": [{"id": "10904571_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "10904571_2_Ent1", "role": "Treatment", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "10904571_2_Ent2", "role": "Treatment_Drug", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "10904571_2_Ent0", "role": "Effect", "text": "myopathy", "start": 3, "end": 4}, {"entity_id": "10904571_2_Ent3", "role": "Treatment_Disorder", "text": "renal failure", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "10904571_2_Ent1", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10904571_2_Ent2", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10904571_2_Ent0", "text": "myopathy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10904571_2_Ent3", "text": "renal failure", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "10907391_2", "wnd_id": "10907391_2_1", "text": "Phantom limb pain as a manifestation of paclitaxel neurotoxicity .", "tokens": ["Phantom", "limb", "pain", "as", "a", "manifestation", "of", "paclitaxel", "neurotoxicity", "."], "event_mentions": [{"id": "10907391_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifestation", "start": 5, "end": 6}, "arguments": [{"entity_id": "10907391_2_Ent0", "role": "Effect", "text": "Phantom limb pain", "start": 0, "end": 3}, {"entity_id": "10907391_2_Ent1", "role": "Treatment", "text": "paclitaxel", "start": 7, "end": 8}, {"entity_id": "10907391_2_Ent2", "role": "Treatment_Drug", "text": "paclitaxel", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "10907391_2_Ent0", "text": "Phantom limb pain", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "10907391_2_Ent1", "text": "paclitaxel", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10907391_2_Ent2", "text": "paclitaxel", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "10928688_1", "wnd_id": "10928688_1_1", "text": "Our experience supports hemodialysis for ESRF patients with atenolol toxicity .", "tokens": ["Our", "experience", "supports", "hemodialysis", "for", "ESRF", "patients", "with", "atenolol", "toxicity", "."], "event_mentions": [{"id": "10928688_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 4, "end": 5}, "arguments": [{"entity_id": "10928688_1_Ent2", "role": "Treatment", "text": "hemodialysis", "start": 3, "end": 4}, {"entity_id": "10928688_1_Ent3", "role": "Treatment_Drug", "text": "hemodialysis", "start": 3, "end": 4}, {"entity_id": "10928688_1_Ent1", "role": "Subject_Disorder", "text": "ESRF", "start": 5, "end": 6}, {"entity_id": "10928688_1_Ent0", "role": "Subject", "text": "ESRF patients with atenolol toxicity", "start": 5, "end": 10}, {"entity_id": "10928688_1_Ent4", "role": "Treatment_Disorder", "text": "atenolol toxicity", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "10928688_1_Ent2", "text": "hemodialysis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10928688_1_Ent3", "text": "hemodialysis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10928688_1_Ent1", "text": "ESRF", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10928688_1_Ent0", "text": "ESRF patients with atenolol toxicity", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "10928688_1_Ent4", "text": "atenolol toxicity", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "10970989_2", "wnd_id": "10970989_2_1", "text": "We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine .", "tokens": ["We", "present", "an", "AIDS", "patient", "with", "severe", "and", "prolonged", "lactic", "acidosis", "on", "stavudine", "and", "lamivudine", "."], "event_mentions": [{"id": "10970989_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "present", "start": 1, "end": 2}, "arguments": [{"entity_id": "10970989_2_Ent0", "role": "Subject", "text": "an AIDS patient", "start": 2, "end": 5}, {"entity_id": "10970989_2_Ent3", "role": "Treatment_Disorder", "text": "AIDS", "start": 3, "end": 4}, {"entity_id": "10970989_2_Ent1", "role": "Effect", "text": "severe and prolonged lactic acidosis", "start": 6, "end": 11}, {"entity_id": "10970989_2_Ent4", "role": "Treatment_Drug", "text": "stavudine", "start": 12, "end": 13}, {"entity_id": "10970989_2_Ent6", "role": "Combination_Drug", "text": "stavudine", "start": 12, "end": 13}, {"entity_id": "10970989_2_Ent2", "role": "Treatment", "text": "stavudine and lamivudine", "start": 12, "end": 15}, {"entity_id": "10970989_2_Ent5", "role": "Treatment_Drug", "text": "lamivudine", "start": 14, "end": 15}, {"entity_id": "10970989_2_Ent7", "role": "Combination_Drug", "text": "lamivudine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "10970989_2_Ent0", "text": "an AIDS patient", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "10970989_2_Ent3", "text": "AIDS", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10970989_2_Ent1", "text": "severe and prolonged lactic acidosis", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "10970989_2_Ent4", "text": "stavudine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10970989_2_Ent6", "text": "stavudine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10970989_2_Ent2", "text": "stavudine and lamivudine", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10970989_2_Ent5", "text": "lamivudine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "10970989_2_Ent7", "text": "lamivudine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "10981493_1", "wnd_id": "10981493_1_1", "text": "Ataxia caused by propafenone has been reported to the pharmaceutical companies and drug monitoring agencies , but has not been well described or emphasized in the medical literature .", "tokens": ["Ataxia", "caused", "by", "propafenone", "has", "been", "reported", "to", "the", "pharmaceutical", "companies", "and", "drug", "monitoring", "agencies", ",", "but", "has", "not", "been", "well", "described", "or", "emphasized", "in", "the", "medical", "literature", "."], "event_mentions": [{"id": "10981493_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 1, "end": 2}, "arguments": [{"entity_id": "10981493_1_Ent0", "role": "Effect", "text": "Ataxia", "start": 0, "end": 1}, {"entity_id": "10981493_1_Ent1", "role": "Treatment", "text": "propafenone", "start": 3, "end": 4}, {"entity_id": "10981493_1_Ent2", "role": "Treatment_Drug", "text": "propafenone", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "10981493_1_Ent0", "text": "Ataxia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10981493_1_Ent1", "text": "propafenone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10981493_1_Ent2", "text": "propafenone", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "10981493_4", "wnd_id": "10981493_4_1", "text": "We describe 3 elderly patients with moderate to severe ataxia that occurred while they were taking propafenone .", "tokens": ["We", "describe", "3", "elderly", "patients", "with", "moderate", "to", "severe", "ataxia", "that", "occurred", "while", "they", "were", "taking", "propafenone", "."], "event_mentions": [{"id": "10981493_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 11, "end": 12}, "arguments": [{"entity_id": "10981493_4_Ent2", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "10981493_4_Ent0", "role": "Subject", "text": "3 elderly patients", "start": 2, "end": 5}, {"entity_id": "10981493_4_Ent1", "role": "Subject_Age", "text": "elderly", "start": 3, "end": 4}, {"entity_id": "10981493_4_Ent3", "role": "Effect", "text": "moderate to severe ataxia", "start": 6, "end": 10}, {"entity_id": "10981493_4_Ent4", "role": "Treatment", "text": "taking propafenone", "start": 15, "end": 17}, {"entity_id": "10981493_4_Ent5", "role": "Treatment_Drug", "text": "propafenone", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "10981493_4_Ent2", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10981493_4_Ent0", "text": "3 elderly patients", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "10981493_4_Ent1", "text": "elderly", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10981493_4_Ent3", "text": "moderate to severe ataxia", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "10981493_4_Ent4", "text": "taking propafenone", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "10981493_4_Ent5", "text": "propafenone", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "10987357_2", "wnd_id": "10987357_2_1", "text": "A 74 - year - old man received oral administration of pilsicainide , a pure sodium channel blocker with slow recovery kinetics , to convert paroxysmal atrial fibrillation to sinus rhythm and developed loss of consciousness two days later .", "tokens": ["A", "74", "-", "year", "-", "old", "man", "received", "oral", "administration", "of", "pilsicainide", ",", "a", "pure", "sodium", "channel", "blocker", "with", "slow", "recovery", "kinetics", ",", "to", "convert", "paroxysmal", "atrial", "fibrillation", "to", "sinus", "rhythm", "and", "developed", "loss", "of", "consciousness", "two", "days", "later", "."], "event_mentions": [{"id": "10987357_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 32, "end": 33}, "arguments": [{"entity_id": "10987357_2_Ent0", "role": "Subject", "text": "A 74 - year - old man", "start": 0, "end": 7}, {"entity_id": "10987357_2_Ent1", "role": "Subject_Age", "text": "74 - year - old", "start": 1, "end": 6}, {"entity_id": "10987357_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "10987357_2_Ent6", "role": "Treatment_Route", "text": "oral", "start": 8, "end": 9}, {"entity_id": "10987357_2_Ent4", "role": "Treatment", "text": "oral administration of pilsicainide", "start": 8, "end": 12}, {"entity_id": "10987357_2_Ent7", "role": "Treatment_Drug", "text": "pilsicainide", "start": 11, "end": 12}, {"entity_id": "10987357_2_Ent8", "role": "Treatment_Disorder", "text": "paroxysmal atrial fibrillation", "start": 25, "end": 28}, {"entity_id": "10987357_2_Ent3", "role": "Effect", "text": "loss of consciousness", "start": 33, "end": 36}, {"entity_id": "10987357_2_Ent5", "role": "Treatment", "text": "two days later", "start": 36, "end": 39}, {"entity_id": "10987357_2_Ent9", "role": "Treatment_Time_elapsed", "text": "two days later", "start": 36, "end": 39}]}], "entity_mentions": [{"id": "10987357_2_Ent0", "text": "A 74 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "10987357_2_Ent1", "text": "74 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10987357_2_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10987357_2_Ent6", "text": "oral", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10987357_2_Ent4", "text": "oral administration of pilsicainide", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "10987357_2_Ent7", "text": "pilsicainide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10987357_2_Ent8", "text": "paroxysmal atrial fibrillation", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "10987357_2_Ent3", "text": "loss of consciousness", "entity_type": "Entity", "start": 33, "end": 36}, {"id": "10987357_2_Ent5", "text": "two days later", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "10987357_2_Ent9", "text": "two days later", "entity_type": "Entity", "start": 36, "end": 39}], "lang": "en"}
{"doc_id": "11008259_1", "wnd_id": "11008259_1_1", "text": "Provocation of non - convulsive status epilepticus by tiagabine in three adolescent patients .", "tokens": ["Provocation", "of", "non", "-", "convulsive", "status", "epilepticus", "by", "tiagabine", "in", "three", "adolescent", "patients", "."], "event_mentions": [{"id": "11008259_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Provocation", "start": 0, "end": 1}, "arguments": [{"entity_id": "11008259_1_Ent3", "role": "Effect", "text": "non - convulsive status epilepticus", "start": 2, "end": 7}, {"entity_id": "11008259_1_Ent4", "role": "Treatment", "text": "tiagabine", "start": 8, "end": 9}, {"entity_id": "11008259_1_Ent5", "role": "Treatment_Drug", "text": "tiagabine", "start": 8, "end": 9}, {"entity_id": "11008259_1_Ent1", "role": "Subject_Population", "text": "three", "start": 10, "end": 11}, {"entity_id": "11008259_1_Ent0", "role": "Subject", "text": "three adolescent patients", "start": 10, "end": 13}, {"entity_id": "11008259_1_Ent2", "role": "Subject_Age", "text": "adolescent", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11008259_1_Ent3", "text": "non - convulsive status epilepticus", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "11008259_1_Ent4", "text": "tiagabine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11008259_1_Ent5", "text": "tiagabine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11008259_1_Ent1", "text": "three", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11008259_1_Ent0", "text": "three adolescent patients", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "11008259_1_Ent2", "text": "adolescent", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11008259_2", "wnd_id": "11008259_2_1", "text": "The events of non - convulsive status epilepticus subsided following reduction in tiagabine dosages .", "tokens": ["The", "events", "of", "non", "-", "convulsive", "status", "epilepticus", "subsided", "following", "reduction", "in", "tiagabine", "dosages", "."], "event_mentions": [{"id": "11008259_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "11008259_2_Ent0", "role": "Effect", "text": "non - convulsive status epilepticus subsided", "start": 3, "end": 9}, {"entity_id": "11008259_2_Ent1", "role": "Treatment", "text": "reduction in tiagabine dosages", "start": 10, "end": 14}, {"entity_id": "11008259_2_Ent2", "role": "Treatment_Drug", "text": "tiagabine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "11008259_2_Ent0", "text": "non - convulsive status epilepticus subsided", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "11008259_2_Ent1", "text": "reduction in tiagabine dosages", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "11008259_2_Ent2", "text": "tiagabine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "110153_1", "wnd_id": "110153_1_1", "text": "There have been many reports of probable lithium - induced organic brain syndromes occurring when serum lithium levels are within or close to the therapeutic range .", "tokens": ["There", "have", "been", "many", "reports", "of", "probable", "lithium", "-", "induced", "organic", "brain", "syndromes", "occurring", "when", "serum", "lithium", "levels", "are", "within", "or", "close", "to", "the", "therapeutic", "range", "."], "event_mentions": [{"id": "110153_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "110153_1_Ent1", "role": "Treatment", "text": "lithium", "start": 7, "end": 8}, {"entity_id": "110153_1_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 7, "end": 8}, {"entity_id": "110153_1_Ent0", "role": "Effect", "text": "organic brain syndromes", "start": 10, "end": 13}, {"entity_id": "110153_1_Ent2", "role": "Treatment", "text": "when serum lithium levels are within or close to the therapeutic range", "start": 14, "end": 26}]}], "entity_mentions": [{"id": "110153_1_Ent1", "text": "lithium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "110153_1_Ent3", "text": "lithium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "110153_1_Ent0", "text": "organic brain syndromes", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "110153_1_Ent2", "text": "when serum lithium levels are within or close to the therapeutic range", "entity_type": "Entity", "start": 14, "end": 26}], "lang": "en"}
{"doc_id": "11020127_4", "wnd_id": "11020127_4_1", "text": "The patient was diagnosed with carbamazepine toxicity related to the introduction of ritonavir .", "tokens": ["The", "patient", "was", "diagnosed", "with", "carbamazepine", "toxicity", "related", "to", "the", "introduction", "of", "ritonavir", "."], "event_mentions": [{"id": "11020127_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 7, "end": 8}, "arguments": [{"entity_id": "11020127_4_Ent0", "role": "Subject", "text": "patient", "start": 1, "end": 2}, {"entity_id": "11020127_4_Ent1", "role": "Effect", "text": "carbamazepine toxicity", "start": 5, "end": 7}, {"entity_id": "11020127_4_Ent2", "role": "Treatment", "text": "ritonavir", "start": 12, "end": 13}, {"entity_id": "11020127_4_Ent3", "role": "Treatment_Drug", "text": "ritonavir", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "11020127_4_Ent0", "text": "patient", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11020127_4_Ent1", "text": "carbamazepine toxicity", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11020127_4_Ent2", "text": "ritonavir", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11020127_4_Ent3", "text": "ritonavir", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "11022272_3", "wnd_id": "11022272_3_1", "text": "The intramuscular challenge test with 25 UI of Miacalcic was positive with an immediate anaphylactic reaction .", "tokens": ["The", "intramuscular", "challenge", "test", "with", "25", "UI", "of", "Miacalcic", "was", "positive", "with", "an", "immediate", "anaphylactic", "reaction", "."], "event_mentions": [{"id": "11022272_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reaction", "start": 15, "end": 16}, "arguments": [{"entity_id": "11022272_3_Ent4", "role": "Treatment_Dosage", "text": "25 UI", "start": 5, "end": 7}, {"entity_id": "11022272_3_Ent1", "role": "Treatment", "text": "25 UI of Miacalcic", "start": 5, "end": 9}, {"entity_id": "11022272_3_Ent3", "role": "Treatment_Drug", "text": "Miacalcic", "start": 8, "end": 9}, {"entity_id": "11022272_3_Ent2", "role": "Treatment", "text": "immediate", "start": 13, "end": 14}, {"entity_id": "11022272_3_Ent5", "role": "Treatment_Time_elapsed", "text": "immediate", "start": 13, "end": 14}, {"entity_id": "11022272_3_Ent0", "role": "Effect", "text": "anaphylactic reaction", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "11022272_3_Ent4", "text": "25 UI", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11022272_3_Ent1", "text": "25 UI of Miacalcic", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "11022272_3_Ent3", "text": "Miacalcic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11022272_3_Ent2", "text": "immediate", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11022272_3_Ent5", "text": "immediate", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11022272_3_Ent0", "text": "anaphylactic reaction", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "11026106_1", "wnd_id": "11026106_1_1", "text": "Minocycline as a cause of drug - induced autoimmune hepatitis .", "tokens": ["Minocycline", "as", "a", "cause", "of", "drug", "-", "induced", "autoimmune", "hepatitis", "."], "event_mentions": [{"id": "11026106_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "11026106_1_Ent1", "role": "Treatment", "text": "Minocycline", "start": 0, "end": 1}, {"entity_id": "11026106_1_Ent2", "role": "Treatment_Drug", "text": "Minocycline", "start": 0, "end": 1}, {"entity_id": "11026106_1_Ent0", "role": "Effect", "text": "autoimmune hepatitis", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "11026106_1_Ent1", "text": "Minocycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11026106_1_Ent2", "text": "Minocycline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11026106_1_Ent0", "text": "autoimmune hepatitis", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "11030530_1", "wnd_id": "11030530_1_1", "text": "L - asparaginase - provoked seizures as singular expression of central nervous toxicity .", "tokens": ["L", "-", "asparaginase", "-", "provoked", "seizures", "as", "singular", "expression", "of", "central", "nervous", "toxicity", "."], "event_mentions": [{"id": "11030530_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoked", "start": 4, "end": 5}, "arguments": [{"entity_id": "11030530_1_Ent1", "role": "Treatment", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "11030530_1_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "11030530_1_Ent0", "role": "Effect", "text": "seizures as singular expression of central nervous toxicity", "start": 5, "end": 13}]}], "entity_mentions": [{"id": "11030530_1_Ent1", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11030530_1_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11030530_1_Ent0", "text": "seizures as singular expression of central nervous toxicity", "entity_type": "Entity", "start": 5, "end": 13}], "lang": "en"}
{"doc_id": "11033836_2", "wnd_id": "11033836_2_1", "text": "Placebo - controlled clinical trials of recombinant human interleukin - 11 ( rhIL - 11 , also known as oprelvekin [ Neumega ] ) in patients with nonmyeloid malignancies have demonstrated significant efficacy in preventing postchemotherapy platelet nadirs of < or = 20,000/microL , and reducing the need for platelet transfusions while continuing chemotherapy without dose reductions .", "tokens": ["Placebo", "-", "controlled", "clinical", "trials", "of", "recombinant", "human", "interleukin", "-", "11", "(", "rhIL", "-", "11", ",", "also", "known", "as", "oprelvekin", "[", "Neumega", "]", ")", "in", "patients", "with", "nonmyeloid", "malignancies", "have", "demonstrated", "significant", "efficacy", "in", "preventing", "postchemotherapy", "platelet", "nadirs", "of", "<", "or", "=", "20,000/microL", ",", "and", "reducing", "the", "need", "for", "platelet", "transfusions", "while", "continuing", "chemotherapy", "without", "dose", "reductions", "."], "event_mentions": [{"id": "11033836_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "preventing", "start": 34, "end": 35}, "arguments": [{"entity_id": "11033836_2_Ent4", "role": "Treatment_Drug", "text": "recombinant human interleukin - 11", "start": 6, "end": 11}, {"entity_id": "11033836_2_Ent2", "role": "Treatment", "text": "recombinant human interleukin - 11 ( rhIL - 11 , also known as oprelvekin [ Neumega ] )", "start": 6, "end": 24}, {"entity_id": "11033836_2_Ent0", "role": "Subject", "text": "patients with nonmyeloid malignancies", "start": 25, "end": 29}, {"entity_id": "11033836_2_Ent1", "role": "Subject_Disorder", "text": "nonmyeloid malignancies", "start": 27, "end": 29}, {"entity_id": "11033836_2_Ent3", "role": "Treatment_Disorder", "text": "postchemotherapy platelet nadirs of < or = 20,000/microL", "start": 35, "end": 43}]}], "entity_mentions": [{"id": "11033836_2_Ent4", "text": "recombinant human interleukin - 11", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "11033836_2_Ent2", "text": "recombinant human interleukin - 11 ( rhIL - 11 , also known as oprelvekin [ Neumega ] )", "entity_type": "Entity", "start": 6, "end": 24}, {"id": "11033836_2_Ent0", "text": "patients with nonmyeloid malignancies", "entity_type": "Entity", "start": 25, "end": 29}, {"id": "11033836_2_Ent1", "text": "nonmyeloid malignancies", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "11033836_2_Ent3", "text": "postchemotherapy platelet nadirs of < or = 20,000/microL", "entity_type": "Entity", "start": 35, "end": 43}], "lang": "en"}
{"doc_id": "11059196_2", "wnd_id": "11059196_2_1", "text": "We describe a 10 - year - old boy with ulcerative colitis who developed acute pancreatitis while on long - term treatment with 5 - aminosalicylic acid .", "tokens": ["We", "describe", "a", "10", "-", "year", "-", "old", "boy", "with", "ulcerative", "colitis", "who", "developed", "acute", "pancreatitis", "while", "on", "long", "-", "term", "treatment", "with", "5", "-", "aminosalicylic", "acid", "."], "event_mentions": [{"id": "11059196_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "11059196_2_Ent0", "role": "Subject", "text": "a 10 - year - old boy with ulcerative colitis", "start": 2, "end": 12}, {"entity_id": "11059196_2_Ent1", "role": "Subject_Age", "text": "10 - year - old", "start": 3, "end": 8}, {"entity_id": "11059196_2_Ent2", "role": "Subject_Gender", "text": "boy", "start": 8, "end": 9}, {"entity_id": "11059196_2_Ent7", "role": "Treatment_Disorder", "text": "ulcerative colitis", "start": 10, "end": 12}, {"entity_id": "11059196_2_Ent3", "role": "Effect", "text": "acute pancreatitis", "start": 14, "end": 16}, {"entity_id": "11059196_2_Ent5", "role": "Treatment_Freq", "text": "long - term treatment", "start": 18, "end": 22}, {"entity_id": "11059196_2_Ent4", "role": "Treatment", "text": "long - term treatment with 5 - aminosalicylic acid", "start": 18, "end": 27}, {"entity_id": "11059196_2_Ent6", "role": "Treatment_Drug", "text": "5 - aminosalicylic acid", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "11059196_2_Ent0", "text": "a 10 - year - old boy with ulcerative colitis", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "11059196_2_Ent1", "text": "10 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11059196_2_Ent2", "text": "boy", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11059196_2_Ent7", "text": "ulcerative colitis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11059196_2_Ent3", "text": "acute pancreatitis", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "11059196_2_Ent5", "text": "long - term treatment", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "11059196_2_Ent4", "text": "long - term treatment with 5 - aminosalicylic acid", "entity_type": "Entity", "start": 18, "end": 27}, {"id": "11059196_2_Ent6", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "11077455_1", "wnd_id": "11077455_1_1", "text": "CONCLUSION : Marked visual field constriction appears to be associated with vigabatrin therapy .", "tokens": ["CONCLUSION", ":", "Marked", "visual", "field", "constriction", "appears", "to", "be", "associated", "with", "vigabatrin", "therapy", "."], "event_mentions": [{"id": "11077455_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "11077455_1_Ent0", "role": "Effect", "text": "Marked visual field constriction", "start": 2, "end": 6}, {"entity_id": "11077455_1_Ent2", "role": "Treatment_Drug", "text": "vigabatrin", "start": 11, "end": 12}, {"entity_id": "11077455_1_Ent1", "role": "Treatment", "text": "vigabatrin therapy", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "11077455_1_Ent0", "text": "Marked visual field constriction", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "11077455_1_Ent2", "text": "vigabatrin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11077455_1_Ent1", "text": "vigabatrin therapy", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "1109248_9", "wnd_id": "1109248_9_1", "text": "It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy .", "tokens": ["It", "is", "concluded", "that", "chloral", "hydrate", "and", "methaqualone", "may", "be", "administered", "safely", "without", "additional", "caution", "in", "prothrombin", "test", "monitoring", "during", "oral", "anticoagulant", "therapy", "."], "event_mentions": [{"id": "1109248_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caution", "start": 14, "end": 15}, "arguments": [{"entity_id": "1109248_9_Ent2", "role": "Treatment_Drug", "text": "chloral hydrate", "start": 4, "end": 6}, {"entity_id": "1109248_9_Ent6", "role": "Combination_Drug", "text": "chloral hydrate", "start": 4, "end": 6}, {"entity_id": "1109248_9_Ent0", "role": "Treatment", "text": "chloral hydrate and methaqualone", "start": 4, "end": 8}, {"entity_id": "1109248_9_Ent3", "role": "Treatment_Drug", "text": "methaqualone", "start": 7, "end": 8}, {"entity_id": "1109248_9_Ent7", "role": "Combination_Drug", "text": "methaqualone", "start": 7, "end": 8}, {"entity_id": "1109248_9_Ent1", "role": "Treatment", "text": "during oral anticoagulant therapy", "start": 19, "end": 23}, {"entity_id": "1109248_9_Ent5", "role": "Treatment_Route", "text": "oral", "start": 20, "end": 21}, {"entity_id": "1109248_9_Ent4", "role": "Treatment_Drug", "text": "anticoagulant", "start": 21, "end": 22}, {"entity_id": "1109248_9_Ent8", "role": "Combination_Drug", "text": "anticoagulant", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "1109248_9_Ent2", "text": "chloral hydrate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1109248_9_Ent6", "text": "chloral hydrate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1109248_9_Ent0", "text": "chloral hydrate and methaqualone", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "1109248_9_Ent3", "text": "methaqualone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1109248_9_Ent7", "text": "methaqualone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1109248_9_Ent1", "text": "during oral anticoagulant therapy", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "1109248_9_Ent5", "text": "oral", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "1109248_9_Ent4", "text": "anticoagulant", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "1109248_9_Ent8", "text": "anticoagulant", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "11109149_2", "wnd_id": "11109149_2_1", "text": "This supports the well - reported potential of bleomycin to trigger acral vascular toxicity .", "tokens": ["This", "supports", "the", "well", "-", "reported", "potential", "of", "bleomycin", "to", "trigger", "acral", "vascular", "toxicity", "."], "event_mentions": [{"id": "11109149_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "trigger", "start": 10, "end": 11}, "arguments": [{"entity_id": "11109149_2_Ent1", "role": "Treatment", "text": "bleomycin", "start": 8, "end": 9}, {"entity_id": "11109149_2_Ent2", "role": "Treatment_Drug", "text": "bleomycin", "start": 8, "end": 9}, {"entity_id": "11109149_2_Ent0", "role": "Effect", "text": "acral vascular toxicity", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "11109149_2_Ent1", "text": "bleomycin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11109149_2_Ent2", "text": "bleomycin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11109149_2_Ent0", "text": "acral vascular toxicity", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "11131346_4", "wnd_id": "11131346_4_1", "text": "CONCLUSION : To the best of our knowledge , this is the first time colchicine intoxication in this age group has been described in the English literature .", "tokens": ["CONCLUSION", ":", "To", "the", "best", "of", "our", "knowledge", ",", "this", "is", "the", "first", "time", "colchicine", "intoxication", "in", "this", "age", "group", "has", "been", "described", "in", "the", "English", "literature", "."], "event_mentions": [{"id": "11131346_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "intoxication", "start": 15, "end": 16}, "arguments": [{"entity_id": "11131346_4_Ent1", "role": "Treatment", "text": "colchicine", "start": 14, "end": 15}, {"entity_id": "11131346_4_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 14, "end": 15}, {"entity_id": "11131346_4_Ent0", "role": "Effect", "text": "colchicine intoxication", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "11131346_4_Ent1", "text": "colchicine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11131346_4_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11131346_4_Ent0", "text": "colchicine intoxication", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "11144696_10", "wnd_id": "11144696_10_1", "text": "Venlafaxine - associated seizures at therapeutic doses have not been reported in the literature .", "tokens": ["Venlafaxine", "-", "associated", "seizures", "at", "therapeutic", "doses", "have", "not", "been", "reported", "in", "the", "literature", "."], "event_mentions": [{"id": "11144696_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11144696_10_Ent1", "role": "Treatment", "text": "Venlafaxine", "start": 0, "end": 1}, {"entity_id": "11144696_10_Ent2", "role": "Treatment_Drug", "text": "Venlafaxine", "start": 0, "end": 1}, {"entity_id": "11144696_10_Ent0", "role": "Effect", "text": "seizures", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "11144696_10_Ent1", "text": "Venlafaxine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11144696_10_Ent2", "text": "Venlafaxine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11144696_10_Ent0", "text": "seizures", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "11144696_11", "wnd_id": "11144696_11_1", "text": "We hypothesize that a pharmacodynamic or pharmacokinetic drug interaction between venlafaxine and trimipramine involving the CYP2D6 isoenzyme may have played a role in inducing the seizures .", "tokens": ["We", "hypothesize", "that", "a", "pharmacodynamic", "or", "pharmacokinetic", "drug", "interaction", "between", "venlafaxine", "and", "trimipramine", "involving", "the", "CYP2D6", "isoenzyme", "may", "have", "played", "a", "role", "in", "inducing", "the", "seizures", "."], "event_mentions": [{"id": "11144696_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "inducing", "start": 23, "end": 24}, "arguments": [{"entity_id": "11144696_11_Ent2", "role": "Treatment_Drug", "text": "venlafaxine", "start": 10, "end": 11}, {"entity_id": "11144696_11_Ent4", "role": "Combination_Drug", "text": "venlafaxine", "start": 10, "end": 11}, {"entity_id": "11144696_11_Ent1", "role": "Treatment", "text": "venlafaxine and trimipramine", "start": 10, "end": 13}, {"entity_id": "11144696_11_Ent3", "role": "Treatment_Drug", "text": "trimipramine", "start": 12, "end": 13}, {"entity_id": "11144696_11_Ent5", "role": "Combination_Drug", "text": "trimipramine", "start": 12, "end": 13}, {"entity_id": "11144696_11_Ent0", "role": "Effect", "text": "seizures", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "11144696_11_Ent2", "text": "venlafaxine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11144696_11_Ent4", "text": "venlafaxine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11144696_11_Ent1", "text": "venlafaxine and trimipramine", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "11144696_11_Ent3", "text": "trimipramine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11144696_11_Ent5", "text": "trimipramine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11144696_11_Ent0", "text": "seizures", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "11160777_11", "wnd_id": "11160777_11_1", "text": "Long - term studies are needed to determine whether the insulin - sensitizing effects of the glitazones can prevent or delay premature atherosclerotic cardiovascular disease , morbidity , and death .", "tokens": ["Long", "-", "term", "studies", "are", "needed", "to", "determine", "whether", "the", "insulin", "-", "sensitizing", "effects", "of", "the", "glitazones", "can", "prevent", "or", "delay", "premature", "atherosclerotic", "cardiovascular", "disease", ",", "morbidity", ",", "and", "death", "."], "event_mentions": [{"id": "11160777_11_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prevent", "start": 18, "end": 19}, "arguments": [{"entity_id": "11160777_11_Ent0", "role": "Treatment", "text": "glitazones", "start": 16, "end": 17}, {"entity_id": "11160777_11_Ent2", "role": "Treatment_Drug", "text": "glitazones", "start": 16, "end": 17}, {"entity_id": "11160777_11_Ent1", "role": "Treatment_Disorder", "text": "premature atherosclerotic cardiovascular disease , morbidity , and death", "start": 21, "end": 30}]}], "entity_mentions": [{"id": "11160777_11_Ent0", "text": "glitazones", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11160777_11_Ent2", "text": "glitazones", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11160777_11_Ent1", "text": "premature atherosclerotic cardiovascular disease , morbidity , and death", "entity_type": "Entity", "start": 21, "end": 30}], "lang": "en"}
{"doc_id": "11171531_3", "wnd_id": "11171531_3_1", "text": "Poorly controlled hypertension in a painter with chronic lead toxicity .", "tokens": ["Poorly", "controlled", "hypertension", "in", "a", "painter", "with", "chronic", "lead", "toxicity", "."], "event_mentions": [{"id": "11171531_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 6, "end": 7}, "arguments": [{"entity_id": "11171531_3_Ent1", "role": "Effect", "text": "Poorly controlled hypertension", "start": 0, "end": 3}, {"entity_id": "11171531_3_Ent0", "role": "Subject", "text": "a painter", "start": 4, "end": 6}, {"entity_id": "11171531_3_Ent2", "role": "Treatment", "text": "lead", "start": 8, "end": 9}, {"entity_id": "11171531_3_Ent3", "role": "Treatment_Drug", "text": "lead", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "11171531_3_Ent1", "text": "Poorly controlled hypertension", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11171531_3_Ent0", "text": "a painter", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11171531_3_Ent2", "text": "lead", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11171531_3_Ent3", "text": "lead", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "11181395_1", "wnd_id": "11181395_1_1", "text": "Restoration of vancomycin susceptibility in Enterococcus faecalis by antiresistance determinant gene transfer .", "tokens": ["Restoration", "of", "vancomycin", "susceptibility", "in", "Enterococcus", "faecalis", "by", "antiresistance", "determinant", "gene", "transfer", "."], "event_mentions": [{"id": "11181395_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "by", "start": 7, "end": 8}, "arguments": [{"entity_id": "11181395_1_Ent0", "role": "Effect", "text": "Restoration of vancomycin susceptibility in Enterococcus faecalis", "start": 0, "end": 7}, {"entity_id": "11181395_1_Ent2", "role": "Treatment_Drug", "text": "vancomycin", "start": 2, "end": 3}, {"entity_id": "11181395_1_Ent1", "role": "Treatment", "text": "antiresistance determinant gene transfer", "start": 8, "end": 12}]}], "entity_mentions": [{"id": "11181395_1_Ent0", "text": "Restoration of vancomycin susceptibility in Enterococcus faecalis", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "11181395_1_Ent2", "text": "vancomycin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11181395_1_Ent1", "text": "antiresistance determinant gene transfer", "entity_type": "Entity", "start": 8, "end": 12}], "lang": "en"}
{"doc_id": "11207969_1", "wnd_id": "11207969_1_1", "text": "ARA - C is frequently associated with dermatologic toxicity , but this is only the second case of toxic epidermal necrolysis described in connection with this drug .", "tokens": ["ARA", "-", "C", "is", "frequently", "associated", "with", "dermatologic", "toxicity", ",", "but", "this", "is", "only", "the", "second", "case", "of", "toxic", "epidermal", "necrolysis", "described", "in", "connection", "with", "this", "drug", "."], "event_mentions": [{"id": "11207969_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "11207969_1_Ent1", "role": "Treatment", "text": "ARA - C", "start": 0, "end": 3}, {"entity_id": "11207969_1_Ent2", "role": "Treatment_Drug", "text": "ARA - C", "start": 0, "end": 3}, {"entity_id": "11207969_1_Ent0", "role": "Effect", "text": "dermatologic toxicity", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "11207969_1_Ent1", "text": "ARA - C", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11207969_1_Ent2", "text": "ARA - C", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11207969_1_Ent0", "text": "dermatologic toxicity", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "11207969_4", "wnd_id": "11207969_4_1", "text": "We report a fatal case of toxic epidermal necrolysis ( TEN ) resulting from a high dose of cytosine arabinoside ( ARA - C ) .", "tokens": ["We", "report", "a", "fatal", "case", "of", "toxic", "epidermal", "necrolysis", "(", "TEN", ")", "resulting", "from", "a", "high", "dose", "of", "cytosine", "arabinoside", "(", "ARA", "-", "C", ")", "."], "event_mentions": [{"id": "11207969_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting from", "start": 12, "end": 14}, "arguments": [{"entity_id": "11207969_4_Ent0", "role": "Effect", "text": "toxic epidermal necrolysis ( TEN )", "start": 6, "end": 12}, {"entity_id": "11207969_4_Ent3", "role": "Treatment_Dosage", "text": "high dose", "start": 15, "end": 17}, {"entity_id": "11207969_4_Ent1", "role": "Treatment", "text": "high dose of cytosine arabinoside ( ARA - C )", "start": 15, "end": 25}, {"entity_id": "11207969_4_Ent2", "role": "Treatment_Drug", "text": "cytosine arabinoside ( ARA - C )", "start": 18, "end": 25}]}], "entity_mentions": [{"id": "11207969_4_Ent0", "text": "toxic epidermal necrolysis ( TEN )", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "11207969_4_Ent3", "text": "high dose", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "11207969_4_Ent1", "text": "high dose of cytosine arabinoside ( ARA - C )", "entity_type": "Entity", "start": 15, "end": 25}, {"id": "11207969_4_Ent2", "text": "cytosine arabinoside ( ARA - C )", "entity_type": "Entity", "start": 18, "end": 25}], "lang": "en"}
{"doc_id": "11215836_1", "wnd_id": "11215836_1_1", "text": "He was diagnosed with possible serotonin syndrome ; his symptoms resolved after clomipramine was stopped but before clozapine was restarted eight days later .", "tokens": ["He", "was", "diagnosed", "with", "possible", "serotonin", "syndrome", ";", "his", "symptoms", "resolved", "after", "clomipramine", "was", "stopped", "but", "before", "clozapine", "was", "restarted", "eight", "days", "later", "."], "event_mentions": [{"id": "11215836_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resolved", "start": 10, "end": 11}, "arguments": [{"entity_id": "11215836_1_Ent0", "role": "Subject", "text": "He", "start": 0, "end": 1}, {"entity_id": "11215836_1_Ent1", "role": "Subject_Gender", "text": "He", "start": 0, "end": 1}, {"entity_id": "11215836_1_Ent2", "role": "Effect", "text": "possible serotonin syndrome", "start": 4, "end": 7}, {"entity_id": "11215836_1_Ent3", "role": "Treatment", "text": "clozapine", "start": 17, "end": 18}, {"entity_id": "11215836_1_Ent4", "role": "Treatment_Drug", "text": "clozapine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "11215836_1_Ent0", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11215836_1_Ent1", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11215836_1_Ent2", "text": "possible serotonin syndrome", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11215836_1_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11215836_1_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "11225532_2", "wnd_id": "11225532_2_1", "text": "The cause of his bleeding was a severe thrombocytopoaenia , induced by chronic ingestion of quinine .", "tokens": ["The", "cause", "of", "his", "bleeding", "was", "a", "severe", "thrombocytopoaenia", ",", "induced", "by", "chronic", "ingestion", "of", "quinine", "."], "event_mentions": [{"id": "11225532_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "11225532_2_Ent0", "role": "Effect", "text": "thrombocytopoaenia", "start": 8, "end": 9}, {"entity_id": "11225532_2_Ent1", "role": "Treatment", "text": "chronic ingestion of quinine", "start": 12, "end": 16}, {"entity_id": "11225532_2_Ent2", "role": "Treatment_Route", "text": "ingestion", "start": 13, "end": 14}, {"entity_id": "11225532_2_Ent3", "role": "Treatment_Drug", "text": "quinine", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "11225532_2_Ent0", "text": "thrombocytopoaenia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11225532_2_Ent1", "text": "chronic ingestion of quinine", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "11225532_2_Ent2", "text": "ingestion", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11225532_2_Ent3", "text": "quinine", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "11225565_6", "wnd_id": "11225565_6_1", "text": "Delavirdine and efavirenz ( but not nevirapine ) also were strong inhibitors of CYP3A , consistent with clinical hazards of initial cotreatment with either of these drugs and substrates of CYP3A.", "tokens": ["Delavirdine", "and", "efavirenz", "(", "but", "not", "nevirapine", ")", "also", "were", "strong", "inhibitors", "of", "CYP3A", ",", "consistent", "with", "clinical", "hazards", "of", "initial", "cotreatment", "with", "either", "of", "these", "drugs", "and", "substrates", "of", "CYP3A."], "event_mentions": [{"id": "11225565_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "consistent with", "start": 15, "end": 17}, "arguments": [{"entity_id": "11225565_6_Ent2", "role": "Treatment_Drug", "text": "Delavirdine", "start": 0, "end": 1}, {"entity_id": "11225565_6_Ent1", "role": "Treatment", "text": "Delavirdine and efavirenz ( but not nevirapine )", "start": 0, "end": 8}, {"entity_id": "11225565_6_Ent3", "role": "Treatment_Drug", "text": "efavirenz", "start": 2, "end": 3}, {"entity_id": "11225565_6_Ent0", "role": "Effect", "text": "clinical hazards", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "11225565_6_Ent2", "text": "Delavirdine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11225565_6_Ent1", "text": "Delavirdine and efavirenz ( but not nevirapine )", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "11225565_6_Ent3", "text": "efavirenz", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11225565_6_Ent0", "text": "clinical hazards", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "11236070_1", "wnd_id": "11236070_1_1", "text": "Dose - dependent olanzapine - associated leukopenia : three case reports .", "tokens": ["Dose", "-", "dependent", "olanzapine", "-", "associated", "leukopenia", ":", "three", "case", "reports", "."], "event_mentions": [{"id": "11236070_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "11236070_1_Ent3", "role": "Treatment", "text": "olanzapine", "start": 3, "end": 4}, {"entity_id": "11236070_1_Ent4", "role": "Treatment_Drug", "text": "olanzapine", "start": 3, "end": 4}, {"entity_id": "11236070_1_Ent2", "role": "Effect", "text": "leukopenia", "start": 6, "end": 7}, {"entity_id": "11236070_1_Ent1", "role": "Subject_Population", "text": "three", "start": 8, "end": 9}, {"entity_id": "11236070_1_Ent0", "role": "Subject", "text": "three case", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "11236070_1_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11236070_1_Ent4", "text": "olanzapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11236070_1_Ent2", "text": "leukopenia", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11236070_1_Ent1", "text": "three", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11236070_1_Ent0", "text": "three case", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "11236070_2", "wnd_id": "11236070_2_1", "text": "These cases suggest the possibility that , in some patients , leukopenia or agranulocytosis during olanzapine treatment might be dose - related .", "tokens": ["These", "cases", "suggest", "the", "possibility", "that", ",", "in", "some", "patients", ",", "leukopenia", "or", "agranulocytosis", "during", "olanzapine", "treatment", "might", "be", "dose", "-", "related", "."], "event_mentions": [{"id": "11236070_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 14, "end": 15}, "arguments": [{"entity_id": "11236070_2_Ent0", "role": "Subject", "text": "in some patients", "start": 7, "end": 10}, {"entity_id": "11236070_2_Ent1", "role": "Effect", "text": "leukopenia or agranulocytosis", "start": 11, "end": 14}, {"entity_id": "11236070_2_Ent3", "role": "Treatment_Drug", "text": "olanzapine", "start": 15, "end": 16}, {"entity_id": "11236070_2_Ent2", "role": "Treatment", "text": "olanzapine treatment", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "11236070_2_Ent0", "text": "in some patients", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11236070_2_Ent1", "text": "leukopenia or agranulocytosis", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "11236070_2_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11236070_2_Ent2", "text": "olanzapine treatment", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "11243427_2", "wnd_id": "11243427_2_1", "text": "Differential diagnoses included ocular rosacea with cicatrizing conjunctivitis and 5 - FU - induced ectropion .", "tokens": ["Differential", "diagnoses", "included", "ocular", "rosacea", "with", "cicatrizing", "conjunctivitis", "and", "5", "-", "FU", "-", "induced", "ectropion", "."], "event_mentions": [{"id": "11243427_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "11243427_2_Ent1", "role": "Treatment", "text": "5 - FU", "start": 9, "end": 12}, {"entity_id": "11243427_2_Ent2", "role": "Treatment_Drug", "text": "5 - FU", "start": 9, "end": 12}, {"entity_id": "11243427_2_Ent0", "role": "Effect", "text": "ectropion", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "11243427_2_Ent1", "text": "5 - FU", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "11243427_2_Ent2", "text": "5 - FU", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "11243427_2_Ent0", "text": "ectropion", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "1124417_1", "wnd_id": "1124417_1_1", "text": "Presented is a case of acute renal failure induced by acetazolamide therapy for glaucoma .", "tokens": ["Presented", "is", "a", "case", "of", "acute", "renal", "failure", "induced", "by", "acetazolamide", "therapy", "for", "glaucoma", "."], "event_mentions": [{"id": "1124417_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "1124417_1_Ent0", "role": "Effect", "text": "acute renal failure", "start": 5, "end": 8}, {"entity_id": "1124417_1_Ent2", "role": "Treatment_Drug", "text": "acetazolamide", "start": 10, "end": 11}, {"entity_id": "1124417_1_Ent1", "role": "Treatment", "text": "acetazolamide therapy for glaucoma", "start": 10, "end": 14}, {"entity_id": "1124417_1_Ent3", "role": "Treatment_Disorder", "text": "glaucoma", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "1124417_1_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "1124417_1_Ent2", "text": "acetazolamide", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1124417_1_Ent1", "text": "acetazolamide therapy for glaucoma", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "1124417_1_Ent3", "text": "glaucoma", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "1124417_3", "wnd_id": "1124417_3_1", "text": "This sulfonamide like nephropathy should be differentiated from acetazolamide - related calcium phosphate nephrolithiasis .", "tokens": ["This", "sulfonamide", "like", "nephropathy", "should", "be", "differentiated", "from", "acetazolamide", "-", "related", "calcium", "phosphate", "nephrolithiasis", "."], "event_mentions": [{"id": "1124417_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 10, "end": 11}, "arguments": [{"entity_id": "1124417_3_Ent1", "role": "Treatment", "text": "acetazolamide", "start": 8, "end": 9}, {"entity_id": "1124417_3_Ent2", "role": "Treatment_Drug", "text": "acetazolamide", "start": 8, "end": 9}, {"entity_id": "1124417_3_Ent0", "role": "Effect", "text": "calcium phosphate nephrolithiasis .", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "1124417_3_Ent1", "text": "acetazolamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1124417_3_Ent2", "text": "acetazolamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1124417_3_Ent0", "text": "calcium phosphate nephrolithiasis .", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "11250985_1", "wnd_id": "11250985_1_1", "text": "As these cases revealed , close monitoring of blood chemistry is mandatory after starting spironolactone , and patients should be advised to stop spironolactone immediately if diarrhoea develops .", "tokens": ["As", "these", "cases", "revealed", ",", "close", "monitoring", "of", "blood", "chemistry", "is", "mandatory", "after", "starting", "spironolactone", ",", "and", "patients", "should", "be", "advised", "to", "stop", "spironolactone", "immediately", "if", "diarrhoea", "develops", "."], "event_mentions": [{"id": "11250985_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develops", "start": 27, "end": 28}, "arguments": [{"entity_id": "11250985_1_Ent2", "role": "Treatment", "text": "spironolactone", "start": 14, "end": 15}, {"entity_id": "11250985_1_Ent3", "role": "Treatment_Drug", "text": "spironolactone", "start": 14, "end": 15}, {"entity_id": "11250985_1_Ent0", "role": "Subject", "text": "patients", "start": 17, "end": 18}, {"entity_id": "11250985_1_Ent1", "role": "Effect", "text": "diarrhoea", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "11250985_1_Ent2", "text": "spironolactone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11250985_1_Ent3", "text": "spironolactone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11250985_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11250985_1_Ent1", "text": "diarrhoea", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "11283125_2", "wnd_id": "11283125_2_1", "text": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high - dose ( HD ) intravenous ( IV ) cytarabine ( Ara - C ) added to HD IV methotrexate ( MTX ) to reduce the incidence of CNS and systemic relapses in children with increased - risk acute lymphoblastic leukemia ( ALL ) or stage III and IV lymphoblastic lymphoma treated with a Berlin - Frankfurt - Munster ( BFM) - based regimen .", "tokens": ["The", "European", "Organization", "for", "Research", "and", "Treatment", "of", "Cancer", "58881", "study", "was", "designed", "to", "test", "in", "a", "prospective", "multicentric", "randomized", "trial", "the", "value", "of", "high", "-", "dose", "(", "HD", ")", "intravenous", "(", "IV", ")", "cytarabine", "(", "Ara", "-", "C", ")", "added", "to", "HD", "IV", "methotrexate", "(", "MTX", ")", "to", "reduce", "the", "incidence", "of", "CNS", "and", "systemic", "relapses", "in", "children", "with", "increased", "-", "risk", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", "or", "stage", "III", "and", "IV", "lymphoblastic", "lymphoma", "treated", "with", "a", "Berlin", "-", "Frankfurt", "-", "Munster", "(", "BFM)", "-", "based", "regimen", "."], "event_mentions": [{"id": "11283125_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "to", "start": 48, "end": 49}, "arguments": [{"entity_id": "11283125_2_Ent4", "role": "Treatment_Dosage", "text": "high - dose", "start": 24, "end": 27}, {"entity_id": "11283125_2_Ent3", "role": "Treatment", "text": "high - dose ( HD ) intravenous ( IV ) cytarabine ( Ara - C ) added to HD IV methotrexate ( MTX )", "start": 24, "end": 48}, {"entity_id": "11283125_2_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 30, "end": 31}, {"entity_id": "11283125_2_Ent6", "role": "Treatment_Drug", "text": "cytarabine", "start": 34, "end": 35}, {"entity_id": "11283125_2_Ent10", "role": "Combination_Drug", "text": "cytarabine", "start": 34, "end": 35}, {"entity_id": "11283125_2_Ent7", "role": "Treatment_Drug", "text": "methotrexate", "start": 44, "end": 45}, {"entity_id": "11283125_2_Ent11", "role": "Combination_Drug", "text": "methotrexate", "start": 44, "end": 45}, {"entity_id": "11283125_2_Ent2", "role": "Effect", "text": "reduce the incidence of CNS and systemic relapses", "start": 49, "end": 57}, {"entity_id": "11283125_2_Ent1", "role": "Subject_Age", "text": "children", "start": 58, "end": 59}, {"entity_id": "11283125_2_Ent0", "role": "Subject", "text": "children with increased - risk acute lymphoblastic leukemia ( ALL ) or stage III and IV lymphoblastic lymphoma", "start": 58, "end": 76}, {"entity_id": "11283125_2_Ent8", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 63, "end": 66}, {"entity_id": "11283125_2_Ent9", "role": "Treatment_Disorder", "text": "stage III and IV lymphoblastic lymphoma", "start": 70, "end": 76}]}], "entity_mentions": [{"id": "11283125_2_Ent4", "text": "high - dose", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "11283125_2_Ent3", "text": "high - dose ( HD ) intravenous ( IV ) cytarabine ( Ara - C ) added to HD IV methotrexate ( MTX )", "entity_type": "Entity", "start": 24, "end": 48}, {"id": "11283125_2_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "11283125_2_Ent6", "text": "cytarabine", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "11283125_2_Ent10", "text": "cytarabine", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "11283125_2_Ent7", "text": "methotrexate", "entity_type": "Entity", "start": 44, "end": 45}, {"id": "11283125_2_Ent11", "text": "methotrexate", "entity_type": "Entity", "start": 44, "end": 45}, {"id": "11283125_2_Ent2", "text": "reduce the incidence of CNS and systemic relapses", "entity_type": "Entity", "start": 49, "end": 57}, {"id": "11283125_2_Ent1", "text": "children", "entity_type": "Entity", "start": 58, "end": 59}, {"id": "11283125_2_Ent0", "text": "children with increased - risk acute lymphoblastic leukemia ( ALL ) or stage III and IV lymphoblastic lymphoma", "entity_type": "Entity", "start": 58, "end": 76}, {"id": "11283125_2_Ent8", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 63, "end": 66}, {"id": "11283125_2_Ent9", "text": "stage III and IV lymphoblastic lymphoma", "entity_type": "Entity", "start": 70, "end": 76}], "lang": "en"}
{"doc_id": "11310527_2", "wnd_id": "11310527_2_1", "text": "A patient was treated with warfarin for atrial fibrillation .", "tokens": ["A", "patient", "was", "treated", "with", "warfarin", "for", "atrial", "fibrillation", "."], "event_mentions": [{"id": "11310527_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 3, "end": 4}, "arguments": [{"entity_id": "11310527_2_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "11310527_2_Ent1", "role": "Treatment", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "11310527_2_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "11310527_2_Ent2", "role": "Treatment_Disorder", "text": "atrial fibrillation", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "11310527_2_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11310527_2_Ent1", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11310527_2_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11310527_2_Ent2", "text": "atrial fibrillation", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "11319599_2", "wnd_id": "11319599_2_1", "text": "We describe two patients with aspergillus arthritis of the knee joint following fludarabine - based non - myeloablative stem cell transplantation .", "tokens": ["We", "describe", "two", "patients", "with", "aspergillus", "arthritis", "of", "the", "knee", "joint", "following", "fludarabine", "-", "based", "non", "-", "myeloablative", "stem", "cell", "transplantation", "."], "event_mentions": [{"id": "11319599_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 11, "end": 12}, "arguments": [{"entity_id": "11319599_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "11319599_2_Ent0", "role": "Subject", "text": "two patients", "start": 2, "end": 4}, {"entity_id": "11319599_2_Ent2", "role": "Effect", "text": "aspergillus arthritis of the knee joint", "start": 5, "end": 11}, {"entity_id": "11319599_2_Ent4", "role": "Treatment_Drug", "text": "fludarabine", "start": 12, "end": 13}, {"entity_id": "11319599_2_Ent3", "role": "Treatment", "text": "fludarabine - based non - myeloablative stem cell transplantation", "start": 12, "end": 21}]}], "entity_mentions": [{"id": "11319599_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11319599_2_Ent0", "text": "two patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11319599_2_Ent2", "text": "aspergillus arthritis of the knee joint", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "11319599_2_Ent4", "text": "fludarabine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11319599_2_Ent3", "text": "fludarabine - based non - myeloablative stem cell transplantation", "entity_type": "Entity", "start": 12, "end": 21}], "lang": "en"}
{"doc_id": "11341670_1", "wnd_id": "11341670_1_1", "text": "During dose - finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole , three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid .", "tokens": ["During", "dose", "-", "finding", "studies", "for", "intravenous", "proton", "pump", "inhibitors", "omeprazole", "and", "pantoprazole", ",", "three", "of", "six", "young", "female", "volunteers", "receiving", "omeprazole", "and", "two", "young", "female", "volunteers", "receiving", "pantoprazole", "developed", "peripheral", "edema", "within", "8", "hr", "when", "high", "doses", "of", "the", "proton", "pump", "inhibitors", "were", "applied", "by", "continuous", "infusion", "together", "with", "large", "volumes", "of", "fluid", "."], "event_mentions": [{"id": "11341670_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 29, "end": 30}, "arguments": [{"entity_id": "11341670_1_Ent1", "role": "Subject_Population", "text": "three", "start": 14, "end": 15}, {"entity_id": "11341670_1_Ent0", "role": "Subject", "text": "three of six young female volunteers", "start": 14, "end": 20}, {"entity_id": "11341670_1_Ent2", "role": "Subject_Age", "text": "young", "start": 17, "end": 18}, {"entity_id": "11341670_1_Ent3", "role": "Subject_Gender", "text": "female", "start": 18, "end": 19}, {"entity_id": "11341670_1_Ent5", "role": "Treatment", "text": "omeprazole", "start": 21, "end": 22}, {"entity_id": "11341670_1_Ent7", "role": "Treatment_Drug", "text": "omeprazole", "start": 21, "end": 22}, {"entity_id": "11341670_1_Ent4", "role": "Effect", "text": "peripheral edema within 8 hr", "start": 30, "end": 35}, {"entity_id": "11341670_1_Ent6", "role": "Treatment", "text": "high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid", "start": 36, "end": 54}]}, {"id": "11341670_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 29, "end": 30}, "arguments": [{"entity_id": "11341670_1_Ent9", "role": "Subject_Population", "text": "two", "start": 23, "end": 24}, {"entity_id": "11341670_1_Ent8", "role": "Subject", "text": "two young female volunteers", "start": 23, "end": 27}, {"entity_id": "11341670_1_Ent10", "role": "Subject_Age", "text": "young", "start": 24, "end": 25}, {"entity_id": "11341670_1_Ent11", "role": "Subject_Gender", "text": "female", "start": 25, "end": 26}, {"entity_id": "11341670_1_Ent13", "role": "Treatment", "text": "pantoprazole", "start": 28, "end": 29}, {"entity_id": "11341670_1_Ent15", "role": "Treatment_Drug", "text": "pantoprazole", "start": 28, "end": 29}, {"entity_id": "11341670_1_Ent12", "role": "Effect", "text": "peripheral edema within 8 hr", "start": 30, "end": 35}, {"entity_id": "11341670_1_Ent14", "role": "Treatment", "text": "high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid", "start": 36, "end": 54}]}], "entity_mentions": [{"id": "11341670_1_Ent1", "text": "three", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11341670_1_Ent0", "text": "three of six young female volunteers", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "11341670_1_Ent2", "text": "young", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11341670_1_Ent3", "text": "female", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "11341670_1_Ent5", "text": "omeprazole", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11341670_1_Ent7", "text": "omeprazole", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11341670_1_Ent9", "text": "two", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11341670_1_Ent8", "text": "two young female volunteers", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "11341670_1_Ent10", "text": "young", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11341670_1_Ent11", "text": "female", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11341670_1_Ent13", "text": "pantoprazole", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11341670_1_Ent15", "text": "pantoprazole", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11341670_1_Ent4", "text": "peripheral edema within 8 hr", "entity_type": "Entity", "start": 30, "end": 35}, {"id": "11341670_1_Ent12", "text": "peripheral edema within 8 hr", "entity_type": "Entity", "start": 30, "end": 35}, {"id": "11341670_1_Ent6", "text": "high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid", "entity_type": "Entity", "start": 36, "end": 54}, {"id": "11341670_1_Ent14", "text": "high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid", "entity_type": "Entity", "start": 36, "end": 54}], "lang": "en"}
{"doc_id": "11352235_1", "wnd_id": "11352235_1_1", "text": "CONCLUSION : Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide .", "tokens": ["CONCLUSION", ":", "Significant", "weight", "loss", "is", "a", "potential", "adverse", "event", "in", "patients", "with", "rheumatoid", "arthritis", "treated", "with", "leflunomide", "."], "event_mentions": [{"id": "11352235_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "potential adverse event", "start": 7, "end": 10}, "arguments": [{"entity_id": "11352235_1_Ent0", "role": "Effect", "text": "Significant weight loss", "start": 2, "end": 5}, {"entity_id": "11352235_1_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 13, "end": 15}, {"entity_id": "11352235_1_Ent1", "role": "Treatment", "text": "leflunomide", "start": 17, "end": 18}, {"entity_id": "11352235_1_Ent2", "role": "Treatment_Drug", "text": "leflunomide", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "11352235_1_Ent0", "text": "Significant weight loss", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "11352235_1_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "11352235_1_Ent1", "text": "leflunomide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11352235_1_Ent2", "text": "leflunomide", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "11352235_5", "wnd_id": "11352235_5_1", "text": "RESULTS : Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies .", "tokens": ["RESULTS", ":", "Five", "of", "70", "patients", "who", "had", "begun", "leflunomide", "therapy", "had", "significant", "weight", "loss", "that", "could", "not", "be", "linked", "to", "other", "identifiable", "etiologies", "."], "event_mentions": [{"id": "11352235_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 11, "end": 12}, "arguments": [{"entity_id": "11352235_5_Ent1", "role": "Subject_Population", "text": "Five of 70", "start": 2, "end": 5}, {"entity_id": "11352235_5_Ent0", "role": "Subject", "text": "Five of 70 patients", "start": 2, "end": 6}, {"entity_id": "11352235_5_Ent3", "role": "Treatment", "text": "leflunomide", "start": 9, "end": 10}, {"entity_id": "11352235_5_Ent4", "role": "Treatment_Drug", "text": "leflunomide", "start": 9, "end": 10}, {"entity_id": "11352235_5_Ent2", "role": "Effect", "text": "significant weight loss", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "11352235_5_Ent1", "text": "Five of 70", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "11352235_5_Ent0", "text": "Five of 70 patients", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "11352235_5_Ent3", "text": "leflunomide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11352235_5_Ent4", "text": "leflunomide", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11352235_5_Ent2", "text": "significant weight loss", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "11373877_1", "wnd_id": "11373877_1_1", "text": "Avascular necrosis of the femoral head in patients with prostate cancer treated with cyproterone acetate and radiotherapy .", "tokens": ["Avascular", "necrosis", "of", "the", "femoral", "head", "in", "patients", "with", "prostate", "cancer", "treated", "with", "cyproterone", "acetate", "and", "radiotherapy", "."], "event_mentions": [{"id": "11373877_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 6, "end": 7}, "arguments": [{"entity_id": "11373877_1_Ent1", "role": "Effect", "text": "Avascular necrosis of the femoral head", "start": 0, "end": 6}, {"entity_id": "11373877_1_Ent0", "role": "Subject", "text": "patients with prostate cancer", "start": 7, "end": 11}, {"entity_id": "11373877_1_Ent3", "role": "Treatment_Disorder", "text": "prostate cancer", "start": 9, "end": 11}, {"entity_id": "11373877_1_Ent4", "role": "Treatment_Drug", "text": "cyproterone acetate", "start": 13, "end": 15}, {"entity_id": "11373877_1_Ent2", "role": "Treatment", "text": "cyproterone acetate and radiotherapy", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "11373877_1_Ent1", "text": "Avascular necrosis of the femoral head", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "11373877_1_Ent0", "text": "patients with prostate cancer", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "11373877_1_Ent3", "text": "prostate cancer", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11373877_1_Ent4", "text": "cyproterone acetate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "11373877_1_Ent2", "text": "cyproterone acetate and radiotherapy", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "11388112_1", "wnd_id": "11388112_1_1", "text": "Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval .", "tokens": ["Levofloxacin", "induced", "polymorphic", "ventricular", "tachycardia", "with", "normal", "QT", "interval", "."], "event_mentions": [{"id": "11388112_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "11388112_1_Ent1", "role": "Treatment", "text": "Levofloxacin", "start": 0, "end": 1}, {"entity_id": "11388112_1_Ent2", "role": "Treatment_Drug", "text": "Levofloxacin", "start": 0, "end": 1}, {"entity_id": "11388112_1_Ent0", "role": "Effect", "text": "polymorphic ventricular tachycardia with normal QT interval", "start": 2, "end": 9}]}], "entity_mentions": [{"id": "11388112_1_Ent1", "text": "Levofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11388112_1_Ent2", "text": "Levofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11388112_1_Ent0", "text": "polymorphic ventricular tachycardia with normal QT interval", "entity_type": "Entity", "start": 2, "end": 9}], "lang": "en"}
{"doc_id": "11399735_3", "wnd_id": "11399735_3_1", "text": "Ticlopidine - induced interstitial pulmonary disease : a case report .", "tokens": ["Ticlopidine", "-", "induced", "interstitial", "pulmonary", "disease", ":", "a", "case", "report", "."], "event_mentions": [{"id": "11399735_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "11399735_3_Ent1", "role": "Treatment", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "11399735_3_Ent2", "role": "Treatment_Drug", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "11399735_3_Ent0", "role": "Effect", "text": "interstitial pulmonary disease", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "11399735_3_Ent1", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11399735_3_Ent2", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11399735_3_Ent0", "text": "interstitial pulmonary disease", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "11431864_1", "wnd_id": "11431864_1_1", "text": "After the dose of methylprednisolone was reduced from 40 mg to 20 mg i.v . q6h and shifted to other anti - asthma treatment by procaterol metered dose inhaler via spacer , the psychotic reaction disappeared a few hours later .", "tokens": ["After", "the", "dose", "of", "methylprednisolone", "was", "reduced", "from", "40", "mg", "to", "20", "mg", "i.v", ".", "q6h", "and", "shifted", "to", "other", "anti", "-", "asthma", "treatment", "by", "procaterol", "metered", "dose", "inhaler", "via", "spacer", ",", "the", "psychotic", "reaction", "disappeared", "a", "few", "hours", "later", "."], "event_mentions": [{"id": "11431864_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "disappeared", "start": 35, "end": 36}, "arguments": [{"entity_id": "11431864_1_Ent0", "role": "Treatment", "text": "After the dose of methylprednisolone was reduced from 40 mg to 20 mg i.v . q6h and shifted to other anti - asthma treatment by procaterol metered dose inhaler via spacer", "start": 0, "end": 31}, {"entity_id": "11431864_1_Ent4", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 4, "end": 5}, {"entity_id": "11431864_1_Ent5", "role": "Treatment_Dosage", "text": "reduced from 40 mg to 20 mg i.v . q6h", "start": 6, "end": 16}, {"entity_id": "11431864_1_Ent6", "role": "Treatment_Route", "text": "spacer", "start": 30, "end": 31}, {"entity_id": "11431864_1_Ent2", "role": "Treatment_Disorder", "text": "psychotic reaction", "start": 33, "end": 35}, {"entity_id": "11431864_1_Ent3", "role": "Treatment_Time_elapsed", "text": "a few hours", "start": 36, "end": 39}, {"entity_id": "11431864_1_Ent1", "role": "Treatment", "text": "a few hours later", "start": 36, "end": 40}]}], "entity_mentions": [{"id": "11431864_1_Ent0", "text": "After the dose of methylprednisolone was reduced from 40 mg to 20 mg i.v . q6h and shifted to other anti - asthma treatment by procaterol metered dose inhaler via spacer", "entity_type": "Entity", "start": 0, "end": 31}, {"id": "11431864_1_Ent4", "text": "methylprednisolone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11431864_1_Ent5", "text": "reduced from 40 mg to 20 mg i.v . q6h", "entity_type": "Entity", "start": 6, "end": 16}, {"id": "11431864_1_Ent6", "text": "spacer", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "11431864_1_Ent2", "text": "psychotic reaction", "entity_type": "Entity", "start": 33, "end": 35}, {"id": "11431864_1_Ent3", "text": "a few hours", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "11431864_1_Ent1", "text": "a few hours later", "entity_type": "Entity", "start": 36, "end": 40}], "lang": "en"}
{"doc_id": "11483161_1", "wnd_id": "11483161_1_1", "text": "Possible linkage of amprenavir with intracranial bleeding in an HIV - infected hemophiliac .", "tokens": ["Possible", "linkage", "of", "amprenavir", "with", "intracranial", "bleeding", "in", "an", "HIV", "-", "infected", "hemophiliac", "."], "event_mentions": [{"id": "11483161_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "linkage", "start": 1, "end": 2}, "arguments": [{"entity_id": "11483161_1_Ent2", "role": "Treatment", "text": "amprenavir", "start": 3, "end": 4}, {"entity_id": "11483161_1_Ent3", "role": "Treatment_Drug", "text": "amprenavir", "start": 3, "end": 4}, {"entity_id": "11483161_1_Ent1", "role": "Effect", "text": "intracranial bleeding", "start": 5, "end": 7}, {"entity_id": "11483161_1_Ent0", "role": "Subject", "text": "an HIV - infected hemophiliac", "start": 8, "end": 13}, {"entity_id": "11483161_1_Ent4", "role": "Treatment_Disorder", "text": "HIV", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11483161_1_Ent2", "text": "amprenavir", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11483161_1_Ent3", "text": "amprenavir", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11483161_1_Ent1", "text": "intracranial bleeding", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11483161_1_Ent0", "text": "an HIV - infected hemophiliac", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "11483161_1_Ent4", "text": "HIV", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11485141_4", "wnd_id": "11485141_4_1", "text": "OBJECTIVE : To report a case of linear immunoglobulin ( Ig ) A bullous dermatosis ( LABD ) induced by gemcitabine .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "linear", "immunoglobulin", "(", "Ig", ")", "A", "bullous", "dermatosis", "(", "LABD", ")", "induced", "by", "gemcitabine", "."], "event_mentions": [{"id": "11485141_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 18, "end": 19}, "arguments": [{"entity_id": "11485141_4_Ent0", "role": "Subject", "text": "a case", "start": 4, "end": 6}, {"entity_id": "11485141_4_Ent1", "role": "Effect", "text": "linear immunoglobulin ( Ig ) A bullous dermatosis ( LABD )", "start": 7, "end": 18}, {"entity_id": "11485141_4_Ent2", "role": "Treatment", "text": "gemcitabine", "start": 20, "end": 21}, {"entity_id": "11485141_4_Ent3", "role": "Treatment_Drug", "text": "gemcitabine", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "11485141_4_Ent0", "text": "a case", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11485141_4_Ent1", "text": "linear immunoglobulin ( Ig ) A bullous dermatosis ( LABD )", "entity_type": "Entity", "start": 7, "end": 18}, {"id": "11485141_4_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11485141_4_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "11485141_6", "wnd_id": "11485141_6_1", "text": "Vancomycin is the most frequently implicated drug , but other agents have been reported to cause LABD .", "tokens": ["Vancomycin", "is", "the", "most", "frequently", "implicated", "drug", ",", "but", "other", "agents", "have", "been", "reported", "to", "cause", "LABD", "."], "event_mentions": [{"id": "11485141_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 15, "end": 16}, "arguments": [{"entity_id": "11485141_6_Ent1", "role": "Treatment", "text": "Vancomycin", "start": 0, "end": 1}, {"entity_id": "11485141_6_Ent2", "role": "Treatment_Drug", "text": "Vancomycin", "start": 0, "end": 1}, {"entity_id": "11485141_6_Ent0", "role": "Effect", "text": "LABD", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "11485141_6_Ent1", "text": "Vancomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11485141_6_Ent2", "text": "Vancomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11485141_6_Ent0", "text": "LABD", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "11489400_1", "wnd_id": "11489400_1_1", "text": "Relief by naloxone of morphine - induced spasm of the sphincter of Oddi in a post - cholecystectomy patient .", "tokens": ["Relief", "by", "naloxone", "of", "morphine", "-", "induced", "spasm", "of", "the", "sphincter", "of", "Oddi", "in", "a", "post", "-", "cholecystectomy", "patient", "."], "event_mentions": [{"id": "11489400_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Relief", "start": 0, "end": 1}, "arguments": [{"entity_id": "11489400_1_Ent1", "role": "Treatment", "text": "naloxone", "start": 2, "end": 3}, {"entity_id": "11489400_1_Ent3", "role": "Treatment_Drug", "text": "naloxone", "start": 2, "end": 3}, {"entity_id": "11489400_1_Ent2", "role": "Treatment_Disorder", "text": "morphine - induced spasm of the sphincter of Oddi", "start": 4, "end": 13}, {"entity_id": "11489400_1_Ent0", "role": "Subject", "text": "post - cholecystectomy patient .", "start": 15, "end": 20}]}, {"id": "11489400_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "11489400_1_Ent6", "role": "Treatment", "text": "morphine", "start": 4, "end": 5}, {"entity_id": "11489400_1_Ent7", "role": "Treatment_Drug", "text": "morphine", "start": 4, "end": 5}, {"entity_id": "11489400_1_Ent5", "role": "Effect", "text": "spasm of the sphincter of Oddi", "start": 7, "end": 13}, {"entity_id": "11489400_1_Ent4", "role": "Subject", "text": "post - cholecystectomy patient .", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "11489400_1_Ent1", "text": "naloxone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11489400_1_Ent3", "text": "naloxone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11489400_1_Ent6", "text": "morphine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11489400_1_Ent7", "text": "morphine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11489400_1_Ent2", "text": "morphine - induced spasm of the sphincter of Oddi", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "11489400_1_Ent5", "text": "spasm of the sphincter of Oddi", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "11489400_1_Ent0", "text": "post - cholecystectomy patient .", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "11489400_1_Ent4", "text": "post - cholecystectomy patient .", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "11518127_1", "wnd_id": "11518127_1_1", "text": "A 62 - year - old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever .", "tokens": ["A", "62", "-", "year", "-", "old", "woman", "treated", "with", "pranlukast", "for", "2", "months", "developed", "interstitial", "pneumonitis", "with", "a", "high", "fever", "."], "event_mentions": [{"id": "11518127_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "11518127_1_Ent0", "role": "Subject", "text": "A 62 - year - old woman", "start": 0, "end": 7}, {"entity_id": "11518127_1_Ent1", "role": "Subject_Age", "text": "62 - year - old", "start": 1, "end": 6}, {"entity_id": "11518127_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "11518127_1_Ent4", "role": "Treatment", "text": "treated with pranlukast for 2 months", "start": 7, "end": 13}, {"entity_id": "11518127_1_Ent5", "role": "Treatment_Drug", "text": "pranlukast", "start": 9, "end": 10}, {"entity_id": "11518127_1_Ent6", "role": "Treatment_Duration", "text": "2 months", "start": 11, "end": 13}, {"entity_id": "11518127_1_Ent3", "role": "Effect", "text": "interstitial pneumonitis with a high fever", "start": 14, "end": 20}]}], "entity_mentions": [{"id": "11518127_1_Ent0", "text": "A 62 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "11518127_1_Ent1", "text": "62 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "11518127_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11518127_1_Ent4", "text": "treated with pranlukast for 2 months", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "11518127_1_Ent5", "text": "pranlukast", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11518127_1_Ent6", "text": "2 months", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "11518127_1_Ent3", "text": "interstitial pneumonitis with a high fever", "entity_type": "Entity", "start": 14, "end": 20}], "lang": "en"}
{"doc_id": "11545487_3", "wnd_id": "11545487_3_1", "text": "Papillary necrosis associated with the HIV protease inhibitor indinavir .", "tokens": ["Papillary", "necrosis", "associated", "with", "the", "HIV", "protease", "inhibitor", "indinavir", "."], "event_mentions": [{"id": "11545487_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11545487_3_Ent0", "role": "Effect", "text": "Papillary necrosis", "start": 0, "end": 2}, {"entity_id": "11545487_3_Ent3", "role": "Treatment_Disorder", "text": "HIV", "start": 5, "end": 6}, {"entity_id": "11545487_3_Ent1", "role": "Treatment", "text": "indinavir", "start": 8, "end": 9}, {"entity_id": "11545487_3_Ent2", "role": "Treatment_Drug", "text": "indinavir", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "11545487_3_Ent0", "text": "Papillary necrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11545487_3_Ent3", "text": "HIV", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11545487_3_Ent1", "text": "indinavir", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11545487_3_Ent2", "text": "indinavir", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "11545487_5", "wnd_id": "11545487_5_1", "text": "The HIV protease inhibitor indinavir may cause nephrolithiasis and interstitial nephritis .", "tokens": ["The", "HIV", "protease", "inhibitor", "indinavir", "may", "cause", "nephrolithiasis", "and", "interstitial", "nephritis", "."], "event_mentions": [{"id": "11545487_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 6, "end": 7}, "arguments": [{"entity_id": "11545487_5_Ent1", "role": "Treatment", "text": "HIV protease inhibitor indinavir", "start": 1, "end": 5}, {"entity_id": "11545487_5_Ent2", "role": "Treatment_Drug", "text": "indinavir", "start": 4, "end": 5}, {"entity_id": "11545487_5_Ent0", "role": "Effect", "text": "nephrolithiasis and interstitial nephritis", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "11545487_5_Ent1", "text": "HIV protease inhibitor indinavir", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "11545487_5_Ent2", "text": "indinavir", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11545487_5_Ent0", "text": "nephrolithiasis and interstitial nephritis", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "11545487_7", "wnd_id": "11545487_7_1", "text": "We report a case of papillary necrosis in a patient treated with indinavir .", "tokens": ["We", "report", "a", "case", "of", "papillary", "necrosis", "in", "a", "patient", "treated", "with", "indinavir", "."], "event_mentions": [{"id": "11545487_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 10, "end": 11}, "arguments": [{"entity_id": "11545487_7_Ent1", "role": "Effect", "text": "papillary necrosis", "start": 5, "end": 7}, {"entity_id": "11545487_7_Ent0", "role": "Subject", "text": "a patient", "start": 8, "end": 10}, {"entity_id": "11545487_7_Ent2", "role": "Treatment", "text": "indinavir", "start": 12, "end": 13}, {"entity_id": "11545487_7_Ent3", "role": "Treatment_Drug", "text": "indinavir", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "11545487_7_Ent1", "text": "papillary necrosis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11545487_7_Ent0", "text": "a patient", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "11545487_7_Ent2", "text": "indinavir", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11545487_7_Ent3", "text": "indinavir", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "11573852_2", "wnd_id": "11573852_2_1", "text": "CASE SUMMARY : A 46 - year - old African - American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B , then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time .", "tokens": ["CASE", "SUMMARY", ":", "A", "46", "-", "year", "-", "old", "African", "-", "American", "man", "experienced", "recurrent", "grand", "mal", "seizures", "during", "intravenous", "infusion", "of", "amphotericin", "B", ",", "then", "petit", "mal", "seizures", "as", "the", "infusion", "was", "stopped", "and", "the", "drug", "concentrations", "decreased", "with", "time", "."], "event_mentions": [{"id": "11573852_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 13, "end": 14}, "arguments": [{"entity_id": "11573852_2_Ent0", "role": "Subject", "text": "A 46 - year - old African - American man", "start": 3, "end": 13}, {"entity_id": "11573852_2_Ent1", "role": "Subject_Age", "text": "46 - year - old", "start": 4, "end": 9}, {"entity_id": "11573852_2_Ent2", "role": "Subject_Race", "text": "African - American", "start": 9, "end": 12}, {"entity_id": "11573852_2_Ent3", "role": "Subject_Gender", "text": "man", "start": 12, "end": 13}, {"entity_id": "11573852_2_Ent4", "role": "Effect", "text": "recurrent grand mal seizures", "start": 14, "end": 18}, {"entity_id": "11573852_2_Ent6", "role": "Treatment_Route", "text": "intravenous infusion", "start": 19, "end": 21}, {"entity_id": "11573852_2_Ent5", "role": "Treatment", "text": "intravenous infusion of amphotericin B", "start": 19, "end": 24}, {"entity_id": "11573852_2_Ent7", "role": "Treatment_Drug", "text": "amphotericin B", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "11573852_2_Ent0", "text": "A 46 - year - old African - American man", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "11573852_2_Ent1", "text": "46 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "11573852_2_Ent2", "text": "African - American", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "11573852_2_Ent3", "text": "man", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11573852_2_Ent4", "text": "recurrent grand mal seizures", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "11573852_2_Ent6", "text": "intravenous infusion", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "11573852_2_Ent5", "text": "intravenous infusion of amphotericin B", "entity_type": "Entity", "start": 19, "end": 24}, {"id": "11573852_2_Ent7", "text": "amphotericin B", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "11573852_8", "wnd_id": "11573852_8_1", "text": "To date , only three cases of seizures associated with amphotericin B have been reported in the literature , but healthcare providers should be aware of the potential for this rare adverse effect .", "tokens": ["To", "date", ",", "only", "three", "cases", "of", "seizures", "associated", "with", "amphotericin", "B", "have", "been", "reported", "in", "the", "literature", ",", "but", "healthcare", "providers", "should", "be", "aware", "of", "the", "potential", "for", "this", "rare", "adverse", "effect", "."], "event_mentions": [{"id": "11573852_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "11573852_8_Ent1", "role": "Subject_Population", "text": "three", "start": 4, "end": 5}, {"entity_id": "11573852_8_Ent0", "role": "Subject", "text": "three cases", "start": 4, "end": 6}, {"entity_id": "11573852_8_Ent2", "role": "Effect", "text": "seizures", "start": 7, "end": 8}, {"entity_id": "11573852_8_Ent3", "role": "Treatment", "text": "amphotericin B", "start": 10, "end": 12}, {"entity_id": "11573852_8_Ent4", "role": "Treatment_Drug", "text": "amphotericin B", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "11573852_8_Ent1", "text": "three", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11573852_8_Ent0", "text": "three cases", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11573852_8_Ent2", "text": "seizures", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11573852_8_Ent3", "text": "amphotericin B", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11573852_8_Ent4", "text": "amphotericin B", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "11590881_1", "wnd_id": "11590881_1_1", "text": "Carbamazepine induced right bundle branch block in a Greenlandic patient .", "tokens": ["Carbamazepine", "induced", "right", "bundle", "branch", "block", "in", "a", "Greenlandic", "patient", "."], "event_mentions": [{"id": "11590881_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "11590881_1_Ent3", "role": "Treatment", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "11590881_1_Ent4", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "11590881_1_Ent2", "role": "Effect", "text": "right bundle branch block", "start": 2, "end": 6}, {"entity_id": "11590881_1_Ent1", "role": "Subject_Race", "text": "Greenlandic", "start": 8, "end": 9}, {"entity_id": "11590881_1_Ent0", "role": "Subject", "text": "Greenlandic patient", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "11590881_1_Ent3", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11590881_1_Ent4", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11590881_1_Ent2", "text": "right bundle branch block", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "11590881_1_Ent1", "text": "Greenlandic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11590881_1_Ent0", "text": "Greenlandic patient", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "11597289_14", "wnd_id": "11597289_14_1", "text": "In patients receiving antithrombin III and concomitant heparin , a significantly increased bleeding incidence was observed ( 23.8 % for antithrombin III group vs 13.5 % for placebo group ; P<.001 ) .", "tokens": ["In", "patients", "receiving", "antithrombin", "III", "and", "concomitant", "heparin", ",", "a", "significantly", "increased", "bleeding", "incidence", "was", "observed", "(", "23.8", "%", "for", "antithrombin", "III", "group", "vs", "13.5", "%", "for", "placebo", "group", ";", "P<.001", ")", "."], "event_mentions": [{"id": "11597289_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increased", "start": 11, "end": 12}, "arguments": [{"entity_id": "11597289_14_Ent0", "role": "Subject", "text": "patients", "start": 1, "end": 2}, {"entity_id": "11597289_14_Ent4", "role": "Treatment_Drug", "text": "antithrombin III", "start": 3, "end": 5}, {"entity_id": "11597289_14_Ent5", "role": "Combination_Drug", "text": "antithrombin III", "start": 3, "end": 5}, {"entity_id": "11597289_14_Ent2", "role": "Treatment", "text": "antithrombin III and concomitant heparin", "start": 3, "end": 8}, {"entity_id": "11597289_14_Ent3", "role": "Treatment_Drug", "text": "concomitant heparin", "start": 6, "end": 8}, {"entity_id": "11597289_14_Ent6", "role": "Combination_Drug", "text": "concomitant heparin", "start": 6, "end": 8}, {"entity_id": "11597289_14_Ent1", "role": "Effect", "text": "bleeding incidence", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "11597289_14_Ent0", "text": "patients", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11597289_14_Ent4", "text": "antithrombin III", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11597289_14_Ent5", "text": "antithrombin III", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11597289_14_Ent2", "text": "antithrombin III and concomitant heparin", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11597289_14_Ent3", "text": "concomitant heparin", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11597289_14_Ent6", "text": "concomitant heparin", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11597289_14_Ent1", "text": "bleeding incidence", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "11597289_2", "wnd_id": "11597289_2_1", "text": "High - dose antithrombin III in severe sepsis : a randomized controlled trial .", "tokens": ["High", "-", "dose", "antithrombin", "III", "in", "severe", "sepsis", ":", "a", "randomized", "controlled", "trial", "."], "event_mentions": [{"id": "11597289_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "11597289_2_Ent2", "role": "Treatment_Dosage", "text": "High - dose", "start": 0, "end": 3}, {"entity_id": "11597289_2_Ent0", "role": "Treatment", "text": "High - dose antithrombin III", "start": 0, "end": 5}, {"entity_id": "11597289_2_Ent3", "role": "Treatment_Drug", "text": "antithrombin III", "start": 3, "end": 5}, {"entity_id": "11597289_2_Ent1", "role": "Treatment_Disorder", "text": "severe sepsis", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "11597289_2_Ent2", "text": "High - dose", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11597289_2_Ent0", "text": "High - dose antithrombin III", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "11597289_2_Ent3", "text": "antithrombin III", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11597289_2_Ent1", "text": "severe sepsis", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "11642488_2", "wnd_id": "11642488_2_1", "text": "CONCLUSIONS : Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion .", "tokens": ["CONCLUSIONS", ":", "Cicatrization", "in", "the", "substantia", "propria", "of", "the", "conjunctiva", "by", "excessive", "lymphocytic", "infiltration", "after", "topically", "administered", "antiglaucoma", "drugs", "including", "dipivefrin", "is", "a", "possible", "mechanism", "of", "action", "for", "entropion", "."], "event_mentions": [{"id": "11642488_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "mechanism of action", "start": 24, "end": 27}, "arguments": [{"entity_id": "11642488_2_Ent3", "role": "Treatment_Drug", "text": "antiglaucoma drugs", "start": 17, "end": 19}, {"entity_id": "11642488_2_Ent1", "role": "Treatment", "text": "antiglaucoma drugs including dipivefrin", "start": 17, "end": 21}, {"entity_id": "11642488_2_Ent2", "role": "Treatment_Drug", "text": "dipivefrin", "start": 20, "end": 21}, {"entity_id": "11642488_2_Ent0", "role": "Effect", "text": "entropion", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "11642488_2_Ent3", "text": "antiglaucoma drugs", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11642488_2_Ent1", "text": "antiglaucoma drugs including dipivefrin", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "11642488_2_Ent2", "text": "dipivefrin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11642488_2_Ent0", "text": "entropion", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "11672959_1", "wnd_id": "11672959_1_1", "text": "A 34 - year - old lady developed a constellation of dermatitis , fever , lymphadenopathy and hepatitis , beginning on the 17th day of a course of oral sulphasalazine for sero - negative rheumatoid arthritis .", "tokens": ["A", "34", "-", "year", "-", "old", "lady", "developed", "a", "constellation", "of", "dermatitis", ",", "fever", ",", "lymphadenopathy", "and", "hepatitis", ",", "beginning", "on", "the", "17th", "day", "of", "a", "course", "of", "oral", "sulphasalazine", "for", "sero", "-", "negative", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "11672959_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "11672959_1_Ent0", "role": "Subject", "text": "A 34 - year - old lady", "start": 0, "end": 7}, {"entity_id": "11672959_1_Ent1", "role": "Subject_Age", "text": "34 - year - old", "start": 1, "end": 6}, {"entity_id": "11672959_1_Ent2", "role": "Subject_Gender", "text": "lady", "start": 6, "end": 7}, {"entity_id": "11672959_1_Ent3", "role": "Effect", "text": "a constellation of dermatitis , fever , lymphadenopathy and hepatitis", "start": 8, "end": 18}, {"entity_id": "11672959_1_Ent8", "role": "Treatment_Duration", "text": "17th day", "start": 22, "end": 24}, {"entity_id": "11672959_1_Ent4", "role": "Treatment", "text": "a course of oral sulphasalazine", "start": 25, "end": 30}, {"entity_id": "11672959_1_Ent5", "role": "Treatment_Route", "text": "oral", "start": 28, "end": 29}, {"entity_id": "11672959_1_Ent6", "role": "Treatment_Drug", "text": "sulphasalazine", "start": 29, "end": 30}, {"entity_id": "11672959_1_Ent7", "role": "Treatment_Disorder", "text": "sero - negative rheumatoid arthritis", "start": 31, "end": 36}]}], "entity_mentions": [{"id": "11672959_1_Ent0", "text": "A 34 - year - old lady", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "11672959_1_Ent1", "text": "34 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "11672959_1_Ent2", "text": "lady", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11672959_1_Ent3", "text": "a constellation of dermatitis , fever , lymphadenopathy and hepatitis", "entity_type": "Entity", "start": 8, "end": 18}, {"id": "11672959_1_Ent8", "text": "17th day", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "11672959_1_Ent4", "text": "a course of oral sulphasalazine", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "11672959_1_Ent5", "text": "oral", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11672959_1_Ent6", "text": "sulphasalazine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "11672959_1_Ent7", "text": "sero - negative rheumatoid arthritis", "entity_type": "Entity", "start": 31, "end": 36}], "lang": "en"}
{"doc_id": "11688826_2", "wnd_id": "11688826_2_1", "text": "Syndrome of inappropriate secretion of ADH ( SIADH ) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion .", "tokens": ["Syndrome", "of", "inappropriate", "secretion", "of", "ADH", "(", "SIADH", ")", "following", "cisplatin", "administration", "in", "a", "pulmonary", "adenocarcinoma", "patient", "with", "a", "malignant", "pleural", "effusion", "."], "event_mentions": [{"id": "11688826_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "11688826_2_Ent2", "role": "Effect", "text": "Syndrome of inappropriate secretion of ADH ( SIADH )", "start": 0, "end": 9}, {"entity_id": "11688826_2_Ent3", "role": "Treatment", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "11688826_2_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "11688826_2_Ent0", "role": "Subject", "text": "a pulmonary adenocarcinoma patient with a malignant pleural effusion", "start": 13, "end": 22}, {"entity_id": "11688826_2_Ent4", "role": "Treatment_Disorder", "text": "pulmonary adenocarcinoma", "start": 14, "end": 16}, {"entity_id": "11688826_2_Ent1", "role": "Subject_Disorder", "text": "malignant pleural effusion", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "11688826_2_Ent2", "text": "Syndrome of inappropriate secretion of ADH ( SIADH )", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "11688826_2_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11688826_2_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11688826_2_Ent0", "text": "a pulmonary adenocarcinoma patient with a malignant pleural effusion", "entity_type": "Entity", "start": 13, "end": 22}, {"id": "11688826_2_Ent4", "text": "pulmonary adenocarcinoma", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "11688826_2_Ent1", "text": "malignant pleural effusion", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "11700998_1", "wnd_id": "11700998_1_1", "text": "De novo absence status of late onset following withdrawal of lorazepam : a case report .", "tokens": ["De", "novo", "absence", "status", "of", "late", "onset", "following", "withdrawal", "of", "lorazepam", ":", "a", "case", "report", "."], "event_mentions": [{"id": "11700998_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 7, "end": 8}, "arguments": [{"entity_id": "11700998_1_Ent0", "role": "Effect", "text": "De novo absence status of late onset", "start": 0, "end": 7}, {"entity_id": "11700998_1_Ent1", "role": "Treatment", "text": "withdrawal of lorazepam", "start": 8, "end": 11}, {"entity_id": "11700998_1_Ent2", "role": "Treatment_Drug", "text": "lorazepam", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11700998_1_Ent0", "text": "De novo absence status of late onset", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "11700998_1_Ent1", "text": "withdrawal of lorazepam", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "11700998_1_Ent2", "text": "lorazepam", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11712064_2", "wnd_id": "11712064_2_1", "text": "We describe a patient who had a systemic allergic contact dermatitis to 8 - MOP develop during her second course of PUVA treatment for psoriasis .", "tokens": ["We", "describe", "a", "patient", "who", "had", "a", "systemic", "allergic", "contact", "dermatitis", "to", "8", "-", "MOP", "develop", "during", "her", "second", "course", "of", "PUVA", "treatment", "for", "psoriasis", "."], "event_mentions": [{"id": "11712064_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 15, "end": 16}, "arguments": [{"entity_id": "11712064_2_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "11712064_2_Ent1", "role": "Effect", "text": "systemic allergic contact dermatitis to 8 - MOP", "start": 7, "end": 15}, {"entity_id": "11712064_2_Ent2", "role": "Treatment", "text": "PUVA", "start": 21, "end": 22}, {"entity_id": "11712064_2_Ent4", "role": "Treatment_Drug", "text": "PUVA", "start": 21, "end": 22}, {"entity_id": "11712064_2_Ent3", "role": "Treatment_Disorder", "text": "psoriasis", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "11712064_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11712064_2_Ent1", "text": "systemic allergic contact dermatitis to 8 - MOP", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "11712064_2_Ent2", "text": "PUVA", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11712064_2_Ent4", "text": "PUVA", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11712064_2_Ent3", "text": "psoriasis", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "11720625_4", "wnd_id": "11720625_4_1", "text": "We describe a case of TdP caused by a drug interaction in a 76 - year - old woman taking long - term disopyramide after she was given clarithromycin concomitantly for chronic bronchitis .", "tokens": ["We", "describe", "a", "case", "of", "TdP", "caused", "by", "a", "drug", "interaction", "in", "a", "76", "-", "year", "-", "old", "woman", "taking", "long", "-", "term", "disopyramide", "after", "she", "was", "given", "clarithromycin", "concomitantly", "for", "chronic", "bronchitis", "."], "event_mentions": [{"id": "11720625_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 19, "end": 20}, "arguments": [{"entity_id": "11720625_4_Ent3", "role": "Effect", "text": "TdP", "start": 5, "end": 6}, {"entity_id": "11720625_4_Ent1", "role": "Subject_Age", "text": "76 - year - old", "start": 13, "end": 18}, {"entity_id": "11720625_4_Ent0", "role": "Subject", "text": "76 - year - old woman", "start": 13, "end": 19}, {"entity_id": "11720625_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 18, "end": 19}, {"entity_id": "11720625_4_Ent4", "role": "Treatment", "text": "long - term disopyramide", "start": 20, "end": 24}, {"entity_id": "11720625_4_Ent7", "role": "Treatment_Drug", "text": "long - term disopyramide", "start": 20, "end": 24}, {"entity_id": "11720625_4_Ent9", "role": "Combination_Drug", "text": "long - term disopyramide", "start": 20, "end": 24}, {"entity_id": "11720625_4_Ent5", "role": "Treatment", "text": "clarithromycin", "start": 28, "end": 29}, {"entity_id": "11720625_4_Ent8", "role": "Treatment_Drug", "text": "clarithromycin", "start": 28, "end": 29}, {"entity_id": "11720625_4_Ent10", "role": "Combination_Drug", "text": "clarithromycin", "start": 28, "end": 29}, {"entity_id": "11720625_4_Ent6", "role": "Treatment_Disorder", "text": "chronic bronchitis", "start": 31, "end": 33}]}], "entity_mentions": [{"id": "11720625_4_Ent3", "text": "TdP", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11720625_4_Ent1", "text": "76 - year - old", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "11720625_4_Ent0", "text": "76 - year - old woman", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "11720625_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "11720625_4_Ent4", "text": "long - term disopyramide", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "11720625_4_Ent7", "text": "long - term disopyramide", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "11720625_4_Ent9", "text": "long - term disopyramide", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "11720625_4_Ent5", "text": "clarithromycin", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11720625_4_Ent8", "text": "clarithromycin", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11720625_4_Ent10", "text": "clarithromycin", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11720625_4_Ent6", "text": "chronic bronchitis", "entity_type": "Entity", "start": 31, "end": 33}], "lang": "en"}
{"doc_id": "11722307_1", "wnd_id": "11722307_1_1", "text": "Agranulocytosis and granulocytopenia associated with quetiapine .", "tokens": ["Agranulocytosis", "and", "granulocytopenia", "associated", "with", "quetiapine", "."], "event_mentions": [{"id": "11722307_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "11722307_1_Ent0", "role": "Effect", "text": "Agranulocytosis and granulocytopenia", "start": 0, "end": 3}, {"entity_id": "11722307_1_Ent1", "role": "Treatment", "text": "quetiapine", "start": 5, "end": 6}, {"entity_id": "11722307_1_Ent2", "role": "Treatment_Drug", "text": "quetiapine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "11722307_1_Ent0", "text": "Agranulocytosis and granulocytopenia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11722307_1_Ent1", "text": "quetiapine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11722307_1_Ent2", "text": "quetiapine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "11722307_2", "wnd_id": "11722307_2_1", "text": "CONCLUSION : Although a definite association has not been proven , clinicians should be aware of the possibility of agranulocytosis while using quetiapine .", "tokens": ["CONCLUSION", ":", "Although", "a", "definite", "association", "has", "not", "been", "proven", ",", "clinicians", "should", "be", "aware", "of", "the", "possibility", "of", "agranulocytosis", "while", "using", "quetiapine", "."], "event_mentions": [{"id": "11722307_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "using", "start": 21, "end": 22}, "arguments": [{"entity_id": "11722307_2_Ent0", "role": "Effect", "text": "agranulocytosis", "start": 19, "end": 20}, {"entity_id": "11722307_2_Ent1", "role": "Treatment", "text": "quetiapine", "start": 22, "end": 23}, {"entity_id": "11722307_2_Ent2", "role": "Treatment_Drug", "text": "quetiapine", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "11722307_2_Ent0", "text": "agranulocytosis", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11722307_2_Ent1", "text": "quetiapine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "11722307_2_Ent2", "text": "quetiapine", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "11722307_3", "wnd_id": "11722307_3_1", "text": "METHOD : We describe three case - reports concerning haematological adverse effects of quetiapine .", "tokens": ["METHOD", ":", "We", "describe", "three", "case", "-", "reports", "concerning", "haematological", "adverse", "effects", "of", "quetiapine", "."], "event_mentions": [{"id": "11722307_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effects", "start": 10, "end": 12}, "arguments": [{"entity_id": "11722307_3_Ent0", "role": "Effect", "text": "haematological adverse effects", "start": 9, "end": 12}, {"entity_id": "11722307_3_Ent1", "role": "Treatment", "text": "quetiapine", "start": 13, "end": 14}, {"entity_id": "11722307_3_Ent2", "role": "Treatment_Drug", "text": "quetiapine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "11722307_3_Ent0", "text": "haematological adverse effects", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "11722307_3_Ent1", "text": "quetiapine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11722307_3_Ent2", "text": "quetiapine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "11724089_2", "wnd_id": "11724089_2_1", "text": "However , a large case - control study included three cases of either Stevens - Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use , but no details of the cases were given .", "tokens": ["However", ",", "a", "large", "case", "-", "control", "study", "included", "three", "cases", "of", "either", "Stevens", "-", "Johnson", "syndrome", "or", "toxic", "epidermal", "necrolysis", "associated", "with", "ofloxacin", "use", ",", "but", "no", "details", "of", "the", "cases", "were", "given", "."], "event_mentions": [{"id": "11724089_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 21, "end": 22}, "arguments": [{"entity_id": "11724089_2_Ent1", "role": "Subject_Population", "text": "three", "start": 9, "end": 10}, {"entity_id": "11724089_2_Ent0", "role": "Subject", "text": "three cases", "start": 9, "end": 11}, {"entity_id": "11724089_2_Ent2", "role": "Effect", "text": "Stevens - Johnson syndrome or toxic epidermal necrolysis", "start": 13, "end": 21}, {"entity_id": "11724089_2_Ent3", "role": "Treatment", "text": "ofloxacin", "start": 23, "end": 24}, {"entity_id": "11724089_2_Ent4", "role": "Treatment_Drug", "text": "ofloxacin", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "11724089_2_Ent1", "text": "three", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11724089_2_Ent0", "text": "three cases", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11724089_2_Ent2", "text": "Stevens - Johnson syndrome or toxic epidermal necrolysis", "entity_type": "Entity", "start": 13, "end": 21}, {"id": "11724089_2_Ent3", "text": "ofloxacin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11724089_2_Ent4", "text": "ofloxacin", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "11724089_4", "wnd_id": "11724089_4_1", "text": "OBJECTIVE : To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "fatal", "case", "of", "toxic", "epidermal", "necrolysis", "in", "a", "man", "who", "was", "treated", "with", "oral", "ofloxacin", "for", "epididymitis", "."], "event_mentions": [{"id": "11724089_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 16, "end": 17}, "arguments": [{"entity_id": "11724089_4_Ent2", "role": "Effect", "text": "fatal case of toxic epidermal necrolysis", "start": 5, "end": 11}, {"entity_id": "11724089_4_Ent0", "role": "Subject", "text": "man", "start": 13, "end": 14}, {"entity_id": "11724089_4_Ent1", "role": "Subject_Gender", "text": "man", "start": 13, "end": 14}, {"entity_id": "11724089_4_Ent4", "role": "Treatment_Route", "text": "oral", "start": 18, "end": 19}, {"entity_id": "11724089_4_Ent3", "role": "Treatment", "text": "oral ofloxacin", "start": 18, "end": 20}, {"entity_id": "11724089_4_Ent5", "role": "Treatment_Drug", "text": "ofloxacin", "start": 19, "end": 20}, {"entity_id": "11724089_4_Ent6", "role": "Treatment_Disorder", "text": "epididymitis", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "11724089_4_Ent2", "text": "fatal case of toxic epidermal necrolysis", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "11724089_4_Ent0", "text": "man", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11724089_4_Ent1", "text": "man", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11724089_4_Ent4", "text": "oral", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "11724089_4_Ent3", "text": "oral ofloxacin", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "11724089_4_Ent5", "text": "ofloxacin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11724089_4_Ent6", "text": "epididymitis", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "11724089_5", "wnd_id": "11724089_5_1", "text": "Ofloxacin : a probable cause of toxic epidermal necrolysis .", "tokens": ["Ofloxacin", ":", "a", "probable", "cause", "of", "toxic", "epidermal", "necrolysis", "."], "event_mentions": [{"id": "11724089_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "11724089_5_Ent1", "role": "Treatment", "text": "Ofloxacin", "start": 0, "end": 1}, {"entity_id": "11724089_5_Ent2", "role": "Treatment_Drug", "text": "Ofloxacin", "start": 0, "end": 1}, {"entity_id": "11724089_5_Ent0", "role": "Effect", "text": "toxic epidermal necrolysis", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "11724089_5_Ent1", "text": "Ofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11724089_5_Ent2", "text": "Ofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11724089_5_Ent0", "text": "toxic epidermal necrolysis", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "11737689_1", "wnd_id": "11737689_1_1", "text": "A boy with chronic neutropenia and recurrent inflammatory skin lesions developed multiple erythematous nodules following administration of G - CSF .", "tokens": ["A", "boy", "with", "chronic", "neutropenia", "and", "recurrent", "inflammatory", "skin", "lesions", "developed", "multiple", "erythematous", "nodules", "following", "administration", "of", "G", "-", "CSF", "."], "event_mentions": [{"id": "11737689_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "11737689_1_Ent0", "role": "Subject", "text": "A boy with chronic neutropenia and recurrent inflammatory skin lesions", "start": 0, "end": 10}, {"entity_id": "11737689_1_Ent1", "role": "Subject_Gender", "text": "boy", "start": 1, "end": 2}, {"entity_id": "11737689_1_Ent4", "role": "Treatment_Disorder", "text": "chronic neutropenia and recurrent inflammatory skin lesions", "start": 3, "end": 10}, {"entity_id": "11737689_1_Ent2", "role": "Effect", "text": "multiple erythematous nodules", "start": 11, "end": 14}, {"entity_id": "11737689_1_Ent3", "role": "Treatment", "text": "G - CSF", "start": 17, "end": 20}, {"entity_id": "11737689_1_Ent5", "role": "Treatment_Drug", "text": "G - CSF", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "11737689_1_Ent0", "text": "A boy with chronic neutropenia and recurrent inflammatory skin lesions", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "11737689_1_Ent1", "text": "boy", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11737689_1_Ent4", "text": "chronic neutropenia and recurrent inflammatory skin lesions", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "11737689_1_Ent2", "text": "multiple erythematous nodules", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "11737689_1_Ent3", "text": "G - CSF", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "11737689_1_Ent5", "text": "G - CSF", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "11737689_4", "wnd_id": "11737689_4_1", "text": "Painful neutrophilic skin lesions were observed in two children receiving granulocyte colony - stimulating factor ( G - CSF ) for treatment of idiopathic neutropenia .", "tokens": ["Painful", "neutrophilic", "skin", "lesions", "were", "observed", "in", "two", "children", "receiving", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", "for", "treatment", "of", "idiopathic", "neutropenia", "."], "event_mentions": [{"id": "11737689_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 5, "end": 6}, "arguments": [{"entity_id": "11737689_4_Ent3", "role": "Effect", "text": "Painful neutrophilic skin lesions", "start": 0, "end": 4}, {"entity_id": "11737689_4_Ent1", "role": "Subject_Population", "text": "two", "start": 7, "end": 8}, {"entity_id": "11737689_4_Ent0", "role": "Subject", "text": "two children", "start": 7, "end": 9}, {"entity_id": "11737689_4_Ent2", "role": "Subject_Age", "text": "children", "start": 8, "end": 9}, {"entity_id": "11737689_4_Ent5", "role": "Treatment_Drug", "text": "granulocyte colony - stimulating factor", "start": 10, "end": 15}, {"entity_id": "11737689_4_Ent4", "role": "Treatment", "text": "granulocyte colony - stimulating factor ( G - CSF )", "start": 10, "end": 20}, {"entity_id": "11737689_4_Ent6", "role": "Treatment_Disorder", "text": "idiopathic neutropenia", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "11737689_4_Ent3", "text": "Painful neutrophilic skin lesions", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "11737689_4_Ent1", "text": "two", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11737689_4_Ent0", "text": "two children", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "11737689_4_Ent2", "text": "children", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11737689_4_Ent5", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "11737689_4_Ent4", "text": "granulocyte colony - stimulating factor ( G - CSF )", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "11737689_4_Ent6", "text": "idiopathic neutropenia", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "11737689_5", "wnd_id": "11737689_5_1", "text": "We believe that these skin eruptions belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by G - CSF therapy .", "tokens": ["We", "believe", "that", "these", "skin", "eruptions", "belong", "to", "a", "spectrum", "of", "neutrophilic", "dermatoses", "that", "can", "be", "induced", "or", "aggravated", "by", "G", "-", "CSF", "therapy", "."], "event_mentions": [{"id": "11737689_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 16, "end": 17}, "arguments": [{"entity_id": "11737689_5_Ent0", "role": "Effect", "text": "skin eruptions", "start": 4, "end": 6}, {"entity_id": "11737689_5_Ent1", "role": "Treatment", "text": "G - CSF", "start": 20, "end": 23}, {"entity_id": "11737689_5_Ent2", "role": "Treatment_Drug", "text": "G - CSF", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "11737689_5_Ent0", "text": "skin eruptions", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11737689_5_Ent1", "text": "G - CSF", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "11737689_5_Ent2", "text": "G - CSF", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "11804071_2", "wnd_id": "11804071_2_1", "text": "Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption .", "tokens": ["Isonicotinic", "acid", "hydrazide", "induced", "anagen", "effluvium", "and", "associated", "lichenoid", "eruption", "."], "event_mentions": [{"id": "11804071_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "11804071_2_Ent1", "role": "Treatment", "text": "Isonicotinic acid hydrazide", "start": 0, "end": 3}, {"entity_id": "11804071_2_Ent2", "role": "Treatment_Drug", "text": "Isonicotinic acid hydrazide", "start": 0, "end": 3}, {"entity_id": "11804071_2_Ent0", "role": "Effect", "text": "anagen effluvium and associated lichenoid eruption", "start": 4, "end": 10}]}], "entity_mentions": [{"id": "11804071_2_Ent1", "text": "Isonicotinic acid hydrazide", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11804071_2_Ent2", "text": "Isonicotinic acid hydrazide", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11804071_2_Ent0", "text": "anagen effluvium and associated lichenoid eruption", "entity_type": "Entity", "start": 4, "end": 10}], "lang": "en"}
{"doc_id": "11816261_2", "wnd_id": "11816261_2_1", "text": "CONCLUSIONS : Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single , conventional dose .", "tokens": ["CONCLUSIONS", ":", "Clinicians", "should", "be", "aware", "of", "a", "risk", "of", "serotonin", "syndrome", "with", "serious", "extrapyramidal", "reactions", "in", "patients", "receiving", "sertraline", "or", "venlafaxine", "when", "metoclopramide", "is", "coadministered", "even", "in", "a", "single", ",", "conventional", "dose", "."], "event_mentions": [{"id": "11816261_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 18, "end": 19}, "arguments": [{"entity_id": "11816261_2_Ent1", "role": "Effect", "text": "serotonin syndrome with serious extrapyramidal reactions", "start": 10, "end": 16}, {"entity_id": "11816261_2_Ent0", "role": "Subject", "text": "patients", "start": 17, "end": 18}, {"entity_id": "11816261_2_Ent3", "role": "Treatment_Drug", "text": "sertraline", "start": 19, "end": 20}, {"entity_id": "11816261_2_Ent9", "role": "Combination_Drug", "text": "sertraline", "start": 19, "end": 20}, {"entity_id": "11816261_2_Ent2", "role": "Treatment", "text": "sertraline or venlafaxine when metoclopramide is coadministered even in a single , conventional dose", "start": 19, "end": 33}, {"entity_id": "11816261_2_Ent4", "role": "Treatment_Drug", "text": "venlafaxine", "start": 21, "end": 22}, {"entity_id": "11816261_2_Ent8", "role": "Combination_Drug", "text": "venlafaxine", "start": 21, "end": 22}, {"entity_id": "11816261_2_Ent5", "role": "Treatment_Drug", "text": "metoclopramide", "start": 23, "end": 24}, {"entity_id": "11816261_2_Ent7", "role": "Combination_Drug", "text": "metoclopramide", "start": 23, "end": 24}, {"entity_id": "11816261_2_Ent6", "role": "Treatment_Dosage", "text": "single , conventional dose", "start": 29, "end": 33}]}], "entity_mentions": [{"id": "11816261_2_Ent1", "text": "serotonin syndrome with serious extrapyramidal reactions", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "11816261_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11816261_2_Ent3", "text": "sertraline", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11816261_2_Ent9", "text": "sertraline", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11816261_2_Ent2", "text": "sertraline or venlafaxine when metoclopramide is coadministered even in a single , conventional dose", "entity_type": "Entity", "start": 19, "end": 33}, {"id": "11816261_2_Ent4", "text": "venlafaxine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11816261_2_Ent8", "text": "venlafaxine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11816261_2_Ent5", "text": "metoclopramide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11816261_2_Ent7", "text": "metoclopramide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11816261_2_Ent6", "text": "single , conventional dose", "entity_type": "Entity", "start": 29, "end": 33}], "lang": "en"}
{"doc_id": "11816261_4", "wnd_id": "11816261_4_1", "text": "Serotonin syndrome caused by selective serotonin reuptake - inhibitors - metoclopramide interaction .", "tokens": ["Serotonin", "syndrome", "caused", "by", "selective", "serotonin", "reuptake", "-", "inhibitors", "-", "metoclopramide", "interaction", "."], "event_mentions": [{"id": "11816261_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 2, "end": 3}, "arguments": [{"entity_id": "11816261_4_Ent0", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "11816261_4_Ent3", "role": "Treatment_Drug", "text": "selective serotonin reuptake - inhibitors", "start": 4, "end": 9}, {"entity_id": "11816261_4_Ent5", "role": "Combination_Drug", "text": "selective serotonin reuptake - inhibitors", "start": 4, "end": 9}, {"entity_id": "11816261_4_Ent1", "role": "Treatment", "text": "selective serotonin reuptake - inhibitors - metoclopramide interaction", "start": 4, "end": 12}, {"entity_id": "11816261_4_Ent2", "role": "Treatment_Drug", "text": "metoclopramide", "start": 10, "end": 11}, {"entity_id": "11816261_4_Ent4", "role": "Combination_Drug", "text": "metoclopramide", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11816261_4_Ent0", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11816261_4_Ent3", "text": "selective serotonin reuptake - inhibitors", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "11816261_4_Ent5", "text": "selective serotonin reuptake - inhibitors", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "11816261_4_Ent1", "text": "selective serotonin reuptake - inhibitors - metoclopramide interaction", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "11816261_4_Ent2", "text": "metoclopramide", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11816261_4_Ent4", "text": "metoclopramide", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11834188_2", "wnd_id": "11834188_2_1", "text": "Captopril is an angiotensin - converting enzyme ( ACE ) inhibitor and their cutaneous side - effects are documented , but little has been published concerning the usefulness of patch test when they occur .", "tokens": ["Captopril", "is", "an", "angiotensin", "-", "converting", "enzyme", "(", "ACE", ")", "inhibitor", "and", "their", "cutaneous", "side", "-", "effects", "are", "documented", ",", "but", "little", "has", "been", "published", "concerning", "the", "usefulness", "of", "patch", "test", "when", "they", "occur", "."], "event_mentions": [{"id": "11834188_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "documented", "start": 18, "end": 19}, "arguments": [{"entity_id": "11834188_2_Ent1", "role": "Treatment", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "11834188_2_Ent2", "role": "Treatment_Drug", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "11834188_2_Ent0", "role": "Effect", "text": "cutaneous side - effects", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "11834188_2_Ent1", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11834188_2_Ent2", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11834188_2_Ent0", "text": "cutaneous side - effects", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "11850606_4", "wnd_id": "11850606_4_1", "text": "To treat hepatitis B , interferon alpha was administered until the proximal muscle weakness developed .", "tokens": ["To", "treat", "hepatitis", "B", ",", "interferon", "alpha", "was", "administered", "until", "the", "proximal", "muscle", "weakness", "developed", "."], "event_mentions": [{"id": "11850606_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "11850606_4_Ent2", "role": "Treatment_Disorder", "text": "hepatitis B", "start": 2, "end": 4}, {"entity_id": "11850606_4_Ent1", "role": "Treatment", "text": "interferon alpha", "start": 5, "end": 7}, {"entity_id": "11850606_4_Ent3", "role": "Treatment_Drug", "text": "interferon alpha", "start": 5, "end": 7}, {"entity_id": "11850606_4_Ent0", "role": "Effect", "text": "proximal muscle weakness", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "11850606_4_Ent2", "text": "hepatitis B", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11850606_4_Ent1", "text": "interferon alpha", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11850606_4_Ent3", "text": "interferon alpha", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11850606_4_Ent0", "text": "proximal muscle weakness", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "11881322_2", "wnd_id": "11881322_2_1", "text": "CONCLUSIONS : Itraconazole - induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts , possibly leading to ductopenia .", "tokens": ["CONCLUSIONS", ":", "Itraconazole", "-", "induced", "liver", "injury", "presents", "with", "a", "cholestatic", "pattern", "of", "injury", "with", "damage", "to", "the", "interlobular", "bile", "ducts", ",", "possibly", "leading", "to", "ductopenia", "."], "event_mentions": [{"id": "11881322_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "11881322_2_Ent1", "role": "Treatment", "text": "Itraconazole", "start": 2, "end": 3}, {"entity_id": "11881322_2_Ent2", "role": "Treatment_Drug", "text": "Itraconazole", "start": 2, "end": 3}, {"entity_id": "11881322_2_Ent0", "role": "Effect", "text": "liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts , possibly leading to ductopenia", "start": 5, "end": 26}]}], "entity_mentions": [{"id": "11881322_2_Ent1", "text": "Itraconazole", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11881322_2_Ent2", "text": "Itraconazole", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11881322_2_Ent0", "text": "liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts , possibly leading to ductopenia", "entity_type": "Entity", "start": 5, "end": 26}], "lang": "en"}
{"doc_id": "11881322_3", "wnd_id": "11881322_3_1", "text": "Hepatotoxicity related to itraconazole : report of three cases .", "tokens": ["Hepatotoxicity", "related", "to", "itraconazole", ":", "report", "of", "three", "cases", "."], "event_mentions": [{"id": "11881322_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 1, "end": 2}, "arguments": [{"entity_id": "11881322_3_Ent2", "role": "Effect", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "11881322_3_Ent3", "role": "Treatment", "text": "itraconazole", "start": 3, "end": 4}, {"entity_id": "11881322_3_Ent4", "role": "Treatment_Drug", "text": "itraconazole", "start": 3, "end": 4}, {"entity_id": "11881322_3_Ent1", "role": "Subject_Population", "text": "three", "start": 7, "end": 8}, {"entity_id": "11881322_3_Ent0", "role": "Subject", "text": "three cases", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "11881322_3_Ent2", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11881322_3_Ent3", "text": "itraconazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11881322_3_Ent4", "text": "itraconazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11881322_3_Ent1", "text": "three", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11881322_3_Ent0", "text": "three cases", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "11886466_3", "wnd_id": "11886466_3_1", "text": "We have recently encountered a patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke while being treated with pFVIII .", "tokens": ["We", "have", "recently", "encountered", "a", "patient", "with", "acquired", "haemophilia", "who", "developed", "a", "thrombotic", "left", "middle", "cerebral", "artery", "distribution", "stroke", "while", "being", "treated", "with", "pFVIII", "."], "event_mentions": [{"id": "11886466_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 21, "end": 22}, "arguments": [{"entity_id": "11886466_3_Ent0", "role": "Subject", "text": "patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke", "start": 5, "end": 19}, {"entity_id": "11886466_3_Ent3", "role": "Treatment_Disorder", "text": "acquired haemophilia", "start": 7, "end": 9}, {"entity_id": "11886466_3_Ent1", "role": "Effect", "text": "thrombotic left middle cerebral artery distribution stroke", "start": 12, "end": 19}, {"entity_id": "11886466_3_Ent2", "role": "Treatment", "text": "pFVIII", "start": 23, "end": 24}, {"entity_id": "11886466_3_Ent4", "role": "Treatment_Drug", "text": "pFVIII", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "11886466_3_Ent0", "text": "patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke", "entity_type": "Entity", "start": 5, "end": 19}, {"id": "11886466_3_Ent3", "text": "acquired haemophilia", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "11886466_3_Ent1", "text": "thrombotic left middle cerebral artery distribution stroke", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "11886466_3_Ent2", "text": "pFVIII", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11886466_3_Ent4", "text": "pFVIII", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "11889149_14", "wnd_id": "11889149_14_1", "text": "RLX+ALN reduced bone turnover more than either drug alone , resulting in greater BMD increment , but whether this difference reflects better fracture risk reduction was not assessed in this study .", "tokens": ["RLX+ALN", "reduced", "bone", "turnover", "more", "than", "either", "drug", "alone", ",", "resulting", "in", "greater", "BMD", "increment", ",", "but", "whether", "this", "difference", "reflects", "better", "fracture", "risk", "reduction", "was", "not", "assessed", "in", "this", "study", "."], "event_mentions": [{"id": "11889149_14_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reduced", "start": 1, "end": 2}, "arguments": [{"entity_id": "11889149_14_Ent1", "role": "Treatment", "text": "RLX+ALN", "start": 0, "end": 1}, {"entity_id": "11889149_14_Ent2", "role": "Treatment", "text": "RLX+ALN", "start": 0, "end": 1}, {"entity_id": "11889149_14_Ent3", "role": "Treatment_Drug", "text": "RLX+ALN", "start": 0, "end": 1}, {"entity_id": "11889149_14_Ent4", "role": "Treatment_Drug", "text": "RLX+ALN", "start": 0, "end": 1}, {"entity_id": "11889149_14_Ent5", "role": "Combination_Drug", "text": "RLX+ALN", "start": 0, "end": 1}, {"entity_id": "11889149_14_Ent6", "role": "Combination_Drug", "text": "RLX+ALN", "start": 0, "end": 1}, {"entity_id": "11889149_14_Ent0", "role": "Effect", "text": "bone turnover more than either drug alone , resulting in greater BMD increment", "start": 2, "end": 15}]}], "entity_mentions": [{"id": "11889149_14_Ent1", "text": "RLX+ALN", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11889149_14_Ent2", "text": "RLX+ALN", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11889149_14_Ent3", "text": "RLX+ALN", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11889149_14_Ent4", "text": "RLX+ALN", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11889149_14_Ent5", "text": "RLX+ALN", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11889149_14_Ent6", "text": "RLX+ALN", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11889149_14_Ent0", "text": "bone turnover more than either drug alone , resulting in greater BMD increment", "entity_type": "Entity", "start": 2, "end": 15}], "lang": "en"}
{"doc_id": "11903249_2", "wnd_id": "11903249_2_1", "text": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin .", "tokens": ["There", "have", "been", "more", "than", "20", "observations", "of", "the", "appearance", "or", "aggravation", "of", "this", "granulomatosis", "with", "interferon", "alfa", "and", "more", "recently", "with", "the", "combination", "of", "interferon", "alfa", "plus", "ribavirin", "."], "event_mentions": [{"id": "11903249_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 15, "end": 16}, "arguments": [{"entity_id": "11903249_2_Ent0", "role": "Effect", "text": "more than 20 observations of the appearance or aggravation of this granulomatosis", "start": 3, "end": 15}, {"entity_id": "11903249_2_Ent2", "role": "Treatment_Drug", "text": "interferon alfa", "start": 16, "end": 18}, {"entity_id": "11903249_2_Ent1", "role": "Treatment", "text": "interferon alfa and more recently with the combination of interferon alfa plus ribavirin", "start": 16, "end": 29}, {"entity_id": "11903249_2_Ent3", "role": "Treatment_Drug", "text": "interferon alfa", "start": 25, "end": 27}, {"entity_id": "11903249_2_Ent5", "role": "Combination_Drug", "text": "interferon alfa", "start": 25, "end": 27}, {"entity_id": "11903249_2_Ent4", "role": "Treatment_Drug", "text": "ribavirin", "start": 28, "end": 29}, {"entity_id": "11903249_2_Ent6", "role": "Combination_Drug", "text": "ribavirin", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "11903249_2_Ent0", "text": "more than 20 observations of the appearance or aggravation of this granulomatosis", "entity_type": "Entity", "start": 3, "end": 15}, {"id": "11903249_2_Ent2", "text": "interferon alfa", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "11903249_2_Ent1", "text": "interferon alfa and more recently with the combination of interferon alfa plus ribavirin", "entity_type": "Entity", "start": 16, "end": 29}, {"id": "11903249_2_Ent3", "text": "interferon alfa", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "11903249_2_Ent5", "text": "interferon alfa", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "11903249_2_Ent4", "text": "ribavirin", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11903249_2_Ent6", "text": "ribavirin", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "11918514_4", "wnd_id": "11918514_4_1", "text": "Severe serotonin syndrome induced by mirtazapine monotherapy .", "tokens": ["Severe", "serotonin", "syndrome", "induced", "by", "mirtazapine", "monotherapy", "."], "event_mentions": [{"id": "11918514_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced by", "start": 3, "end": 5}, "arguments": [{"entity_id": "11918514_4_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 1, "end": 3}, {"entity_id": "11918514_4_Ent2", "role": "Treatment_Drug", "text": "mirtazapine", "start": 5, "end": 6}, {"entity_id": "11918514_4_Ent1", "role": "Treatment", "text": "mirtazapine monotherapy", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "11918514_4_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "11918514_4_Ent2", "text": "mirtazapine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11918514_4_Ent1", "text": "mirtazapine monotherapy", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "11943900_1", "wnd_id": "11943900_1_1", "text": "Pulmonary toxicity secondary to procarbazine .", "tokens": ["Pulmonary", "toxicity", "secondary", "to", "procarbazine", "."], "event_mentions": [{"id": "11943900_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 2, "end": 3}, "arguments": [{"entity_id": "11943900_1_Ent0", "role": "Effect", "text": "Pulmonary toxicity", "start": 0, "end": 2}, {"entity_id": "11943900_1_Ent1", "role": "Treatment", "text": "procarbazine", "start": 4, "end": 5}, {"entity_id": "11943900_1_Ent2", "role": "Treatment_Drug", "text": "procarbazine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "11943900_1_Ent0", "text": "Pulmonary toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11943900_1_Ent1", "text": "procarbazine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11943900_1_Ent2", "text": "procarbazine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "11984077_3", "wnd_id": "11984077_3_1", "text": "The patient suffered a life - threatening anaphylactoid reaction to amifostine .", "tokens": ["The", "patient", "suffered", "a", "life", "-", "threatening", "anaphylactoid", "reaction", "to", "amifostine", "."], "event_mentions": [{"id": "11984077_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffered", "start": 2, "end": 3}, "arguments": [{"entity_id": "11984077_3_Ent0", "role": "Subject", "text": "patient", "start": 1, "end": 2}, {"entity_id": "11984077_3_Ent1", "role": "Effect", "text": "life - threatening anaphylactoid reaction", "start": 4, "end": 9}, {"entity_id": "11984077_3_Ent2", "role": "Treatment", "text": "amifostine", "start": 10, "end": 11}, {"entity_id": "11984077_3_Ent3", "role": "Treatment_Drug", "text": "amifostine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11984077_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11984077_3_Ent1", "text": "life - threatening anaphylactoid reaction", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "11984077_3_Ent2", "text": "amifostine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11984077_3_Ent3", "text": "amifostine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11999915_1", "wnd_id": "11999915_1_1", "text": "Agranulocytosis during clozapine therapy .", "tokens": ["Agranulocytosis", "during", "clozapine", "therapy", "."], "event_mentions": [{"id": "11999915_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 1, "end": 2}, "arguments": [{"entity_id": "11999915_1_Ent0", "role": "Effect", "text": "Agranulocytosis", "start": 0, "end": 1}, {"entity_id": "11999915_1_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 2, "end": 3}, {"entity_id": "11999915_1_Ent1", "role": "Treatment", "text": "clozapine therapy", "start": 2, "end": 4}]}], "entity_mentions": [{"id": "11999915_1_Ent0", "text": "Agranulocytosis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11999915_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11999915_1_Ent1", "text": "clozapine therapy", "entity_type": "Entity", "start": 2, "end": 4}], "lang": "en"}
{"doc_id": "11999915_2", "wnd_id": "11999915_2_1", "text": "Granulocytopenia and agranulocytosis are considered among the most dangerous adverse effects of clozapine .", "tokens": ["Granulocytopenia", "and", "agranulocytosis", "are", "considered", "among", "the", "most", "dangerous", "adverse", "effects", "of", "clozapine", "."], "event_mentions": [{"id": "11999915_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "among", "start": 5, "end": 6}, "arguments": [{"entity_id": "11999915_2_Ent0", "role": "Effect", "text": "Granulocytopenia and agranulocytosis", "start": 0, "end": 3}, {"entity_id": "11999915_2_Ent1", "role": "Treatment", "text": "clozapine", "start": 12, "end": 13}, {"entity_id": "11999915_2_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "11999915_2_Ent0", "text": "Granulocytopenia and agranulocytosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11999915_2_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11999915_2_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12013364_2", "wnd_id": "12013364_2_1", "text": "Atypical neuroleptic malignant syndrome associated with olanzapine .", "tokens": ["Atypical", "neuroleptic", "malignant", "syndrome", "associated", "with", "olanzapine", "."], "event_mentions": [{"id": "12013364_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "12013364_2_Ent0", "role": "Effect", "text": "Atypical neuroleptic malignant syndrome", "start": 0, "end": 4}, {"entity_id": "12013364_2_Ent1", "role": "Treatment", "text": "olanzapine", "start": 6, "end": 7}, {"entity_id": "12013364_2_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "12013364_2_Ent0", "text": "Atypical neuroleptic malignant syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12013364_2_Ent1", "text": "olanzapine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12013364_2_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "12042592_1", "wnd_id": "12042592_1_1", "text": "After identification of the index patient , additional inquiry revealed that the patient 's mother was hospitalized previously for overwhelming sepsis associated with metamizole use .", "tokens": ["After", "identification", "of", "the", "index", "patient", ",", "additional", "inquiry", "revealed", "that", "the", "patient", "'s", "mother", "was", "hospitalized", "previously", "for", "overwhelming", "sepsis", "associated", "with", "metamizole", "use", "."], "event_mentions": [{"id": "12042592_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 21, "end": 22}, "arguments": [{"entity_id": "12042592_1_Ent0", "role": "Subject", "text": "the patient 's mother", "start": 11, "end": 15}, {"entity_id": "12042592_1_Ent1", "role": "Effect", "text": "overwhelming sepsis", "start": 19, "end": 21}, {"entity_id": "12042592_1_Ent2", "role": "Treatment", "text": "metamizole", "start": 23, "end": 24}, {"entity_id": "12042592_1_Ent3", "role": "Treatment_Drug", "text": "metamizole", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "12042592_1_Ent0", "text": "the patient 's mother", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "12042592_1_Ent1", "text": "overwhelming sepsis", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "12042592_1_Ent2", "text": "metamizole", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "12042592_1_Ent3", "text": "metamizole", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "12042592_2", "wnd_id": "12042592_2_1", "text": "Metamizole , a nonsteroidal antiinflammatory agent , is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries .", "tokens": ["Metamizole", ",", "a", "nonsteroidal", "antiinflammatory", "agent", ",", "is", "prohibited", "in", "the", "United", "States", "because", "of", "the", "risk", "of", "agranulocytosis", "but", "is", "widely", "used", "in", "Mexico", "and", "other", "countries", "."], "event_mentions": [{"id": "12042592_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 16, "end": 17}, "arguments": [{"entity_id": "12042592_2_Ent1", "role": "Treatment", "text": "Metamizole", "start": 0, "end": 1}, {"entity_id": "12042592_2_Ent2", "role": "Treatment_Drug", "text": "Metamizole", "start": 0, "end": 1}, {"entity_id": "12042592_2_Ent0", "role": "Effect", "text": "agranulocytosis", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "12042592_2_Ent1", "text": "Metamizole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12042592_2_Ent2", "text": "Metamizole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12042592_2_Ent0", "text": "agranulocytosis", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "12053072_1", "wnd_id": "12053072_1_1", "text": "Erythropoietin is beneficial in mitomycin - induced hemolytic - uremic syndrome .", "tokens": ["Erythropoietin", "is", "beneficial", "in", "mitomycin", "-", "induced", "hemolytic", "-", "uremic", "syndrome", "."], "event_mentions": [{"id": "12053072_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "beneficial", "start": 2, "end": 3}, "arguments": [{"entity_id": "12053072_1_Ent0", "role": "Treatment", "text": "Erythropoietin", "start": 0, "end": 1}, {"entity_id": "12053072_1_Ent2", "role": "Treatment_Drug", "text": "Erythropoietin", "start": 0, "end": 1}, {"entity_id": "12053072_1_Ent1", "role": "Treatment_Disorder", "text": "mitomycin - induced hemolytic - uremic syndrome", "start": 4, "end": 11}]}, {"id": "12053072_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "12053072_1_Ent4", "role": "Treatment", "text": "mitomycin", "start": 4, "end": 5}, {"entity_id": "12053072_1_Ent5", "role": "Treatment_Drug", "text": "mitomycin", "start": 4, "end": 5}, {"entity_id": "12053072_1_Ent3", "role": "Effect", "text": "hemolytic - uremic syndrome", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "12053072_1_Ent0", "text": "Erythropoietin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12053072_1_Ent2", "text": "Erythropoietin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12053072_1_Ent4", "text": "mitomycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12053072_1_Ent5", "text": "mitomycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12053072_1_Ent1", "text": "mitomycin - induced hemolytic - uremic syndrome", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "12053072_1_Ent3", "text": "hemolytic - uremic syndrome", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "12053072_2", "wnd_id": "12053072_2_1", "text": "We describe a patient who developed HUS after treatment with mitomycin C ( total dose 144 mg / m2 ) due to a carcinoma of the ascending colon .", "tokens": ["We", "describe", "a", "patient", "who", "developed", "HUS", "after", "treatment", "with", "mitomycin", "C", "(", "total", "dose", "144", "mg", "/", "m2", ")", "due", "to", "a", "carcinoma", "of", "the", "ascending", "colon", "."], "event_mentions": [{"id": "12053072_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "12053072_2_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "12053072_2_Ent1", "role": "Effect", "text": "HUS", "start": 6, "end": 7}, {"entity_id": "12053072_2_Ent3", "role": "Treatment_Drug", "text": "mitomycin C", "start": 10, "end": 12}, {"entity_id": "12053072_2_Ent2", "role": "Treatment", "text": "mitomycin C ( total dose 144 mg / m2 )", "start": 10, "end": 20}, {"entity_id": "12053072_2_Ent4", "role": "Treatment_Dosage", "text": "144 mg / m2", "start": 15, "end": 19}, {"entity_id": "12053072_2_Ent5", "role": "Treatment_Disorder", "text": "carcinoma of the ascending colon", "start": 23, "end": 28}]}], "entity_mentions": [{"id": "12053072_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12053072_2_Ent1", "text": "HUS", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12053072_2_Ent3", "text": "mitomycin C", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12053072_2_Ent2", "text": "mitomycin C ( total dose 144 mg / m2 )", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "12053072_2_Ent4", "text": "144 mg / m2", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "12053072_2_Ent5", "text": "carcinoma of the ascending colon", "entity_type": "Entity", "start": 23, "end": 28}], "lang": "en"}
{"doc_id": "12086549_3", "wnd_id": "12086549_3_1", "text": "Subcutaneous IL - 2 is safe and well tolerated , with a mortality rate < 3 % .", "tokens": ["Subcutaneous", "IL", "-", "2", "is", "safe", "and", "well", "tolerated", ",", "with", "a", "mortality", "rate", "<", "3", "%", "."], "event_mentions": [{"id": "12086549_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 10, "end": 11}, "arguments": [{"entity_id": "12086549_3_Ent2", "role": "Treatment_Route", "text": "Subcutaneous", "start": 0, "end": 1}, {"entity_id": "12086549_3_Ent1", "role": "Treatment", "text": "Subcutaneous IL - 2", "start": 0, "end": 4}, {"entity_id": "12086549_3_Ent3", "role": "Treatment_Drug", "text": "IL - 2", "start": 1, "end": 4}, {"entity_id": "12086549_3_Ent0", "role": "Effect", "text": "mortality rate < 3 %", "start": 12, "end": 17}]}], "entity_mentions": [{"id": "12086549_3_Ent2", "text": "Subcutaneous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12086549_3_Ent1", "text": "Subcutaneous IL - 2", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12086549_3_Ent3", "text": "IL - 2", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "12086549_3_Ent0", "text": "mortality rate < 3 %", "entity_type": "Entity", "start": 12, "end": 17}], "lang": "en"}
{"doc_id": "12111771_1", "wnd_id": "12111771_1_1", "text": "A 73 - year - old woman presented with fever and cough 2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia ( CLL ) .", "tokens": ["A", "73", "-", "year", "-", "old", "woman", "presented", "with", "fever", "and", "cough", "2", "weeks", "after", "completing", "the", "third", "cycle", "of", "fludarabine", "for", "chronic", "lymphocytic", "leukemia", "(", "CLL", ")", "."], "event_mentions": [{"id": "12111771_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 7, "end": 8}, "arguments": [{"entity_id": "12111771_1_Ent0", "role": "Subject", "text": "A 73 - year - old woman", "start": 0, "end": 7}, {"entity_id": "12111771_1_Ent1", "role": "Subject_Age", "text": "73 - year - old", "start": 1, "end": 6}, {"entity_id": "12111771_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "12111771_1_Ent3", "role": "Effect", "text": "fever and cough", "start": 9, "end": 12}, {"entity_id": "12111771_1_Ent6", "role": "Treatment_Time_elapsed", "text": "2 weeks", "start": 12, "end": 14}, {"entity_id": "12111771_1_Ent4", "role": "Treatment", "text": "2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia ( CLL )", "start": 12, "end": 28}, {"entity_id": "12111771_1_Ent7", "role": "Treatment_Drug", "text": "fludarabine", "start": 20, "end": 21}, {"entity_id": "12111771_1_Ent5", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukemia ( CLL )", "start": 22, "end": 28}]}], "entity_mentions": [{"id": "12111771_1_Ent0", "text": "A 73 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12111771_1_Ent1", "text": "73 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12111771_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12111771_1_Ent3", "text": "fever and cough", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12111771_1_Ent6", "text": "2 weeks", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "12111771_1_Ent4", "text": "2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia ( CLL )", "entity_type": "Entity", "start": 12, "end": 28}, {"id": "12111771_1_Ent7", "text": "fludarabine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "12111771_1_Ent5", "text": "chronic lymphocytic leukemia ( CLL )", "entity_type": "Entity", "start": 22, "end": 28}], "lang": "en"}
{"doc_id": "12121061_2", "wnd_id": "12121061_2_1", "text": "A 50 - year - old diabetic and hypertensive male patient is reported who had ticlopidine - induced marrow aplasia partially responsive to colony - stimulating factors and corticosteroids , but experienced complete recovery with cyclosporine .", "tokens": ["A", "50", "-", "year", "-", "old", "diabetic", "and", "hypertensive", "male", "patient", "is", "reported", "who", "had", "ticlopidine", "-", "induced", "marrow", "aplasia", "partially", "responsive", "to", "colony", "-", "stimulating", "factors", "and", "corticosteroids", ",", "but", "experienced", "complete", "recovery", "with", "cyclosporine", "."], "event_mentions": [{"id": "12121061_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 17, "end": 18}, "arguments": [{"entity_id": "12121061_2_Ent2", "role": "Subject_Age", "text": "50 - year - old", "start": 1, "end": 6}, {"entity_id": "12121061_2_Ent0", "role": "Subject", "text": "50 - year - old diabetic and hypertensive male patient", "start": 1, "end": 11}, {"entity_id": "12121061_2_Ent1", "role": "Subject_Disorder", "text": "diabetic and hypertensive", "start": 6, "end": 9}, {"entity_id": "12121061_2_Ent3", "role": "Subject_Gender", "text": "male", "start": 9, "end": 10}, {"entity_id": "12121061_2_Ent5", "role": "Treatment", "text": "ticlopidine", "start": 15, "end": 16}, {"entity_id": "12121061_2_Ent6", "role": "Treatment_Drug", "text": "ticlopidine", "start": 15, "end": 16}, {"entity_id": "12121061_2_Ent4", "role": "Effect", "text": "marrow aplasia", "start": 18, "end": 20}]}, {"id": "12121061_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "with", "start": 34, "end": 35}, "arguments": [{"entity_id": "12121061_2_Ent9", "role": "Subject_Age", "text": "50 - year - old", "start": 1, "end": 6}, {"entity_id": "12121061_2_Ent7", "role": "Subject", "text": "50 - year - old diabetic and hypertensive male patient", "start": 1, "end": 11}, {"entity_id": "12121061_2_Ent8", "role": "Subject_Disorder", "text": "diabetic and hypertensive", "start": 6, "end": 9}, {"entity_id": "12121061_2_Ent10", "role": "Subject_Gender", "text": "male", "start": 9, "end": 10}, {"entity_id": "12121061_2_Ent13", "role": "Treatment_Disorder", "text": "ticlopidine - induced marrow aplasia", "start": 15, "end": 20}, {"entity_id": "12121061_2_Ent11", "role": "Effect", "text": "experienced complete recovery", "start": 31, "end": 34}, {"entity_id": "12121061_2_Ent12", "role": "Treatment", "text": "cyclosporine", "start": 35, "end": 36}, {"entity_id": "12121061_2_Ent14", "role": "Treatment_Drug", "text": "cyclosporine", "start": 35, "end": 36}]}], "entity_mentions": [{"id": "12121061_2_Ent2", "text": "50 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12121061_2_Ent9", "text": "50 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12121061_2_Ent0", "text": "50 - year - old diabetic and hypertensive male patient", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "12121061_2_Ent7", "text": "50 - year - old diabetic and hypertensive male patient", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "12121061_2_Ent1", "text": "diabetic and hypertensive", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12121061_2_Ent8", "text": "diabetic and hypertensive", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12121061_2_Ent3", "text": "male", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12121061_2_Ent10", "text": "male", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12121061_2_Ent5", "text": "ticlopidine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12121061_2_Ent6", "text": "ticlopidine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12121061_2_Ent13", "text": "ticlopidine - induced marrow aplasia", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "12121061_2_Ent4", "text": "marrow aplasia", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "12121061_2_Ent11", "text": "experienced complete recovery", "entity_type": "Entity", "start": 31, "end": 34}, {"id": "12121061_2_Ent12", "text": "cyclosporine", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "12121061_2_Ent14", "text": "cyclosporine", "entity_type": "Entity", "start": 35, "end": 36}], "lang": "en"}
{"doc_id": "12126225_1", "wnd_id": "12126225_1_1", "text": "A 53 - year - old man developed lower leg edema 4 weeks after rosiglitazone was increased from 4 mg once / day to 4 mg twice / day .", "tokens": ["A", "53", "-", "year", "-", "old", "man", "developed", "lower", "leg", "edema", "4", "weeks", "after", "rosiglitazone", "was", "increased", "from", "4", "mg", "once", "/", "day", "to", "4", "mg", "twice", "/", "day", "."], "event_mentions": [{"id": "12126225_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "12126225_1_Ent0", "role": "Subject", "text": "A 53 - year - old man", "start": 0, "end": 7}, {"entity_id": "12126225_1_Ent1", "role": "Subject_Age", "text": "53 - year - old", "start": 1, "end": 6}, {"entity_id": "12126225_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "12126225_1_Ent3", "role": "Effect", "text": "lower leg edema", "start": 8, "end": 11}, {"entity_id": "12126225_1_Ent5", "role": "Treatment_Time_elapsed", "text": "4 weeks", "start": 11, "end": 13}, {"entity_id": "12126225_1_Ent4", "role": "Treatment", "text": "4 weeks after rosiglitazone was increased from 4 mg once / day to 4 mg twice / day", "start": 11, "end": 29}, {"entity_id": "12126225_1_Ent6", "role": "Treatment_Drug", "text": "rosiglitazone", "start": 14, "end": 15}, {"entity_id": "12126225_1_Ent7", "role": "Treatment_Dosage", "text": "4 mg", "start": 24, "end": 26}, {"entity_id": "12126225_1_Ent8", "role": "Treatment_Freq", "text": "twice / day", "start": 26, "end": 29}]}], "entity_mentions": [{"id": "12126225_1_Ent0", "text": "A 53 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12126225_1_Ent1", "text": "53 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12126225_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12126225_1_Ent3", "text": "lower leg edema", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "12126225_1_Ent5", "text": "4 weeks", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "12126225_1_Ent4", "text": "4 weeks after rosiglitazone was increased from 4 mg once / day to 4 mg twice / day", "entity_type": "Entity", "start": 11, "end": 29}, {"id": "12126225_1_Ent6", "text": "rosiglitazone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12126225_1_Ent7", "text": "4 mg", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "12126225_1_Ent8", "text": "twice / day", "entity_type": "Entity", "start": 26, "end": 29}], "lang": "en"}
{"doc_id": "12135176_3", "wnd_id": "12135176_3_1", "text": "We describe two cases of PSVT that changed to non - sustained polymorphic ventricular tachycardia after administration of verapamil .", "tokens": ["We", "describe", "two", "cases", "of", "PSVT", "that", "changed", "to", "non", "-", "sustained", "polymorphic", "ventricular", "tachycardia", "after", "administration", "of", "verapamil", "."], "event_mentions": [{"id": "12135176_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "changed", "start": 7, "end": 8}, "arguments": [{"entity_id": "12135176_3_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "12135176_3_Ent0", "role": "Subject", "text": "two cases of PSVT", "start": 2, "end": 6}, {"entity_id": "12135176_3_Ent5", "role": "Treatment_Disorder", "text": "PSVT", "start": 5, "end": 6}, {"entity_id": "12135176_3_Ent2", "role": "Effect", "text": "non - sustained polymorphic ventricular tachycardia", "start": 9, "end": 15}, {"entity_id": "12135176_3_Ent3", "role": "Treatment", "text": "administration of verapamil .", "start": 16, "end": 20}, {"entity_id": "12135176_3_Ent4", "role": "Treatment_Drug", "text": "verapamil", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "12135176_3_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12135176_3_Ent0", "text": "two cases of PSVT", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "12135176_3_Ent5", "text": "PSVT", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12135176_3_Ent2", "text": "non - sustained polymorphic ventricular tachycardia", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "12135176_3_Ent3", "text": "administration of verapamil .", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "12135176_3_Ent4", "text": "verapamil", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "12149193_2", "wnd_id": "12149193_2_1", "text": "Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis ( DVT ) .", "tokens": ["Ten", "percent", "of", "newly", "diagnosed", "myeloma", "patients", "treated", "with", "any", "type", "of", "chemotherapy", "develop", "deep", "venous", "thrombosis", "(", "DVT", ")", "."], "event_mentions": [{"id": "12149193_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 13, "end": 14}, "arguments": [{"entity_id": "12149193_2_Ent3", "role": "Treatment_Disorder", "text": "myeloma", "start": 5, "end": 6}, {"entity_id": "12149193_2_Ent0", "role": "Subject", "text": "myeloma patients", "start": 5, "end": 7}, {"entity_id": "12149193_2_Ent2", "role": "Treatment", "text": "any type of chemotherapy", "start": 9, "end": 13}, {"entity_id": "12149193_2_Ent4", "role": "Treatment_Route", "text": "chemotherapy", "start": 12, "end": 13}, {"entity_id": "12149193_2_Ent1", "role": "Effect", "text": "deep venous thrombosis ( DVT )", "start": 14, "end": 20}]}], "entity_mentions": [{"id": "12149193_2_Ent3", "text": "myeloma", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12149193_2_Ent0", "text": "myeloma patients", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12149193_2_Ent2", "text": "any type of chemotherapy", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "12149193_2_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12149193_2_Ent1", "text": "deep venous thrombosis ( DVT )", "entity_type": "Entity", "start": 14, "end": 20}], "lang": "en"}
{"doc_id": "12149193_3", "wnd_id": "12149193_3_1", "text": "Thalidomide has proven activity in refractory multiple myeloma ( MM ) , and although single - agent thalidomide has minimal prothrombogenic activity , its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT .", "tokens": ["Thalidomide", "has", "proven", "activity", "in", "refractory", "multiple", "myeloma", "(", "MM", ")", ",", "and", "although", "single", "-", "agent", "thalidomide", "has", "minimal", "prothrombogenic", "activity", ",", "its", "combination", "with", "cytotoxic", "chemotherapy", "is", "associated", "with", "a", "significantly", "increased", "risk", "of", "DVT", "."], "event_mentions": [{"id": "12149193_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 29, "end": 30}, "arguments": [{"entity_id": "12149193_3_Ent3", "role": "Treatment_Disorder", "text": "refractory multiple myeloma ( MM )", "start": 5, "end": 11}, {"entity_id": "12149193_3_Ent1", "role": "Treatment", "text": "single - agent thalidomide", "start": 14, "end": 18}, {"entity_id": "12149193_3_Ent4", "role": "Treatment_Drug", "text": "thalidomide", "start": 17, "end": 18}, {"entity_id": "12149193_3_Ent7", "role": "Combination_Drug", "text": "thalidomide", "start": 17, "end": 18}, {"entity_id": "12149193_3_Ent2", "role": "Treatment", "text": "combination with cytotoxic chemotherapy", "start": 24, "end": 28}, {"entity_id": "12149193_3_Ent5", "role": "Treatment_Drug", "text": "cytotoxic", "start": 26, "end": 27}, {"entity_id": "12149193_3_Ent8", "role": "Combination_Drug", "text": "cytotoxic", "start": 26, "end": 27}, {"entity_id": "12149193_3_Ent6", "role": "Treatment_Route", "text": "chemotherapy", "start": 27, "end": 28}, {"entity_id": "12149193_3_Ent0", "role": "Effect", "text": "significantly increased risk of DVT", "start": 32, "end": 37}]}], "entity_mentions": [{"id": "12149193_3_Ent3", "text": "refractory multiple myeloma ( MM )", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "12149193_3_Ent1", "text": "single - agent thalidomide", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "12149193_3_Ent4", "text": "thalidomide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "12149193_3_Ent7", "text": "thalidomide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "12149193_3_Ent2", "text": "combination with cytotoxic chemotherapy", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "12149193_3_Ent5", "text": "cytotoxic", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "12149193_3_Ent8", "text": "cytotoxic", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "12149193_3_Ent6", "text": "chemotherapy", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "12149193_3_Ent0", "text": "significantly increased risk of DVT", "entity_type": "Entity", "start": 32, "end": 37}], "lang": "en"}
{"doc_id": "12149193_4", "wnd_id": "12149193_4_1", "text": "We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols that differed only by the inclusion of doxorubicin in one .", "tokens": ["We", "analyzed", "the", "incidence", "of", "DVT", "in", "232", "MM", "patients", "who", "received", "a", "combination", "of", "chemotherapy", "and", "thalidomide", "on", "2", "protocols", "that", "differed", "only", "by", "the", "inclusion", "of", "doxorubicin", "in", "one", "."], "event_mentions": [{"id": "12149193_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "incidence", "start": 3, "end": 4}, "arguments": [{"entity_id": "12149193_4_Ent2", "role": "Effect", "text": "DVT", "start": 5, "end": 6}, {"entity_id": "12149193_4_Ent1", "role": "Subject_Population", "text": "232", "start": 7, "end": 8}, {"entity_id": "12149193_4_Ent0", "role": "Subject", "text": "232 MM patients", "start": 7, "end": 10}, {"entity_id": "12149193_4_Ent5", "role": "Treatment_Disorder", "text": "MM", "start": 8, "end": 9}, {"entity_id": "12149193_4_Ent3", "role": "Treatment", "text": "chemotherapy", "start": 15, "end": 16}, {"entity_id": "12149193_4_Ent6", "role": "Treatment_Drug", "text": "chemotherapy", "start": 15, "end": 16}, {"entity_id": "12149193_4_Ent8", "role": "Combination_Drug", "text": "chemotherapy", "start": 15, "end": 16}, {"entity_id": "12149193_4_Ent4", "role": "Treatment", "text": "thalidomide", "start": 17, "end": 18}, {"entity_id": "12149193_4_Ent7", "role": "Treatment_Drug", "text": "thalidomide", "start": 17, "end": 18}, {"entity_id": "12149193_4_Ent9", "role": "Combination_Drug", "text": "thalidomide", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "12149193_4_Ent2", "text": "DVT", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12149193_4_Ent1", "text": "232", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12149193_4_Ent0", "text": "232 MM patients", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "12149193_4_Ent5", "text": "MM", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12149193_4_Ent3", "text": "chemotherapy", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12149193_4_Ent6", "text": "chemotherapy", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12149193_4_Ent8", "text": "chemotherapy", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12149193_4_Ent4", "text": "thalidomide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "12149193_4_Ent7", "text": "thalidomide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "12149193_4_Ent9", "text": "thalidomide", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "12149193_9", "wnd_id": "12149193_9_1", "text": "MM patients treated with thalidomide and doxorubicin have a high risk of developing DVT .", "tokens": ["MM", "patients", "treated", "with", "thalidomide", "and", "doxorubicin", "have", "a", "high", "risk", "of", "developing", "DVT", "."], "event_mentions": [{"id": "12149193_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have", "start": 7, "end": 8}, "arguments": [{"entity_id": "12149193_9_Ent3", "role": "Treatment_Disorder", "text": "MM", "start": 0, "end": 1}, {"entity_id": "12149193_9_Ent0", "role": "Subject", "text": "MM patients", "start": 0, "end": 2}, {"entity_id": "12149193_9_Ent4", "role": "Treatment_Drug", "text": "thalidomide", "start": 4, "end": 5}, {"entity_id": "12149193_9_Ent6", "role": "Combination_Drug", "text": "thalidomide", "start": 4, "end": 5}, {"entity_id": "12149193_9_Ent2", "role": "Treatment", "text": "thalidomide and doxorubicin", "start": 4, "end": 7}, {"entity_id": "12149193_9_Ent5", "role": "Treatment_Drug", "text": "doxorubicin", "start": 6, "end": 7}, {"entity_id": "12149193_9_Ent7", "role": "Combination_Drug", "text": "doxorubicin", "start": 6, "end": 7}, {"entity_id": "12149193_9_Ent1", "role": "Effect", "text": "a high risk of developing DVT", "start": 8, "end": 14}]}], "entity_mentions": [{"id": "12149193_9_Ent3", "text": "MM", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12149193_9_Ent0", "text": "MM patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12149193_9_Ent4", "text": "thalidomide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12149193_9_Ent6", "text": "thalidomide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12149193_9_Ent2", "text": "thalidomide and doxorubicin", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "12149193_9_Ent5", "text": "doxorubicin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12149193_9_Ent7", "text": "doxorubicin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12149193_9_Ent1", "text": "a high risk of developing DVT", "entity_type": "Entity", "start": 8, "end": 14}], "lang": "en"}
{"doc_id": "12150593_1", "wnd_id": "12150593_1_1", "text": "Neonatal mydriasis : intravenous lidocaine adverse reaction .", "tokens": ["Neonatal", "mydriasis", ":", "intravenous", "lidocaine", "adverse", "reaction", "."], "event_mentions": [{"id": "12150593_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse reaction", "start": 5, "end": 7}, "arguments": [{"entity_id": "12150593_1_Ent0", "role": "Subject", "text": "Neonatal", "start": 0, "end": 1}, {"entity_id": "12150593_1_Ent1", "role": "Subject_Age", "text": "Neonatal", "start": 0, "end": 1}, {"entity_id": "12150593_1_Ent2", "role": "Effect", "text": "Neonatal mydriasis", "start": 0, "end": 2}, {"entity_id": "12150593_1_Ent3", "role": "Treatment", "text": "lidocaine", "start": 4, "end": 5}, {"entity_id": "12150593_1_Ent4", "role": "Treatment_Drug", "text": "lidocaine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "12150593_1_Ent0", "text": "Neonatal", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12150593_1_Ent1", "text": "Neonatal", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12150593_1_Ent2", "text": "Neonatal mydriasis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12150593_1_Ent3", "text": "lidocaine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12150593_1_Ent4", "text": "lidocaine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "12150593_3", "wnd_id": "12150593_3_1", "text": "We suggest adding this side effect to the list of untoward effects of lidocaine and to the differential diagnosis of fixed dilated pupils in neonates treated with lidocaine .", "tokens": ["We", "suggest", "adding", "this", "side", "effect", "to", "the", "list", "of", "untoward", "effects", "of", "lidocaine", "and", "to", "the", "differential", "diagnosis", "of", "fixed", "dilated", "pupils", "in", "neonates", "treated", "with", "lidocaine", "."], "event_mentions": [{"id": "12150593_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 25, "end": 26}, "arguments": [{"entity_id": "12150593_3_Ent2", "role": "Effect", "text": "side effect", "start": 4, "end": 6}, {"entity_id": "12150593_3_Ent0", "role": "Subject", "text": "neonates", "start": 24, "end": 25}, {"entity_id": "12150593_3_Ent1", "role": "Subject_Age", "text": "neonates", "start": 24, "end": 25}, {"entity_id": "12150593_3_Ent3", "role": "Treatment", "text": "lidocaine", "start": 27, "end": 28}, {"entity_id": "12150593_3_Ent4", "role": "Treatment_Drug", "text": "lidocaine", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "12150593_3_Ent2", "text": "side effect", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "12150593_3_Ent0", "text": "neonates", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "12150593_3_Ent1", "text": "neonates", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "12150593_3_Ent3", "text": "lidocaine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "12150593_3_Ent4", "text": "lidocaine", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "12163813_3", "wnd_id": "12163813_3_1", "text": "Skin necrosis after extravasation of low - dose vasopressin administered for septic shock .", "tokens": ["Skin", "necrosis", "after", "extravasation", "of", "low", "-", "dose", "vasopressin", "administered", "for", "septic", "shock", "."], "event_mentions": [{"id": "12163813_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "extravasation", "start": 3, "end": 4}, "arguments": [{"entity_id": "12163813_3_Ent0", "role": "Effect", "text": "Skin necrosis", "start": 0, "end": 2}, {"entity_id": "12163813_3_Ent1", "role": "Treatment", "text": "vasopressin", "start": 8, "end": 9}, {"entity_id": "12163813_3_Ent2", "role": "Treatment_Drug", "text": "vasopressin", "start": 8, "end": 9}, {"entity_id": "12163813_3_Ent3", "role": "Treatment_Disorder", "text": "septic shock", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "12163813_3_Ent0", "text": "Skin necrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12163813_3_Ent1", "text": "vasopressin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12163813_3_Ent2", "text": "vasopressin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12163813_3_Ent3", "text": "septic shock", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "12187348_2", "wnd_id": "12187348_2_1", "text": "Drug - induced mammary hyperplasias have been reported as rare complications of D - penicillamine and Neothetazone .", "tokens": ["Drug", "-", "induced", "mammary", "hyperplasias", "have", "been", "reported", "as", "rare", "complications", "of", "D", "-", "penicillamine", "and", "Neothetazone", "."], "event_mentions": [{"id": "12187348_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12187348_2_Ent1", "role": "Treatment", "text": "Drug", "start": 0, "end": 1}, {"entity_id": "12187348_2_Ent3", "role": "Treatment_Drug", "text": "Drug", "start": 0, "end": 1}, {"entity_id": "12187348_2_Ent0", "role": "Effect", "text": "mammary hyperplasias", "start": 3, "end": 5}, {"entity_id": "12187348_2_Ent5", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 12, "end": 15}, {"entity_id": "12187348_2_Ent6", "role": "Combination_Drug", "text": "D - penicillamine", "start": 12, "end": 15}, {"entity_id": "12187348_2_Ent2", "role": "Treatment", "text": "D - penicillamine and Neothetazone", "start": 12, "end": 17}, {"entity_id": "12187348_2_Ent4", "role": "Treatment_Drug", "text": "Neothetazone", "start": 16, "end": 17}, {"entity_id": "12187348_2_Ent7", "role": "Combination_Drug", "text": "Neothetazone", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12187348_2_Ent1", "text": "Drug", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12187348_2_Ent3", "text": "Drug", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12187348_2_Ent0", "text": "mammary hyperplasias", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "12187348_2_Ent5", "text": "D - penicillamine", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "12187348_2_Ent6", "text": "D - penicillamine", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "12187348_2_Ent2", "text": "D - penicillamine and Neothetazone", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "12187348_2_Ent4", "text": "Neothetazone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12187348_2_Ent7", "text": "Neothetazone", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12221670_1", "wnd_id": "12221670_1_1", "text": "The first case concerns a 70 - year - old man who developed severe aplastic anemia 7 weeks after treatment with 500 mg of ticlopidine daily .", "tokens": ["The", "first", "case", "concerns", "a", "70", "-", "year", "-", "old", "man", "who", "developed", "severe", "aplastic", "anemia", "7", "weeks", "after", "treatment", "with", "500", "mg", "of", "ticlopidine", "daily", "."], "event_mentions": [{"id": "12221670_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "12221670_1_Ent1", "role": "Subject_Age", "text": "70 - year - old", "start": 5, "end": 10}, {"entity_id": "12221670_1_Ent0", "role": "Subject", "text": "70 - year - old man", "start": 5, "end": 11}, {"entity_id": "12221670_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 10, "end": 11}, {"entity_id": "12221670_1_Ent3", "role": "Effect", "text": "severe aplastic anemia", "start": 13, "end": 16}, {"entity_id": "12221670_1_Ent5", "role": "Treatment_Time_elapsed", "text": "7 weeks", "start": 16, "end": 18}, {"entity_id": "12221670_1_Ent4", "role": "Treatment", "text": "7 weeks after treatment with 500 mg of ticlopidine daily", "start": 16, "end": 26}, {"entity_id": "12221670_1_Ent6", "role": "Treatment_Dosage", "text": "500 mg", "start": 21, "end": 23}, {"entity_id": "12221670_1_Ent7", "role": "Treatment_Drug", "text": "ticlopidine", "start": 24, "end": 25}, {"entity_id": "12221670_1_Ent8", "role": "Treatment_Freq", "text": "daily", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "12221670_1_Ent1", "text": "70 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12221670_1_Ent0", "text": "70 - year - old man", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "12221670_1_Ent2", "text": "man", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12221670_1_Ent3", "text": "severe aplastic anemia", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "12221670_1_Ent5", "text": "7 weeks", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "12221670_1_Ent4", "text": "7 weeks after treatment with 500 mg of ticlopidine daily", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "12221670_1_Ent6", "text": "500 mg", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "12221670_1_Ent7", "text": "ticlopidine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "12221670_1_Ent8", "text": "daily", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "12221670_3", "wnd_id": "12221670_3_1", "text": "Ticlopidine - induced aplastic anemia ( TIAA ) is considered very uncommon .", "tokens": ["Ticlopidine", "-", "induced", "aplastic", "anemia", "(", "TIAA", ")", "is", "considered", "very", "uncommon", "."], "event_mentions": [{"id": "12221670_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12221670_3_Ent1", "role": "Treatment", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "12221670_3_Ent2", "role": "Treatment_Drug", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "12221670_3_Ent0", "role": "Effect", "text": "aplastic anemia ( TIAA )", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "12221670_3_Ent1", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12221670_3_Ent2", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12221670_3_Ent0", "text": "aplastic anemia ( TIAA )", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "12221670_4", "wnd_id": "12221670_4_1", "text": "Ticlopidine - induced aplastic anemia : two new case reports , review , and meta - analysis of 55 additional cases .", "tokens": ["Ticlopidine", "-", "induced", "aplastic", "anemia", ":", "two", "new", "case", "reports", ",", "review", ",", "and", "meta", "-", "analysis", "of", "55", "additional", "cases", "."], "event_mentions": [{"id": "12221670_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12221670_4_Ent1", "role": "Treatment", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "12221670_4_Ent2", "role": "Treatment_Drug", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "12221670_4_Ent0", "role": "Effect", "text": "aplastic anemia", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "12221670_4_Ent1", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12221670_4_Ent2", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12221670_4_Ent0", "text": "aplastic anemia", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "12243603_2", "wnd_id": "12243603_2_1", "text": "To report a case of rhabdomyolysis and acute hepatitis associated with the coadministration of atorvastatin and diltiazem .", "tokens": ["To", "report", "a", "case", "of", "rhabdomyolysis", "and", "acute", "hepatitis", "associated", "with", "the", "coadministration", "of", "atorvastatin", "and", "diltiazem", "."], "event_mentions": [{"id": "12243603_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "12243603_2_Ent0", "role": "Effect", "text": "rhabdomyolysis and acute hepatitis", "start": 5, "end": 9}, {"entity_id": "12243603_2_Ent1", "role": "Treatment", "text": "coadministration of atorvastatin and diltiazem", "start": 12, "end": 17}, {"entity_id": "12243603_2_Ent2", "role": "Treatment_Drug", "text": "atorvastatin", "start": 14, "end": 15}, {"entity_id": "12243603_2_Ent4", "role": "Combination_Drug", "text": "atorvastatin", "start": 14, "end": 15}, {"entity_id": "12243603_2_Ent3", "role": "Treatment_Drug", "text": "diltiazem", "start": 16, "end": 17}, {"entity_id": "12243603_2_Ent5", "role": "Combination_Drug", "text": "diltiazem", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12243603_2_Ent0", "text": "rhabdomyolysis and acute hepatitis", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "12243603_2_Ent1", "text": "coadministration of atorvastatin and diltiazem", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "12243603_2_Ent2", "text": "atorvastatin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12243603_2_Ent4", "text": "atorvastatin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12243603_2_Ent3", "text": "diltiazem", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12243603_2_Ent5", "text": "diltiazem", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12243603_7", "wnd_id": "12243603_7_1", "text": "Atorvastatin is the most potent of this class of agents currently available and is commonly used in the treatment of hyperlipidemia .", "tokens": ["Atorvastatin", "is", "the", "most", "potent", "of", "this", "class", "of", "agents", "currently", "available", "and", "is", "commonly", "used", "in", "the", "treatment", "of", "hyperlipidemia", "."], "event_mentions": [{"id": "12243603_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 18, "end": 19}, "arguments": [{"entity_id": "12243603_7_Ent1", "role": "Treatment", "text": "Atorvastatin", "start": 0, "end": 1}, {"entity_id": "12243603_7_Ent3", "role": "Treatment_Drug", "text": "Atorvastatin", "start": 0, "end": 1}, {"entity_id": "12243603_7_Ent0", "role": "Effect", "text": "most potent", "start": 3, "end": 5}, {"entity_id": "12243603_7_Ent2", "role": "Treatment_Disorder", "text": "hyperlipidemia", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "12243603_7_Ent1", "text": "Atorvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12243603_7_Ent3", "text": "Atorvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12243603_7_Ent0", "text": "most potent", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "12243603_7_Ent2", "text": "hyperlipidemia", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "12324937_3", "wnd_id": "12324937_3_1", "text": "Gemcitabine - associated hemolytic - uremic syndrome .", "tokens": ["Gemcitabine", "-", "associated", "hemolytic", "-", "uremic", "syndrome", "."], "event_mentions": [{"id": "12324937_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "12324937_3_Ent1", "role": "Treatment", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "12324937_3_Ent2", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "12324937_3_Ent0", "role": "Effect", "text": "hemolytic - uremic syndrome", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "12324937_3_Ent1", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12324937_3_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12324937_3_Ent0", "text": "hemolytic - uremic syndrome", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "12324937_6", "wnd_id": "12324937_6_1", "text": "RESULTS : Including our own patient , a total of 26 cases of gemcitabine - associated HUS were identified .", "tokens": ["RESULTS", ":", "Including", "our", "own", "patient", ",", "a", "total", "of", "26", "cases", "of", "gemcitabine", "-", "associated", "HUS", "were", "identified", "."], "event_mentions": [{"id": "12324937_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "12324937_6_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 13, "end": 14}, {"entity_id": "12324937_6_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 13, "end": 14}, {"entity_id": "12324937_6_Ent0", "role": "Effect", "text": "HUS", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12324937_6_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12324937_6_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12324937_6_Ent0", "text": "HUS", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12365708_3", "wnd_id": "12365708_3_1", "text": "CASE REPORT : Soon after initiation of amiodarone HCl ( 200 mg / day ) , a 76 - year - old man came to us with symptoms of visual \" shining , \" glare , color vision anomalies , and gradually decreased vision .", "tokens": ["CASE", "REPORT", ":", "Soon", "after", "initiation", "of", "amiodarone", "HCl", "(", "200", "mg", "/", "day", ")", ",", "a", "76", "-", "year", "-", "old", "man", "came", "to", "us", "with", "symptoms", "of", "visual", "\"", "shining", ",", "\"", "glare", ",", "color", "vision", "anomalies", ",", "and", "gradually", "decreased", "vision", "."], "event_mentions": [{"id": "12365708_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after initiation", "start": 4, "end": 6}, "arguments": [{"entity_id": "12365708_3_Ent4", "role": "Treatment", "text": "amiodarone HCl", "start": 7, "end": 9}, {"entity_id": "12365708_3_Ent5", "role": "Treatment_Drug", "text": "amiodarone HCl", "start": 7, "end": 9}, {"entity_id": "12365708_3_Ent6", "role": "Treatment_Dosage", "text": "( 200 mg", "start": 9, "end": 12}, {"entity_id": "12365708_3_Ent7", "role": "Treatment_Freq", "text": "day", "start": 13, "end": 14}, {"entity_id": "12365708_3_Ent0", "role": "Subject", "text": "a 76 - year - old man", "start": 16, "end": 23}, {"entity_id": "12365708_3_Ent1", "role": "Subject_Age", "text": "76 - year - old", "start": 17, "end": 22}, {"entity_id": "12365708_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 22, "end": 23}, {"entity_id": "12365708_3_Ent3", "role": "Effect", "text": "symptoms of visual \" shining , \" glare , color vision anomalies , and gradually decreased vision", "start": 27, "end": 44}]}], "entity_mentions": [{"id": "12365708_3_Ent4", "text": "amiodarone HCl", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "12365708_3_Ent5", "text": "amiodarone HCl", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "12365708_3_Ent6", "text": "( 200 mg", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12365708_3_Ent7", "text": "day", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12365708_3_Ent0", "text": "a 76 - year - old man", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "12365708_3_Ent1", "text": "76 - year - old", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "12365708_3_Ent2", "text": "man", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12365708_3_Ent3", "text": "symptoms of visual \" shining , \" glare , color vision anomalies , and gradually decreased vision", "entity_type": "Entity", "start": 27, "end": 44}], "lang": "en"}
{"doc_id": "12365708_5", "wnd_id": "12365708_5_1", "text": "While both amiodarone and digoxin can cause permanent visual changes , the ocular effects are often reversible .", "tokens": ["While", "both", "amiodarone", "and", "digoxin", "can", "cause", "permanent", "visual", "changes", ",", "the", "ocular", "effects", "are", "often", "reversible", "."], "event_mentions": [{"id": "12365708_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 6, "end": 7}, "arguments": [{"entity_id": "12365708_5_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 2, "end": 3}, {"entity_id": "12365708_5_Ent4", "role": "Combination_Drug", "text": "amiodarone", "start": 2, "end": 3}, {"entity_id": "12365708_5_Ent1", "role": "Treatment", "text": "amiodarone and digoxin", "start": 2, "end": 5}, {"entity_id": "12365708_5_Ent3", "role": "Treatment_Drug", "text": "digoxin", "start": 4, "end": 5}, {"entity_id": "12365708_5_Ent5", "role": "Combination_Drug", "text": "digoxin", "start": 4, "end": 5}, {"entity_id": "12365708_5_Ent0", "role": "Effect", "text": "permanent visual changes", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "12365708_5_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12365708_5_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12365708_5_Ent1", "text": "amiodarone and digoxin", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "12365708_5_Ent3", "text": "digoxin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12365708_5_Ent5", "text": "digoxin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12365708_5_Ent0", "text": "permanent visual changes", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "12410494_1", "wnd_id": "12410494_1_1", "text": "Simvastatin - nelfinavir interaction implicated in rhabdomyolysis and death .", "tokens": ["Simvastatin", "-", "nelfinavir", "interaction", "implicated", "in", "rhabdomyolysis", "and", "death", "."], "event_mentions": [{"id": "12410494_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "implicated", "start": 4, "end": 5}, "arguments": [{"entity_id": "12410494_1_Ent3", "role": "Treatment_Drug", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "12410494_1_Ent5", "role": "Combination_Drug", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "12410494_1_Ent1", "role": "Treatment", "text": "Simvastatin - nelfinavir interaction", "start": 0, "end": 4}, {"entity_id": "12410494_1_Ent2", "role": "Treatment_Drug", "text": "nelfinavir", "start": 2, "end": 3}, {"entity_id": "12410494_1_Ent4", "role": "Combination_Drug", "text": "nelfinavir", "start": 2, "end": 3}, {"entity_id": "12410494_1_Ent0", "role": "Effect", "text": "rhabdomyolysis and death", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "12410494_1_Ent3", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12410494_1_Ent5", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12410494_1_Ent1", "text": "Simvastatin - nelfinavir interaction", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12410494_1_Ent2", "text": "nelfinavir", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12410494_1_Ent4", "text": "nelfinavir", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12410494_1_Ent0", "text": "rhabdomyolysis and death", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "12410494_2", "wnd_id": "12410494_2_1", "text": "We report the first death associated with rhabdomyolysis in a patient treated with a statin and a protease inhibitor , which produced a significant drug - drug interaction .", "tokens": ["We", "report", "the", "first", "death", "associated", "with", "rhabdomyolysis", "in", "a", "patient", "treated", "with", "a", "statin", "and", "a", "protease", "inhibitor", ",", "which", "produced", "a", "significant", "drug", "-", "drug", "interaction", "."], "event_mentions": [{"id": "12410494_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 11, "end": 12}, "arguments": [{"entity_id": "12410494_2_Ent1", "role": "Effect", "text": "death associated with rhabdomyolysis", "start": 4, "end": 8}, {"entity_id": "12410494_2_Ent0", "role": "Subject", "text": "a patient", "start": 9, "end": 11}, {"entity_id": "12410494_2_Ent2", "role": "Treatment", "text": "a statin and a protease inhibitor", "start": 13, "end": 19}, {"entity_id": "12410494_2_Ent3", "role": "Treatment_Drug", "text": "statin", "start": 14, "end": 15}, {"entity_id": "12410494_2_Ent5", "role": "Combination_Drug", "text": "statin", "start": 14, "end": 15}, {"entity_id": "12410494_2_Ent4", "role": "Treatment_Drug", "text": "protease inhibitor", "start": 17, "end": 19}, {"entity_id": "12410494_2_Ent6", "role": "Combination_Drug", "text": "protease inhibitor", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "12410494_2_Ent1", "text": "death associated with rhabdomyolysis", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "12410494_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "12410494_2_Ent2", "text": "a statin and a protease inhibitor", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "12410494_2_Ent3", "text": "statin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12410494_2_Ent5", "text": "statin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12410494_2_Ent4", "text": "protease inhibitor", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "12410494_2_Ent6", "text": "protease inhibitor", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "12439602_2", "wnd_id": "12439602_2_1", "text": "Carboplatin hypersensitivity presenting as coronary vasospasm - a case report .", "tokens": ["Carboplatin", "hypersensitivity", "presenting", "as", "coronary", "vasospasm", "-", "a", "case", "report", "."], "event_mentions": [{"id": "12439602_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presenting", "start": 2, "end": 3}, "arguments": [{"entity_id": "12439602_2_Ent1", "role": "Treatment", "text": "Carboplatin", "start": 0, "end": 1}, {"entity_id": "12439602_2_Ent2", "role": "Treatment_Drug", "text": "Carboplatin", "start": 0, "end": 1}, {"entity_id": "12439602_2_Ent0", "role": "Effect", "text": "coronary vasospasm", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "12439602_2_Ent1", "text": "Carboplatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12439602_2_Ent2", "text": "Carboplatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12439602_2_Ent0", "text": "coronary vasospasm", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "1244265_1", "wnd_id": "1244265_1_1", "text": "A 60 - year - old white man with chronic bronchitis was noted to develop acute respiratory failure and metabolic acidosis four days after being started on methazolamide ( Neptazane ) for an ophthalmologic problem .", "tokens": ["A", "60", "-", "year", "-", "old", "white", "man", "with", "chronic", "bronchitis", "was", "noted", "to", "develop", "acute", "respiratory", "failure", "and", "metabolic", "acidosis", "four", "days", "after", "being", "started", "on", "methazolamide", "(", "Neptazane", ")", "for", "an", "ophthalmologic", "problem", "."], "event_mentions": [{"id": "1244265_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 14, "end": 15}, "arguments": [{"entity_id": "1244265_1_Ent0", "role": "Subject", "text": "A 60 - year - old white man with chronic bronchitis", "start": 0, "end": 11}, {"entity_id": "1244265_1_Ent1", "role": "Subject_Age", "text": "60 - year - old", "start": 1, "end": 6}, {"entity_id": "1244265_1_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "1244265_1_Ent3", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "1244265_1_Ent4", "role": "Subject_Disorder", "text": "chronic bronchitis", "start": 9, "end": 11}, {"entity_id": "1244265_1_Ent5", "role": "Effect", "text": "acute respiratory failure and metabolic acidosis", "start": 15, "end": 21}, {"entity_id": "1244265_1_Ent9", "role": "Treatment_Time_elapsed", "text": "four days after", "start": 21, "end": 24}, {"entity_id": "1244265_1_Ent7", "role": "Treatment_Drug", "text": "methazolamide", "start": 27, "end": 28}, {"entity_id": "1244265_1_Ent6", "role": "Treatment", "text": "methazolamide ( Neptazane )", "start": 27, "end": 31}, {"entity_id": "1244265_1_Ent8", "role": "Treatment_Disorder", "text": "ophthalmologic problem", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "1244265_1_Ent0", "text": "A 60 - year - old white man with chronic bronchitis", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "1244265_1_Ent1", "text": "60 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "1244265_1_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1244265_1_Ent3", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1244265_1_Ent4", "text": "chronic bronchitis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "1244265_1_Ent5", "text": "acute respiratory failure and metabolic acidosis", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "1244265_1_Ent9", "text": "four days after", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "1244265_1_Ent7", "text": "methazolamide", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "1244265_1_Ent6", "text": "methazolamide ( Neptazane )", "entity_type": "Entity", "start": 27, "end": 31}, {"id": "1244265_1_Ent8", "text": "ophthalmologic problem", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "12452753_4", "wnd_id": "12452753_4_1", "text": "It was postulated that the allergic reaction was most likely caused by capecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge , pharmacokinetic data , and well - tolerance of fluorouracil .", "tokens": ["It", "was", "postulated", "that", "the", "allergic", "reaction", "was", "most", "likely", "caused", "by", "capecitabine", "or", "the", "intermediate", "metabolites", "based", "on", "the", "immediate", "reappearance", "of", "symptoms", "from", "the", "rechallenge", ",", "pharmacokinetic", "data", ",", "and", "well", "-", "tolerance", "of", "fluorouracil", "."], "event_mentions": [{"id": "12452753_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 10, "end": 11}, "arguments": [{"entity_id": "12452753_4_Ent0", "role": "Effect", "text": "allergic reaction", "start": 5, "end": 7}, {"entity_id": "12452753_4_Ent2", "role": "Treatment_Drug", "text": "capecitabine", "start": 12, "end": 13}, {"entity_id": "12452753_4_Ent1", "role": "Treatment", "text": "capecitabine or the intermediate metabolites", "start": 12, "end": 17}]}], "entity_mentions": [{"id": "12452753_4_Ent0", "text": "allergic reaction", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12452753_4_Ent2", "text": "capecitabine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12452753_4_Ent1", "text": "capecitabine or the intermediate metabolites", "entity_type": "Entity", "start": 12, "end": 17}], "lang": "en"}
{"doc_id": "12455453_2", "wnd_id": "12455453_2_1", "text": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia .", "tokens": ["Reduction", "of", "methylprednisolone", "dosage", "rather", "than", "insulin", "therapy", "resulted", "in", "better", "control", "of", "glycemia", "."], "event_mentions": [{"id": "12455453_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resulted", "start": 8, "end": 9}, "arguments": [{"entity_id": "12455453_2_Ent2", "role": "Treatment_Dosage", "text": "Reduction", "start": 0, "end": 1}, {"entity_id": "12455453_2_Ent0", "role": "Treatment", "text": "Reduction of methylprednisolone dosage rather than insulin therapy", "start": 0, "end": 8}, {"entity_id": "12455453_2_Ent1", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 2, "end": 3}, {"entity_id": "12455453_2_Ent3", "role": "Treatment_Disorder", "text": "glycemia", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "12455453_2_Ent2", "text": "Reduction", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12455453_2_Ent0", "text": "Reduction of methylprednisolone dosage rather than insulin therapy", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "12455453_2_Ent1", "text": "methylprednisolone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12455453_2_Ent3", "text": "glycemia", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "12460237_4", "wnd_id": "12460237_4_1", "text": "We report a patient with recurrent , increasingly severe episodes of PPE , ultimately complicated by a severe bullous eruption , following successive cycles of high - dose cytarabine for the treatment of acute lymphoblastic leukaemia .", "tokens": ["We", "report", "a", "patient", "with", "recurrent", ",", "increasingly", "severe", "episodes", "of", "PPE", ",", "ultimately", "complicated", "by", "a", "severe", "bullous", "eruption", ",", "following", "successive", "cycles", "of", "high", "-", "dose", "cytarabine", "for", "the", "treatment", "of", "acute", "lymphoblastic", "leukaemia", "."], "event_mentions": [{"id": "12460237_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 21, "end": 22}, "arguments": [{"entity_id": "12460237_4_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "12460237_4_Ent1", "role": "Effect", "text": "recurrent , increasingly severe episodes of PPE , ultimately complicated by a severe bullous eruption", "start": 5, "end": 20}, {"entity_id": "12460237_4_Ent2", "role": "Treatment", "text": "cycles of high - dose cytarabine for the treatment of acute lymphoblastic leukaemia", "start": 23, "end": 36}, {"entity_id": "12460237_4_Ent4", "role": "Treatment_Dosage", "text": "high - dose", "start": 25, "end": 28}, {"entity_id": "12460237_4_Ent5", "role": "Treatment_Drug", "text": "cytarabine", "start": 28, "end": 29}, {"entity_id": "12460237_4_Ent3", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukaemia", "start": 33, "end": 36}]}], "entity_mentions": [{"id": "12460237_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12460237_4_Ent1", "text": "recurrent , increasingly severe episodes of PPE , ultimately complicated by a severe bullous eruption", "entity_type": "Entity", "start": 5, "end": 20}, {"id": "12460237_4_Ent2", "text": "cycles of high - dose cytarabine for the treatment of acute lymphoblastic leukaemia", "entity_type": "Entity", "start": 23, "end": 36}, {"id": "12460237_4_Ent4", "text": "high - dose", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "12460237_4_Ent5", "text": "cytarabine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "12460237_4_Ent3", "text": "acute lymphoblastic leukaemia", "entity_type": "Entity", "start": 33, "end": 36}], "lang": "en"}
{"doc_id": "12488741_2", "wnd_id": "12488741_2_1", "text": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment .", "tokens": ["Proton", "MRS", "examination", "demonstrated", "a", "persistent", "lactate", "elevation", "during", "metronidazole", "treatment", "."], "event_mentions": [{"id": "12488741_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "12488741_2_Ent0", "role": "Effect", "text": "persistent lactate elevation", "start": 5, "end": 8}, {"entity_id": "12488741_2_Ent1", "role": "Treatment", "text": "metronidazole", "start": 9, "end": 10}, {"entity_id": "12488741_2_Ent2", "role": "Treatment_Drug", "text": "metronidazole", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "12488741_2_Ent0", "text": "persistent lactate elevation", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "12488741_2_Ent1", "text": "metronidazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12488741_2_Ent2", "text": "metronidazole", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "12503933_5", "wnd_id": "12503933_5_1", "text": "Fulminant liver failure associated with clarithromycin .", "tokens": ["Fulminant", "liver", "failure", "associated", "with", "clarithromycin", "."], "event_mentions": [{"id": "12503933_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "12503933_5_Ent0", "role": "Effect", "text": "Fulminant liver failure", "start": 0, "end": 3}, {"entity_id": "12503933_5_Ent1", "role": "Treatment", "text": "clarithromycin", "start": 5, "end": 6}, {"entity_id": "12503933_5_Ent2", "role": "Treatment_Drug", "text": "clarithromycin", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "12503933_5_Ent0", "text": "Fulminant liver failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12503933_5_Ent1", "text": "clarithromycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12503933_5_Ent2", "text": "clarithromycin", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "12504711_4", "wnd_id": "12504711_4_1", "text": "RESULTS : Brimonidine was observed to cause IOP elevation , confirmed on rechallenge , scoring 8 ( strong probability ) on an adverse drug reaction probability score .", "tokens": ["RESULTS", ":", "Brimonidine", "was", "observed", "to", "cause", "IOP", "elevation", ",", "confirmed", "on", "rechallenge", ",", "scoring", "8", "(", "strong", "probability", ")", "on", "an", "adverse", "drug", "reaction", "probability", "score", "."], "event_mentions": [{"id": "12504711_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 6, "end": 7}, "arguments": [{"entity_id": "12504711_4_Ent1", "role": "Treatment", "text": "Brimonidine", "start": 2, "end": 3}, {"entity_id": "12504711_4_Ent2", "role": "Treatment_Drug", "text": "Brimonidine", "start": 2, "end": 3}, {"entity_id": "12504711_4_Ent0", "role": "Effect", "text": "IOP elevation", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "12504711_4_Ent1", "text": "Brimonidine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12504711_4_Ent2", "text": "Brimonidine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12504711_4_Ent0", "text": "IOP elevation", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "12507063_2", "wnd_id": "12507063_2_1", "text": "Gabapentin withdrawal presenting as status epilepticus .", "tokens": ["Gabapentin", "withdrawal", "presenting", "as", "status", "epilepticus", "."], "event_mentions": [{"id": "12507063_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presenting", "start": 2, "end": 3}, "arguments": [{"entity_id": "12507063_2_Ent2", "role": "Treatment_Drug", "text": "Gabapentin", "start": 0, "end": 1}, {"entity_id": "12507063_2_Ent1", "role": "Treatment", "text": "Gabapentin withdrawal", "start": 0, "end": 2}, {"entity_id": "12507063_2_Ent0", "role": "Effect", "text": "status epilepticus", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "12507063_2_Ent2", "text": "Gabapentin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12507063_2_Ent1", "text": "Gabapentin withdrawal", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12507063_2_Ent0", "text": "status epilepticus", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "12540009_4", "wnd_id": "12540009_4_1", "text": "We report the first case of doxycycline - induced hypoglycemia in a young nondiabetic man .", "tokens": ["We", "report", "the", "first", "case", "of", "doxycycline", "-", "induced", "hypoglycemia", "in", "a", "young", "nondiabetic", "man", "."], "event_mentions": [{"id": "12540009_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "12540009_4_Ent5", "role": "Treatment", "text": "doxycycline", "start": 6, "end": 7}, {"entity_id": "12540009_4_Ent6", "role": "Treatment_Drug", "text": "doxycycline", "start": 6, "end": 7}, {"entity_id": "12540009_4_Ent4", "role": "Effect", "text": "hypoglycemia", "start": 9, "end": 10}, {"entity_id": "12540009_4_Ent0", "role": "Subject", "text": "a young nondiabetic man", "start": 11, "end": 15}, {"entity_id": "12540009_4_Ent1", "role": "Subject_Age", "text": "young", "start": 12, "end": 13}, {"entity_id": "12540009_4_Ent2", "role": "Subject_Disorder", "text": "nondiabetic", "start": 13, "end": 14}, {"entity_id": "12540009_4_Ent3", "role": "Subject_Gender", "text": "man", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "12540009_4_Ent5", "text": "doxycycline", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12540009_4_Ent6", "text": "doxycycline", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12540009_4_Ent4", "text": "hypoglycemia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12540009_4_Ent0", "text": "a young nondiabetic man", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "12540009_4_Ent1", "text": "young", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12540009_4_Ent2", "text": "nondiabetic", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12540009_4_Ent3", "text": "man", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "12561997_1", "wnd_id": "12561997_1_1", "text": "Gelatinous transformation of bone marrow following chemotherapy for myeloma .", "tokens": ["Gelatinous", "transformation", "of", "bone", "marrow", "following", "chemotherapy", "for", "myeloma", "."], "event_mentions": [{"id": "12561997_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "12561997_1_Ent0", "role": "Effect", "text": "Gelatinous transformation of bone marrow", "start": 0, "end": 5}, {"entity_id": "12561997_1_Ent1", "role": "Treatment", "text": "chemotherapy", "start": 6, "end": 7}, {"entity_id": "12561997_1_Ent2", "role": "Treatment_Route", "text": "chemotherapy", "start": 6, "end": 7}, {"entity_id": "12561997_1_Ent3", "role": "Treatment_Disorder", "text": "myeloma", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "12561997_1_Ent0", "text": "Gelatinous transformation of bone marrow", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "12561997_1_Ent1", "text": "chemotherapy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12561997_1_Ent2", "text": "chemotherapy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12561997_1_Ent3", "text": "myeloma", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "12581772_1", "wnd_id": "12581772_1_1", "text": "Interstitial pneumonitis associated with sirolimus : a dilemma for lung transplantation .", "tokens": ["Interstitial", "pneumonitis", "associated", "with", "sirolimus", ":", "a", "dilemma", "for", "lung", "transplantation", "."], "event_mentions": [{"id": "12581772_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "12581772_1_Ent0", "role": "Effect", "text": "Interstitial pneumonitis", "start": 0, "end": 2}, {"entity_id": "12581772_1_Ent1", "role": "Treatment", "text": "sirolimus", "start": 4, "end": 5}, {"entity_id": "12581772_1_Ent2", "role": "Treatment_Drug", "text": "sirolimus", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "12581772_1_Ent0", "text": "Interstitial pneumonitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12581772_1_Ent1", "text": "sirolimus", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12581772_1_Ent2", "text": "sirolimus", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "12587815_1", "wnd_id": "12587815_1_1", "text": "A 16 - year - old boy developed fever , generalized rigidity , leukocytosis , and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and lithium .", "tokens": ["A", "16", "-", "year", "-", "old", "boy", "developed", "fever", ",", "generalized", "rigidity", ",", "leukocytosis", ",", "and", "increased", "serum", "transaminase", "and", "creatine", "kinase", "levels", "while", "receiving", "treatment", "with", "olanzapine", "and", "lithium", "."], "event_mentions": [{"id": "12587815_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "while", "start": 23, "end": 24}, "arguments": [{"entity_id": "12587815_1_Ent0", "role": "Subject", "text": "A 16 - year - old boy", "start": 0, "end": 7}, {"entity_id": "12587815_1_Ent1", "role": "Subject_Age", "text": "16 - year - old", "start": 1, "end": 6}, {"entity_id": "12587815_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "12587815_1_Ent3", "role": "Effect", "text": "fever , generalized rigidity , leukocytosis , and increased serum transaminase and creatine kinase levels", "start": 8, "end": 23}, {"entity_id": "12587815_1_Ent5", "role": "Treatment_Drug", "text": "olanzapine", "start": 27, "end": 28}, {"entity_id": "12587815_1_Ent7", "role": "Combination_Drug", "text": "olanzapine", "start": 27, "end": 28}, {"entity_id": "12587815_1_Ent4", "role": "Treatment", "text": "olanzapine and lithium", "start": 27, "end": 30}, {"entity_id": "12587815_1_Ent6", "role": "Treatment_Drug", "text": "lithium", "start": 29, "end": 30}, {"entity_id": "12587815_1_Ent8", "role": "Combination_Drug", "text": "lithium", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "12587815_1_Ent0", "text": "A 16 - year - old boy", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12587815_1_Ent1", "text": "16 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12587815_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12587815_1_Ent3", "text": "fever , generalized rigidity , leukocytosis , and increased serum transaminase and creatine kinase levels", "entity_type": "Entity", "start": 8, "end": 23}, {"id": "12587815_1_Ent5", "text": "olanzapine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "12587815_1_Ent7", "text": "olanzapine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "12587815_1_Ent4", "text": "olanzapine and lithium", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "12587815_1_Ent6", "text": "lithium", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "12587815_1_Ent8", "text": "lithium", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "12590235_1", "wnd_id": "12590235_1_1", "text": "Both 6 - MP and AZA are widely used and are known to cause hepatotoxicity in a proportion of patients .", "tokens": ["Both", "6", "-", "MP", "and", "AZA", "are", "widely", "used", "and", "are", "known", "to", "cause", "hepatotoxicity", "in", "a", "proportion", "of", "patients", "."], "event_mentions": [{"id": "12590235_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "used", "start": 8, "end": 9}, "arguments": [{"entity_id": "12590235_1_Ent4", "role": "Treatment_Drug", "text": "6 - MP", "start": 1, "end": 4}, {"entity_id": "12590235_1_Ent5", "role": "Combination_Drug", "text": "6 - MP", "start": 1, "end": 4}, {"entity_id": "12590235_1_Ent2", "role": "Treatment", "text": "6 - MP and AZA", "start": 1, "end": 6}, {"entity_id": "12590235_1_Ent3", "role": "Treatment_Drug", "text": "AZA", "start": 5, "end": 6}, {"entity_id": "12590235_1_Ent6", "role": "Combination_Drug", "text": "AZA", "start": 5, "end": 6}, {"entity_id": "12590235_1_Ent1", "role": "Effect", "text": "hepatotoxicity", "start": 14, "end": 15}, {"entity_id": "12590235_1_Ent0", "role": "Subject", "text": "a proportion of patients", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "12590235_1_Ent4", "text": "6 - MP", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "12590235_1_Ent5", "text": "6 - MP", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "12590235_1_Ent2", "text": "6 - MP and AZA", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12590235_1_Ent3", "text": "AZA", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12590235_1_Ent6", "text": "AZA", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12590235_1_Ent1", "text": "hepatotoxicity", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12590235_1_Ent0", "text": "a proportion of patients", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "12621956_2", "wnd_id": "12621956_2_1", "text": "This is a case report of subtle , mild hypothermia in a 54 - year old female patient receiving risperidone for schizophrenia .", "tokens": ["This", "is", "a", "case", "report", "of", "subtle", ",", "mild", "hypothermia", "in", "a", "54", "-", "year", "old", "female", "patient", "receiving", "risperidone", "for", "schizophrenia", "."], "event_mentions": [{"id": "12621956_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 18, "end": 19}, "arguments": [{"entity_id": "12621956_2_Ent3", "role": "Effect", "text": "mild hypothermia", "start": 8, "end": 10}, {"entity_id": "12621956_2_Ent0", "role": "Subject", "text": "a 54 - year old female patient", "start": 11, "end": 18}, {"entity_id": "12621956_2_Ent1", "role": "Subject_Age", "text": "54 - year old", "start": 12, "end": 16}, {"entity_id": "12621956_2_Ent2", "role": "Subject_Gender", "text": "female", "start": 16, "end": 17}, {"entity_id": "12621956_2_Ent4", "role": "Treatment", "text": "risperidone", "start": 19, "end": 20}, {"entity_id": "12621956_2_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 19, "end": 20}, {"entity_id": "12621956_2_Ent6", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "12621956_2_Ent3", "text": "mild hypothermia", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "12621956_2_Ent0", "text": "a 54 - year old female patient", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "12621956_2_Ent1", "text": "54 - year old", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "12621956_2_Ent2", "text": "female", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12621956_2_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "12621956_2_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "12621956_2_Ent6", "text": "schizophrenia", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "12625995_3", "wnd_id": "12625995_3_1", "text": "Two cases of childhood - onset schizophrenia associated with clozapine - induced akathisia responsive to beta - blocker treatment are described .", "tokens": ["Two", "cases", "of", "childhood", "-", "onset", "schizophrenia", "associated", "with", "clozapine", "-", "induced", "akathisia", "responsive", "to", "beta", "-", "blocker", "treatment", "are", "described", "."], "event_mentions": [{"id": "12625995_3_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "12625995_3_Ent8", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "12625995_3_Ent7", "role": "Subject", "text": "Two cases of childhood - onset schizophrenia", "start": 0, "end": 7}, {"entity_id": "12625995_3_Ent9", "role": "Subject_Age", "text": "childhood", "start": 3, "end": 4}, {"entity_id": "12625995_3_Ent12", "role": "Treatment_Disorder", "text": "clozapine - induced akathisia responsive", "start": 9, "end": 14}, {"entity_id": "12625995_3_Ent11", "role": "Treatment_Drug", "text": "beta - blocker", "start": 15, "end": 18}, {"entity_id": "12625995_3_Ent10", "role": "Treatment", "text": "beta - blocker treatment", "start": 15, "end": 19}]}, {"id": "12625995_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "12625995_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "12625995_3_Ent0", "role": "Subject", "text": "Two cases of childhood - onset schizophrenia", "start": 0, "end": 7}, {"entity_id": "12625995_3_Ent2", "role": "Subject_Age", "text": "childhood", "start": 3, "end": 4}, {"entity_id": "12625995_3_Ent6", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 6, "end": 7}, {"entity_id": "12625995_3_Ent4", "role": "Treatment", "text": "clozapine", "start": 9, "end": 10}, {"entity_id": "12625995_3_Ent5", "role": "Treatment_Drug", "text": "clozapine", "start": 9, "end": 10}, {"entity_id": "12625995_3_Ent3", "role": "Effect", "text": "akathisia responsive", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "12625995_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12625995_3_Ent8", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12625995_3_Ent0", "text": "Two cases of childhood - onset schizophrenia", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12625995_3_Ent7", "text": "Two cases of childhood - onset schizophrenia", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12625995_3_Ent2", "text": "childhood", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12625995_3_Ent9", "text": "childhood", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12625995_3_Ent6", "text": "schizophrenia", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12625995_3_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12625995_3_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12625995_3_Ent12", "text": "clozapine - induced akathisia responsive", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "12625995_3_Ent3", "text": "akathisia responsive", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "12625995_3_Ent11", "text": "beta - blocker", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "12625995_3_Ent10", "text": "beta - blocker treatment", "entity_type": "Entity", "start": 15, "end": 19}], "lang": "en"}
{"doc_id": "12656748_2", "wnd_id": "12656748_2_1", "text": "Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia .", "tokens": ["Emergence", "of", "Philadelphia", "positive", "chronic", "myeloid", "leukaemia", "during", "treatment", "with", "hydroxyurea", "for", "Philadelphia", "negative", "essential", "thrombocythaemia", "."], "event_mentions": [{"id": "12656748_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 8, "end": 9}, "arguments": [{"entity_id": "12656748_2_Ent0", "role": "Effect", "text": "Emergence of Philadelphia positive chronic myeloid leukaemia", "start": 0, "end": 7}, {"entity_id": "12656748_2_Ent1", "role": "Treatment", "text": "hydroxyurea", "start": 10, "end": 11}, {"entity_id": "12656748_2_Ent2", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 10, "end": 11}, {"entity_id": "12656748_2_Ent3", "role": "Treatment_Disorder", "text": "Philadelphia negative essential thrombocythaemia", "start": 12, "end": 16}]}], "entity_mentions": [{"id": "12656748_2_Ent0", "text": "Emergence of Philadelphia positive chronic myeloid leukaemia", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12656748_2_Ent1", "text": "hydroxyurea", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12656748_2_Ent2", "text": "hydroxyurea", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12656748_2_Ent3", "text": "Philadelphia negative essential thrombocythaemia", "entity_type": "Entity", "start": 12, "end": 16}], "lang": "en"}
{"doc_id": "1267457_3", "wnd_id": "1267457_3_1", "text": "The sulfonamides are the best verified drug - trigger for erythema multiforme and Stevens - Johnson syndrome .", "tokens": ["The", "sulfonamides", "are", "the", "best", "verified", "drug", "-", "trigger", "for", "erythema", "multiforme", "and", "Stevens", "-", "Johnson", "syndrome", "."], "event_mentions": [{"id": "1267457_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "drug - trigger", "start": 6, "end": 9}, "arguments": [{"entity_id": "1267457_3_Ent1", "role": "Treatment", "text": "sulfonamides", "start": 1, "end": 2}, {"entity_id": "1267457_3_Ent2", "role": "Treatment_Drug", "text": "sulfonamides", "start": 1, "end": 2}, {"entity_id": "1267457_3_Ent0", "role": "Effect", "text": "erythema multiforme and Stevens - Johnson syndrome", "start": 10, "end": 17}]}], "entity_mentions": [{"id": "1267457_3_Ent1", "text": "sulfonamides", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "1267457_3_Ent2", "text": "sulfonamides", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "1267457_3_Ent0", "text": "erythema multiforme and Stevens - Johnson syndrome", "entity_type": "Entity", "start": 10, "end": 17}], "lang": "en"}
{"doc_id": "12680486_1", "wnd_id": "12680486_1_1", "text": "Based on these findings , the patient was diagnosed with diabetes insipidus secondary to lithium therapy and was treated successfully with amiloride .", "tokens": ["Based", "on", "these", "findings", ",", "the", "patient", "was", "diagnosed", "with", "diabetes", "insipidus", "secondary", "to", "lithium", "therapy", "and", "was", "treated", "successfully", "with", "amiloride", "."], "event_mentions": [{"id": "12680486_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 8, "end": 9}, "arguments": [{"entity_id": "12680486_1_Ent0", "role": "Effect", "text": "diabetes insipidus", "start": 10, "end": 12}, {"entity_id": "12680486_1_Ent1", "role": "Treatment", "text": "lithium", "start": 14, "end": 15}, {"entity_id": "12680486_1_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 14, "end": 15}]}, {"id": "12680486_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 18, "end": 19}, "arguments": [{"entity_id": "12680486_1_Ent5", "role": "Treatment_Disorder", "text": "diabetes insipidus secondary to lithium therapy", "start": 10, "end": 16}, {"entity_id": "12680486_1_Ent3", "role": "Effect", "text": "successfully", "start": 19, "end": 20}, {"entity_id": "12680486_1_Ent4", "role": "Treatment", "text": "amiloride", "start": 21, "end": 22}, {"entity_id": "12680486_1_Ent6", "role": "Treatment_Drug", "text": "amiloride", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "12680486_1_Ent0", "text": "diabetes insipidus", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12680486_1_Ent5", "text": "diabetes insipidus secondary to lithium therapy", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "12680486_1_Ent1", "text": "lithium", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12680486_1_Ent2", "text": "lithium", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12680486_1_Ent3", "text": "successfully", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "12680486_1_Ent4", "text": "amiloride", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "12680486_1_Ent6", "text": "amiloride", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "12707728_2", "wnd_id": "12707728_2_1", "text": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously .", "tokens": ["We", "describe", "a", "patient", "who", "developed", "acute", "cerebellar", "syndrome", "after", "prophylactic", "intrathecal", "methotrexate", "administration", "and", "recovered", "spontaneously", "."], "event_mentions": [{"id": "12707728_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "12707728_2_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "12707728_2_Ent1", "role": "Effect", "text": "acute cerebellar syndrome", "start": 6, "end": 9}, {"entity_id": "12707728_2_Ent2", "role": "Treatment", "text": "prophylactic intrathecal methotrexate administration", "start": 10, "end": 14}, {"entity_id": "12707728_2_Ent4", "role": "Treatment_Route", "text": "intrathecal", "start": 11, "end": 12}, {"entity_id": "12707728_2_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12707728_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12707728_2_Ent1", "text": "acute cerebellar syndrome", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12707728_2_Ent2", "text": "prophylactic intrathecal methotrexate administration", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "12707728_2_Ent4", "text": "intrathecal", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12707728_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12751276_1", "wnd_id": "12751276_1_1", "text": "Isoniazid - induced anaphylaxis .", "tokens": ["Isoniazid", "-", "induced", "anaphylaxis", "."], "event_mentions": [{"id": "12751276_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12751276_1_Ent1", "role": "Treatment", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "12751276_1_Ent2", "role": "Treatment_Drug", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "12751276_1_Ent0", "role": "Effect", "text": "anaphylaxis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "12751276_1_Ent1", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12751276_1_Ent2", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12751276_1_Ent0", "text": "anaphylaxis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "12757344_1", "wnd_id": "12757344_1_1", "text": "Carbamazepine - related hyponatremia following cardiopulmonary bypass .", "tokens": ["Carbamazepine", "-", "related", "hyponatremia", "following", "cardiopulmonary", "bypass", "."], "event_mentions": [{"id": "12757344_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "12757344_1_Ent1", "role": "Treatment", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "12757344_1_Ent2", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "12757344_1_Ent0", "role": "Effect", "text": "hyponatremia", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "12757344_1_Ent1", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12757344_1_Ent2", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12757344_1_Ent0", "text": "hyponatremia", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "12757344_2", "wnd_id": "12757344_2_1", "text": "We discuss the association between carbamazepine and hyponatremia and the causes of hyponatremia after cardiopulmonary bypass .", "tokens": ["We", "discuss", "the", "association", "between", "carbamazepine", "and", "hyponatremia", "and", "the", "causes", "of", "hyponatremia", "after", "cardiopulmonary", "bypass", "."], "event_mentions": [{"id": "12757344_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 3, "end": 4}, "arguments": [{"entity_id": "12757344_2_Ent1", "role": "Treatment", "text": "carbamazepine", "start": 5, "end": 6}, {"entity_id": "12757344_2_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 5, "end": 6}, {"entity_id": "12757344_2_Ent0", "role": "Effect", "text": "hyponatremia", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "12757344_2_Ent1", "text": "carbamazepine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12757344_2_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12757344_2_Ent0", "text": "hyponatremia", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "12763355_2", "wnd_id": "12763355_2_1", "text": "Sensorimotor polyneuropathy with 5 - aminosalicylic acid : a case report .", "tokens": ["Sensorimotor", "polyneuropathy", "with", "5", "-", "aminosalicylic", "acid", ":", "a", "case", "report", "."], "event_mentions": [{"id": "12763355_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "12763355_2_Ent1", "role": "Effect", "text": "Sensorimotor polyneuropathy", "start": 0, "end": 2}, {"entity_id": "12763355_2_Ent2", "role": "Treatment", "text": "5 - aminosalicylic acid", "start": 3, "end": 7}, {"entity_id": "12763355_2_Ent3", "role": "Treatment_Drug", "text": "5 - aminosalicylic acid", "start": 3, "end": 7}, {"entity_id": "12763355_2_Ent0", "role": "Subject", "text": "a case", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "12763355_2_Ent1", "text": "Sensorimotor polyneuropathy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12763355_2_Ent2", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "12763355_2_Ent3", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "12763355_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "12786839_2", "wnd_id": "12786839_2_1", "text": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis - like syndrome induced by salazosulfapyridine .", "tokens": ["Slow", "acetylator", "genotypes", "as", "a", "possible", "risk", "factor", "for", "infectious", "mononucleosis", "-", "like", "syndrome", "induced", "by", "salazosulfapyridine", "."], "event_mentions": [{"id": "12786839_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced by", "start": 14, "end": 16}, "arguments": [{"entity_id": "12786839_2_Ent0", "role": "Effect", "text": "infectious mononucleosis - like syndrome", "start": 9, "end": 14}, {"entity_id": "12786839_2_Ent1", "role": "Treatment", "text": "salazosulfapyridine", "start": 16, "end": 17}, {"entity_id": "12786839_2_Ent2", "role": "Treatment_Drug", "text": "salazosulfapyridine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12786839_2_Ent0", "text": "infectious mononucleosis - like syndrome", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "12786839_2_Ent1", "text": "salazosulfapyridine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12786839_2_Ent2", "text": "salazosulfapyridine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12792223_1", "wnd_id": "12792223_1_1", "text": "A 45 - year - old woman with steroid - dependent Crohn 's colitis , successfully managed with maintenance infliximab infusions and methotrexate , developed a lupus - like syndrome eight months after her initial infusion .", "tokens": ["A", "45", "-", "year", "-", "old", "woman", "with", "steroid", "-", "dependent", "Crohn", "'s", "colitis", ",", "successfully", "managed", "with", "maintenance", "infliximab", "infusions", "and", "methotrexate", ",", "developed", "a", "lupus", "-", "like", "syndrome", "eight", "months", "after", "her", "initial", "infusion", "."], "event_mentions": [{"id": "12792223_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 24, "end": 25}, "arguments": [{"entity_id": "12792223_1_Ent0", "role": "Subject", "text": "A 45 - year - old woman with steroid - dependent Crohn 's colitis", "start": 0, "end": 14}, {"entity_id": "12792223_1_Ent1", "role": "Subject_Age", "text": "45 - year - old", "start": 1, "end": 6}, {"entity_id": "12792223_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "12792223_1_Ent10", "role": "Treatment_Disorder", "text": "steroid - dependent Crohn 's colitis", "start": 8, "end": 14}, {"entity_id": "12792223_1_Ent4", "role": "Treatment", "text": "maintenance infliximab infusions and methotrexate", "start": 18, "end": 23}, {"entity_id": "12792223_1_Ent7", "role": "Treatment_Drug", "text": "infliximab", "start": 19, "end": 20}, {"entity_id": "12792223_1_Ent11", "role": "Combination_Drug", "text": "infliximab", "start": 19, "end": 20}, {"entity_id": "12792223_1_Ent9", "role": "Treatment_Route", "text": "infusions", "start": 20, "end": 21}, {"entity_id": "12792223_1_Ent8", "role": "Treatment_Drug", "text": "methotrexate", "start": 22, "end": 23}, {"entity_id": "12792223_1_Ent12", "role": "Combination_Drug", "text": "methotrexate", "start": 22, "end": 23}, {"entity_id": "12792223_1_Ent3", "role": "Effect", "text": "lupus - like syndrome", "start": 26, "end": 30}, {"entity_id": "12792223_1_Ent6", "role": "Treatment_Time_elapsed", "text": "eight months", "start": 30, "end": 32}, {"entity_id": "12792223_1_Ent5", "role": "Treatment", "text": "eight months after her initial infusion", "start": 30, "end": 36}]}], "entity_mentions": [{"id": "12792223_1_Ent0", "text": "A 45 - year - old woman with steroid - dependent Crohn 's colitis", "entity_type": "Entity", "start": 0, "end": 14}, {"id": "12792223_1_Ent1", "text": "45 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12792223_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12792223_1_Ent10", "text": "steroid - dependent Crohn 's colitis", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "12792223_1_Ent4", "text": "maintenance infliximab infusions and methotrexate", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "12792223_1_Ent7", "text": "infliximab", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "12792223_1_Ent11", "text": "infliximab", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "12792223_1_Ent9", "text": "infusions", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "12792223_1_Ent8", "text": "methotrexate", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12792223_1_Ent12", "text": "methotrexate", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12792223_1_Ent3", "text": "lupus - like syndrome", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "12792223_1_Ent6", "text": "eight months", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "12792223_1_Ent5", "text": "eight months after her initial infusion", "entity_type": "Entity", "start": 30, "end": 36}], "lang": "en"}
{"doc_id": "12792223_4", "wnd_id": "12792223_4_1", "text": "We report in detail an unusual adverse reaction to infliximab therapy , a drug - induced lupus - like clinical syndrome .", "tokens": ["We", "report", "in", "detail", "an", "unusual", "adverse", "reaction", "to", "infliximab", "therapy", ",", "a", "drug", "-", "induced", "lupus", "-", "like", "clinical", "syndrome", "."], "event_mentions": [{"id": "12792223_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "12792223_4_Ent1", "role": "Treatment", "text": "infliximab", "start": 9, "end": 10}, {"entity_id": "12792223_4_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 9, "end": 10}, {"entity_id": "12792223_4_Ent0", "role": "Effect", "text": "lupus - like clinical syndrome", "start": 16, "end": 21}]}], "entity_mentions": [{"id": "12792223_4_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12792223_4_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12792223_4_Ent0", "text": "lupus - like clinical syndrome", "entity_type": "Entity", "start": 16, "end": 21}], "lang": "en"}
{"doc_id": "12851279_13", "wnd_id": "12851279_13_1", "text": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts ( 6.5 % tifacogin and 4.8 % placebo for high INR ; 6.0 % tifacogin and 3.3 % placebo for low INR ) .", "tokens": ["There", "was", "an", "increase", "in", "serious", "adverse", "events", "with", "bleeding", "in", "the", "tifacogin", "group", "in", "both", "cohorts", "(", "6.5", "%", "tifacogin", "and", "4.8", "%", "placebo", "for", "high", "INR", ";", "6.0", "%", "tifacogin", "and", "3.3", "%", "placebo", "for", "low", "INR", ")", "."], "event_mentions": [{"id": "12851279_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse events", "start": 6, "end": 8}, "arguments": [{"entity_id": "12851279_13_Ent0", "role": "Effect", "text": "bleeding", "start": 9, "end": 10}, {"entity_id": "12851279_13_Ent1", "role": "Treatment", "text": "tifacogin", "start": 12, "end": 13}, {"entity_id": "12851279_13_Ent2", "role": "Treatment_Drug", "text": "tifacogin", "start": 12, "end": 13}, {"entity_id": "12851279_13_Ent3", "role": "Treatment_Disorder", "text": "high INR", "start": 26, "end": 28}, {"entity_id": "12851279_13_Ent4", "role": "Treatment_Disorder", "text": "low INR", "start": 37, "end": 39}]}], "entity_mentions": [{"id": "12851279_13_Ent0", "text": "bleeding", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12851279_13_Ent1", "text": "tifacogin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12851279_13_Ent2", "text": "tifacogin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12851279_13_Ent3", "text": "high INR", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "12851279_13_Ent4", "text": "low INR", "entity_type": "Entity", "start": 37, "end": 39}], "lang": "en"}
{"doc_id": "12885108_1", "wnd_id": "12885108_1_1", "text": "Possible heart failure exacerbation associated with rosiglitazone : case report and literature review .", "tokens": ["Possible", "heart", "failure", "exacerbation", "associated", "with", "rosiglitazone", ":", "case", "report", "and", "literature", "review", "."], "event_mentions": [{"id": "12885108_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "12885108_1_Ent0", "role": "Effect", "text": "heart failure exacerbation", "start": 1, "end": 4}, {"entity_id": "12885108_1_Ent1", "role": "Treatment", "text": "rosiglitazone", "start": 6, "end": 7}, {"entity_id": "12885108_1_Ent2", "role": "Treatment_Drug", "text": "rosiglitazone", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "12885108_1_Ent0", "text": "heart failure exacerbation", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "12885108_1_Ent1", "text": "rosiglitazone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12885108_1_Ent2", "text": "rosiglitazone", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "12889716_2", "wnd_id": "12889716_2_1", "text": "Only one case of a generalized maculopapular rash with enoxaparin has been reported in Europe .", "tokens": ["Only", "one", "case", "of", "a", "generalized", "maculopapular", "rash", "with", "enoxaparin", "has", "been", "reported", "in", "Europe", "."], "event_mentions": [{"id": "12889716_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 8, "end": 9}, "arguments": [{"entity_id": "12889716_2_Ent1", "role": "Subject_Population", "text": "one", "start": 1, "end": 2}, {"entity_id": "12889716_2_Ent0", "role": "Subject", "text": "one case", "start": 1, "end": 3}, {"entity_id": "12889716_2_Ent2", "role": "Effect", "text": "generalized maculopapular rash", "start": 5, "end": 8}, {"entity_id": "12889716_2_Ent3", "role": "Treatment", "text": "enoxaparin", "start": 9, "end": 10}, {"entity_id": "12889716_2_Ent4", "role": "Treatment_Drug", "text": "enoxaparin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "12889716_2_Ent1", "text": "one", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "12889716_2_Ent0", "text": "one case", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "12889716_2_Ent2", "text": "generalized maculopapular rash", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "12889716_2_Ent3", "text": "enoxaparin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12889716_2_Ent4", "text": "enoxaparin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "12921505_2", "wnd_id": "12921505_2_1", "text": "Argatroban for heparin - induced thrombocytopenia in hepato - renal failure and CVVHD .", "tokens": ["Argatroban", "for", "heparin", "-", "induced", "thrombocytopenia", "in", "hepato", "-", "renal", "failure", "and", "CVVHD", "."], "event_mentions": [{"id": "12921505_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 1, "end": 2}, "arguments": [{"entity_id": "12921505_2_Ent0", "role": "Treatment", "text": "Argatroban", "start": 0, "end": 1}, {"entity_id": "12921505_2_Ent2", "role": "Treatment_Drug", "text": "Argatroban", "start": 0, "end": 1}, {"entity_id": "12921505_2_Ent1", "role": "Treatment_Disorder", "text": "hepato - renal failure", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "12921505_2_Ent0", "text": "Argatroban", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12921505_2_Ent2", "text": "Argatroban", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12921505_2_Ent1", "text": "hepato - renal failure", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "12921505_4", "wnd_id": "12921505_4_1", "text": "OBJECTIVE : To report a case of significant hepatic and renal failure with the use of argatroban in a patient with heparin - induced thrombocytopenia ( HIT ) requiring continuous veno - veno hemodialysis ( CVVHD ) .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "significant", "hepatic", "and", "renal", "failure", "with", "the", "use", "of", "argatroban", "in", "a", "patient", "with", "heparin", "-", "induced", "thrombocytopenia", "(", "HIT", ")", "requiring", "continuous", "veno", "-", "veno", "hemodialysis", "(", "CVVHD", ")", "."], "event_mentions": [{"id": "12921505_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "use", "start": 14, "end": 15}, "arguments": [{"entity_id": "12921505_4_Ent2", "role": "Effect", "text": "significant hepatic and renal failure", "start": 7, "end": 12}, {"entity_id": "12921505_4_Ent3", "role": "Treatment", "text": "argatroban", "start": 16, "end": 17}, {"entity_id": "12921505_4_Ent4", "role": "Treatment_Drug", "text": "argatroban", "start": 16, "end": 17}, {"entity_id": "12921505_4_Ent0", "role": "Subject", "text": "a patient with heparin - induced thrombocytopenia ( HIT ) requiring continuous veno - veno hemodialysis ( CVVHD )", "start": 18, "end": 37}, {"entity_id": "12921505_4_Ent1", "role": "Subject_Disorder", "text": "heparin - induced thrombocytopenia ( HIT )", "start": 21, "end": 28}]}, {"id": "12921505_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 23, "end": 24}, "arguments": [{"entity_id": "12921505_4_Ent6", "role": "Treatment", "text": "heparin", "start": 21, "end": 22}, {"entity_id": "12921505_4_Ent7", "role": "Treatment_Drug", "text": "heparin", "start": 21, "end": 22}, {"entity_id": "12921505_4_Ent5", "role": "Effect", "text": "thrombocytopenia", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "12921505_4_Ent2", "text": "significant hepatic and renal failure", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "12921505_4_Ent3", "text": "argatroban", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12921505_4_Ent4", "text": "argatroban", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12921505_4_Ent0", "text": "a patient with heparin - induced thrombocytopenia ( HIT ) requiring continuous veno - veno hemodialysis ( CVVHD )", "entity_type": "Entity", "start": 18, "end": 37}, {"id": "12921505_4_Ent6", "text": "heparin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "12921505_4_Ent7", "text": "heparin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "12921505_4_Ent1", "text": "heparin - induced thrombocytopenia ( HIT )", "entity_type": "Entity", "start": 21, "end": 28}, {"id": "12921505_4_Ent5", "text": "thrombocytopenia", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "12944250_1", "wnd_id": "12944250_1_1", "text": "It is concluded that simultaneous administration of ciprofloxacin and tazobactam / piperacillin may cause marked thrombocytosis .", "tokens": ["It", "is", "concluded", "that", "simultaneous", "administration", "of", "ciprofloxacin", "and", "tazobactam", "/", "piperacillin", "may", "cause", "marked", "thrombocytosis", "."], "event_mentions": [{"id": "12944250_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 13, "end": 14}, "arguments": [{"entity_id": "12944250_1_Ent1", "role": "Treatment", "text": "simultaneous administration of ciprofloxacin and tazobactam / piperacillin", "start": 4, "end": 12}, {"entity_id": "12944250_1_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "12944250_1_Ent4", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "12944250_1_Ent3", "role": "Treatment_Drug", "text": "tazobactam / piperacillin", "start": 9, "end": 12}, {"entity_id": "12944250_1_Ent5", "role": "Combination_Drug", "text": "tazobactam / piperacillin", "start": 9, "end": 12}, {"entity_id": "12944250_1_Ent0", "role": "Effect", "text": "marked thrombocytosis", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "12944250_1_Ent1", "text": "simultaneous administration of ciprofloxacin and tazobactam / piperacillin", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "12944250_1_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12944250_1_Ent4", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12944250_1_Ent3", "text": "tazobactam / piperacillin", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12944250_1_Ent5", "text": "tazobactam / piperacillin", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12944250_1_Ent0", "text": "marked thrombocytosis", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "12962465_1", "wnd_id": "12962465_1_1", "text": "After four months , while receiving RH , he developed painful bilateral gynaecomastia .", "tokens": ["After", "four", "months", ",", "while", "receiving", "RH", ",", "he", "developed", "painful", "bilateral", "gynaecomastia", "."], "event_mentions": [{"id": "12962465_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "12962465_1_Ent3", "role": "Treatment_Time_elapsed", "text": "After four months", "start": 0, "end": 3}, {"entity_id": "12962465_1_Ent1", "role": "Treatment", "text": "receiving RH", "start": 5, "end": 7}, {"entity_id": "12962465_1_Ent2", "role": "Treatment_Drug", "text": "RH", "start": 6, "end": 7}, {"entity_id": "12962465_1_Ent0", "role": "Effect", "text": "painful bilateral gynaecomastia", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "12962465_1_Ent3", "text": "After four months", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12962465_1_Ent1", "text": "receiving RH", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12962465_1_Ent2", "text": "RH", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12962465_1_Ent0", "text": "painful bilateral gynaecomastia", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "1348483_1", "wnd_id": "1348483_1_1", "text": "A patient with Parkinson 's disease , initially treated with bromocriptine and subsequently with cabergoline , developed progressive pleuropulmonary abnormalities during the latter therapy .", "tokens": ["A", "patient", "with", "Parkinson", "'s", "disease", ",", "initially", "treated", "with", "bromocriptine", "and", "subsequently", "with", "cabergoline", ",", "developed", "progressive", "pleuropulmonary", "abnormalities", "during", "the", "latter", "therapy", "."], "event_mentions": [{"id": "1348483_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "1348483_1_Ent0", "role": "Subject", "text": "A patient with Parkinson 's disease", "start": 0, "end": 6}, {"entity_id": "1348483_1_Ent3", "role": "Treatment_Disorder", "text": "Parkinson 's disease", "start": 3, "end": 6}, {"entity_id": "1348483_1_Ent2", "role": "Treatment", "text": "initially treated with bromocriptine and subsequently with cabergoline", "start": 7, "end": 15}, {"entity_id": "1348483_1_Ent4", "role": "Treatment_Drug", "text": "bromocriptine", "start": 10, "end": 11}, {"entity_id": "1348483_1_Ent5", "role": "Treatment_Drug", "text": "cabergoline", "start": 14, "end": 15}, {"entity_id": "1348483_1_Ent1", "role": "Effect", "text": "progressive pleuropulmonary abnormalities during the latter therapy", "start": 17, "end": 24}]}], "entity_mentions": [{"id": "1348483_1_Ent0", "text": "A patient with Parkinson 's disease", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "1348483_1_Ent3", "text": "Parkinson 's disease", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "1348483_1_Ent2", "text": "initially treated with bromocriptine and subsequently with cabergoline", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "1348483_1_Ent4", "text": "bromocriptine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1348483_1_Ent5", "text": "cabergoline", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1348483_1_Ent1", "text": "progressive pleuropulmonary abnormalities during the latter therapy", "entity_type": "Entity", "start": 17, "end": 24}], "lang": "en"}
{"doc_id": "1359782_3", "wnd_id": "1359782_3_1", "text": "Sulfasalazine - induced lung disorder is an extremely rare entity which must be considered in all ulcerative colitis patients while on sulfasalazine therapy , despite the absence of pulmonary symptomatology .", "tokens": ["Sulfasalazine", "-", "induced", "lung", "disorder", "is", "an", "extremely", "rare", "entity", "which", "must", "be", "considered", "in", "all", "ulcerative", "colitis", "patients", "while", "on", "sulfasalazine", "therapy", ",", "despite", "the", "absence", "of", "pulmonary", "symptomatology", "."], "event_mentions": [{"id": "1359782_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1359782_3_Ent1", "role": "Treatment", "text": "Sulfasalazine", "start": 0, "end": 1}, {"entity_id": "1359782_3_Ent2", "role": "Treatment_Disorder", "text": "Sulfasalazine", "start": 0, "end": 1}, {"entity_id": "1359782_3_Ent0", "role": "Effect", "text": "lung disorder", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "1359782_3_Ent1", "text": "Sulfasalazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1359782_3_Ent2", "text": "Sulfasalazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1359782_3_Ent0", "text": "lung disorder", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "1388041_2", "wnd_id": "1388041_2_1", "text": "Paroxetine is a selective serotonin reuptake inhibitor possessing anti - depressant activity .", "tokens": ["Paroxetine", "is", "a", "selective", "serotonin", "reuptake", "inhibitor", "possessing", "anti", "-", "depressant", "activity", "."], "event_mentions": [{"id": "1388041_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "possessing", "start": 7, "end": 8}, "arguments": [{"entity_id": "1388041_2_Ent0", "role": "Treatment", "text": "Paroxetine", "start": 0, "end": 1}, {"entity_id": "1388041_2_Ent2", "role": "Treatment_Drug", "text": "Paroxetine", "start": 0, "end": 1}, {"entity_id": "1388041_2_Ent1", "role": "Treatment_Disorder", "text": "anti - depressant activity", "start": 8, "end": 12}]}], "entity_mentions": [{"id": "1388041_2_Ent0", "text": "Paroxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1388041_2_Ent2", "text": "Paroxetine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1388041_2_Ent1", "text": "anti - depressant activity", "entity_type": "Entity", "start": 8, "end": 12}], "lang": "en"}
{"doc_id": "1414247_2", "wnd_id": "1414247_2_1", "text": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease .", "tokens": ["Valproic", "acid", "induced", "coma", "is", "presented", "in", "an", "adult", "patient", "without", "a", "history", "of", "metabolic", "disease", "."], "event_mentions": [{"id": "1414247_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1414247_2_Ent3", "role": "Treatment", "text": "Valproic acid", "start": 0, "end": 2}, {"entity_id": "1414247_2_Ent4", "role": "Treatment_Drug", "text": "Valproic acid", "start": 0, "end": 2}, {"entity_id": "1414247_2_Ent2", "role": "Effect", "text": "coma", "start": 3, "end": 4}, {"entity_id": "1414247_2_Ent1", "role": "Subject_Age", "text": "adult", "start": 8, "end": 9}, {"entity_id": "1414247_2_Ent0", "role": "Subject", "text": "adult patient without a history of metabolic disease", "start": 8, "end": 16}]}], "entity_mentions": [{"id": "1414247_2_Ent3", "text": "Valproic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1414247_2_Ent4", "text": "Valproic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1414247_2_Ent2", "text": "coma", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1414247_2_Ent1", "text": "adult", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1414247_2_Ent0", "text": "adult patient without a history of metabolic disease", "entity_type": "Entity", "start": 8, "end": 16}], "lang": "en"}
{"doc_id": "1422497_2", "wnd_id": "1422497_2_1", "text": "Hemorrhagic cystitis is a significant toxic effect of cyclophosphamide therapy .", "tokens": ["Hemorrhagic", "cystitis", "is", "a", "significant", "toxic", "effect", "of", "cyclophosphamide", "therapy", "."], "event_mentions": [{"id": "1422497_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "significant toxic effect", "start": 4, "end": 7}, "arguments": [{"entity_id": "1422497_2_Ent0", "role": "Effect", "text": "Hemorrhagic cystitis", "start": 0, "end": 2}, {"entity_id": "1422497_2_Ent1", "role": "Treatment", "text": "cyclophosphamide", "start": 8, "end": 9}, {"entity_id": "1422497_2_Ent2", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "1422497_2_Ent0", "text": "Hemorrhagic cystitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1422497_2_Ent1", "text": "cyclophosphamide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1422497_2_Ent2", "text": "cyclophosphamide", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "1445134_2", "wnd_id": "1445134_2_1", "text": "However , follow - up revealed that gestational diabetes when associated with norethisterone had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance .", "tokens": ["However", ",", "follow", "-", "up", "revealed", "that", "gestational", "diabetes", "when", "associated", "with", "norethisterone", "had", "a", "lesser", "risk", "of", "emerging", "diabetes", "mellitus", "and", "impaired", "glucose", "tolerance", "."], "event_mentions": [{"id": "1445134_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "emerging", "start": 18, "end": 19}, "arguments": [{"entity_id": "1445134_2_Ent1", "role": "Treatment", "text": "norethisterone", "start": 12, "end": 13}, {"entity_id": "1445134_2_Ent2", "role": "Treatment_Drug", "text": "norethisterone", "start": 12, "end": 13}, {"entity_id": "1445134_2_Ent0", "role": "Effect", "text": "diabetes mellitus and impaired glucose tolerance", "start": 19, "end": 25}]}], "entity_mentions": [{"id": "1445134_2_Ent1", "text": "norethisterone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1445134_2_Ent2", "text": "norethisterone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1445134_2_Ent0", "text": "diabetes mellitus and impaired glucose tolerance", "entity_type": "Entity", "start": 19, "end": 25}], "lang": "en"}
{"doc_id": "1445134_5", "wnd_id": "1445134_5_1", "text": "Norethisterone in these 69 pregnancies accounted for 33.3 % ( 5 of 15 ) cases of clitoral hypertrophy diagnosed in 100,756 consecutive births .", "tokens": ["Norethisterone", "in", "these", "69", "pregnancies", "accounted", "for", "33.3", "%", "(", "5", "of", "15", ")", "cases", "of", "clitoral", "hypertrophy", "diagnosed", "in", "100,756", "consecutive", "births", "."], "event_mentions": [{"id": "1445134_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "accounted", "start": 5, "end": 6}, "arguments": [{"entity_id": "1445134_5_Ent3", "role": "Treatment", "text": "Norethisterone", "start": 0, "end": 1}, {"entity_id": "1445134_5_Ent4", "role": "Treatment_Drug", "text": "Norethisterone", "start": 0, "end": 1}, {"entity_id": "1445134_5_Ent1", "role": "Subject_Population", "text": "69", "start": 3, "end": 4}, {"entity_id": "1445134_5_Ent0", "role": "Subject", "text": "69 pregnancies", "start": 3, "end": 5}, {"entity_id": "1445134_5_Ent2", "role": "Effect", "text": "clitoral hypertrophy", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "1445134_5_Ent3", "text": "Norethisterone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1445134_5_Ent4", "text": "Norethisterone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1445134_5_Ent1", "text": "69", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1445134_5_Ent0", "text": "69 pregnancies", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "1445134_5_Ent2", "text": "clitoral hypertrophy", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "1450506_3", "wnd_id": "1450506_3_1", "text": "Sixteen hours after the first administration of IFN , IFN was suspended by the symptoms of congestive heart failure ( CHF ) .", "tokens": ["Sixteen", "hours", "after", "the", "first", "administration", "of", "IFN", ",", "IFN", "was", "suspended", "by", "the", "symptoms", "of", "congestive", "heart", "failure", "(", "CHF", ")", "."], "event_mentions": [{"id": "1450506_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suspended", "start": 11, "end": 12}, "arguments": [{"entity_id": "1450506_3_Ent1", "role": "Treatment", "text": "IFN", "start": 9, "end": 10}, {"entity_id": "1450506_3_Ent2", "role": "Treatment_Drug", "text": "IFN", "start": 9, "end": 10}, {"entity_id": "1450506_3_Ent0", "role": "Effect", "text": "congestive heart failure ( CHF )", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "1450506_3_Ent1", "text": "IFN", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1450506_3_Ent2", "text": "IFN", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1450506_3_Ent0", "text": "congestive heart failure ( CHF )", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "14526130_2", "wnd_id": "14526130_2_1", "text": "CASE REPORT : We report the case of a 58 year old patient who , after 2 days of treatment with roxithromycin and betamethasone , manifested acute pancreatitis .", "tokens": ["CASE", "REPORT", ":", "We", "report", "the", "case", "of", "a", "58", "year", "old", "patient", "who", ",", "after", "2", "days", "of", "treatment", "with", "roxithromycin", "and", "betamethasone", ",", "manifested", "acute", "pancreatitis", "."], "event_mentions": [{"id": "14526130_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifested", "start": 25, "end": 26}, "arguments": [{"entity_id": "14526130_2_Ent0", "role": "Subject", "text": "a 58 year old patient", "start": 8, "end": 13}, {"entity_id": "14526130_2_Ent1", "role": "Subject_Age", "text": "58 year old", "start": 9, "end": 12}, {"entity_id": "14526130_2_Ent3", "role": "Treatment", "text": "after 2 days of treatment with roxithromycin", "start": 15, "end": 22}, {"entity_id": "14526130_2_Ent7", "role": "Treatment_Time_elapsed", "text": "2 days", "start": 16, "end": 18}, {"entity_id": "14526130_2_Ent5", "role": "Treatment_Drug", "text": "roxithromycin", "start": 21, "end": 22}, {"entity_id": "14526130_2_Ent8", "role": "Combination_Drug", "text": "roxithromycin", "start": 21, "end": 22}, {"entity_id": "14526130_2_Ent4", "role": "Treatment", "text": "betamethasone", "start": 23, "end": 24}, {"entity_id": "14526130_2_Ent6", "role": "Treatment_Drug", "text": "betamethasone", "start": 23, "end": 24}, {"entity_id": "14526130_2_Ent9", "role": "Combination_Drug", "text": "betamethasone", "start": 23, "end": 24}, {"entity_id": "14526130_2_Ent2", "role": "Effect", "text": "acute pancreatitis", "start": 26, "end": 28}]}], "entity_mentions": [{"id": "14526130_2_Ent0", "text": "a 58 year old patient", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "14526130_2_Ent1", "text": "58 year old", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "14526130_2_Ent3", "text": "after 2 days of treatment with roxithromycin", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "14526130_2_Ent7", "text": "2 days", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "14526130_2_Ent5", "text": "roxithromycin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "14526130_2_Ent8", "text": "roxithromycin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "14526130_2_Ent4", "text": "betamethasone", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "14526130_2_Ent6", "text": "betamethasone", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "14526130_2_Ent9", "text": "betamethasone", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "14526130_2_Ent2", "text": "acute pancreatitis", "entity_type": "Entity", "start": 26, "end": 28}], "lang": "en"}
{"doc_id": "14601701_1", "wnd_id": "14601701_1_1", "text": "Ocular ethambutol toxicity .", "tokens": ["Ocular", "ethambutol", "toxicity", "."], "event_mentions": [{"id": "14601701_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 2, "end": 3}, "arguments": [{"entity_id": "14601701_1_Ent2", "role": "Treatment_Route", "text": "Ocular", "start": 0, "end": 1}, {"entity_id": "14601701_1_Ent1", "role": "Treatment", "text": "Ocular ethambutol", "start": 0, "end": 2}, {"entity_id": "14601701_1_Ent3", "role": "Treatment_Drug", "text": "ethambutol", "start": 1, "end": 2}, {"entity_id": "14601701_1_Ent0", "role": "Effect", "text": "toxicity", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "14601701_1_Ent2", "text": "Ocular", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14601701_1_Ent1", "text": "Ocular ethambutol", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14601701_1_Ent3", "text": "ethambutol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "14601701_1_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "14601701_2", "wnd_id": "14601701_2_1", "text": "Ethambutol is an antimicrobial agent used frequently to treat tuberculosis .", "tokens": ["Ethambutol", "is", "an", "antimicrobial", "agent", "used", "frequently", "to", "treat", "tuberculosis", "."], "event_mentions": [{"id": "14601701_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treat", "start": 8, "end": 9}, "arguments": [{"entity_id": "14601701_2_Ent0", "role": "Treatment", "text": "Ethambutol", "start": 0, "end": 1}, {"entity_id": "14601701_2_Ent2", "role": "Treatment_Drug", "text": "Ethambutol", "start": 0, "end": 1}, {"entity_id": "14601701_2_Ent1", "role": "Treatment_Disorder", "text": "tuberculosis", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "14601701_2_Ent0", "text": "Ethambutol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14601701_2_Ent2", "text": "Ethambutol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14601701_2_Ent1", "text": "tuberculosis", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "14607011_1", "wnd_id": "14607011_1_1", "text": "Fatal cold medication intoxication in an infant .", "tokens": ["Fatal", "cold", "medication", "intoxication", "in", "an", "infant", "."], "event_mentions": [{"id": "14607011_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 4, "end": 5}, "arguments": [{"entity_id": "14607011_1_Ent2", "role": "Effect", "text": "Fatal cold medication intoxication", "start": 0, "end": 4}, {"entity_id": "14607011_1_Ent3", "role": "Treatment", "text": "cold medication", "start": 1, "end": 3}, {"entity_id": "14607011_1_Ent4", "role": "Treatment_Drug", "text": "cold medication", "start": 1, "end": 3}, {"entity_id": "14607011_1_Ent0", "role": "Subject", "text": "infant", "start": 6, "end": 7}, {"entity_id": "14607011_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "14607011_1_Ent2", "text": "Fatal cold medication intoxication", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "14607011_1_Ent3", "text": "cold medication", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "14607011_1_Ent4", "text": "cold medication", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "14607011_1_Ent0", "text": "infant", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14607011_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "14614357_1", "wnd_id": "14614357_1_1", "text": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9 .", "tokens": ["Early", "overanticoagulation", "with", "acenocoumarol", "due", "to", "a", "genetic", "polymorphism", "of", "cytochrome", "P450", "CYP2C9", "."], "event_mentions": [{"id": "14614357_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "14614357_1_Ent0", "role": "Effect", "text": "Early overanticoagulation", "start": 0, "end": 2}, {"entity_id": "14614357_1_Ent1", "role": "Treatment", "text": "acenocoumarol", "start": 3, "end": 4}, {"entity_id": "14614357_1_Ent2", "role": "Treatment_Drug", "text": "acenocoumarol", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "14614357_1_Ent0", "text": "Early overanticoagulation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14614357_1_Ent1", "text": "acenocoumarol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14614357_1_Ent2", "text": "acenocoumarol", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "14632592_1", "wnd_id": "14632592_1_1", "text": "Colchicine - induced myopathy in a teenager with familial Mediterranean fever .", "tokens": ["Colchicine", "-", "induced", "myopathy", "in", "a", "teenager", "with", "familial", "Mediterranean", "fever", "."], "event_mentions": [{"id": "14632592_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "14632592_1_Ent3", "role": "Treatment", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "14632592_1_Ent5", "role": "Treatment_Drug", "text": "Colchicine", "start": 0, "end": 1}, {"entity_id": "14632592_1_Ent2", "role": "Effect", "text": "myopathy", "start": 3, "end": 4}, {"entity_id": "14632592_1_Ent0", "role": "Subject", "text": "a teenager with familial Mediterranean fever", "start": 5, "end": 11}, {"entity_id": "14632592_1_Ent1", "role": "Subject_Age", "text": "teenager", "start": 6, "end": 7}, {"entity_id": "14632592_1_Ent4", "role": "Treatment_Disorder", "text": "Mediterranean fever", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "14632592_1_Ent3", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14632592_1_Ent5", "text": "Colchicine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14632592_1_Ent2", "text": "myopathy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14632592_1_Ent0", "text": "a teenager with familial Mediterranean fever", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "14632592_1_Ent1", "text": "teenager", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14632592_1_Ent4", "text": "Mediterranean fever", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "14641354_2", "wnd_id": "14641354_2_1", "text": "We report a 43 - year - old woman who developed sore throat , swelling of the lips and oral cavity and dysphagia , 2 weeks after the use of budesonide spray ( Budefat ) for treatment of bronchial asthma .", "tokens": ["We", "report", "a", "43", "-", "year", "-", "old", "woman", "who", "developed", "sore", "throat", ",", "swelling", "of", "the", "lips", "and", "oral", "cavity", "and", "dysphagia", ",", "2", "weeks", "after", "the", "use", "of", "budesonide", "spray", "(", "Budefat", ")", "for", "treatment", "of", "bronchial", "asthma", "."], "event_mentions": [{"id": "14641354_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "14641354_2_Ent0", "role": "Subject", "text": "a 43 - year - old woman", "start": 2, "end": 9}, {"entity_id": "14641354_2_Ent1", "role": "Subject_Age", "text": "43 - year - old", "start": 3, "end": 8}, {"entity_id": "14641354_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "14641354_2_Ent3", "role": "Effect", "text": "sore throat , swelling of the lips and oral cavity and dysphagia", "start": 11, "end": 23}, {"entity_id": "14641354_2_Ent5", "role": "Treatment_Time_elapsed", "text": "2 weeks after", "start": 24, "end": 27}, {"entity_id": "14641354_2_Ent4", "role": "Treatment", "text": "2 weeks after the use of budesonide spray ( Budefat )", "start": 24, "end": 35}, {"entity_id": "14641354_2_Ent6", "role": "Treatment_Drug", "text": "budesonide", "start": 30, "end": 31}, {"entity_id": "14641354_2_Ent9", "role": "Treatment_Route", "text": "spray", "start": 31, "end": 32}, {"entity_id": "14641354_2_Ent7", "role": "Treatment_Drug", "text": "Budefat", "start": 33, "end": 34}, {"entity_id": "14641354_2_Ent8", "role": "Treatment_Disorder", "text": "bronchial asthma .", "start": 38, "end": 41}]}], "entity_mentions": [{"id": "14641354_2_Ent0", "text": "a 43 - year - old woman", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "14641354_2_Ent1", "text": "43 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "14641354_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14641354_2_Ent3", "text": "sore throat , swelling of the lips and oral cavity and dysphagia", "entity_type": "Entity", "start": 11, "end": 23}, {"id": "14641354_2_Ent5", "text": "2 weeks after", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "14641354_2_Ent4", "text": "2 weeks after the use of budesonide spray ( Budefat )", "entity_type": "Entity", "start": 24, "end": 35}, {"id": "14641354_2_Ent6", "text": "budesonide", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "14641354_2_Ent9", "text": "spray", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "14641354_2_Ent7", "text": "Budefat", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "14641354_2_Ent8", "text": "bronchial asthma .", "entity_type": "Entity", "start": 38, "end": 41}], "lang": "en"}
{"doc_id": "14674674_1", "wnd_id": "14674674_1_1", "text": "A diagnosis of infliximab - induced lupus was made and the drug treatment was withdrawn .", "tokens": ["A", "diagnosis", "of", "infliximab", "-", "induced", "lupus", "was", "made", "and", "the", "drug", "treatment", "was", "withdrawn", "."], "event_mentions": [{"id": "14674674_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "14674674_1_Ent1", "role": "Treatment", "text": "infliximab", "start": 3, "end": 4}, {"entity_id": "14674674_1_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 3, "end": 4}, {"entity_id": "14674674_1_Ent0", "role": "Effect", "text": "lupus", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "14674674_1_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14674674_1_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14674674_1_Ent0", "text": "lupus", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "14684937_3", "wnd_id": "14684937_3_1", "text": "The present case is the first report of hypercalcemia induced by vitamin D3 ointment and thiazide simultaneously .", "tokens": ["The", "present", "case", "is", "the", "first", "report", "of", "hypercalcemia", "induced", "by", "vitamin", "D3", "ointment", "and", "thiazide", "simultaneously", "."], "event_mentions": [{"id": "14684937_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "14684937_3_Ent0", "role": "Subject", "text": "The present case", "start": 0, "end": 3}, {"entity_id": "14684937_3_Ent1", "role": "Effect", "text": "hypercalcemia", "start": 8, "end": 9}, {"entity_id": "14684937_3_Ent3", "role": "Treatment_Drug", "text": "vitamin D3", "start": 11, "end": 13}, {"entity_id": "14684937_3_Ent6", "role": "Combination_Drug", "text": "vitamin D3", "start": 11, "end": 13}, {"entity_id": "14684937_3_Ent2", "role": "Treatment", "text": "vitamin D3 ointment and thiazide simultaneously", "start": 11, "end": 17}, {"entity_id": "14684937_3_Ent5", "role": "Treatment_Route", "text": "ointment", "start": 13, "end": 14}, {"entity_id": "14684937_3_Ent4", "role": "Treatment_Drug", "text": "thiazide", "start": 15, "end": 16}, {"entity_id": "14684937_3_Ent7", "role": "Combination_Drug", "text": "thiazide", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "14684937_3_Ent0", "text": "The present case", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14684937_3_Ent1", "text": "hypercalcemia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14684937_3_Ent3", "text": "vitamin D3", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "14684937_3_Ent6", "text": "vitamin D3", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "14684937_3_Ent2", "text": "vitamin D3 ointment and thiazide simultaneously", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "14684937_3_Ent5", "text": "ointment", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14684937_3_Ent4", "text": "thiazide", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "14684937_3_Ent7", "text": "thiazide", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "14690166_6", "wnd_id": "14690166_6_1", "text": "Therefore , it is reasonable to conclude that : 1 ) 2 - CdA can induce durable complete remission in MCD patients but unfortunately it can not cure the disease ; 2 ) the possibility that 2 - CdA may accelerate the transformation of MCD to NHL can not be ruled out .", "tokens": ["Therefore", ",", "it", "is", "reasonable", "to", "conclude", "that", ":", "1", ")", "2", "-", "CdA", "can", "induce", "durable", "complete", "remission", "in", "MCD", "patients", "but", "unfortunately", "it", "can", "not", "cure", "the", "disease", ";", "2", ")", "the", "possibility", "that", "2", "-", "CdA", "may", "accelerate", "the", "transformation", "of", "MCD", "to", "NHL", "can", "not", "be", "ruled", "out", "."], "event_mentions": [{"id": "14690166_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "induce", "start": 15, "end": 16}, "arguments": [{"entity_id": "14690166_6_Ent1", "role": "Treatment", "text": "2 - CdA", "start": 11, "end": 14}, {"entity_id": "14690166_6_Ent3", "role": "Treatment_Drug", "text": "2 - CdA", "start": 11, "end": 14}, {"entity_id": "14690166_6_Ent0", "role": "Effect", "text": "durable complete remission", "start": 16, "end": 19}, {"entity_id": "14690166_6_Ent2", "role": "Treatment_Disorder", "text": "MCD", "start": 20, "end": 21}]}, {"id": "14690166_6_Evt1", "event_type": "Adverse_event", "trigger": {"text": "accelerate", "start": 40, "end": 41}, "arguments": [{"entity_id": "14690166_6_Ent5", "role": "Treatment", "text": "2 - CdA", "start": 36, "end": 39}, {"entity_id": "14690166_6_Ent6", "role": "Treatment_Drug", "text": "2 - CdA", "start": 36, "end": 39}, {"entity_id": "14690166_6_Ent4", "role": "Effect", "text": "the transformation of MCD to NHL", "start": 41, "end": 47}]}], "entity_mentions": [{"id": "14690166_6_Ent1", "text": "2 - CdA", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "14690166_6_Ent3", "text": "2 - CdA", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "14690166_6_Ent0", "text": "durable complete remission", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "14690166_6_Ent2", "text": "MCD", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "14690166_6_Ent5", "text": "2 - CdA", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "14690166_6_Ent6", "text": "2 - CdA", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "14690166_6_Ent4", "text": "the transformation of MCD to NHL", "entity_type": "Entity", "start": 41, "end": 47}], "lang": "en"}
{"doc_id": "14697943_2", "wnd_id": "14697943_2_1", "text": "Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus .", "tokens": ["Reflex", "sympathetic", "dystrophy", "syndrome", "in", "renal", "transplanted", "patients", "under", "immunosuppression", "with", "tacrolimus", "."], "event_mentions": [{"id": "14697943_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 10, "end": 11}, "arguments": [{"entity_id": "14697943_2_Ent2", "role": "Effect", "text": "Reflex sympathetic dystrophy syndrome", "start": 0, "end": 4}, {"entity_id": "14697943_2_Ent1", "role": "Subject_Disorder", "text": "renal transplanted", "start": 5, "end": 7}, {"entity_id": "14697943_2_Ent0", "role": "Subject", "text": "renal transplanted patients", "start": 5, "end": 8}, {"entity_id": "14697943_2_Ent3", "role": "Treatment", "text": "tacrolimus", "start": 11, "end": 12}, {"entity_id": "14697943_2_Ent4", "role": "Treatment_Drug", "text": "tacrolimus", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "14697943_2_Ent2", "text": "Reflex sympathetic dystrophy syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "14697943_2_Ent1", "text": "renal transplanted", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "14697943_2_Ent0", "text": "renal transplanted patients", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "14697943_2_Ent3", "text": "tacrolimus", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14697943_2_Ent4", "text": "tacrolimus", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "14712320_3", "wnd_id": "14712320_3_1", "text": "Hydroxymethylglutaryl coenzyme A reductase inhibitors ( statins ) have been associated with myopathy and rhabdomyolysis .", "tokens": ["Hydroxymethylglutaryl", "coenzyme", "A", "reductase", "inhibitors", "(", "statins", ")", "have", "been", "associated", "with", "myopathy", "and", "rhabdomyolysis", "."], "event_mentions": [{"id": "14712320_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 10, "end": 11}, "arguments": [{"entity_id": "14712320_3_Ent2", "role": "Treatment_Drug", "text": "Hydroxymethylglutaryl coenzyme A reductase inhibitors", "start": 0, "end": 5}, {"entity_id": "14712320_3_Ent1", "role": "Treatment", "text": "Hydroxymethylglutaryl coenzyme A reductase inhibitors ( statins )", "start": 0, "end": 8}, {"entity_id": "14712320_3_Ent0", "role": "Effect", "text": "myopathy and rhabdomyolysis", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "14712320_3_Ent2", "text": "Hydroxymethylglutaryl coenzyme A reductase inhibitors", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "14712320_3_Ent1", "text": "Hydroxymethylglutaryl coenzyme A reductase inhibitors ( statins )", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "14712320_3_Ent0", "text": "myopathy and rhabdomyolysis", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "14712320_5", "wnd_id": "14712320_5_1", "text": "Rhabdomyolysis can occur with all statins when used alone and particularly when combined with other drugs that are themselves myotoxic or that elevate the concentration of the statin .", "tokens": ["Rhabdomyolysis", "can", "occur", "with", "all", "statins", "when", "used", "alone", "and", "particularly", "when", "combined", "with", "other", "drugs", "that", "are", "themselves", "myotoxic", "or", "that", "elevate", "the", "concentration", "of", "the", "statin", "."], "event_mentions": [{"id": "14712320_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 2, "end": 3}, "arguments": [{"entity_id": "14712320_5_Ent0", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "14712320_5_Ent1", "role": "Treatment", "text": "statins", "start": 5, "end": 6}, {"entity_id": "14712320_5_Ent3", "role": "Treatment_Drug", "text": "statins", "start": 5, "end": 6}, {"entity_id": "14712320_5_Ent2", "role": "Treatment", "text": "other drugs that are themselves myotoxic or that elevate the concentration of the statin", "start": 14, "end": 28}]}], "entity_mentions": [{"id": "14712320_5_Ent0", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14712320_5_Ent1", "text": "statins", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14712320_5_Ent3", "text": "statins", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "14712320_5_Ent2", "text": "other drugs that are themselves myotoxic or that elevate the concentration of the statin", "entity_type": "Entity", "start": 14, "end": 28}], "lang": "en"}
{"doc_id": "14740795_1", "wnd_id": "14740795_1_1", "text": "A 56 - year - old Caucasian man who received concomitant chemotherapy and radiation for head and neck cancer developed fever concurrent with the administration of amifostine .", "tokens": ["A", "56", "-", "year", "-", "old", "Caucasian", "man", "who", "received", "concomitant", "chemotherapy", "and", "radiation", "for", "head", "and", "neck", "cancer", "developed", "fever", "concurrent", "with", "the", "administration", "of", "amifostine", "."], "event_mentions": [{"id": "14740795_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "14740795_1_Ent0", "role": "Subject", "text": "A 56 - year - old Caucasian man", "start": 0, "end": 8}, {"entity_id": "14740795_1_Ent1", "role": "Subject_Age", "text": "56 - year - old", "start": 1, "end": 6}, {"entity_id": "14740795_1_Ent2", "role": "Subject_Race", "text": "Caucasian", "start": 6, "end": 7}, {"entity_id": "14740795_1_Ent3", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "14740795_1_Ent5", "role": "Treatment", "text": "concomitant chemotherapy and radiation for head and neck cancer", "start": 10, "end": 19}, {"entity_id": "14740795_1_Ent10", "role": "Treatment_Drug", "text": "chemotherapy", "start": 11, "end": 12}, {"entity_id": "14740795_1_Ent13", "role": "Combination_Drug", "text": "chemotherapy", "start": 11, "end": 12}, {"entity_id": "14740795_1_Ent9", "role": "Treatment_Drug", "text": "radiation", "start": 13, "end": 14}, {"entity_id": "14740795_1_Ent12", "role": "Combination_Drug", "text": "radiation", "start": 13, "end": 14}, {"entity_id": "14740795_1_Ent7", "role": "Treatment_Disorder", "text": "head and neck cancer", "start": 15, "end": 19}, {"entity_id": "14740795_1_Ent4", "role": "Effect", "text": "fever", "start": 20, "end": 21}, {"entity_id": "14740795_1_Ent6", "role": "Treatment", "text": "concurrent with the administration of amifostine", "start": 21, "end": 27}, {"entity_id": "14740795_1_Ent8", "role": "Treatment_Drug", "text": "amifostine", "start": 26, "end": 27}, {"entity_id": "14740795_1_Ent11", "role": "Combination_Drug", "text": "amifostine", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "14740795_1_Ent0", "text": "A 56 - year - old Caucasian man", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "14740795_1_Ent1", "text": "56 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "14740795_1_Ent2", "text": "Caucasian", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14740795_1_Ent3", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14740795_1_Ent5", "text": "concomitant chemotherapy and radiation for head and neck cancer", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "14740795_1_Ent10", "text": "chemotherapy", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14740795_1_Ent13", "text": "chemotherapy", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14740795_1_Ent9", "text": "radiation", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14740795_1_Ent12", "text": "radiation", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14740795_1_Ent7", "text": "head and neck cancer", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "14740795_1_Ent4", "text": "fever", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "14740795_1_Ent6", "text": "concurrent with the administration of amifostine", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "14740795_1_Ent8", "text": "amifostine", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "14740795_1_Ent11", "text": "amifostine", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "14742791_5", "wnd_id": "14742791_5_1", "text": "There have been several reported cases of omeprazole - induced AIN .", "tokens": ["There", "have", "been", "several", "reported", "cases", "of", "omeprazole", "-", "induced", "AIN", "."], "event_mentions": [{"id": "14742791_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "14742791_5_Ent1", "role": "Treatment", "text": "omeprazole", "start": 7, "end": 8}, {"entity_id": "14742791_5_Ent2", "role": "Treatment_Drug", "text": "omeprazole", "start": 7, "end": 8}, {"entity_id": "14742791_5_Ent0", "role": "Effect", "text": "AIN", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "14742791_5_Ent1", "text": "omeprazole", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14742791_5_Ent2", "text": "omeprazole", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14742791_5_Ent0", "text": "AIN", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "1495728_1", "wnd_id": "1495728_1_1", "text": "Methotrexate pneumonitis in nonsurgical treatment of ectopic pregnancy .", "tokens": ["Methotrexate", "pneumonitis", "in", "nonsurgical", "treatment", "of", "ectopic", "pregnancy", "."], "event_mentions": [{"id": "1495728_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 2, "end": 3}, "arguments": [{"entity_id": "1495728_1_Ent0", "role": "Effect", "text": "Methotrexate pneumonitis", "start": 0, "end": 2}, {"entity_id": "1495728_1_Ent1", "role": "Treatment", "text": "nonsurgical treatment", "start": 3, "end": 5}, {"entity_id": "1495728_1_Ent2", "role": "Treatment_Disorder", "text": "ectopic pregnancy", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "1495728_1_Ent0", "text": "Methotrexate pneumonitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1495728_1_Ent1", "text": "nonsurgical treatment", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "1495728_1_Ent2", "text": "ectopic pregnancy", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "1495728_2", "wnd_id": "1495728_2_1", "text": "We describe a case of pneumonitis following local administration of methotrexate for nonsurgical termination of an ectopic pregnancy .", "tokens": ["We", "describe", "a", "case", "of", "pneumonitis", "following", "local", "administration", "of", "methotrexate", "for", "nonsurgical", "termination", "of", "an", "ectopic", "pregnancy", "."], "event_mentions": [{"id": "1495728_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "1495728_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "1495728_2_Ent1", "role": "Effect", "text": "pneumonitis", "start": 5, "end": 6}, {"entity_id": "1495728_2_Ent2", "role": "Treatment", "text": "local administration of methotrexate", "start": 7, "end": 11}, {"entity_id": "1495728_2_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 10, "end": 11}, {"entity_id": "1495728_2_Ent4", "role": "Treatment_Disorder", "text": "ectopic pregnancy", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "1495728_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1495728_2_Ent1", "text": "pneumonitis", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1495728_2_Ent2", "text": "local administration of methotrexate", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "1495728_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1495728_2_Ent4", "text": "ectopic pregnancy", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "1495728_4", "wnd_id": "1495728_4_1", "text": "We believe that methotrexate represents a relatively effective alternative to surgery in patients with early unruptured tubal pregnancy , but suggest that it be used with caution in view of possible systemic toxicity .", "tokens": ["We", "believe", "that", "methotrexate", "represents", "a", "relatively", "effective", "alternative", "to", "surgery", "in", "patients", "with", "early", "unruptured", "tubal", "pregnancy", ",", "but", "suggest", "that", "it", "be", "used", "with", "caution", "in", "view", "of", "possible", "systemic", "toxicity", "."], "event_mentions": [{"id": "1495728_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caution", "start": 26, "end": 27}, "arguments": [{"entity_id": "1495728_4_Ent2", "role": "Treatment", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "1495728_4_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "1495728_4_Ent0", "role": "Subject", "text": "patients with early unruptured tubal pregnancy", "start": 12, "end": 18}, {"entity_id": "1495728_4_Ent4", "role": "Treatment_Disorder", "text": "early unruptured tubal pregnancy", "start": 14, "end": 18}, {"entity_id": "1495728_4_Ent1", "role": "Effect", "text": "systemic toxicity", "start": 31, "end": 33}]}], "entity_mentions": [{"id": "1495728_4_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1495728_4_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1495728_4_Ent0", "text": "patients with early unruptured tubal pregnancy", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "1495728_4_Ent4", "text": "early unruptured tubal pregnancy", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "1495728_4_Ent1", "text": "systemic toxicity", "entity_type": "Entity", "start": 31, "end": 33}], "lang": "en"}
{"doc_id": "14960440_2", "wnd_id": "14960440_2_1", "text": "CASE REPORT : A woman of 80 years , on long - term warfarin therapy presented with an acute dissecting thoracic aortic aneurysm ; on investigation the only precipitating factor found was an international normalised ratio of 4.8 .", "tokens": ["CASE", "REPORT", ":", "A", "woman", "of", "80", "years", ",", "on", "long", "-", "term", "warfarin", "therapy", "presented", "with", "an", "acute", "dissecting", "thoracic", "aortic", "aneurysm", ";", "on", "investigation", "the", "only", "precipitating", "factor", "found", "was", "an", "international", "normalised", "ratio", "of", "4.8", "."], "event_mentions": [{"id": "14960440_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 15, "end": 16}, "arguments": [{"entity_id": "14960440_2_Ent0", "role": "Subject", "text": "A woman of 80 years", "start": 3, "end": 8}, {"entity_id": "14960440_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 4, "end": 5}, {"entity_id": "14960440_2_Ent2", "role": "Subject_Age", "text": "80 years", "start": 6, "end": 8}, {"entity_id": "14960440_2_Ent4", "role": "Treatment", "text": "on long - term warfarin", "start": 9, "end": 14}, {"entity_id": "14960440_2_Ent5", "role": "Treatment_Duration", "text": "long - term", "start": 10, "end": 13}, {"entity_id": "14960440_2_Ent6", "role": "Treatment_Drug", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "14960440_2_Ent3", "role": "Effect", "text": "acute dissecting thoracic aortic aneurysm", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "14960440_2_Ent0", "text": "A woman of 80 years", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "14960440_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "14960440_2_Ent2", "text": "80 years", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "14960440_2_Ent4", "text": "on long - term warfarin", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "14960440_2_Ent5", "text": "long - term", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "14960440_2_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14960440_2_Ent3", "text": "acute dissecting thoracic aortic aneurysm", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "14964753_2", "wnd_id": "14964753_2_1", "text": "A 61 - year - old patient who had been treated with lisinopril in the past without any problems was commenced on ramipril for left ventricular dysfunction .", "tokens": ["A", "61", "-", "year", "-", "old", "patient", "who", "had", "been", "treated", "with", "lisinopril", "in", "the", "past", "without", "any", "problems", "was", "commenced", "on", "ramipril", "for", "left", "ventricular", "dysfunction", "."], "event_mentions": [{"id": "14964753_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "commenced", "start": 20, "end": 21}, "arguments": [{"entity_id": "14964753_2_Ent0", "role": "Subject", "text": "A 61 - year - old patient who had been treated with lisinopril in the past without any problems", "start": 0, "end": 19}, {"entity_id": "14964753_2_Ent1", "role": "Subject_Age", "text": "61 - year - old", "start": 1, "end": 6}, {"entity_id": "14964753_2_Ent2", "role": "Treatment", "text": "ramipril", "start": 22, "end": 23}, {"entity_id": "14964753_2_Ent3", "role": "Treatment_Drug", "text": "ramipril", "start": 22, "end": 23}, {"entity_id": "14964753_2_Ent4", "role": "Treatment_Disorder", "text": "left ventricular dysfunction", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "14964753_2_Ent0", "text": "A 61 - year - old patient who had been treated with lisinopril in the past without any problems", "entity_type": "Entity", "start": 0, "end": 19}, {"id": "14964753_2_Ent1", "text": "61 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "14964753_2_Ent2", "text": "ramipril", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "14964753_2_Ent3", "text": "ramipril", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "14964753_2_Ent4", "text": "left ventricular dysfunction", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "14964753_9", "wnd_id": "14964753_9_1", "text": "Here we report ramipril - induced cutaneous vasculitis in a patient who required steroid therapy to control it .", "tokens": ["Here", "we", "report", "ramipril", "-", "induced", "cutaneous", "vasculitis", "in", "a", "patient", "who", "required", "steroid", "therapy", "to", "control", "it", "."], "event_mentions": [{"id": "14964753_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "14964753_9_Ent2", "role": "Treatment", "text": "ramipril", "start": 3, "end": 4}, {"entity_id": "14964753_9_Ent3", "role": "Treatment_Drug", "text": "ramipril", "start": 3, "end": 4}, {"entity_id": "14964753_9_Ent1", "role": "Effect", "text": "cutaneous vasculitis", "start": 6, "end": 8}, {"entity_id": "14964753_9_Ent0", "role": "Subject", "text": "a patient", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "14964753_9_Ent2", "text": "ramipril", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14964753_9_Ent3", "text": "ramipril", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14964753_9_Ent1", "text": "cutaneous vasculitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "14964753_9_Ent0", "text": "a patient", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "14998226_10", "wnd_id": "14998226_10_1", "text": "Pravastatin does not appear to interact with warfarin but has caused an increased INR when combined with the anticoagulant fluindione .", "tokens": ["Pravastatin", "does", "not", "appear", "to", "interact", "with", "warfarin", "but", "has", "caused", "an", "increased", "INR", "when", "combined", "with", "the", "anticoagulant", "fluindione", "."], "event_mentions": [{"id": "14998226_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 10, "end": 11}, "arguments": [{"entity_id": "14998226_10_Ent1", "role": "Treatment", "text": "Pravastatin", "start": 0, "end": 1}, {"entity_id": "14998226_10_Ent3", "role": "Treatment_Drug", "text": "Pravastatin", "start": 0, "end": 1}, {"entity_id": "14998226_10_Ent5", "role": "Combination_Drug", "text": "Pravastatin", "start": 0, "end": 1}, {"entity_id": "14998226_10_Ent0", "role": "Effect", "text": "increased INR", "start": 12, "end": 14}, {"entity_id": "14998226_10_Ent2", "role": "Treatment", "text": "combined with the anticoagulant fluindione", "start": 15, "end": 20}, {"entity_id": "14998226_10_Ent4", "role": "Treatment_Drug", "text": "anticoagulant fluindione", "start": 18, "end": 20}, {"entity_id": "14998226_10_Ent6", "role": "Combination_Drug", "text": "anticoagulant fluindione", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "14998226_10_Ent1", "text": "Pravastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14998226_10_Ent3", "text": "Pravastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14998226_10_Ent5", "text": "Pravastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14998226_10_Ent0", "text": "increased INR", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "14998226_10_Ent2", "text": "combined with the anticoagulant fluindione", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "14998226_10_Ent4", "text": "anticoagulant fluindione", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "14998226_10_Ent6", "text": "anticoagulant fluindione", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "14998226_9", "wnd_id": "14998226_9_1", "text": "One case report describes an interaction between simvastatin and the anticoagulant acenocoumarol , which resulted in an elevated INR .", "tokens": ["One", "case", "report", "describes", "an", "interaction", "between", "simvastatin", "and", "the", "anticoagulant", "acenocoumarol", ",", "which", "resulted", "in", "an", "elevated", "INR", "."], "event_mentions": [{"id": "14998226_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 14, "end": 15}, "arguments": [{"entity_id": "14998226_9_Ent1", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "14998226_9_Ent0", "role": "Subject", "text": "One case", "start": 0, "end": 2}, {"entity_id": "14998226_9_Ent4", "role": "Treatment_Drug", "text": "simvastatin", "start": 7, "end": 8}, {"entity_id": "14998226_9_Ent6", "role": "Combination_Drug", "text": "simvastatin", "start": 7, "end": 8}, {"entity_id": "14998226_9_Ent3", "role": "Treatment", "text": "simvastatin and the anticoagulant acenocoumarol", "start": 7, "end": 12}, {"entity_id": "14998226_9_Ent5", "role": "Treatment_Drug", "text": "anticoagulant acenocoumarol", "start": 10, "end": 12}, {"entity_id": "14998226_9_Ent7", "role": "Combination_Drug", "text": "anticoagulant acenocoumarol", "start": 10, "end": 12}, {"entity_id": "14998226_9_Ent2", "role": "Effect", "text": "elevated INR", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "14998226_9_Ent1", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14998226_9_Ent0", "text": "One case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14998226_9_Ent4", "text": "simvastatin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14998226_9_Ent6", "text": "simvastatin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "14998226_9_Ent3", "text": "simvastatin and the anticoagulant acenocoumarol", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "14998226_9_Ent5", "text": "anticoagulant acenocoumarol", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "14998226_9_Ent7", "text": "anticoagulant acenocoumarol", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "14998226_9_Ent2", "text": "elevated INR", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "15028328_1", "wnd_id": "15028328_1_1", "text": "Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine , a recalled medication .", "tokens": ["Cerebral", "infarcts", "in", "a", "pediatric", "patient", "secondary", "to", "phenylpropanolamine", ",", "a", "recalled", "medication", "."], "event_mentions": [{"id": "15028328_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 6, "end": 7}, "arguments": [{"entity_id": "15028328_1_Ent2", "role": "Effect", "text": "Cerebral infarcts", "start": 0, "end": 2}, {"entity_id": "15028328_1_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 4, "end": 5}, {"entity_id": "15028328_1_Ent0", "role": "Subject", "text": "pediatric patient", "start": 4, "end": 6}, {"entity_id": "15028328_1_Ent3", "role": "Treatment", "text": "phenylpropanolamine", "start": 8, "end": 9}, {"entity_id": "15028328_1_Ent4", "role": "Treatment_Drug", "text": "phenylpropanolamine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "15028328_1_Ent2", "text": "Cerebral infarcts", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15028328_1_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15028328_1_Ent0", "text": "pediatric patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15028328_1_Ent3", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15028328_1_Ent4", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "15028964_2", "wnd_id": "15028964_2_1", "text": "Many patients with cardiac arrhythmias require concomitant therapy with warfarin and amiodarone .", "tokens": ["Many", "patients", "with", "cardiac", "arrhythmias", "require", "concomitant", "therapy", "with", "warfarin", "and", "amiodarone", "."], "event_mentions": [{"id": "15028964_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "require", "start": 5, "end": 6}, "arguments": [{"entity_id": "15028964_2_Ent0", "role": "Subject", "text": "Many patients with cardiac arrhythmias", "start": 0, "end": 5}, {"entity_id": "15028964_2_Ent4", "role": "Treatment_Disorder", "text": "cardiac arrhythmias", "start": 3, "end": 5}, {"entity_id": "15028964_2_Ent1", "role": "Treatment", "text": "concomitant therapy with warfarin and amiodarone", "start": 6, "end": 12}, {"entity_id": "15028964_2_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 9, "end": 10}, {"entity_id": "15028964_2_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 9, "end": 10}, {"entity_id": "15028964_2_Ent3", "role": "Treatment_Drug", "text": "amiodarone", "start": 11, "end": 12}, {"entity_id": "15028964_2_Ent6", "role": "Combination_Drug", "text": "amiodarone", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15028964_2_Ent0", "text": "Many patients with cardiac arrhythmias", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "15028964_2_Ent4", "text": "cardiac arrhythmias", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15028964_2_Ent1", "text": "concomitant therapy with warfarin and amiodarone", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "15028964_2_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15028964_2_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15028964_2_Ent3", "text": "amiodarone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15028964_2_Ent6", "text": "amiodarone", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "1504404_1", "wnd_id": "1504404_1_1", "text": "Central nervous system effects secondary to ciprofloxacin treatment are uncommon and usually consist only of minor dizziness or mild headache , although rare occurrences of seizures and hallucinations have been reported .", "tokens": ["Central", "nervous", "system", "effects", "secondary", "to", "ciprofloxacin", "treatment", "are", "uncommon", "and", "usually", "consist", "only", "of", "minor", "dizziness", "or", "mild", "headache", ",", "although", "rare", "occurrences", "of", "seizures", "and", "hallucinations", "have", "been", "reported", "."], "event_mentions": [{"id": "1504404_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "consist", "start": 12, "end": 13}, "arguments": [{"entity_id": "1504404_1_Ent1", "role": "Treatment", "text": "secondary to ciprofloxacin treatment", "start": 4, "end": 8}, {"entity_id": "1504404_1_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 6, "end": 7}, {"entity_id": "1504404_1_Ent0", "role": "Effect", "text": "minor dizziness or mild headache , although rare occurrences of seizures and hallucinations", "start": 15, "end": 28}]}], "entity_mentions": [{"id": "1504404_1_Ent1", "text": "secondary to ciprofloxacin treatment", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "1504404_1_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1504404_1_Ent0", "text": "minor dizziness or mild headache , although rare occurrences of seizures and hallucinations", "entity_type": "Entity", "start": 15, "end": 28}], "lang": "en"}
{"doc_id": "15053046_4", "wnd_id": "15053046_4_1", "text": "The agranulocytosis was rapidly resolved by granulocyte colony - stimulating factor ( G - CSF ) therapy and by the discontinuation of vancomycin .", "tokens": ["The", "agranulocytosis", "was", "rapidly", "resolved", "by", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", "therapy", "and", "by", "the", "discontinuation", "of", "vancomycin", "."], "event_mentions": [{"id": "15053046_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 4, "end": 5}, "arguments": [{"entity_id": "15053046_4_Ent0", "role": "Effect", "text": "agranulocytosis", "start": 1, "end": 2}, {"entity_id": "15053046_4_Ent2", "role": "Treatment_Drug", "text": "granulocyte colony - stimulating factor", "start": 6, "end": 11}, {"entity_id": "15053046_4_Ent1", "role": "Treatment", "text": "granulocyte colony - stimulating factor ( G - CSF ) therapy and by the discontinuation of vancomycin", "start": 6, "end": 23}, {"entity_id": "15053046_4_Ent3", "role": "Treatment_Drug", "text": "vancomycin", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "15053046_4_Ent0", "text": "agranulocytosis", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15053046_4_Ent2", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "15053046_4_Ent1", "text": "granulocyte colony - stimulating factor ( G - CSF ) therapy and by the discontinuation of vancomycin", "entity_type": "Entity", "start": 6, "end": 23}, {"id": "15053046_4_Ent3", "text": "vancomycin", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "15072497_2", "wnd_id": "15072497_2_1", "text": "However here we reported two patients , presenting with PD during high dose colchicine treatment for familiar mediterranean fever ( FMF ) .", "tokens": ["However", "here", "we", "reported", "two", "patients", ",", "presenting", "with", "PD", "during", "high", "dose", "colchicine", "treatment", "for", "familiar", "mediterranean", "fever", "(", "FMF", ")", "."], "event_mentions": [{"id": "15072497_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 10, "end": 11}, "arguments": [{"entity_id": "15072497_2_Ent1", "role": "Subject_Population", "text": "two", "start": 4, "end": 5}, {"entity_id": "15072497_2_Ent0", "role": "Subject", "text": "two patients ,", "start": 4, "end": 7}, {"entity_id": "15072497_2_Ent2", "role": "Effect", "text": "PD", "start": 9, "end": 10}, {"entity_id": "15072497_2_Ent4", "role": "Treatment_Dosage", "text": "high dose", "start": 11, "end": 13}, {"entity_id": "15072497_2_Ent3", "role": "Treatment", "text": "high dose colchicine treatment", "start": 11, "end": 15}, {"entity_id": "15072497_2_Ent5", "role": "Treatment_Drug", "text": "colchicine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "15072497_2_Ent1", "text": "two", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15072497_2_Ent0", "text": "two patients ,", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "15072497_2_Ent2", "text": "PD", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15072497_2_Ent4", "text": "high dose", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "15072497_2_Ent3", "text": "high dose colchicine treatment", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "15072497_2_Ent5", "text": "colchicine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "1509179_1", "wnd_id": "1509179_1_1", "text": "A case of phenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy .", "tokens": ["A", "case", "of", "phenobarbital", "exacerbation", "of", "a", "preexisting", "maladaptive", "behavior", "partially", "suppressed", "by", "chlorpromazine", "and", "misinterpreted", "as", "chlorpromazine", "efficacy", "."], "event_mentions": [{"id": "1509179_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exacerbation", "start": 4, "end": 5}, "arguments": [{"entity_id": "1509179_1_Ent3", "role": "Treatment", "text": "phenobarbital", "start": 3, "end": 4}, {"entity_id": "1509179_1_Ent5", "role": "Treatment_Drug", "text": "phenobarbital", "start": 3, "end": 4}, {"entity_id": "1509179_1_Ent7", "role": "Combination_Drug", "text": "phenobarbital", "start": 3, "end": 4}, {"entity_id": "1509179_1_Ent2", "role": "Effect", "text": "exacerbation of a preexisting maladaptive behavior", "start": 4, "end": 10}, {"entity_id": "1509179_1_Ent0", "role": "Subject", "text": "preexisting maladaptive behavior", "start": 7, "end": 10}, {"entity_id": "1509179_1_Ent1", "role": "Subject_Disorder", "text": "preexisting maladaptive behavior", "start": 7, "end": 10}, {"entity_id": "1509179_1_Ent4", "role": "Treatment", "text": "partially suppressed by chlorpromazine", "start": 10, "end": 14}, {"entity_id": "1509179_1_Ent6", "role": "Treatment_Drug", "text": "chlorpromazine", "start": 13, "end": 14}, {"entity_id": "1509179_1_Ent8", "role": "Combination_Drug", "text": "chlorpromazine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "1509179_1_Ent3", "text": "phenobarbital", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1509179_1_Ent5", "text": "phenobarbital", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1509179_1_Ent7", "text": "phenobarbital", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1509179_1_Ent2", "text": "exacerbation of a preexisting maladaptive behavior", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "1509179_1_Ent0", "text": "preexisting maladaptive behavior", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "1509179_1_Ent1", "text": "preexisting maladaptive behavior", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "1509179_1_Ent4", "text": "partially suppressed by chlorpromazine", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "1509179_1_Ent6", "text": "chlorpromazine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "1509179_1_Ent8", "text": "chlorpromazine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "15093850_2", "wnd_id": "15093850_2_1", "text": "We report a case of unintentional overdose of oral pilocarpine tablets that resulted in bradycardia , mild hypotension , and muscarinic symptoms in a patient with Sjogren 's syndrome .", "tokens": ["We", "report", "a", "case", "of", "unintentional", "overdose", "of", "oral", "pilocarpine", "tablets", "that", "resulted", "in", "bradycardia", ",", "mild", "hypotension", ",", "and", "muscarinic", "symptoms", "in", "a", "patient", "with", "Sjogren", "'s", "syndrome", "."], "event_mentions": [{"id": "15093850_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 12, "end": 13}, "arguments": [{"entity_id": "15093850_2_Ent2", "role": "Treatment_Route", "text": "oral", "start": 8, "end": 9}, {"entity_id": "15093850_2_Ent1", "role": "Treatment", "text": "pilocarpine", "start": 9, "end": 10}, {"entity_id": "15093850_2_Ent3", "role": "Treatment_Drug", "text": "pilocarpine", "start": 9, "end": 10}, {"entity_id": "15093850_2_Ent0", "role": "Effect", "text": "bradycardia , mild hypotension , and muscarinic symptoms", "start": 14, "end": 22}]}], "entity_mentions": [{"id": "15093850_2_Ent2", "text": "oral", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15093850_2_Ent1", "text": "pilocarpine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15093850_2_Ent3", "text": "pilocarpine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15093850_2_Ent0", "text": "bradycardia , mild hypotension , and muscarinic symptoms", "entity_type": "Entity", "start": 14, "end": 22}], "lang": "en"}
{"doc_id": "15097937_2", "wnd_id": "15097937_2_1", "text": "Anticonvulsant hypersensitivity syndrome associated with Bellamine S , a therapy for menopausal symptoms .", "tokens": ["Anticonvulsant", "hypersensitivity", "syndrome", "associated", "with", "Bellamine", "S", ",", "a", "therapy", "for", "menopausal", "symptoms", "."], "event_mentions": [{"id": "15097937_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "15097937_2_Ent0", "role": "Effect", "text": "Anticonvulsant hypersensitivity syndrome", "start": 0, "end": 3}, {"entity_id": "15097937_2_Ent3", "role": "Treatment_Drug", "text": "Bellamine S", "start": 5, "end": 7}, {"entity_id": "15097937_2_Ent1", "role": "Treatment", "text": "Bellamine S , a therapy for menopausal symptoms", "start": 5, "end": 13}, {"entity_id": "15097937_2_Ent2", "role": "Treatment_Disorder", "text": "menopausal symptoms .", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "15097937_2_Ent0", "text": "Anticonvulsant hypersensitivity syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15097937_2_Ent3", "text": "Bellamine S", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15097937_2_Ent1", "text": "Bellamine S , a therapy for menopausal symptoms", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "15097937_2_Ent2", "text": "menopausal symptoms .", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "15107195_1", "wnd_id": "15107195_1_1", "text": "A case of heatstroke is reported in a 32 - year - old man diagnosed with schizophrenia and on clozapine monotherapy .", "tokens": ["A", "case", "of", "heatstroke", "is", "reported", "in", "a", "32", "-", "year", "-", "old", "man", "diagnosed", "with", "schizophrenia", "and", "on", "clozapine", "monotherapy", "."], "event_mentions": [{"id": "15107195_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 5, "end": 6}, "arguments": [{"entity_id": "15107195_1_Ent3", "role": "Effect", "text": "heatstroke", "start": 3, "end": 4}, {"entity_id": "15107195_1_Ent0", "role": "Subject", "text": "a 32 - year - old man diagnosed with schizophrenia", "start": 7, "end": 17}, {"entity_id": "15107195_1_Ent1", "role": "Subject_Age", "text": "32 - year - old", "start": 8, "end": 13}, {"entity_id": "15107195_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 13, "end": 14}, {"entity_id": "15107195_1_Ent6", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 16, "end": 17}, {"entity_id": "15107195_1_Ent5", "role": "Treatment_Drug", "text": "clozapine", "start": 19, "end": 20}, {"entity_id": "15107195_1_Ent4", "role": "Treatment", "text": "clozapine monotherapy", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "15107195_1_Ent3", "text": "heatstroke", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15107195_1_Ent0", "text": "a 32 - year - old man diagnosed with schizophrenia", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "15107195_1_Ent1", "text": "32 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "15107195_1_Ent2", "text": "man", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15107195_1_Ent6", "text": "schizophrenia", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15107195_1_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "15107195_1_Ent4", "text": "clozapine monotherapy", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "15112258_8", "wnd_id": "15112258_8_1", "text": "The literature search found 12 cases of radiation recall caused by gemcitabine .", "tokens": ["The", "literature", "search", "found", "12", "cases", "of", "radiation", "recall", "caused", "by", "gemcitabine", "."], "event_mentions": [{"id": "15112258_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 9, "end": 10}, "arguments": [{"entity_id": "15112258_8_Ent1", "role": "Subject_Population", "text": "12", "start": 4, "end": 5}, {"entity_id": "15112258_8_Ent0", "role": "Subject", "text": "12 cases", "start": 4, "end": 6}, {"entity_id": "15112258_8_Ent2", "role": "Effect", "text": "radiation recall", "start": 7, "end": 9}, {"entity_id": "15112258_8_Ent3", "role": "Treatment", "text": "gemcitabine", "start": 11, "end": 12}, {"entity_id": "15112258_8_Ent4", "role": "Treatment_Drug", "text": "gemcitabine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15112258_8_Ent1", "text": "12", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15112258_8_Ent0", "text": "12 cases", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15112258_8_Ent2", "text": "radiation recall", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15112258_8_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15112258_8_Ent4", "text": "gemcitabine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "15126179_1", "wnd_id": "15126179_1_1", "text": "Cystoid macular edema in a low - risk patient after switching from latanoprost to bimatoprost .", "tokens": ["Cystoid", "macular", "edema", "in", "a", "low", "-", "risk", "patient", "after", "switching", "from", "latanoprost", "to", "bimatoprost", "."], "event_mentions": [{"id": "15126179_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "15126179_1_Ent1", "role": "Effect", "text": "Cystoid macular edema", "start": 0, "end": 3}, {"entity_id": "15126179_1_Ent0", "role": "Subject", "text": "low - risk patient", "start": 5, "end": 9}, {"entity_id": "15126179_1_Ent2", "role": "Treatment", "text": "switching from latanoprost to bimatoprost", "start": 10, "end": 15}, {"entity_id": "15126179_1_Ent4", "role": "Treatment_Drug", "text": "latanoprost", "start": 12, "end": 13}, {"entity_id": "15126179_1_Ent5", "role": "Combination_Drug", "text": "latanoprost", "start": 12, "end": 13}, {"entity_id": "15126179_1_Ent3", "role": "Treatment_Drug", "text": "bimatoprost", "start": 14, "end": 15}, {"entity_id": "15126179_1_Ent6", "role": "Combination_Drug", "text": "bimatoprost", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "15126179_1_Ent1", "text": "Cystoid macular edema", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15126179_1_Ent0", "text": "low - risk patient", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "15126179_1_Ent2", "text": "switching from latanoprost to bimatoprost", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "15126179_1_Ent4", "text": "latanoprost", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15126179_1_Ent5", "text": "latanoprost", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15126179_1_Ent3", "text": "bimatoprost", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15126179_1_Ent6", "text": "bimatoprost", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "15197722_3", "wnd_id": "15197722_3_1", "text": "Restless legs syndrome may thus be an adverse effect of IFN alpha treatment .", "tokens": ["Restless", "legs", "syndrome", "may", "thus", "be", "an", "adverse", "effect", "of", "IFN", "alpha", "treatment", "."], "event_mentions": [{"id": "15197722_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effect", "start": 7, "end": 9}, "arguments": [{"entity_id": "15197722_3_Ent0", "role": "Effect", "text": "Restless legs syndrome", "start": 0, "end": 3}, {"entity_id": "15197722_3_Ent2", "role": "Treatment_Drug", "text": "IFN alpha", "start": 10, "end": 12}, {"entity_id": "15197722_3_Ent1", "role": "Treatment", "text": "IFN alpha treatment .", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "15197722_3_Ent0", "text": "Restless legs syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15197722_3_Ent2", "text": "IFN alpha", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "15197722_3_Ent1", "text": "IFN alpha treatment .", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "15224368_2", "wnd_id": "15224368_2_1", "text": "Sweet 's syndrome is an acute febrile neutrophilic dermatosis that is a known complication of the administration of filgrastim , a drug that causes increased neutrophil proliferation and differentiation .", "tokens": ["Sweet", "'s", "syndrome", "is", "an", "acute", "febrile", "neutrophilic", "dermatosis", "that", "is", "a", "known", "complication", "of", "the", "administration", "of", "filgrastim", ",", "a", "drug", "that", "causes", "increased", "neutrophil", "proliferation", "and", "differentiation", "."], "event_mentions": [{"id": "15224368_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 23, "end": 24}, "arguments": [{"entity_id": "15224368_2_Ent0", "role": "Effect", "text": "Sweet 's syndrome is an acute febrile neutrophilic dermatosis", "start": 0, "end": 9}, {"entity_id": "15224368_2_Ent2", "role": "Treatment", "text": "filgrastim", "start": 18, "end": 19}, {"entity_id": "15224368_2_Ent3", "role": "Treatment_Drug", "text": "filgrastim", "start": 18, "end": 19}, {"entity_id": "15224368_2_Ent1", "role": "Effect", "text": "increased neutrophil proliferation and differentiation", "start": 24, "end": 29}]}], "entity_mentions": [{"id": "15224368_2_Ent0", "text": "Sweet 's syndrome is an acute febrile neutrophilic dermatosis", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "15224368_2_Ent2", "text": "filgrastim", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15224368_2_Ent3", "text": "filgrastim", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15224368_2_Ent1", "text": "increased neutrophil proliferation and differentiation", "entity_type": "Entity", "start": 24, "end": 29}], "lang": "en"}
{"doc_id": "15239684_1", "wnd_id": "15239684_1_1", "text": "Purple glove syndrome , named for its distinctive purple discoloration and swelling of the hands in the distribution of a glove , is an uncommon complication of intravenous phenytoin administration through small dorsal veins of the hands .", "tokens": ["Purple", "glove", "syndrome", ",", "named", "for", "its", "distinctive", "purple", "discoloration", "and", "swelling", "of", "the", "hands", "in", "the", "distribution", "of", "a", "glove", ",", "is", "an", "uncommon", "complication", "of", "intravenous", "phenytoin", "administration", "through", "small", "dorsal", "veins", "of", "the", "hands", "."], "event_mentions": [{"id": "15239684_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 25, "end": 26}, "arguments": [{"entity_id": "15239684_1_Ent0", "role": "Effect", "text": "Purple glove syndrome", "start": 0, "end": 3}, {"entity_id": "15239684_1_Ent1", "role": "Effect", "text": "purple discoloration and swelling of the hands in the distribution of a glove", "start": 8, "end": 21}, {"entity_id": "15239684_1_Ent3", "role": "Treatment_Route", "text": "intravenous", "start": 27, "end": 28}, {"entity_id": "15239684_1_Ent2", "role": "Treatment", "text": "intravenous phenytoin administration through small dorsal veins of the hands", "start": 27, "end": 37}, {"entity_id": "15239684_1_Ent4", "role": "Treatment_Drug", "text": "phenytoin", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "15239684_1_Ent0", "text": "Purple glove syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15239684_1_Ent1", "text": "purple discoloration and swelling of the hands in the distribution of a glove", "entity_type": "Entity", "start": 8, "end": 21}, {"id": "15239684_1_Ent3", "text": "intravenous", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "15239684_1_Ent2", "text": "intravenous phenytoin administration through small dorsal veins of the hands", "entity_type": "Entity", "start": 27, "end": 37}, {"id": "15239684_1_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "15266150_3", "wnd_id": "15266150_3_1", "text": "Trichiasis associated with prostaglandin analog use .", "tokens": ["Trichiasis", "associated", "with", "prostaglandin", "analog", "use", "."], "event_mentions": [{"id": "15266150_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "15266150_3_Ent0", "role": "Effect", "text": "Trichiasis", "start": 0, "end": 1}, {"entity_id": "15266150_3_Ent1", "role": "Treatment", "text": "prostaglandin analog", "start": 3, "end": 5}, {"entity_id": "15266150_3_Ent2", "role": "Treatment_Drug", "text": "prostaglandin analog", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "15266150_3_Ent0", "text": "Trichiasis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15266150_3_Ent1", "text": "prostaglandin analog", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15266150_3_Ent2", "text": "prostaglandin analog", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "15279668_2", "wnd_id": "15279668_2_1", "text": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA ( fludarabine and cytarabine ) regime .", "tokens": ["We", "discuss", "a", "case", "with", "significant", "progressive", "peripheral", "neurological", "deterioration", "following", "administration", "of", "both", "fludarabine", "and", "cytarabine", "as", "part", "of", "the", "FLA", "(", "fludarabine", "and", "cytarabine", ")", "regime", "."], "event_mentions": [{"id": "15279668_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 10, "end": 11}, "arguments": [{"entity_id": "15279668_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "15279668_2_Ent1", "role": "Effect", "text": "significant progressive peripheral neurological deterioration", "start": 5, "end": 10}, {"entity_id": "15279668_2_Ent4", "role": "Treatment_Drug", "text": "fludarabine", "start": 14, "end": 15}, {"entity_id": "15279668_2_Ent7", "role": "Combination_Drug", "text": "fludarabine", "start": 14, "end": 15}, {"entity_id": "15279668_2_Ent2", "role": "Treatment", "text": "fludarabine and cytarabine", "start": 14, "end": 17}, {"entity_id": "15279668_2_Ent5", "role": "Treatment_Drug", "text": "cytarabine", "start": 16, "end": 17}, {"entity_id": "15279668_2_Ent8", "role": "Combination_Drug", "text": "cytarabine", "start": 16, "end": 17}, {"entity_id": "15279668_2_Ent6", "role": "Treatment_Drug", "text": "FLA ( fludarabine and cytarabine )", "start": 21, "end": 27}, {"entity_id": "15279668_2_Ent3", "role": "Treatment", "text": "FLA ( fludarabine and cytarabine ) regime", "start": 21, "end": 28}]}], "entity_mentions": [{"id": "15279668_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15279668_2_Ent1", "text": "significant progressive peripheral neurological deterioration", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "15279668_2_Ent4", "text": "fludarabine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15279668_2_Ent7", "text": "fludarabine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15279668_2_Ent2", "text": "fludarabine and cytarabine", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "15279668_2_Ent5", "text": "cytarabine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15279668_2_Ent8", "text": "cytarabine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15279668_2_Ent6", "text": "FLA ( fludarabine and cytarabine )", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "15279668_2_Ent3", "text": "FLA ( fludarabine and cytarabine ) regime", "entity_type": "Entity", "start": 21, "end": 28}], "lang": "en"}
{"doc_id": "15307435_1", "wnd_id": "15307435_1_1", "text": "Case report : life - threatening hypoglycaemia associated with sulfadoxine - pyrimethamine , a commonly used antimalarial drug .", "tokens": ["Case", "report", ":", "life", "-", "threatening", "hypoglycaemia", "associated", "with", "sulfadoxine", "-", "pyrimethamine", ",", "a", "commonly", "used", "antimalarial", "drug", "."], "event_mentions": [{"id": "15307435_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "15307435_1_Ent0", "role": "Subject", "text": "Case", "start": 0, "end": 1}, {"entity_id": "15307435_1_Ent1", "role": "Effect", "text": "life - threatening hypoglycaemia", "start": 3, "end": 7}, {"entity_id": "15307435_1_Ent2", "role": "Treatment", "text": "sulfadoxine - pyrimethamine", "start": 9, "end": 12}, {"entity_id": "15307435_1_Ent3", "role": "Treatment_Drug", "text": "sulfadoxine - pyrimethamine", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "15307435_1_Ent0", "text": "Case", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15307435_1_Ent1", "text": "life - threatening hypoglycaemia", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "15307435_1_Ent2", "text": "sulfadoxine - pyrimethamine", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "15307435_1_Ent3", "text": "sulfadoxine - pyrimethamine", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "15316423_1", "wnd_id": "15316423_1_1", "text": "Extensive forearm deep venous thrombosis following a severe infliximab infusion reaction .", "tokens": ["Extensive", "forearm", "deep", "venous", "thrombosis", "following", "a", "severe", "infliximab", "infusion", "reaction", "."], "event_mentions": [{"id": "15316423_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "15316423_1_Ent0", "role": "Effect", "text": "Extensive forearm deep venous thrombosis", "start": 0, "end": 5}, {"entity_id": "15316423_1_Ent2", "role": "Treatment", "text": "infliximab", "start": 8, "end": 9}, {"entity_id": "15316423_1_Ent3", "role": "Treatment_Drug", "text": "infliximab", "start": 8, "end": 9}, {"entity_id": "15316423_1_Ent1", "role": "Effect", "text": "infusion reaction", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "15316423_1_Ent0", "text": "Extensive forearm deep venous thrombosis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "15316423_1_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15316423_1_Ent3", "text": "infliximab", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15316423_1_Ent1", "text": "infusion reaction", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "15316423_2", "wnd_id": "15316423_2_1", "text": "Here we describe a patient with Crohn 's disease who developed a severe infliximab infusion reaction ( IIR ) , complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion .", "tokens": ["Here", "we", "describe", "a", "patient", "with", "Crohn", "'s", "disease", "who", "developed", "a", "severe", "infliximab", "infusion", "reaction", "(", "IIR", ")", ",", "complicated", "1", "day", "later", "by", "severe", "swelling", "of", "the", "forearm", "and", "hand", "ipsilateral", "to", "the", "site", "of", "infliximab", "infusion", "."], "event_mentions": [{"id": "15316423_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "15316423_2_Ent0", "role": "Subject", "text": "a patient with Crohn 's disease", "start": 3, "end": 9}, {"entity_id": "15316423_2_Ent5", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 6, "end": 9}, {"entity_id": "15316423_2_Ent1", "role": "Effect", "text": "severe infliximab infusion reaction ( IIR ) , complicated 1 day later by severe swelling of the forearm and hand ipsilateral", "start": 12, "end": 33}, {"entity_id": "15316423_2_Ent3", "role": "Treatment_Drug", "text": "infliximab", "start": 37, "end": 38}, {"entity_id": "15316423_2_Ent2", "role": "Treatment", "text": "infliximab infusion", "start": 37, "end": 39}, {"entity_id": "15316423_2_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 38, "end": 39}]}], "entity_mentions": [{"id": "15316423_2_Ent0", "text": "a patient with Crohn 's disease", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "15316423_2_Ent5", "text": "Crohn 's disease", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15316423_2_Ent1", "text": "severe infliximab infusion reaction ( IIR ) , complicated 1 day later by severe swelling of the forearm and hand ipsilateral", "entity_type": "Entity", "start": 12, "end": 33}, {"id": "15316423_2_Ent3", "text": "infliximab", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "15316423_2_Ent2", "text": "infliximab infusion", "entity_type": "Entity", "start": 37, "end": 39}, {"id": "15316423_2_Ent4", "text": "infusion", "entity_type": "Entity", "start": 38, "end": 39}], "lang": "en"}
{"doc_id": "15331204_4", "wnd_id": "15331204_4_1", "text": "RESULTS : After 4 - to 14 - month period of therapy with the combination of indapamide ( 2.5 mg / day ) and fosinopril ( 10 mg / day ) in three patients and 6 - month period of monotherapy with indapamide ( 2.5 mg / day ) in one patient , glucose levels of all patients increased and achieve criteria of diabetes diagnoses .", "tokens": ["RESULTS", ":", "After", "4", "-", "to", "14", "-", "month", "period", "of", "therapy", "with", "the", "combination", "of", "indapamide", "(", "2.5", "mg", "/", "day", ")", "and", "fosinopril", "(", "10", "mg", "/", "day", ")", "in", "three", "patients", "and", "6", "-", "month", "period", "of", "monotherapy", "with", "indapamide", "(", "2.5", "mg", "/", "day", ")", "in", "one", "patient", ",", "glucose", "levels", "of", "all", "patients", "increased", "and", "achieve", "criteria", "of", "diabetes", "diagnoses", "."], "event_mentions": [{"id": "15331204_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "achieve", "start": 60, "end": 61}, "arguments": [{"entity_id": "15331204_4_Ent4", "role": "Treatment_Duration", "text": "6 - month", "start": 35, "end": 38}, {"entity_id": "15331204_4_Ent3", "role": "Treatment", "text": "6 - month period of monotherapy with indapamide ( 2.5 mg / day )", "start": 35, "end": 49}, {"entity_id": "15331204_4_Ent5", "role": "Treatment_Drug", "text": "indapamide", "start": 42, "end": 43}, {"entity_id": "15331204_4_Ent6", "role": "Treatment_Dosage", "text": "2.5 mg / day", "start": 44, "end": 48}, {"entity_id": "15331204_4_Ent1", "role": "Subject_Population", "text": "one", "start": 50, "end": 51}, {"entity_id": "15331204_4_Ent0", "role": "Subject", "text": "one patient", "start": 50, "end": 52}, {"entity_id": "15331204_4_Ent2", "role": "Effect", "text": "glucose levels of all patients increased and achieve criteria of diabetes diagnoses", "start": 53, "end": 65}]}, {"id": "15331204_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "achieve", "start": 60, "end": 61}, "arguments": [{"entity_id": "15331204_4_Ent10", "role": "Treatment", "text": "After 4 - to 14 - month period of therapy with the combination of indapamide ( 2.5 mg / day ) and fosinopril ( 10 mg / day )", "start": 2, "end": 31}, {"entity_id": "15331204_4_Ent11", "role": "Treatment_Time_elapsed", "text": "4 - to 14 - month", "start": 3, "end": 9}, {"entity_id": "15331204_4_Ent12", "role": "Treatment_Drug", "text": "indapamide", "start": 16, "end": 17}, {"entity_id": "15331204_4_Ent16", "role": "Combination_Drug", "text": "indapamide", "start": 16, "end": 17}, {"entity_id": "15331204_4_Ent14", "role": "Treatment_Dosage", "text": "2.5 mg / day", "start": 18, "end": 22}, {"entity_id": "15331204_4_Ent13", "role": "Treatment_Drug", "text": "fosinopril", "start": 24, "end": 25}, {"entity_id": "15331204_4_Ent17", "role": "Combination_Drug", "text": "fosinopril", "start": 24, "end": 25}, {"entity_id": "15331204_4_Ent15", "role": "Treatment_Dosage", "text": "10 mg / day", "start": 26, "end": 30}, {"entity_id": "15331204_4_Ent8", "role": "Subject_Population", "text": "three", "start": 32, "end": 33}, {"entity_id": "15331204_4_Ent7", "role": "Subject", "text": "three patients", "start": 32, "end": 34}, {"entity_id": "15331204_4_Ent9", "role": "Effect", "text": "glucose levels of all patients increased and achieve criteria of diabetes diagnoses", "start": 53, "end": 65}]}], "entity_mentions": [{"id": "15331204_4_Ent10", "text": "After 4 - to 14 - month period of therapy with the combination of indapamide ( 2.5 mg / day ) and fosinopril ( 10 mg / day )", "entity_type": "Entity", "start": 2, "end": 31}, {"id": "15331204_4_Ent11", "text": "4 - to 14 - month", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "15331204_4_Ent12", "text": "indapamide", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15331204_4_Ent16", "text": "indapamide", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15331204_4_Ent14", "text": "2.5 mg / day", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "15331204_4_Ent13", "text": "fosinopril", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "15331204_4_Ent17", "text": "fosinopril", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "15331204_4_Ent15", "text": "10 mg / day", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "15331204_4_Ent8", "text": "three", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "15331204_4_Ent7", "text": "three patients", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "15331204_4_Ent4", "text": "6 - month", "entity_type": "Entity", "start": 35, "end": 38}, {"id": "15331204_4_Ent3", "text": "6 - month period of monotherapy with indapamide ( 2.5 mg / day )", "entity_type": "Entity", "start": 35, "end": 49}, {"id": "15331204_4_Ent5", "text": "indapamide", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "15331204_4_Ent6", "text": "2.5 mg / day", "entity_type": "Entity", "start": 44, "end": 48}, {"id": "15331204_4_Ent1", "text": "one", "entity_type": "Entity", "start": 50, "end": 51}, {"id": "15331204_4_Ent0", "text": "one patient", "entity_type": "Entity", "start": 50, "end": 52}, {"id": "15331204_4_Ent2", "text": "glucose levels of all patients increased and achieve criteria of diabetes diagnoses", "entity_type": "Entity", "start": 53, "end": 65}, {"id": "15331204_4_Ent9", "text": "glucose levels of all patients increased and achieve criteria of diabetes diagnoses", "entity_type": "Entity", "start": 53, "end": 65}], "lang": "en"}
{"doc_id": "15338554_3", "wnd_id": "15338554_3_1", "text": "In addition to disease refractoriness , rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported .", "tokens": ["In", "addition", "to", "disease", "refractoriness", ",", "rare", "instances", "of", "disease", "progression", "from", "chronic", "phase", "to", "blast", "crisis", "during", "imatinib", "therapy", "have", "recently", "been", "anecdotally", "reported", "."], "event_mentions": [{"id": "15338554_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 17, "end": 18}, "arguments": [{"entity_id": "15338554_3_Ent0", "role": "Effect", "text": "disease progression from chronic phase to blast crisis", "start": 9, "end": 17}, {"entity_id": "15338554_3_Ent2", "role": "Treatment_Drug", "text": "imatinib", "start": 18, "end": 19}, {"entity_id": "15338554_3_Ent1", "role": "Treatment", "text": "imatinib therapy", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "15338554_3_Ent0", "text": "disease progression from chronic phase to blast crisis", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "15338554_3_Ent2", "text": "imatinib", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15338554_3_Ent1", "text": "imatinib therapy", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "15338554_5", "wnd_id": "15338554_5_1", "text": "Our findings suggest that significant progression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and , in some patients with CML , imatinib may promote cytogenetic clonal evolution , resulting in a poor response to treatment .", "tokens": ["Our", "findings", "suggest", "that", "significant", "progression", "of", "marrow", "reticulin", "fibrosis", "during", "imatinib", "therapy", "can", "be", "an", "indicator", "for", "a", "return", "or", "progression", "of", "CML", "and", ",", "in", "some", "patients", "with", "CML", ",", "imatinib", "may", "promote", "cytogenetic", "clonal", "evolution", ",", "resulting", "in", "a", "poor", "response", "to", "treatment", "."], "event_mentions": [{"id": "15338554_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 10, "end": 11}, "arguments": [{"entity_id": "15338554_5_Ent0", "role": "Effect", "text": "significant progression of marrow reticulin fibrosis", "start": 4, "end": 10}, {"entity_id": "15338554_5_Ent1", "role": "Treatment", "text": "imatinib", "start": 11, "end": 12}, {"entity_id": "15338554_5_Ent2", "role": "Treatment_Drug", "text": "imatinib", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "15338554_5_Ent0", "text": "significant progression of marrow reticulin fibrosis", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "15338554_5_Ent1", "text": "imatinib", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15338554_5_Ent2", "text": "imatinib", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "1536494_1", "wnd_id": "1536494_1_1", "text": "Aminophylline hypersensitivity apparently due to ethylenediamine .", "tokens": ["Aminophylline", "hypersensitivity", "apparently", "due", "to", "ethylenediamine", "."], "event_mentions": [{"id": "1536494_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 3, "end": 4}, "arguments": [{"entity_id": "1536494_1_Ent0", "role": "Effect", "text": "Aminophylline hypersensitivity", "start": 0, "end": 2}, {"entity_id": "1536494_1_Ent1", "role": "Treatment", "text": "ethylenediamine", "start": 5, "end": 6}, {"entity_id": "1536494_1_Ent2", "role": "Treatment_Drug", "text": "ethylenediamine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "1536494_1_Ent0", "text": "Aminophylline hypersensitivity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1536494_1_Ent1", "text": "ethylenediamine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1536494_1_Ent2", "text": "ethylenediamine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "1536494_2", "wnd_id": "1536494_2_1", "text": "We present a case of ethylenediamine - induced delayed hypersensitivity reaction in a 46 - year - old woman who received parenteral aminophylline for an acute asthma exacerbation .", "tokens": ["We", "present", "a", "case", "of", "ethylenediamine", "-", "induced", "delayed", "hypersensitivity", "reaction", "in", "a", "46", "-", "year", "-", "old", "woman", "who", "received", "parenteral", "aminophylline", "for", "an", "acute", "asthma", "exacerbation", "."], "event_mentions": [{"id": "1536494_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "1536494_2_Ent4", "role": "Treatment", "text": "ethylenediamine", "start": 5, "end": 6}, {"entity_id": "1536494_2_Ent5", "role": "Treatment_Drug", "text": "ethylenediamine", "start": 5, "end": 6}, {"entity_id": "1536494_2_Ent3", "role": "Effect", "text": "delayed hypersensitivity reaction", "start": 8, "end": 11}, {"entity_id": "1536494_2_Ent0", "role": "Subject", "text": "a 46 - year - old woman", "start": 12, "end": 19}, {"entity_id": "1536494_2_Ent1", "role": "Subject_Age", "text": "46 - year - old", "start": 13, "end": 18}, {"entity_id": "1536494_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 18, "end": 19}]}, {"id": "1536494_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 20, "end": 21}, "arguments": [{"entity_id": "1536494_2_Ent6", "role": "Subject", "text": "a 46 - year - old woman", "start": 12, "end": 19}, {"entity_id": "1536494_2_Ent7", "role": "Subject_Age", "text": "46 - year - old", "start": 13, "end": 18}, {"entity_id": "1536494_2_Ent8", "role": "Subject_Gender", "text": "woman", "start": 18, "end": 19}, {"entity_id": "1536494_2_Ent11", "role": "Treatment_Route", "text": "parenteral", "start": 21, "end": 22}, {"entity_id": "1536494_2_Ent9", "role": "Treatment", "text": "parenteral aminophylline", "start": 21, "end": 23}, {"entity_id": "1536494_2_Ent12", "role": "Treatment_Drug", "text": "aminophylline", "start": 22, "end": 23}, {"entity_id": "1536494_2_Ent10", "role": "Treatment_Disorder", "text": "acute asthma exacerbation", "start": 25, "end": 28}]}], "entity_mentions": [{"id": "1536494_2_Ent4", "text": "ethylenediamine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1536494_2_Ent5", "text": "ethylenediamine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1536494_2_Ent3", "text": "delayed hypersensitivity reaction", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "1536494_2_Ent0", "text": "a 46 - year - old woman", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "1536494_2_Ent6", "text": "a 46 - year - old woman", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "1536494_2_Ent1", "text": "46 - year - old", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "1536494_2_Ent7", "text": "46 - year - old", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "1536494_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1536494_2_Ent8", "text": "woman", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1536494_2_Ent11", "text": "parenteral", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "1536494_2_Ent9", "text": "parenteral aminophylline", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "1536494_2_Ent12", "text": "aminophylline", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1536494_2_Ent10", "text": "acute asthma exacerbation", "entity_type": "Entity", "start": 25, "end": 28}], "lang": "en"}
{"doc_id": "15383642_1", "wnd_id": "15383642_1_1", "text": "Hypotension due to interaction between lisinopril and tizanidine .", "tokens": ["Hypotension", "due", "to", "interaction", "between", "lisinopril", "and", "tizanidine", "."], "event_mentions": [{"id": "15383642_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 1, "end": 3}, "arguments": [{"entity_id": "15383642_1_Ent0", "role": "Effect", "text": "Hypotension", "start": 0, "end": 1}, {"entity_id": "15383642_1_Ent1", "role": "Treatment", "text": "interaction between lisinopril and tizanidine", "start": 3, "end": 8}, {"entity_id": "15383642_1_Ent3", "role": "Treatment_Drug", "text": "lisinopril", "start": 5, "end": 6}, {"entity_id": "15383642_1_Ent4", "role": "Combination_Drug", "text": "lisinopril", "start": 5, "end": 6}, {"entity_id": "15383642_1_Ent2", "role": "Treatment_Drug", "text": "tizanidine", "start": 7, "end": 8}, {"entity_id": "15383642_1_Ent5", "role": "Combination_Drug", "text": "tizanidine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "15383642_1_Ent0", "text": "Hypotension", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15383642_1_Ent1", "text": "interaction between lisinopril and tizanidine", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "15383642_1_Ent3", "text": "lisinopril", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15383642_1_Ent4", "text": "lisinopril", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15383642_1_Ent2", "text": "tizanidine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15383642_1_Ent5", "text": "tizanidine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "15383642_14", "wnd_id": "15383642_14_1", "text": "With its characteristics , tizanidine has the potential to compromise hemodynamic stability during concomitant angiotensin - converting enzyme inhibitor use .", "tokens": ["With", "its", "characteristics", ",", "tizanidine", "has", "the", "potential", "to", "compromise", "hemodynamic", "stability", "during", "concomitant", "angiotensin", "-", "converting", "enzyme", "inhibitor", "use", "."], "event_mentions": [{"id": "15383642_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "compromise", "start": 9, "end": 10}, "arguments": [{"entity_id": "15383642_14_Ent1", "role": "Treatment", "text": "tizanidine", "start": 4, "end": 5}, {"entity_id": "15383642_14_Ent3", "role": "Treatment_Drug", "text": "tizanidine", "start": 4, "end": 5}, {"entity_id": "15383642_14_Ent5", "role": "Combination_Drug", "text": "tizanidine", "start": 4, "end": 5}, {"entity_id": "15383642_14_Ent0", "role": "Effect", "text": "compromise hemodynamic stability", "start": 9, "end": 12}, {"entity_id": "15383642_14_Ent2", "role": "Treatment", "text": "during concomitant angiotensin - converting enzyme inhibitor use", "start": 12, "end": 20}, {"entity_id": "15383642_14_Ent4", "role": "Treatment_Drug", "text": "angiotensin - converting enzyme inhibitor", "start": 14, "end": 19}, {"entity_id": "15383642_14_Ent6", "role": "Combination_Drug", "text": "angiotensin - converting enzyme inhibitor", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "15383642_14_Ent1", "text": "tizanidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15383642_14_Ent3", "text": "tizanidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15383642_14_Ent5", "text": "tizanidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15383642_14_Ent0", "text": "compromise hemodynamic stability", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "15383642_14_Ent2", "text": "during concomitant angiotensin - converting enzyme inhibitor use", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "15383642_14_Ent4", "text": "angiotensin - converting enzyme inhibitor", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "15383642_14_Ent6", "text": "angiotensin - converting enzyme inhibitor", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "15383642_6", "wnd_id": "15383642_6_1", "text": "Three weeks later , the decerebrate rigidity and high BP remained , and tizanidine was initiated to see whether the decrease in muscle tone could facilitate hypertension control and motor recovery .", "tokens": ["Three", "weeks", "later", ",", "the", "decerebrate", "rigidity", "and", "high", "BP", "remained", ",", "and", "tizanidine", "was", "initiated", "to", "see", "whether", "the", "decrease", "in", "muscle", "tone", "could", "facilitate", "hypertension", "control", "and", "motor", "recovery", "."], "event_mentions": [{"id": "15383642_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "initiated", "start": 15, "end": 16}, "arguments": [{"entity_id": "15383642_6_Ent0", "role": "Subject", "text": "decerebrate rigidity and high BP", "start": 5, "end": 10}, {"entity_id": "15383642_6_Ent4", "role": "Treatment_Disorder", "text": "decerebrate rigidity and high BP", "start": 5, "end": 10}, {"entity_id": "15383642_6_Ent2", "role": "Treatment", "text": "tizanidine", "start": 13, "end": 14}, {"entity_id": "15383642_6_Ent3", "role": "Treatment_Drug", "text": "tizanidine", "start": 13, "end": 14}, {"entity_id": "15383642_6_Ent1", "role": "Effect", "text": "hypertension control and motor recovery", "start": 26, "end": 31}]}], "entity_mentions": [{"id": "15383642_6_Ent0", "text": "decerebrate rigidity and high BP", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "15383642_6_Ent4", "text": "decerebrate rigidity and high BP", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "15383642_6_Ent2", "text": "tizanidine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15383642_6_Ent3", "text": "tizanidine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15383642_6_Ent1", "text": "hypertension control and motor recovery", "entity_type": "Entity", "start": 26, "end": 31}], "lang": "en"}
{"doc_id": "15454180_2", "wnd_id": "15454180_2_1", "text": "As linezolid has been shown to have hematologic side effects , blood count monitoring is recommended in patients receiving this drug for long - term therapy .", "tokens": ["As", "linezolid", "has", "been", "shown", "to", "have", "hematologic", "side", "effects", ",", "blood", "count", "monitoring", "is", "recommended", "in", "patients", "receiving", "this", "drug", "for", "long", "-", "term", "therapy", "."], "event_mentions": [{"id": "15454180_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have", "start": 6, "end": 7}, "arguments": [{"entity_id": "15454180_2_Ent1", "role": "Treatment", "text": "linezolid", "start": 1, "end": 2}, {"entity_id": "15454180_2_Ent2", "role": "Treatment_Drug", "text": "linezolid", "start": 1, "end": 2}, {"entity_id": "15454180_2_Ent0", "role": "Effect", "text": "hematologic side effects", "start": 7, "end": 10}, {"entity_id": "15454180_2_Ent3", "role": "Treatment_Duration", "text": "long - term", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "15454180_2_Ent1", "text": "linezolid", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15454180_2_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15454180_2_Ent0", "text": "hematologic side effects", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15454180_2_Ent3", "text": "long - term", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "15482394_3", "wnd_id": "15482394_3_1", "text": "Despite the low dosage of warfarin , international normalized ratio ( INR ) was markedly elevated from 1.15 to 11.28 for only 4 days , and bleeding symptoms concurrently developed .", "tokens": ["Despite", "the", "low", "dosage", "of", "warfarin", ",", "international", "normalized", "ratio", "(", "INR", ")", "was", "markedly", "elevated", "from", "1.15", "to", "11.28", "for", "only", "4", "days", ",", "and", "bleeding", "symptoms", "concurrently", "developed", "."], "event_mentions": [{"id": "15482394_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 29, "end": 30}, "arguments": [{"entity_id": "15482394_3_Ent4", "role": "Treatment_Dosage", "text": "low dosage", "start": 2, "end": 4}, {"entity_id": "15482394_3_Ent2", "role": "Treatment", "text": "low dosage of warfarin", "start": 2, "end": 6}, {"entity_id": "15482394_3_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 5, "end": 6}, {"entity_id": "15482394_3_Ent0", "role": "Effect", "text": "international normalized ratio ( INR ) was markedly elevated", "start": 7, "end": 16}, {"entity_id": "15482394_3_Ent5", "role": "Treatment_Dosage", "text": "1.15", "start": 17, "end": 18}, {"entity_id": "15482394_3_Ent6", "role": "Treatment_Dosage", "text": "11.28", "start": 19, "end": 20}, {"entity_id": "15482394_3_Ent7", "role": "Treatment_Duration", "text": "4 days", "start": 22, "end": 24}, {"entity_id": "15482394_3_Ent1", "role": "Effect", "text": "bleeding symptoms", "start": 26, "end": 28}]}], "entity_mentions": [{"id": "15482394_3_Ent4", "text": "low dosage", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15482394_3_Ent2", "text": "low dosage of warfarin", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "15482394_3_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15482394_3_Ent0", "text": "international normalized ratio ( INR ) was markedly elevated", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "15482394_3_Ent5", "text": "1.15", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15482394_3_Ent6", "text": "11.28", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "15482394_3_Ent7", "text": "4 days", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "15482394_3_Ent1", "text": "bleeding symptoms", "entity_type": "Entity", "start": 26, "end": 28}], "lang": "en"}
{"doc_id": "15489872_1", "wnd_id": "15489872_1_1", "text": "We report an allogeneic bone marrow transplant recipient who developed CMV infection refractory to sequential therapy with ganciclovir , foscarnet , and cidofovir .", "tokens": ["We", "report", "an", "allogeneic", "bone", "marrow", "transplant", "recipient", "who", "developed", "CMV", "infection", "refractory", "to", "sequential", "therapy", "with", "ganciclovir", ",", "foscarnet", ",", "and", "cidofovir", "."], "event_mentions": [{"id": "15489872_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "refractory", "start": 12, "end": 13}, "arguments": [{"entity_id": "15489872_1_Ent1", "role": "Subject_Disorder", "text": "allogeneic bone marrow transplant", "start": 3, "end": 7}, {"entity_id": "15489872_1_Ent0", "role": "Subject", "text": "allogeneic bone marrow transplant recipient", "start": 3, "end": 8}, {"entity_id": "15489872_1_Ent3", "role": "Treatment_Disorder", "text": "CMV infection", "start": 10, "end": 12}, {"entity_id": "15489872_1_Ent2", "role": "Treatment", "text": "sequential therapy with ganciclovir , foscarnet , and cidofovir", "start": 14, "end": 23}, {"entity_id": "15489872_1_Ent4", "role": "Treatment_Drug", "text": "ganciclovir", "start": 17, "end": 18}, {"entity_id": "15489872_1_Ent7", "role": "Combination_Drug", "text": "ganciclovir", "start": 17, "end": 18}, {"entity_id": "15489872_1_Ent5", "role": "Treatment_Drug", "text": "foscarnet", "start": 19, "end": 20}, {"entity_id": "15489872_1_Ent8", "role": "Combination_Drug", "text": "foscarnet", "start": 19, "end": 20}, {"entity_id": "15489872_1_Ent6", "role": "Treatment_Drug", "text": "cidofovir", "start": 22, "end": 23}, {"entity_id": "15489872_1_Ent9", "role": "Combination_Drug", "text": "cidofovir", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "15489872_1_Ent1", "text": "allogeneic bone marrow transplant", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "15489872_1_Ent0", "text": "allogeneic bone marrow transplant recipient", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "15489872_1_Ent3", "text": "CMV infection", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "15489872_1_Ent2", "text": "sequential therapy with ganciclovir , foscarnet , and cidofovir", "entity_type": "Entity", "start": 14, "end": 23}, {"id": "15489872_1_Ent4", "text": "ganciclovir", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15489872_1_Ent7", "text": "ganciclovir", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15489872_1_Ent5", "text": "foscarnet", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "15489872_1_Ent8", "text": "foscarnet", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "15489872_1_Ent6", "text": "cidofovir", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15489872_1_Ent9", "text": "cidofovir", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "15494638_16", "wnd_id": "15494638_16_1", "text": "We conclude peripheral neuropathy with 5 - FU is rare .", "tokens": ["We", "conclude", "peripheral", "neuropathy", "with", "5", "-", "FU", "is", "rare", "."], "event_mentions": [{"id": "15494638_16_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 4, "end": 5}, "arguments": [{"entity_id": "15494638_16_Ent0", "role": "Effect", "text": "peripheral neuropathy", "start": 2, "end": 4}, {"entity_id": "15494638_16_Ent1", "role": "Treatment", "text": "5 - FU", "start": 5, "end": 8}, {"entity_id": "15494638_16_Ent2", "role": "Treatment_Drug", "text": "5 - FU", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "15494638_16_Ent0", "text": "peripheral neuropathy", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15494638_16_Ent1", "text": "5 - FU", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "15494638_16_Ent2", "text": "5 - FU", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "15494638_20", "wnd_id": "15494638_20_1", "text": "Neurologic symptoms resolved after stopping CAP for 4 weeks in Patient A , with no recurrence after reinitiating CAP alone at 2000 mg / m2 .", "tokens": ["Neurologic", "symptoms", "resolved", "after", "stopping", "CAP", "for", "4", "weeks", "in", "Patient", "A", ",", "with", "no", "recurrence", "after", "reinitiating", "CAP", "alone", "at", "2000", "mg", "/", "m2", "."], "event_mentions": [{"id": "15494638_20_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "15494638_20_Ent0", "role": "Effect", "text": "Neurologic symptoms resolved", "start": 0, "end": 3}, {"entity_id": "15494638_20_Ent1", "role": "Treatment", "text": "stopping CAP for 4 weeks", "start": 4, "end": 9}, {"entity_id": "15494638_20_Ent2", "role": "Treatment_Drug", "text": "CAP", "start": 5, "end": 6}, {"entity_id": "15494638_20_Ent3", "role": "Treatment_Time_elapsed", "text": "4 weeks", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "15494638_20_Ent0", "text": "Neurologic symptoms resolved", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15494638_20_Ent1", "text": "stopping CAP for 4 weeks", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "15494638_20_Ent2", "text": "CAP", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15494638_20_Ent3", "text": "4 weeks", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "15504988_2", "wnd_id": "15504988_2_1", "text": "We report three patients , all of whom had preexisting diabetic dyslipidemia , who showed a profound reduction in plasma HDL cholesterol and apolipoprotein AI levels soon after the initiation of rosiglitazone therapy .", "tokens": ["We", "report", "three", "patients", ",", "all", "of", "whom", "had", "preexisting", "diabetic", "dyslipidemia", ",", "who", "showed", "a", "profound", "reduction", "in", "plasma", "HDL", "cholesterol", "and", "apolipoprotein", "AI", "levels", "soon", "after", "the", "initiation", "of", "rosiglitazone", "therapy", "."], "event_mentions": [{"id": "15504988_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "initiation", "start": 29, "end": 30}, "arguments": [{"entity_id": "15504988_2_Ent1", "role": "Subject_Population", "text": "three", "start": 2, "end": 3}, {"entity_id": "15504988_2_Ent0", "role": "Subject", "text": "three patients", "start": 2, "end": 4}, {"entity_id": "15504988_2_Ent6", "role": "Treatment_Disorder", "text": "preexisting diabetic dyslipidemia", "start": 9, "end": 12}, {"entity_id": "15504988_2_Ent2", "role": "Effect", "text": "profound reduction in plasma HDL cholesterol and apolipoprotein AI levels", "start": 16, "end": 26}, {"entity_id": "15504988_2_Ent5", "role": "Treatment_Time_elapsed", "text": "soon after", "start": 26, "end": 28}, {"entity_id": "15504988_2_Ent4", "role": "Treatment_Drug", "text": "rosiglitazone", "start": 31, "end": 32}, {"entity_id": "15504988_2_Ent3", "role": "Treatment", "text": "rosiglitazone therapy", "start": 31, "end": 33}]}], "entity_mentions": [{"id": "15504988_2_Ent1", "text": "three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15504988_2_Ent0", "text": "three patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15504988_2_Ent6", "text": "preexisting diabetic dyslipidemia", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "15504988_2_Ent2", "text": "profound reduction in plasma HDL cholesterol and apolipoprotein AI levels", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "15504988_2_Ent5", "text": "soon after", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "15504988_2_Ent4", "text": "rosiglitazone", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "15504988_2_Ent3", "text": "rosiglitazone therapy", "entity_type": "Entity", "start": 31, "end": 33}], "lang": "en"}
{"doc_id": "15507779_2", "wnd_id": "15507779_2_1", "text": "Nevirapine is a non - nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus ( HIV) - infected patients and in post - exposure prophylaxis .", "tokens": ["Nevirapine", "is", "a", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "used", "in", "the", "treatment", "of", "human", "immunodeficiency", "virus", "(", "HIV)", "-", "infected", "patients", "and", "in", "post", "-", "exposure", "prophylaxis", "."], "event_mentions": [{"id": "15507779_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 12, "end": 13}, "arguments": [{"entity_id": "15507779_2_Ent1", "role": "Treatment", "text": "Nevirapine", "start": 0, "end": 1}, {"entity_id": "15507779_2_Ent2", "role": "Treatment_Drug", "text": "Nevirapine", "start": 0, "end": 1}, {"entity_id": "15507779_2_Ent0", "role": "Subject", "text": "human immunodeficiency virus ( HIV) - infected patients", "start": 14, "end": 22}, {"entity_id": "15507779_2_Ent3", "role": "Treatment_Disorder", "text": "immunodeficiency virus", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "15507779_2_Ent1", "text": "Nevirapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15507779_2_Ent2", "text": "Nevirapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15507779_2_Ent0", "text": "human immunodeficiency virus ( HIV) - infected patients", "entity_type": "Entity", "start": 14, "end": 22}, {"id": "15507779_2_Ent3", "text": "immunodeficiency virus", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "15522120_10", "wnd_id": "15522120_10_1", "text": "The symptoms disappeared with clemastine and betametasone treatment .", "tokens": ["The", "symptoms", "disappeared", "with", "clemastine", "and", "betametasone", "treatment", "."], "event_mentions": [{"id": "15522120_10_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "disappeared", "start": 2, "end": 3}, "arguments": [{"entity_id": "15522120_10_Ent0", "role": "Effect", "text": "The symptoms disappeared", "start": 0, "end": 3}, {"entity_id": "15522120_10_Ent2", "role": "Treatment_Drug", "text": "clemastine", "start": 4, "end": 5}, {"entity_id": "15522120_10_Ent5", "role": "Combination_Drug", "text": "clemastine", "start": 4, "end": 5}, {"entity_id": "15522120_10_Ent1", "role": "Treatment", "text": "clemastine and betametasone", "start": 4, "end": 7}, {"entity_id": "15522120_10_Ent3", "role": "Treatment_Drug", "text": "betametasone", "start": 6, "end": 7}, {"entity_id": "15522120_10_Ent4", "role": "Combination_Drug", "text": "betametasone", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "15522120_10_Ent0", "text": "The symptoms disappeared", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15522120_10_Ent2", "text": "clemastine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15522120_10_Ent5", "text": "clemastine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15522120_10_Ent1", "text": "clemastine and betametasone", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "15522120_10_Ent3", "text": "betametasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15522120_10_Ent4", "text": "betametasone", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "15522120_13", "wnd_id": "15522120_13_1", "text": "The itch spread to the arms , abdomen and legs and the patient treated himself with clemastine and the itch disappeared .", "tokens": ["The", "itch", "spread", "to", "the", "arms", ",", "abdomen", "and", "legs", "and", "the", "patient", "treated", "himself", "with", "clemastine", "and", "the", "itch", "disappeared", "."], "event_mentions": [{"id": "15522120_13_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "disappeared", "start": 20, "end": 21}, "arguments": [{"entity_id": "15522120_13_Ent0", "role": "Subject", "text": "The itch spread to the arms , abdomen and legs and the patient", "start": 0, "end": 13}, {"entity_id": "15522120_13_Ent6", "role": "Treatment_Disorder", "text": "itch", "start": 1, "end": 2}, {"entity_id": "15522120_13_Ent1", "role": "Subject", "text": "himself", "start": 14, "end": 15}, {"entity_id": "15522120_13_Ent2", "role": "Subject_Gender", "text": "himself", "start": 14, "end": 15}, {"entity_id": "15522120_13_Ent4", "role": "Treatment", "text": "clemastine", "start": 16, "end": 17}, {"entity_id": "15522120_13_Ent5", "role": "Treatment_Drug", "text": "clemastine", "start": 16, "end": 17}, {"entity_id": "15522120_13_Ent3", "role": "Effect", "text": "itch disappeared", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "15522120_13_Ent0", "text": "The itch spread to the arms , abdomen and legs and the patient", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "15522120_13_Ent6", "text": "itch", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15522120_13_Ent1", "text": "himself", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15522120_13_Ent2", "text": "himself", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15522120_13_Ent4", "text": "clemastine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15522120_13_Ent5", "text": "clemastine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15522120_13_Ent3", "text": "itch disappeared", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "15533031_2", "wnd_id": "15533031_2_1", "text": "We report the case of a patient with increased cerebral cortical excitability following intoxication with flupirtine , a centrally acting analgesic and antispastic drug .", "tokens": ["We", "report", "the", "case", "of", "a", "patient", "with", "increased", "cerebral", "cortical", "excitability", "following", "intoxication", "with", "flupirtine", ",", "a", "centrally", "acting", "analgesic", "and", "antispastic", "drug", "."], "event_mentions": [{"id": "15533031_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 12, "end": 13}, "arguments": [{"entity_id": "15533031_2_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "15533031_2_Ent1", "role": "Effect", "text": "increased cerebral cortical excitability", "start": 8, "end": 12}, {"entity_id": "15533031_2_Ent2", "role": "Treatment", "text": "flupirtine", "start": 15, "end": 16}, {"entity_id": "15533031_2_Ent3", "role": "Treatment_Drug", "text": "flupirtine", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "15533031_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15533031_2_Ent1", "text": "increased cerebral cortical excitability", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "15533031_2_Ent2", "text": "flupirtine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15533031_2_Ent3", "text": "flupirtine", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "15543388_2", "wnd_id": "15543388_2_1", "text": "Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C.", "tokens": ["Celiac", "disease", "onset", "after", "pegylated", "interferon", "and", "ribavirin", "treatment", "of", "chronic", "hepatitis", "C."], "event_mentions": [{"id": "15543388_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "onset", "start": 2, "end": 3}, "arguments": [{"entity_id": "15543388_2_Ent0", "role": "Effect", "text": "Celiac disease", "start": 0, "end": 2}, {"entity_id": "15543388_2_Ent2", "role": "Treatment_Drug", "text": "pegylated interferon", "start": 4, "end": 6}, {"entity_id": "15543388_2_Ent5", "role": "Combination_Drug", "text": "pegylated interferon", "start": 4, "end": 6}, {"entity_id": "15543388_2_Ent1", "role": "Treatment", "text": "pegylated interferon and ribavirin treatment of chronic hepatitis C.", "start": 4, "end": 13}, {"entity_id": "15543388_2_Ent3", "role": "Treatment_Drug", "text": "ribavirin treatment", "start": 7, "end": 9}, {"entity_id": "15543388_2_Ent6", "role": "Combination_Drug", "text": "ribavirin treatment", "start": 7, "end": 9}, {"entity_id": "15543388_2_Ent4", "role": "Treatment_Disorder", "text": "chronic hepatitis C.", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "15543388_2_Ent0", "text": "Celiac disease", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15543388_2_Ent2", "text": "pegylated interferon", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15543388_2_Ent5", "text": "pegylated interferon", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15543388_2_Ent1", "text": "pegylated interferon and ribavirin treatment of chronic hepatitis C.", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "15543388_2_Ent3", "text": "ribavirin treatment", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15543388_2_Ent6", "text": "ribavirin treatment", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15543388_2_Ent4", "text": "chronic hepatitis C.", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "15554737_1", "wnd_id": "15554737_1_1", "text": "In this article , we describe another case of subcutaneous changes following repeated glatiramer acetate injection , presented as localized panniculitis in the area around the injection sites , in a 46 - year - old female patient who was treated with glatiramer acetate for 18 months .", "tokens": ["In", "this", "article", ",", "we", "describe", "another", "case", "of", "subcutaneous", "changes", "following", "repeated", "glatiramer", "acetate", "injection", ",", "presented", "as", "localized", "panniculitis", "in", "the", "area", "around", "the", "injection", "sites", ",", "in", "a", "46", "-", "year", "-", "old", "female", "patient", "who", "was", "treated", "with", "glatiramer", "acetate", "for", "18", "months", "."], "event_mentions": [{"id": "15554737_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 11, "end": 12}, "arguments": [{"entity_id": "15554737_1_Ent3", "role": "Effect", "text": "subcutaneous changes", "start": 9, "end": 11}, {"entity_id": "15554737_1_Ent5", "role": "Treatment", "text": "repeated glatiramer acetate injection", "start": 12, "end": 16}, {"entity_id": "15554737_1_Ent6", "role": "Treatment_Drug", "text": "glatiramer acetate", "start": 13, "end": 15}, {"entity_id": "15554737_1_Ent7", "role": "Treatment_Route", "text": "injection", "start": 15, "end": 16}, {"entity_id": "15554737_1_Ent4", "role": "Effect", "text": "presented as localized panniculitis in the area around the injection sites", "start": 17, "end": 28}, {"entity_id": "15554737_1_Ent0", "role": "Subject", "text": "a 46 - year - old female patient", "start": 30, "end": 38}, {"entity_id": "15554737_1_Ent1", "role": "Subject_Age", "text": "46 - year - old", "start": 31, "end": 36}, {"entity_id": "15554737_1_Ent2", "role": "Subject_Gender", "text": "female", "start": 36, "end": 37}]}, {"id": "15554737_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 40, "end": 41}, "arguments": [{"entity_id": "15554737_1_Ent8", "role": "Subject", "text": "a 46 - year - old female patient", "start": 30, "end": 38}, {"entity_id": "15554737_1_Ent9", "role": "Subject_Age", "text": "46 - year - old", "start": 31, "end": 36}, {"entity_id": "15554737_1_Ent10", "role": "Subject_Gender", "text": "female", "start": 36, "end": 37}, {"entity_id": "15554737_1_Ent12", "role": "Treatment_Drug", "text": "glatiramer acetate", "start": 42, "end": 44}, {"entity_id": "15554737_1_Ent11", "role": "Treatment", "text": "glatiramer acetate for 18 months", "start": 42, "end": 47}, {"entity_id": "15554737_1_Ent13", "role": "Treatment_Time_elapsed", "text": "18 months .", "start": 45, "end": 48}]}], "entity_mentions": [{"id": "15554737_1_Ent3", "text": "subcutaneous changes", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15554737_1_Ent5", "text": "repeated glatiramer acetate injection", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "15554737_1_Ent6", "text": "glatiramer acetate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "15554737_1_Ent7", "text": "injection", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15554737_1_Ent4", "text": "presented as localized panniculitis in the area around the injection sites", "entity_type": "Entity", "start": 17, "end": 28}, {"id": "15554737_1_Ent0", "text": "a 46 - year - old female patient", "entity_type": "Entity", "start": 30, "end": 38}, {"id": "15554737_1_Ent8", "text": "a 46 - year - old female patient", "entity_type": "Entity", "start": 30, "end": 38}, {"id": "15554737_1_Ent1", "text": "46 - year - old", "entity_type": "Entity", "start": 31, "end": 36}, {"id": "15554737_1_Ent9", "text": "46 - year - old", "entity_type": "Entity", "start": 31, "end": 36}, {"id": "15554737_1_Ent2", "text": "female", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "15554737_1_Ent10", "text": "female", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "15554737_1_Ent12", "text": "glatiramer acetate", "entity_type": "Entity", "start": 42, "end": 44}, {"id": "15554737_1_Ent11", "text": "glatiramer acetate for 18 months", "entity_type": "Entity", "start": 42, "end": 47}, {"id": "15554737_1_Ent13", "text": "18 months .", "entity_type": "Entity", "start": 45, "end": 48}], "lang": "en"}
{"doc_id": "15580406_1", "wnd_id": "15580406_1_1", "text": "Here , we describe a case of Vogt - Koyanagi - Harada disease occurring 4 months after the start of interferon alpha treatment , probably induced by the immunomodulatory effects of interferon .", "tokens": ["Here", ",", "we", "describe", "a", "case", "of", "Vogt", "-", "Koyanagi", "-", "Harada", "disease", "occurring", "4", "months", "after", "the", "start", "of", "interferon", "alpha", "treatment", ",", "probably", "induced", "by", "the", "immunomodulatory", "effects", "of", "interferon", "."], "event_mentions": [{"id": "15580406_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 13, "end": 14}, "arguments": [{"entity_id": "15580406_1_Ent0", "role": "Subject", "text": "a case", "start": 4, "end": 6}, {"entity_id": "15580406_1_Ent1", "role": "Effect", "text": "Vogt - Koyanagi - Harada disease", "start": 7, "end": 13}, {"entity_id": "15580406_1_Ent3", "role": "Treatment_Time_elapsed", "text": "4 months", "start": 14, "end": 16}, {"entity_id": "15580406_1_Ent2", "role": "Treatment", "text": "4 months after the start of interferon alpha", "start": 14, "end": 22}, {"entity_id": "15580406_1_Ent4", "role": "Treatment_Drug", "text": "interferon alpha", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "15580406_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15580406_1_Ent1", "text": "Vogt - Koyanagi - Harada disease", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "15580406_1_Ent3", "text": "4 months", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "15580406_1_Ent2", "text": "4 months after the start of interferon alpha", "entity_type": "Entity", "start": 14, "end": 22}, {"id": "15580406_1_Ent4", "text": "interferon alpha", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "15588385_1", "wnd_id": "15588385_1_1", "text": "Acute hepatic failure is a rare and potentially lethal complication of propylthiouracil ( PTU ) use for hyperthyroidism .", "tokens": ["Acute", "hepatic", "failure", "is", "a", "rare", "and", "potentially", "lethal", "complication", "of", "propylthiouracil", "(", "PTU", ")", "use", "for", "hyperthyroidism", "."], "event_mentions": [{"id": "15588385_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 9, "end": 10}, "arguments": [{"entity_id": "15588385_1_Ent0", "role": "Effect", "text": "Acute hepatic failure", "start": 0, "end": 3}, {"entity_id": "15588385_1_Ent3", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 11, "end": 12}, {"entity_id": "15588385_1_Ent1", "role": "Treatment", "text": "propylthiouracil ( PTU )", "start": 11, "end": 15}, {"entity_id": "15588385_1_Ent2", "role": "Treatment_Disorder", "text": "hyperthyroidism", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "15588385_1_Ent0", "text": "Acute hepatic failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15588385_1_Ent3", "text": "propylthiouracil", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15588385_1_Ent1", "text": "propylthiouracil ( PTU )", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "15588385_1_Ent2", "text": "hyperthyroidism", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "15595320_2", "wnd_id": "15595320_2_1", "text": "Methotrexate ( MTX ) is a commonly used second line agent for RA , and there have been several recent reports of Epstein - Barr virus ( EBV) - associated polyclonal B cell lymphoproliferative disorder in MTX - treated RA patients .", "tokens": ["Methotrexate", "(", "MTX", ")", "is", "a", "commonly", "used", "second", "line", "agent", "for", "RA", ",", "and", "there", "have", "been", "several", "recent", "reports", "of", "Epstein", "-", "Barr", "virus", "(", "EBV)", "-", "associated", "polyclonal", "B", "cell", "lymphoproliferative", "disorder", "in", "MTX", "-", "treated", "RA", "patients", "."], "event_mentions": [{"id": "15595320_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reports", "start": 20, "end": 21}, "arguments": [{"entity_id": "15595320_2_Ent1", "role": "Effect", "text": "Epstein - Barr virus ( EBV) - associated polyclonal B cell lymphoproliferative disorder", "start": 22, "end": 35}, {"entity_id": "15595320_2_Ent3", "role": "Treatment_Drug", "text": "MTX", "start": 36, "end": 37}, {"entity_id": "15595320_2_Ent2", "role": "Treatment", "text": "MTX - treated", "start": 36, "end": 39}, {"entity_id": "15595320_2_Ent4", "role": "Treatment_Disorder", "text": "RA", "start": 39, "end": 40}, {"entity_id": "15595320_2_Ent0", "role": "Subject", "text": "RA patients", "start": 39, "end": 41}]}], "entity_mentions": [{"id": "15595320_2_Ent1", "text": "Epstein - Barr virus ( EBV) - associated polyclonal B cell lymphoproliferative disorder", "entity_type": "Entity", "start": 22, "end": 35}, {"id": "15595320_2_Ent3", "text": "MTX", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "15595320_2_Ent2", "text": "MTX - treated", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "15595320_2_Ent4", "text": "RA", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "15595320_2_Ent0", "text": "RA patients", "entity_type": "Entity", "start": 39, "end": 41}], "lang": "en"}
{"doc_id": "15611427_4", "wnd_id": "15611427_4_1", "text": "The exacerbation of psoriasis was accompanied by a massive induction of lesional type I interferon activity , detected by MxA expression after imiquimod therapy .", "tokens": ["The", "exacerbation", "of", "psoriasis", "was", "accompanied", "by", "a", "massive", "induction", "of", "lesional", "type", "I", "interferon", "activity", ",", "detected", "by", "MxA", "expression", "after", "imiquimod", "therapy", "."], "event_mentions": [{"id": "15611427_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "detected", "start": 17, "end": 18}, "arguments": [{"entity_id": "15611427_4_Ent0", "role": "Effect", "text": "exacerbation of psoriasis", "start": 1, "end": 4}, {"entity_id": "15611427_4_Ent1", "role": "Effect", "text": "a massive induction of lesional type I interferon activity", "start": 7, "end": 16}, {"entity_id": "15611427_4_Ent2", "role": "Treatment", "text": "imiquimod", "start": 22, "end": 23}, {"entity_id": "15611427_4_Ent3", "role": "Treatment_Drug", "text": "imiquimod", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "15611427_4_Ent0", "text": "exacerbation of psoriasis", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "15611427_4_Ent1", "text": "a massive induction of lesional type I interferon activity", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "15611427_4_Ent2", "text": "imiquimod", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15611427_4_Ent3", "text": "imiquimod", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "15628319_4", "wnd_id": "15628319_4_1", "text": "We report AZA - induced drug eruption that developed in two cases of systemic scleroderma with polymyositis .", "tokens": ["We", "report", "AZA", "-", "induced", "drug", "eruption", "that", "developed", "in", "two", "cases", "of", "systemic", "scleroderma", "with", "polymyositis", "."], "event_mentions": [{"id": "15628319_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "15628319_4_Ent3", "role": "Treatment", "text": "AZA", "start": 2, "end": 3}, {"entity_id": "15628319_4_Ent4", "role": "Treatment_Drug", "text": "AZA", "start": 2, "end": 3}, {"entity_id": "15628319_4_Ent2", "role": "Effect", "text": "drug eruption", "start": 5, "end": 7}, {"entity_id": "15628319_4_Ent1", "role": "Subject_Population", "text": "two", "start": 10, "end": 11}, {"entity_id": "15628319_4_Ent0", "role": "Subject", "text": "two cases of systemic scleroderma with polymyositis", "start": 10, "end": 17}, {"entity_id": "15628319_4_Ent5", "role": "Treatment_Disorder", "text": "systemic scleroderma with polymyositis", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "15628319_4_Ent3", "text": "AZA", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15628319_4_Ent4", "text": "AZA", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15628319_4_Ent2", "text": "drug eruption", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15628319_4_Ent1", "text": "two", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15628319_4_Ent0", "text": "two cases of systemic scleroderma with polymyositis", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "15628319_4_Ent5", "text": "systemic scleroderma with polymyositis", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "15671134_1", "wnd_id": "15671134_1_1", "text": "A case of clozapine - induced tonic - clonic seizures managed with valproate : implications for clinical care .", "tokens": ["A", "case", "of", "clozapine", "-", "induced", "tonic", "-", "clonic", "seizures", "managed", "with", "valproate", ":", "implications", "for", "clinical", "care", "."], "event_mentions": [{"id": "15671134_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "15671134_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "15671134_1_Ent2", "role": "Treatment", "text": "clozapine", "start": 3, "end": 4}, {"entity_id": "15671134_1_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 3, "end": 4}, {"entity_id": "15671134_1_Ent1", "role": "Effect", "text": "tonic - clonic seizures", "start": 6, "end": 10}]}, {"id": "15671134_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "managed", "start": 10, "end": 11}, "arguments": [{"entity_id": "15671134_1_Ent4", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "15671134_1_Ent7", "role": "Treatment_Disorder", "text": "clozapine - induced tonic - clonic seizures", "start": 3, "end": 10}, {"entity_id": "15671134_1_Ent5", "role": "Treatment", "text": "valproate", "start": 12, "end": 13}, {"entity_id": "15671134_1_Ent6", "role": "Treatment_Drug", "text": "valproate", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "15671134_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15671134_1_Ent4", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15671134_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15671134_1_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15671134_1_Ent7", "text": "clozapine - induced tonic - clonic seizures", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "15671134_1_Ent1", "text": "tonic - clonic seizures", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "15671134_1_Ent5", "text": "valproate", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15671134_1_Ent6", "text": "valproate", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "15671134_4", "wnd_id": "15671134_4_1", "text": "We describe a case of clozapine - induced seizures in a patient with treatment - resistant schizophrenia .", "tokens": ["We", "describe", "a", "case", "of", "clozapine", "-", "induced", "seizures", "in", "a", "patient", "with", "treatment", "-", "resistant", "schizophrenia", "."], "event_mentions": [{"id": "15671134_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "15671134_4_Ent2", "role": "Treatment", "text": "clozapine", "start": 5, "end": 6}, {"entity_id": "15671134_4_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 5, "end": 6}, {"entity_id": "15671134_4_Ent1", "role": "Effect", "text": "seizures", "start": 8, "end": 9}, {"entity_id": "15671134_4_Ent0", "role": "Subject", "text": "a patient with treatment - resistant schizophrenia", "start": 10, "end": 17}, {"entity_id": "15671134_4_Ent4", "role": "Treatment_Disorder", "text": "treatment - resistant schizophrenia", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "15671134_4_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15671134_4_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15671134_4_Ent1", "text": "seizures", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15671134_4_Ent0", "text": "a patient with treatment - resistant schizophrenia", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "15671134_4_Ent4", "text": "treatment - resistant schizophrenia", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "1569260_2", "wnd_id": "1569260_2_1", "text": "We report a case of drug - induced pemphigus caused by an angiotensin - converting enzyme inhibitor , captopril .", "tokens": ["We", "report", "a", "case", "of", "drug", "-", "induced", "pemphigus", "caused", "by", "an", "angiotensin", "-", "converting", "enzyme", "inhibitor", ",", "captopril", "."], "event_mentions": [{"id": "1569260_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "1569260_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "1569260_2_Ent1", "role": "Effect", "text": "pemphigus", "start": 8, "end": 9}, {"entity_id": "1569260_2_Ent2", "role": "Treatment", "text": "captopril", "start": 18, "end": 19}, {"entity_id": "1569260_2_Ent3", "role": "Treatment_Drug", "text": "captopril", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "1569260_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1569260_2_Ent1", "text": "pemphigus", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1569260_2_Ent2", "text": "captopril", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "1569260_2_Ent3", "text": "captopril", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "15701285_2", "wnd_id": "15701285_2_1", "text": "Following are two clinical case reports demonstrating profound cerebral edema associated with implantation of Gliadel wafers .", "tokens": ["Following", "are", "two", "clinical", "case", "reports", "demonstrating", "profound", "cerebral", "edema", "associated", "with", "implantation", "of", "Gliadel", "wafers", "."], "event_mentions": [{"id": "15701285_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 10, "end": 11}, "arguments": [{"entity_id": "15701285_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "15701285_2_Ent0", "role": "Subject", "text": "two clinical case", "start": 2, "end": 5}, {"entity_id": "15701285_2_Ent2", "role": "Effect", "text": "profound cerebral edema", "start": 7, "end": 10}, {"entity_id": "15701285_2_Ent4", "role": "Treatment_Route", "text": "implantation", "start": 12, "end": 13}, {"entity_id": "15701285_2_Ent3", "role": "Treatment", "text": "implantation of Gliadel wafers", "start": 12, "end": 16}, {"entity_id": "15701285_2_Ent5", "role": "Treatment_Drug", "text": "Gliadel wafers", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "15701285_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15701285_2_Ent0", "text": "two clinical case", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "15701285_2_Ent2", "text": "profound cerebral edema", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15701285_2_Ent4", "text": "implantation", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15701285_2_Ent3", "text": "implantation of Gliadel wafers", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "15701285_2_Ent5", "text": "Gliadel wafers", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "15729090_1", "wnd_id": "15729090_1_1", "text": "Quetiapine - induced myoclonus .", "tokens": ["Quetiapine", "-", "induced", "myoclonus", "."], "event_mentions": [{"id": "15729090_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15729090_1_Ent1", "role": "Treatment", "text": "Quetiapine", "start": 0, "end": 1}, {"entity_id": "15729090_1_Ent2", "role": "Treatment_Drug", "text": "Quetiapine", "start": 0, "end": 1}, {"entity_id": "15729090_1_Ent0", "role": "Effect", "text": "myoclonus", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "15729090_1_Ent1", "text": "Quetiapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15729090_1_Ent2", "text": "Quetiapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15729090_1_Ent0", "text": "myoclonus", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "15735923_3", "wnd_id": "15735923_3_1", "text": "We report a 44 - year - old woman with t - MDS ( refractory anemia with excess blasts ) following treatment of recurrent anaplastic astrocytoma with temozolomide ( TMZ ) .", "tokens": ["We", "report", "a", "44", "-", "year", "-", "old", "woman", "with", "t", "-", "MDS", "(", "refractory", "anemia", "with", "excess", "blasts", ")", "following", "treatment", "of", "recurrent", "anaplastic", "astrocytoma", "with", "temozolomide", "(", "TMZ", ")", "."], "event_mentions": [{"id": "15735923_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 20, "end": 21}, "arguments": [{"entity_id": "15735923_3_Ent3", "role": "Subject_Population", "text": "a", "start": 2, "end": 3}, {"entity_id": "15735923_3_Ent0", "role": "Subject", "text": "a 44 - year - old woman", "start": 2, "end": 9}, {"entity_id": "15735923_3_Ent1", "role": "Subject_Age", "text": "44 - year - old", "start": 3, "end": 8}, {"entity_id": "15735923_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "15735923_3_Ent4", "role": "Effect", "text": "t - MDS ( refractory anemia with excess blasts )", "start": 10, "end": 20}, {"entity_id": "15735923_3_Ent5", "role": "Treatment", "text": "treatment of recurrent anaplastic astrocytoma with temozolomide ( TMZ )", "start": 21, "end": 31}, {"entity_id": "15735923_3_Ent6", "role": "Treatment_Disorder", "text": "recurrent anaplastic astrocytoma", "start": 23, "end": 26}, {"entity_id": "15735923_3_Ent7", "role": "Treatment_Drug", "text": "temozolomide", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "15735923_3_Ent3", "text": "a", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15735923_3_Ent0", "text": "a 44 - year - old woman", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "15735923_3_Ent1", "text": "44 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "15735923_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15735923_3_Ent4", "text": "t - MDS ( refractory anemia with excess blasts )", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "15735923_3_Ent5", "text": "treatment of recurrent anaplastic astrocytoma with temozolomide ( TMZ )", "entity_type": "Entity", "start": 21, "end": 31}, {"id": "15735923_3_Ent6", "text": "recurrent anaplastic astrocytoma", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "15735923_3_Ent7", "text": "temozolomide", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "15735923_5", "wnd_id": "15735923_5_1", "text": "MDS was diagnosed 8.4 months after beginning TMZ .", "tokens": ["MDS", "was", "diagnosed", "8.4", "months", "after", "beginning", "TMZ", "."], "event_mentions": [{"id": "15735923_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 2, "end": 3}, "arguments": [{"entity_id": "15735923_5_Ent0", "role": "Effect", "text": "MDS", "start": 0, "end": 1}, {"entity_id": "15735923_5_Ent3", "role": "Treatment_Time_elapsed", "text": "8.4 months", "start": 3, "end": 5}, {"entity_id": "15735923_5_Ent1", "role": "Treatment", "text": "8.4 months after beginning TMZ", "start": 3, "end": 8}, {"entity_id": "15735923_5_Ent2", "role": "Treatment_Drug", "text": "TMZ", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "15735923_5_Ent0", "text": "MDS", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15735923_5_Ent3", "text": "8.4 months", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "15735923_5_Ent1", "text": "8.4 months after beginning TMZ", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "15735923_5_Ent2", "text": "TMZ", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "15752306_1", "wnd_id": "15752306_1_1", "text": "Livedo reticularis associated with interferon alpha therapy in two melanoma patients .", "tokens": ["Livedo", "reticularis", "associated", "with", "interferon", "alpha", "therapy", "in", "two", "melanoma", "patients", "."], "event_mentions": [{"id": "15752306_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "15752306_1_Ent2", "role": "Effect", "text": "Livedo reticularis", "start": 0, "end": 2}, {"entity_id": "15752306_1_Ent5", "role": "Treatment_Drug", "text": "interferon alpha", "start": 4, "end": 6}, {"entity_id": "15752306_1_Ent3", "role": "Treatment", "text": "interferon alpha therapy", "start": 4, "end": 7}, {"entity_id": "15752306_1_Ent1", "role": "Subject_Population", "text": "two", "start": 8, "end": 9}, {"entity_id": "15752306_1_Ent0", "role": "Subject", "text": "two melanoma patients", "start": 8, "end": 11}, {"entity_id": "15752306_1_Ent4", "role": "Treatment_Disorder", "text": "melanoma", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15752306_1_Ent2", "text": "Livedo reticularis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15752306_1_Ent5", "text": "interferon alpha", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15752306_1_Ent3", "text": "interferon alpha therapy", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "15752306_1_Ent1", "text": "two", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15752306_1_Ent0", "text": "two melanoma patients", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "15752306_1_Ent4", "text": "melanoma", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15752306_6", "wnd_id": "15752306_6_1", "text": "These cases highlight the occurrence of livedo reticularis as an uncommon side - effect of interferon alpha treatment .", "tokens": ["These", "cases", "highlight", "the", "occurrence", "of", "livedo", "reticularis", "as", "an", "uncommon", "side", "-", "effect", "of", "interferon", "alpha", "treatment", "."], "event_mentions": [{"id": "15752306_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side - effect", "start": 11, "end": 14}, "arguments": [{"entity_id": "15752306_6_Ent0", "role": "Subject", "text": "These cases", "start": 0, "end": 2}, {"entity_id": "15752306_6_Ent1", "role": "Effect", "text": "livedo reticularis", "start": 6, "end": 8}, {"entity_id": "15752306_6_Ent2", "role": "Treatment", "text": "interferon alpha", "start": 15, "end": 17}, {"entity_id": "15752306_6_Ent3", "role": "Treatment_Drug", "text": "interferon alpha", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "15752306_6_Ent0", "text": "These cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15752306_6_Ent1", "text": "livedo reticularis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15752306_6_Ent2", "text": "interferon alpha", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "15752306_6_Ent3", "text": "interferon alpha", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "15760792_3", "wnd_id": "15760792_3_1", "text": "Propylthiouracil - induced sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies .", "tokens": ["Propylthiouracil", "-", "induced", "sensorineural", "hearing", "loss", "associated", "with", "antineutrophil", "cytoplasmic", "antibodies", "."], "event_mentions": [{"id": "15760792_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15760792_3_Ent1", "role": "Treatment", "text": "Propylthiouracil", "start": 0, "end": 1}, {"entity_id": "15760792_3_Ent2", "role": "Treatment_Drug", "text": "Propylthiouracil", "start": 0, "end": 1}, {"entity_id": "15760792_3_Ent0", "role": "Effect", "text": "sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies", "start": 3, "end": 11}]}], "entity_mentions": [{"id": "15760792_3_Ent1", "text": "Propylthiouracil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15760792_3_Ent2", "text": "Propylthiouracil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15760792_3_Ent0", "text": "sensorineural hearing loss associated with antineutrophil cytoplasmic antibodies", "entity_type": "Entity", "start": 3, "end": 11}], "lang": "en"}
{"doc_id": "15773973_2", "wnd_id": "15773973_2_1", "text": "It is well - recognized that flucloxacillin may occasionally result in fatal hepatic injury .", "tokens": ["It", "is", "well", "-", "recognized", "that", "flucloxacillin", "may", "occasionally", "result", "in", "fatal", "hepatic", "injury", "."], "event_mentions": [{"id": "15773973_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 9, "end": 10}, "arguments": [{"entity_id": "15773973_2_Ent1", "role": "Treatment", "text": "flucloxacillin", "start": 6, "end": 7}, {"entity_id": "15773973_2_Ent2", "role": "Treatment_Drug", "text": "flucloxacillin", "start": 6, "end": 7}, {"entity_id": "15773973_2_Ent0", "role": "Effect", "text": "hepatic injury", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "15773973_2_Ent1", "text": "flucloxacillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15773973_2_Ent2", "text": "flucloxacillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15773973_2_Ent0", "text": "hepatic injury", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "15779196_1", "wnd_id": "15779196_1_1", "text": "Four days after intravenous Zoledronic acid , the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm .", "tokens": ["Four", "days", "after", "intravenous", "Zoledronic", "acid", ",", "the", "patient", "presented", "to", "emergency", "room", "with", "complaints", "of", "carpopedal", "spasm", "and", "bronchospasm", "."], "event_mentions": [{"id": "15779196_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complaints", "start": 14, "end": 15}, "arguments": [{"entity_id": "15779196_1_Ent3", "role": "Treatment_Time_elapsed", "text": "Four days after", "start": 0, "end": 3}, {"entity_id": "15779196_1_Ent2", "role": "Treatment", "text": "Four days after intravenous Zoledronic acid", "start": 0, "end": 6}, {"entity_id": "15779196_1_Ent4", "role": "Treatment_Route", "text": "intravenous", "start": 3, "end": 4}, {"entity_id": "15779196_1_Ent5", "role": "Treatment_Drug", "text": "Zoledronic acid", "start": 4, "end": 6}, {"entity_id": "15779196_1_Ent0", "role": "Subject", "text": "patient", "start": 8, "end": 9}, {"entity_id": "15779196_1_Ent1", "role": "Effect", "text": "carpopedal spasm and bronchospasm", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "15779196_1_Ent3", "text": "Four days after", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15779196_1_Ent2", "text": "Four days after intravenous Zoledronic acid", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "15779196_1_Ent4", "text": "intravenous", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15779196_1_Ent5", "text": "Zoledronic acid", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15779196_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15779196_1_Ent1", "text": "carpopedal spasm and bronchospasm", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "15785053_1", "wnd_id": "15785053_1_1", "text": "Mucosal pigmentation after oral lichen planus treatment with topical tacrolimus .", "tokens": ["Mucosal", "pigmentation", "after", "oral", "lichen", "planus", "treatment", "with", "topical", "tacrolimus", "."], "event_mentions": [{"id": "15785053_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 6, "end": 7}, "arguments": [{"entity_id": "15785053_1_Ent0", "role": "Effect", "text": "Mucosal pigmentation", "start": 0, "end": 2}, {"entity_id": "15785053_1_Ent2", "role": "Treatment_Disorder", "text": "oral lichen planus", "start": 3, "end": 6}, {"entity_id": "15785053_1_Ent4", "role": "Treatment_Route", "text": "topical", "start": 8, "end": 9}, {"entity_id": "15785053_1_Ent1", "role": "Treatment", "text": "topical tacrolimus", "start": 8, "end": 10}, {"entity_id": "15785053_1_Ent3", "role": "Treatment_Drug", "text": "tacrolimus", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15785053_1_Ent0", "text": "Mucosal pigmentation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15785053_1_Ent2", "text": "oral lichen planus", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15785053_1_Ent4", "text": "topical", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15785053_1_Ent1", "text": "topical tacrolimus", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15785053_1_Ent3", "text": "tacrolimus", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15806568_1", "wnd_id": "15806568_1_1", "text": "In this study , we report on three individual patients who received BTX - B and who subsequently developed parasympathetic dysfunction of the visual system after injections of BTX - B at remote sites .", "tokens": ["In", "this", "study", ",", "we", "report", "on", "three", "individual", "patients", "who", "received", "BTX", "-", "B", "and", "who", "subsequently", "developed", "parasympathetic", "dysfunction", "of", "the", "visual", "system", "after", "injections", "of", "BTX", "-", "B", "at", "remote", "sites", "."], "event_mentions": [{"id": "15806568_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "15806568_1_Ent1", "role": "Subject_Population", "text": "three", "start": 7, "end": 8}, {"entity_id": "15806568_1_Ent0", "role": "Subject", "text": "three individual patients", "start": 7, "end": 10}, {"entity_id": "15806568_1_Ent3", "role": "Treatment", "text": "BTX - B", "start": 12, "end": 15}, {"entity_id": "15806568_1_Ent5", "role": "Treatment_Drug", "text": "BTX - B", "start": 12, "end": 15}, {"entity_id": "15806568_1_Ent2", "role": "Effect", "text": "parasympathetic dysfunction of the visual system", "start": 19, "end": 25}, {"entity_id": "15806568_1_Ent4", "role": "Treatment", "text": "BTX - B", "start": 28, "end": 31}, {"entity_id": "15806568_1_Ent6", "role": "Treatment_Drug", "text": "BTX - B", "start": 28, "end": 31}]}], "entity_mentions": [{"id": "15806568_1_Ent1", "text": "three", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15806568_1_Ent0", "text": "three individual patients", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "15806568_1_Ent3", "text": "BTX - B", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "15806568_1_Ent5", "text": "BTX - B", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "15806568_1_Ent2", "text": "parasympathetic dysfunction of the visual system", "entity_type": "Entity", "start": 19, "end": 25}, {"id": "15806568_1_Ent4", "text": "BTX - B", "entity_type": "Entity", "start": 28, "end": 31}, {"id": "15806568_1_Ent6", "text": "BTX - B", "entity_type": "Entity", "start": 28, "end": 31}], "lang": "en"}
{"doc_id": "15827071_13", "wnd_id": "15827071_13_1", "text": "A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid , generally within 1 - 3 days .", "tokens": ["A", "review", "of", "published", "case", "reports", "showed", "a", "short", "time", "to", "onset", "of", "symptoms", "following", "the", "introduction", "of", "linezolid", ",", "generally", "within", "1", "-", "3", "days", "."], "event_mentions": [{"id": "15827071_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 14, "end": 15}, "arguments": [{"entity_id": "15827071_13_Ent0", "role": "Effect", "text": "a short time to onset of symptoms", "start": 7, "end": 14}, {"entity_id": "15827071_13_Ent1", "role": "Treatment", "text": "introduction of linezolid , generally within 1 - 3 days", "start": 16, "end": 26}, {"entity_id": "15827071_13_Ent2", "role": "Treatment_Drug", "text": "linezolid", "start": 18, "end": 19}, {"entity_id": "15827071_13_Ent3", "role": "Treatment_Time_elapsed", "text": "within 1 - 3 days", "start": 21, "end": 26}]}], "entity_mentions": [{"id": "15827071_13_Ent0", "text": "a short time to onset of symptoms", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "15827071_13_Ent1", "text": "introduction of linezolid , generally within 1 - 3 days", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "15827071_13_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15827071_13_Ent3", "text": "within 1 - 3 days", "entity_type": "Entity", "start": 21, "end": 26}], "lang": "en"}
{"doc_id": "15827071_8", "wnd_id": "15827071_8_1", "text": "A 37 - year - old male with multiple myeloma received citalopram 40 mg / day and trazodone 150 mg / day for anxiety - related disorders .", "tokens": ["A", "37", "-", "year", "-", "old", "male", "with", "multiple", "myeloma", "received", "citalopram", "40", "mg", "/", "day", "and", "trazodone", "150", "mg", "/", "day", "for", "anxiety", "-", "related", "disorders", "."], "event_mentions": [{"id": "15827071_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 22, "end": 23}, "arguments": [{"entity_id": "15827071_8_Ent0", "role": "Subject", "text": "A 37 - year - old male with multiple myeloma", "start": 0, "end": 10}, {"entity_id": "15827071_8_Ent1", "role": "Subject_Age", "text": "37 - year - old", "start": 1, "end": 6}, {"entity_id": "15827071_8_Ent2", "role": "Subject_Gender", "text": "male", "start": 6, "end": 7}, {"entity_id": "15827071_8_Ent3", "role": "Subject_Disorder", "text": "multiple myeloma", "start": 8, "end": 10}, {"entity_id": "15827071_8_Ent6", "role": "Treatment_Drug", "text": "citalopram", "start": 11, "end": 12}, {"entity_id": "15827071_8_Ent10", "role": "Combination_Drug", "text": "citalopram", "start": 11, "end": 12}, {"entity_id": "15827071_8_Ent4", "role": "Treatment", "text": "citalopram 40 mg / day and trazodone 150 mg / day", "start": 11, "end": 22}, {"entity_id": "15827071_8_Ent8", "role": "Treatment_Dosage", "text": "40 mg / day", "start": 12, "end": 16}, {"entity_id": "15827071_8_Ent7", "role": "Treatment_Drug", "text": "trazodone", "start": 17, "end": 18}, {"entity_id": "15827071_8_Ent11", "role": "Combination_Drug", "text": "trazodone", "start": 17, "end": 18}, {"entity_id": "15827071_8_Ent9", "role": "Treatment_Dosage", "text": "150 mg / day", "start": 18, "end": 22}, {"entity_id": "15827071_8_Ent5", "role": "Treatment_Disorder", "text": "anxiety - related disorders", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "15827071_8_Ent0", "text": "A 37 - year - old male with multiple myeloma", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "15827071_8_Ent1", "text": "37 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "15827071_8_Ent2", "text": "male", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15827071_8_Ent3", "text": "multiple myeloma", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15827071_8_Ent6", "text": "citalopram", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15827071_8_Ent10", "text": "citalopram", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15827071_8_Ent4", "text": "citalopram 40 mg / day and trazodone 150 mg / day", "entity_type": "Entity", "start": 11, "end": 22}, {"id": "15827071_8_Ent8", "text": "40 mg / day", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "15827071_8_Ent7", "text": "trazodone", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15827071_8_Ent11", "text": "trazodone", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15827071_8_Ent9", "text": "150 mg / day", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "15827071_8_Ent5", "text": "anxiety - related disorders", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "15836666_2", "wnd_id": "15836666_2_1", "text": "We report a case of a 64 - year - old man with secondary adrenocortical insufficiency who has been on a chronic transdermal fentanyl treatment because of sciatic pain syndrome .", "tokens": ["We", "report", "a", "case", "of", "a", "64", "-", "year", "-", "old", "man", "with", "secondary", "adrenocortical", "insufficiency", "who", "has", "been", "on", "a", "chronic", "transdermal", "fentanyl", "treatment", "because", "of", "sciatic", "pain", "syndrome", "."], "event_mentions": [{"id": "15836666_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 12, "end": 13}, "arguments": [{"entity_id": "15836666_2_Ent0", "role": "Subject", "text": "a 64 - year - old man", "start": 5, "end": 12}, {"entity_id": "15836666_2_Ent1", "role": "Subject_Age", "text": "64 - year - old", "start": 6, "end": 11}, {"entity_id": "15836666_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "15836666_2_Ent3", "role": "Effect", "text": "secondary adrenocortical insufficiency", "start": 13, "end": 16}, {"entity_id": "15836666_2_Ent4", "role": "Treatment", "text": "a chronic transdermal fentanyl treatment", "start": 20, "end": 25}, {"entity_id": "15836666_2_Ent8", "role": "Treatment_Freq", "text": "chronic", "start": 21, "end": 22}, {"entity_id": "15836666_2_Ent7", "role": "Treatment_Route", "text": "transdermal", "start": 22, "end": 23}, {"entity_id": "15836666_2_Ent5", "role": "Treatment_Drug", "text": "fentanyl", "start": 23, "end": 24}, {"entity_id": "15836666_2_Ent6", "role": "Treatment_Disorder", "text": "sciatic pain syndrome", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "15836666_2_Ent0", "text": "a 64 - year - old man", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "15836666_2_Ent1", "text": "64 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "15836666_2_Ent2", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15836666_2_Ent3", "text": "secondary adrenocortical insufficiency", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "15836666_2_Ent4", "text": "a chronic transdermal fentanyl treatment", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "15836666_2_Ent8", "text": "chronic", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15836666_2_Ent7", "text": "transdermal", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15836666_2_Ent5", "text": "fentanyl", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15836666_2_Ent6", "text": "sciatic pain syndrome", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "15863610_4", "wnd_id": "15863610_4_1", "text": "We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene , which is also a selective estrogen receptor modulator .", "tokens": ["We", "report", "a", "case", "of", "a", "women", "in", "whom", "a", "malignant", "mixed", "mesodermal", "tumor", "was", "diagnosed", "while", "she", "was", "taking", "raloxifene", ",", "which", "is", "also", "a", "selective", "estrogen", "receptor", "modulator", "."], "event_mentions": [{"id": "15863610_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 15, "end": 16}, "arguments": [{"entity_id": "15863610_4_Ent0", "role": "Subject", "text": "a women", "start": 5, "end": 7}, {"entity_id": "15863610_4_Ent1", "role": "Subject_Gender", "text": "women", "start": 6, "end": 7}, {"entity_id": "15863610_4_Ent2", "role": "Effect", "text": "a malignant mixed mesodermal tumor", "start": 9, "end": 14}, {"entity_id": "15863610_4_Ent3", "role": "Treatment", "text": "while she was taking raloxifene", "start": 16, "end": 21}, {"entity_id": "15863610_4_Ent4", "role": "Treatment_Drug", "text": "raloxifene", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "15863610_4_Ent0", "text": "a women", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15863610_4_Ent1", "text": "women", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15863610_4_Ent2", "text": "a malignant mixed mesodermal tumor", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "15863610_4_Ent3", "text": "while she was taking raloxifene", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "15863610_4_Ent4", "text": "raloxifene", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "15866658_1", "wnd_id": "15866658_1_1", "text": "Herein we report four patients who underwent liver transplantation and developed neutropenia while receiving MMF .", "tokens": ["Herein", "we", "report", "four", "patients", "who", "underwent", "liver", "transplantation", "and", "developed", "neutropenia", "while", "receiving", "MMF", "."], "event_mentions": [{"id": "15866658_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "15866658_1_Ent1", "role": "Subject_Population", "text": "four", "start": 3, "end": 4}, {"entity_id": "15866658_1_Ent0", "role": "Subject", "text": "four patients who underwent liver transplantation", "start": 3, "end": 9}, {"entity_id": "15866658_1_Ent2", "role": "Subject_Disorder", "text": "liver transplantation", "start": 7, "end": 9}, {"entity_id": "15866658_1_Ent3", "role": "Effect", "text": "neutropenia", "start": 11, "end": 12}, {"entity_id": "15866658_1_Ent4", "role": "Treatment", "text": "MMF", "start": 14, "end": 15}, {"entity_id": "15866658_1_Ent5", "role": "Treatment_Drug", "text": "MMF", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "15866658_1_Ent1", "text": "four", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15866658_1_Ent0", "text": "four patients who underwent liver transplantation", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "15866658_1_Ent2", "text": "liver transplantation", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15866658_1_Ent3", "text": "neutropenia", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15866658_1_Ent4", "text": "MMF", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15866658_1_Ent5", "text": "MMF", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "15866658_4", "wnd_id": "15866658_4_1", "text": "The side effects of MMF , such as bone marrow toxicity , have been reported .", "tokens": ["The", "side", "effects", "of", "MMF", ",", "such", "as", "bone", "marrow", "toxicity", ",", "have", "been", "reported", "."], "event_mentions": [{"id": "15866658_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 14, "end": 15}, "arguments": [{"entity_id": "15866658_4_Ent1", "role": "Treatment", "text": "MMF", "start": 4, "end": 5}, {"entity_id": "15866658_4_Ent2", "role": "Treatment_Drug", "text": "MMF", "start": 4, "end": 5}, {"entity_id": "15866658_4_Ent0", "role": "Effect", "text": "bone marrow toxicity", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "15866658_4_Ent1", "text": "MMF", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15866658_4_Ent2", "text": "MMF", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15866658_4_Ent0", "text": "bone marrow toxicity", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "15878975_2", "wnd_id": "15878975_2_1", "text": "Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D ) immune globulin intravenous administration for immune thrombocytopenic purpura .", "tokens": ["Disseminated", "intravascular", "coagulation", "associated", "with", "acute", "hemoglobinemia", "or", "hemoglobinuria", "following", "Rh(0)(D", ")", "immune", "globulin", "intravenous", "administration", "for", "immune", "thrombocytopenic", "purpura", "."], "event_mentions": [{"id": "15878975_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "15878975_2_Ent0", "role": "Effect", "text": "Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria", "start": 0, "end": 9}, {"entity_id": "15878975_2_Ent2", "role": "Treatment_Drug", "text": "Rh(0)(D ) immune globulin", "start": 10, "end": 14}, {"entity_id": "15878975_2_Ent1", "role": "Treatment", "text": "Rh(0)(D ) immune globulin intravenous", "start": 10, "end": 15}, {"entity_id": "15878975_2_Ent3", "role": "Treatment_Route", "text": "intravenous", "start": 14, "end": 15}, {"entity_id": "15878975_2_Ent4", "role": "Treatment_Disorder", "text": "immune thrombocytopenic purpura", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "15878975_2_Ent0", "text": "Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "15878975_2_Ent2", "text": "Rh(0)(D ) immune globulin", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "15878975_2_Ent1", "text": "Rh(0)(D ) immune globulin intravenous", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "15878975_2_Ent3", "text": "intravenous", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15878975_2_Ent4", "text": "immune thrombocytopenic purpura", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "15895899_1", "wnd_id": "15895899_1_1", "text": "After the second infliximab infusion , he was found to have a severe transient neutropenia ( 0.5 x 10(9)/L ) .", "tokens": ["After", "the", "second", "infliximab", "infusion", ",", "he", "was", "found", "to", "have", "a", "severe", "transient", "neutropenia", "(", "0.5", "x", "10(9)/L", ")", "."], "event_mentions": [{"id": "15895899_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "found", "start": 8, "end": 9}, "arguments": [{"entity_id": "15895899_1_Ent3", "role": "Treatment", "text": "infliximab", "start": 3, "end": 4}, {"entity_id": "15895899_1_Ent4", "role": "Treatment_Drug", "text": "infliximab", "start": 3, "end": 4}, {"entity_id": "15895899_1_Ent5", "role": "Treatment_Route", "text": "infusion", "start": 4, "end": 5}, {"entity_id": "15895899_1_Ent0", "role": "Subject", "text": "he", "start": 6, "end": 7}, {"entity_id": "15895899_1_Ent1", "role": "Subject_Gender", "text": "he", "start": 6, "end": 7}, {"entity_id": "15895899_1_Ent2", "role": "Effect", "text": "severe transient neutropenia ( 0.5 x 10(9)/L )", "start": 12, "end": 20}]}], "entity_mentions": [{"id": "15895899_1_Ent3", "text": "infliximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15895899_1_Ent4", "text": "infliximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15895899_1_Ent5", "text": "infusion", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15895899_1_Ent0", "text": "he", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15895899_1_Ent1", "text": "he", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15895899_1_Ent2", "text": "severe transient neutropenia ( 0.5 x 10(9)/L )", "entity_type": "Entity", "start": 12, "end": 20}], "lang": "en"}
{"doc_id": "15895899_2", "wnd_id": "15895899_2_1", "text": "Drug - induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy .", "tokens": ["Drug", "-", "induced", "agranulocytosis", "during", "treatment", "with", "infliximab", "in", "enteropathic", "spondyloarthropathy", "."], "event_mentions": [{"id": "15895899_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 4, "end": 5}, "arguments": [{"entity_id": "15895899_2_Ent0", "role": "Effect", "text": "Drug - induced agranulocytosis", "start": 0, "end": 4}, {"entity_id": "15895899_2_Ent1", "role": "Treatment", "text": "infliximab", "start": 7, "end": 8}, {"entity_id": "15895899_2_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 7, "end": 8}, {"entity_id": "15895899_2_Ent3", "role": "Treatment_Disorder", "text": "enteropathic spondyloarthropathy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "15895899_2_Ent0", "text": "Drug - induced agranulocytosis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15895899_2_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15895899_2_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15895899_2_Ent3", "text": "enteropathic spondyloarthropathy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "15920338_2", "wnd_id": "15920338_2_1", "text": "High - grade endometrial stromal sarcoma after tamoxifen therapy for breast cancer .", "tokens": ["High", "-", "grade", "endometrial", "stromal", "sarcoma", "after", "tamoxifen", "therapy", "for", "breast", "cancer", "."], "event_mentions": [{"id": "15920338_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "15920338_2_Ent0", "role": "Effect", "text": "High - grade endometrial stromal sarcoma", "start": 0, "end": 6}, {"entity_id": "15920338_2_Ent1", "role": "Treatment", "text": "tamoxifen", "start": 7, "end": 8}, {"entity_id": "15920338_2_Ent2", "role": "Treatment_Drug", "text": "tamoxifen", "start": 7, "end": 8}, {"entity_id": "15920338_2_Ent3", "role": "Treatment_Disorder", "text": "breast cancer", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "15920338_2_Ent0", "text": "High - grade endometrial stromal sarcoma", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "15920338_2_Ent1", "text": "tamoxifen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15920338_2_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15920338_2_Ent3", "text": "breast cancer", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "15920338_3", "wnd_id": "15920338_3_1", "text": "In deciding if tamoxifen therapy is warranted , all potentially life - threatening adverse events associated with tamoxifen should be considered , including endometrial adenocarcinoma or uterine sarcoma .", "tokens": ["In", "deciding", "if", "tamoxifen", "therapy", "is", "warranted", ",", "all", "potentially", "life", "-", "threatening", "adverse", "events", "associated", "with", "tamoxifen", "should", "be", "considered", ",", "including", "endometrial", "adenocarcinoma", "or", "uterine", "sarcoma", "."], "event_mentions": [{"id": "15920338_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 15, "end": 17}, "arguments": [{"entity_id": "15920338_3_Ent3", "role": "Treatment_Drug", "text": "tamoxifen", "start": 3, "end": 4}, {"entity_id": "15920338_3_Ent5", "role": "Treatment_Drug", "text": "tamoxifen", "start": 3, "end": 4}, {"entity_id": "15920338_3_Ent0", "role": "Effect", "text": "potentially life - threatening adverse events", "start": 9, "end": 15}, {"entity_id": "15920338_3_Ent2", "role": "Treatment", "text": "tamoxifen", "start": 17, "end": 18}, {"entity_id": "15920338_3_Ent4", "role": "Treatment_Drug", "text": "tamoxifen", "start": 17, "end": 18}, {"entity_id": "15920338_3_Ent1", "role": "Effect", "text": "including endometrial adenocarcinoma or uterine sarcoma", "start": 22, "end": 28}]}], "entity_mentions": [{"id": "15920338_3_Ent3", "text": "tamoxifen", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15920338_3_Ent5", "text": "tamoxifen", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15920338_3_Ent0", "text": "potentially life - threatening adverse events", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "15920338_3_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15920338_3_Ent4", "text": "tamoxifen", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15920338_3_Ent1", "text": "including endometrial adenocarcinoma or uterine sarcoma", "entity_type": "Entity", "start": 22, "end": 28}], "lang": "en"}
{"doc_id": "15927910_2", "wnd_id": "15927910_2_1", "text": "Although various manifestations of pentamidine - induced cardiotoxicity have been reported , to our knowledge , second - degree heart block associated with this agent has not been described .", "tokens": ["Although", "various", "manifestations", "of", "pentamidine", "-", "induced", "cardiotoxicity", "have", "been", "reported", ",", "to", "our", "knowledge", ",", "second", "-", "degree", "heart", "block", "associated", "with", "this", "agent", "has", "not", "been", "described", "."], "event_mentions": [{"id": "15927910_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "15927910_2_Ent1", "role": "Treatment", "text": "pentamidine", "start": 4, "end": 5}, {"entity_id": "15927910_2_Ent2", "role": "Treatment_Drug", "text": "pentamidine", "start": 4, "end": 5}, {"entity_id": "15927910_2_Ent0", "role": "Effect", "text": "cardiotoxicity", "start": 7, "end": 8}]}, {"id": "15927910_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 21, "end": 22}, "arguments": [{"entity_id": "15927910_2_Ent4", "role": "Treatment", "text": "pentamidine", "start": 4, "end": 5}, {"entity_id": "15927910_2_Ent5", "role": "Treatment_Drug", "text": "pentamidine", "start": 4, "end": 5}, {"entity_id": "15927910_2_Ent3", "role": "Effect", "text": "second - degree heart block", "start": 16, "end": 21}]}], "entity_mentions": [{"id": "15927910_2_Ent1", "text": "pentamidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15927910_2_Ent2", "text": "pentamidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15927910_2_Ent4", "text": "pentamidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15927910_2_Ent5", "text": "pentamidine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15927910_2_Ent0", "text": "cardiotoxicity", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15927910_2_Ent3", "text": "second - degree heart block", "entity_type": "Entity", "start": 16, "end": 21}], "lang": "en"}
{"doc_id": "1592841_2", "wnd_id": "1592841_2_1", "text": "RESULTS : Both patients experienced a previously unreported side effect -- falling backward -- associated with bupropion use .", "tokens": ["RESULTS", ":", "Both", "patients", "experienced", "a", "previously", "unreported", "side", "effect", "--", "falling", "backward", "--", "associated", "with", "bupropion", "use", "."], "event_mentions": [{"id": "1592841_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 14, "end": 15}, "arguments": [{"entity_id": "1592841_2_Ent1", "role": "Subject_Population", "text": "Both", "start": 2, "end": 3}, {"entity_id": "1592841_2_Ent0", "role": "Subject", "text": "Both patients", "start": 2, "end": 4}, {"entity_id": "1592841_2_Ent2", "role": "Effect", "text": "falling backward", "start": 11, "end": 13}, {"entity_id": "1592841_2_Ent3", "role": "Treatment", "text": "bupropion", "start": 16, "end": 17}, {"entity_id": "1592841_2_Ent4", "role": "Treatment_Drug", "text": "bupropion", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "1592841_2_Ent1", "text": "Both", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "1592841_2_Ent0", "text": "Both patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1592841_2_Ent2", "text": "falling backward", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "1592841_2_Ent3", "text": "bupropion", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "1592841_2_Ent4", "text": "bupropion", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "15941649_2", "wnd_id": "15941649_2_1", "text": "The knowledge concerning VGB - associated visual dysfunction in pediatric patients , particularly in those who have been exposed to VGB in utero is limited .", "tokens": ["The", "knowledge", "concerning", "VGB", "-", "associated", "visual", "dysfunction", "in", "pediatric", "patients", ",", "particularly", "in", "those", "who", "have", "been", "exposed", "to", "VGB", "in", "utero", "is", "limited", "."], "event_mentions": [{"id": "15941649_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "15941649_2_Ent3", "role": "Treatment", "text": "VGB", "start": 3, "end": 4}, {"entity_id": "15941649_2_Ent4", "role": "Treatment_Drug", "text": "VGB", "start": 3, "end": 4}, {"entity_id": "15941649_2_Ent2", "role": "Effect", "text": "visual dysfunction", "start": 6, "end": 8}, {"entity_id": "15941649_2_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 9, "end": 10}, {"entity_id": "15941649_2_Ent0", "role": "Subject", "text": "pediatric patients", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "15941649_2_Ent3", "text": "VGB", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15941649_2_Ent4", "text": "VGB", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15941649_2_Ent2", "text": "visual dysfunction", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15941649_2_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15941649_2_Ent0", "text": "pediatric patients", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "15944830_1", "wnd_id": "15944830_1_1", "text": "BACKGROUND : Interferon ( IFN) - associated retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus , but visual function is usually maintained .", "tokens": ["BACKGROUND", ":", "Interferon", "(", "IFN)", "-", "associated", "retinopathy", "is", "typically", "characterized", "by", "retinal", "hemorrhages", "and", "cotton", "wool", "spots", "at", "the", "posterior", "fundus", ",", "but", "visual", "function", "is", "usually", "maintained", "."], "event_mentions": [{"id": "15944830_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "15944830_1_Ent2", "role": "Treatment_Drug", "text": "Interferon", "start": 2, "end": 3}, {"entity_id": "15944830_1_Ent1", "role": "Treatment", "text": "Interferon ( IFN)", "start": 2, "end": 5}, {"entity_id": "15944830_1_Ent0", "role": "Effect", "text": "retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus", "start": 7, "end": 22}]}], "entity_mentions": [{"id": "15944830_1_Ent2", "text": "Interferon", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15944830_1_Ent1", "text": "Interferon ( IFN)", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "15944830_1_Ent0", "text": "retinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus", "entity_type": "Entity", "start": 7, "end": 22}], "lang": "en"}
{"doc_id": "15944830_4", "wnd_id": "15944830_4_1", "text": "Ophthalmologists should be aware of the ocular side effects of IFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia .", "tokens": ["Ophthalmologists", "should", "be", "aware", "of", "the", "ocular", "side", "effects", "of", "IFN", "therapy", "and", "carefully", "monitor", "patients", "for", "the", "possible", "occurrence", "of", "hypoalbuminemia", "and", "thrombocytopenia", "."], "event_mentions": [{"id": "15944830_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "aware", "start": 3, "end": 4}, "arguments": [{"entity_id": "15944830_4_Ent1", "role": "Effect", "text": "ocular side effects", "start": 6, "end": 9}, {"entity_id": "15944830_4_Ent3", "role": "Treatment", "text": "IFN", "start": 10, "end": 11}, {"entity_id": "15944830_4_Ent4", "role": "Treatment_Drug", "text": "IFN", "start": 10, "end": 11}, {"entity_id": "15944830_4_Ent0", "role": "Subject", "text": "patients", "start": 15, "end": 16}, {"entity_id": "15944830_4_Ent2", "role": "Effect", "text": "hypoalbuminemia and thrombocytopenia", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "15944830_4_Ent1", "text": "ocular side effects", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15944830_4_Ent3", "text": "IFN", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15944830_4_Ent4", "text": "IFN", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15944830_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15944830_4_Ent2", "text": "hypoalbuminemia and thrombocytopenia", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "15961942_2", "wnd_id": "15961942_2_1", "text": "OBJECTIVE : To report the late development of immune - mediated diabetes mellitus after completion of alfa - interferon therapy for hepatitis C in an Asian patient .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "late", "development", "of", "immune", "-", "mediated", "diabetes", "mellitus", "after", "completion", "of", "alfa", "-", "interferon", "therapy", "for", "hepatitis", "C", "in", "an", "Asian", "patient", "."], "event_mentions": [{"id": "15961942_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "15961942_2_Ent2", "role": "Effect", "text": "the late development of immune - mediated diabetes mellitus", "start": 4, "end": 13}, {"entity_id": "15961942_2_Ent3", "role": "Treatment", "text": "alfa - interferon", "start": 16, "end": 19}, {"entity_id": "15961942_2_Ent4", "role": "Treatment_Drug", "text": "alfa - interferon", "start": 16, "end": 19}, {"entity_id": "15961942_2_Ent5", "role": "Treatment_Disorder", "text": "hepatitis C", "start": 21, "end": 23}, {"entity_id": "15961942_2_Ent0", "role": "Subject", "text": "an Asian patient", "start": 24, "end": 27}, {"entity_id": "15961942_2_Ent1", "role": "Subject_Race", "text": "Asian", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "15961942_2_Ent2", "text": "the late development of immune - mediated diabetes mellitus", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "15961942_2_Ent3", "text": "alfa - interferon", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "15961942_2_Ent4", "text": "alfa - interferon", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "15961942_2_Ent5", "text": "hepatitis C", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "15961942_2_Ent0", "text": "an Asian patient", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "15961942_2_Ent1", "text": "Asian", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "15965422_1", "wnd_id": "15965422_1_1", "text": "Cutaneous necrosis after injection of polyethylene glycol - modified interferon alfa .", "tokens": ["Cutaneous", "necrosis", "after", "injection", "of", "polyethylene", "glycol", "-", "modified", "interferon", "alfa", "."], "event_mentions": [{"id": "15965422_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "15965422_1_Ent0", "role": "Effect", "text": "Cutaneous necrosis", "start": 0, "end": 2}, {"entity_id": "15965422_1_Ent3", "role": "Treatment_Route", "text": "injection", "start": 3, "end": 4}, {"entity_id": "15965422_1_Ent1", "role": "Treatment", "text": "injection of polyethylene glycol - modified interferon alfa", "start": 3, "end": 11}, {"entity_id": "15965422_1_Ent2", "role": "Treatment_Drug", "text": "polyethylene glycol - modified interferon alfa .", "start": 5, "end": 12}]}], "entity_mentions": [{"id": "15965422_1_Ent0", "text": "Cutaneous necrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15965422_1_Ent3", "text": "injection", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15965422_1_Ent1", "text": "injection of polyethylene glycol - modified interferon alfa", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "15965422_1_Ent2", "text": "polyethylene glycol - modified interferon alfa .", "entity_type": "Entity", "start": 5, "end": 12}], "lang": "en"}
{"doc_id": "16005413_2", "wnd_id": "16005413_2_1", "text": "To describe the potential for interaction between opioids and serotonergic antidepressants leading to the development of serotonin syndrome ( SS ) , mechanism of the interaction , and the spectrum of SS in elderly residents of a long - term care facility .", "tokens": ["To", "describe", "the", "potential", "for", "interaction", "between", "opioids", "and", "serotonergic", "antidepressants", "leading", "to", "the", "development", "of", "serotonin", "syndrome", "(", "SS", ")", ",", "mechanism", "of", "the", "interaction", ",", "and", "the", "spectrum", "of", "SS", "in", "elderly", "residents", "of", "a", "long", "-", "term", "care", "facility", "."], "event_mentions": [{"id": "16005413_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "leading", "start": 11, "end": 12}, "arguments": [{"entity_id": "16005413_2_Ent3", "role": "Treatment", "text": "opioids", "start": 7, "end": 8}, {"entity_id": "16005413_2_Ent5", "role": "Treatment_Drug", "text": "opioids", "start": 7, "end": 8}, {"entity_id": "16005413_2_Ent7", "role": "Combination_Drug", "text": "opioids", "start": 7, "end": 8}, {"entity_id": "16005413_2_Ent4", "role": "Treatment", "text": "serotonergic antidepressants", "start": 9, "end": 11}, {"entity_id": "16005413_2_Ent6", "role": "Treatment_Drug", "text": "serotonergic antidepressants", "start": 9, "end": 11}, {"entity_id": "16005413_2_Ent8", "role": "Combination_Drug", "text": "serotonergic antidepressants", "start": 9, "end": 11}, {"entity_id": "16005413_2_Ent2", "role": "Effect", "text": "serotonin syndrome", "start": 16, "end": 18}, {"entity_id": "16005413_2_Ent1", "role": "Subject_Age", "text": "elderly", "start": 33, "end": 34}, {"entity_id": "16005413_2_Ent0", "role": "Subject", "text": "elderly residents", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "16005413_2_Ent3", "text": "opioids", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16005413_2_Ent5", "text": "opioids", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16005413_2_Ent7", "text": "opioids", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16005413_2_Ent4", "text": "serotonergic antidepressants", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16005413_2_Ent6", "text": "serotonergic antidepressants", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16005413_2_Ent8", "text": "serotonergic antidepressants", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16005413_2_Ent2", "text": "serotonin syndrome", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "16005413_2_Ent1", "text": "elderly", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "16005413_2_Ent0", "text": "elderly residents", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "16005413_9", "wnd_id": "16005413_9_1", "text": "While many can benefit from coadministration of serotonergic antidepressants and opioids , it appears that some individuals are at increased risk for SS .", "tokens": ["While", "many", "can", "benefit", "from", "coadministration", "of", "serotonergic", "antidepressants", "and", "opioids", ",", "it", "appears", "that", "some", "individuals", "are", "at", "increased", "risk", "for", "SS", "."], "event_mentions": [{"id": "16005413_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 20, "end": 21}, "arguments": [{"entity_id": "16005413_9_Ent2", "role": "Treatment", "text": "coadministration of serotonergic antidepressants and opioids", "start": 5, "end": 11}, {"entity_id": "16005413_9_Ent3", "role": "Treatment_Drug", "text": "serotonergic antidepressants", "start": 7, "end": 9}, {"entity_id": "16005413_9_Ent6", "role": "Combination_Drug", "text": "serotonergic antidepressants", "start": 7, "end": 9}, {"entity_id": "16005413_9_Ent4", "role": "Treatment_Drug", "text": "opioids", "start": 10, "end": 11}, {"entity_id": "16005413_9_Ent5", "role": "Combination_Drug", "text": "opioids", "start": 10, "end": 11}, {"entity_id": "16005413_9_Ent0", "role": "Subject", "text": "some individuals", "start": 15, "end": 17}, {"entity_id": "16005413_9_Ent1", "role": "Effect", "text": "SS", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "16005413_9_Ent2", "text": "coadministration of serotonergic antidepressants and opioids", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "16005413_9_Ent3", "text": "serotonergic antidepressants", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16005413_9_Ent6", "text": "serotonergic antidepressants", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16005413_9_Ent4", "text": "opioids", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16005413_9_Ent5", "text": "opioids", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16005413_9_Ent0", "text": "some individuals", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "16005413_9_Ent1", "text": "SS", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "16018164_4", "wnd_id": "16018164_4_1", "text": "Since 1979 , over 30 published case reports have documented the relationship between phenylpropanolamine and stroke .", "tokens": ["Since", "1979", ",", "over", "30", "published", "case", "reports", "have", "documented", "the", "relationship", "between", "phenylpropanolamine", "and", "stroke", "."], "event_mentions": [{"id": "16018164_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 11, "end": 12}, "arguments": [{"entity_id": "16018164_4_Ent1", "role": "Treatment", "text": "phenylpropanolamine", "start": 13, "end": 14}, {"entity_id": "16018164_4_Ent2", "role": "Treatment_Drug", "text": "phenylpropanolamine", "start": 13, "end": 14}, {"entity_id": "16018164_4_Ent0", "role": "Effect", "text": "stroke", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "16018164_4_Ent1", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16018164_4_Ent2", "text": "phenylpropanolamine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16018164_4_Ent0", "text": "stroke", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "16025424_2", "wnd_id": "16025424_2_1", "text": "We report a case of reversible DKA and new - onset DM that developed in a demented patient who was treated with quetiapine for 14 days .", "tokens": ["We", "report", "a", "case", "of", "reversible", "DKA", "and", "new", "-", "onset", "DM", "that", "developed", "in", "a", "demented", "patient", "who", "was", "treated", "with", "quetiapine", "for", "14", "days", "."], "event_mentions": [{"id": "16025424_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "16025424_2_Ent1", "role": "Effect", "text": "reversible DKA and new - onset DM", "start": 5, "end": 12}, {"entity_id": "16025424_2_Ent3", "role": "Treatment_Disorder", "text": "demented", "start": 16, "end": 17}, {"entity_id": "16025424_2_Ent0", "role": "Subject", "text": "demented patient", "start": 16, "end": 18}, {"entity_id": "16025424_2_Ent4", "role": "Treatment_Drug", "text": "quetiapine", "start": 22, "end": 23}, {"entity_id": "16025424_2_Ent2", "role": "Treatment", "text": "quetiapine for 14 days", "start": 22, "end": 26}, {"entity_id": "16025424_2_Ent5", "role": "Treatment_Duration", "text": "14 days", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "16025424_2_Ent1", "text": "reversible DKA and new - onset DM", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "16025424_2_Ent3", "text": "demented", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16025424_2_Ent0", "text": "demented patient", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "16025424_2_Ent4", "text": "quetiapine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "16025424_2_Ent2", "text": "quetiapine for 14 days", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "16025424_2_Ent5", "text": "14 days", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "16029707_3", "wnd_id": "16029707_3_1", "text": "The multiple comedones and ruptured epidermoid cysts are newly reported adverse effects of imiquimod therapy .", "tokens": ["The", "multiple", "comedones", "and", "ruptured", "epidermoid", "cysts", "are", "newly", "reported", "adverse", "effects", "of", "imiquimod", "therapy", "."], "event_mentions": [{"id": "16029707_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 9, "end": 10}, "arguments": [{"entity_id": "16029707_3_Ent0", "role": "Effect", "text": "multiple comedones and ruptured epidermoid cysts", "start": 1, "end": 7}, {"entity_id": "16029707_3_Ent2", "role": "Treatment_Drug", "text": "imiquimod", "start": 13, "end": 14}, {"entity_id": "16029707_3_Ent1", "role": "Treatment", "text": "imiquimod therapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "16029707_3_Ent0", "text": "multiple comedones and ruptured epidermoid cysts", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "16029707_3_Ent2", "text": "imiquimod", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16029707_3_Ent1", "text": "imiquimod therapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "160443_1", "wnd_id": "160443_1_1", "text": "Five personal observations of an acute amnestic episode in younger individuals after intake of clioquinol are described together with three observations from the medical literature .", "tokens": ["Five", "personal", "observations", "of", "an", "acute", "amnestic", "episode", "in", "younger", "individuals", "after", "intake", "of", "clioquinol", "are", "described", "together", "with", "three", "observations", "from", "the", "medical", "literature", "."], "event_mentions": [{"id": "160443_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "160443_1_Ent2", "role": "Effect", "text": "acute amnestic episode", "start": 5, "end": 8}, {"entity_id": "160443_1_Ent1", "role": "Subject_Age", "text": "younger", "start": 9, "end": 10}, {"entity_id": "160443_1_Ent0", "role": "Subject", "text": "younger individuals", "start": 9, "end": 11}, {"entity_id": "160443_1_Ent5", "role": "Treatment_Route", "text": "intake", "start": 12, "end": 13}, {"entity_id": "160443_1_Ent3", "role": "Treatment", "text": "intake of clioquinol", "start": 12, "end": 15}, {"entity_id": "160443_1_Ent4", "role": "Treatment_Drug", "text": "clioquinol", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "160443_1_Ent2", "text": "acute amnestic episode", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "160443_1_Ent1", "text": "younger", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "160443_1_Ent0", "text": "younger individuals", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "160443_1_Ent5", "text": "intake", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "160443_1_Ent3", "text": "intake of clioquinol", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "160443_1_Ent4", "text": "clioquinol", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "16062101_3", "wnd_id": "16062101_3_1", "text": "The authors report two cases of acute dystonic reactions ( ADRs ) as a side effect of lamivudine .", "tokens": ["The", "authors", "report", "two", "cases", "of", "acute", "dystonic", "reactions", "(", "ADRs", ")", "as", "a", "side", "effect", "of", "lamivudine", "."], "event_mentions": [{"id": "16062101_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "effect", "start": 15, "end": 16}, "arguments": [{"entity_id": "16062101_3_Ent1", "role": "Subject_Population", "text": "two", "start": 3, "end": 4}, {"entity_id": "16062101_3_Ent0", "role": "Subject", "text": "two cases", "start": 3, "end": 5}, {"entity_id": "16062101_3_Ent2", "role": "Effect", "text": "acute dystonic reactions ( ADRs )", "start": 6, "end": 12}, {"entity_id": "16062101_3_Ent3", "role": "Treatment", "text": "lamivudine", "start": 17, "end": 18}, {"entity_id": "16062101_3_Ent4", "role": "Treatment_Drug", "text": "lamivudine", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "16062101_3_Ent1", "text": "two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16062101_3_Ent0", "text": "two cases", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16062101_3_Ent2", "text": "acute dystonic reactions ( ADRs )", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "16062101_3_Ent3", "text": "lamivudine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16062101_3_Ent4", "text": "lamivudine", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "16092915_2", "wnd_id": "16092915_2_1", "text": "OBJECTIVE : To our knowledge , this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new - onset psychotic and increased mood symptoms during treatment with risperidone .", "tokens": ["OBJECTIVE", ":", "To", "our", "knowledge", ",", "this", "is", "the", "first", "published", "case", "report", "of", "an", "adolescent", "girl", "with", "a", "mitochondrial", "disorder", "and", "depression", "who", "displayed", "both", "new", "-", "onset", "psychotic", "and", "increased", "mood", "symptoms", "during", "treatment", "with", "risperidone", "."], "event_mentions": [{"id": "16092915_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 34, "end": 35}, "arguments": [{"entity_id": "16092915_2_Ent0", "role": "Subject", "text": "an adolescent girl with a mitochondrial disorder and depression", "start": 14, "end": 23}, {"entity_id": "16092915_2_Ent1", "role": "Subject_Age", "text": "adolescent", "start": 15, "end": 16}, {"entity_id": "16092915_2_Ent2", "role": "Subject_Gender", "text": "girl", "start": 16, "end": 17}, {"entity_id": "16092915_2_Ent6", "role": "Treatment_Disorder", "text": "mitochondrial disorder", "start": 19, "end": 21}, {"entity_id": "16092915_2_Ent7", "role": "Treatment_Disorder", "text": "depression", "start": 22, "end": 23}, {"entity_id": "16092915_2_Ent3", "role": "Effect", "text": "new - onset psychotic and increased mood symptoms", "start": 26, "end": 34}, {"entity_id": "16092915_2_Ent4", "role": "Treatment", "text": "risperidone", "start": 37, "end": 38}, {"entity_id": "16092915_2_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "16092915_2_Ent0", "text": "an adolescent girl with a mitochondrial disorder and depression", "entity_type": "Entity", "start": 14, "end": 23}, {"id": "16092915_2_Ent1", "text": "adolescent", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16092915_2_Ent2", "text": "girl", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16092915_2_Ent6", "text": "mitochondrial disorder", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "16092915_2_Ent7", "text": "depression", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "16092915_2_Ent3", "text": "new - onset psychotic and increased mood symptoms", "entity_type": "Entity", "start": 26, "end": 34}, {"id": "16092915_2_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "16092915_2_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "16109609_1", "wnd_id": "16109609_1_1", "text": "Gemcitabine - induced pericardial effusion and tamponade after unblocked cardiac irradiation .", "tokens": ["Gemcitabine", "-", "induced", "pericardial", "effusion", "and", "tamponade", "after", "unblocked", "cardiac", "irradiation", "."], "event_mentions": [{"id": "16109609_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16109609_1_Ent1", "role": "Treatment", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "16109609_1_Ent2", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "16109609_1_Ent0", "role": "Effect", "text": "pericardial effusion and tamponade", "start": 3, "end": 7}, {"entity_id": "16109609_1_Ent3", "role": "Treatment_Disorder", "text": "unblocked cardiac irradiation", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "16109609_1_Ent1", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16109609_1_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16109609_1_Ent0", "text": "pericardial effusion and tamponade", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16109609_1_Ent3", "text": "unblocked cardiac irradiation", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "16116136_4", "wnd_id": "16116136_4_1", "text": "Primary CNS lymphoma regressed on withdrawal of MM .", "tokens": ["Primary", "CNS", "lymphoma", "regressed", "on", "withdrawal", "of", "MM", "."], "event_mentions": [{"id": "16116136_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "regressed", "start": 3, "end": 4}, "arguments": [{"entity_id": "16116136_4_Ent0", "role": "Effect", "text": "Primary CNS lymphoma", "start": 0, "end": 3}, {"entity_id": "16116136_4_Ent1", "role": "Treatment", "text": "withdrawal of MM", "start": 5, "end": 8}, {"entity_id": "16116136_4_Ent2", "role": "Treatment_Drug", "text": "MM", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "16116136_4_Ent0", "text": "Primary CNS lymphoma", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16116136_4_Ent1", "text": "withdrawal of MM", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "16116136_4_Ent2", "text": "MM", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "16119501_3", "wnd_id": "16119501_3_1", "text": "The patient continued to have fever and autonomic instability without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral baclofen .", "tokens": ["The", "patient", "continued", "to", "have", "fever", "and", "autonomic", "instability", "without", "evidence", "of", "infection", "which", "entirely", "resolved", "within", "24", "hours", "of", "reinstitution", "of", "full", "preadmission", "dosing", "of", "oral", "baclofen", "."], "event_mentions": [{"id": "16119501_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "have", "start": 4, "end": 5}, "arguments": [{"entity_id": "16119501_3_Ent0", "role": "Effect", "text": "fever and autonomic instability without evidence of infection which entirely resolved", "start": 5, "end": 16}, {"entity_id": "16119501_3_Ent4", "role": "Treatment_Time_elapsed", "text": "24 hours", "start": 17, "end": 19}, {"entity_id": "16119501_3_Ent1", "role": "Treatment", "text": "24 hours of reinstitution of full preadmission dosing of oral baclofen", "start": 17, "end": 28}, {"entity_id": "16119501_3_Ent2", "role": "Treatment_Route", "text": "oral", "start": 26, "end": 27}, {"entity_id": "16119501_3_Ent3", "role": "Treatment_Drug", "text": "baclofen", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "16119501_3_Ent0", "text": "fever and autonomic instability without evidence of infection which entirely resolved", "entity_type": "Entity", "start": 5, "end": 16}, {"id": "16119501_3_Ent4", "text": "24 hours", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "16119501_3_Ent1", "text": "24 hours of reinstitution of full preadmission dosing of oral baclofen", "entity_type": "Entity", "start": 17, "end": 28}, {"id": "16119501_3_Ent2", "text": "oral", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "16119501_3_Ent3", "text": "baclofen", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "16122280_19", "wnd_id": "16122280_19_1", "text": "In phase III clinical trials , the telithromycin 800 mg once - daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae , Haemophilus influenzae and Staphylococcus aureus in patients with community - acquired pneumonia .", "tokens": ["In", "phase", "III", "clinical", "trials", ",", "the", "telithromycin", "800", "mg", "once", "-", "daily", "dose", "has", "been", "shown", "to", "provide", "close", "to", "the", "maximum", "antimicrobial", "activity", "against", "S.", "pneumoniae", ",", "Haemophilus", "influenzae", "and", "Staphylococcus", "aureus", "in", "patients", "with", "community", "-", "acquired", "pneumonia", "."], "event_mentions": [{"id": "16122280_19_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "provide", "start": 18, "end": 19}, "arguments": [{"entity_id": "16122280_19_Ent6", "role": "Treatment_Drug", "text": "telithromycin", "start": 7, "end": 8}, {"entity_id": "16122280_19_Ent1", "role": "Treatment", "text": "telithromycin 800 mg once - daily dose", "start": 7, "end": 14}, {"entity_id": "16122280_19_Ent7", "role": "Treatment_Dosage", "text": "800 mg", "start": 8, "end": 10}, {"entity_id": "16122280_19_Ent8", "role": "Treatment_Freq", "text": "once - daily", "start": 10, "end": 13}, {"entity_id": "16122280_19_Ent2", "role": "Treatment_Disorder", "text": "S. pneumoniae", "start": 26, "end": 28}, {"entity_id": "16122280_19_Ent3", "role": "Treatment_Disorder", "text": "Haemophilus influenzae", "start": 29, "end": 31}, {"entity_id": "16122280_19_Ent4", "role": "Treatment_Disorder", "text": "Staphylococcus aureus", "start": 32, "end": 34}, {"entity_id": "16122280_19_Ent0", "role": "Subject", "text": "patients with community - acquired pneumonia", "start": 35, "end": 41}, {"entity_id": "16122280_19_Ent5", "role": "Treatment_Disorder", "text": "pneumonia", "start": 40, "end": 41}]}], "entity_mentions": [{"id": "16122280_19_Ent6", "text": "telithromycin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16122280_19_Ent1", "text": "telithromycin 800 mg once - daily dose", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "16122280_19_Ent7", "text": "800 mg", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16122280_19_Ent8", "text": "once - daily", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "16122280_19_Ent2", "text": "S. pneumoniae", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "16122280_19_Ent3", "text": "Haemophilus influenzae", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "16122280_19_Ent4", "text": "Staphylococcus aureus", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "16122280_19_Ent0", "text": "patients with community - acquired pneumonia", "entity_type": "Entity", "start": 35, "end": 41}, {"id": "16122280_19_Ent5", "text": "pneumonia", "entity_type": "Entity", "start": 40, "end": 41}], "lang": "en"}
{"doc_id": "16146480_1", "wnd_id": "16146480_1_1", "text": "Can propofol precipitate pancreatitis in patients with Cushing 's syndrome ?", "tokens": ["Can", "propofol", "precipitate", "pancreatitis", "in", "patients", "with", "Cushing", "'s", "syndrome", "?"], "event_mentions": [{"id": "16146480_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitate", "start": 2, "end": 3}, "arguments": [{"entity_id": "16146480_1_Ent2", "role": "Treatment", "text": "propofol", "start": 1, "end": 2}, {"entity_id": "16146480_1_Ent3", "role": "Treatment_Drug", "text": "propofol", "start": 1, "end": 2}, {"entity_id": "16146480_1_Ent1", "role": "Effect", "text": "pancreatitis", "start": 3, "end": 4}, {"entity_id": "16146480_1_Ent0", "role": "Subject", "text": "patients with Cushing 's syndrome ?", "start": 5, "end": 11}, {"entity_id": "16146480_1_Ent4", "role": "Treatment_Disorder", "text": "Cushing 's syndrome", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "16146480_1_Ent2", "text": "propofol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16146480_1_Ent3", "text": "propofol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16146480_1_Ent1", "text": "pancreatitis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16146480_1_Ent0", "text": "patients with Cushing 's syndrome ?", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "16146480_1_Ent4", "text": "Cushing 's syndrome", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "16164579_2", "wnd_id": "16164579_2_1", "text": "To our knowledge , our report is one of the first on shock and angio - oedema from irbesartan .", "tokens": ["To", "our", "knowledge", ",", "our", "report", "is", "one", "of", "the", "first", "on", "shock", "and", "angio", "-", "oedema", "from", "irbesartan", "."], "event_mentions": [{"id": "16164579_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 17, "end": 18}, "arguments": [{"entity_id": "16164579_2_Ent0", "role": "Effect", "text": "shock and angio - oedema", "start": 12, "end": 17}, {"entity_id": "16164579_2_Ent1", "role": "Treatment", "text": "irbesartan", "start": 18, "end": 19}, {"entity_id": "16164579_2_Ent2", "role": "Treatment_Drug", "text": "irbesartan", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "16164579_2_Ent0", "text": "shock and angio - oedema", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "16164579_2_Ent1", "text": "irbesartan", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16164579_2_Ent2", "text": "irbesartan", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "16216617_2", "wnd_id": "16216617_2_1", "text": "While on a maximal dose of phenylephrine she developed prominent positive U waves , which disappeared with the cessation of the drug .", "tokens": ["While", "on", "a", "maximal", "dose", "of", "phenylephrine", "she", "developed", "prominent", "positive", "U", "waves", ",", "which", "disappeared", "with", "the", "cessation", "of", "the", "drug", "."], "event_mentions": [{"id": "16216617_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "16216617_2_Ent4", "role": "Treatment_Dosage", "text": "maximal dose", "start": 3, "end": 5}, {"entity_id": "16216617_2_Ent3", "role": "Treatment", "text": "maximal dose of phenylephrine", "start": 3, "end": 7}, {"entity_id": "16216617_2_Ent5", "role": "Treatment_Drug", "text": "phenylephrine", "start": 6, "end": 7}, {"entity_id": "16216617_2_Ent0", "role": "Subject", "text": "she", "start": 7, "end": 8}, {"entity_id": "16216617_2_Ent1", "role": "Subject_Gender", "text": "she", "start": 7, "end": 8}, {"entity_id": "16216617_2_Ent2", "role": "Effect", "text": "positive U waves", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "16216617_2_Ent4", "text": "maximal dose", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16216617_2_Ent3", "text": "maximal dose of phenylephrine", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16216617_2_Ent5", "text": "phenylephrine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16216617_2_Ent0", "text": "she", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16216617_2_Ent1", "text": "she", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16216617_2_Ent2", "text": "positive U waves", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "16225183_1", "wnd_id": "16225183_1_1", "text": "Nephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a .", "tokens": ["Nephrotic", "syndrome", "in", "a", "multiple", "sclerosis", "patient", "treated", "with", "interferon", "beta", "1a", "."], "event_mentions": [{"id": "16225183_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 7, "end": 8}, "arguments": [{"entity_id": "16225183_1_Ent1", "role": "Effect", "text": "Nephrotic syndrome", "start": 0, "end": 2}, {"entity_id": "16225183_1_Ent0", "role": "Subject", "text": "a multiple sclerosis patient", "start": 3, "end": 7}, {"entity_id": "16225183_1_Ent4", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 4, "end": 6}, {"entity_id": "16225183_1_Ent2", "role": "Treatment", "text": "interferon beta 1a", "start": 9, "end": 12}, {"entity_id": "16225183_1_Ent3", "role": "Treatment_Drug", "text": "interferon beta 1a", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "16225183_1_Ent1", "text": "Nephrotic syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16225183_1_Ent0", "text": "a multiple sclerosis patient", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16225183_1_Ent4", "text": "multiple sclerosis", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "16225183_1_Ent2", "text": "interferon beta 1a", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "16225183_1_Ent3", "text": "interferon beta 1a", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "16237130_1", "wnd_id": "16237130_1_1", "text": "Capecitabine - induced multifocal leukoencephalopathy : a report of five cases .", "tokens": ["Capecitabine", "-", "induced", "multifocal", "leukoencephalopathy", ":", "a", "report", "of", "five", "cases", "."], "event_mentions": [{"id": "16237130_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16237130_1_Ent3", "role": "Treatment", "text": "Capecitabine", "start": 0, "end": 1}, {"entity_id": "16237130_1_Ent4", "role": "Treatment_Drug", "text": "Capecitabine", "start": 0, "end": 1}, {"entity_id": "16237130_1_Ent2", "role": "Effect", "text": "multifocal leukoencephalopathy", "start": 3, "end": 5}, {"entity_id": "16237130_1_Ent1", "role": "Subject_Population", "text": "five", "start": 9, "end": 10}, {"entity_id": "16237130_1_Ent0", "role": "Subject", "text": "five cases", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "16237130_1_Ent3", "text": "Capecitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16237130_1_Ent4", "text": "Capecitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16237130_1_Ent2", "text": "multifocal leukoencephalopathy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16237130_1_Ent1", "text": "five", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16237130_1_Ent0", "text": "five cases", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "16244351_3", "wnd_id": "16244351_3_1", "text": "We report a case admitted with a first - detected , symptomatic paroxysmal atrial fibrillation in a healthy patient after self - medication with vardenafil .", "tokens": ["We", "report", "a", "case", "admitted", "with", "a", "first", "-", "detected", ",", "symptomatic", "paroxysmal", "atrial", "fibrillation", "in", "a", "healthy", "patient", "after", "self", "-", "medication", "with", "vardenafil", "."], "event_mentions": [{"id": "16244351_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 19, "end": 20}, "arguments": [{"entity_id": "16244351_3_Ent1", "role": "Effect", "text": "symptomatic paroxysmal atrial fibrillation", "start": 11, "end": 15}, {"entity_id": "16244351_3_Ent0", "role": "Subject", "text": "a healthy patient", "start": 16, "end": 19}, {"entity_id": "16244351_3_Ent2", "role": "Treatment", "text": "vardenafil", "start": 24, "end": 25}, {"entity_id": "16244351_3_Ent3", "role": "Treatment_Drug", "text": "vardenafil", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "16244351_3_Ent1", "text": "symptomatic paroxysmal atrial fibrillation", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "16244351_3_Ent0", "text": "a healthy patient", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "16244351_3_Ent2", "text": "vardenafil", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16244351_3_Ent3", "text": "vardenafil", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "16249064_1", "wnd_id": "16249064_1_1", "text": "We describe a case of infection with Mycobacterium abscessus in a 67 - year - old woman receiving infliximab as a component of her therapy for RA .", "tokens": ["We", "describe", "a", "case", "of", "infection", "with", "Mycobacterium", "abscessus", "in", "a", "67", "-", "year", "-", "old", "woman", "receiving", "infliximab", "as", "a", "component", "of", "her", "therapy", "for", "RA", "."], "event_mentions": [{"id": "16249064_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 17, "end": 18}, "arguments": [{"entity_id": "16249064_1_Ent4", "role": "Effect", "text": "infection with Mycobacterium abscessus", "start": 5, "end": 9}, {"entity_id": "16249064_1_Ent0", "role": "Subject", "text": "a 67 - year - old woman", "start": 10, "end": 17}, {"entity_id": "16249064_1_Ent2", "role": "Subject_Age", "text": "67 - year - old", "start": 11, "end": 16}, {"entity_id": "16249064_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 16, "end": 17}, {"entity_id": "16249064_1_Ent6", "role": "Treatment_Drug", "text": "infliximab", "start": 18, "end": 19}, {"entity_id": "16249064_1_Ent5", "role": "Treatment", "text": "infliximab as a component of her therapy", "start": 18, "end": 25}, {"entity_id": "16249064_1_Ent1", "role": "Subject", "text": "RA", "start": 26, "end": 27}, {"entity_id": "16249064_1_Ent7", "role": "Treatment_Disorder", "text": "RA", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "16249064_1_Ent4", "text": "infection with Mycobacterium abscessus", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "16249064_1_Ent0", "text": "a 67 - year - old woman", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "16249064_1_Ent2", "text": "67 - year - old", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "16249064_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16249064_1_Ent6", "text": "infliximab", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16249064_1_Ent5", "text": "infliximab as a component of her therapy", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "16249064_1_Ent1", "text": "RA", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "16249064_1_Ent7", "text": "RA", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "16265343_1", "wnd_id": "16265343_1_1", "text": "DIAGNOSIS : Interferon alpha - 2b - induced cardiomyopathy .", "tokens": ["DIAGNOSIS", ":", "Interferon", "alpha", "-", "2b", "-", "induced", "cardiomyopathy", "."], "event_mentions": [{"id": "16265343_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "16265343_1_Ent1", "role": "Treatment", "text": "Interferon alpha - 2b", "start": 2, "end": 6}, {"entity_id": "16265343_1_Ent2", "role": "Treatment_Drug", "text": "Interferon alpha - 2b", "start": 2, "end": 6}, {"entity_id": "16265343_1_Ent0", "role": "Effect", "text": "cardiomyopathy", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "16265343_1_Ent1", "text": "Interferon alpha - 2b", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "16265343_1_Ent2", "text": "Interferon alpha - 2b", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "16265343_1_Ent0", "text": "cardiomyopathy", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "16268429_2", "wnd_id": "16268429_2_1", "text": "Subacute cholestatic hepatitis likely related to the use of senna for chronic constipation .", "tokens": ["Subacute", "cholestatic", "hepatitis", "likely", "related", "to", "the", "use", "of", "senna", "for", "chronic", "constipation", "."], "event_mentions": [{"id": "16268429_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related to", "start": 4, "end": 6}, "arguments": [{"entity_id": "16268429_2_Ent0", "role": "Effect", "text": "Subacute cholestatic hepatitis", "start": 0, "end": 3}, {"entity_id": "16268429_2_Ent1", "role": "Treatment", "text": "use of senna", "start": 7, "end": 10}, {"entity_id": "16268429_2_Ent2", "role": "Treatment_Drug", "text": "senna", "start": 9, "end": 10}, {"entity_id": "16268429_2_Ent3", "role": "Treatment_Disorder", "text": "chronic constipation .", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "16268429_2_Ent0", "text": "Subacute cholestatic hepatitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16268429_2_Ent1", "text": "use of senna", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "16268429_2_Ent2", "text": "senna", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16268429_2_Ent3", "text": "chronic constipation .", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "16268429_3", "wnd_id": "16268429_3_1", "text": "We report a case of senna - induced cholestatic hepatitis which was not diagnosed at presentation .", "tokens": ["We", "report", "a", "case", "of", "senna", "-", "induced", "cholestatic", "hepatitis", "which", "was", "not", "diagnosed", "at", "presentation", "."], "event_mentions": [{"id": "16268429_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "16268429_3_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "16268429_3_Ent2", "role": "Treatment", "text": "senna", "start": 5, "end": 6}, {"entity_id": "16268429_3_Ent3", "role": "Treatment_Drug", "text": "senna", "start": 5, "end": 6}, {"entity_id": "16268429_3_Ent1", "role": "Effect", "text": "cholestatic hepatitis", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "16268429_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16268429_3_Ent2", "text": "senna", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16268429_3_Ent3", "text": "senna", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16268429_3_Ent1", "text": "cholestatic hepatitis", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "16284443_1", "wnd_id": "16284443_1_1", "text": "Based on the history and clinical features , a diagnosis of insulin - induced lipohypertrophy was made .", "tokens": ["Based", "on", "the", "history", "and", "clinical", "features", ",", "a", "diagnosis", "of", "insulin", "-", "induced", "lipohypertrophy", "was", "made", "."], "event_mentions": [{"id": "16284443_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "16284443_1_Ent1", "role": "Treatment", "text": "insulin", "start": 11, "end": 12}, {"entity_id": "16284443_1_Ent2", "role": "Treatment_Drug", "text": "insulin", "start": 11, "end": 12}, {"entity_id": "16284443_1_Ent0", "role": "Effect", "text": "lipohypertrophy", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "16284443_1_Ent1", "text": "insulin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16284443_1_Ent2", "text": "insulin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16284443_1_Ent0", "text": "lipohypertrophy", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "16288069_2", "wnd_id": "16288069_2_1", "text": "CASE SUMMARY : A 45 - year - old HIV - positive man ( CD4 + count 450 cells / mm(3 ) and history of AIDS - defining illness ) presented with JHR after an initial intravenous dose of penicillin G for presumed neurosyphilis .", "tokens": ["CASE", "SUMMARY", ":", "A", "45", "-", "year", "-", "old", "HIV", "-", "positive", "man", "(", "CD4", "+", "count", "450", "cells", "/", "mm(3", ")", "and", "history", "of", "AIDS", "-", "defining", "illness", ")", "presented", "with", "JHR", "after", "an", "initial", "intravenous", "dose", "of", "penicillin", "G", "for", "presumed", "neurosyphilis", "."], "event_mentions": [{"id": "16288069_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 33, "end": 34}, "arguments": [{"entity_id": "16288069_2_Ent0", "role": "Subject", "text": "A 45 - year - old HIV - positive man ( CD4 + count 450 cells / mm(3 ) and history of AIDS - defining illness )", "start": 3, "end": 30}, {"entity_id": "16288069_2_Ent1", "role": "Subject_Age", "text": "45 - year - old", "start": 4, "end": 9}, {"entity_id": "16288069_2_Ent2", "role": "Subject_Disorder", "text": "HIV - positive", "start": 9, "end": 12}, {"entity_id": "16288069_2_Ent3", "role": "Effect", "text": "JHR", "start": 32, "end": 33}, {"entity_id": "16288069_2_Ent8", "role": "Treatment_Dosage", "text": "an initial intravenous dose", "start": 34, "end": 38}, {"entity_id": "16288069_2_Ent4", "role": "Treatment", "text": "an initial intravenous dose of penicillin G", "start": 34, "end": 41}, {"entity_id": "16288069_2_Ent7", "role": "Treatment_Route", "text": "intravenous", "start": 36, "end": 37}, {"entity_id": "16288069_2_Ent5", "role": "Treatment_Drug", "text": "penicillin G", "start": 39, "end": 41}, {"entity_id": "16288069_2_Ent6", "role": "Treatment_Disorder", "text": "neurosyphilis", "start": 43, "end": 44}]}], "entity_mentions": [{"id": "16288069_2_Ent0", "text": "A 45 - year - old HIV - positive man ( CD4 + count 450 cells / mm(3 ) and history of AIDS - defining illness )", "entity_type": "Entity", "start": 3, "end": 30}, {"id": "16288069_2_Ent1", "text": "45 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "16288069_2_Ent2", "text": "HIV - positive", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "16288069_2_Ent3", "text": "JHR", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16288069_2_Ent8", "text": "an initial intravenous dose", "entity_type": "Entity", "start": 34, "end": 38}, {"id": "16288069_2_Ent4", "text": "an initial intravenous dose of penicillin G", "entity_type": "Entity", "start": 34, "end": 41}, {"id": "16288069_2_Ent7", "text": "intravenous", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "16288069_2_Ent5", "text": "penicillin G", "entity_type": "Entity", "start": 39, "end": 41}, {"id": "16288069_2_Ent6", "text": "neurosyphilis", "entity_type": "Entity", "start": 43, "end": 44}], "lang": "en"}
{"doc_id": "16298824_2", "wnd_id": "16298824_2_1", "text": "ARDS has been associated with the administration of other monoclonal antibodies , such as infliximab , gemtuzumab ozogamicin , and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines .", "tokens": ["ARDS", "has", "been", "associated", "with", "the", "administration", "of", "other", "monoclonal", "antibodies", ",", "such", "as", "infliximab", ",", "gemtuzumab", "ozogamicin", ",", "and", "OKT3", "and", "is", "believed", "to", "be", "directly", "mediated", "by", "release", "of", "proinflammatory", "cytokines", "."], "event_mentions": [{"id": "16298824_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "16298824_2_Ent0", "role": "Effect", "text": "ARDS", "start": 0, "end": 1}, {"entity_id": "16298824_2_Ent1", "role": "Treatment", "text": "the administration of other monoclonal antibodies , such as infliximab , gemtuzumab ozogamicin , and OKT3", "start": 5, "end": 21}, {"entity_id": "16298824_2_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 14, "end": 15}, {"entity_id": "16298824_2_Ent3", "role": "Treatment_Drug", "text": "gemtuzumab", "start": 16, "end": 17}, {"entity_id": "16298824_2_Ent4", "role": "Treatment_Drug", "text": "ozogamicin", "start": 17, "end": 18}, {"entity_id": "16298824_2_Ent5", "role": "Treatment_Drug", "text": "OKT3", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "16298824_2_Ent0", "text": "ARDS", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16298824_2_Ent1", "text": "the administration of other monoclonal antibodies , such as infliximab , gemtuzumab ozogamicin , and OKT3", "entity_type": "Entity", "start": 5, "end": 21}, {"id": "16298824_2_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16298824_2_Ent3", "text": "gemtuzumab", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16298824_2_Ent4", "text": "ozogamicin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16298824_2_Ent5", "text": "OKT3", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "16298824_3", "wnd_id": "16298824_3_1", "text": "ARDS is rarely associated with rituximab infusion for lympho - proliferative disorders , but it should be considered by those administering rituximab , especially when a patient develops severe pulmonary symptoms soon after infusion .", "tokens": ["ARDS", "is", "rarely", "associated", "with", "rituximab", "infusion", "for", "lympho", "-", "proliferative", "disorders", ",", "but", "it", "should", "be", "considered", "by", "those", "administering", "rituximab", ",", "especially", "when", "a", "patient", "develops", "severe", "pulmonary", "symptoms", "soon", "after", "infusion", "."], "event_mentions": [{"id": "16298824_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 32, "end": 33}, "arguments": [{"entity_id": "16298824_3_Ent1", "role": "Effect", "text": "ARDS", "start": 0, "end": 1}, {"entity_id": "16298824_3_Ent4", "role": "Treatment", "text": "rituximab", "start": 21, "end": 22}, {"entity_id": "16298824_3_Ent6", "role": "Treatment_Drug", "text": "rituximab", "start": 21, "end": 22}, {"entity_id": "16298824_3_Ent0", "role": "Subject", "text": "a patient", "start": 25, "end": 27}, {"entity_id": "16298824_3_Ent2", "role": "Effect", "text": "severe pulmonary symptoms", "start": 28, "end": 31}, {"entity_id": "16298824_3_Ent3", "role": "Treatment", "text": "infusion", "start": 33, "end": 34}, {"entity_id": "16298824_3_Ent5", "role": "Treatment_Route", "text": "infusion", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "16298824_3_Ent1", "text": "ARDS", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16298824_3_Ent4", "text": "rituximab", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16298824_3_Ent6", "text": "rituximab", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16298824_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "16298824_3_Ent2", "text": "severe pulmonary symptoms", "entity_type": "Entity", "start": 28, "end": 31}, {"id": "16298824_3_Ent3", "text": "infusion", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "16298824_3_Ent5", "text": "infusion", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "16298824_4", "wnd_id": "16298824_4_1", "text": "Dyspnea , hypoxemia , and pleuritic chest pain occurred within 24 hours of rituximab administration , and there was no other apparent explanation .", "tokens": ["Dyspnea", ",", "hypoxemia", ",", "and", "pleuritic", "chest", "pain", "occurred", "within", "24", "hours", "of", "rituximab", "administration", ",", "and", "there", "was", "no", "other", "apparent", "explanation", "."], "event_mentions": [{"id": "16298824_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 8, "end": 9}, "arguments": [{"entity_id": "16298824_4_Ent0", "role": "Effect", "text": "Dyspnea , hypoxemia , and pleuritic chest pain", "start": 0, "end": 8}, {"entity_id": "16298824_4_Ent2", "role": "Treatment_Time_elapsed", "text": "24 hours", "start": 10, "end": 12}, {"entity_id": "16298824_4_Ent3", "role": "Treatment_Drug", "text": "rituximab", "start": 13, "end": 14}, {"entity_id": "16298824_4_Ent1", "role": "Treatment", "text": "rituximab administration", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "16298824_4_Ent0", "text": "Dyspnea , hypoxemia , and pleuritic chest pain", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "16298824_4_Ent2", "text": "24 hours", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16298824_4_Ent3", "text": "rituximab", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16298824_4_Ent1", "text": "rituximab administration", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "16298824_6", "wnd_id": "16298824_6_1", "text": "We report the case of a 43 - year - old man with ITP refractory to steroids and intravenous immunoglobulin who developed acute respiratory distress syndrome ( ARDS ) after a single infusion of rituximab .", "tokens": ["We", "report", "the", "case", "of", "a", "43", "-", "year", "-", "old", "man", "with", "ITP", "refractory", "to", "steroids", "and", "intravenous", "immunoglobulin", "who", "developed", "acute", "respiratory", "distress", "syndrome", "(", "ARDS", ")", "after", "a", "single", "infusion", "of", "rituximab", "."], "event_mentions": [{"id": "16298824_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 21, "end": 22}, "arguments": [{"entity_id": "16298824_6_Ent0", "role": "Subject", "text": "the case of a 43 - year - old man with ITP refractory to steroids and intravenous immunoglobulin", "start": 2, "end": 20}, {"entity_id": "16298824_6_Ent1", "role": "Subject_Age", "text": "43 - year - old", "start": 6, "end": 11}, {"entity_id": "16298824_6_Ent2", "role": "Subject_Gender", "text": "man", "start": 11, "end": 12}, {"entity_id": "16298824_6_Ent8", "role": "Treatment_Disorder", "text": "ITP", "start": 13, "end": 14}, {"entity_id": "16298824_6_Ent3", "role": "Subject_Disorder", "text": "refractory to steroids and intravenous immunoglobulin", "start": 14, "end": 20}, {"entity_id": "16298824_6_Ent4", "role": "Effect", "text": "acute respiratory distress syndrome ( ARDS )", "start": 22, "end": 29}, {"entity_id": "16298824_6_Ent5", "role": "Treatment", "text": "single infusion of rituximab", "start": 31, "end": 35}, {"entity_id": "16298824_6_Ent6", "role": "Treatment_Route", "text": "infusion", "start": 32, "end": 33}, {"entity_id": "16298824_6_Ent7", "role": "Treatment_Drug", "text": "rituximab", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "16298824_6_Ent0", "text": "the case of a 43 - year - old man with ITP refractory to steroids and intravenous immunoglobulin", "entity_type": "Entity", "start": 2, "end": 20}, {"id": "16298824_6_Ent1", "text": "43 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16298824_6_Ent2", "text": "man", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16298824_6_Ent8", "text": "ITP", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16298824_6_Ent3", "text": "refractory to steroids and intravenous immunoglobulin", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "16298824_6_Ent4", "text": "acute respiratory distress syndrome ( ARDS )", "entity_type": "Entity", "start": 22, "end": 29}, {"id": "16298824_6_Ent5", "text": "single infusion of rituximab", "entity_type": "Entity", "start": 31, "end": 35}, {"id": "16298824_6_Ent6", "text": "infusion", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16298824_6_Ent7", "text": "rituximab", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "16317298_6", "wnd_id": "16317298_6_1", "text": "We suggest discontinuing gemcitabine if radiation recall is observed .", "tokens": ["We", "suggest", "discontinuing", "gemcitabine", "if", "radiation", "recall", "is", "observed", "."], "event_mentions": [{"id": "16317298_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "if", "start": 4, "end": 5}, "arguments": [{"entity_id": "16317298_6_Ent1", "role": "Treatment", "text": "discontinuing gemcitabine", "start": 2, "end": 4}, {"entity_id": "16317298_6_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 3, "end": 4}, {"entity_id": "16317298_6_Ent0", "role": "Effect", "text": "radiation recall", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "16317298_6_Ent1", "text": "discontinuing gemcitabine", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16317298_6_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16317298_6_Ent0", "text": "radiation recall", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "16341621_3", "wnd_id": "16341621_3_1", "text": "To our knowledge , this is the first granulomatous reaction described after calcium hydroxylapatite injection .", "tokens": ["To", "our", "knowledge", ",", "this", "is", "the", "first", "granulomatous", "reaction", "described", "after", "calcium", "hydroxylapatite", "injection", "."], "event_mentions": [{"id": "16341621_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "16341621_3_Ent0", "role": "Effect", "text": "granulomatous reaction", "start": 8, "end": 10}, {"entity_id": "16341621_3_Ent2", "role": "Treatment_Drug", "text": "calcium hydroxylapatite", "start": 12, "end": 14}, {"entity_id": "16341621_3_Ent1", "role": "Treatment", "text": "calcium hydroxylapatite injection", "start": 12, "end": 15}, {"entity_id": "16341621_3_Ent3", "role": "Treatment_Route", "text": "injection", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "16341621_3_Ent0", "text": "granulomatous reaction", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16341621_3_Ent2", "text": "calcium hydroxylapatite", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16341621_3_Ent1", "text": "calcium hydroxylapatite injection", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "16341621_3_Ent3", "text": "injection", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "16357738_1", "wnd_id": "16357738_1_1", "text": "Moreover , treatment with immunosuppressive drugs such as cyclosporine , cisplatin , tacrolimus , and interferon - alpha can induce a condition resembling RPLS .", "tokens": ["Moreover", ",", "treatment", "with", "immunosuppressive", "drugs", "such", "as", "cyclosporine", ",", "cisplatin", ",", "tacrolimus", ",", "and", "interferon", "-", "alpha", "can", "induce", "a", "condition", "resembling", "RPLS", "."], "event_mentions": [{"id": "16357738_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 19, "end": 20}, "arguments": [{"entity_id": "16357738_1_Ent1", "role": "Treatment", "text": "immunosuppressive drugs such as cyclosporine , cisplatin , tacrolimus , and interferon - alpha", "start": 4, "end": 18}, {"entity_id": "16357738_1_Ent2", "role": "Treatment_Drug", "text": "cyclosporine", "start": 8, "end": 9}, {"entity_id": "16357738_1_Ent3", "role": "Treatment_Drug", "text": "cisplatin", "start": 10, "end": 11}, {"entity_id": "16357738_1_Ent4", "role": "Treatment_Drug", "text": "tacrolimus", "start": 12, "end": 13}, {"entity_id": "16357738_1_Ent5", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 15, "end": 18}, {"entity_id": "16357738_1_Ent0", "role": "Effect", "text": "RPLS", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "16357738_1_Ent1", "text": "immunosuppressive drugs such as cyclosporine , cisplatin , tacrolimus , and interferon - alpha", "entity_type": "Entity", "start": 4, "end": 18}, {"id": "16357738_1_Ent2", "text": "cyclosporine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16357738_1_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16357738_1_Ent4", "text": "tacrolimus", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16357738_1_Ent5", "text": "interferon - alpha", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "16357738_1_Ent0", "text": "RPLS", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "16357738_2", "wnd_id": "16357738_2_1", "text": "Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with cyclosporine .", "tokens": ["Reversible", "posterior", "leukoencephalopathy", "syndrome", "in", "systemic", "lupus", "erythematosus", "with", "thrombocytopenia", "treated", "with", "cyclosporine", "."], "event_mentions": [{"id": "16357738_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 10, "end": 11}, "arguments": [{"entity_id": "16357738_2_Ent2", "role": "Treatment_Disorder", "text": "systemic lupus erythematosus with thrombocytopenia", "start": 5, "end": 10}, {"entity_id": "16357738_2_Ent0", "role": "Treatment", "text": "cyclosporine", "start": 12, "end": 13}, {"entity_id": "16357738_2_Ent1", "role": "Treatment_Drug", "text": "cyclosporine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "16357738_2_Ent2", "text": "systemic lupus erythematosus with thrombocytopenia", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "16357738_2_Ent0", "text": "cyclosporine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16357738_2_Ent1", "text": "cyclosporine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "16371793_1", "wnd_id": "16371793_1_1", "text": "Intravitreal triamcinolone acetonide for persisting cystoid macular edema after penetrating keratoplasty .", "tokens": ["Intravitreal", "triamcinolone", "acetonide", "for", "persisting", "cystoid", "macular", "edema", "after", "penetrating", "keratoplasty", "."], "event_mentions": [{"id": "16371793_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 3, "end": 4}, "arguments": [{"entity_id": "16371793_1_Ent3", "role": "Treatment_Route", "text": "Intravitreal", "start": 0, "end": 1}, {"entity_id": "16371793_1_Ent0", "role": "Treatment", "text": "Intravitreal triamcinolone acetonide", "start": 0, "end": 3}, {"entity_id": "16371793_1_Ent2", "role": "Treatment_Drug", "text": "triamcinolone acetonide", "start": 1, "end": 3}, {"entity_id": "16371793_1_Ent1", "role": "Treatment_Disorder", "text": "persisting cystoid macular edema", "start": 4, "end": 8}]}, {"id": "16371793_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "16371793_1_Ent4", "role": "Effect", "text": "persisting cystoid macular edema", "start": 4, "end": 8}, {"entity_id": "16371793_1_Ent5", "role": "Treatment", "text": "penetrating keratoplasty", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "16371793_1_Ent3", "text": "Intravitreal", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16371793_1_Ent0", "text": "Intravitreal triamcinolone acetonide", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16371793_1_Ent2", "text": "triamcinolone acetonide", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "16371793_1_Ent1", "text": "persisting cystoid macular edema", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "16371793_1_Ent4", "text": "persisting cystoid macular edema", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "16371793_1_Ent5", "text": "penetrating keratoplasty", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "16393774_5", "wnd_id": "16393774_5_1", "text": "The first patient developed a monoarthritis 2 weeks after initiation of IFN - beta , which persisted during the 14 months of therapy and resolved with discontinuation of the medication .", "tokens": ["The", "first", "patient", "developed", "a", "monoarthritis", "2", "weeks", "after", "initiation", "of", "IFN", "-", "beta", ",", "which", "persisted", "during", "the", "14", "months", "of", "therapy", "and", "resolved", "with", "discontinuation", "of", "the", "medication", "."], "event_mentions": [{"id": "16393774_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "initiation", "start": 9, "end": 10}, "arguments": [{"entity_id": "16393774_5_Ent0", "role": "Subject", "text": "The first patient", "start": 0, "end": 3}, {"entity_id": "16393774_5_Ent1", "role": "Effect", "text": "monoarthritis", "start": 5, "end": 6}, {"entity_id": "16393774_5_Ent2", "role": "Treatment", "text": "IFN - beta", "start": 11, "end": 14}, {"entity_id": "16393774_5_Ent3", "role": "Treatment_Drug", "text": "IFN - beta", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "16393774_5_Ent0", "text": "The first patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16393774_5_Ent1", "text": "monoarthritis", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16393774_5_Ent2", "text": "IFN - beta", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "16393774_5_Ent3", "text": "IFN - beta", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "16393774_6", "wnd_id": "16393774_6_1", "text": "The second patient developed both autoimmune thyroid disease and a refractory pre - patellar bursitis after 50 months of IFN - beta therapy .", "tokens": ["The", "second", "patient", "developed", "both", "autoimmune", "thyroid", "disease", "and", "a", "refractory", "pre", "-", "patellar", "bursitis", "after", "50", "months", "of", "IFN", "-", "beta", "therapy", "."], "event_mentions": [{"id": "16393774_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "16393774_6_Ent0", "role": "Subject", "text": "second patient", "start": 1, "end": 3}, {"entity_id": "16393774_6_Ent1", "role": "Effect", "text": "both autoimmune thyroid disease and a refractory pre - patellar bursitis", "start": 4, "end": 15}, {"entity_id": "16393774_6_Ent4", "role": "Treatment_Time_elapsed", "text": "50 months", "start": 16, "end": 18}, {"entity_id": "16393774_6_Ent2", "role": "Treatment", "text": "50 months of IFN - beta therapy", "start": 16, "end": 23}, {"entity_id": "16393774_6_Ent3", "role": "Treatment_Drug", "text": "IFN - beta", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "16393774_6_Ent0", "text": "second patient", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "16393774_6_Ent1", "text": "both autoimmune thyroid disease and a refractory pre - patellar bursitis", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "16393774_6_Ent4", "text": "50 months", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "16393774_6_Ent2", "text": "50 months of IFN - beta therapy", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "16393774_6_Ent3", "text": "IFN - beta", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "16432996_1", "wnd_id": "16432996_1_1", "text": "Development of sarcoidosis during interferon alpha 2b and ribavirin combination therapy for chronic hepatitis C -- a case report and review of the literature .", "tokens": ["Development", "of", "sarcoidosis", "during", "interferon", "alpha", "2b", "and", "ribavirin", "combination", "therapy", "for", "chronic", "hepatitis", "C", "--", "a", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "16432996_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Development", "start": 0, "end": 1}, "arguments": [{"entity_id": "16432996_1_Ent0", "role": "Effect", "text": "sarcoidosis", "start": 2, "end": 3}, {"entity_id": "16432996_1_Ent2", "role": "Treatment_Drug", "text": "interferon alpha 2b", "start": 4, "end": 7}, {"entity_id": "16432996_1_Ent6", "role": "Combination_Drug", "text": "interferon alpha 2b", "start": 4, "end": 7}, {"entity_id": "16432996_1_Ent1", "role": "Treatment", "text": "interferon alpha 2b and ribavirin", "start": 4, "end": 9}, {"entity_id": "16432996_1_Ent3", "role": "Treatment_Drug", "text": "ribavirin", "start": 8, "end": 9}, {"entity_id": "16432996_1_Ent5", "role": "Combination_Drug", "text": "ribavirin", "start": 8, "end": 9}, {"entity_id": "16432996_1_Ent4", "role": "Treatment_Disorder", "text": "chronic hepatitis C", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "16432996_1_Ent0", "text": "sarcoidosis", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16432996_1_Ent2", "text": "interferon alpha 2b", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "16432996_1_Ent6", "text": "interferon alpha 2b", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "16432996_1_Ent1", "text": "interferon alpha 2b and ribavirin", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "16432996_1_Ent3", "text": "ribavirin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16432996_1_Ent5", "text": "ribavirin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16432996_1_Ent4", "text": "chronic hepatitis C", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "16459502_2", "wnd_id": "16459502_2_1", "text": "Disseminated tuberculous lesions post intravesical BCG therapy are rare but need to be identified and treated quickly .", "tokens": ["Disseminated", "tuberculous", "lesions", "post", "intravesical", "BCG", "therapy", "are", "rare", "but", "need", "to", "be", "identified", "and", "treated", "quickly", "."], "event_mentions": [{"id": "16459502_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "post", "start": 3, "end": 4}, "arguments": [{"entity_id": "16459502_2_Ent0", "role": "Effect", "text": "Disseminated tuberculous lesions", "start": 0, "end": 3}, {"entity_id": "16459502_2_Ent1", "role": "Treatment", "text": "BCG", "start": 5, "end": 6}, {"entity_id": "16459502_2_Ent2", "role": "Treatment_Drug", "text": "BCG", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "16459502_2_Ent0", "text": "Disseminated tuberculous lesions", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16459502_2_Ent1", "text": "BCG", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16459502_2_Ent2", "text": "BCG", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "16463436_1", "wnd_id": "16463436_1_1", "text": "Some patients develop hypersensitivity rash in response to HCQ .", "tokens": ["Some", "patients", "develop", "hypersensitivity", "rash", "in", "response", "to", "HCQ", "."], "event_mentions": [{"id": "16463436_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 2, "end": 3}, "arguments": [{"entity_id": "16463436_1_Ent1", "role": "Subject_Population", "text": "Some", "start": 0, "end": 1}, {"entity_id": "16463436_1_Ent0", "role": "Subject", "text": "Some patients", "start": 0, "end": 2}, {"entity_id": "16463436_1_Ent2", "role": "Effect", "text": "hypersensitivity rash", "start": 3, "end": 5}, {"entity_id": "16463436_1_Ent3", "role": "Treatment", "text": "HCQ", "start": 8, "end": 9}, {"entity_id": "16463436_1_Ent4", "role": "Treatment_Drug", "text": "HCQ", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "16463436_1_Ent1", "text": "Some", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16463436_1_Ent0", "text": "Some patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16463436_1_Ent2", "text": "hypersensitivity rash", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16463436_1_Ent3", "text": "HCQ", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16463436_1_Ent4", "text": "HCQ", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "16498048_5", "wnd_id": "16498048_5_1", "text": "We have described three patients with hepatitis C for whom IFN - alpha and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves ' disease .", "tokens": ["We", "have", "described", "three", "patients", "with", "hepatitis", "C", "for", "whom", "IFN", "-", "alpha", "and", "ribavirin", "were", "prescribed", "and", "who", "developed", "two", "successive", "phases", "of", "silent", "thyroiditis", "followed", "by", "hyperthryroidism", "relapse", "due", "to", "Graves", "'", "disease", "."], "event_mentions": [{"id": "16498048_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "16498048_5_Ent1", "role": "Subject_Population", "text": "three", "start": 3, "end": 4}, {"entity_id": "16498048_5_Ent0", "role": "Subject", "text": "three patients with hepatitis C", "start": 3, "end": 8}, {"entity_id": "16498048_5_Ent5", "role": "Treatment_Disorder", "text": "hepatitis C", "start": 6, "end": 8}, {"entity_id": "16498048_5_Ent6", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 10, "end": 13}, {"entity_id": "16498048_5_Ent4", "role": "Treatment", "text": "IFN - alpha and ribavirin", "start": 10, "end": 15}, {"entity_id": "16498048_5_Ent7", "role": "Treatment_Drug", "text": "ribavirin", "start": 14, "end": 15}, {"entity_id": "16498048_5_Ent3", "role": "Effect", "text": "two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves ' disease", "start": 20, "end": 35}, {"entity_id": "16498048_5_Ent2", "role": "Subject_Disorder", "text": "Graves ' disease", "start": 32, "end": 35}]}], "entity_mentions": [{"id": "16498048_5_Ent1", "text": "three", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16498048_5_Ent0", "text": "three patients with hepatitis C", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "16498048_5_Ent5", "text": "hepatitis C", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16498048_5_Ent6", "text": "IFN - alpha", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "16498048_5_Ent4", "text": "IFN - alpha and ribavirin", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "16498048_5_Ent7", "text": "ribavirin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16498048_5_Ent3", "text": "two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves ' disease", "entity_type": "Entity", "start": 20, "end": 35}, {"id": "16498048_5_Ent2", "text": "Graves ' disease", "entity_type": "Entity", "start": 32, "end": 35}], "lang": "en"}
{"doc_id": "16503727_1", "wnd_id": "16503727_1_1", "text": "Dipyrone , also known as metamizole , is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with agranulocytosis .", "tokens": ["Dipyrone", ",", "also", "known", "as", "metamizole", ",", "is", "an", "analgesic", "and", "antipyretic", "drug", "that", "was", "banned", "by", "the", "United", "States", "Food", "and", "Drug", "Administration", "because", "of", "its", "association", "with", "agranulocytosis", "."], "event_mentions": [{"id": "16503727_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 27, "end": 28}, "arguments": [{"entity_id": "16503727_1_Ent2", "role": "Treatment_Drug", "text": "Dipyrone", "start": 0, "end": 1}, {"entity_id": "16503727_1_Ent1", "role": "Treatment", "text": "Dipyrone , also known as metamizole", "start": 0, "end": 6}, {"entity_id": "16503727_1_Ent0", "role": "Effect", "text": "agranulocytosis", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "16503727_1_Ent2", "text": "Dipyrone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16503727_1_Ent1", "text": "Dipyrone , also known as metamizole", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "16503727_1_Ent0", "text": "agranulocytosis", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "16529136_4", "wnd_id": "16529136_4_1", "text": "Long known to psychiatrists , monoamine oxidase inhibitors ( MAOIs ) and complications of their use may be unfamiliar to medical and surgical practitioners who may thus unwittingly precipitate a hypertensive crisis or serotonin syndrome .", "tokens": ["Long", "known", "to", "psychiatrists", ",", "monoamine", "oxidase", "inhibitors", "(", "MAOIs", ")", "and", "complications", "of", "their", "use", "may", "be", "unfamiliar", "to", "medical", "and", "surgical", "practitioners", "who", "may", "thus", "unwittingly", "precipitate", "a", "hypertensive", "crisis", "or", "serotonin", "syndrome", "."], "event_mentions": [{"id": "16529136_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitate", "start": 28, "end": 29}, "arguments": [{"entity_id": "16529136_4_Ent2", "role": "Treatment_Drug", "text": "monoamine oxidase inhibitors", "start": 5, "end": 8}, {"entity_id": "16529136_4_Ent1", "role": "Treatment", "text": "monoamine oxidase inhibitors ( MAOIs )", "start": 5, "end": 11}, {"entity_id": "16529136_4_Ent0", "role": "Effect", "text": "hypertensive crisis or serotonin syndrome", "start": 30, "end": 35}]}], "entity_mentions": [{"id": "16529136_4_Ent2", "text": "monoamine oxidase inhibitors", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "16529136_4_Ent1", "text": "monoamine oxidase inhibitors ( MAOIs )", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "16529136_4_Ent0", "text": "hypertensive crisis or serotonin syndrome", "entity_type": "Entity", "start": 30, "end": 35}], "lang": "en"}
{"doc_id": "16531969_3", "wnd_id": "16531969_3_1", "text": "Post marketing studies of Interferon - beta ( IFN beta ) therapy in multiple sclerosis ( MS ) have demonstrated surprisingly high rates of hepatotoxicity .", "tokens": ["Post", "marketing", "studies", "of", "Interferon", "-", "beta", "(", "IFN", "beta", ")", "therapy", "in", "multiple", "sclerosis", "(", "MS", ")", "have", "demonstrated", "surprisingly", "high", "rates", "of", "hepatotoxicity", "."], "event_mentions": [{"id": "16531969_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "demonstrated", "start": 19, "end": 20}, "arguments": [{"entity_id": "16531969_3_Ent1", "role": "Treatment", "text": "Interferon - beta", "start": 4, "end": 7}, {"entity_id": "16531969_3_Ent2", "role": "Treatment_Drug", "text": "Interferon - beta ( IFN beta )", "start": 4, "end": 11}, {"entity_id": "16531969_3_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "16531969_3_Ent1", "text": "Interferon - beta", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "16531969_3_Ent2", "text": "Interferon - beta ( IFN beta )", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "16531969_3_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "16531969_4", "wnd_id": "16531969_4_1", "text": "We report three cases of IFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug - induced liver injury .", "tokens": ["We", "report", "three", "cases", "of", "IFN", "beta", "induced", "hepatitis", "in", "MS", "and", "discuss", "the", "pathology", "findings", "and", "possible", "mechanisms", "of", "drug", "-", "induced", "liver", "injury", "."], "event_mentions": [{"id": "16531969_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "16531969_4_Ent1", "role": "Subject_Population", "text": "three", "start": 2, "end": 3}, {"entity_id": "16531969_4_Ent0", "role": "Subject", "text": "three cases", "start": 2, "end": 4}, {"entity_id": "16531969_4_Ent3", "role": "Treatment", "text": "IFN beta", "start": 5, "end": 7}, {"entity_id": "16531969_4_Ent4", "role": "Treatment_Drug", "text": "IFN beta", "start": 5, "end": 7}, {"entity_id": "16531969_4_Ent2", "role": "Effect", "text": "hepatitis in MS", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "16531969_4_Ent1", "text": "three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16531969_4_Ent0", "text": "three cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16531969_4_Ent3", "text": "IFN beta", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16531969_4_Ent4", "text": "IFN beta", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16531969_4_Ent2", "text": "hepatitis in MS", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "16537817_10", "wnd_id": "16537817_10_1", "text": "An objective causal assessment suggests that rhabdomyolysis , renal failure , and possibly hepatotoxicity were probably related to an amiodarone - simvastatin interaction .", "tokens": ["An", "objective", "causal", "assessment", "suggests", "that", "rhabdomyolysis", ",", "renal", "failure", ",", "and", "possibly", "hepatotoxicity", "were", "probably", "related", "to", "an", "amiodarone", "-", "simvastatin", "interaction", "."], "event_mentions": [{"id": "16537817_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 16, "end": 17}, "arguments": [{"entity_id": "16537817_10_Ent0", "role": "Effect", "text": "rhabdomyolysis , renal failure , and possibly hepatotoxicity", "start": 6, "end": 14}, {"entity_id": "16537817_10_Ent1", "role": "Treatment", "text": "an amiodarone - simvastatin interaction", "start": 18, "end": 23}, {"entity_id": "16537817_10_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 19, "end": 20}, {"entity_id": "16537817_10_Ent4", "role": "Combination_Drug", "text": "amiodarone", "start": 19, "end": 20}, {"entity_id": "16537817_10_Ent3", "role": "Treatment_Drug", "text": "simvastatin", "start": 21, "end": 22}, {"entity_id": "16537817_10_Ent5", "role": "Combination_Drug", "text": "simvastatin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "16537817_10_Ent0", "text": "rhabdomyolysis , renal failure , and possibly hepatotoxicity", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "16537817_10_Ent1", "text": "an amiodarone - simvastatin interaction", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "16537817_10_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16537817_10_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16537817_10_Ent3", "text": "simvastatin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16537817_10_Ent5", "text": "simvastatin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "16580907_2", "wnd_id": "16580907_2_1", "text": "A 72 - year - old woman with renal insufficiency who was taking oral pilsicainide ( 150 mg / d ) complained of feeling faint 3 days after she was prescribed oral cetirizine ( 20 mg / d ) .", "tokens": ["A", "72", "-", "year", "-", "old", "woman", "with", "renal", "insufficiency", "who", "was", "taking", "oral", "pilsicainide", "(", "150", "mg", "/", "d", ")", "complained", "of", "feeling", "faint", "3", "days", "after", "she", "was", "prescribed", "oral", "cetirizine", "(", "20", "mg", "/", "d", ")", "."], "event_mentions": [{"id": "16580907_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complained", "start": 21, "end": 22}, "arguments": [{"entity_id": "16580907_2_Ent0", "role": "Subject", "text": "A 72 - year - old woman with renal insufficiency", "start": 0, "end": 10}, {"entity_id": "16580907_2_Ent2", "role": "Subject_Age", "text": "72 - year - old", "start": 1, "end": 6}, {"entity_id": "16580907_2_Ent3", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "16580907_2_Ent1", "role": "Subject_Disorder", "text": "renal insufficiency", "start": 8, "end": 10}, {"entity_id": "16580907_2_Ent5", "role": "Treatment", "text": "taking oral pilsicainide ( 150 mg / d )", "start": 12, "end": 21}, {"entity_id": "16580907_2_Ent7", "role": "Treatment_Route", "text": "oral", "start": 13, "end": 14}, {"entity_id": "16580907_2_Ent9", "role": "Treatment_Drug", "text": "pilsicainide", "start": 14, "end": 15}, {"entity_id": "16580907_2_Ent15", "role": "Combination_Drug", "text": "pilsicainide", "start": 14, "end": 15}, {"entity_id": "16580907_2_Ent11", "role": "Treatment_Dosage", "text": "150 mg / d", "start": 16, "end": 20}, {"entity_id": "16580907_2_Ent4", "role": "Effect", "text": "feeling faint", "start": 23, "end": 25}, {"entity_id": "16580907_2_Ent13", "role": "Treatment_Time_elapsed", "text": "3 days", "start": 25, "end": 27}, {"entity_id": "16580907_2_Ent6", "role": "Treatment", "text": "3 days after she was prescribed oral cetirizine ( 20 mg / d )", "start": 25, "end": 39}, {"entity_id": "16580907_2_Ent8", "role": "Treatment_Route", "text": "oral", "start": 31, "end": 32}, {"entity_id": "16580907_2_Ent10", "role": "Treatment_Drug", "text": "cetirizine", "start": 32, "end": 33}, {"entity_id": "16580907_2_Ent14", "role": "Combination_Drug", "text": "cetirizine", "start": 32, "end": 33}, {"entity_id": "16580907_2_Ent12", "role": "Treatment_Dosage", "text": "20 mg / d", "start": 34, "end": 38}]}], "entity_mentions": [{"id": "16580907_2_Ent0", "text": "A 72 - year - old woman with renal insufficiency", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "16580907_2_Ent2", "text": "72 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "16580907_2_Ent3", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16580907_2_Ent1", "text": "renal insufficiency", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16580907_2_Ent5", "text": "taking oral pilsicainide ( 150 mg / d )", "entity_type": "Entity", "start": 12, "end": 21}, {"id": "16580907_2_Ent7", "text": "oral", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16580907_2_Ent9", "text": "pilsicainide", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16580907_2_Ent15", "text": "pilsicainide", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16580907_2_Ent11", "text": "150 mg / d", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "16580907_2_Ent4", "text": "feeling faint", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "16580907_2_Ent13", "text": "3 days", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "16580907_2_Ent6", "text": "3 days after she was prescribed oral cetirizine ( 20 mg / d )", "entity_type": "Entity", "start": 25, "end": 39}, {"id": "16580907_2_Ent8", "text": "oral", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "16580907_2_Ent10", "text": "cetirizine", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16580907_2_Ent14", "text": "cetirizine", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16580907_2_Ent12", "text": "20 mg / d", "entity_type": "Entity", "start": 34, "end": 38}], "lang": "en"}
{"doc_id": "16599252_2", "wnd_id": "16599252_2_1", "text": "We present a case of hypereosinophilia related to zafirlukast therapy .", "tokens": ["We", "present", "a", "case", "of", "hypereosinophilia", "related", "to", "zafirlukast", "therapy", "."], "event_mentions": [{"id": "16599252_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 6, "end": 7}, "arguments": [{"entity_id": "16599252_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "16599252_2_Ent1", "role": "Effect", "text": "hypereosinophilia", "start": 5, "end": 6}, {"entity_id": "16599252_2_Ent3", "role": "Treatment_Drug", "text": "zafirlukast", "start": 8, "end": 9}, {"entity_id": "16599252_2_Ent2", "role": "Treatment", "text": "zafirlukast therapy .", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "16599252_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16599252_2_Ent1", "text": "hypereosinophilia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16599252_2_Ent3", "text": "zafirlukast", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16599252_2_Ent2", "text": "zafirlukast therapy .", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "16609346_1", "wnd_id": "16609346_1_1", "text": "A few recent individual case reports have suggested that a myasthenic syndrome may be associated with statin treatment , but this association is not well described .", "tokens": ["A", "few", "recent", "individual", "case", "reports", "have", "suggested", "that", "a", "myasthenic", "syndrome", "may", "be", "associated", "with", "statin", "treatment", ",", "but", "this", "association", "is", "not", "well", "described", "."], "event_mentions": [{"id": "16609346_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 14, "end": 15}, "arguments": [{"entity_id": "16609346_1_Ent0", "role": "Subject", "text": "A few recent individual case", "start": 0, "end": 5}, {"entity_id": "16609346_1_Ent1", "role": "Effect", "text": "myasthenic syndrome", "start": 10, "end": 12}, {"entity_id": "16609346_1_Ent3", "role": "Treatment_Drug", "text": "statin", "start": 16, "end": 17}, {"entity_id": "16609346_1_Ent2", "role": "Treatment", "text": "statin treatment", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "16609346_1_Ent0", "text": "A few recent individual case", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16609346_1_Ent1", "text": "myasthenic syndrome", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16609346_1_Ent3", "text": "statin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16609346_1_Ent2", "text": "statin treatment", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "16620273_1", "wnd_id": "16620273_1_1", "text": "CONCLUSIONS : The increasing prevalence of Type 2 diabetes and its treatment with metformin might result in more cases of lactic acidosis .", "tokens": ["CONCLUSIONS", ":", "The", "increasing", "prevalence", "of", "Type", "2", "diabetes", "and", "its", "treatment", "with", "metformin", "might", "result", "in", "more", "cases", "of", "lactic", "acidosis", "."], "event_mentions": [{"id": "16620273_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 15, "end": 16}, "arguments": [{"entity_id": "16620273_1_Ent3", "role": "Treatment_Disorder", "text": "Type 2 diabetes", "start": 6, "end": 9}, {"entity_id": "16620273_1_Ent1", "role": "Treatment", "text": "metformin", "start": 13, "end": 14}, {"entity_id": "16620273_1_Ent2", "role": "Treatment_Drug", "text": "metformin", "start": 13, "end": 14}, {"entity_id": "16620273_1_Ent0", "role": "Effect", "text": "lactic acidosis", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "16620273_1_Ent3", "text": "Type 2 diabetes", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "16620273_1_Ent1", "text": "metformin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16620273_1_Ent2", "text": "metformin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16620273_1_Ent0", "text": "lactic acidosis", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "16641839_4", "wnd_id": "16641839_4_1", "text": "Cutaneous rashes and eruptions can be caused by many medications , including carbamazepine .", "tokens": ["Cutaneous", "rashes", "and", "eruptions", "can", "be", "caused", "by", "many", "medications", ",", "including", "carbamazepine", "."], "event_mentions": [{"id": "16641839_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 6, "end": 7}, "arguments": [{"entity_id": "16641839_4_Ent0", "role": "Effect", "text": "Cutaneous rashes and eruptions", "start": 0, "end": 4}, {"entity_id": "16641839_4_Ent1", "role": "Treatment", "text": "carbamazepine", "start": 12, "end": 13}, {"entity_id": "16641839_4_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "16641839_4_Ent0", "text": "Cutaneous rashes and eruptions", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16641839_4_Ent1", "text": "carbamazepine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16641839_4_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "16678268_2", "wnd_id": "16678268_2_1", "text": "We report a case of severe AVP three weeks following the administration of infliximab for the treatment of Crohn 's disease ( CD ) .", "tokens": ["We", "report", "a", "case", "of", "severe", "AVP", "three", "weeks", "following", "the", "administration", "of", "infliximab", "for", "the", "treatment", "of", "Crohn", "'s", "disease", "(", "CD", ")", "."], "event_mentions": [{"id": "16678268_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "16678268_2_Ent0", "role": "Effect", "text": "AVP", "start": 6, "end": 7}, {"entity_id": "16678268_2_Ent2", "role": "Treatment_Time_elapsed", "text": "three weeks", "start": 7, "end": 9}, {"entity_id": "16678268_2_Ent1", "role": "Treatment", "text": "infliximab", "start": 13, "end": 14}, {"entity_id": "16678268_2_Ent3", "role": "Treatment_Drug", "text": "infliximab", "start": 13, "end": 14}, {"entity_id": "16678268_2_Ent4", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "16678268_2_Ent0", "text": "AVP", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16678268_2_Ent2", "text": "three weeks", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "16678268_2_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16678268_2_Ent3", "text": "infliximab", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16678268_2_Ent4", "text": "Crohn 's disease", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "16682062_3", "wnd_id": "16682062_3_1", "text": "We report the case of a 20 - year - old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis , identified 1 month after a single dose of ivermectin .", "tokens": ["We", "report", "the", "case", "of", "a", "20", "-", "year", "-", "old", "woman", "originally", "from", "Cameroon", "who", "was", "infected", "by", "the", "L.", "loa", "parasite", "and", "developed", "severe", "hepatitis", ",", "identified", "1", "month", "after", "a", "single", "dose", "of", "ivermectin", "."], "event_mentions": [{"id": "16682062_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 24, "end": 25}, "arguments": [{"entity_id": "16682062_3_Ent1", "role": "Subject_Age", "text": "20 - year - old", "start": 6, "end": 11}, {"entity_id": "16682062_3_Ent0", "role": "Subject", "text": "20 - year - old woman originally from Cameroon who was infected by the L. loa parasite", "start": 6, "end": 23}, {"entity_id": "16682062_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "16682062_3_Ent3", "role": "Subject_Race", "text": "Cameroon", "start": 14, "end": 15}, {"entity_id": "16682062_3_Ent6", "role": "Treatment_Disorder", "text": "infected by the L. loa parasite", "start": 17, "end": 23}, {"entity_id": "16682062_3_Ent4", "role": "Effect", "text": "severe hepatitis", "start": 25, "end": 27}, {"entity_id": "16682062_3_Ent7", "role": "Treatment_Time_elapsed", "text": "1 month", "start": 29, "end": 31}, {"entity_id": "16682062_3_Ent5", "role": "Treatment", "text": "1 month after a single dose of ivermectin", "start": 29, "end": 37}, {"entity_id": "16682062_3_Ent8", "role": "Treatment_Dosage", "text": "single dose", "start": 33, "end": 35}, {"entity_id": "16682062_3_Ent9", "role": "Treatment_Drug", "text": "ivermectin", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "16682062_3_Ent1", "text": "20 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16682062_3_Ent0", "text": "20 - year - old woman originally from Cameroon who was infected by the L. loa parasite", "entity_type": "Entity", "start": 6, "end": 23}, {"id": "16682062_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16682062_3_Ent3", "text": "Cameroon", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16682062_3_Ent6", "text": "infected by the L. loa parasite", "entity_type": "Entity", "start": 17, "end": 23}, {"id": "16682062_3_Ent4", "text": "severe hepatitis", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "16682062_3_Ent7", "text": "1 month", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "16682062_3_Ent5", "text": "1 month after a single dose of ivermectin", "entity_type": "Entity", "start": 29, "end": 37}, {"id": "16682062_3_Ent8", "text": "single dose", "entity_type": "Entity", "start": 33, "end": 35}, {"id": "16682062_3_Ent9", "text": "ivermectin", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "16685007_12", "wnd_id": "16685007_12_1", "text": "Study results suggest that ciclesonide significantly reduces the need for OCS in patients with severe , persistent asthma , while maintaining asthma control .", "tokens": ["Study", "results", "suggest", "that", "ciclesonide", "significantly", "reduces", "the", "need", "for", "OCS", "in", "patients", "with", "severe", ",", "persistent", "asthma", ",", "while", "maintaining", "asthma", "control", "."], "event_mentions": [{"id": "16685007_12_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reduces", "start": 6, "end": 7}, "arguments": [{"entity_id": "16685007_12_Ent1", "role": "Treatment", "text": "ciclesonide", "start": 4, "end": 5}, {"entity_id": "16685007_12_Ent3", "role": "Treatment_Drug", "text": "ciclesonide", "start": 4, "end": 5}, {"entity_id": "16685007_12_Ent2", "role": "Treatment_Drug", "text": "OCS", "start": 10, "end": 11}, {"entity_id": "16685007_12_Ent0", "role": "Subject", "text": "patients with severe , persistent asthma", "start": 12, "end": 18}, {"entity_id": "16685007_12_Ent4", "role": "Treatment_Disorder", "text": "severe , persistent asthma", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "16685007_12_Ent1", "text": "ciclesonide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16685007_12_Ent3", "text": "ciclesonide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16685007_12_Ent2", "text": "OCS", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16685007_12_Ent0", "text": "patients with severe , persistent asthma", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "16685007_12_Ent4", "text": "severe , persistent asthma", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "16728538_3", "wnd_id": "16728538_3_1", "text": "The hepatic enzyme disturbances normalized after discontinuation of pegvisomant .", "tokens": ["The", "hepatic", "enzyme", "disturbances", "normalized", "after", "discontinuation", "of", "pegvisomant", "."], "event_mentions": [{"id": "16728538_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "16728538_3_Ent0", "role": "Effect", "text": "The hepatic enzyme disturbances", "start": 0, "end": 4}, {"entity_id": "16728538_3_Ent1", "role": "Treatment", "text": "pegvisomant", "start": 8, "end": 9}, {"entity_id": "16728538_3_Ent2", "role": "Treatment_Drug", "text": "pegvisomant", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "16728538_3_Ent0", "text": "The hepatic enzyme disturbances", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16728538_3_Ent1", "text": "pegvisomant", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16728538_3_Ent2", "text": "pegvisomant", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "1673494_1", "wnd_id": "1673494_1_1", "text": "Amphotericin B ( AmB ) is effective , but its use is limited by toxicity : renal impairment , anaemia , fever , malaise , and hypokalaemia are common .", "tokens": ["Amphotericin", "B", "(", "AmB", ")", "is", "effective", ",", "but", "its", "use", "is", "limited", "by", "toxicity", ":", "renal", "impairment", ",", "anaemia", ",", "fever", ",", "malaise", ",", "and", "hypokalaemia", "are", "common", "."], "event_mentions": [{"id": "1673494_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 13, "end": 14}, "arguments": [{"entity_id": "1673494_1_Ent2", "role": "Treatment_Drug", "text": "Amphotericin B", "start": 0, "end": 2}, {"entity_id": "1673494_1_Ent1", "role": "Treatment", "text": "Amphotericin B ( AmB )", "start": 0, "end": 5}, {"entity_id": "1673494_1_Ent0", "role": "Effect", "text": "toxicity : renal impairment , anaemia , fever , malaise , and hypokalaemia", "start": 14, "end": 27}]}], "entity_mentions": [{"id": "1673494_1_Ent2", "text": "Amphotericin B", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1673494_1_Ent1", "text": "Amphotericin B ( AmB )", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "1673494_1_Ent0", "text": "toxicity : renal impairment , anaemia , fever , malaise , and hypokalaemia", "entity_type": "Entity", "start": 14, "end": 27}], "lang": "en"}
{"doc_id": "16765687_1", "wnd_id": "16765687_1_1", "text": "PURPOSE : Topiramate - induced angle - closure glaucoma ( TiACG ) is believed to be related to its sulfonamide moiety .", "tokens": ["PURPOSE", ":", "Topiramate", "-", "induced", "angle", "-", "closure", "glaucoma", "(", "TiACG", ")", "is", "believed", "to", "be", "related", "to", "its", "sulfonamide", "moiety", "."], "event_mentions": [{"id": "16765687_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "16765687_1_Ent1", "role": "Treatment", "text": "Topiramate", "start": 2, "end": 3}, {"entity_id": "16765687_1_Ent2", "role": "Treatment_Drug", "text": "Topiramate", "start": 2, "end": 3}, {"entity_id": "16765687_1_Ent0", "role": "Effect", "text": "angle - closure glaucoma ( TiACG )", "start": 5, "end": 12}]}], "entity_mentions": [{"id": "16765687_1_Ent1", "text": "Topiramate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16765687_1_Ent2", "text": "Topiramate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16765687_1_Ent0", "text": "angle - closure glaucoma ( TiACG )", "entity_type": "Entity", "start": 5, "end": 12}], "lang": "en"}
{"doc_id": "16791713_4", "wnd_id": "16791713_4_1", "text": "We conclude that myocardial infarction may develop in patients treated with high - dose glucocorticoids for Graves ' ophthalmopathy , and increased blood pressure may herald this complication .", "tokens": ["We", "conclude", "that", "myocardial", "infarction", "may", "develop", "in", "patients", "treated", "with", "high", "-", "dose", "glucocorticoids", "for", "Graves", "'", "ophthalmopathy", ",", "and", "increased", "blood", "pressure", "may", "herald", "this", "complication", "."], "event_mentions": [{"id": "16791713_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 6, "end": 7}, "arguments": [{"entity_id": "16791713_4_Ent1", "role": "Effect", "text": "myocardial infarction", "start": 3, "end": 5}, {"entity_id": "16791713_4_Ent0", "role": "Subject", "text": "patients", "start": 8, "end": 9}, {"entity_id": "16791713_4_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 11, "end": 14}, {"entity_id": "16791713_4_Ent3", "role": "Treatment", "text": "high - dose glucocorticoids", "start": 11, "end": 15}, {"entity_id": "16791713_4_Ent4", "role": "Treatment_Drug", "text": "glucocorticoids", "start": 14, "end": 15}, {"entity_id": "16791713_4_Ent6", "role": "Treatment_Disorder", "text": "Graves ' ophthalmopathy", "start": 16, "end": 19}, {"entity_id": "16791713_4_Ent2", "role": "Effect", "text": "increased blood pressure", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "16791713_4_Ent1", "text": "myocardial infarction", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16791713_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16791713_4_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "16791713_4_Ent3", "text": "high - dose glucocorticoids", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "16791713_4_Ent4", "text": "glucocorticoids", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16791713_4_Ent6", "text": "Graves ' ophthalmopathy", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "16791713_4_Ent2", "text": "increased blood pressure", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "1680596_1", "wnd_id": "1680596_1_1", "text": "Presented is a case story of a woman with classical rheumatoid arthritis , who during introduction of sulphasalazine ( SASP ) therapy developed a severe and lasting psoriasis - like skin reaction .", "tokens": ["Presented", "is", "a", "case", "story", "of", "a", "woman", "with", "classical", "rheumatoid", "arthritis", ",", "who", "during", "introduction", "of", "sulphasalazine", "(", "SASP", ")", "therapy", "developed", "a", "severe", "and", "lasting", "psoriasis", "-", "like", "skin", "reaction", "."], "event_mentions": [{"id": "1680596_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 22, "end": 23}, "arguments": [{"entity_id": "1680596_1_Ent0", "role": "Subject", "text": "a woman with classical rheumatoid arthritis", "start": 6, "end": 12}, {"entity_id": "1680596_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "1680596_1_Ent5", "role": "Treatment_Disorder", "text": "classical rheumatoid arthritis", "start": 9, "end": 12}, {"entity_id": "1680596_1_Ent3", "role": "Treatment", "text": "during introduction of sulphasalazine ( SASP ) therapy", "start": 14, "end": 22}, {"entity_id": "1680596_1_Ent4", "role": "Treatment_Drug", "text": "sulphasalazine", "start": 17, "end": 18}, {"entity_id": "1680596_1_Ent2", "role": "Effect", "text": "psoriasis - like skin reaction", "start": 27, "end": 32}]}], "entity_mentions": [{"id": "1680596_1_Ent0", "text": "a woman with classical rheumatoid arthritis", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "1680596_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1680596_1_Ent5", "text": "classical rheumatoid arthritis", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "1680596_1_Ent3", "text": "during introduction of sulphasalazine ( SASP ) therapy", "entity_type": "Entity", "start": 14, "end": 22}, {"id": "1680596_1_Ent4", "text": "sulphasalazine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "1680596_1_Ent2", "text": "psoriasis - like skin reaction", "entity_type": "Entity", "start": 27, "end": 32}], "lang": "en"}
{"doc_id": "16882112_3", "wnd_id": "16882112_3_1", "text": "The concomitant use of antidepressant drugs associated with lithium as a co - adjuvant seems to increase the risk of this adverse reaction .", "tokens": ["The", "concomitant", "use", "of", "antidepressant", "drugs", "associated", "with", "lithium", "as", "a", "co", "-", "adjuvant", "seems", "to", "increase", "the", "risk", "of", "this", "adverse", "reaction", "."], "event_mentions": [{"id": "16882112_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 16, "end": 17}, "arguments": [{"entity_id": "16882112_3_Ent1", "role": "Treatment", "text": "concomitant use of antidepressant drugs associated with lithium as a co - adjuvant", "start": 1, "end": 14}, {"entity_id": "16882112_3_Ent2", "role": "Treatment_Drug", "text": "antidepressant drugs", "start": 4, "end": 6}, {"entity_id": "16882112_3_Ent4", "role": "Combination_Drug", "text": "antidepressant drugs", "start": 4, "end": 6}, {"entity_id": "16882112_3_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 8, "end": 9}, {"entity_id": "16882112_3_Ent5", "role": "Combination_Drug", "text": "lithium", "start": 8, "end": 9}, {"entity_id": "16882112_3_Ent0", "role": "Effect", "text": "adverse reaction", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "16882112_3_Ent1", "text": "concomitant use of antidepressant drugs associated with lithium as a co - adjuvant", "entity_type": "Entity", "start": 1, "end": 14}, {"id": "16882112_3_Ent2", "text": "antidepressant drugs", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "16882112_3_Ent4", "text": "antidepressant drugs", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "16882112_3_Ent3", "text": "lithium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16882112_3_Ent5", "text": "lithium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16882112_3_Ent0", "text": "adverse reaction", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "16884425_1", "wnd_id": "16884425_1_1", "text": "A 35 - year - old woman presented with neurotoxicity correlated to an i.v . regimen of 5 - fluorouracil as episodes of acute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum .", "tokens": ["A", "35", "-", "year", "-", "old", "woman", "presented", "with", "neurotoxicity", "correlated", "to", "an", "i.v", ".", "regimen", "of", "5", "-", "fluorouracil", "as", "episodes", "of", "acute", "confusional", "state", "and", "abnormalities", "of", "symmetrically", "restricted", "diffusion", "in", "the", "periventricular", "white", "matter", "and", "corpus", "callosum", "."], "event_mentions": [{"id": "16884425_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "correlated", "start": 10, "end": 11}, "arguments": [{"entity_id": "16884425_1_Ent0", "role": "Subject", "text": "A 35 - year - old woman", "start": 0, "end": 7}, {"entity_id": "16884425_1_Ent1", "role": "Subject_Age", "text": "35 - year - old", "start": 1, "end": 6}, {"entity_id": "16884425_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "16884425_1_Ent3", "role": "Effect", "text": "neurotoxicity", "start": 9, "end": 10}, {"entity_id": "16884425_1_Ent5", "role": "Treatment", "text": "an i.v . regimen of 5 - fluorouracil", "start": 12, "end": 20}, {"entity_id": "16884425_1_Ent7", "role": "Treatment_Route", "text": "i.v .", "start": 13, "end": 15}, {"entity_id": "16884425_1_Ent6", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 17, "end": 20}, {"entity_id": "16884425_1_Ent4", "role": "Effect", "text": "acute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum", "start": 23, "end": 40}]}], "entity_mentions": [{"id": "16884425_1_Ent0", "text": "A 35 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "16884425_1_Ent1", "text": "35 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "16884425_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16884425_1_Ent3", "text": "neurotoxicity", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16884425_1_Ent5", "text": "an i.v . regimen of 5 - fluorouracil", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "16884425_1_Ent7", "text": "i.v .", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "16884425_1_Ent6", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "16884425_1_Ent4", "text": "acute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum", "entity_type": "Entity", "start": 23, "end": 40}], "lang": "en"}
{"doc_id": "16889287_3", "wnd_id": "16889287_3_1", "text": "We report the case of a 21 - year - old female patient with dapsone hypersensitivity syndrome .", "tokens": ["We", "report", "the", "case", "of", "a", "21", "-", "year", "-", "old", "female", "patient", "with", "dapsone", "hypersensitivity", "syndrome", "."], "event_mentions": [{"id": "16889287_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 13, "end": 14}, "arguments": [{"entity_id": "16889287_3_Ent0", "role": "Subject", "text": "a 21 - year - old female patient", "start": 5, "end": 13}, {"entity_id": "16889287_3_Ent1", "role": "Subject_Age", "text": "21 - year - old", "start": 6, "end": 11}, {"entity_id": "16889287_3_Ent2", "role": "Subject_Gender", "text": "female", "start": 11, "end": 12}, {"entity_id": "16889287_3_Ent4", "role": "Treatment", "text": "dapsone", "start": 14, "end": 15}, {"entity_id": "16889287_3_Ent5", "role": "Treatment_Drug", "text": "dapsone", "start": 14, "end": 15}, {"entity_id": "16889287_3_Ent3", "role": "Effect", "text": "hypersensitivity syndrome", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "16889287_3_Ent0", "text": "a 21 - year - old female patient", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "16889287_3_Ent1", "text": "21 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16889287_3_Ent2", "text": "female", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16889287_3_Ent4", "text": "dapsone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16889287_3_Ent5", "text": "dapsone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16889287_3_Ent3", "text": "hypersensitivity syndrome", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "1695794_5", "wnd_id": "1695794_5_1", "text": "Disopyramide was started on admission for supraventricular tachycardia .", "tokens": ["Disopyramide", "was", "started", "on", "admission", "for", "supraventricular", "tachycardia", "."], "event_mentions": [{"id": "1695794_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "started", "start": 2, "end": 3}, "arguments": [{"entity_id": "1695794_5_Ent0", "role": "Treatment", "text": "Disopyramide", "start": 0, "end": 1}, {"entity_id": "1695794_5_Ent2", "role": "Treatment_Drug", "text": "Disopyramide", "start": 0, "end": 1}, {"entity_id": "1695794_5_Ent1", "role": "Treatment_Disorder", "text": "supraventricular tachycardia", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "1695794_5_Ent0", "text": "Disopyramide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1695794_5_Ent2", "text": "Disopyramide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1695794_5_Ent1", "text": "supraventricular tachycardia", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "16960880_1", "wnd_id": "16960880_1_1", "text": "Despite a very low complication rate , several severe arterial thrombotic events have been reported following thrombin injection of pseudoaneurysms .", "tokens": ["Despite", "a", "very", "low", "complication", "rate", ",", "several", "severe", "arterial", "thrombotic", "events", "have", "been", "reported", "following", "thrombin", "injection", "of", "pseudoaneurysms", "."], "event_mentions": [{"id": "16960880_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 15, "end": 16}, "arguments": [{"entity_id": "16960880_1_Ent0", "role": "Effect", "text": "arterial thrombotic", "start": 9, "end": 11}, {"entity_id": "16960880_1_Ent2", "role": "Treatment_Drug", "text": "thrombin", "start": 16, "end": 17}, {"entity_id": "16960880_1_Ent1", "role": "Treatment", "text": "thrombin injection", "start": 16, "end": 18}, {"entity_id": "16960880_1_Ent3", "role": "Treatment_Route", "text": "injection", "start": 17, "end": 18}, {"entity_id": "16960880_1_Ent4", "role": "Treatment_Disorder", "text": "pseudoaneurysms", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "16960880_1_Ent0", "text": "arterial thrombotic", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16960880_1_Ent2", "text": "thrombin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16960880_1_Ent1", "text": "thrombin injection", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "16960880_1_Ent3", "text": "injection", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16960880_1_Ent4", "text": "pseudoaneurysms", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "16960880_2", "wnd_id": "16960880_2_1", "text": "Lower extremity arterial thrombosis following sonographically guided thrombin injection of a femoral pseudoaneurysm .", "tokens": ["Lower", "extremity", "arterial", "thrombosis", "following", "sonographically", "guided", "thrombin", "injection", "of", "a", "femoral", "pseudoaneurysm", "."], "event_mentions": [{"id": "16960880_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "16960880_2_Ent0", "role": "Effect", "text": "Lower extremity arterial thrombosis", "start": 0, "end": 4}, {"entity_id": "16960880_2_Ent2", "role": "Treatment_Drug", "text": "thrombin", "start": 7, "end": 8}, {"entity_id": "16960880_2_Ent1", "role": "Treatment", "text": "thrombin injection of a femoral pseudoaneurysm", "start": 7, "end": 13}, {"entity_id": "16960880_2_Ent3", "role": "Treatment_Route", "text": "injection", "start": 8, "end": 9}, {"entity_id": "16960880_2_Ent4", "role": "Treatment_Disorder", "text": "femoral pseudoaneurysm", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "16960880_2_Ent0", "text": "Lower extremity arterial thrombosis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16960880_2_Ent2", "text": "thrombin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16960880_2_Ent1", "text": "thrombin injection of a femoral pseudoaneurysm", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "16960880_2_Ent3", "text": "injection", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16960880_2_Ent4", "text": "femoral pseudoaneurysm", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "16968538_8", "wnd_id": "16968538_8_1", "text": "CONCLUSION : The hemolytic - uremic syndrome may be a rare complication of oxaliplatin - based chemotherapy .", "tokens": ["CONCLUSION", ":", "The", "hemolytic", "-", "uremic", "syndrome", "may", "be", "a", "rare", "complication", "of", "oxaliplatin", "-", "based", "chemotherapy", "."], "event_mentions": [{"id": "16968538_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 11, "end": 12}, "arguments": [{"entity_id": "16968538_8_Ent0", "role": "Effect", "text": "hemolytic - uremic syndrome", "start": 3, "end": 7}, {"entity_id": "16968538_8_Ent2", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 13, "end": 14}, {"entity_id": "16968538_8_Ent1", "role": "Treatment", "text": "oxaliplatin - based chemotherapy", "start": 13, "end": 17}, {"entity_id": "16968538_8_Ent3", "role": "Treatment_Route", "text": "chemotherapy", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "16968538_8_Ent0", "text": "hemolytic - uremic syndrome", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16968538_8_Ent2", "text": "oxaliplatin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16968538_8_Ent1", "text": "oxaliplatin - based chemotherapy", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "16968538_8_Ent3", "text": "chemotherapy", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "16997047_2", "wnd_id": "16997047_2_1", "text": "In this case , unlike those previously reported , hyponatremia recurred 5 months after switching from citalopram to mirtazapine , which is believed to be a safe antidepressant .", "tokens": ["In", "this", "case", ",", "unlike", "those", "previously", "reported", ",", "hyponatremia", "recurred", "5", "months", "after", "switching", "from", "citalopram", "to", "mirtazapine", ",", "which", "is", "believed", "to", "be", "a", "safe", "antidepressant", "."], "event_mentions": [{"id": "16997047_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 13, "end": 14}, "arguments": [{"entity_id": "16997047_2_Ent0", "role": "Effect", "text": "hyponatremia", "start": 9, "end": 10}, {"entity_id": "16997047_2_Ent4", "role": "Treatment_Time_elapsed", "text": "5 months", "start": 11, "end": 13}, {"entity_id": "16997047_2_Ent1", "role": "Treatment", "text": "switching from citalopram to mirtazapine", "start": 14, "end": 19}, {"entity_id": "16997047_2_Ent2", "role": "Treatment_Drug", "text": "citalopram", "start": 16, "end": 17}, {"entity_id": "16997047_2_Ent3", "role": "Treatment_Drug", "text": "mirtazapine", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "16997047_2_Ent0", "text": "hyponatremia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16997047_2_Ent4", "text": "5 months", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "16997047_2_Ent1", "text": "switching from citalopram to mirtazapine", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "16997047_2_Ent2", "text": "citalopram", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16997047_2_Ent3", "text": "mirtazapine", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "17009081_4", "wnd_id": "17009081_4_1", "text": "Though proteinuria and nephrotic syndrome is a rare adverse effect of IFN - beta - 1b therapy , physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings .", "tokens": ["Though", "proteinuria", "and", "nephrotic", "syndrome", "is", "a", "rare", "adverse", "effect", "of", "IFN", "-", "beta", "-", "1b", "therapy", ",", "physicians", "treating", "MS", "patients", "with", "this", "agent", "should", "pay", "careful", "attention", "to", "new", "clinical", "symptoms", "and", "laboratory", "findings", "."], "event_mentions": [{"id": "17009081_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effect", "start": 8, "end": 10}, "arguments": [{"entity_id": "17009081_4_Ent1", "role": "Effect", "text": "proteinuria and nephrotic syndrome", "start": 1, "end": 5}, {"entity_id": "17009081_4_Ent2", "role": "Treatment", "text": "IFN - beta - 1b", "start": 11, "end": 16}, {"entity_id": "17009081_4_Ent3", "role": "Treatment_Drug", "text": "IFN - beta - 1b", "start": 11, "end": 16}, {"entity_id": "17009081_4_Ent4", "role": "Treatment_Disorder", "text": "MS", "start": 20, "end": 21}, {"entity_id": "17009081_4_Ent0", "role": "Subject", "text": "MS patients", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "17009081_4_Ent1", "text": "proteinuria and nephrotic syndrome", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "17009081_4_Ent2", "text": "IFN - beta - 1b", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "17009081_4_Ent3", "text": "IFN - beta - 1b", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "17009081_4_Ent4", "text": "MS", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17009081_4_Ent0", "text": "MS patients", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "17034541_2", "wnd_id": "17034541_2_1", "text": "Several such HBV reactivations were reported after combined rituximab and multiagent chemotherapy for B - cell lymphomas .", "tokens": ["Several", "such", "HBV", "reactivations", "were", "reported", "after", "combined", "rituximab", "and", "multiagent", "chemotherapy", "for", "B", "-", "cell", "lymphomas", "."], "event_mentions": [{"id": "17034541_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "17034541_2_Ent0", "role": "Effect", "text": "Several such HBV reactivations", "start": 0, "end": 4}, {"entity_id": "17034541_2_Ent1", "role": "Treatment", "text": "combined rituximab and multiagent chemotherapy", "start": 7, "end": 12}, {"entity_id": "17034541_2_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 8, "end": 9}, {"entity_id": "17034541_2_Ent4", "role": "Treatment_Route", "text": "chemotherapy", "start": 11, "end": 12}, {"entity_id": "17034541_2_Ent3", "role": "Treatment_Disorder", "text": "B - cell lymphomas", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "17034541_2_Ent0", "text": "Several such HBV reactivations", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17034541_2_Ent1", "text": "combined rituximab and multiagent chemotherapy", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "17034541_2_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17034541_2_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17034541_2_Ent3", "text": "B - cell lymphomas", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "17068466_3", "wnd_id": "17068466_3_1", "text": "Severe corneal toxicity after topical fluoroquinolone therapy : report of two cases .", "tokens": ["Severe", "corneal", "toxicity", "after", "topical", "fluoroquinolone", "therapy", ":", "report", "of", "two", "cases", "."], "event_mentions": [{"id": "17068466_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "17068466_3_Ent0", "role": "Effect", "text": "corneal toxicity", "start": 1, "end": 3}, {"entity_id": "17068466_3_Ent1", "role": "Treatment", "text": "topical fluoroquinolone therapy", "start": 4, "end": 7}, {"entity_id": "17068466_3_Ent2", "role": "Treatment_Drug", "text": "fluoroquinolone", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "17068466_3_Ent0", "text": "corneal toxicity", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "17068466_3_Ent1", "text": "topical fluoroquinolone therapy", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "17068466_3_Ent2", "text": "fluoroquinolone", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "17083890_2", "wnd_id": "17083890_2_1", "text": "Nail and skin alterations associated with the use of chemotherapy have been described in the last decade involving various combinations of two different types of nail changes .", "tokens": ["Nail", "and", "skin", "alterations", "associated", "with", "the", "use", "of", "chemotherapy", "have", "been", "described", "in", "the", "last", "decade", "involving", "various", "combinations", "of", "two", "different", "types", "of", "nail", "changes", "."], "event_mentions": [{"id": "17083890_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "17083890_2_Ent0", "role": "Effect", "text": "Nail and skin alterations", "start": 0, "end": 4}, {"entity_id": "17083890_2_Ent1", "role": "Treatment", "text": "chemotherapy", "start": 9, "end": 10}, {"entity_id": "17083890_2_Ent2", "role": "Treatment_Route", "text": "chemotherapy", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "17083890_2_Ent0", "text": "Nail and skin alterations", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17083890_2_Ent1", "text": "chemotherapy", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17083890_2_Ent2", "text": "chemotherapy", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "17090724_3", "wnd_id": "17090724_3_1", "text": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient .", "tokens": ["Use", "of", "the", "Naranjo", "probability", "scale", "indicated", "a", "highly", "probable", "relationship", "between", "the", "observed", "cardiac", "toxicity", "and", "amphotericin", "B", "deoxycholate", "therapy", "in", "this", "patient", "."], "event_mentions": [{"id": "17090724_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 10, "end": 11}, "arguments": [{"entity_id": "17090724_3_Ent1", "role": "Effect", "text": "cardiac toxicity", "start": 14, "end": 16}, {"entity_id": "17090724_3_Ent2", "role": "Treatment", "text": "amphotericin B deoxycholate", "start": 17, "end": 20}, {"entity_id": "17090724_3_Ent3", "role": "Treatment_Drug", "text": "amphotericin B deoxycholate", "start": 17, "end": 20}, {"entity_id": "17090724_3_Ent0", "role": "Subject", "text": "patient", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "17090724_3_Ent1", "text": "cardiac toxicity", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "17090724_3_Ent2", "text": "amphotericin B deoxycholate", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "17090724_3_Ent3", "text": "amphotericin B deoxycholate", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "17090724_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "1711090_6", "wnd_id": "1711090_6_1", "text": "The main side - effects of Lp - TAE combined with HT were low - grade fever , localized pain , myelo - suppression and liver dysfunction , but these were transient and eventually disappeared .", "tokens": ["The", "main", "side", "-", "effects", "of", "Lp", "-", "TAE", "combined", "with", "HT", "were", "low", "-", "grade", "fever", ",", "localized", "pain", ",", "myelo", "-", "suppression", "and", "liver", "dysfunction", ",", "but", "these", "were", "transient", "and", "eventually", "disappeared", "."], "event_mentions": [{"id": "1711090_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side - effects", "start": 2, "end": 5}, "arguments": [{"entity_id": "1711090_6_Ent2", "role": "Treatment_Drug", "text": "Lp - TAE", "start": 6, "end": 9}, {"entity_id": "1711090_6_Ent4", "role": "Combination_Drug", "text": "Lp - TAE", "start": 6, "end": 9}, {"entity_id": "1711090_6_Ent1", "role": "Treatment", "text": "Lp - TAE combined with HT", "start": 6, "end": 12}, {"entity_id": "1711090_6_Ent3", "role": "Treatment_Drug", "text": "HT", "start": 11, "end": 12}, {"entity_id": "1711090_6_Ent5", "role": "Combination_Drug", "text": "HT", "start": 11, "end": 12}, {"entity_id": "1711090_6_Ent0", "role": "Effect", "text": "low - grade fever , localized pain , myelo - suppression and liver dysfunction", "start": 13, "end": 27}]}], "entity_mentions": [{"id": "1711090_6_Ent2", "text": "Lp - TAE", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "1711090_6_Ent4", "text": "Lp - TAE", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "1711090_6_Ent1", "text": "Lp - TAE combined with HT", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "1711090_6_Ent3", "text": "HT", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "1711090_6_Ent5", "text": "HT", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "1711090_6_Ent0", "text": "low - grade fever , localized pain , myelo - suppression and liver dysfunction", "entity_type": "Entity", "start": 13, "end": 27}], "lang": "en"}
{"doc_id": "17122225_1", "wnd_id": "17122225_1_1", "text": "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs .", "tokens": ["Serotonin", "syndrome", "from", "the", "interaction", "of", "cyclobenzaprine", "with", "other", "serotoninergic", "drugs", "."], "event_mentions": [{"id": "17122225_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "17122225_1_Ent0", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "17122225_1_Ent1", "role": "Treatment", "text": "interaction of cyclobenzaprine with other serotoninergic drugs", "start": 4, "end": 11}, {"entity_id": "17122225_1_Ent2", "role": "Treatment_Drug", "text": "cyclobenzaprine", "start": 6, "end": 7}, {"entity_id": "17122225_1_Ent3", "role": "Treatment_Drug", "text": "serotoninergic drugs", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "17122225_1_Ent0", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17122225_1_Ent1", "text": "interaction of cyclobenzaprine with other serotoninergic drugs", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "17122225_1_Ent2", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17122225_1_Ent3", "text": "serotoninergic drugs", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "17122225_4", "wnd_id": "17122225_4_1", "text": "We report two cases of severe serotonin syndrome induced by the administration of cyclobenzaprine in postoperative patients already receiving another proserotoninergic drug ( phenelzine in one case and duloxetine in the other ) .", "tokens": ["We", "report", "two", "cases", "of", "severe", "serotonin", "syndrome", "induced", "by", "the", "administration", "of", "cyclobenzaprine", "in", "postoperative", "patients", "already", "receiving", "another", "proserotoninergic", "drug", "(", "phenelzine", "in", "one", "case", "and", "duloxetine", "in", "the", "other", ")", "."], "event_mentions": [{"id": "17122225_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "17122225_4_Ent2", "role": "Effect", "text": "serotonin syndrome", "start": 6, "end": 8}, {"entity_id": "17122225_4_Ent3", "role": "Treatment", "text": "cyclobenzaprine", "start": 13, "end": 14}, {"entity_id": "17122225_4_Ent6", "role": "Combination_Drug", "text": "cyclobenzaprine", "start": 13, "end": 14}, {"entity_id": "17122225_4_Ent1", "role": "Subject_Disorder", "text": "postoperative", "start": 15, "end": 16}, {"entity_id": "17122225_4_Ent0", "role": "Subject", "text": "postoperative patients", "start": 15, "end": 17}, {"entity_id": "17122225_4_Ent4", "role": "Treatment", "text": "duloxetine", "start": 28, "end": 29}, {"entity_id": "17122225_4_Ent5", "role": "Treatment_Drug", "text": "duloxetine", "start": 28, "end": 29}, {"entity_id": "17122225_4_Ent7", "role": "Combination_Drug", "text": "duloxetine", "start": 28, "end": 29}]}, {"id": "17122225_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "17122225_4_Ent10", "role": "Effect", "text": "serotonin syndrome", "start": 6, "end": 8}, {"entity_id": "17122225_4_Ent11", "role": "Treatment", "text": "cyclobenzaprine", "start": 13, "end": 14}, {"entity_id": "17122225_4_Ent13", "role": "Treatment_Drug", "text": "cyclobenzaprine", "start": 13, "end": 14}, {"entity_id": "17122225_4_Ent15", "role": "Combination_Drug", "text": "cyclobenzaprine", "start": 13, "end": 14}, {"entity_id": "17122225_4_Ent9", "role": "Subject_Disorder", "text": "postoperative", "start": 15, "end": 16}, {"entity_id": "17122225_4_Ent8", "role": "Subject", "text": "postoperative patients", "start": 15, "end": 17}, {"entity_id": "17122225_4_Ent12", "role": "Treatment", "text": "phenelzine", "start": 23, "end": 24}, {"entity_id": "17122225_4_Ent14", "role": "Treatment_Drug", "text": "phenelzine", "start": 23, "end": 24}, {"entity_id": "17122225_4_Ent16", "role": "Combination_Drug", "text": "phenelzine", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "17122225_4_Ent2", "text": "serotonin syndrome", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17122225_4_Ent10", "text": "serotonin syndrome", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17122225_4_Ent3", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17122225_4_Ent6", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17122225_4_Ent11", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17122225_4_Ent13", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17122225_4_Ent15", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17122225_4_Ent1", "text": "postoperative", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17122225_4_Ent9", "text": "postoperative", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17122225_4_Ent0", "text": "postoperative patients", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "17122225_4_Ent8", "text": "postoperative patients", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "17122225_4_Ent12", "text": "phenelzine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17122225_4_Ent14", "text": "phenelzine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17122225_4_Ent16", "text": "phenelzine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17122225_4_Ent4", "text": "duloxetine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "17122225_4_Ent5", "text": "duloxetine", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "17122225_4_Ent7", "text": "duloxetine", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "17199845_1", "wnd_id": "17199845_1_1", "text": "However , cyclosporine dependency is associated with the risk of nephrotoxicity .", "tokens": ["However", ",", "cyclosporine", "dependency", "is", "associated", "with", "the", "risk", "of", "nephrotoxicity", "."], "event_mentions": [{"id": "17199845_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "17199845_1_Ent2", "role": "Treatment_Drug", "text": "cyclosporine", "start": 2, "end": 3}, {"entity_id": "17199845_1_Ent1", "role": "Treatment", "text": "cyclosporine dependency", "start": 2, "end": 4}, {"entity_id": "17199845_1_Ent0", "role": "Effect", "text": "nephrotoxicity", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17199845_1_Ent2", "text": "cyclosporine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17199845_1_Ent1", "text": "cyclosporine dependency", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "17199845_1_Ent0", "text": "nephrotoxicity", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "172214_1", "wnd_id": "172214_1_1", "text": "Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin - D and mithramycin .", "tokens": ["Cardiomyopathy", "after", "widely", "separated", "courses", "of", "adriamycin", "exacerbated", "by", "actinomycin", "-", "D", "and", "mithramycin", "."], "event_mentions": [{"id": "172214_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exacerbated", "start": 7, "end": 8}, "arguments": [{"entity_id": "172214_1_Ent0", "role": "Effect", "text": "Cardiomyopathy", "start": 0, "end": 1}, {"entity_id": "172214_1_Ent2", "role": "Treatment", "text": "widely separated courses of adriamycin", "start": 2, "end": 7}, {"entity_id": "172214_1_Ent4", "role": "Treatment_Drug", "text": "adriamycin", "start": 6, "end": 7}, {"entity_id": "172214_1_Ent7", "role": "Combination_Drug", "text": "adriamycin", "start": 6, "end": 7}, {"entity_id": "172214_1_Ent1", "role": "Effect", "text": "exacerbated", "start": 7, "end": 8}, {"entity_id": "172214_1_Ent5", "role": "Treatment_Drug", "text": "actinomycin - D", "start": 9, "end": 12}, {"entity_id": "172214_1_Ent8", "role": "Combination_Drug", "text": "actinomycin - D", "start": 9, "end": 12}, {"entity_id": "172214_1_Ent3", "role": "Treatment", "text": "actinomycin - D and mithramycin", "start": 9, "end": 14}, {"entity_id": "172214_1_Ent6", "role": "Treatment_Drug", "text": "mithramycin", "start": 13, "end": 14}, {"entity_id": "172214_1_Ent9", "role": "Combination_Drug", "text": "mithramycin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "172214_1_Ent0", "text": "Cardiomyopathy", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "172214_1_Ent2", "text": "widely separated courses of adriamycin", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "172214_1_Ent4", "text": "adriamycin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "172214_1_Ent7", "text": "adriamycin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "172214_1_Ent1", "text": "exacerbated", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "172214_1_Ent5", "text": "actinomycin - D", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "172214_1_Ent8", "text": "actinomycin - D", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "172214_1_Ent3", "text": "actinomycin - D and mithramycin", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "172214_1_Ent6", "text": "mithramycin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "172214_1_Ent9", "text": "mithramycin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "17316160_5", "wnd_id": "17316160_5_1", "text": "To our knowledge , this is the first published report of a possible drug interaction in a critically ill patient receiving concomitant linezolid and rifampin .", "tokens": ["To", "our", "knowledge", ",", "this", "is", "the", "first", "published", "report", "of", "a", "possible", "drug", "interaction", "in", "a", "critically", "ill", "patient", "receiving", "concomitant", "linezolid", "and", "rifampin", "."], "event_mentions": [{"id": "17316160_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 20, "end": 21}, "arguments": [{"entity_id": "17316160_5_Ent2", "role": "Effect", "text": "drug interaction", "start": 13, "end": 15}, {"entity_id": "17316160_5_Ent0", "role": "Subject", "text": "a critically ill patient", "start": 16, "end": 20}, {"entity_id": "17316160_5_Ent1", "role": "Subject_Disorder", "text": "critically ill", "start": 17, "end": 19}, {"entity_id": "17316160_5_Ent3", "role": "Treatment", "text": "concomitant linezolid and rifampin", "start": 21, "end": 25}, {"entity_id": "17316160_5_Ent4", "role": "Treatment_Drug", "text": "linezolid", "start": 22, "end": 23}, {"entity_id": "17316160_5_Ent6", "role": "Combination_Drug", "text": "linezolid", "start": 22, "end": 23}, {"entity_id": "17316160_5_Ent5", "role": "Treatment_Drug", "text": "rifampin", "start": 24, "end": 25}, {"entity_id": "17316160_5_Ent7", "role": "Combination_Drug", "text": "rifampin", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "17316160_5_Ent2", "text": "drug interaction", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "17316160_5_Ent0", "text": "a critically ill patient", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "17316160_5_Ent1", "text": "critically ill", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "17316160_5_Ent3", "text": "concomitant linezolid and rifampin", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "17316160_5_Ent4", "text": "linezolid", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17316160_5_Ent6", "text": "linezolid", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17316160_5_Ent5", "text": "rifampin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "17316160_5_Ent7", "text": "rifampin", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "17329303_10", "wnd_id": "17329303_10_1", "text": "Functional regulation of certain neuroreceptors during risperidone treatment may lead to altered behavioural responses upon switching to methylphenidate .", "tokens": ["Functional", "regulation", "of", "certain", "neuroreceptors", "during", "risperidone", "treatment", "may", "lead", "to", "altered", "behavioural", "responses", "upon", "switching", "to", "methylphenidate", "."], "event_mentions": [{"id": "17329303_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 9, "end": 10}, "arguments": [{"entity_id": "17329303_10_Ent1", "role": "Treatment", "text": "risperidone", "start": 6, "end": 7}, {"entity_id": "17329303_10_Ent3", "role": "Treatment_Drug", "text": "risperidone", "start": 6, "end": 7}, {"entity_id": "17329303_10_Ent0", "role": "Effect", "text": "altered behavioural responses", "start": 11, "end": 14}, {"entity_id": "17329303_10_Ent2", "role": "Treatment", "text": "switching to methylphenidate", "start": 15, "end": 18}, {"entity_id": "17329303_10_Ent4", "role": "Treatment_Drug", "text": "methylphenidate", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17329303_10_Ent1", "text": "risperidone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17329303_10_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17329303_10_Ent0", "text": "altered behavioural responses", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "17329303_10_Ent2", "text": "switching to methylphenidate", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "17329303_10_Ent4", "text": "methylphenidate", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17331261_1", "wnd_id": "17331261_1_1", "text": "CASE PRESENTATION : We report a patient with CF who developed recurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative - free tobramycin by inhalation , beginning at 16 months of age .", "tokens": ["CASE", "PRESENTATION", ":", "We", "report", "a", "patient", "with", "CF", "who", "developed", "recurrent", "eosinophilia", "and", "severe", "persistent", "bronchospasm", "following", "repeated", "administration", "of", "preservative", "-", "free", "tobramycin", "by", "inhalation", ",", "beginning", "at", "16", "months", "of", "age", "."], "event_mentions": [{"id": "17331261_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "17331261_1_Ent0", "role": "Subject", "text": "a patient with CF", "start": 5, "end": 9}, {"entity_id": "17331261_1_Ent5", "role": "Treatment_Disorder", "text": "CF", "start": 8, "end": 9}, {"entity_id": "17331261_1_Ent3", "role": "Effect", "text": "recurrent eosinophilia and severe persistent bronchospasm", "start": 11, "end": 17}, {"entity_id": "17331261_1_Ent4", "role": "Treatment", "text": "repeated administration of preservative - free tobramycin by inhalation", "start": 18, "end": 27}, {"entity_id": "17331261_1_Ent6", "role": "Treatment_Drug", "text": "tobramycin", "start": 24, "end": 25}, {"entity_id": "17331261_1_Ent7", "role": "Treatment_Route", "text": "inhalation", "start": 26, "end": 27}, {"entity_id": "17331261_1_Ent1", "role": "Subject", "text": "beginning at 16 months of age", "start": 28, "end": 34}, {"entity_id": "17331261_1_Ent2", "role": "Subject_Age", "text": "16 months", "start": 30, "end": 32}]}], "entity_mentions": [{"id": "17331261_1_Ent0", "text": "a patient with CF", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "17331261_1_Ent5", "text": "CF", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17331261_1_Ent3", "text": "recurrent eosinophilia and severe persistent bronchospasm", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "17331261_1_Ent4", "text": "repeated administration of preservative - free tobramycin by inhalation", "entity_type": "Entity", "start": 18, "end": 27}, {"id": "17331261_1_Ent6", "text": "tobramycin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "17331261_1_Ent7", "text": "inhalation", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "17331261_1_Ent1", "text": "beginning at 16 months of age", "entity_type": "Entity", "start": 28, "end": 34}, {"id": "17331261_1_Ent2", "text": "16 months", "entity_type": "Entity", "start": 30, "end": 32}], "lang": "en"}
{"doc_id": "17346586_1", "wnd_id": "17346586_1_1", "text": "The most serious dental side effect of bisphosphonate treatment ( particularly when it is administered intravenously ) is , paradoxically , osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone .", "tokens": ["The", "most", "serious", "dental", "side", "effect", "of", "bisphosphonate", "treatment", "(", "particularly", "when", "it", "is", "administered", "intravenously", ")", "is", ",", "paradoxically", ",", "osteonecrosis", "of", "the", "mandible", "or", "the", "maxilla", "represented", "by", "exposed", "nonhealing", "bone", "."], "event_mentions": [{"id": "17346586_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effect", "start": 4, "end": 6}, "arguments": [{"entity_id": "17346586_1_Ent2", "role": "Treatment_Drug", "text": "bisphosphonate", "start": 7, "end": 8}, {"entity_id": "17346586_1_Ent1", "role": "Treatment", "text": "bisphosphonate treatment ( particularly when it is administered intravenously )", "start": 7, "end": 17}, {"entity_id": "17346586_1_Ent3", "role": "Treatment_Route", "text": "intravenously", "start": 15, "end": 16}, {"entity_id": "17346586_1_Ent0", "role": "Effect", "text": "osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone", "start": 21, "end": 33}]}], "entity_mentions": [{"id": "17346586_1_Ent2", "text": "bisphosphonate", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17346586_1_Ent1", "text": "bisphosphonate treatment ( particularly when it is administered intravenously )", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "17346586_1_Ent3", "text": "intravenously", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17346586_1_Ent0", "text": "osteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone", "entity_type": "Entity", "start": 21, "end": 33}], "lang": "en"}
{"doc_id": "17352036_3", "wnd_id": "17352036_3_1", "text": "Under the suspicion of amiodarone - induced acute pancreatitis , amiodarone was substituted by propafenone .", "tokens": ["Under", "the", "suspicion", "of", "amiodarone", "-", "induced", "acute", "pancreatitis", ",", "amiodarone", "was", "substituted", "by", "propafenone", "."], "event_mentions": [{"id": "17352036_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "17352036_3_Ent1", "role": "Treatment", "text": "amiodarone", "start": 4, "end": 5}, {"entity_id": "17352036_3_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 4, "end": 5}, {"entity_id": "17352036_3_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "17352036_3_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17352036_3_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17352036_3_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "17364199_4", "wnd_id": "17364199_4_1", "text": "We report the first case of tuberculous uveitis due to etanercept .", "tokens": ["We", "report", "the", "first", "case", "of", "tuberculous", "uveitis", "due", "to", "etanercept", "."], "event_mentions": [{"id": "17364199_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 8, "end": 10}, "arguments": [{"entity_id": "17364199_4_Ent0", "role": "Effect", "text": "tuberculous uveitis", "start": 6, "end": 8}, {"entity_id": "17364199_4_Ent1", "role": "Treatment", "text": "etanercept", "start": 10, "end": 11}, {"entity_id": "17364199_4_Ent2", "role": "Treatment_Drug", "text": "etanercept", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17364199_4_Ent0", "text": "tuberculous uveitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17364199_4_Ent1", "text": "etanercept", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17364199_4_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17373180_2", "wnd_id": "17373180_2_1", "text": "Osteomyelitis occurring during infliximab treatment of severe psoriasis .", "tokens": ["Osteomyelitis", "occurring", "during", "infliximab", "treatment", "of", "severe", "psoriasis", "."], "event_mentions": [{"id": "17373180_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 4, "end": 5}, "arguments": [{"entity_id": "17373180_2_Ent0", "role": "Effect", "text": "Osteomyelitis", "start": 0, "end": 1}, {"entity_id": "17373180_2_Ent1", "role": "Treatment", "text": "infliximab", "start": 3, "end": 4}, {"entity_id": "17373180_2_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 3, "end": 4}, {"entity_id": "17373180_2_Ent3", "role": "Treatment_Disorder", "text": "severe psoriasis", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "17373180_2_Ent0", "text": "Osteomyelitis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17373180_2_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17373180_2_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17373180_2_Ent3", "text": "severe psoriasis", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "17381671_11", "wnd_id": "17381671_11_1", "text": "OBJECTIVE : To report a case of serotonin syndrome associated with interaction between fentanyl and citalopram , as evidenced by medication history , clinical features and reversal following discontinuation of fentanyl .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "serotonin", "syndrome", "associated", "with", "interaction", "between", "fentanyl", "and", "citalopram", ",", "as", "evidenced", "by", "medication", "history", ",", "clinical", "features", "and", "reversal", "following", "discontinuation", "of", "fentanyl", "."], "event_mentions": [{"id": "17381671_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "interaction", "start": 11, "end": 12}, "arguments": [{"entity_id": "17381671_11_Ent0", "role": "Subject", "text": "a case", "start": 4, "end": 6}, {"entity_id": "17381671_11_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 7, "end": 9}, {"entity_id": "17381671_11_Ent3", "role": "Treatment_Drug", "text": "fentanyl", "start": 13, "end": 14}, {"entity_id": "17381671_11_Ent5", "role": "Combination_Drug", "text": "fentanyl", "start": 13, "end": 14}, {"entity_id": "17381671_11_Ent2", "role": "Treatment", "text": "fentanyl and citalopram", "start": 13, "end": 16}, {"entity_id": "17381671_11_Ent4", "role": "Treatment_Drug", "text": "citalopram", "start": 15, "end": 16}, {"entity_id": "17381671_11_Ent6", "role": "Combination_Drug", "text": "citalopram", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "17381671_11_Ent0", "text": "a case", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "17381671_11_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "17381671_11_Ent3", "text": "fentanyl", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17381671_11_Ent5", "text": "fentanyl", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17381671_11_Ent2", "text": "fentanyl and citalopram", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "17381671_11_Ent4", "text": "citalopram", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17381671_11_Ent6", "text": "citalopram", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "17383767_2", "wnd_id": "17383767_2_1", "text": "Brain metastases are a frequent finding in patients with advanced non - small cell lung cancer and concomitant administration of antiepileptic and chemotherapeutic drugs or epidermal growth factor receptor ( EGFR ) inhibitor is necessary in many cases .", "tokens": ["Brain", "metastases", "are", "a", "frequent", "finding", "in", "patients", "with", "advanced", "non", "-", "small", "cell", "lung", "cancer", "and", "concomitant", "administration", "of", "antiepileptic", "and", "chemotherapeutic", "drugs", "or", "epidermal", "growth", "factor", "receptor", "(", "EGFR", ")", "inhibitor", "is", "necessary", "in", "many", "cases", "."], "event_mentions": [{"id": "17383767_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "necessary", "start": 34, "end": 35}, "arguments": [{"entity_id": "17383767_2_Ent6", "role": "Treatment_Disorder", "text": "Brain metastases", "start": 0, "end": 2}, {"entity_id": "17383767_2_Ent0", "role": "Subject", "text": "patients with advanced non - small cell lung cancer", "start": 7, "end": 16}, {"entity_id": "17383767_2_Ent1", "role": "Subject_Disorder", "text": "advanced non - small cell lung cancer", "start": 9, "end": 16}, {"entity_id": "17383767_2_Ent2", "role": "Treatment", "text": "concomitant administration of antiepileptic and chemotherapeutic drugs or epidermal growth factor receptor ( EGFR ) inhibitor", "start": 17, "end": 33}, {"entity_id": "17383767_2_Ent3", "role": "Treatment_Drug", "text": "antiepileptic", "start": 20, "end": 21}, {"entity_id": "17383767_2_Ent7", "role": "Combination_Drug", "text": "antiepileptic", "start": 20, "end": 21}, {"entity_id": "17383767_2_Ent4", "role": "Treatment_Drug", "text": "chemotherapeutic", "start": 22, "end": 23}, {"entity_id": "17383767_2_Ent8", "role": "Combination_Drug", "text": "chemotherapeutic", "start": 22, "end": 23}, {"entity_id": "17383767_2_Ent5", "role": "Treatment_Drug", "text": "epidermal growth factor receptor ( EGFR ) inhibitor", "start": 25, "end": 33}]}], "entity_mentions": [{"id": "17383767_2_Ent6", "text": "Brain metastases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17383767_2_Ent0", "text": "patients with advanced non - small cell lung cancer", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "17383767_2_Ent1", "text": "advanced non - small cell lung cancer", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "17383767_2_Ent2", "text": "concomitant administration of antiepileptic and chemotherapeutic drugs or epidermal growth factor receptor ( EGFR ) inhibitor", "entity_type": "Entity", "start": 17, "end": 33}, {"id": "17383767_2_Ent3", "text": "antiepileptic", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17383767_2_Ent7", "text": "antiepileptic", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17383767_2_Ent4", "text": "chemotherapeutic", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17383767_2_Ent8", "text": "chemotherapeutic", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17383767_2_Ent5", "text": "epidermal growth factor receptor ( EGFR ) inhibitor", "entity_type": "Entity", "start": 25, "end": 33}], "lang": "en"}
{"doc_id": "17406804_1", "wnd_id": "17406804_1_1", "text": "A case of recall pneumonitis induced by gemcitabine is reported .", "tokens": ["A", "case", "of", "recall", "pneumonitis", "induced", "by", "gemcitabine", "is", "reported", "."], "event_mentions": [{"id": "17406804_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "17406804_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "17406804_1_Ent1", "role": "Effect", "text": "recall pneumonitis", "start": 3, "end": 5}, {"entity_id": "17406804_1_Ent2", "role": "Treatment", "text": "gemcitabine", "start": 7, "end": 8}, {"entity_id": "17406804_1_Ent3", "role": "Treatment_Drug", "text": "gemcitabine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "17406804_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17406804_1_Ent1", "text": "recall pneumonitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "17406804_1_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17406804_1_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "17406804_2", "wnd_id": "17406804_2_1", "text": "After having received gemcitabine on day 1 of the second course , the patient developed dry cough , subfebrile temperatures and dyspnea within 48 h.", "tokens": ["After", "having", "received", "gemcitabine", "on", "day", "1", "of", "the", "second", "course", ",", "the", "patient", "developed", "dry", "cough", ",", "subfebrile", "temperatures", "and", "dyspnea", "within", "48", "h."], "event_mentions": [{"id": "17406804_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "17406804_2_Ent2", "role": "Treatment", "text": "received gemcitabine on day 1 of the second course", "start": 2, "end": 11}, {"entity_id": "17406804_2_Ent3", "role": "Treatment_Drug", "text": "gemcitabine", "start": 3, "end": 4}, {"entity_id": "17406804_2_Ent0", "role": "Subject", "text": "the patient", "start": 12, "end": 14}, {"entity_id": "17406804_2_Ent1", "role": "Effect", "text": "dry cough , subfebrile temperatures and dyspnea within 48 h.", "start": 15, "end": 25}, {"entity_id": "17406804_2_Ent4", "role": "Treatment_Time_elapsed", "text": "within 48 h.", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "17406804_2_Ent2", "text": "received gemcitabine on day 1 of the second course", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "17406804_2_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17406804_2_Ent0", "text": "the patient", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "17406804_2_Ent1", "text": "dry cough , subfebrile temperatures and dyspnea within 48 h.", "entity_type": "Entity", "start": 15, "end": 25}, {"id": "17406804_2_Ent4", "text": "within 48 h.", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "17444802_4", "wnd_id": "17444802_4_1", "text": "RESULTS : An 81 - year - old man with a history of neoplasies of the colon and prostate and anticoagulant treatment was referred for treatment of an ocular surface neoplasia on his left eye .", "tokens": ["RESULTS", ":", "An", "81", "-", "year", "-", "old", "man", "with", "a", "history", "of", "neoplasies", "of", "the", "colon", "and", "prostate", "and", "anticoagulant", "treatment", "was", "referred", "for", "treatment", "of", "an", "ocular", "surface", "neoplasia", "on", "his", "left", "eye", "."], "event_mentions": [{"id": "17444802_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "referred", "start": 23, "end": 24}, "arguments": [{"entity_id": "17444802_4_Ent0", "role": "Subject", "text": "An 81 - year - old man with a history of neoplasies of the colon and prostate", "start": 2, "end": 19}, {"entity_id": "17444802_4_Ent1", "role": "Subject_Age", "text": "81 - year - old", "start": 3, "end": 8}, {"entity_id": "17444802_4_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "17444802_4_Ent6", "role": "Treatment_Disorder", "text": "neoplasies of the colon and prostate", "start": 13, "end": 19}, {"entity_id": "17444802_4_Ent4", "role": "Treatment", "text": "anticoagulant", "start": 20, "end": 21}, {"entity_id": "17444802_4_Ent5", "role": "Treatment_Drug", "text": "anticoagulant", "start": 20, "end": 21}, {"entity_id": "17444802_4_Ent3", "role": "Effect", "text": "an ocular surface neoplasia on his left eye", "start": 27, "end": 35}]}], "entity_mentions": [{"id": "17444802_4_Ent0", "text": "An 81 - year - old man with a history of neoplasies of the colon and prostate", "entity_type": "Entity", "start": 2, "end": 19}, {"id": "17444802_4_Ent1", "text": "81 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "17444802_4_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17444802_4_Ent6", "text": "neoplasies of the colon and prostate", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "17444802_4_Ent4", "text": "anticoagulant", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17444802_4_Ent5", "text": "anticoagulant", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17444802_4_Ent3", "text": "an ocular surface neoplasia on his left eye", "entity_type": "Entity", "start": 27, "end": 35}], "lang": "en"}
{"doc_id": "17448102_1", "wnd_id": "17448102_1_1", "text": "Managing cardiovascular collapse in severe flecainide overdose without recourse to extracorporeal therapy .", "tokens": ["Managing", "cardiovascular", "collapse", "in", "severe", "flecainide", "overdose", "without", "recourse", "to", "extracorporeal", "therapy", "."], "event_mentions": [{"id": "17448102_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "17448102_1_Ent0", "role": "Effect", "text": "cardiovascular collapse", "start": 1, "end": 3}, {"entity_id": "17448102_1_Ent1", "role": "Treatment", "text": "severe flecainide overdose", "start": 4, "end": 7}, {"entity_id": "17448102_1_Ent2", "role": "Treatment_Drug", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "17448102_1_Ent3", "role": "Treatment_Dosage", "text": "overdose", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "17448102_1_Ent0", "text": "cardiovascular collapse", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "17448102_1_Ent1", "text": "severe flecainide overdose", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "17448102_1_Ent2", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17448102_1_Ent3", "text": "overdose", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "17473920_8", "wnd_id": "17473920_8_1", "text": "After starting nevirapine treatment , nine out of ten patients experienced symptoms of abstinence syndrome , and methadone dose had to be increased by 20 % on average during the course of the study .", "tokens": ["After", "starting", "nevirapine", "treatment", ",", "nine", "out", "of", "ten", "patients", "experienced", "symptoms", "of", "abstinence", "syndrome", ",", "and", "methadone", "dose", "had", "to", "be", "increased", "by", "20", "%", "on", "average", "during", "the", "course", "of", "the", "study", "."], "event_mentions": [{"id": "17473920_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 10, "end": 11}, "arguments": [{"entity_id": "17473920_8_Ent3", "role": "Treatment", "text": "nevirapine", "start": 2, "end": 3}, {"entity_id": "17473920_8_Ent4", "role": "Treatment_Drug", "text": "nevirapine", "start": 2, "end": 3}, {"entity_id": "17473920_8_Ent1", "role": "Subject_Population", "text": "nine out of ten", "start": 5, "end": 9}, {"entity_id": "17473920_8_Ent0", "role": "Subject", "text": "nine out of ten patients", "start": 5, "end": 10}, {"entity_id": "17473920_8_Ent2", "role": "Effect", "text": "abstinence syndrome", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "17473920_8_Ent3", "text": "nevirapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17473920_8_Ent4", "text": "nevirapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17473920_8_Ent1", "text": "nine out of ten", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "17473920_8_Ent0", "text": "nine out of ten patients", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "17473920_8_Ent2", "text": "abstinence syndrome", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "1751354_1", "wnd_id": "1751354_1_1", "text": "Psoriasis induced by interferon - alpha .", "tokens": ["Psoriasis", "induced", "by", "interferon", "-", "alpha", "."], "event_mentions": [{"id": "1751354_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "1751354_1_Ent0", "role": "Effect", "text": "Psoriasis", "start": 0, "end": 1}, {"entity_id": "1751354_1_Ent1", "role": "Treatment", "text": "interferon - alpha", "start": 3, "end": 6}, {"entity_id": "1751354_1_Ent2", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "1751354_1_Ent0", "text": "Psoriasis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1751354_1_Ent1", "text": "interferon - alpha", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "1751354_1_Ent2", "text": "interferon - alpha", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "17526968_2", "wnd_id": "17526968_2_1", "text": "Hyperpigmentation is one of the cutaneous side effects of chemotherapautic agents , but it is usually accepted as a cosmetic problem .", "tokens": ["Hyperpigmentation", "is", "one", "of", "the", "cutaneous", "side", "effects", "of", "chemotherapautic", "agents", ",", "but", "it", "is", "usually", "accepted", "as", "a", "cosmetic", "problem", "."], "event_mentions": [{"id": "17526968_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 8, "end": 9}, "arguments": [{"entity_id": "17526968_2_Ent0", "role": "Effect", "text": "Hyperpigmentation", "start": 0, "end": 1}, {"entity_id": "17526968_2_Ent1", "role": "Treatment", "text": "chemotherapautic agents", "start": 9, "end": 11}, {"entity_id": "17526968_2_Ent2", "role": "Treatment_Drug", "text": "chemotherapautic agents", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "17526968_2_Ent0", "text": "Hyperpigmentation", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17526968_2_Ent1", "text": "chemotherapautic agents", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "17526968_2_Ent2", "text": "chemotherapautic agents", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "17551408_1", "wnd_id": "17551408_1_1", "text": "We postulate that gastritis caused by dexamethasone , mucositis caused by doxorubicin , and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event .", "tokens": ["We", "postulate", "that", "gastritis", "caused", "by", "dexamethasone", ",", "mucositis", "caused", "by", "doxorubicin", ",", "and", "the", "unique", "anatomic", "nature", "of", "a", "Meckel", "diverticulum", "may", "have", "contributed", "to", "this", "extremely", "unlikely", "and", "previously", "unreported", "event", "."], "event_mentions": [{"id": "17551408_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 4, "end": 5}, "arguments": [{"entity_id": "17551408_1_Ent0", "role": "Effect", "text": "gastritis", "start": 3, "end": 4}, {"entity_id": "17551408_1_Ent1", "role": "Treatment", "text": "dexamethasone", "start": 6, "end": 7}, {"entity_id": "17551408_1_Ent2", "role": "Treatment_Drug", "text": "dexamethasone", "start": 6, "end": 7}]}, {"id": "17551408_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 9, "end": 10}, "arguments": [{"entity_id": "17551408_1_Ent3", "role": "Effect", "text": "mucositis", "start": 8, "end": 9}, {"entity_id": "17551408_1_Ent4", "role": "Treatment", "text": "doxorubicin", "start": 11, "end": 12}, {"entity_id": "17551408_1_Ent5", "role": "Treatment_Drug", "text": "doxorubicin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "17551408_1_Ent0", "text": "gastritis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17551408_1_Ent1", "text": "dexamethasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17551408_1_Ent2", "text": "dexamethasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17551408_1_Ent3", "text": "mucositis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17551408_1_Ent4", "text": "doxorubicin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17551408_1_Ent5", "text": "doxorubicin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "1756352_1", "wnd_id": "1756352_1_1", "text": "A woman developed delusional parasitosis when taking phenelzine .", "tokens": ["A", "woman", "developed", "delusional", "parasitosis", "when", "taking", "phenelzine", "."], "event_mentions": [{"id": "1756352_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "1756352_1_Ent0", "role": "Subject", "text": "A woman", "start": 0, "end": 2}, {"entity_id": "1756352_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 1, "end": 2}, {"entity_id": "1756352_1_Ent2", "role": "Effect", "text": "delusional parasitosis", "start": 3, "end": 5}, {"entity_id": "1756352_1_Ent3", "role": "Treatment", "text": "phenelzine", "start": 7, "end": 8}, {"entity_id": "1756352_1_Ent4", "role": "Treatment_Drug", "text": "phenelzine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "1756352_1_Ent0", "text": "A woman", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1756352_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "1756352_1_Ent2", "text": "delusional parasitosis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "1756352_1_Ent3", "text": "phenelzine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1756352_1_Ent4", "text": "phenelzine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "17596682_1", "wnd_id": "17596682_1_1", "text": "Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab : case report and review of the literature .", "tokens": ["Interstitial", "pneumonitis", "and", "alveolar", "hemorrhage", "complicating", "use", "of", "rituximab", ":", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "17596682_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicating", "start": 5, "end": 6}, "arguments": [{"entity_id": "17596682_1_Ent0", "role": "Effect", "text": "Interstitial pneumonitis and alveolar hemorrhage", "start": 0, "end": 5}, {"entity_id": "17596682_1_Ent1", "role": "Treatment", "text": "rituximab", "start": 8, "end": 9}, {"entity_id": "17596682_1_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "17596682_1_Ent0", "text": "Interstitial pneumonitis and alveolar hemorrhage", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "17596682_1_Ent1", "text": "rituximab", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17596682_1_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "17596682_2", "wnd_id": "17596682_2_1", "text": "The use of rituximab has been uncommonly associated with delayed pulmonary toxicity .", "tokens": ["The", "use", "of", "rituximab", "has", "been", "uncommonly", "associated", "with", "delayed", "pulmonary", "toxicity", "."], "event_mentions": [{"id": "17596682_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "17596682_2_Ent1", "role": "Treatment", "text": "rituximab", "start": 3, "end": 4}, {"entity_id": "17596682_2_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 3, "end": 4}, {"entity_id": "17596682_2_Ent0", "role": "Effect", "text": "delayed pulmonary toxicity", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "17596682_2_Ent1", "text": "rituximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17596682_2_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17596682_2_Ent0", "text": "delayed pulmonary toxicity", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "17610180_2", "wnd_id": "17610180_2_1", "text": "The results of the ultrasound examination combined with clinical anamnesis allowed diagnosis of gastric mucosa foveolar hyperplasia due to prolonged PGE1 therapy .", "tokens": ["The", "results", "of", "the", "ultrasound", "examination", "combined", "with", "clinical", "anamnesis", "allowed", "diagnosis", "of", "gastric", "mucosa", "foveolar", "hyperplasia", "due", "to", "prolonged", "PGE1", "therapy", "."], "event_mentions": [{"id": "17610180_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 17, "end": 18}, "arguments": [{"entity_id": "17610180_2_Ent0", "role": "Effect", "text": "gastric mucosa foveolar hyperplasia", "start": 13, "end": 17}, {"entity_id": "17610180_2_Ent3", "role": "Treatment_Duration", "text": "prolonged", "start": 19, "end": 20}, {"entity_id": "17610180_2_Ent1", "role": "Treatment", "text": "prolonged PGE1 therapy", "start": 19, "end": 22}, {"entity_id": "17610180_2_Ent2", "role": "Treatment_Drug", "text": "PGE1", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "17610180_2_Ent0", "text": "gastric mucosa foveolar hyperplasia", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "17610180_2_Ent3", "text": "prolonged", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17610180_2_Ent1", "text": "prolonged PGE1 therapy", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "17610180_2_Ent2", "text": "PGE1", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "17655517_2", "wnd_id": "17655517_2_1", "text": "Linezolid is an oxazolidinone antibacterial agent indicated for serious gram - positive infections .", "tokens": ["Linezolid", "is", "an", "oxazolidinone", "antibacterial", "agent", "indicated", "for", "serious", "gram", "-", "positive", "infections", "."], "event_mentions": [{"id": "17655517_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "indicated", "start": 6, "end": 7}, "arguments": [{"entity_id": "17655517_2_Ent0", "role": "Treatment", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "17655517_2_Ent2", "role": "Treatment_Drug", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "17655517_2_Ent1", "role": "Treatment_Disorder", "text": "serious gram - positive infections", "start": 8, "end": 13}]}], "entity_mentions": [{"id": "17655517_2_Ent0", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655517_2_Ent2", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655517_2_Ent1", "text": "serious gram - positive infections", "entity_type": "Entity", "start": 8, "end": 13}], "lang": "en"}
{"doc_id": "1765991_2", "wnd_id": "1765991_2_1", "text": "The development of systemic lupus erythematosus ( SLE ) after 38 months of therapy with recombinant human interferon gamma ( rIFN - gamma ) was observed in a patient with rheumatoid arthritis .", "tokens": ["The", "development", "of", "systemic", "lupus", "erythematosus", "(", "SLE", ")", "after", "38", "months", "of", "therapy", "with", "recombinant", "human", "interferon", "gamma", "(", "rIFN", "-", "gamma", ")", "was", "observed", "in", "a", "patient", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "1765991_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 1, "end": 2}, "arguments": [{"entity_id": "1765991_2_Ent1", "role": "Effect", "text": "systemic lupus erythematosus", "start": 3, "end": 6}, {"entity_id": "1765991_2_Ent2", "role": "Treatment", "text": "after 38 months", "start": 9, "end": 12}, {"entity_id": "1765991_2_Ent4", "role": "Treatment_Time_elapsed", "text": "after 38 months", "start": 9, "end": 12}, {"entity_id": "1765991_2_Ent3", "role": "Treatment", "text": "recombinant human interferon gamma", "start": 15, "end": 19}, {"entity_id": "1765991_2_Ent5", "role": "Treatment_Drug", "text": "recombinant human interferon gamma", "start": 15, "end": 19}, {"entity_id": "1765991_2_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis .", "start": 27, "end": 33}, {"entity_id": "1765991_2_Ent6", "role": "Treatment_Disorder", "text": "rheumatoid arthritis .", "start": 30, "end": 33}]}], "entity_mentions": [{"id": "1765991_2_Ent1", "text": "systemic lupus erythematosus", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "1765991_2_Ent2", "text": "after 38 months", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "1765991_2_Ent4", "text": "after 38 months", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "1765991_2_Ent3", "text": "recombinant human interferon gamma", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "1765991_2_Ent5", "text": "recombinant human interferon gamma", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "1765991_2_Ent0", "text": "a patient with rheumatoid arthritis .", "entity_type": "Entity", "start": 27, "end": 33}, {"id": "1765991_2_Ent6", "text": "rheumatoid arthritis .", "entity_type": "Entity", "start": 30, "end": 33}], "lang": "en"}
{"doc_id": "17665812_3", "wnd_id": "17665812_3_1", "text": "Occasionally , despite good therapeutic response , clozapine must be stopped due to dangerous side effects such as agranulocytosis .", "tokens": ["Occasionally", ",", "despite", "good", "therapeutic", "response", ",", "clozapine", "must", "be", "stopped", "due", "to", "dangerous", "side", "effects", "such", "as", "agranulocytosis", "."], "event_mentions": [{"id": "17665812_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 11, "end": 13}, "arguments": [{"entity_id": "17665812_3_Ent1", "role": "Treatment", "text": "clozapine", "start": 7, "end": 8}, {"entity_id": "17665812_3_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 7, "end": 8}, {"entity_id": "17665812_3_Ent0", "role": "Effect", "text": "dangerous side effects such as agranulocytosis", "start": 13, "end": 19}]}], "entity_mentions": [{"id": "17665812_3_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17665812_3_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17665812_3_Ent0", "text": "dangerous side effects such as agranulocytosis", "entity_type": "Entity", "start": 13, "end": 19}], "lang": "en"}
{"doc_id": "17667887_1", "wnd_id": "17667887_1_1", "text": "Serotonin syndrome in elderly patients treated for psychotic depression with atypical antipsychotics and antidepressants : two case reports .", "tokens": ["Serotonin", "syndrome", "in", "elderly", "patients", "treated", "for", "psychotic", "depression", "with", "atypical", "antipsychotics", "and", "antidepressants", ":", "two", "case", "reports", "."], "event_mentions": [{"id": "17667887_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 9, "end": 10}, "arguments": [{"entity_id": "17667887_1_Ent2", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "17667887_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 3, "end": 4}, {"entity_id": "17667887_1_Ent0", "role": "Subject", "text": "elderly patients", "start": 3, "end": 5}, {"entity_id": "17667887_1_Ent7", "role": "Treatment_Disorder", "text": "psychotic depression", "start": 7, "end": 9}, {"entity_id": "17667887_1_Ent3", "role": "Treatment", "text": "atypical antipsychotics", "start": 10, "end": 12}, {"entity_id": "17667887_1_Ent5", "role": "Treatment_Drug", "text": "atypical antipsychotics", "start": 10, "end": 12}, {"entity_id": "17667887_1_Ent8", "role": "Combination_Drug", "text": "atypical antipsychotics", "start": 10, "end": 12}, {"entity_id": "17667887_1_Ent4", "role": "Treatment", "text": "antidepressants", "start": 13, "end": 14}, {"entity_id": "17667887_1_Ent6", "role": "Treatment_Drug", "text": "antidepressants", "start": 13, "end": 14}, {"entity_id": "17667887_1_Ent9", "role": "Combination_Drug", "text": "antidepressants", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "17667887_1_Ent2", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17667887_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17667887_1_Ent0", "text": "elderly patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "17667887_1_Ent7", "text": "psychotic depression", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "17667887_1_Ent3", "text": "atypical antipsychotics", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "17667887_1_Ent5", "text": "atypical antipsychotics", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "17667887_1_Ent8", "text": "atypical antipsychotics", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "17667887_1_Ent4", "text": "antidepressants", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17667887_1_Ent6", "text": "antidepressants", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17667887_1_Ent9", "text": "antidepressants", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "17667887_3", "wnd_id": "17667887_3_1", "text": "The first case is a 69 - year - old man who was admitted for depression with psychosis and treated with trazodone , risperidone , and sertraline .", "tokens": ["The", "first", "case", "is", "a", "69", "-", "year", "-", "old", "man", "who", "was", "admitted", "for", "depression", "with", "psychosis", "and", "treated", "with", "trazodone", ",", "risperidone", ",", "and", "sertraline", "."], "event_mentions": [{"id": "17667887_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 19, "end": 20}, "arguments": [{"entity_id": "17667887_3_Ent0", "role": "Subject", "text": "a 69 - year - old man who was admitted for depression with psychosis", "start": 4, "end": 18}, {"entity_id": "17667887_3_Ent1", "role": "Subject_Age", "text": "69 - year - old", "start": 5, "end": 10}, {"entity_id": "17667887_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 10, "end": 11}, {"entity_id": "17667887_3_Ent7", "role": "Treatment_Disorder", "text": "depression with psychosis", "start": 15, "end": 18}, {"entity_id": "17667887_3_Ent4", "role": "Treatment_Drug", "text": "trazodone", "start": 21, "end": 22}, {"entity_id": "17667887_3_Ent10", "role": "Combination_Drug", "text": "trazodone", "start": 21, "end": 22}, {"entity_id": "17667887_3_Ent3", "role": "Treatment", "text": "trazodone , risperidone , and sertraline", "start": 21, "end": 27}, {"entity_id": "17667887_3_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 23, "end": 24}, {"entity_id": "17667887_3_Ent8", "role": "Combination_Drug", "text": "risperidone", "start": 23, "end": 24}, {"entity_id": "17667887_3_Ent6", "role": "Treatment_Drug", "text": "sertraline", "start": 26, "end": 27}, {"entity_id": "17667887_3_Ent9", "role": "Combination_Drug", "text": "sertraline", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "17667887_3_Ent0", "text": "a 69 - year - old man who was admitted for depression with psychosis", "entity_type": "Entity", "start": 4, "end": 18}, {"id": "17667887_3_Ent1", "text": "69 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "17667887_3_Ent2", "text": "man", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17667887_3_Ent7", "text": "depression with psychosis", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "17667887_3_Ent4", "text": "trazodone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17667887_3_Ent10", "text": "trazodone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17667887_3_Ent3", "text": "trazodone , risperidone , and sertraline", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "17667887_3_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17667887_3_Ent8", "text": "risperidone", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17667887_3_Ent6", "text": "sertraline", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "17667887_3_Ent9", "text": "sertraline", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "17671884_1", "wnd_id": "17671884_1_1", "text": "Red blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and prednisone .", "tokens": ["Red", "blood", "cell", "anemia", "in", "a", "patient", "with", "pemphigus", "vulgaris", "induced", "by", "the", "use", "of", "mycophenolate", "mofetil", "and", "prednisone", "."], "event_mentions": [{"id": "17671884_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "17671884_1_Ent1", "role": "Effect", "text": "Red blood cell anemia", "start": 0, "end": 4}, {"entity_id": "17671884_1_Ent0", "role": "Subject", "text": "a patient with pemphigus vulgaris", "start": 5, "end": 10}, {"entity_id": "17671884_1_Ent3", "role": "Treatment_Disorder", "text": "pemphigus vulgaris", "start": 8, "end": 10}, {"entity_id": "17671884_1_Ent4", "role": "Treatment_Drug", "text": "mycophenolate mofetil", "start": 15, "end": 17}, {"entity_id": "17671884_1_Ent6", "role": "Combination_Drug", "text": "mycophenolate mofetil", "start": 15, "end": 17}, {"entity_id": "17671884_1_Ent2", "role": "Treatment", "text": "mycophenolate mofetil and prednisone", "start": 15, "end": 19}, {"entity_id": "17671884_1_Ent5", "role": "Treatment_Drug", "text": "prednisone", "start": 18, "end": 19}, {"entity_id": "17671884_1_Ent7", "role": "Combination_Drug", "text": "prednisone", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "17671884_1_Ent1", "text": "Red blood cell anemia", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17671884_1_Ent0", "text": "a patient with pemphigus vulgaris", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "17671884_1_Ent3", "text": "pemphigus vulgaris", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17671884_1_Ent4", "text": "mycophenolate mofetil", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "17671884_1_Ent6", "text": "mycophenolate mofetil", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "17671884_1_Ent2", "text": "mycophenolate mofetil and prednisone", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "17671884_1_Ent5", "text": "prednisone", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17671884_1_Ent7", "text": "prednisone", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "17671884_3", "wnd_id": "17671884_3_1", "text": "An apparent link is described between the use of MMF with prednisone to treat pemphigus vulgaris and the development of red blood cell anemia .", "tokens": ["An", "apparent", "link", "is", "described", "between", "the", "use", "of", "MMF", "with", "prednisone", "to", "treat", "pemphigus", "vulgaris", "and", "the", "development", "of", "red", "blood", "cell", "anemia", "."], "event_mentions": [{"id": "17671884_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 18, "end": 19}, "arguments": [{"entity_id": "17671884_3_Ent3", "role": "Treatment_Drug", "text": "MMF", "start": 9, "end": 10}, {"entity_id": "17671884_3_Ent5", "role": "Combination_Drug", "text": "MMF", "start": 9, "end": 10}, {"entity_id": "17671884_3_Ent1", "role": "Treatment", "text": "MMF with prednisone to treat pemphigus vulgaris", "start": 9, "end": 16}, {"entity_id": "17671884_3_Ent4", "role": "Treatment_Drug", "text": "prednisone", "start": 11, "end": 12}, {"entity_id": "17671884_3_Ent6", "role": "Combination_Drug", "text": "prednisone", "start": 11, "end": 12}, {"entity_id": "17671884_3_Ent2", "role": "Treatment_Disorder", "text": "pemphigus vulgaris", "start": 14, "end": 16}, {"entity_id": "17671884_3_Ent0", "role": "Effect", "text": "red blood cell anemia", "start": 20, "end": 24}]}], "entity_mentions": [{"id": "17671884_3_Ent3", "text": "MMF", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17671884_3_Ent5", "text": "MMF", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17671884_3_Ent1", "text": "MMF with prednisone to treat pemphigus vulgaris", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "17671884_3_Ent4", "text": "prednisone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17671884_3_Ent6", "text": "prednisone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17671884_3_Ent2", "text": "pemphigus vulgaris", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "17671884_3_Ent0", "text": "red blood cell anemia", "entity_type": "Entity", "start": 20, "end": 24}], "lang": "en"}
{"doc_id": "17823522_3", "wnd_id": "17823522_3_1", "text": "Here we present the case of a generalized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and ribavirin .", "tokens": ["Here", "we", "present", "the", "case", "of", "a", "generalized", "lichen", "nitidus", "with", "involvement", "of", "the", "palms", "in", "a", "patient", "with", "hepatitis", "C", "after", "systemic", "treatment", "with", "interferon", "alpha", "and", "ribavirin", "."], "event_mentions": [{"id": "17823522_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 21, "end": 22}, "arguments": [{"entity_id": "17823522_3_Ent1", "role": "Effect", "text": "a generalized lichen nitidus with involvement of the palms", "start": 6, "end": 15}, {"entity_id": "17823522_3_Ent0", "role": "Subject", "text": "a patient with hepatitis C", "start": 16, "end": 21}, {"entity_id": "17823522_3_Ent3", "role": "Treatment_Disorder", "text": "hepatitis C", "start": 19, "end": 21}, {"entity_id": "17823522_3_Ent6", "role": "Treatment_Route", "text": "systemic", "start": 22, "end": 23}, {"entity_id": "17823522_3_Ent2", "role": "Treatment", "text": "systemic treatment with interferon alpha and ribavirin", "start": 22, "end": 29}, {"entity_id": "17823522_3_Ent4", "role": "Treatment_Drug", "text": "interferon alpha", "start": 25, "end": 27}, {"entity_id": "17823522_3_Ent8", "role": "Combination_Drug", "text": "interferon alpha", "start": 25, "end": 27}, {"entity_id": "17823522_3_Ent5", "role": "Treatment_Drug", "text": "ribavirin", "start": 28, "end": 29}, {"entity_id": "17823522_3_Ent7", "role": "Combination_Drug", "text": "ribavirin", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "17823522_3_Ent1", "text": "a generalized lichen nitidus with involvement of the palms", "entity_type": "Entity", "start": 6, "end": 15}, {"id": "17823522_3_Ent0", "text": "a patient with hepatitis C", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "17823522_3_Ent3", "text": "hepatitis C", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "17823522_3_Ent6", "text": "systemic", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17823522_3_Ent2", "text": "systemic treatment with interferon alpha and ribavirin", "entity_type": "Entity", "start": 22, "end": 29}, {"id": "17823522_3_Ent4", "text": "interferon alpha", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "17823522_3_Ent8", "text": "interferon alpha", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "17823522_3_Ent5", "text": "ribavirin", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "17823522_3_Ent7", "text": "ribavirin", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "17823522_5", "wnd_id": "17823522_5_1", "text": "It is tempting to speculate that interferon alpha may be involved in the pathogenesis of lichen nitidus .", "tokens": ["It", "is", "tempting", "to", "speculate", "that", "interferon", "alpha", "may", "be", "involved", "in", "the", "pathogenesis", "of", "lichen", "nitidus", "."], "event_mentions": [{"id": "17823522_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "involved", "start": 10, "end": 11}, "arguments": [{"entity_id": "17823522_5_Ent1", "role": "Treatment", "text": "interferon alpha", "start": 6, "end": 8}, {"entity_id": "17823522_5_Ent2", "role": "Treatment_Drug", "text": "interferon alpha", "start": 6, "end": 8}, {"entity_id": "17823522_5_Ent0", "role": "Effect", "text": "lichen nitidus", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "17823522_5_Ent1", "text": "interferon alpha", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17823522_5_Ent2", "text": "interferon alpha", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17823522_5_Ent0", "text": "lichen nitidus", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "17852449_3", "wnd_id": "17852449_3_1", "text": "Treatment of APL in pregnancy is controversial as the use of ATRA has been questioned due to the teratogenic effect of retinoids .", "tokens": ["Treatment", "of", "APL", "in", "pregnancy", "is", "controversial", "as", "the", "use", "of", "ATRA", "has", "been", "questioned", "due", "to", "the", "teratogenic", "effect", "of", "retinoids", "."], "event_mentions": [{"id": "17852449_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 15, "end": 16}, "arguments": [{"entity_id": "17852449_3_Ent0", "role": "Effect", "text": "teratogenic effect", "start": 18, "end": 20}, {"entity_id": "17852449_3_Ent1", "role": "Treatment", "text": "retinoids", "start": 21, "end": 22}, {"entity_id": "17852449_3_Ent2", "role": "Treatment_Drug", "text": "retinoids", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "17852449_3_Ent0", "text": "teratogenic effect", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "17852449_3_Ent1", "text": "retinoids", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17852449_3_Ent2", "text": "retinoids", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "17873198_5", "wnd_id": "17873198_5_1", "text": "We report a case of fatal pulmonary toxicity in a patient with advanced non - small cell lung cancer who received erlotinib .", "tokens": ["We", "report", "a", "case", "of", "fatal", "pulmonary", "toxicity", "in", "a", "patient", "with", "advanced", "non", "-", "small", "cell", "lung", "cancer", "who", "received", "erlotinib", "."], "event_mentions": [{"id": "17873198_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "received", "start": 20, "end": 21}, "arguments": [{"entity_id": "17873198_5_Ent1", "role": "Effect", "text": "pulmonary toxicity", "start": 6, "end": 8}, {"entity_id": "17873198_5_Ent0", "role": "Subject", "text": "a patient with advanced non - small cell lung cancer", "start": 9, "end": 19}, {"entity_id": "17873198_5_Ent3", "role": "Treatment_Disorder", "text": "advanced non - small cell lung cancer", "start": 12, "end": 19}, {"entity_id": "17873198_5_Ent2", "role": "Treatment", "text": "erlotinib", "start": 21, "end": 22}, {"entity_id": "17873198_5_Ent4", "role": "Treatment_Drug", "text": "erlotinib", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "17873198_5_Ent1", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17873198_5_Ent0", "text": "a patient with advanced non - small cell lung cancer", "entity_type": "Entity", "start": 9, "end": 19}, {"id": "17873198_5_Ent3", "text": "advanced non - small cell lung cancer", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "17873198_5_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "17873198_5_Ent4", "text": "erlotinib", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "17921794_1", "wnd_id": "17921794_1_1", "text": "Both colchicine and statin therapy may be associated with myopathy , which usually occurs after several months of therapy .", "tokens": ["Both", "colchicine", "and", "statin", "therapy", "may", "be", "associated", "with", "myopathy", ",", "which", "usually", "occurs", "after", "several", "months", "of", "therapy", "."], "event_mentions": [{"id": "17921794_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "17921794_1_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 1, "end": 2}, {"entity_id": "17921794_1_Ent4", "role": "Combination_Drug", "text": "colchicine", "start": 1, "end": 2}, {"entity_id": "17921794_1_Ent1", "role": "Treatment", "text": "colchicine and statin therapy", "start": 1, "end": 5}, {"entity_id": "17921794_1_Ent3", "role": "Treatment_Drug", "text": "statin", "start": 3, "end": 4}, {"entity_id": "17921794_1_Ent5", "role": "Combination_Drug", "text": "statin", "start": 3, "end": 4}, {"entity_id": "17921794_1_Ent0", "role": "Effect", "text": "myopathy", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "17921794_1_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17921794_1_Ent4", "text": "colchicine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17921794_1_Ent1", "text": "colchicine and statin therapy", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "17921794_1_Ent3", "text": "statin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17921794_1_Ent5", "text": "statin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17921794_1_Ent0", "text": "myopathy", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "17921794_4", "wnd_id": "17921794_4_1", "text": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis .", "tokens": ["We", "report", "a", "case", "of", "a", "patient", "with", "mild", "chronic", "renal", "insufficiency", "who", "had", "been", "taking", "simvastatin", "for", "over", "a", "year", "and", "developed", "acute", "weakness", "within", "3", "weeks", "after", "the", "start", "of", "treatment", "with", "colchicine", "for", "acute", "gouty", "bursitis", "."], "event_mentions": [{"id": "17921794_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 22, "end": 23}, "arguments": [{"entity_id": "17921794_4_Ent0", "role": "Subject", "text": "a patient with mild chronic renal insufficiency", "start": 5, "end": 12}, {"entity_id": "17921794_4_Ent1", "role": "Subject_Disorder", "text": "mild chronic renal insufficiency", "start": 8, "end": 12}, {"entity_id": "17921794_4_Ent3", "role": "Treatment", "text": "taking simvastatin for over a year", "start": 15, "end": 21}, {"entity_id": "17921794_4_Ent6", "role": "Treatment_Drug", "text": "simvastatin", "start": 16, "end": 17}, {"entity_id": "17921794_4_Ent10", "role": "Combination_Drug", "text": "simvastatin", "start": 16, "end": 17}, {"entity_id": "17921794_4_Ent8", "role": "Treatment_Time_elapsed", "text": "over a year", "start": 18, "end": 21}, {"entity_id": "17921794_4_Ent2", "role": "Effect", "text": "acute weakness", "start": 23, "end": 25}, {"entity_id": "17921794_4_Ent9", "role": "Treatment_Time_elapsed", "text": "3 weeks", "start": 26, "end": 28}, {"entity_id": "17921794_4_Ent4", "role": "Treatment", "text": "3 weeks after the start of treatment with colchicine for acute gouty bursitis", "start": 26, "end": 39}, {"entity_id": "17921794_4_Ent7", "role": "Treatment_Drug", "text": "colchicine", "start": 34, "end": 35}, {"entity_id": "17921794_4_Ent11", "role": "Combination_Drug", "text": "colchicine", "start": 34, "end": 35}, {"entity_id": "17921794_4_Ent5", "role": "Treatment_Disorder", "text": "acute gouty bursitis", "start": 36, "end": 39}]}], "entity_mentions": [{"id": "17921794_4_Ent0", "text": "a patient with mild chronic renal insufficiency", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "17921794_4_Ent1", "text": "mild chronic renal insufficiency", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "17921794_4_Ent3", "text": "taking simvastatin for over a year", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "17921794_4_Ent6", "text": "simvastatin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17921794_4_Ent10", "text": "simvastatin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17921794_4_Ent8", "text": "over a year", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "17921794_4_Ent2", "text": "acute weakness", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "17921794_4_Ent9", "text": "3 weeks", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "17921794_4_Ent4", "text": "3 weeks after the start of treatment with colchicine for acute gouty bursitis", "entity_type": "Entity", "start": 26, "end": 39}, {"id": "17921794_4_Ent7", "text": "colchicine", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "17921794_4_Ent11", "text": "colchicine", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "17921794_4_Ent5", "text": "acute gouty bursitis", "entity_type": "Entity", "start": 36, "end": 39}], "lang": "en"}
{"doc_id": "17937473_2", "wnd_id": "17937473_2_1", "text": "Leflunomide - associated infections in rheumatoid arthritis .", "tokens": ["Leflunomide", "-", "associated", "infections", "in", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "17937473_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "17937473_2_Ent1", "role": "Treatment", "text": "Leflunomide", "start": 0, "end": 1}, {"entity_id": "17937473_2_Ent2", "role": "Treatment_Drug", "text": "Leflunomide", "start": 0, "end": 1}, {"entity_id": "17937473_2_Ent0", "role": "Effect", "text": "infections", "start": 3, "end": 4}, {"entity_id": "17937473_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "17937473_2_Ent1", "text": "Leflunomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17937473_2_Ent2", "text": "Leflunomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17937473_2_Ent0", "text": "infections", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17937473_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "17959575_1", "wnd_id": "17959575_1_1", "text": "Myoclonus associated with continuous dobutamine infusion in a patient with end - stage renal disease .", "tokens": ["Myoclonus", "associated", "with", "continuous", "dobutamine", "infusion", "in", "a", "patient", "with", "end", "-", "stage", "renal", "disease", "."], "event_mentions": [{"id": "17959575_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "17959575_1_Ent1", "role": "Effect", "text": "Myoclonus", "start": 0, "end": 1}, {"entity_id": "17959575_1_Ent2", "role": "Treatment", "text": "continuous dobutamine infusion", "start": 3, "end": 6}, {"entity_id": "17959575_1_Ent3", "role": "Treatment_Drug", "text": "dobutamine", "start": 4, "end": 5}, {"entity_id": "17959575_1_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 5, "end": 6}, {"entity_id": "17959575_1_Ent0", "role": "Subject", "text": "a patient with end - stage renal disease", "start": 7, "end": 15}, {"entity_id": "17959575_1_Ent5", "role": "Treatment_Disorder", "text": "end - stage renal disease", "start": 10, "end": 15}]}], "entity_mentions": [{"id": "17959575_1_Ent1", "text": "Myoclonus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17959575_1_Ent2", "text": "continuous dobutamine infusion", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "17959575_1_Ent3", "text": "dobutamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17959575_1_Ent4", "text": "infusion", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17959575_1_Ent0", "text": "a patient with end - stage renal disease", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "17959575_1_Ent5", "text": "end - stage renal disease", "entity_type": "Entity", "start": 10, "end": 15}], "lang": "en"}
{"doc_id": "17959575_16", "wnd_id": "17959575_16_1", "text": "CONCLUSION : A patient with CHF and ESRD developed myoclonic muscle spasms after receiving dobutamine by continuous i.v .", "tokens": ["CONCLUSION", ":", "A", "patient", "with", "CHF", "and", "ESRD", "developed", "myoclonic", "muscle", "spasms", "after", "receiving", "dobutamine", "by", "continuous", "i.v", "."], "event_mentions": [{"id": "17959575_16_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "17959575_16_Ent0", "role": "Subject", "text": "A patient with CHF and ESRD", "start": 2, "end": 8}, {"entity_id": "17959575_16_Ent7", "role": "Treatment_Disorder", "text": "CHF", "start": 5, "end": 6}, {"entity_id": "17959575_16_Ent1", "role": "Subject_Disorder", "text": "ESRD", "start": 7, "end": 8}, {"entity_id": "17959575_16_Ent2", "role": "Effect", "text": "myoclonic muscle spasms", "start": 9, "end": 12}, {"entity_id": "17959575_16_Ent4", "role": "Treatment_Drug", "text": "dobutamine", "start": 14, "end": 15}, {"entity_id": "17959575_16_Ent3", "role": "Treatment", "text": "dobutamine by continuous i.v", "start": 14, "end": 18}, {"entity_id": "17959575_16_Ent5", "role": "Treatment_Freq", "text": "continuous", "start": 16, "end": 17}, {"entity_id": "17959575_16_Ent6", "role": "Treatment_Route", "text": "i.v", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "17959575_16_Ent0", "text": "A patient with CHF and ESRD", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "17959575_16_Ent7", "text": "CHF", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17959575_16_Ent1", "text": "ESRD", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17959575_16_Ent2", "text": "myoclonic muscle spasms", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "17959575_16_Ent4", "text": "dobutamine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17959575_16_Ent3", "text": "dobutamine by continuous i.v", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "17959575_16_Ent5", "text": "continuous", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17959575_16_Ent6", "text": "i.v", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "17968817_2", "wnd_id": "17968817_2_1", "text": "We report ( to our knowledge , for the first time in a child ) the emergence of psychosis in a 12 - year old white girl with an increased efavirenz concentration and heterozygous gene polymorphism of the CYP2B6 - G516T.", "tokens": ["We", "report", "(", "to", "our", "knowledge", ",", "for", "the", "first", "time", "in", "a", "child", ")", "the", "emergence", "of", "psychosis", "in", "a", "12", "-", "year", "old", "white", "girl", "with", "an", "increased", "efavirenz", "concentration", "and", "heterozygous", "gene", "polymorphism", "of", "the", "CYP2B6", "-", "G516T."], "event_mentions": [{"id": "17968817_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "emergence", "start": 16, "end": 17}, "arguments": [{"entity_id": "17968817_2_Ent5", "role": "Effect", "text": "psychosis", "start": 18, "end": 19}, {"entity_id": "17968817_2_Ent0", "role": "Subject", "text": "a 12 - year old white girl", "start": 20, "end": 27}, {"entity_id": "17968817_2_Ent2", "role": "Subject_Age", "text": "12 - year old", "start": 21, "end": 25}, {"entity_id": "17968817_2_Ent3", "role": "Subject_Race", "text": "white", "start": 25, "end": 26}, {"entity_id": "17968817_2_Ent4", "role": "Subject_Gender", "text": "girl", "start": 26, "end": 27}, {"entity_id": "17968817_2_Ent6", "role": "Treatment", "text": "increased efavirenz concentration", "start": 29, "end": 32}, {"entity_id": "17968817_2_Ent7", "role": "Treatment_Drug", "text": "efavirenz", "start": 30, "end": 31}, {"entity_id": "17968817_2_Ent1", "role": "Subject", "text": "heterozygous gene polymorphism of the CYP2B6 - G516T.", "start": 33, "end": 41}]}], "entity_mentions": [{"id": "17968817_2_Ent5", "text": "psychosis", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17968817_2_Ent0", "text": "a 12 - year old white girl", "entity_type": "Entity", "start": 20, "end": 27}, {"id": "17968817_2_Ent2", "text": "12 - year old", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "17968817_2_Ent3", "text": "white", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "17968817_2_Ent4", "text": "girl", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "17968817_2_Ent6", "text": "increased efavirenz concentration", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "17968817_2_Ent7", "text": "efavirenz", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "17968817_2_Ent1", "text": "heterozygous gene polymorphism of the CYP2B6 - G516T.", "entity_type": "Entity", "start": 33, "end": 41}], "lang": "en"}
{"doc_id": "17987285_3", "wnd_id": "17987285_3_1", "text": "Recent reports suggest that concomitant administration of CYP3A inhibitors with fentanyl may lead to dangerous drug interactions .", "tokens": ["Recent", "reports", "suggest", "that", "concomitant", "administration", "of", "CYP3A", "inhibitors", "with", "fentanyl", "may", "lead", "to", "dangerous", "drug", "interactions", "."], "event_mentions": [{"id": "17987285_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 12, "end": 13}, "arguments": [{"entity_id": "17987285_3_Ent1", "role": "Treatment", "text": "concomitant administration of CYP3A inhibitors with fentanyl", "start": 4, "end": 11}, {"entity_id": "17987285_3_Ent2", "role": "Treatment_Drug", "text": "CYP3A inhibitors", "start": 7, "end": 9}, {"entity_id": "17987285_3_Ent4", "role": "Combination_Drug", "text": "CYP3A inhibitors", "start": 7, "end": 9}, {"entity_id": "17987285_3_Ent3", "role": "Treatment_Drug", "text": "fentanyl", "start": 10, "end": 11}, {"entity_id": "17987285_3_Ent5", "role": "Combination_Drug", "text": "fentanyl", "start": 10, "end": 11}, {"entity_id": "17987285_3_Ent0", "role": "Effect", "text": "drug interactions", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "17987285_3_Ent1", "text": "concomitant administration of CYP3A inhibitors with fentanyl", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "17987285_3_Ent2", "text": "CYP3A inhibitors", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "17987285_3_Ent4", "text": "CYP3A inhibitors", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "17987285_3_Ent3", "text": "fentanyl", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17987285_3_Ent5", "text": "fentanyl", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17987285_3_Ent0", "text": "drug interactions", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "18006091_2", "wnd_id": "18006091_2_1", "text": "We present a case of a sustained monomorphic ventricular tachycardia following adenosine infusion .", "tokens": ["We", "present", "a", "case", "of", "a", "sustained", "monomorphic", "ventricular", "tachycardia", "following", "adenosine", "infusion", "."], "event_mentions": [{"id": "18006091_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 10, "end": 11}, "arguments": [{"entity_id": "18006091_2_Ent0", "role": "Effect", "text": "sustained monomorphic ventricular tachycardia", "start": 6, "end": 10}, {"entity_id": "18006091_2_Ent2", "role": "Treatment_Drug", "text": "adenosine", "start": 11, "end": 12}, {"entity_id": "18006091_2_Ent1", "role": "Treatment", "text": "adenosine infusion", "start": 11, "end": 13}, {"entity_id": "18006091_2_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "18006091_2_Ent0", "text": "sustained monomorphic ventricular tachycardia", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "18006091_2_Ent2", "text": "adenosine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18006091_2_Ent1", "text": "adenosine infusion", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18006091_2_Ent3", "text": "infusion", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "18042092_3", "wnd_id": "18042092_3_1", "text": "This case is remarkable since 1 ) ECM developed after subcutaneous and not after intramuscular injection , 2 ) the injection was given by the patient himself , and 3 ) glatiramer acetate can induce skin necrosis as a side effect .", "tokens": ["This", "case", "is", "remarkable", "since", "1", ")", "ECM", "developed", "after", "subcutaneous", "and", "not", "after", "intramuscular", "injection", ",", "2", ")", "the", "injection", "was", "given", "by", "the", "patient", "himself", ",", "and", "3", ")", "glatiramer", "acetate", "can", "induce", "skin", "necrosis", "as", "a", "side", "effect", "."], "event_mentions": [{"id": "18042092_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 34, "end": 35}, "arguments": [{"entity_id": "18042092_3_Ent1", "role": "Treatment", "text": "glatiramer acetate", "start": 31, "end": 33}, {"entity_id": "18042092_3_Ent2", "role": "Treatment_Drug", "text": "glatiramer acetate", "start": 31, "end": 33}, {"entity_id": "18042092_3_Ent0", "role": "Effect", "text": "skin necrosis", "start": 35, "end": 37}]}], "entity_mentions": [{"id": "18042092_3_Ent1", "text": "glatiramer acetate", "entity_type": "Entity", "start": 31, "end": 33}, {"id": "18042092_3_Ent2", "text": "glatiramer acetate", "entity_type": "Entity", "start": 31, "end": 33}, {"id": "18042092_3_Ent0", "text": "skin necrosis", "entity_type": "Entity", "start": 35, "end": 37}], "lang": "en"}
{"doc_id": "18067642_4", "wnd_id": "18067642_4_1", "text": "This is the first report on the histopathological findings of thyroid tissue from a patient with amiodarone - induced hypothyroidism .", "tokens": ["This", "is", "the", "first", "report", "on", "the", "histopathological", "findings", "of", "thyroid", "tissue", "from", "a", "patient", "with", "amiodarone", "-", "induced", "hypothyroidism", "."], "event_mentions": [{"id": "18067642_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 18, "end": 19}, "arguments": [{"entity_id": "18067642_4_Ent1", "role": "Treatment", "text": "amiodarone", "start": 16, "end": 17}, {"entity_id": "18067642_4_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 16, "end": 17}, {"entity_id": "18067642_4_Ent0", "role": "Effect", "text": "hypothyroidism", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "18067642_4_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18067642_4_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18067642_4_Ent0", "text": "hypothyroidism", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "18076602_2", "wnd_id": "18076602_2_1", "text": "Palpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of amphotericin B treatment .", "tokens": ["Palpable", "purpuric", "skin", "lesions", "on", "the", "anterior", "surface", "of", "both", "legs", "appeared", "on", "the", "55th", "day", "of", "amphotericin", "B", "treatment", "."], "event_mentions": [{"id": "18076602_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appeared", "start": 11, "end": 12}, "arguments": [{"entity_id": "18076602_2_Ent0", "role": "Effect", "text": "Palpable purpuric skin lesions on the anterior surface of both legs", "start": 0, "end": 11}, {"entity_id": "18076602_2_Ent2", "role": "Treatment_Duration", "text": "55th day", "start": 14, "end": 16}, {"entity_id": "18076602_2_Ent1", "role": "Treatment", "text": "55th day of amphotericin B treatment", "start": 14, "end": 20}, {"entity_id": "18076602_2_Ent3", "role": "Treatment_Drug", "text": "amphotericin B", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "18076602_2_Ent0", "text": "Palpable purpuric skin lesions on the anterior surface of both legs", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "18076602_2_Ent2", "text": "55th day", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "18076602_2_Ent1", "text": "55th day of amphotericin B treatment", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "18076602_2_Ent3", "text": "amphotericin B", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "18094347_3", "wnd_id": "18094347_3_1", "text": "DISCUSSION : Methotrexate - induced papular eruption is rarely reported shortly after beginning methotrexate therapy in patients with acute exacerbation of collagen vascular diseases .", "tokens": ["DISCUSSION", ":", "Methotrexate", "-", "induced", "papular", "eruption", "is", "rarely", "reported", "shortly", "after", "beginning", "methotrexate", "therapy", "in", "patients", "with", "acute", "exacerbation", "of", "collagen", "vascular", "diseases", "."], "event_mentions": [{"id": "18094347_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "18094347_3_Ent3", "role": "Treatment", "text": "Methotrexate", "start": 2, "end": 3}, {"entity_id": "18094347_3_Ent4", "role": "Treatment_Drug", "text": "Methotrexate", "start": 2, "end": 3}, {"entity_id": "18094347_3_Ent2", "role": "Effect", "text": "papular eruption", "start": 5, "end": 7}, {"entity_id": "18094347_3_Ent5", "role": "Treatment_Time_elapsed", "text": "shortly after", "start": 10, "end": 12}, {"entity_id": "18094347_3_Ent0", "role": "Subject", "text": "patients with acute exacerbation of collagen vascular diseases", "start": 16, "end": 24}, {"entity_id": "18094347_3_Ent1", "role": "Subject_Disorder", "text": "acute exacerbation of collagen vascular diseases", "start": 18, "end": 24}]}], "entity_mentions": [{"id": "18094347_3_Ent3", "text": "Methotrexate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18094347_3_Ent4", "text": "Methotrexate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18094347_3_Ent2", "text": "papular eruption", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "18094347_3_Ent5", "text": "shortly after", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18094347_3_Ent0", "text": "patients with acute exacerbation of collagen vascular diseases", "entity_type": "Entity", "start": 16, "end": 24}, {"id": "18094347_3_Ent1", "text": "acute exacerbation of collagen vascular diseases", "entity_type": "Entity", "start": 18, "end": 24}], "lang": "en"}
{"doc_id": "18094347_8", "wnd_id": "18094347_8_1", "text": "Ten hours after the second methotrexate injection , the patient experienced a diffuse pruritic papular eruption located mainly on the limbs .", "tokens": ["Ten", "hours", "after", "the", "second", "methotrexate", "injection", ",", "the", "patient", "experienced", "a", "diffuse", "pruritic", "papular", "eruption", "located", "mainly", "on", "the", "limbs", "."], "event_mentions": [{"id": "18094347_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 10, "end": 11}, "arguments": [{"entity_id": "18094347_8_Ent5", "role": "Treatment_Time_elapsed", "text": "Ten hours", "start": 0, "end": 2}, {"entity_id": "18094347_8_Ent2", "role": "Treatment", "text": "Ten hours after the second methotrexate injection", "start": 0, "end": 7}, {"entity_id": "18094347_8_Ent6", "role": "Treatment_Time_elapsed", "text": "second", "start": 4, "end": 5}, {"entity_id": "18094347_8_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "18094347_8_Ent4", "role": "Treatment_Route", "text": "injection", "start": 6, "end": 7}, {"entity_id": "18094347_8_Ent0", "role": "Subject", "text": "the patient", "start": 8, "end": 10}, {"entity_id": "18094347_8_Ent1", "role": "Effect", "text": "diffuse pruritic papular eruption located mainly on the limbs", "start": 12, "end": 21}]}], "entity_mentions": [{"id": "18094347_8_Ent5", "text": "Ten hours", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18094347_8_Ent2", "text": "Ten hours after the second methotrexate injection", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "18094347_8_Ent6", "text": "second", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18094347_8_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18094347_8_Ent4", "text": "injection", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18094347_8_Ent0", "text": "the patient", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18094347_8_Ent1", "text": "diffuse pruritic papular eruption located mainly on the limbs", "entity_type": "Entity", "start": 12, "end": 21}], "lang": "en"}
{"doc_id": "18166746_2", "wnd_id": "18166746_2_1", "text": "To report a case of autonomic , neurological and neuromuscular instability following methylene blue infusion for parathyroidectomy ; to advance the argument for a diagnosis of serotonin syndrome ; and to consider this diagnosis in previous , unexplained reports of adverse reactions amongst patients undergoing parathyroidectomy using methylene blue .", "tokens": ["To", "report", "a", "case", "of", "autonomic", ",", "neurological", "and", "neuromuscular", "instability", "following", "methylene", "blue", "infusion", "for", "parathyroidectomy", ";", "to", "advance", "the", "argument", "for", "a", "diagnosis", "of", "serotonin", "syndrome", ";", "and", "to", "consider", "this", "diagnosis", "in", "previous", ",", "unexplained", "reports", "of", "adverse", "reactions", "amongst", "patients", "undergoing", "parathyroidectomy", "using", "methylene", "blue", "."], "event_mentions": [{"id": "18166746_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 11, "end": 12}, "arguments": [{"entity_id": "18166746_2_Ent0", "role": "Effect", "text": "autonomic , neurological and neuromuscular instability", "start": 5, "end": 11}, {"entity_id": "18166746_2_Ent2", "role": "Treatment_Drug", "text": "methylene blue", "start": 12, "end": 14}, {"entity_id": "18166746_2_Ent1", "role": "Treatment", "text": "methylene blue infusion for parathyroidectomy", "start": 12, "end": 17}, {"entity_id": "18166746_2_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "18166746_2_Ent0", "text": "autonomic , neurological and neuromuscular instability", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "18166746_2_Ent2", "text": "methylene blue", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "18166746_2_Ent1", "text": "methylene blue infusion for parathyroidectomy", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "18166746_2_Ent3", "text": "infusion", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "18166746_3", "wnd_id": "18166746_3_1", "text": "Methylene blue was administered to a 58 - yr - old woman undergoing a parathyroidectomy under general anesthesia .", "tokens": ["Methylene", "blue", "was", "administered", "to", "a", "58", "-", "yr", "-", "old", "woman", "undergoing", "a", "parathyroidectomy", "under", "general", "anesthesia", "."], "event_mentions": [{"id": "18166746_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "administered to", "start": 3, "end": 5}, "arguments": [{"entity_id": "18166746_3_Ent3", "role": "Treatment", "text": "Methylene blue", "start": 0, "end": 2}, {"entity_id": "18166746_3_Ent4", "role": "Treatment_Drug", "text": "Methylene blue", "start": 0, "end": 2}, {"entity_id": "18166746_3_Ent0", "role": "Subject", "text": "a 58 - yr - old woman undergoing a parathyroidectomy under general anesthesia", "start": 5, "end": 18}, {"entity_id": "18166746_3_Ent1", "role": "Subject_Age", "text": "58 - yr - old", "start": 6, "end": 11}, {"entity_id": "18166746_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "18166746_3_Ent3", "text": "Methylene blue", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18166746_3_Ent4", "text": "Methylene blue", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18166746_3_Ent0", "text": "a 58 - yr - old woman undergoing a parathyroidectomy under general anesthesia", "entity_type": "Entity", "start": 5, "end": 18}, {"id": "18166746_3_Ent1", "text": "58 - yr - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "18166746_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "18166746_4", "wnd_id": "18166746_4_1", "text": "The patient had a background of obsessive compulsive disorder treated with paroxetine .", "tokens": ["The", "patient", "had", "a", "background", "of", "obsessive", "compulsive", "disorder", "treated", "with", "paroxetine", "."], "event_mentions": [{"id": "18166746_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 9, "end": 10}, "arguments": [{"entity_id": "18166746_4_Ent0", "role": "Subject", "text": "The patient had a background of obsessive compulsive disorder", "start": 0, "end": 9}, {"entity_id": "18166746_4_Ent2", "role": "Treatment_Disorder", "text": "obsessive compulsive disorder", "start": 6, "end": 9}, {"entity_id": "18166746_4_Ent1", "role": "Treatment", "text": "paroxetine", "start": 11, "end": 12}, {"entity_id": "18166746_4_Ent3", "role": "Treatment_Drug", "text": "paroxetine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "18166746_4_Ent0", "text": "The patient had a background of obsessive compulsive disorder", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "18166746_4_Ent2", "text": "obsessive compulsive disorder", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "18166746_4_Ent1", "text": "paroxetine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18166746_4_Ent3", "text": "paroxetine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "18171260_2", "wnd_id": "18171260_2_1", "text": "Serotonin syndrome has been reported with administration of linezolid and serotonin reuptake inhibitors .", "tokens": ["Serotonin", "syndrome", "has", "been", "reported", "with", "administration", "of", "linezolid", "and", "serotonin", "reuptake", "inhibitors", "."], "event_mentions": [{"id": "18171260_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported with", "start": 4, "end": 6}, "arguments": [{"entity_id": "18171260_2_Ent0", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "18171260_2_Ent1", "role": "Treatment", "text": "administration of linezolid and serotonin reuptake inhibitors", "start": 6, "end": 13}, {"entity_id": "18171260_2_Ent2", "role": "Treatment_Drug", "text": "linezolid", "start": 8, "end": 9}, {"entity_id": "18171260_2_Ent4", "role": "Combination_Drug", "text": "linezolid", "start": 8, "end": 9}, {"entity_id": "18171260_2_Ent3", "role": "Treatment_Drug", "text": "serotonin reuptake inhibitors", "start": 10, "end": 13}, {"entity_id": "18171260_2_Ent5", "role": "Combination_Drug", "text": "serotonin reuptake inhibitors", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "18171260_2_Ent0", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18171260_2_Ent1", "text": "administration of linezolid and serotonin reuptake inhibitors", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "18171260_2_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18171260_2_Ent4", "text": "linezolid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18171260_2_Ent3", "text": "serotonin reuptake inhibitors", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18171260_2_Ent5", "text": "serotonin reuptake inhibitors", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "18176653_12", "wnd_id": "18176653_12_1", "text": "Although HAART is very important in the treatment of HIV , its side effects are responsible for patients ' non - adherence to medications .", "tokens": ["Although", "HAART", "is", "very", "important", "in", "the", "treatment", "of", "HIV", ",", "its", "side", "effects", "are", "responsible", "for", "patients", "'", "non", "-", "adherence", "to", "medications", "."], "event_mentions": [{"id": "18176653_12_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 12, "end": 14}, "arguments": [{"entity_id": "18176653_12_Ent2", "role": "Treatment", "text": "HAART", "start": 1, "end": 2}, {"entity_id": "18176653_12_Ent4", "role": "Treatment_Drug", "text": "HAART", "start": 1, "end": 2}, {"entity_id": "18176653_12_Ent3", "role": "Treatment_Disorder", "text": "HIV", "start": 9, "end": 10}, {"entity_id": "18176653_12_Ent0", "role": "Subject", "text": "patients", "start": 17, "end": 18}, {"entity_id": "18176653_12_Ent1", "role": "Effect", "text": "non - adherence to medications", "start": 19, "end": 24}]}], "entity_mentions": [{"id": "18176653_12_Ent2", "text": "HAART", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18176653_12_Ent4", "text": "HAART", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18176653_12_Ent3", "text": "HIV", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18176653_12_Ent0", "text": "patients", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18176653_12_Ent1", "text": "non - adherence to medications", "entity_type": "Entity", "start": 19, "end": 24}], "lang": "en"}
{"doc_id": "18176653_4", "wnd_id": "18176653_4_1", "text": "CASE REPORT : A 29 - year - old black man , HIV - infected since 1996 , began highly active antiretroviral therapy ( HAART ) with zidovudine , lamivudine , and indinavir .", "tokens": ["CASE", "REPORT", ":", "A", "29", "-", "year", "-", "old", "black", "man", ",", "HIV", "-", "infected", "since", "1996", ",", "began", "highly", "active", "antiretroviral", "therapy", "(", "HAART", ")", "with", "zidovudine", ",", "lamivudine", ",", "and", "indinavir", "."], "event_mentions": [{"id": "18176653_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "began", "start": 18, "end": 19}, "arguments": [{"entity_id": "18176653_4_Ent0", "role": "Subject", "text": "A 29 - year - old black man , HIV - infected since 1996", "start": 3, "end": 17}, {"entity_id": "18176653_4_Ent1", "role": "Subject_Age", "text": "29 - year - old", "start": 4, "end": 9}, {"entity_id": "18176653_4_Ent2", "role": "Subject_Race", "text": "black", "start": 9, "end": 10}, {"entity_id": "18176653_4_Ent3", "role": "Subject_Gender", "text": "man", "start": 10, "end": 11}, {"entity_id": "18176653_4_Ent8", "role": "Treatment_Disorder", "text": "HIV", "start": 12, "end": 13}, {"entity_id": "18176653_4_Ent4", "role": "Treatment", "text": "highly active antiretroviral therapy ( HAART ) with zidovudine , lamivudine , and indinavir", "start": 19, "end": 33}, {"entity_id": "18176653_4_Ent5", "role": "Treatment_Drug", "text": "zidovudine", "start": 27, "end": 28}, {"entity_id": "18176653_4_Ent9", "role": "Combination_Drug", "text": "zidovudine", "start": 27, "end": 28}, {"entity_id": "18176653_4_Ent6", "role": "Treatment_Drug", "text": "lamivudine", "start": 29, "end": 30}, {"entity_id": "18176653_4_Ent10", "role": "Combination_Drug", "text": "lamivudine", "start": 29, "end": 30}, {"entity_id": "18176653_4_Ent7", "role": "Treatment_Drug", "text": "indinavir", "start": 32, "end": 33}, {"entity_id": "18176653_4_Ent11", "role": "Combination_Drug", "text": "indinavir", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "18176653_4_Ent0", "text": "A 29 - year - old black man , HIV - infected since 1996", "entity_type": "Entity", "start": 3, "end": 17}, {"id": "18176653_4_Ent1", "text": "29 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "18176653_4_Ent2", "text": "black", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18176653_4_Ent3", "text": "man", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18176653_4_Ent8", "text": "HIV", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18176653_4_Ent4", "text": "highly active antiretroviral therapy ( HAART ) with zidovudine , lamivudine , and indinavir", "entity_type": "Entity", "start": 19, "end": 33}, {"id": "18176653_4_Ent5", "text": "zidovudine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "18176653_4_Ent9", "text": "zidovudine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "18176653_4_Ent6", "text": "lamivudine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "18176653_4_Ent10", "text": "lamivudine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "18176653_4_Ent7", "text": "indinavir", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "18176653_4_Ent11", "text": "indinavir", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "18191947_3", "wnd_id": "18191947_3_1", "text": "We describe longitudinal diffusion - weighted MRI findings of sub - acute leukoencephalopathy following methotrexate therapy in a 24 - year - old man diagnosed with pre - B - cell acute lymphoblastic leukemia ( ALL ) , presenting with right - sided paralysis and aphasia after second consolidation with intrathecal triple - drug therapy given intrathecally .", "tokens": ["We", "describe", "longitudinal", "diffusion", "-", "weighted", "MRI", "findings", "of", "sub", "-", "acute", "leukoencephalopathy", "following", "methotrexate", "therapy", "in", "a", "24", "-", "year", "-", "old", "man", "diagnosed", "with", "pre", "-", "B", "-", "cell", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", ",", "presenting", "with", "right", "-", "sided", "paralysis", "and", "aphasia", "after", "second", "consolidation", "with", "intrathecal", "triple", "-", "drug", "therapy", "given", "intrathecally", "."], "event_mentions": [{"id": "18191947_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 13, "end": 14}, "arguments": [{"entity_id": "18191947_3_Ent3", "role": "Effect", "text": "longitudinal diffusion - weighted MRI findings of sub - acute leukoencephalopathy", "start": 2, "end": 13}, {"entity_id": "18191947_3_Ent4", "role": "Treatment", "text": "methotrexate", "start": 14, "end": 15}, {"entity_id": "18191947_3_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 14, "end": 15}, {"entity_id": "18191947_3_Ent0", "role": "Subject", "text": "a 24 - year - old man", "start": 17, "end": 24}, {"entity_id": "18191947_3_Ent1", "role": "Subject_Age", "text": "24 - year - old", "start": 18, "end": 23}, {"entity_id": "18191947_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 23, "end": 24}]}, {"id": "18191947_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 46, "end": 47}, "arguments": [{"entity_id": "18191947_3_Ent6", "role": "Subject", "text": "a 24 - year - old man", "start": 17, "end": 24}, {"entity_id": "18191947_3_Ent7", "role": "Subject_Age", "text": "24 - year - old", "start": 18, "end": 23}, {"entity_id": "18191947_3_Ent8", "role": "Subject_Gender", "text": "man", "start": 23, "end": 24}, {"entity_id": "18191947_3_Ent11", "role": "Treatment_Disorder", "text": "pre - B - cell acute lymphoblastic leukemia ( ALL )", "start": 26, "end": 37}, {"entity_id": "18191947_3_Ent9", "role": "Effect", "text": "presenting with right - sided paralysis and aphasia", "start": 38, "end": 46}, {"entity_id": "18191947_3_Ent10", "role": "Treatment", "text": "second consolidation with intrathecal triple - drug therapy given intrathecally", "start": 47, "end": 57}, {"entity_id": "18191947_3_Ent12", "role": "Treatment_Route", "text": "intrathecally", "start": 56, "end": 57}]}], "entity_mentions": [{"id": "18191947_3_Ent3", "text": "longitudinal diffusion - weighted MRI findings of sub - acute leukoencephalopathy", "entity_type": "Entity", "start": 2, "end": 13}, {"id": "18191947_3_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18191947_3_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18191947_3_Ent0", "text": "a 24 - year - old man", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "18191947_3_Ent6", "text": "a 24 - year - old man", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "18191947_3_Ent1", "text": "24 - year - old", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "18191947_3_Ent7", "text": "24 - year - old", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "18191947_3_Ent2", "text": "man", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "18191947_3_Ent8", "text": "man", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "18191947_3_Ent11", "text": "pre - B - cell acute lymphoblastic leukemia ( ALL )", "entity_type": "Entity", "start": 26, "end": 37}, {"id": "18191947_3_Ent9", "text": "presenting with right - sided paralysis and aphasia", "entity_type": "Entity", "start": 38, "end": 46}, {"id": "18191947_3_Ent10", "text": "second consolidation with intrathecal triple - drug therapy given intrathecally", "entity_type": "Entity", "start": 47, "end": 57}, {"id": "18191947_3_Ent12", "text": "intrathecally", "entity_type": "Entity", "start": 56, "end": 57}], "lang": "en"}
{"doc_id": "18252776_1", "wnd_id": "18252776_1_1", "text": "Upper gastrointestinal haemorrhage is a serious complication of aspirin and clopidogrel ( dual ) anti - platelet therapy with a high morbidity and mortality .", "tokens": ["Upper", "gastrointestinal", "haemorrhage", "is", "a", "serious", "complication", "of", "aspirin", "and", "clopidogrel", "(", "dual", ")", "anti", "-", "platelet", "therapy", "with", "a", "high", "morbidity", "and", "mortality", "."], "event_mentions": [{"id": "18252776_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 6, "end": 7}, "arguments": [{"entity_id": "18252776_1_Ent0", "role": "Effect", "text": "Upper gastrointestinal haemorrhage", "start": 0, "end": 3}, {"entity_id": "18252776_1_Ent1", "role": "Treatment", "text": "aspirin and clopidogrel ( dual )", "start": 8, "end": 14}]}], "entity_mentions": [{"id": "18252776_1_Ent0", "text": "Upper gastrointestinal haemorrhage", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18252776_1_Ent1", "text": "aspirin and clopidogrel ( dual )", "entity_type": "Entity", "start": 8, "end": 14}], "lang": "en"}
{"doc_id": "18262450_8", "wnd_id": "18262450_8_1", "text": "Oxycodone - gabapentin reduced pain score by 33 % from baseline to end of treatment .", "tokens": ["Oxycodone", "-", "gabapentin", "reduced", "pain", "score", "by", "33", "%", "from", "baseline", "to", "end", "of", "treatment", "."], "event_mentions": [{"id": "18262450_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reduced", "start": 3, "end": 4}, "arguments": [{"entity_id": "18262450_8_Ent3", "role": "Treatment_Drug", "text": "Oxycodone", "start": 0, "end": 1}, {"entity_id": "18262450_8_Ent5", "role": "Combination_Drug", "text": "Oxycodone", "start": 0, "end": 1}, {"entity_id": "18262450_8_Ent1", "role": "Treatment", "text": "Oxycodone - gabapentin", "start": 0, "end": 3}, {"entity_id": "18262450_8_Ent4", "role": "Treatment_Drug", "text": "gabapentin", "start": 2, "end": 3}, {"entity_id": "18262450_8_Ent6", "role": "Combination_Drug", "text": "gabapentin", "start": 2, "end": 3}, {"entity_id": "18262450_8_Ent0", "role": "Effect", "text": "reduced pain score by 33 % from baseline", "start": 3, "end": 11}, {"entity_id": "18262450_8_Ent2", "role": "Treatment_Disorder", "text": "pain", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "18262450_8_Ent3", "text": "Oxycodone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18262450_8_Ent5", "text": "Oxycodone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18262450_8_Ent1", "text": "Oxycodone - gabapentin", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18262450_8_Ent4", "text": "gabapentin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18262450_8_Ent6", "text": "gabapentin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18262450_8_Ent0", "text": "reduced pain score by 33 % from baseline", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "18262450_8_Ent2", "text": "pain", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "1827039_1", "wnd_id": "1827039_1_1", "text": "Severe hepatocellular dysfunction following cyproterone acetate therapy .", "tokens": ["Severe", "hepatocellular", "dysfunction", "following", "cyproterone", "acetate", "therapy", "."], "event_mentions": [{"id": "1827039_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "1827039_1_Ent0", "role": "Effect", "text": "Severe hepatocellular dysfunction", "start": 0, "end": 3}, {"entity_id": "1827039_1_Ent1", "role": "Treatment", "text": "cyproterone acetate", "start": 4, "end": 6}, {"entity_id": "1827039_1_Ent2", "role": "Treatment_Drug", "text": "cyproterone acetate", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "1827039_1_Ent0", "text": "Severe hepatocellular dysfunction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1827039_1_Ent1", "text": "cyproterone acetate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1827039_1_Ent2", "text": "cyproterone acetate", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "18294121_2", "wnd_id": "18294121_2_1", "text": "Clinicians should be aware that an erythematous and exfoliative rash may be induced by temozolomide , and be familiar with the pharmacologic and supportive measures necessary for its treatment .", "tokens": ["Clinicians", "should", "be", "aware", "that", "an", "erythematous", "and", "exfoliative", "rash", "may", "be", "induced", "by", "temozolomide", ",", "and", "be", "familiar", "with", "the", "pharmacologic", "and", "supportive", "measures", "necessary", "for", "its", "treatment", "."], "event_mentions": [{"id": "18294121_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "18294121_2_Ent0", "role": "Effect", "text": "an erythematous and exfoliative rash", "start": 5, "end": 10}, {"entity_id": "18294121_2_Ent1", "role": "Treatment", "text": "temozolomide", "start": 14, "end": 15}, {"entity_id": "18294121_2_Ent2", "role": "Treatment_Drug", "text": "temozolomide", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "18294121_2_Ent0", "text": "an erythematous and exfoliative rash", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "18294121_2_Ent1", "text": "temozolomide", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18294121_2_Ent2", "text": "temozolomide", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "18294121_4", "wnd_id": "18294121_4_1", "text": "Temozolomide - induced desquamative skin rash in a patient with metastatic melanoma .", "tokens": ["Temozolomide", "-", "induced", "desquamative", "skin", "rash", "in", "a", "patient", "with", "metastatic", "melanoma", "."], "event_mentions": [{"id": "18294121_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18294121_4_Ent2", "role": "Treatment", "text": "Temozolomide", "start": 0, "end": 1}, {"entity_id": "18294121_4_Ent3", "role": "Treatment_Drug", "text": "Temozolomide", "start": 0, "end": 1}, {"entity_id": "18294121_4_Ent1", "role": "Effect", "text": "desquamative skin rash", "start": 3, "end": 6}, {"entity_id": "18294121_4_Ent0", "role": "Subject", "text": "a patient with metastatic melanoma", "start": 7, "end": 12}, {"entity_id": "18294121_4_Ent4", "role": "Treatment_Disorder", "text": "metastatic melanoma", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "18294121_4_Ent2", "text": "Temozolomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18294121_4_Ent3", "text": "Temozolomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18294121_4_Ent1", "text": "desquamative skin rash", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "18294121_4_Ent0", "text": "a patient with metastatic melanoma", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18294121_4_Ent4", "text": "metastatic melanoma", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "18294121_5", "wnd_id": "18294121_5_1", "text": "Temozolomide was restarted 2 months later ; the patient again developed a fever .", "tokens": ["Temozolomide", "was", "restarted", "2", "months", "later", ";", "the", "patient", "again", "developed", "a", "fever", "."], "event_mentions": [{"id": "18294121_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "18294121_5_Ent2", "role": "Treatment", "text": "Temozolomide", "start": 0, "end": 1}, {"entity_id": "18294121_5_Ent3", "role": "Treatment_Drug", "text": "Temozolomide", "start": 0, "end": 1}, {"entity_id": "18294121_5_Ent0", "role": "Subject", "text": "the patient", "start": 7, "end": 9}, {"entity_id": "18294121_5_Ent1", "role": "Effect", "text": "fever", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "18294121_5_Ent2", "text": "Temozolomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18294121_5_Ent3", "text": "Temozolomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18294121_5_Ent0", "text": "the patient", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18294121_5_Ent1", "text": "fever", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "1834424_2", "wnd_id": "1834424_2_1", "text": "Allergic contact dermatitis from 4 - chloro - 7 - nitrobenzofurazan .", "tokens": ["Allergic", "contact", "dermatitis", "from", "4", "-", "chloro", "-", "7", "-", "nitrobenzofurazan", "."], "event_mentions": [{"id": "1834424_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 3, "end": 4}, "arguments": [{"entity_id": "1834424_2_Ent0", "role": "Effect", "text": "Allergic contact dermatitis", "start": 0, "end": 3}, {"entity_id": "1834424_2_Ent1", "role": "Treatment", "text": "4 - chloro - 7 - nitrobenzofurazan", "start": 4, "end": 11}, {"entity_id": "1834424_2_Ent2", "role": "Treatment_Drug", "text": "4 - chloro - 7 - nitrobenzofurazan", "start": 4, "end": 11}]}], "entity_mentions": [{"id": "1834424_2_Ent0", "text": "Allergic contact dermatitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1834424_2_Ent1", "text": "4 - chloro - 7 - nitrobenzofurazan", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "1834424_2_Ent2", "text": "4 - chloro - 7 - nitrobenzofurazan", "entity_type": "Entity", "start": 4, "end": 11}], "lang": "en"}
{"doc_id": "18344734_1", "wnd_id": "18344734_1_1", "text": "Photo - onycholysis caused by olanzapine and aripiprazole .", "tokens": ["Photo", "-", "onycholysis", "caused", "by", "olanzapine", "and", "aripiprazole", "."], "event_mentions": [{"id": "18344734_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 3, "end": 4}, "arguments": [{"entity_id": "18344734_1_Ent0", "role": "Effect", "text": "Photo - onycholysis", "start": 0, "end": 3}, {"entity_id": "18344734_1_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 5, "end": 6}, {"entity_id": "18344734_1_Ent1", "role": "Treatment", "text": "olanzapine and aripiprazole", "start": 5, "end": 8}, {"entity_id": "18344734_1_Ent3", "role": "Treatment_Drug", "text": "aripiprazole", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "18344734_1_Ent0", "text": "Photo - onycholysis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18344734_1_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18344734_1_Ent1", "text": "olanzapine and aripiprazole", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "18344734_1_Ent3", "text": "aripiprazole", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "18347524_1", "wnd_id": "18347524_1_1", "text": "Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis .", "tokens": ["Diffuse", "alveolar", "hemorrhage", "after", "leflunomide", "therapy", "in", "a", "patient", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "18347524_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "18347524_1_Ent1", "role": "Effect", "text": "Diffuse alveolar hemorrhage", "start": 0, "end": 3}, {"entity_id": "18347524_1_Ent2", "role": "Treatment", "text": "leflunomide", "start": 4, "end": 5}, {"entity_id": "18347524_1_Ent4", "role": "Treatment_Drug", "text": "leflunomide", "start": 4, "end": 5}, {"entity_id": "18347524_1_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 7, "end": 12}, {"entity_id": "18347524_1_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "18347524_1_Ent1", "text": "Diffuse alveolar hemorrhage", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18347524_1_Ent2", "text": "leflunomide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18347524_1_Ent4", "text": "leflunomide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18347524_1_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18347524_1_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "18359591_1", "wnd_id": "18359591_1_1", "text": "In the present paper , we describe two patients with active UC who developed a severe systemic CMV infection during a treatment with an oral microemulsion form of cyclosporine .", "tokens": ["In", "the", "present", "paper", ",", "we", "describe", "two", "patients", "with", "active", "UC", "who", "developed", "a", "severe", "systemic", "CMV", "infection", "during", "a", "treatment", "with", "an", "oral", "microemulsion", "form", "of", "cyclosporine", "."], "event_mentions": [{"id": "18359591_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 21, "end": 22}, "arguments": [{"entity_id": "18359591_1_Ent1", "role": "Subject_Population", "text": "two", "start": 7, "end": 8}, {"entity_id": "18359591_1_Ent0", "role": "Subject", "text": "two patients with active UC", "start": 7, "end": 12}, {"entity_id": "18359591_1_Ent6", "role": "Treatment_Disorder", "text": "active UC", "start": 10, "end": 12}, {"entity_id": "18359591_1_Ent2", "role": "Effect", "text": "severe systemic CMV infection", "start": 15, "end": 19}, {"entity_id": "18359591_1_Ent4", "role": "Treatment_Route", "text": "oral", "start": 24, "end": 25}, {"entity_id": "18359591_1_Ent3", "role": "Treatment", "text": "oral microemulsion form of cyclosporine", "start": 24, "end": 29}, {"entity_id": "18359591_1_Ent5", "role": "Treatment_Drug", "text": "cyclosporine", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "18359591_1_Ent1", "text": "two", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18359591_1_Ent0", "text": "two patients with active UC", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18359591_1_Ent6", "text": "active UC", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18359591_1_Ent2", "text": "severe systemic CMV infection", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "18359591_1_Ent4", "text": "oral", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18359591_1_Ent3", "text": "oral microemulsion form of cyclosporine", "entity_type": "Entity", "start": 24, "end": 29}, {"id": "18359591_1_Ent5", "text": "cyclosporine", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "18362995_1", "wnd_id": "18362995_1_1", "text": "A short review on imatinib - related hepatotoxicity is also presented .", "tokens": ["A", "short", "review", "on", "imatinib", "-", "related", "hepatotoxicity", "is", "also", "presented", "."], "event_mentions": [{"id": "18362995_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 6, "end": 7}, "arguments": [{"entity_id": "18362995_1_Ent1", "role": "Treatment", "text": "imatinib", "start": 4, "end": 5}, {"entity_id": "18362995_1_Ent2", "role": "Treatment_Drug", "text": "imatinib", "start": 4, "end": 5}, {"entity_id": "18362995_1_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "18362995_1_Ent1", "text": "imatinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18362995_1_Ent2", "text": "imatinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18362995_1_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "18362995_4", "wnd_id": "18362995_4_1", "text": "We report a 45 - year - old Chinese man with CML and chronic hepatitis B virus infection , on imatinib treatment , presenting with herpetic rash and acute liver failure .", "tokens": ["We", "report", "a", "45", "-", "year", "-", "old", "Chinese", "man", "with", "CML", "and", "chronic", "hepatitis", "B", "virus", "infection", ",", "on", "imatinib", "treatment", ",", "presenting", "with", "herpetic", "rash", "and", "acute", "liver", "failure", "."], "event_mentions": [{"id": "18362995_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presenting", "start": 23, "end": 24}, "arguments": [{"entity_id": "18362995_4_Ent0", "role": "Subject", "text": "a 45 - year - old Chinese man with CML and chronic hepatitis B virus infection", "start": 2, "end": 18}, {"entity_id": "18362995_4_Ent1", "role": "Subject_Age", "text": "45 - year - old", "start": 3, "end": 8}, {"entity_id": "18362995_4_Ent2", "role": "Subject_Race", "text": "Chinese", "start": 8, "end": 9}, {"entity_id": "18362995_4_Ent3", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "18362995_4_Ent7", "role": "Treatment_Disorder", "text": "CML and chronic hepatitis B", "start": 11, "end": 16}, {"entity_id": "18362995_4_Ent5", "role": "Treatment", "text": "on imatinib treatment", "start": 19, "end": 22}, {"entity_id": "18362995_4_Ent6", "role": "Treatment_Drug", "text": "imatinib", "start": 20, "end": 21}, {"entity_id": "18362995_4_Ent4", "role": "Effect", "text": "herpetic rash and acute liver failure", "start": 25, "end": 31}]}], "entity_mentions": [{"id": "18362995_4_Ent0", "text": "a 45 - year - old Chinese man with CML and chronic hepatitis B virus infection", "entity_type": "Entity", "start": 2, "end": 18}, {"id": "18362995_4_Ent1", "text": "45 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "18362995_4_Ent2", "text": "Chinese", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18362995_4_Ent3", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18362995_4_Ent7", "text": "CML and chronic hepatitis B", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "18362995_4_Ent5", "text": "on imatinib treatment", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "18362995_4_Ent6", "text": "imatinib", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "18362995_4_Ent4", "text": "herpetic rash and acute liver failure", "entity_type": "Entity", "start": 25, "end": 31}], "lang": "en"}
{"doc_id": "18364401_2", "wnd_id": "18364401_2_1", "text": "OBJECTIVE : To report a case of rapidly occurring hyperglycemia that occurred in a geriatric patient 3 days after treatment with olanzapine .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "rapidly", "occurring", "hyperglycemia", "that", "occurred", "in", "a", "geriatric", "patient", "3", "days", "after", "treatment", "with", "olanzapine", "."], "event_mentions": [{"id": "18364401_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 8, "end": 9}, "arguments": [{"entity_id": "18364401_2_Ent2", "role": "Effect", "text": "hyperglycemia", "start": 9, "end": 10}, {"entity_id": "18364401_2_Ent0", "role": "Subject", "text": "a geriatric patient", "start": 13, "end": 16}, {"entity_id": "18364401_2_Ent1", "role": "Subject_Age", "text": "geriatric", "start": 14, "end": 15}, {"entity_id": "18364401_2_Ent5", "role": "Treatment_Time_elapsed", "text": "3 days", "start": 16, "end": 18}, {"entity_id": "18364401_2_Ent3", "role": "Treatment", "text": "olanzapine", "start": 21, "end": 22}, {"entity_id": "18364401_2_Ent4", "role": "Treatment_Drug", "text": "olanzapine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "18364401_2_Ent2", "text": "hyperglycemia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18364401_2_Ent0", "text": "a geriatric patient", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "18364401_2_Ent1", "text": "geriatric", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18364401_2_Ent5", "text": "3 days", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "18364401_2_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "18364401_2_Ent4", "text": "olanzapine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "18396749_4", "wnd_id": "18396749_4_1", "text": "In the absence of evidence of a potential role for concomitant medication i.e. hydroxychloroquine sulfate to play a role in the clinical , biochemical and morphological picture , an interaction between the herbal preparation and tibolone was suspected as the likely cause of liver damage .", "tokens": ["In", "the", "absence", "of", "evidence", "of", "a", "potential", "role", "for", "concomitant", "medication", "i.e.", "hydroxychloroquine", "sulfate", "to", "play", "a", "role", "in", "the", "clinical", ",", "biochemical", "and", "morphological", "picture", ",", "an", "interaction", "between", "the", "herbal", "preparation", "and", "tibolone", "was", "suspected", "as", "the", "likely", "cause", "of", "liver", "damage", "."], "event_mentions": [{"id": "18396749_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suspected", "start": 37, "end": 38}, "arguments": [{"entity_id": "18396749_4_Ent1", "role": "Treatment", "text": "an interaction between the herbal preparation and tibolone", "start": 28, "end": 36}, {"entity_id": "18396749_4_Ent2", "role": "Treatment_Drug", "text": "herbal preparation", "start": 32, "end": 34}, {"entity_id": "18396749_4_Ent4", "role": "Combination_Drug", "text": "herbal preparation", "start": 32, "end": 34}, {"entity_id": "18396749_4_Ent3", "role": "Treatment_Drug", "text": "tibolone", "start": 35, "end": 36}, {"entity_id": "18396749_4_Ent5", "role": "Combination_Drug", "text": "tibolone", "start": 35, "end": 36}, {"entity_id": "18396749_4_Ent0", "role": "Effect", "text": "liver damage", "start": 43, "end": 45}]}], "entity_mentions": [{"id": "18396749_4_Ent1", "text": "an interaction between the herbal preparation and tibolone", "entity_type": "Entity", "start": 28, "end": 36}, {"id": "18396749_4_Ent2", "text": "herbal preparation", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "18396749_4_Ent4", "text": "herbal preparation", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "18396749_4_Ent3", "text": "tibolone", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "18396749_4_Ent5", "text": "tibolone", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "18396749_4_Ent0", "text": "liver damage", "entity_type": "Entity", "start": 43, "end": 45}], "lang": "en"}
{"doc_id": "18425523_2", "wnd_id": "18425523_2_1", "text": "CONCLUSION : Severe and sustained ocular hypertension may occur after intravitreal ranibizumab .", "tokens": ["CONCLUSION", ":", "Severe", "and", "sustained", "ocular", "hypertension", "may", "occur", "after", "intravitreal", "ranibizumab", "."], "event_mentions": [{"id": "18425523_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "18425523_2_Ent0", "role": "Effect", "text": "Severe and sustained ocular hypertension", "start": 2, "end": 7}, {"entity_id": "18425523_2_Ent3", "role": "Treatment_Route", "text": "intravitreal", "start": 10, "end": 11}, {"entity_id": "18425523_2_Ent1", "role": "Treatment", "text": "intravitreal ranibizumab", "start": 10, "end": 12}, {"entity_id": "18425523_2_Ent2", "role": "Treatment_Drug", "text": "ranibizumab", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "18425523_2_Ent0", "text": "Severe and sustained ocular hypertension", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "18425523_2_Ent3", "text": "intravitreal", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18425523_2_Ent1", "text": "intravitreal ranibizumab", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18425523_2_Ent2", "text": "ranibizumab", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "18431096_1", "wnd_id": "18431096_1_1", "text": "Methylphenidate and dextroamphetamine - induced peripheral vasculopathy .", "tokens": ["Methylphenidate", "and", "dextroamphetamine", "-", "induced", "peripheral", "vasculopathy", "."], "event_mentions": [{"id": "18431096_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "18431096_1_Ent3", "role": "Treatment_Drug", "text": "Methylphenidate", "start": 0, "end": 1}, {"entity_id": "18431096_1_Ent1", "role": "Treatment", "text": "Methylphenidate and dextroamphetamine", "start": 0, "end": 3}, {"entity_id": "18431096_1_Ent2", "role": "Treatment_Drug", "text": "dextroamphetamine", "start": 2, "end": 3}, {"entity_id": "18431096_1_Ent0", "role": "Effect", "text": "peripheral vasculopathy", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "18431096_1_Ent3", "text": "Methylphenidate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18431096_1_Ent1", "text": "Methylphenidate and dextroamphetamine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18431096_1_Ent2", "text": "dextroamphetamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18431096_1_Ent0", "text": "peripheral vasculopathy", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "18453852_1", "wnd_id": "18453852_1_1", "text": "High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir / ritonavir tablets .", "tokens": ["High", "incidence", "of", "adverse", "events", "in", "healthy", "volunteers", "receiving", "rifampicin", "and", "adjusted", "doses", "of", "lopinavir", "/", "ritonavir", "tablets", "."], "event_mentions": [{"id": "18453852_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 8, "end": 9}, "arguments": [{"entity_id": "18453852_1_Ent1", "role": "Effect", "text": "High incidence of adverse events", "start": 0, "end": 5}, {"entity_id": "18453852_1_Ent0", "role": "Subject", "text": "healthy volunteers", "start": 6, "end": 8}, {"entity_id": "18453852_1_Ent3", "role": "Treatment_Drug", "text": "rifampicin", "start": 9, "end": 10}, {"entity_id": "18453852_1_Ent8", "role": "Combination_Drug", "text": "rifampicin", "start": 9, "end": 10}, {"entity_id": "18453852_1_Ent2", "role": "Treatment", "text": "rifampicin and adjusted doses of lopinavir / ritonavir tablets", "start": 9, "end": 18}, {"entity_id": "18453852_1_Ent7", "role": "Treatment_Dosage", "text": "adjusted doses", "start": 11, "end": 13}, {"entity_id": "18453852_1_Ent4", "role": "Treatment_Drug", "text": "lopinavir", "start": 14, "end": 15}, {"entity_id": "18453852_1_Ent9", "role": "Combination_Drug", "text": "lopinavir", "start": 14, "end": 15}, {"entity_id": "18453852_1_Ent5", "role": "Treatment_Drug", "text": "ritonavir", "start": 16, "end": 17}, {"entity_id": "18453852_1_Ent10", "role": "Combination_Drug", "text": "ritonavir", "start": 16, "end": 17}, {"entity_id": "18453852_1_Ent6", "role": "Treatment_Route", "text": "tablets", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "18453852_1_Ent1", "text": "High incidence of adverse events", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "18453852_1_Ent0", "text": "healthy volunteers", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "18453852_1_Ent3", "text": "rifampicin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18453852_1_Ent8", "text": "rifampicin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18453852_1_Ent2", "text": "rifampicin and adjusted doses of lopinavir / ritonavir tablets", "entity_type": "Entity", "start": 9, "end": 18}, {"id": "18453852_1_Ent7", "text": "adjusted doses", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18453852_1_Ent4", "text": "lopinavir", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18453852_1_Ent9", "text": "lopinavir", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18453852_1_Ent5", "text": "ritonavir", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18453852_1_Ent10", "text": "ritonavir", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18453852_1_Ent6", "text": "tablets", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "18472517_1", "wnd_id": "18472517_1_1", "text": "Enalaprilat induced acute parotitis .", "tokens": ["Enalaprilat", "induced", "acute", "parotitis", "."], "event_mentions": [{"id": "18472517_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "18472517_1_Ent1", "role": "Treatment", "text": "Enalaprilat", "start": 0, "end": 1}, {"entity_id": "18472517_1_Ent2", "role": "Treatment_Drug", "text": "Enalaprilat", "start": 0, "end": 1}, {"entity_id": "18472517_1_Ent0", "role": "Effect", "text": "acute parotitis", "start": 2, "end": 4}]}], "entity_mentions": [{"id": "18472517_1_Ent1", "text": "Enalaprilat", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18472517_1_Ent2", "text": "Enalaprilat", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18472517_1_Ent0", "text": "acute parotitis", "entity_type": "Entity", "start": 2, "end": 4}], "lang": "en"}
{"doc_id": "18476934_3", "wnd_id": "18476934_3_1", "text": "We report a 4 - year - old girl who presented with acute bilateral blindness , a focal seizure and hypertension 10 days after commencing oxybutynin to treat enuresis .", "tokens": ["We", "report", "a", "4", "-", "year", "-", "old", "girl", "who", "presented", "with", "acute", "bilateral", "blindness", ",", "a", "focal", "seizure", "and", "hypertension", "10", "days", "after", "commencing", "oxybutynin", "to", "treat", "enuresis", "."], "event_mentions": [{"id": "18476934_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 23, "end": 24}, "arguments": [{"entity_id": "18476934_3_Ent0", "role": "Subject", "text": "a 4 - year - old girl", "start": 2, "end": 9}, {"entity_id": "18476934_3_Ent1", "role": "Subject_Age", "text": "4 - year - old", "start": 3, "end": 8}, {"entity_id": "18476934_3_Ent2", "role": "Subject_Gender", "text": "girl", "start": 8, "end": 9}, {"entity_id": "18476934_3_Ent3", "role": "Effect", "text": "acute bilateral blindness , a focal seizure and hypertension", "start": 12, "end": 21}, {"entity_id": "18476934_3_Ent5", "role": "Treatment_Time_elapsed", "text": "10 days", "start": 21, "end": 23}, {"entity_id": "18476934_3_Ent4", "role": "Treatment", "text": "oxybutynin", "start": 25, "end": 26}, {"entity_id": "18476934_3_Ent6", "role": "Treatment_Drug", "text": "oxybutynin", "start": 25, "end": 26}, {"entity_id": "18476934_3_Ent7", "role": "Treatment_Disorder", "text": "enuresis", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "18476934_3_Ent0", "text": "a 4 - year - old girl", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "18476934_3_Ent1", "text": "4 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "18476934_3_Ent2", "text": "girl", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18476934_3_Ent3", "text": "acute bilateral blindness , a focal seizure and hypertension", "entity_type": "Entity", "start": 12, "end": 21}, {"id": "18476934_3_Ent5", "text": "10 days", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "18476934_3_Ent4", "text": "oxybutynin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "18476934_3_Ent6", "text": "oxybutynin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "18476934_3_Ent7", "text": "enuresis", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "18477279_3", "wnd_id": "18477279_3_1", "text": "He had been commenced on a course of fusidic acid at discharge in addition to his ongoing statin prescription and presented 4 weeks later with symptoms consistent with rhabdomyolysis .", "tokens": ["He", "had", "been", "commenced", "on", "a", "course", "of", "fusidic", "acid", "at", "discharge", "in", "addition", "to", "his", "ongoing", "statin", "prescription", "and", "presented", "4", "weeks", "later", "with", "symptoms", "consistent", "with", "rhabdomyolysis", "."], "event_mentions": [{"id": "18477279_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 20, "end": 21}, "arguments": [{"entity_id": "18477279_3_Ent1", "role": "Treatment", "text": "a course of fusidic acid at discharge in addition to his ongoing statin prescription", "start": 5, "end": 19}, {"entity_id": "18477279_3_Ent3", "role": "Treatment_Drug", "text": "fusidic acid", "start": 8, "end": 10}, {"entity_id": "18477279_3_Ent5", "role": "Combination_Drug", "text": "fusidic acid", "start": 8, "end": 10}, {"entity_id": "18477279_3_Ent2", "role": "Treatment_Drug", "text": "statin", "start": 17, "end": 18}, {"entity_id": "18477279_3_Ent6", "role": "Combination_Drug", "text": "statin", "start": 17, "end": 18}, {"entity_id": "18477279_3_Ent4", "role": "Treatment_Time_elapsed", "text": "4 weeks later", "start": 21, "end": 24}, {"entity_id": "18477279_3_Ent0", "role": "Effect", "text": "symptoms consistent with rhabdomyolysis", "start": 25, "end": 29}]}], "entity_mentions": [{"id": "18477279_3_Ent1", "text": "a course of fusidic acid at discharge in addition to his ongoing statin prescription", "entity_type": "Entity", "start": 5, "end": 19}, {"id": "18477279_3_Ent3", "text": "fusidic acid", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18477279_3_Ent5", "text": "fusidic acid", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18477279_3_Ent2", "text": "statin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18477279_3_Ent6", "text": "statin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18477279_3_Ent4", "text": "4 weeks later", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "18477279_3_Ent0", "text": "symptoms consistent with rhabdomyolysis", "entity_type": "Entity", "start": 25, "end": 29}], "lang": "en"}
{"doc_id": "18492617_3", "wnd_id": "18492617_3_1", "text": "We describe a patient who , after receiving his first dose of pregabalin to relieve neuropathic pain , presented with a negative myoclonus .", "tokens": ["We", "describe", "a", "patient", "who", ",", "after", "receiving", "his", "first", "dose", "of", "pregabalin", "to", "relieve", "neuropathic", "pain", ",", "presented", "with", "a", "negative", "myoclonus", "."], "event_mentions": [{"id": "18492617_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 18, "end": 19}, "arguments": [{"entity_id": "18492617_3_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "18492617_3_Ent2", "role": "Treatment", "text": "pregabalin", "start": 12, "end": 13}, {"entity_id": "18492617_3_Ent4", "role": "Treatment_Drug", "text": "pregabalin", "start": 12, "end": 13}, {"entity_id": "18492617_3_Ent3", "role": "Treatment_Disorder", "text": "neuropathic pain", "start": 15, "end": 17}, {"entity_id": "18492617_3_Ent1", "role": "Effect", "text": "negative myoclonus", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "18492617_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18492617_3_Ent2", "text": "pregabalin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18492617_3_Ent4", "text": "pregabalin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18492617_3_Ent3", "text": "neuropathic pain", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "18492617_3_Ent1", "text": "negative myoclonus", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "1849334_1", "wnd_id": "1849334_1_1", "text": "Muzolimine - induced severe neuromyeloencephalopathy : report of seven cases .", "tokens": ["Muzolimine", "-", "induced", "severe", "neuromyeloencephalopathy", ":", "report", "of", "seven", "cases", "."], "event_mentions": [{"id": "1849334_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1849334_1_Ent1", "role": "Treatment", "text": "Muzolimine", "start": 0, "end": 1}, {"entity_id": "1849334_1_Ent2", "role": "Treatment_Dosage", "text": "Muzolimine", "start": 0, "end": 1}, {"entity_id": "1849334_1_Ent0", "role": "Effect", "text": "neuromyeloencephalopathy", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "1849334_1_Ent1", "text": "Muzolimine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1849334_1_Ent2", "text": "Muzolimine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1849334_1_Ent0", "text": "neuromyeloencephalopathy", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "18585545_4", "wnd_id": "18585545_4_1", "text": "Levofloxacin - induced delirium with psychotic features .", "tokens": ["Levofloxacin", "-", "induced", "delirium", "with", "psychotic", "features", "."], "event_mentions": [{"id": "18585545_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18585545_4_Ent1", "role": "Treatment", "text": "Levofloxacin", "start": 0, "end": 1}, {"entity_id": "18585545_4_Ent2", "role": "Treatment_Drug", "text": "Levofloxacin", "start": 0, "end": 1}, {"entity_id": "18585545_4_Ent0", "role": "Effect", "text": "delirium with psychotic features", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "18585545_4_Ent1", "text": "Levofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18585545_4_Ent2", "text": "Levofloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18585545_4_Ent0", "text": "delirium with psychotic features", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "18607107_3", "wnd_id": "18607107_3_1", "text": "RESULTS : Our patient developed Crohn 's disease while on Copaxone treatment as a consequence of long - term immunosuppression .", "tokens": ["RESULTS", ":", "Our", "patient", "developed", "Crohn", "'s", "disease", "while", "on", "Copaxone", "treatment", "as", "a", "consequence", "of", "long", "-", "term", "immunosuppression", "."], "event_mentions": [{"id": "18607107_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 4, "end": 5}, "arguments": [{"entity_id": "18607107_3_Ent0", "role": "Subject", "text": "patient", "start": 3, "end": 4}, {"entity_id": "18607107_3_Ent1", "role": "Effect", "text": "Crohn 's disease", "start": 5, "end": 8}, {"entity_id": "18607107_3_Ent3", "role": "Treatment", "text": "Copaxone", "start": 10, "end": 11}, {"entity_id": "18607107_3_Ent4", "role": "Treatment_Drug", "text": "Copaxone", "start": 10, "end": 11}, {"entity_id": "18607107_3_Ent2", "role": "Effect", "text": "long - term immunosuppression", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "18607107_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18607107_3_Ent1", "text": "Crohn 's disease", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "18607107_3_Ent3", "text": "Copaxone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18607107_3_Ent4", "text": "Copaxone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18607107_3_Ent2", "text": "long - term immunosuppression", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "18607107_4", "wnd_id": "18607107_4_1", "text": "She had been on Copaxone 20 mg / day treatment for 2 years when she first exhibited gastrointestinal symptoms .", "tokens": ["She", "had", "been", "on", "Copaxone", "20", "mg", "/", "day", "treatment", "for", "2", "years", "when", "she", "first", "exhibited", "gastrointestinal", "symptoms", "."], "event_mentions": [{"id": "18607107_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exhibited", "start": 16, "end": 17}, "arguments": [{"entity_id": "18607107_4_Ent4", "role": "Treatment_Drug", "text": "Copaxone", "start": 4, "end": 5}, {"entity_id": "18607107_4_Ent3", "role": "Treatment", "text": "Copaxone 20 mg / day treatment for 2 years", "start": 4, "end": 13}, {"entity_id": "18607107_4_Ent5", "role": "Treatment_Dosage", "text": "20 mg / day", "start": 5, "end": 9}, {"entity_id": "18607107_4_Ent6", "role": "Treatment_Duration", "text": "2 years", "start": 11, "end": 13}, {"entity_id": "18607107_4_Ent0", "role": "Subject", "text": "she", "start": 14, "end": 15}, {"entity_id": "18607107_4_Ent1", "role": "Subject_Gender", "text": "she", "start": 14, "end": 15}, {"entity_id": "18607107_4_Ent2", "role": "Effect", "text": "gastrointestinal symptoms", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "18607107_4_Ent4", "text": "Copaxone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18607107_4_Ent3", "text": "Copaxone 20 mg / day treatment for 2 years", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "18607107_4_Ent5", "text": "20 mg / day", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "18607107_4_Ent6", "text": "2 years", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18607107_4_Ent0", "text": "she", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18607107_4_Ent1", "text": "she", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18607107_4_Ent2", "text": "gastrointestinal symptoms", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "18633310_2", "wnd_id": "18633310_2_1", "text": "The patient experienced hallucinations , agitation , vomiting , tachycardia and seizures after ingestion of 1050 ( 48 mg / kg ) of extended - release bupropion .", "tokens": ["The", "patient", "experienced", "hallucinations", ",", "agitation", ",", "vomiting", ",", "tachycardia", "and", "seizures", "after", "ingestion", "of", "1050", "(", "48", "mg", "/", "kg", ")", "of", "extended", "-", "release", "bupropion", "."], "event_mentions": [{"id": "18633310_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18633310_2_Ent0", "role": "Effect", "text": "hallucinations , agitation , vomiting , tachycardia and seizures", "start": 3, "end": 12}, {"entity_id": "18633310_2_Ent2", "role": "Treatment_Route", "text": "ingestion", "start": 13, "end": 14}, {"entity_id": "18633310_2_Ent1", "role": "Treatment", "text": "ingestion of 1050 ( 48 mg / kg ) of extended - release bupropion", "start": 13, "end": 27}, {"entity_id": "18633310_2_Ent3", "role": "Treatment_Dosage", "text": "1050 ( 48 mg / kg )", "start": 15, "end": 22}, {"entity_id": "18633310_2_Ent4", "role": "Treatment_Drug", "text": "bupropion", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "18633310_2_Ent0", "text": "hallucinations , agitation , vomiting , tachycardia and seizures", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "18633310_2_Ent2", "text": "ingestion", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18633310_2_Ent1", "text": "ingestion of 1050 ( 48 mg / kg ) of extended - release bupropion", "entity_type": "Entity", "start": 13, "end": 27}, {"id": "18633310_2_Ent3", "text": "1050 ( 48 mg / kg )", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "18633310_2_Ent4", "text": "bupropion", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "18644535_1", "wnd_id": "18644535_1_1", "text": "Methylphenidate - associated enuresis in attention deficit hyperactivity disorder .", "tokens": ["Methylphenidate", "-", "associated", "enuresis", "in", "attention", "deficit", "hyperactivity", "disorder", "."], "event_mentions": [{"id": "18644535_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "18644535_1_Ent1", "role": "Treatment", "text": "Methylphenidate", "start": 0, "end": 1}, {"entity_id": "18644535_1_Ent2", "role": "Treatment_Drug", "text": "Methylphenidate", "start": 0, "end": 1}, {"entity_id": "18644535_1_Ent0", "role": "Effect", "text": "enuresis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "18644535_1_Ent1", "text": "Methylphenidate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18644535_1_Ent2", "text": "Methylphenidate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18644535_1_Ent0", "text": "enuresis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "18675768_1", "wnd_id": "18675768_1_1", "text": "Adverse effects of propafenone after long - term therapy with the addition of citalopram .", "tokens": ["Adverse", "effects", "of", "propafenone", "after", "long", "-", "term", "therapy", "with", "the", "addition", "of", "citalopram", "."], "event_mentions": [{"id": "18675768_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "18675768_1_Ent0", "role": "Effect", "text": "Adverse effects", "start": 0, "end": 2}, {"entity_id": "18675768_1_Ent2", "role": "Treatment_Drug", "text": "propafenone", "start": 3, "end": 4}, {"entity_id": "18675768_1_Ent6", "role": "Combination_Drug", "text": "propafenone", "start": 3, "end": 4}, {"entity_id": "18675768_1_Ent4", "role": "Treatment_Time_elapsed", "text": "long - term", "start": 5, "end": 8}, {"entity_id": "18675768_1_Ent1", "role": "Treatment", "text": "long - term therapy with the addition of citalopram", "start": 5, "end": 14}, {"entity_id": "18675768_1_Ent3", "role": "Treatment_Drug", "text": "citalopram", "start": 13, "end": 14}, {"entity_id": "18675768_1_Ent5", "role": "Combination_Drug", "text": "citalopram", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "18675768_1_Ent0", "text": "Adverse effects", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18675768_1_Ent2", "text": "propafenone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18675768_1_Ent6", "text": "propafenone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18675768_1_Ent4", "text": "long - term", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "18675768_1_Ent1", "text": "long - term therapy with the addition of citalopram", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "18675768_1_Ent3", "text": "citalopram", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18675768_1_Ent5", "text": "citalopram", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "18675768_13", "wnd_id": "18675768_13_1", "text": "This is the first report of a possible interaction between propafenone and citalopram , which caused propafenone adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease .", "tokens": ["This", "is", "the", "first", "report", "of", "a", "possible", "interaction", "between", "propafenone", "and", "citalopram", ",", "which", "caused", "propafenone", "adverse", "effects", "(", "eg", ",", "dizziness", ",", "falls", ")", "and", "mimicked", "coronary", "artery", "disease", "."], "event_mentions": [{"id": "18675768_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 15, "end": 16}, "arguments": [{"entity_id": "18675768_13_Ent3", "role": "Treatment_Drug", "text": "propafenone", "start": 10, "end": 11}, {"entity_id": "18675768_13_Ent6", "role": "Combination_Drug", "text": "propafenone", "start": 10, "end": 11}, {"entity_id": "18675768_13_Ent1", "role": "Treatment", "text": "propafenone and citalopram", "start": 10, "end": 13}, {"entity_id": "18675768_13_Ent4", "role": "Treatment_Drug", "text": "citalopram", "start": 12, "end": 13}, {"entity_id": "18675768_13_Ent7", "role": "Combination_Drug", "text": "citalopram", "start": 12, "end": 13}, {"entity_id": "18675768_13_Ent2", "role": "Treatment", "text": "propafenone", "start": 16, "end": 17}, {"entity_id": "18675768_13_Ent5", "role": "Treatment_Drug", "text": "propafenone", "start": 16, "end": 17}, {"entity_id": "18675768_13_Ent0", "role": "Effect", "text": "propafenone adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease", "start": 16, "end": 31}]}], "entity_mentions": [{"id": "18675768_13_Ent3", "text": "propafenone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18675768_13_Ent6", "text": "propafenone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18675768_13_Ent1", "text": "propafenone and citalopram", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18675768_13_Ent4", "text": "citalopram", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18675768_13_Ent7", "text": "citalopram", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18675768_13_Ent2", "text": "propafenone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18675768_13_Ent5", "text": "propafenone", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18675768_13_Ent0", "text": "propafenone adverse effects ( eg , dizziness , falls ) and mimicked coronary artery disease", "entity_type": "Entity", "start": 16, "end": 31}], "lang": "en"}
{"doc_id": "18675768_4", "wnd_id": "18675768_4_1", "text": "The goal of this article was to describe a potential drug - drug interaction between propafenone and citalopram , which caused symptoms of propafenone adverse effects .", "tokens": ["The", "goal", "of", "this", "article", "was", "to", "describe", "a", "potential", "drug", "-", "drug", "interaction", "between", "propafenone", "and", "citalopram", ",", "which", "caused", "symptoms", "of", "propafenone", "adverse", "effects", "."], "event_mentions": [{"id": "18675768_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 20, "end": 21}, "arguments": [{"entity_id": "18675768_4_Ent1", "role": "Treatment", "text": "drug - drug interaction between propafenone and citalopram", "start": 10, "end": 18}, {"entity_id": "18675768_4_Ent2", "role": "Treatment_Drug", "text": "propafenone", "start": 15, "end": 16}, {"entity_id": "18675768_4_Ent5", "role": "Combination_Drug", "text": "propafenone", "start": 15, "end": 16}, {"entity_id": "18675768_4_Ent3", "role": "Treatment_Drug", "text": "citalopram", "start": 17, "end": 18}, {"entity_id": "18675768_4_Ent6", "role": "Combination_Drug", "text": "citalopram", "start": 17, "end": 18}, {"entity_id": "18675768_4_Ent0", "role": "Effect", "text": "symptoms of propafenone adverse effects", "start": 21, "end": 26}, {"entity_id": "18675768_4_Ent4", "role": "Treatment_Drug", "text": "propafenone", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "18675768_4_Ent1", "text": "drug - drug interaction between propafenone and citalopram", "entity_type": "Entity", "start": 10, "end": 18}, {"id": "18675768_4_Ent2", "text": "propafenone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18675768_4_Ent5", "text": "propafenone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18675768_4_Ent3", "text": "citalopram", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18675768_4_Ent6", "text": "citalopram", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18675768_4_Ent0", "text": "symptoms of propafenone adverse effects", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "18675768_4_Ent4", "text": "propafenone", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "18675768_5", "wnd_id": "18675768_5_1", "text": "An 80 - year - old white female , followed up at the Memory Clinic for mild cognitive impairment , had been taking propafenone 900 mg / d for > 10 years for paroxysmal atrial fibrillation without adverse effects .", "tokens": ["An", "80", "-", "year", "-", "old", "white", "female", ",", "followed", "up", "at", "the", "Memory", "Clinic", "for", "mild", "cognitive", "impairment", ",", "had", "been", "taking", "propafenone", "900", "mg", "/", "d", "for", ">", "10", "years", "for", "paroxysmal", "atrial", "fibrillation", "without", "adverse", "effects", "."], "event_mentions": [{"id": "18675768_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 32, "end": 33}, "arguments": [{"entity_id": "18675768_5_Ent0", "role": "Subject", "text": "An 80 - year - old white female", "start": 0, "end": 8}, {"entity_id": "18675768_5_Ent1", "role": "Subject_Age", "text": "80 - year - old", "start": 1, "end": 6}, {"entity_id": "18675768_5_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "18675768_5_Ent3", "role": "Subject_Gender", "text": "female", "start": 7, "end": 8}, {"entity_id": "18675768_5_Ent4", "role": "Subject_Disorder", "text": "mild cognitive impairment", "start": 16, "end": 19}, {"entity_id": "18675768_5_Ent7", "role": "Treatment_Drug", "text": "propafenone", "start": 23, "end": 24}, {"entity_id": "18675768_5_Ent5", "role": "Treatment", "text": "propafenone 900 mg / d for > 10 years", "start": 23, "end": 32}, {"entity_id": "18675768_5_Ent8", "role": "Treatment_Dosage", "text": "900 mg / d", "start": 24, "end": 28}, {"entity_id": "18675768_5_Ent9", "role": "Treatment_Duration", "text": "> 10 years", "start": 29, "end": 32}, {"entity_id": "18675768_5_Ent6", "role": "Treatment_Disorder", "text": "paroxysmal atrial fibrillation", "start": 33, "end": 36}]}], "entity_mentions": [{"id": "18675768_5_Ent0", "text": "An 80 - year - old white female", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "18675768_5_Ent1", "text": "80 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "18675768_5_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18675768_5_Ent3", "text": "female", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18675768_5_Ent4", "text": "mild cognitive impairment", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "18675768_5_Ent7", "text": "propafenone", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "18675768_5_Ent5", "text": "propafenone 900 mg / d for > 10 years", "entity_type": "Entity", "start": 23, "end": 32}, {"id": "18675768_5_Ent8", "text": "900 mg / d", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "18675768_5_Ent9", "text": "> 10 years", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "18675768_5_Ent6", "text": "paroxysmal atrial fibrillation", "entity_type": "Entity", "start": 33, "end": 36}], "lang": "en"}
{"doc_id": "1868481_1", "wnd_id": "1868481_1_1", "text": "Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis .", "tokens": ["Seizures", "and", "transient", "blindness", "following", "intravenous", "pulse", "methylprednisolone", "in", "children", "with", "primary", "glomerulonephritis", "."], "event_mentions": [{"id": "1868481_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "1868481_1_Ent2", "role": "Effect", "text": "Seizures and transient blindness", "start": 0, "end": 4}, {"entity_id": "1868481_1_Ent4", "role": "Treatment_Route", "text": "intravenous", "start": 5, "end": 6}, {"entity_id": "1868481_1_Ent3", "role": "Treatment", "text": "intravenous pulse methylprednisolone", "start": 5, "end": 8}, {"entity_id": "1868481_1_Ent5", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 7, "end": 8}, {"entity_id": "1868481_1_Ent1", "role": "Subject_Age", "text": "children", "start": 9, "end": 10}, {"entity_id": "1868481_1_Ent0", "role": "Subject", "text": "children with primary glomerulonephritis", "start": 9, "end": 13}, {"entity_id": "1868481_1_Ent6", "role": "Treatment_Disorder", "text": "primary glomerulonephritis", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "1868481_1_Ent2", "text": "Seizures and transient blindness", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "1868481_1_Ent4", "text": "intravenous", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1868481_1_Ent3", "text": "intravenous pulse methylprednisolone", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "1868481_1_Ent5", "text": "methylprednisolone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1868481_1_Ent1", "text": "children", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1868481_1_Ent0", "text": "children with primary glomerulonephritis", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "1868481_1_Ent6", "text": "primary glomerulonephritis", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "18691992_1", "wnd_id": "18691992_1_1", "text": "BACKGROUND : Hydroxyurea is a cytostatic agent used to treat myeloproliferative disorders and long - term treatment is associated with mucocutaneous adverse events and nail hyperpigmentation .", "tokens": ["BACKGROUND", ":", "Hydroxyurea", "is", "a", "cytostatic", "agent", "used", "to", "treat", "myeloproliferative", "disorders", "and", "long", "-", "term", "treatment", "is", "associated", "with", "mucocutaneous", "adverse", "events", "and", "nail", "hyperpigmentation", "."], "event_mentions": [{"id": "18691992_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 18, "end": 19}, "arguments": [{"entity_id": "18691992_1_Ent2", "role": "Treatment_Drug", "text": "Hydroxyurea", "start": 2, "end": 3}, {"entity_id": "18691992_1_Ent1", "role": "Treatment", "text": "Hydroxyurea is a cytostatic agent", "start": 2, "end": 7}, {"entity_id": "18691992_1_Ent3", "role": "Treatment_Disorder", "text": "myeloproliferative disorders", "start": 10, "end": 12}, {"entity_id": "18691992_1_Ent0", "role": "Effect", "text": "mucocutaneous adverse events and nail hyperpigmentation", "start": 20, "end": 26}]}], "entity_mentions": [{"id": "18691992_1_Ent2", "text": "Hydroxyurea", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18691992_1_Ent1", "text": "Hydroxyurea is a cytostatic agent", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "18691992_1_Ent3", "text": "myeloproliferative disorders", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18691992_1_Ent0", "text": "mucocutaneous adverse events and nail hyperpigmentation", "entity_type": "Entity", "start": 20, "end": 26}], "lang": "en"}
{"doc_id": "18691992_2", "wnd_id": "18691992_2_1", "text": "Based on the Naranjo algorithm , the adverse reaction observed was probably related to the hydroxyurea treatment ( score = 6 ) ; however , the hydroxyurea chemotherapy could not be discontinued because of the myeloproliferative disorder .", "tokens": ["Based", "on", "the", "Naranjo", "algorithm", ",", "the", "adverse", "reaction", "observed", "was", "probably", "related", "to", "the", "hydroxyurea", "treatment", "(", "score", "=", "6", ")", ";", "however", ",", "the", "hydroxyurea", "chemotherapy", "could", "not", "be", "discontinued", "because", "of", "the", "myeloproliferative", "disorder", "."], "event_mentions": [{"id": "18691992_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 12, "end": 13}, "arguments": [{"entity_id": "18691992_2_Ent2", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 15, "end": 16}, {"entity_id": "18691992_2_Ent3", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 26, "end": 27}, {"entity_id": "18691992_2_Ent1", "role": "Treatment", "text": "hydroxyurea chemotherapy", "start": 26, "end": 28}, {"entity_id": "18691992_2_Ent4", "role": "Treatment_Route", "text": "chemotherapy", "start": 27, "end": 28}, {"entity_id": "18691992_2_Ent0", "role": "Effect", "text": "myeloproliferative disorder", "start": 35, "end": 37}]}], "entity_mentions": [{"id": "18691992_2_Ent2", "text": "hydroxyurea", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18691992_2_Ent3", "text": "hydroxyurea", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18691992_2_Ent1", "text": "hydroxyurea chemotherapy", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "18691992_2_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "18691992_2_Ent0", "text": "myeloproliferative disorder", "entity_type": "Entity", "start": 35, "end": 37}], "lang": "en"}
{"doc_id": "18691992_4", "wnd_id": "18691992_4_1", "text": "CONCLUSIONS : We report this case of the concomitant appearance of multiple skin cancers and nail changes associated with hydroxyurea use .", "tokens": ["CONCLUSIONS", ":", "We", "report", "this", "case", "of", "the", "concomitant", "appearance", "of", "multiple", "skin", "cancers", "and", "nail", "changes", "associated", "with", "hydroxyurea", "use", "."], "event_mentions": [{"id": "18691992_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 17, "end": 18}, "arguments": [{"entity_id": "18691992_4_Ent0", "role": "Subject", "text": "case", "start": 5, "end": 6}, {"entity_id": "18691992_4_Ent1", "role": "Effect", "text": "multiple skin cancers and nail changes", "start": 11, "end": 17}, {"entity_id": "18691992_4_Ent2", "role": "Treatment", "text": "hydroxyurea", "start": 19, "end": 20}, {"entity_id": "18691992_4_Ent3", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "18691992_4_Ent0", "text": "case", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18691992_4_Ent1", "text": "multiple skin cancers and nail changes", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "18691992_4_Ent2", "text": "hydroxyurea", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "18691992_4_Ent3", "text": "hydroxyurea", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "18691992_6", "wnd_id": "18691992_6_1", "text": "OBJECTIVE : The purpose of this study was to report the concomitant occurrence of multiple squamous cell carcinomas and diffuse nail hyperpigmentation associated with hydroxyurea treatment , and to describe a successful therapeutic approach using imiquimod 5 % .", "tokens": ["OBJECTIVE", ":", "The", "purpose", "of", "this", "study", "was", "to", "report", "the", "concomitant", "occurrence", "of", "multiple", "squamous", "cell", "carcinomas", "and", "diffuse", "nail", "hyperpigmentation", "associated", "with", "hydroxyurea", "treatment", ",", "and", "to", "describe", "a", "successful", "therapeutic", "approach", "using", "imiquimod", "5", "%", "."], "event_mentions": [{"id": "18691992_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 22, "end": 23}, "arguments": [{"entity_id": "18691992_6_Ent0", "role": "Effect", "text": "multiple squamous cell carcinomas and diffuse nail hyperpigmentation", "start": 14, "end": 22}, {"entity_id": "18691992_6_Ent1", "role": "Treatment", "text": "hydroxyurea", "start": 24, "end": 25}, {"entity_id": "18691992_6_Ent2", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "18691992_6_Ent0", "text": "multiple squamous cell carcinomas and diffuse nail hyperpigmentation", "entity_type": "Entity", "start": 14, "end": 22}, {"id": "18691992_6_Ent1", "text": "hydroxyurea", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18691992_6_Ent2", "text": "hydroxyurea", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "18698687_2", "wnd_id": "18698687_2_1", "text": "Vanishing bile duct and Stevens - Johnson syndrome associated with ciprofloxacin treated with tacrolimus .", "tokens": ["Vanishing", "bile", "duct", "and", "Stevens", "-", "Johnson", "syndrome", "associated", "with", "ciprofloxacin", "treated", "with", "tacrolimus", "."], "event_mentions": [{"id": "18698687_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "18698687_2_Ent0", "role": "Effect", "text": "Vanishing bile duct and Stevens - Johnson syndrome", "start": 0, "end": 8}, {"entity_id": "18698687_2_Ent1", "role": "Treatment", "text": "ciprofloxacin", "start": 10, "end": 11}, {"entity_id": "18698687_2_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "18698687_2_Ent0", "text": "Vanishing bile duct and Stevens - Johnson syndrome", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "18698687_2_Ent1", "text": "ciprofloxacin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18698687_2_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "18715650_2", "wnd_id": "18715650_2_1", "text": "We describe the first case of disseminated salmonellosis in a patient treated with temozolomide .", "tokens": ["We", "describe", "the", "first", "case", "of", "disseminated", "salmonellosis", "in", "a", "patient", "treated", "with", "temozolomide", "."], "event_mentions": [{"id": "18715650_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 8, "end": 9}, "arguments": [{"entity_id": "18715650_2_Ent1", "role": "Effect", "text": "disseminated salmonellosis", "start": 6, "end": 8}, {"entity_id": "18715650_2_Ent0", "role": "Subject", "text": "a patient", "start": 9, "end": 11}, {"entity_id": "18715650_2_Ent2", "role": "Treatment", "text": "temozolomide", "start": 13, "end": 14}, {"entity_id": "18715650_2_Ent3", "role": "Treatment_Drug", "text": "temozolomide", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "18715650_2_Ent1", "text": "disseminated salmonellosis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "18715650_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "18715650_2_Ent2", "text": "temozolomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18715650_2_Ent3", "text": "temozolomide", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "18721173_2", "wnd_id": "18721173_2_1", "text": "Gabapentin toxicity in renal failure : the importance of dose adjustment .", "tokens": ["Gabapentin", "toxicity", "in", "renal", "failure", ":", "the", "importance", "of", "dose", "adjustment", "."], "event_mentions": [{"id": "18721173_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 1, "end": 2}, "arguments": [{"entity_id": "18721173_2_Ent1", "role": "Treatment", "text": "Gabapentin", "start": 0, "end": 1}, {"entity_id": "18721173_2_Ent2", "role": "Treatment_Drug", "text": "Gabapentin", "start": 0, "end": 1}, {"entity_id": "18721173_2_Ent0", "role": "Effect", "text": "renal failure", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "18721173_2_Ent1", "text": "Gabapentin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18721173_2_Ent2", "text": "Gabapentin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18721173_2_Ent0", "text": "renal failure", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "18755414_1", "wnd_id": "18755414_1_1", "text": "Hemorrhage from a falx meningioma after internal use of low - dose aspirin .", "tokens": ["Hemorrhage", "from", "a", "falx", "meningioma", "after", "internal", "use", "of", "low", "-", "dose", "aspirin", "."], "event_mentions": [{"id": "18755414_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "18755414_1_Ent0", "role": "Effect", "text": "Hemorrhage from a falx meningioma", "start": 0, "end": 5}, {"entity_id": "18755414_1_Ent5", "role": "Treatment_Disorder", "text": "falx meningioma", "start": 3, "end": 5}, {"entity_id": "18755414_1_Ent4", "role": "Treatment_Route", "text": "internal", "start": 6, "end": 7}, {"entity_id": "18755414_1_Ent1", "role": "Treatment", "text": "internal use of low - dose aspirin", "start": 6, "end": 13}, {"entity_id": "18755414_1_Ent3", "role": "Treatment_Dosage", "text": "low - dose", "start": 9, "end": 12}, {"entity_id": "18755414_1_Ent2", "role": "Treatment_Drug", "text": "aspirin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "18755414_1_Ent0", "text": "Hemorrhage from a falx meningioma", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "18755414_1_Ent5", "text": "falx meningioma", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18755414_1_Ent4", "text": "internal", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18755414_1_Ent1", "text": "internal use of low - dose aspirin", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "18755414_1_Ent3", "text": "low - dose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "18755414_1_Ent2", "text": "aspirin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "18755414_2", "wnd_id": "18755414_2_1", "text": "We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand , after the internal use of low - dose aspirin for 16 months .", "tokens": ["We", "report", "a", "case", "in", "which", "hemorrhage", "occurred", "in", "an", "asymptomatic", "falx", "meningioma", "known", "beforehand", ",", "after", "the", "internal", "use", "of", "low", "-", "dose", "aspirin", "for", "16", "months", "."], "event_mentions": [{"id": "18755414_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 7, "end": 8}, "arguments": [{"entity_id": "18755414_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "18755414_2_Ent1", "role": "Effect", "text": "hemorrhage", "start": 6, "end": 7}, {"entity_id": "18755414_2_Ent3", "role": "Treatment_Dosage", "text": "low - dose", "start": 21, "end": 24}, {"entity_id": "18755414_2_Ent2", "role": "Treatment", "text": "low - dose aspirin for 16 months", "start": 21, "end": 28}, {"entity_id": "18755414_2_Ent4", "role": "Treatment_Drug", "text": "aspirin", "start": 24, "end": 25}, {"entity_id": "18755414_2_Ent5", "role": "Treatment_Time_elapsed", "text": "16 months", "start": 26, "end": 28}]}], "entity_mentions": [{"id": "18755414_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18755414_2_Ent1", "text": "hemorrhage", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18755414_2_Ent3", "text": "low - dose", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "18755414_2_Ent2", "text": "low - dose aspirin for 16 months", "entity_type": "Entity", "start": 21, "end": 28}, {"id": "18755414_2_Ent4", "text": "aspirin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18755414_2_Ent5", "text": "16 months", "entity_type": "Entity", "start": 26, "end": 28}], "lang": "en"}
{"doc_id": "18765315_3", "wnd_id": "18765315_3_1", "text": "The aim of this study was to describe the occurrence of acute coronary syndromes in 3 cases of rituximab infusions .", "tokens": ["The", "aim", "of", "this", "study", "was", "to", "describe", "the", "occurrence", "of", "acute", "coronary", "syndromes", "in", "3", "cases", "of", "rituximab", "infusions", "."], "event_mentions": [{"id": "18765315_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 9, "end": 10}, "arguments": [{"entity_id": "18765315_3_Ent0", "role": "Effect", "text": "acute coronary syndromes", "start": 11, "end": 14}, {"entity_id": "18765315_3_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 18, "end": 19}, {"entity_id": "18765315_3_Ent1", "role": "Treatment", "text": "rituximab infusions", "start": 18, "end": 20}, {"entity_id": "18765315_3_Ent3", "role": "Treatment_Route", "text": "infusions", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "18765315_3_Ent0", "text": "acute coronary syndromes", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "18765315_3_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18765315_3_Ent1", "text": "rituximab infusions", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "18765315_3_Ent3", "text": "infusions", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "18784429_3", "wnd_id": "18784429_3_1", "text": "High - dose methylprednisolone in a pregnant woman with Crohn 's disease and adrenal suppression in her newborn .", "tokens": ["High", "-", "dose", "methylprednisolone", "in", "a", "pregnant", "woman", "with", "Crohn", "'s", "disease", "and", "adrenal", "suppression", "in", "her", "newborn", "."], "event_mentions": [{"id": "18784429_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 15, "end": 16}, "arguments": [{"entity_id": "18784429_3_Ent6", "role": "Treatment_Drug", "text": "High - dose", "start": 0, "end": 3}, {"entity_id": "18784429_3_Ent4", "role": "Treatment", "text": "High - dose methylprednisolone", "start": 0, "end": 4}, {"entity_id": "18784429_3_Ent7", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 3, "end": 4}, {"entity_id": "18784429_3_Ent0", "role": "Subject", "text": "a pregnant woman with Crohn 's disease", "start": 5, "end": 12}, {"entity_id": "18784429_3_Ent1", "role": "Subject_Age", "text": "pregnant", "start": 6, "end": 7}, {"entity_id": "18784429_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "18784429_3_Ent5", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 9, "end": 12}, {"entity_id": "18784429_3_Ent3", "role": "Effect", "text": "adrenal suppression in her newborn", "start": 13, "end": 18}]}], "entity_mentions": [{"id": "18784429_3_Ent6", "text": "High - dose", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18784429_3_Ent4", "text": "High - dose methylprednisolone", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "18784429_3_Ent7", "text": "methylprednisolone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18784429_3_Ent0", "text": "a pregnant woman with Crohn 's disease", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "18784429_3_Ent1", "text": "pregnant", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18784429_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18784429_3_Ent5", "text": "Crohn 's disease", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "18784429_3_Ent3", "text": "adrenal suppression in her newborn", "entity_type": "Entity", "start": 13, "end": 18}], "lang": "en"}
{"doc_id": "18810448_2", "wnd_id": "18810448_2_1", "text": "Thymic enlargement in a patient with juvenile idiopathic arthritis during etanercept therapy .", "tokens": ["Thymic", "enlargement", "in", "a", "patient", "with", "juvenile", "idiopathic", "arthritis", "during", "etanercept", "therapy", "."], "event_mentions": [{"id": "18810448_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 9, "end": 10}, "arguments": [{"entity_id": "18810448_2_Ent2", "role": "Effect", "text": "Thymic enlargement", "start": 0, "end": 2}, {"entity_id": "18810448_2_Ent0", "role": "Subject", "text": "a patient with juvenile idiopathic arthritis", "start": 3, "end": 9}, {"entity_id": "18810448_2_Ent1", "role": "Subject_Age", "text": "juvenile", "start": 6, "end": 7}, {"entity_id": "18810448_2_Ent5", "role": "Treatment_Disorder", "text": "idiopathic arthritis", "start": 7, "end": 9}, {"entity_id": "18810448_2_Ent3", "role": "Treatment", "text": "etanercept", "start": 10, "end": 11}, {"entity_id": "18810448_2_Ent4", "role": "Treatment_Drug", "text": "etanercept", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "18810448_2_Ent2", "text": "Thymic enlargement", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18810448_2_Ent0", "text": "a patient with juvenile idiopathic arthritis", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "18810448_2_Ent1", "text": "juvenile", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18810448_2_Ent5", "text": "idiopathic arthritis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18810448_2_Ent3", "text": "etanercept", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18810448_2_Ent4", "text": "etanercept", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "18812562_5", "wnd_id": "18812562_5_1", "text": "Intravenous fluconazole 400 mg , followed by 100 mg every 24 hours according to impaired renal function , was immediately started ; to avoid further nephrotoxicity , immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours .", "tokens": ["Intravenous", "fluconazole", "400", "mg", ",", "followed", "by", "100", "mg", "every", "24", "hours", "according", "to", "impaired", "renal", "function", ",", "was", "immediately", "started", ";", "to", "avoid", "further", "nephrotoxicity", ",", "immunosuppressant", "therapy", "was", "switched", "from", "cyclosporine", "plus", "mycophenolate", "mofetil", "to", "oral", "everolimus", "0.75", "mg", "every", "12", "hours", "."], "event_mentions": [{"id": "18812562_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "avoid", "start": 23, "end": 24}, "arguments": [{"entity_id": "18812562_5_Ent4", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "18812562_5_Ent0", "role": "Treatment", "text": "Intravenous fluconazole 400 mg , followed by 100 mg every 24 hours", "start": 0, "end": 12}, {"entity_id": "18812562_5_Ent8", "role": "Treatment_Drug", "text": "fluconazole", "start": 1, "end": 2}, {"entity_id": "18812562_5_Ent13", "role": "Combination_Drug", "text": "fluconazole", "start": 1, "end": 2}, {"entity_id": "18812562_5_Ent10", "role": "Treatment_Dosage", "text": "400 mg , followed by 100 mg every 24 hours", "start": 2, "end": 12}, {"entity_id": "18812562_5_Ent2", "role": "Treatment_Disorder", "text": "nephrotoxicity", "start": 25, "end": 26}, {"entity_id": "18812562_5_Ent1", "role": "Treatment", "text": "immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours", "start": 27, "end": 44}, {"entity_id": "18812562_5_Ent7", "role": "Treatment_Drug", "text": "cyclosporine", "start": 32, "end": 33}, {"entity_id": "18812562_5_Ent11", "role": "Combination_Drug", "text": "cyclosporine", "start": 32, "end": 33}, {"entity_id": "18812562_5_Ent6", "role": "Treatment_Drug", "text": "mycophenolate mofetil", "start": 34, "end": 36}, {"entity_id": "18812562_5_Ent12", "role": "Combination_Drug", "text": "mycophenolate mofetil", "start": 34, "end": 36}, {"entity_id": "18812562_5_Ent3", "role": "Treatment_Route", "text": "oral", "start": 37, "end": 38}, {"entity_id": "18812562_5_Ent5", "role": "Treatment_Drug", "text": "everolimus", "start": 38, "end": 39}, {"entity_id": "18812562_5_Ent14", "role": "Combination_Drug", "text": "everolimus", "start": 38, "end": 39}, {"entity_id": "18812562_5_Ent9", "role": "Treatment_Dosage", "text": "0.75 mg every 12 hours", "start": 39, "end": 44}]}], "entity_mentions": [{"id": "18812562_5_Ent4", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18812562_5_Ent0", "text": "Intravenous fluconazole 400 mg , followed by 100 mg every 24 hours", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "18812562_5_Ent8", "text": "fluconazole", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18812562_5_Ent13", "text": "fluconazole", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18812562_5_Ent10", "text": "400 mg , followed by 100 mg every 24 hours", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "18812562_5_Ent2", "text": "nephrotoxicity", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "18812562_5_Ent1", "text": "immunosuppressant therapy was switched from cyclosporine plus mycophenolate mofetil to oral everolimus 0.75 mg every 12 hours", "entity_type": "Entity", "start": 27, "end": 44}, {"id": "18812562_5_Ent7", "text": "cyclosporine", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "18812562_5_Ent11", "text": "cyclosporine", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "18812562_5_Ent6", "text": "mycophenolate mofetil", "entity_type": "Entity", "start": 34, "end": 36}, {"id": "18812562_5_Ent12", "text": "mycophenolate mofetil", "entity_type": "Entity", "start": 34, "end": 36}, {"id": "18812562_5_Ent3", "text": "oral", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "18812562_5_Ent5", "text": "everolimus", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "18812562_5_Ent14", "text": "everolimus", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "18812562_5_Ent9", "text": "0.75 mg every 12 hours", "entity_type": "Entity", "start": 39, "end": 44}], "lang": "en"}
{"doc_id": "18837734_1", "wnd_id": "18837734_1_1", "text": "Rosaceiform eruption induced by erlotinib .", "tokens": ["Rosaceiform", "eruption", "induced", "by", "erlotinib", "."], "event_mentions": [{"id": "18837734_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18837734_1_Ent0", "role": "Effect", "text": "Rosaceiform eruption", "start": 0, "end": 2}, {"entity_id": "18837734_1_Ent2", "role": "Treatment_Drug", "text": "erlotinib", "start": 4, "end": 5}, {"entity_id": "18837734_1_Ent1", "role": "Treatment", "text": "erlotinib .", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "18837734_1_Ent0", "text": "Rosaceiform eruption", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18837734_1_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18837734_1_Ent1", "text": "erlotinib .", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "1888256_3", "wnd_id": "1888256_3_1", "text": "To our knowledge , drug - induced fever has not been reported with the use of diltiazem hydrochloride , a commonly prescribed calcium channel blocker .", "tokens": ["To", "our", "knowledge", ",", "drug", "-", "induced", "fever", "has", "not", "been", "reported", "with", "the", "use", "of", "diltiazem", "hydrochloride", ",", "a", "commonly", "prescribed", "calcium", "channel", "blocker", "."], "event_mentions": [{"id": "1888256_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "1888256_3_Ent1", "role": "Treatment", "text": "drug", "start": 4, "end": 5}, {"entity_id": "1888256_3_Ent0", "role": "Effect", "text": "fever", "start": 7, "end": 8}, {"entity_id": "1888256_3_Ent2", "role": "Treatment", "text": "with the use of diltiazem hydrochloride , a commonly prescribed calcium channel blocker", "start": 12, "end": 25}, {"entity_id": "1888256_3_Ent3", "role": "Treatment_Drug", "text": "diltiazem hydrochloride", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "1888256_3_Ent1", "text": "drug", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1888256_3_Ent0", "text": "fever", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1888256_3_Ent2", "text": "with the use of diltiazem hydrochloride , a commonly prescribed calcium channel blocker", "entity_type": "Entity", "start": 12, "end": 25}, {"id": "1888256_3_Ent3", "text": "diltiazem hydrochloride", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "18957000_3", "wnd_id": "18957000_3_1", "text": "Heparin - dependent antibodies and thrombosis without heparin - induced thrombocytopenia .", "tokens": ["Heparin", "-", "dependent", "antibodies", "and", "thrombosis", "without", "heparin", "-", "induced", "thrombocytopenia", "."], "event_mentions": [{"id": "18957000_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "18957000_3_Ent1", "role": "Treatment", "text": "heparin", "start": 7, "end": 8}, {"entity_id": "18957000_3_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 7, "end": 8}, {"entity_id": "18957000_3_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "18957000_3_Ent1", "text": "heparin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18957000_3_Ent2", "text": "heparin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18957000_3_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "18991509_2", "wnd_id": "18991509_2_1", "text": "We report the first case of a human immunodeficiency virus type 1 ( HIV - 1) - infected individual receiving combination antiretroviral therapy , which included ritonavir , who developed Cushing syndrome with profound complications after epidural triamcinolone injections .", "tokens": ["We", "report", "the", "first", "case", "of", "a", "human", "immunodeficiency", "virus", "type", "1", "(", "HIV", "-", "1)", "-", "infected", "individual", "receiving", "combination", "antiretroviral", "therapy", ",", "which", "included", "ritonavir", ",", "who", "developed", "Cushing", "syndrome", "with", "profound", "complications", "after", "epidural", "triamcinolone", "injections", "."], "event_mentions": [{"id": "18991509_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 29, "end": 30}, "arguments": [{"entity_id": "18991509_2_Ent0", "role": "Subject", "text": "a human immunodeficiency virus type 1 ( HIV - 1) - infected individual", "start": 6, "end": 19}, {"entity_id": "18991509_2_Ent4", "role": "Treatment_Disorder", "text": "human immunodeficiency virus type 1", "start": 7, "end": 12}, {"entity_id": "18991509_2_Ent2", "role": "Treatment", "text": "combination antiretroviral therapy , which included ritonavir", "start": 20, "end": 27}, {"entity_id": "18991509_2_Ent6", "role": "Treatment_Drug", "text": "ritonavir", "start": 26, "end": 27}, {"entity_id": "18991509_2_Ent9", "role": "Combination_Drug", "text": "ritonavir", "start": 26, "end": 27}, {"entity_id": "18991509_2_Ent1", "role": "Effect", "text": "Cushing syndrome", "start": 30, "end": 32}, {"entity_id": "18991509_2_Ent7", "role": "Treatment_Route", "text": "epidural", "start": 36, "end": 37}, {"entity_id": "18991509_2_Ent3", "role": "Treatment", "text": "epidural triamcinolone injections", "start": 36, "end": 39}, {"entity_id": "18991509_2_Ent5", "role": "Treatment_Drug", "text": "triamcinolone", "start": 37, "end": 38}, {"entity_id": "18991509_2_Ent10", "role": "Combination_Drug", "text": "triamcinolone", "start": 37, "end": 38}, {"entity_id": "18991509_2_Ent8", "role": "Treatment_Route", "text": "injections", "start": 38, "end": 39}]}], "entity_mentions": [{"id": "18991509_2_Ent0", "text": "a human immunodeficiency virus type 1 ( HIV - 1) - infected individual", "entity_type": "Entity", "start": 6, "end": 19}, {"id": "18991509_2_Ent4", "text": "human immunodeficiency virus type 1", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18991509_2_Ent2", "text": "combination antiretroviral therapy , which included ritonavir", "entity_type": "Entity", "start": 20, "end": 27}, {"id": "18991509_2_Ent6", "text": "ritonavir", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18991509_2_Ent9", "text": "ritonavir", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18991509_2_Ent1", "text": "Cushing syndrome", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "18991509_2_Ent7", "text": "epidural", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "18991509_2_Ent3", "text": "epidural triamcinolone injections", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "18991509_2_Ent5", "text": "triamcinolone", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "18991509_2_Ent10", "text": "triamcinolone", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "18991509_2_Ent8", "text": "injections", "entity_type": "Entity", "start": 38, "end": 39}], "lang": "en"}
{"doc_id": "19003750_2", "wnd_id": "19003750_2_1", "text": "Acute ischaemia of the leg following accidental intra - arterial injection of dissolved flunitrazepam tablets .", "tokens": ["Acute", "ischaemia", "of", "the", "leg", "following", "accidental", "intra", "-", "arterial", "injection", "of", "dissolved", "flunitrazepam", "tablets", "."], "event_mentions": [{"id": "19003750_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "19003750_2_Ent0", "role": "Effect", "text": "Acute ischaemia of the leg", "start": 0, "end": 5}, {"entity_id": "19003750_2_Ent1", "role": "Treatment", "text": "intra - arterial injection of dissolved flunitrazepam tablets", "start": 7, "end": 15}, {"entity_id": "19003750_2_Ent2", "role": "Treatment_Route", "text": "injection", "start": 10, "end": 11}, {"entity_id": "19003750_2_Ent3", "role": "Treatment_Drug", "text": "flunitrazepam", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "19003750_2_Ent0", "text": "Acute ischaemia of the leg", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "19003750_2_Ent1", "text": "intra - arterial injection of dissolved flunitrazepam tablets", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "19003750_2_Ent2", "text": "injection", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19003750_2_Ent3", "text": "flunitrazepam", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "19017039_2", "wnd_id": "19017039_2_1", "text": "Syringotropic hypersensitivity reaction associated with infliximab and leflunomide combination therapy in a child with psoriatic arthritis .", "tokens": ["Syringotropic", "hypersensitivity", "reaction", "associated", "with", "infliximab", "and", "leflunomide", "combination", "therapy", "in", "a", "child", "with", "psoriatic", "arthritis", "."], "event_mentions": [{"id": "19017039_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "19017039_2_Ent2", "role": "Effect", "text": "Syringotropic hypersensitivity reaction", "start": 0, "end": 3}, {"entity_id": "19017039_2_Ent4", "role": "Treatment_Drug", "text": "infliximab", "start": 5, "end": 6}, {"entity_id": "19017039_2_Ent8", "role": "Combination_Drug", "text": "infliximab", "start": 5, "end": 6}, {"entity_id": "19017039_2_Ent3", "role": "Treatment", "text": "infliximab and leflunomide combination therapy", "start": 5, "end": 10}, {"entity_id": "19017039_2_Ent5", "role": "Treatment_Drug", "text": "leflunomide", "start": 7, "end": 8}, {"entity_id": "19017039_2_Ent7", "role": "Combination_Drug", "text": "leflunomide", "start": 7, "end": 8}, {"entity_id": "19017039_2_Ent0", "role": "Subject", "text": "a child with psoriatic arthritis", "start": 11, "end": 16}, {"entity_id": "19017039_2_Ent1", "role": "Subject_Age", "text": "child", "start": 12, "end": 13}, {"entity_id": "19017039_2_Ent6", "role": "Treatment_Disorder", "text": "psoriatic arthritis", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "19017039_2_Ent2", "text": "Syringotropic hypersensitivity reaction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19017039_2_Ent4", "text": "infliximab", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19017039_2_Ent8", "text": "infliximab", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19017039_2_Ent3", "text": "infliximab and leflunomide combination therapy", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "19017039_2_Ent5", "text": "leflunomide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19017039_2_Ent7", "text": "leflunomide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19017039_2_Ent0", "text": "a child with psoriatic arthritis", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19017039_2_Ent1", "text": "child", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19017039_2_Ent6", "text": "psoriatic arthritis", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "19034138_1", "wnd_id": "19034138_1_1", "text": "After cessation of amantadine , the edema resolved , and the endothelial cell densities were < or=600/mm .", "tokens": ["After", "cessation", "of", "amantadine", ",", "the", "edema", "resolved", ",", "and", "the", "endothelial", "cell", "densities", "were", "<", "or=600/mm", "."], "event_mentions": [{"id": "19034138_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "19034138_1_Ent1", "role": "Treatment", "text": "cessation of amantadine", "start": 1, "end": 4}, {"entity_id": "19034138_1_Ent2", "role": "Treatment_Drug", "text": "amantadine", "start": 3, "end": 4}, {"entity_id": "19034138_1_Ent0", "role": "Effect", "text": "the edema resolved , and the endothelial cell densities were < or=600/mm", "start": 5, "end": 17}, {"entity_id": "19034138_1_Ent3", "role": "Treatment_Dosage", "text": "< or=600/mm", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "19034138_1_Ent1", "text": "cessation of amantadine", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "19034138_1_Ent2", "text": "amantadine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19034138_1_Ent0", "text": "the edema resolved , and the endothelial cell densities were < or=600/mm", "entity_type": "Entity", "start": 5, "end": 17}, {"id": "19034138_1_Ent3", "text": "< or=600/mm", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "19034138_4", "wnd_id": "19034138_4_1", "text": "Corneal endothelial dysfunction associated with amantadine toxicity .", "tokens": ["Corneal", "endothelial", "dysfunction", "associated", "with", "amantadine", "toxicity", "."], "event_mentions": [{"id": "19034138_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "19034138_4_Ent0", "role": "Effect", "text": "Corneal endothelial dysfunction", "start": 0, "end": 3}, {"entity_id": "19034138_4_Ent1", "role": "Treatment", "text": "amantadine", "start": 5, "end": 6}, {"entity_id": "19034138_4_Ent2", "role": "Treatment_Drug", "text": "amantadine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "19034138_4_Ent0", "text": "Corneal endothelial dysfunction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19034138_4_Ent1", "text": "amantadine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19034138_4_Ent2", "text": "amantadine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "19071894_4", "wnd_id": "19071894_4_1", "text": "Treatment was begun with amphotericin B - deoxycholate but renal toxicity signs led to its substitution by fluconazole .", "tokens": ["Treatment", "was", "begun", "with", "amphotericin", "B", "-", "deoxycholate", "but", "renal", "toxicity", "signs", "led", "to", "its", "substitution", "by", "fluconazole", "."], "event_mentions": [{"id": "19071894_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "signs", "start": 11, "end": 12}, "arguments": [{"entity_id": "19071894_4_Ent1", "role": "Treatment", "text": "amphotericin B - deoxycholate", "start": 4, "end": 8}, {"entity_id": "19071894_4_Ent2", "role": "Treatment_Drug", "text": "amphotericin B - deoxycholate", "start": 4, "end": 8}, {"entity_id": "19071894_4_Ent0", "role": "Effect", "text": "renal toxicity", "start": 9, "end": 11}, {"entity_id": "19071894_4_Ent3", "role": "Treatment_Drug", "text": "fluconazole", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "19071894_4_Ent1", "text": "amphotericin B - deoxycholate", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "19071894_4_Ent2", "text": "amphotericin B - deoxycholate", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "19071894_4_Ent0", "text": "renal toxicity", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "19071894_4_Ent3", "text": "fluconazole", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "19071894_5", "wnd_id": "19071894_5_1", "text": "The infection proceeded even after treatment with fluconazole .", "tokens": ["The", "infection", "proceeded", "even", "after", "treatment", "with", "fluconazole", "."], "event_mentions": [{"id": "19071894_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "19071894_5_Ent0", "role": "Effect", "text": "infection proceeded", "start": 1, "end": 3}, {"entity_id": "19071894_5_Ent1", "role": "Treatment", "text": "fluconazole", "start": 7, "end": 8}, {"entity_id": "19071894_5_Ent2", "role": "Treatment_Drug", "text": "fluconazole", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "19071894_5_Ent0", "text": "infection proceeded", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "19071894_5_Ent1", "text": "fluconazole", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19071894_5_Ent2", "text": "fluconazole", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "19071894_7", "wnd_id": "19071894_7_1", "text": "Renal toxicity signs , induced by amphotericin B , progression of infection after fluconazole , and likely in vivo resistance to this triazole made this case difficult to treat .", "tokens": ["Renal", "toxicity", "signs", ",", "induced", "by", "amphotericin", "B", ",", "progression", "of", "infection", "after", "fluconazole", ",", "and", "likely", "in", "vivo", "resistance", "to", "this", "triazole", "made", "this", "case", "difficult", "to", "treat", "."], "event_mentions": [{"id": "19071894_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "19071894_7_Ent0", "role": "Effect", "text": "Renal toxicity signs", "start": 0, "end": 3}, {"entity_id": "19071894_7_Ent1", "role": "Treatment", "text": "amphotericin B", "start": 6, "end": 8}, {"entity_id": "19071894_7_Ent2", "role": "Treatment_Drug", "text": "amphotericin B", "start": 6, "end": 8}]}, {"id": "19071894_7_Evt1", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "19071894_7_Ent3", "role": "Effect", "text": "infection", "start": 11, "end": 12}, {"entity_id": "19071894_7_Ent4", "role": "Treatment", "text": "fluconazole", "start": 13, "end": 14}, {"entity_id": "19071894_7_Ent5", "role": "Treatment_Drug", "text": "fluconazole", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "19071894_7_Ent0", "text": "Renal toxicity signs", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19071894_7_Ent1", "text": "amphotericin B", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "19071894_7_Ent2", "text": "amphotericin B", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "19071894_7_Ent3", "text": "infection", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19071894_7_Ent4", "text": "fluconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19071894_7_Ent5", "text": "fluconazole", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "19097599_2", "wnd_id": "19097599_2_1", "text": "We herein described an additional patient with BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10 - day treatment with imatinib .", "tokens": ["We", "herein", "described", "an", "additional", "patient", "with", "BCR", "-", "ABL", "(", "ela2", ")", "positive", "acute", "lymphoblastic", "leukemia", "who", "developed", "tumor", "lysis", "syndrome", "after", "10", "-", "day", "treatment", "with", "imatinib", "."], "event_mentions": [{"id": "19097599_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "19097599_2_Ent0", "role": "Subject", "text": "patient with BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia", "start": 5, "end": 17}, {"entity_id": "19097599_2_Ent5", "role": "Treatment_Disorder", "text": "BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia", "start": 7, "end": 17}, {"entity_id": "19097599_2_Ent1", "role": "Effect", "text": "tumor lysis syndrome", "start": 19, "end": 22}, {"entity_id": "19097599_2_Ent4", "role": "Treatment_Time_elapsed", "text": "10 - day", "start": 23, "end": 26}, {"entity_id": "19097599_2_Ent2", "role": "Treatment", "text": "10 - day treatment with imatinib", "start": 23, "end": 29}, {"entity_id": "19097599_2_Ent3", "role": "Treatment_Drug", "text": "imatinib", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "19097599_2_Ent0", "text": "patient with BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia", "entity_type": "Entity", "start": 5, "end": 17}, {"id": "19097599_2_Ent5", "text": "BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia", "entity_type": "Entity", "start": 7, "end": 17}, {"id": "19097599_2_Ent1", "text": "tumor lysis syndrome", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "19097599_2_Ent4", "text": "10 - day", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "19097599_2_Ent2", "text": "10 - day treatment with imatinib", "entity_type": "Entity", "start": 23, "end": 29}, {"id": "19097599_2_Ent3", "text": "imatinib", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "19112808_2", "wnd_id": "19112808_2_1", "text": "The authors describe a case of interstitial granulomatous dermatitis associated with darifenacin .", "tokens": ["The", "authors", "describe", "a", "case", "of", "interstitial", "granulomatous", "dermatitis", "associated", "with", "darifenacin", "."], "event_mentions": [{"id": "19112808_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "19112808_2_Ent0", "role": "Effect", "text": "interstitial granulomatous dermatitis", "start": 6, "end": 9}, {"entity_id": "19112808_2_Ent1", "role": "Treatment", "text": "darifenacin", "start": 11, "end": 12}, {"entity_id": "19112808_2_Ent2", "role": "Treatment_Drug", "text": "darifenacin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "19112808_2_Ent0", "text": "interstitial granulomatous dermatitis", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19112808_2_Ent1", "text": "darifenacin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19112808_2_Ent2", "text": "darifenacin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "19151423_1", "wnd_id": "19151423_1_1", "text": "Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin .", "tokens": ["Rhabdomyolysis", "due", "to", "an", "uncommon", "interaction", "of", "ciprofloxacin", "with", "simvastatin", "."], "event_mentions": [{"id": "19151423_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 1, "end": 2}, "arguments": [{"entity_id": "19151423_1_Ent0", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "19151423_1_Ent1", "role": "Treatment", "text": "interaction of ciprofloxacin with simvastatin", "start": 5, "end": 10}, {"entity_id": "19151423_1_Ent2", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "19151423_1_Ent4", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "19151423_1_Ent3", "role": "Treatment_Drug", "text": "simvastatin", "start": 9, "end": 10}, {"entity_id": "19151423_1_Ent5", "role": "Combination_Drug", "text": "simvastatin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19151423_1_Ent0", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19151423_1_Ent1", "text": "interaction of ciprofloxacin with simvastatin", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "19151423_1_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19151423_1_Ent4", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19151423_1_Ent3", "text": "simvastatin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19151423_1_Ent5", "text": "simvastatin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "19151423_3", "wnd_id": "19151423_3_1", "text": "The addition of ciprofloxacin to chronic simvastatin therapy led to the development of rhabdomyolysis .", "tokens": ["The", "addition", "of", "ciprofloxacin", "to", "chronic", "simvastatin", "therapy", "led", "to", "the", "development", "of", "rhabdomyolysis", "."], "event_mentions": [{"id": "19151423_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "led", "start": 8, "end": 9}, "arguments": [{"entity_id": "19151423_3_Ent1", "role": "Treatment", "text": "ciprofloxacin", "start": 3, "end": 4}, {"entity_id": "19151423_3_Ent3", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 3, "end": 4}, {"entity_id": "19151423_3_Ent5", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 3, "end": 4}, {"entity_id": "19151423_3_Ent2", "role": "Treatment", "text": "chronic simvastatin", "start": 5, "end": 7}, {"entity_id": "19151423_3_Ent4", "role": "Treatment_Drug", "text": "chronic simvastatin", "start": 5, "end": 7}, {"entity_id": "19151423_3_Ent6", "role": "Combination_Drug", "text": "chronic simvastatin", "start": 5, "end": 7}, {"entity_id": "19151423_3_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "19151423_3_Ent1", "text": "ciprofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19151423_3_Ent3", "text": "ciprofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19151423_3_Ent5", "text": "ciprofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19151423_3_Ent2", "text": "chronic simvastatin", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "19151423_3_Ent4", "text": "chronic simvastatin", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "19151423_3_Ent6", "text": "chronic simvastatin", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "19151423_3_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "19203515_2", "wnd_id": "19203515_2_1", "text": "Acute renal failure is a rare complication following the administration of intravenous immunoglobulin ( IVIG ) .", "tokens": ["Acute", "renal", "failure", "is", "a", "rare", "complication", "following", "the", "administration", "of", "intravenous", "immunoglobulin", "(", "IVIG", ")", "."], "event_mentions": [{"id": "19203515_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 6, "end": 7}, "arguments": [{"entity_id": "19203515_2_Ent0", "role": "Effect", "text": "Acute renal failure", "start": 0, "end": 3}, {"entity_id": "19203515_2_Ent2", "role": "Treatment_Route", "text": "intravenous", "start": 11, "end": 12}, {"entity_id": "19203515_2_Ent1", "role": "Treatment", "text": "intravenous immunoglobulin ( IVIG )", "start": 11, "end": 16}, {"entity_id": "19203515_2_Ent3", "role": "Treatment_Drug", "text": "immunoglobulin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "19203515_2_Ent0", "text": "Acute renal failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19203515_2_Ent2", "text": "intravenous", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19203515_2_Ent1", "text": "intravenous immunoglobulin ( IVIG )", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19203515_2_Ent3", "text": "immunoglobulin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "19224802_3", "wnd_id": "19224802_3_1", "text": "dexmedetomidine is used to provide sedation for pediatric patients undergoing nonpainful radiological imaging studies .", "tokens": ["dexmedetomidine", "is", "used", "to", "provide", "sedation", "for", "pediatric", "patients", "undergoing", "nonpainful", "radiological", "imaging", "studies", "."], "event_mentions": [{"id": "19224802_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used to", "start": 2, "end": 4}, "arguments": [{"entity_id": "19224802_3_Ent3", "role": "Treatment", "text": "dexmedetomidine", "start": 0, "end": 1}, {"entity_id": "19224802_3_Ent4", "role": "Treatment_Drug", "text": "dexmedetomidine", "start": 0, "end": 1}, {"entity_id": "19224802_3_Ent2", "role": "Effect", "text": "provide sedation", "start": 4, "end": 6}, {"entity_id": "19224802_3_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 7, "end": 8}, {"entity_id": "19224802_3_Ent0", "role": "Subject", "text": "pediatric patients undergoing nonpainful radiological imaging studies", "start": 7, "end": 14}]}], "entity_mentions": [{"id": "19224802_3_Ent3", "text": "dexmedetomidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19224802_3_Ent4", "text": "dexmedetomidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19224802_3_Ent2", "text": "provide sedation", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "19224802_3_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19224802_3_Ent0", "text": "pediatric patients undergoing nonpainful radiological imaging studies", "entity_type": "Entity", "start": 7, "end": 14}], "lang": "en"}
{"doc_id": "19226083_16", "wnd_id": "19226083_16_1", "text": "Linezolid is a popular choice of antibiotic , especially for the treatment of orthopedic - related MRSA infections .", "tokens": ["Linezolid", "is", "a", "popular", "choice", "of", "antibiotic", ",", "especially", "for", "the", "treatment", "of", "orthopedic", "-", "related", "MRSA", "infections", "."], "event_mentions": [{"id": "19226083_16_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 11, "end": 12}, "arguments": [{"entity_id": "19226083_16_Ent0", "role": "Treatment", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "19226083_16_Ent2", "role": "Treatment_Drug", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "19226083_16_Ent1", "role": "Treatment_Disorder", "text": "orthopedic - related MRSA infections", "start": 13, "end": 18}]}], "entity_mentions": [{"id": "19226083_16_Ent0", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19226083_16_Ent2", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19226083_16_Ent1", "text": "orthopedic - related MRSA infections", "entity_type": "Entity", "start": 13, "end": 18}], "lang": "en"}
{"doc_id": "19226083_17", "wnd_id": "19226083_17_1", "text": "Patients who commonly require linezolid as an antimicrobial are those with complex infections where other antibiotic treatment has failed .", "tokens": ["Patients", "who", "commonly", "require", "linezolid", "as", "an", "antimicrobial", "are", "those", "with", "complex", "infections", "where", "other", "antibiotic", "treatment", "has", "failed", "."], "event_mentions": [{"id": "19226083_17_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "require", "start": 3, "end": 4}, "arguments": [{"entity_id": "19226083_17_Ent0", "role": "Subject", "text": "Patients", "start": 0, "end": 1}, {"entity_id": "19226083_17_Ent3", "role": "Treatment_Drug", "text": "linezolid", "start": 4, "end": 5}, {"entity_id": "19226083_17_Ent2", "role": "Treatment", "text": "linezolid as an antimicrobial", "start": 4, "end": 8}, {"entity_id": "19226083_17_Ent1", "role": "Subject", "text": "complex infections", "start": 11, "end": 13}, {"entity_id": "19226083_17_Ent4", "role": "Treatment_Disorder", "text": "complex infections", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "19226083_17_Ent0", "text": "Patients", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19226083_17_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19226083_17_Ent2", "text": "linezolid as an antimicrobial", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "19226083_17_Ent1", "text": "complex infections", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "19226083_17_Ent4", "text": "complex infections", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "19235747_2", "wnd_id": "19235747_2_1", "text": "Bisphosphonate - related osteonecrosis of the skull base .", "tokens": ["Bisphosphonate", "-", "related", "osteonecrosis", "of", "the", "skull", "base", "."], "event_mentions": [{"id": "19235747_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "19235747_2_Ent1", "role": "Treatment", "text": "Bisphosphonate", "start": 0, "end": 1}, {"entity_id": "19235747_2_Ent2", "role": "Treatment_Drug", "text": "Bisphosphonate", "start": 0, "end": 1}, {"entity_id": "19235747_2_Ent0", "role": "Effect", "text": "osteonecrosis of the skull base", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "19235747_2_Ent1", "text": "Bisphosphonate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19235747_2_Ent2", "text": "Bisphosphonate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19235747_2_Ent0", "text": "osteonecrosis of the skull base", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "19249953_7", "wnd_id": "19249953_7_1", "text": "As it had been 10 months since her last dosage adjustment of diltiazem , it was unlikely that the statin - induced rhabdomyolysis was precipitated by diltiazem .", "tokens": ["As", "it", "had", "been", "10", "months", "since", "her", "last", "dosage", "adjustment", "of", "diltiazem", ",", "it", "was", "unlikely", "that", "the", "statin", "-", "induced", "rhabdomyolysis", "was", "precipitated", "by", "diltiazem", "."], "event_mentions": [{"id": "19249953_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitated", "start": 24, "end": 25}, "arguments": [{"entity_id": "19249953_7_Ent0", "role": "Effect", "text": "statin - induced rhabdomyolysis", "start": 19, "end": 23}, {"entity_id": "19249953_7_Ent1", "role": "Treatment", "text": "diltiazem", "start": 26, "end": 27}, {"entity_id": "19249953_7_Ent2", "role": "Treatment_Drug", "text": "diltiazem", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "19249953_7_Ent0", "text": "statin - induced rhabdomyolysis", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "19249953_7_Ent1", "text": "diltiazem", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "19249953_7_Ent2", "text": "diltiazem", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "19266307_2", "wnd_id": "19266307_2_1", "text": "MATERIALS AND METHODS : We present two cases of significant morbidity related to primary and secondary perforation of the bladder following two instillations of epirubicin .", "tokens": ["MATERIALS", "AND", "METHODS", ":", "We", "present", "two", "cases", "of", "significant", "morbidity", "related", "to", "primary", "and", "secondary", "perforation", "of", "the", "bladder", "following", "two", "instillations", "of", "epirubicin", "."], "event_mentions": [{"id": "19266307_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 20, "end": 21}, "arguments": [{"entity_id": "19266307_2_Ent1", "role": "Subject_Population", "text": "two", "start": 6, "end": 7}, {"entity_id": "19266307_2_Ent0", "role": "Subject", "text": "two cases", "start": 6, "end": 8}, {"entity_id": "19266307_2_Ent2", "role": "Effect", "text": "significant morbidity related to primary and secondary perforation of the bladder", "start": 9, "end": 20}, {"entity_id": "19266307_2_Ent3", "role": "Treatment", "text": "two instillations of epirubicin", "start": 21, "end": 25}, {"entity_id": "19266307_2_Ent4", "role": "Treatment_Route", "text": "instillations", "start": 22, "end": 23}, {"entity_id": "19266307_2_Ent5", "role": "Treatment_Drug", "text": "epirubicin", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "19266307_2_Ent1", "text": "two", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19266307_2_Ent0", "text": "two cases", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "19266307_2_Ent2", "text": "significant morbidity related to primary and secondary perforation of the bladder", "entity_type": "Entity", "start": 9, "end": 20}, {"id": "19266307_2_Ent3", "text": "two instillations of epirubicin", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "19266307_2_Ent4", "text": "instillations", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "19266307_2_Ent5", "text": "epirubicin", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "19275460_6", "wnd_id": "19275460_6_1", "text": "Despite aggressive medical management , including intravenous hydration and broad - spectrum antibiotics , the patient continued to become more confused , agitated , and despondent over the subsequent 24 hours .", "tokens": ["Despite", "aggressive", "medical", "management", ",", "including", "intravenous", "hydration", "and", "broad", "-", "spectrum", "antibiotics", ",", "the", "patient", "continued", "to", "become", "more", "confused", ",", "agitated", ",", "and", "despondent", "over", "the", "subsequent", "24", "hours", "."], "event_mentions": [{"id": "19275460_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "continued", "start": 16, "end": 17}, "arguments": [{"entity_id": "19275460_6_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 6, "end": 7}, {"entity_id": "19275460_6_Ent2", "role": "Treatment", "text": "intravenous hydration and broad - spectrum antibiotics", "start": 6, "end": 13}, {"entity_id": "19275460_6_Ent3", "role": "Treatment_Drug", "text": "hydration", "start": 7, "end": 8}, {"entity_id": "19275460_6_Ent6", "role": "Combination_Drug", "text": "hydration", "start": 7, "end": 8}, {"entity_id": "19275460_6_Ent4", "role": "Treatment_Drug", "text": "broad - spectrum antibiotics", "start": 9, "end": 13}, {"entity_id": "19275460_6_Ent7", "role": "Combination_Drug", "text": "broad - spectrum antibiotics", "start": 9, "end": 13}, {"entity_id": "19275460_6_Ent0", "role": "Subject", "text": "patient", "start": 15, "end": 16}, {"entity_id": "19275460_6_Ent1", "role": "Effect", "text": "become more confused , agitated , and despondent over the subsequent 24 hours", "start": 18, "end": 31}]}], "entity_mentions": [{"id": "19275460_6_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19275460_6_Ent2", "text": "intravenous hydration and broad - spectrum antibiotics", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "19275460_6_Ent3", "text": "hydration", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19275460_6_Ent6", "text": "hydration", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19275460_6_Ent4", "text": "broad - spectrum antibiotics", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "19275460_6_Ent7", "text": "broad - spectrum antibiotics", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "19275460_6_Ent0", "text": "patient", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "19275460_6_Ent1", "text": "become more confused , agitated , and despondent over the subsequent 24 hours", "entity_type": "Entity", "start": 18, "end": 31}], "lang": "en"}
{"doc_id": "19299370_2", "wnd_id": "19299370_2_1", "text": "CONCLUSION : A woman receiving enoxaparin every 12 hours developed signs and symptoms of hepatotoxicity after the second dose .", "tokens": ["CONCLUSION", ":", "A", "woman", "receiving", "enoxaparin", "every", "12", "hours", "developed", "signs", "and", "symptoms", "of", "hepatotoxicity", "after", "the", "second", "dose", "."], "event_mentions": [{"id": "19299370_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "19299370_2_Ent0", "role": "Subject", "text": "A woman", "start": 2, "end": 4}, {"entity_id": "19299370_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 3, "end": 4}, {"entity_id": "19299370_2_Ent5", "role": "Treatment_Drug", "text": "enoxaparin", "start": 5, "end": 6}, {"entity_id": "19299370_2_Ent3", "role": "Treatment", "text": "enoxaparin every 12 hours", "start": 5, "end": 9}, {"entity_id": "19299370_2_Ent6", "role": "Treatment_Freq", "text": "every 12 hours", "start": 6, "end": 9}, {"entity_id": "19299370_2_Ent2", "role": "Effect", "text": "signs and symptoms of hepatotoxicity", "start": 10, "end": 15}, {"entity_id": "19299370_2_Ent4", "role": "Treatment", "text": "after the second dose", "start": 15, "end": 19}, {"entity_id": "19299370_2_Ent7", "role": "Treatment_Dosage", "text": "the second dose .", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "19299370_2_Ent0", "text": "A woman", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19299370_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19299370_2_Ent5", "text": "enoxaparin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19299370_2_Ent3", "text": "enoxaparin every 12 hours", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "19299370_2_Ent6", "text": "every 12 hours", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19299370_2_Ent2", "text": "signs and symptoms of hepatotoxicity", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "19299370_2_Ent4", "text": "after the second dose", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "19299370_2_Ent7", "text": "the second dose .", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "19318596_2", "wnd_id": "19318596_2_1", "text": "In this case , CIPS was considered to be probably associated with cyclosporine according to the Naranjo probability scale .", "tokens": ["In", "this", "case", ",", "CIPS", "was", "considered", "to", "be", "probably", "associated", "with", "cyclosporine", "according", "to", "the", "Naranjo", "probability", "scale", "."], "event_mentions": [{"id": "19318596_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 10, "end": 11}, "arguments": [{"entity_id": "19318596_2_Ent0", "role": "Effect", "text": "CIPS", "start": 4, "end": 5}, {"entity_id": "19318596_2_Ent1", "role": "Treatment", "text": "cyclosporine", "start": 12, "end": 13}, {"entity_id": "19318596_2_Ent2", "role": "Treatment_Drug", "text": "cyclosporine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "19318596_2_Ent0", "text": "CIPS", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19318596_2_Ent1", "text": "cyclosporine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19318596_2_Ent2", "text": "cyclosporine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "19318596_4", "wnd_id": "19318596_4_1", "text": "With the first cyclosporine dose , the patient complained of leg pain that was most severe during the cyclosporine infusion .", "tokens": ["With", "the", "first", "cyclosporine", "dose", ",", "the", "patient", "complained", "of", "leg", "pain", "that", "was", "most", "severe", "during", "the", "cyclosporine", "infusion", "."], "event_mentions": [{"id": "19318596_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complained", "start": 8, "end": 9}, "arguments": [{"entity_id": "19318596_4_Ent0", "role": "Subject", "text": "With", "start": 0, "end": 1}, {"entity_id": "19318596_4_Ent2", "role": "Treatment", "text": "first cyclosporine dose", "start": 2, "end": 5}, {"entity_id": "19318596_4_Ent3", "role": "Treatment_Drug", "text": "cyclosporine", "start": 3, "end": 4}, {"entity_id": "19318596_4_Ent1", "role": "Effect", "text": "leg pain", "start": 10, "end": 12}, {"entity_id": "19318596_4_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "19318596_4_Ent0", "text": "With", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19318596_4_Ent2", "text": "first cyclosporine dose", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "19318596_4_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19318596_4_Ent1", "text": "leg pain", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19318596_4_Ent4", "text": "infusion", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "19331262_3", "wnd_id": "19331262_3_1", "text": "Neuroleptic malignant syndrome is an uncommon and potentially fatal idiosynchratic reaction of antipsychotic drugs , in which the clinical scenario encompass muscular rigidity , hyperthermia , autonomic dysfunction , altered consciousness , high creatinine phosphokinase levels , and leukocytosis .", "tokens": ["Neuroleptic", "malignant", "syndrome", "is", "an", "uncommon", "and", "potentially", "fatal", "idiosynchratic", "reaction", "of", "antipsychotic", "drugs", ",", "in", "which", "the", "clinical", "scenario", "encompass", "muscular", "rigidity", ",", "hyperthermia", ",", "autonomic", "dysfunction", ",", "altered", "consciousness", ",", "high", "creatinine", "phosphokinase", "levels", ",", "and", "leukocytosis", "."], "event_mentions": [{"id": "19331262_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reaction", "start": 10, "end": 11}, "arguments": [{"entity_id": "19331262_3_Ent0", "role": "Effect", "text": "Neuroleptic malignant syndrome", "start": 0, "end": 3}, {"entity_id": "19331262_3_Ent3", "role": "Treatment_Drug", "text": "antipsychotic", "start": 12, "end": 13}, {"entity_id": "19331262_3_Ent2", "role": "Treatment", "text": "antipsychotic drugs", "start": 12, "end": 14}, {"entity_id": "19331262_3_Ent1", "role": "Effect", "text": "muscular rigidity , hyperthermia , autonomic dysfunction , altered consciousness , high creatinine phosphokinase levels , and leukocytosis", "start": 21, "end": 39}]}], "entity_mentions": [{"id": "19331262_3_Ent0", "text": "Neuroleptic malignant syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19331262_3_Ent3", "text": "antipsychotic", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19331262_3_Ent2", "text": "antipsychotic drugs", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "19331262_3_Ent1", "text": "muscular rigidity , hyperthermia , autonomic dysfunction , altered consciousness , high creatinine phosphokinase levels , and leukocytosis", "entity_type": "Entity", "start": 21, "end": 39}], "lang": "en"}
{"doc_id": "19365885_1", "wnd_id": "19365885_1_1", "text": "Herein , we present a patient with severe and prolonged hypoglycemia after long - acting octreotide treatment .", "tokens": ["Herein", ",", "we", "present", "a", "patient", "with", "severe", "and", "prolonged", "hypoglycemia", "after", "long", "-", "acting", "octreotide", "treatment", "."], "event_mentions": [{"id": "19365885_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "19365885_1_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "19365885_1_Ent1", "role": "Effect", "text": "severe and prolonged hypoglycemia", "start": 7, "end": 11}, {"entity_id": "19365885_1_Ent2", "role": "Treatment", "text": "long - acting octreotide treatment", "start": 12, "end": 17}, {"entity_id": "19365885_1_Ent3", "role": "Treatment_Drug", "text": "octreotide", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "19365885_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "19365885_1_Ent1", "text": "severe and prolonged hypoglycemia", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "19365885_1_Ent2", "text": "long - acting octreotide treatment", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "19365885_1_Ent3", "text": "octreotide", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "19390192_1", "wnd_id": "19390192_1_1", "text": "Leukopenia due to parvovirus B19 in a Crohn 's disease patient using azathioprine .", "tokens": ["Leukopenia", "due", "to", "parvovirus", "B19", "in", "a", "Crohn", "'s", "disease", "patient", "using", "azathioprine", "."], "event_mentions": [{"id": "19390192_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 1, "end": 2}, "arguments": [{"entity_id": "19390192_1_Ent2", "role": "Effect", "text": "Leukopenia", "start": 0, "end": 1}, {"entity_id": "19390192_1_Ent1", "role": "Subject_Disorder", "text": "parvovirus B19", "start": 3, "end": 5}, {"entity_id": "19390192_1_Ent0", "role": "Subject", "text": "parvovirus B19 in a Crohn 's disease patient", "start": 3, "end": 11}, {"entity_id": "19390192_1_Ent4", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 7, "end": 10}, {"entity_id": "19390192_1_Ent3", "role": "Treatment", "text": "azathioprine", "start": 12, "end": 13}, {"entity_id": "19390192_1_Ent5", "role": "Treatment_Drug", "text": "azathioprine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "19390192_1_Ent2", "text": "Leukopenia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19390192_1_Ent1", "text": "parvovirus B19", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19390192_1_Ent0", "text": "parvovirus B19 in a Crohn 's disease patient", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "19390192_1_Ent4", "text": "Crohn 's disease", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "19390192_1_Ent3", "text": "azathioprine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19390192_1_Ent5", "text": "azathioprine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "19423610_9", "wnd_id": "19423610_9_1", "text": "Methylene blue is used in a variety of surgical settings as well as for treatment of various types of hypotensive shock and methemoglobinaemia .", "tokens": ["Methylene", "blue", "is", "used", "in", "a", "variety", "of", "surgical", "settings", "as", "well", "as", "for", "treatment", "of", "various", "types", "of", "hypotensive", "shock", "and", "methemoglobinaemia", "."], "event_mentions": [{"id": "19423610_9_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 14, "end": 15}, "arguments": [{"entity_id": "19423610_9_Ent0", "role": "Treatment", "text": "Methylene blue", "start": 0, "end": 2}, {"entity_id": "19423610_9_Ent3", "role": "Treatment_Drug", "text": "Methylene blue", "start": 0, "end": 2}, {"entity_id": "19423610_9_Ent1", "role": "Treatment_Disorder", "text": "hypotensive shock", "start": 19, "end": 21}, {"entity_id": "19423610_9_Ent2", "role": "Treatment_Disorder", "text": "methemoglobinaemia", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "19423610_9_Ent0", "text": "Methylene blue", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19423610_9_Ent3", "text": "Methylene blue", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19423610_9_Ent1", "text": "hypotensive shock", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "19423610_9_Ent2", "text": "methemoglobinaemia", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "19512997_1", "wnd_id": "19512997_1_1", "text": "Divalproex sodium - induced eosinophilic pleural effusion .", "tokens": ["Divalproex", "sodium", "-", "induced", "eosinophilic", "pleural", "effusion", "."], "event_mentions": [{"id": "19512997_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "19512997_1_Ent1", "role": "Treatment", "text": "Divalproex sodium", "start": 0, "end": 2}, {"entity_id": "19512997_1_Ent2", "role": "Treatment_Drug", "text": "Divalproex sodium", "start": 0, "end": 2}, {"entity_id": "19512997_1_Ent0", "role": "Effect", "text": "eosinophilic pleural effusion", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "19512997_1_Ent1", "text": "Divalproex sodium", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19512997_1_Ent2", "text": "Divalproex sodium", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19512997_1_Ent0", "text": "eosinophilic pleural effusion", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "19520277_1", "wnd_id": "19520277_1_1", "text": "Stupor and fast activity on electroencephalography in a child treated with valproate .", "tokens": ["Stupor", "and", "fast", "activity", "on", "electroencephalography", "in", "a", "child", "treated", "with", "valproate", "."], "event_mentions": [{"id": "19520277_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 10, "end": 11}, "arguments": [{"entity_id": "19520277_1_Ent2", "role": "Effect", "text": "Stupor", "start": 0, "end": 1}, {"entity_id": "19520277_1_Ent3", "role": "Effect", "text": "fast activity on electroencephalography", "start": 2, "end": 6}, {"entity_id": "19520277_1_Ent0", "role": "Subject", "text": "a child", "start": 7, "end": 9}, {"entity_id": "19520277_1_Ent1", "role": "Subject_Age", "text": "child", "start": 8, "end": 9}, {"entity_id": "19520277_1_Ent4", "role": "Treatment", "text": "valproate", "start": 11, "end": 12}, {"entity_id": "19520277_1_Ent5", "role": "Treatment_Drug", "text": "valproate", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "19520277_1_Ent2", "text": "Stupor", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19520277_1_Ent3", "text": "fast activity on electroencephalography", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "19520277_1_Ent0", "text": "a child", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "19520277_1_Ent1", "text": "child", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19520277_1_Ent4", "text": "valproate", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19520277_1_Ent5", "text": "valproate", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "19531695_11", "wnd_id": "19531695_11_1", "text": "A MEDLINE search ( 1966 - January 2009 ) revealed one in vivo pharmacokinetic study on the interaction between flecainide , a CYP2D6 substrate , and paroxetine , a CYP2D6 inhibitor , as well as 3 case reports of flecainide - induced delirium .", "tokens": ["A", "MEDLINE", "search", "(", "1966", "-", "January", "2009", ")", "revealed", "one", "in", "vivo", "pharmacokinetic", "study", "on", "the", "interaction", "between", "flecainide", ",", "a", "CYP2D6", "substrate", ",", "and", "paroxetine", ",", "a", "CYP2D6", "inhibitor", ",", "as", "well", "as", "3", "case", "reports", "of", "flecainide", "-", "induced", "delirium", "."], "event_mentions": [{"id": "19531695_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 41, "end": 42}, "arguments": [{"entity_id": "19531695_11_Ent1", "role": "Subject_Population", "text": "3", "start": 35, "end": 36}, {"entity_id": "19531695_11_Ent0", "role": "Subject", "text": "3 case reports", "start": 35, "end": 38}, {"entity_id": "19531695_11_Ent3", "role": "Treatment", "text": "flecainide", "start": 39, "end": 40}, {"entity_id": "19531695_11_Ent4", "role": "Treatment_Drug", "text": "flecainide", "start": 39, "end": 40}, {"entity_id": "19531695_11_Ent2", "role": "Effect", "text": "delirium", "start": 42, "end": 43}]}], "entity_mentions": [{"id": "19531695_11_Ent1", "text": "3", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "19531695_11_Ent0", "text": "3 case reports", "entity_type": "Entity", "start": 35, "end": 38}, {"id": "19531695_11_Ent3", "text": "flecainide", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "19531695_11_Ent4", "text": "flecainide", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "19531695_11_Ent2", "text": "delirium", "entity_type": "Entity", "start": 42, "end": 43}], "lang": "en"}
{"doc_id": "19531695_12", "wnd_id": "19531695_12_1", "text": "According to the Naranjo probability scale , flecainide was the probable cause of the patient 's delirium ; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine .", "tokens": ["According", "to", "the", "Naranjo", "probability", "scale", ",", "flecainide", "was", "the", "probable", "cause", "of", "the", "patient", "'s", "delirium", ";", "the", "Horn", "Drug", "Interaction", "Probability", "Scale", "indicates", "a", "possible", "pharmacokinetic", "drug", "interaction", "between", "flecainide", "and", "paroxetine", "."], "event_mentions": [{"id": "19531695_12_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 11, "end": 12}, "arguments": [{"entity_id": "19531695_12_Ent2", "role": "Treatment", "text": "flecainide", "start": 7, "end": 8}, {"entity_id": "19531695_12_Ent3", "role": "Treatment_Drug", "text": "flecainide", "start": 7, "end": 8}, {"entity_id": "19531695_12_Ent0", "role": "Subject", "text": "the patient", "start": 13, "end": 15}, {"entity_id": "19531695_12_Ent1", "role": "Effect", "text": "delirium", "start": 16, "end": 17}, {"entity_id": "19531695_12_Ent4", "role": "Treatment_Drug", "text": "flecainide", "start": 31, "end": 32}, {"entity_id": "19531695_12_Ent6", "role": "Combination_Drug", "text": "flecainide", "start": 31, "end": 32}, {"entity_id": "19531695_12_Ent5", "role": "Treatment_Drug", "text": "paroxetine", "start": 33, "end": 34}, {"entity_id": "19531695_12_Ent7", "role": "Combination_Drug", "text": "paroxetine", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "19531695_12_Ent2", "text": "flecainide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19531695_12_Ent3", "text": "flecainide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19531695_12_Ent0", "text": "the patient", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "19531695_12_Ent1", "text": "delirium", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19531695_12_Ent4", "text": "flecainide", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "19531695_12_Ent6", "text": "flecainide", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "19531695_12_Ent5", "text": "paroxetine", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "19531695_12_Ent7", "text": "paroxetine", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "19531695_14", "wnd_id": "19531695_14_1", "text": "Because toxicity may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors , flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors .", "tokens": ["Because", "toxicity", "may", "occur", "when", "flecainide", "is", "prescribed", "with", "paroxetine", "and", "other", "potent", "CYP2D6", "inhibitors", ",", "flecainide", "plasma", "concentrations", "should", "be", "monitored", "closely", "with", "commencement", "of", "CYP2D6", "inhibitors", "."], "event_mentions": [{"id": "19531695_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 3, "end": 4}, "arguments": [{"entity_id": "19531695_14_Ent0", "role": "Effect", "text": "toxicity", "start": 1, "end": 2}, {"entity_id": "19531695_14_Ent2", "role": "Treatment_Drug", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "19531695_14_Ent4", "role": "Combination_Drug", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "19531695_14_Ent1", "role": "Treatment", "text": "flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors", "start": 5, "end": 15}, {"entity_id": "19531695_14_Ent3", "role": "Treatment_Drug", "text": "paroxetine", "start": 9, "end": 10}, {"entity_id": "19531695_14_Ent5", "role": "Combination_Drug", "text": "paroxetine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19531695_14_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19531695_14_Ent2", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19531695_14_Ent4", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19531695_14_Ent1", "text": "flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors", "entity_type": "Entity", "start": 5, "end": 15}, {"id": "19531695_14_Ent3", "text": "paroxetine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19531695_14_Ent5", "text": "paroxetine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "19531695_2", "wnd_id": "19531695_2_1", "text": "To describe a case of flecainide - induced delirium associated with a pharmacokinetic drug interaction with paroxetine .", "tokens": ["To", "describe", "a", "case", "of", "flecainide", "-", "induced", "delirium", "associated", "with", "a", "pharmacokinetic", "drug", "interaction", "with", "paroxetine", "."], "event_mentions": [{"id": "19531695_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "19531695_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "19531695_2_Ent2", "role": "Treatment", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "19531695_2_Ent4", "role": "Treatment_Drug", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "19531695_2_Ent7", "role": "Combination_Drug", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "19531695_2_Ent1", "role": "Effect", "text": "delirium", "start": 8, "end": 9}, {"entity_id": "19531695_2_Ent3", "role": "Treatment", "text": "interaction with paroxetine", "start": 14, "end": 17}, {"entity_id": "19531695_2_Ent5", "role": "Treatment_Drug", "text": "paroxetine", "start": 16, "end": 17}, {"entity_id": "19531695_2_Ent6", "role": "Combination_Drug", "text": "paroxetine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "19531695_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19531695_2_Ent2", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19531695_2_Ent4", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19531695_2_Ent7", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19531695_2_Ent1", "text": "delirium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19531695_2_Ent3", "text": "interaction with paroxetine", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "19531695_2_Ent5", "text": "paroxetine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19531695_2_Ent6", "text": "paroxetine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "19540093_3", "wnd_id": "19540093_3_1", "text": "Pancreatitis has been associated with the tetracycline class of antibiotics and concerns about tigecycline - induced acute pancreatitis have recently been raised .", "tokens": ["Pancreatitis", "has", "been", "associated", "with", "the", "tetracycline", "class", "of", "antibiotics", "and", "concerns", "about", "tigecycline", "-", "induced", "acute", "pancreatitis", "have", "recently", "been", "raised", "."], "event_mentions": [{"id": "19540093_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "19540093_3_Ent1", "role": "Treatment", "text": "tigecycline", "start": 13, "end": 14}, {"entity_id": "19540093_3_Ent2", "role": "Treatment_Drug", "text": "tigecycline", "start": 13, "end": 14}, {"entity_id": "19540093_3_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "19540093_3_Ent1", "text": "tigecycline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19540093_3_Ent2", "text": "tigecycline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19540093_3_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "19567656_3", "wnd_id": "19567656_3_1", "text": "OBJECTIVE : To describe a case of sertraline - induced rhabdomyolysis in an elderly patient with dementia and comorbidities .", "tokens": ["OBJECTIVE", ":", "To", "describe", "a", "case", "of", "sertraline", "-", "induced", "rhabdomyolysis", "in", "an", "elderly", "patient", "with", "dementia", "and", "comorbidities", "."], "event_mentions": [{"id": "19567656_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "19567656_3_Ent3", "role": "Treatment", "text": "sertraline", "start": 7, "end": 8}, {"entity_id": "19567656_3_Ent6", "role": "Treatment_Drug", "text": "sertraline", "start": 7, "end": 8}, {"entity_id": "19567656_3_Ent2", "role": "Effect", "text": "rhabdomyolysis", "start": 10, "end": 11}, {"entity_id": "19567656_3_Ent0", "role": "Subject", "text": "an elderly patient with dementia and comorbidities", "start": 12, "end": 19}, {"entity_id": "19567656_3_Ent1", "role": "Subject_Age", "text": "elderly", "start": 13, "end": 14}, {"entity_id": "19567656_3_Ent5", "role": "Treatment_Disorder", "text": "dementia", "start": 16, "end": 17}, {"entity_id": "19567656_3_Ent4", "role": "Treatment_Disorder", "text": "comorbidities", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "19567656_3_Ent3", "text": "sertraline", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19567656_3_Ent6", "text": "sertraline", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19567656_3_Ent2", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19567656_3_Ent0", "text": "an elderly patient with dementia and comorbidities", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "19567656_3_Ent1", "text": "elderly", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19567656_3_Ent5", "text": "dementia", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19567656_3_Ent4", "text": "comorbidities", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "19567656_5", "wnd_id": "19567656_5_1", "text": "The patient 's other comorbidities and medications have not been suggested as possible interactions with sertraline that can cause rhabdomyolysis .", "tokens": ["The", "patient", "'s", "other", "comorbidities", "and", "medications", "have", "not", "been", "suggested", "as", "possible", "interactions", "with", "sertraline", "that", "can", "cause", "rhabdomyolysis", "."], "event_mentions": [{"id": "19567656_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 18, "end": 19}, "arguments": [{"entity_id": "19567656_5_Ent1", "role": "Treatment", "text": "sertraline", "start": 15, "end": 16}, {"entity_id": "19567656_5_Ent2", "role": "Treatment_Drug", "text": "sertraline", "start": 15, "end": 16}, {"entity_id": "19567656_5_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "19567656_5_Ent1", "text": "sertraline", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "19567656_5_Ent2", "text": "sertraline", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "19567656_5_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "19583682_3", "wnd_id": "19583682_3_1", "text": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin - reuptake inhibitors ( SSRI ) and possibly ciprofloxacin .", "tokens": ["We", "report", "a", "case", "of", "serotonin", "syndrome", "induced", "by", "pharmacokinetic", "and", "pharmacodynamic", "interactions", "between", "three", "different", "selective", "serotonin", "-", "reuptake", "inhibitors", "(", "SSRI", ")", "and", "possibly", "ciprofloxacin", "."], "event_mentions": [{"id": "19583682_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "19583682_3_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "19583682_3_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 5, "end": 7}, {"entity_id": "19583682_3_Ent2", "role": "Treatment", "text": "interactions between three different selective serotonin - reuptake inhibitors ( SSRI ) and possibly ciprofloxacin", "start": 12, "end": 27}, {"entity_id": "19583682_3_Ent3", "role": "Treatment_Drug", "text": "selective serotonin - reuptake inhibitors", "start": 16, "end": 21}, {"entity_id": "19583682_3_Ent6", "role": "Combination_Drug", "text": "selective serotonin - reuptake inhibitors", "start": 16, "end": 21}, {"entity_id": "19583682_3_Ent4", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 26, "end": 27}, {"entity_id": "19583682_3_Ent5", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "19583682_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19583682_3_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "19583682_3_Ent2", "text": "interactions between three different selective serotonin - reuptake inhibitors ( SSRI ) and possibly ciprofloxacin", "entity_type": "Entity", "start": 12, "end": 27}, {"id": "19583682_3_Ent3", "text": "selective serotonin - reuptake inhibitors", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "19583682_3_Ent6", "text": "selective serotonin - reuptake inhibitors", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "19583682_3_Ent4", "text": "ciprofloxacin", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "19583682_3_Ent5", "text": "ciprofloxacin", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "19648225_2", "wnd_id": "19648225_2_1", "text": "Possible mechanisms for damage to the urothelium by ketamine are suggested .", "tokens": ["Possible", "mechanisms", "for", "damage", "to", "the", "urothelium", "by", "ketamine", "are", "suggested", "."], "event_mentions": [{"id": "19648225_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 7, "end": 8}, "arguments": [{"entity_id": "19648225_2_Ent0", "role": "Effect", "text": "damage to the urothelium", "start": 3, "end": 7}, {"entity_id": "19648225_2_Ent1", "role": "Treatment", "text": "ketamine", "start": 8, "end": 9}, {"entity_id": "19648225_2_Ent2", "role": "Treatment_Drug", "text": "ketamine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "19648225_2_Ent0", "text": "damage to the urothelium", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "19648225_2_Ent1", "text": "ketamine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19648225_2_Ent2", "text": "ketamine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "19648225_3", "wnd_id": "19648225_3_1", "text": "Presentation of three palliative care patients who were given ketamine as an analgesic and subsequently developed significant and debilitating urological symptoms .", "tokens": ["Presentation", "of", "three", "palliative", "care", "patients", "who", "were", "given", "ketamine", "as", "an", "analgesic", "and", "subsequently", "developed", "significant", "and", "debilitating", "urological", "symptoms", "."], "event_mentions": [{"id": "19648225_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "19648225_3_Ent1", "role": "Subject_Population", "text": "three", "start": 2, "end": 3}, {"entity_id": "19648225_3_Ent0", "role": "Subject", "text": "three palliative care patients", "start": 2, "end": 6}, {"entity_id": "19648225_3_Ent3", "role": "Treatment", "text": "ketamine", "start": 9, "end": 10}, {"entity_id": "19648225_3_Ent4", "role": "Treatment_Drug", "text": "ketamine", "start": 9, "end": 10}, {"entity_id": "19648225_3_Ent2", "role": "Effect", "text": "urological symptoms", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "19648225_3_Ent1", "text": "three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19648225_3_Ent0", "text": "three palliative care patients", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "19648225_3_Ent3", "text": "ketamine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19648225_3_Ent4", "text": "ketamine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19648225_3_Ent2", "text": "urological symptoms", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "19660974_2", "wnd_id": "19660974_2_1", "text": "The ability of tumor necrosis factor ( TNF) - alpha inhibitors to impair pivotal pro - inflammatory host defenses may facilitate the development of disseminated cryptococcosis .", "tokens": ["The", "ability", "of", "tumor", "necrosis", "factor", "(", "TNF)", "-", "alpha", "inhibitors", "to", "impair", "pivotal", "pro", "-", "inflammatory", "host", "defenses", "may", "facilitate", "the", "development", "of", "disseminated", "cryptococcosis", "."], "event_mentions": [{"id": "19660974_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 22, "end": 23}, "arguments": [{"entity_id": "19660974_2_Ent1", "role": "Treatment", "text": "tumor necrosis factor ( TNF) - alpha inhibitors", "start": 3, "end": 11}, {"entity_id": "19660974_2_Ent2", "role": "Treatment_Drug", "text": "tumor necrosis factor ( TNF) - alpha inhibitors", "start": 3, "end": 11}, {"entity_id": "19660974_2_Ent0", "role": "Effect", "text": "disseminated cryptococcosis", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "19660974_2_Ent1", "text": "tumor necrosis factor ( TNF) - alpha inhibitors", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "19660974_2_Ent2", "text": "tumor necrosis factor ( TNF) - alpha inhibitors", "entity_type": "Entity", "start": 3, "end": 11}, {"id": "19660974_2_Ent0", "text": "disseminated cryptococcosis", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "19667003_4", "wnd_id": "19667003_4_1", "text": "After three weeks of carbamazepine therapy , the patient arrived at the emergency department ( ED ) with severe agitation and aggressive behavior .", "tokens": ["After", "three", "weeks", "of", "carbamazepine", "therapy", ",", "the", "patient", "arrived", "at", "the", "emergency", "department", "(", "ED", ")", "with", "severe", "agitation", "and", "aggressive", "behavior", "."], "event_mentions": [{"id": "19667003_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "19667003_4_Ent2", "role": "Treatment", "text": "After three weeks of carbamazepine therapy", "start": 0, "end": 6}, {"entity_id": "19667003_4_Ent3", "role": "Treatment_Duration", "text": "three weeks", "start": 1, "end": 3}, {"entity_id": "19667003_4_Ent4", "role": "Treatment_Drug", "text": "carbamazepine", "start": 4, "end": 5}, {"entity_id": "19667003_4_Ent0", "role": "Subject", "text": "patient", "start": 8, "end": 9}, {"entity_id": "19667003_4_Ent1", "role": "Effect", "text": "severe agitation and aggressive behavior", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "19667003_4_Ent2", "text": "After three weeks of carbamazepine therapy", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "19667003_4_Ent3", "text": "three weeks", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "19667003_4_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19667003_4_Ent0", "text": "patient", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19667003_4_Ent1", "text": "severe agitation and aggressive behavior", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "19707032_4", "wnd_id": "19707032_4_1", "text": "CONCLUSIONS : Patients receiving intravitreal injections of bevacizumab should be evaluated for potential systemic risk factors such as carotid insufficiency , coagulopathy and poorly controlled diabetes mellitus .", "tokens": ["CONCLUSIONS", ":", "Patients", "receiving", "intravitreal", "injections", "of", "bevacizumab", "should", "be", "evaluated", "for", "potential", "systemic", "risk", "factors", "such", "as", "carotid", "insufficiency", ",", "coagulopathy", "and", "poorly", "controlled", "diabetes", "mellitus", "."], "event_mentions": [{"id": "19707032_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 14, "end": 15}, "arguments": [{"entity_id": "19707032_4_Ent3", "role": "Treatment_Route", "text": "intravitreal injections", "start": 4, "end": 6}, {"entity_id": "19707032_4_Ent1", "role": "Treatment", "text": "intravitreal injections of bevacizumab", "start": 4, "end": 8}, {"entity_id": "19707032_4_Ent2", "role": "Treatment_Drug", "text": "bevacizumab", "start": 7, "end": 8}, {"entity_id": "19707032_4_Ent0", "role": "Effect", "text": "carotid insufficiency , coagulopathy and poorly controlled diabetes mellitus", "start": 18, "end": 27}]}], "entity_mentions": [{"id": "19707032_4_Ent3", "text": "intravitreal injections", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "19707032_4_Ent1", "text": "intravitreal injections of bevacizumab", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "19707032_4_Ent2", "text": "bevacizumab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19707032_4_Ent0", "text": "carotid insufficiency , coagulopathy and poorly controlled diabetes mellitus", "entity_type": "Entity", "start": 18, "end": 27}], "lang": "en"}
{"doc_id": "19717383_1", "wnd_id": "19717383_1_1", "text": "Herein , we describe a patient with AIDS who presented to medical attention with pancytopenia 48 months postchemotherapy with etoposide , prednisone , vincristine , cyclophosphamide , doxorubicin , and rituximab ( R - EPOCH ) for diffuse large B - cell lymphoma .", "tokens": ["Herein", ",", "we", "describe", "a", "patient", "with", "AIDS", "who", "presented", "to", "medical", "attention", "with", "pancytopenia", "48", "months", "postchemotherapy", "with", "etoposide", ",", "prednisone", ",", "vincristine", ",", "cyclophosphamide", ",", "doxorubicin", ",", "and", "rituximab", "(", "R", "-", "EPOCH", ")", "for", "diffuse", "large", "B", "-", "cell", "lymphoma", "."], "event_mentions": [{"id": "19717383_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 9, "end": 10}, "arguments": [{"entity_id": "19717383_1_Ent0", "role": "Subject", "text": "a patient with AIDS", "start": 4, "end": 8}, {"entity_id": "19717383_1_Ent1", "role": "Subject_Disorder", "text": "AIDS", "start": 7, "end": 8}, {"entity_id": "19717383_1_Ent2", "role": "Effect", "text": "medical attention with pancytopenia", "start": 11, "end": 15}, {"entity_id": "19717383_1_Ent5", "role": "Treatment_Duration", "text": "48 months", "start": 15, "end": 17}, {"entity_id": "19717383_1_Ent3", "role": "Treatment", "text": "48 months postchemotherapy with etoposide , prednisone , vincristine , cyclophosphamide , doxorubicin , and rituximab ( R - EPOCH )", "start": 15, "end": 36}, {"entity_id": "19717383_1_Ent6", "role": "Treatment_Drug", "text": "etoposide", "start": 19, "end": 20}, {"entity_id": "19717383_1_Ent12", "role": "Combination_Drug", "text": "etoposide", "start": 19, "end": 20}, {"entity_id": "19717383_1_Ent7", "role": "Treatment_Drug", "text": "prednisone", "start": 21, "end": 22}, {"entity_id": "19717383_1_Ent13", "role": "Combination_Drug", "text": "prednisone", "start": 21, "end": 22}, {"entity_id": "19717383_1_Ent8", "role": "Treatment_Drug", "text": "vincristine", "start": 23, "end": 24}, {"entity_id": "19717383_1_Ent14", "role": "Combination_Drug", "text": "vincristine", "start": 23, "end": 24}, {"entity_id": "19717383_1_Ent9", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 25, "end": 26}, {"entity_id": "19717383_1_Ent15", "role": "Combination_Drug", "text": "cyclophosphamide", "start": 25, "end": 26}, {"entity_id": "19717383_1_Ent10", "role": "Treatment_Drug", "text": "doxorubicin", "start": 27, "end": 28}, {"entity_id": "19717383_1_Ent16", "role": "Combination_Drug", "text": "doxorubicin", "start": 27, "end": 28}, {"entity_id": "19717383_1_Ent11", "role": "Treatment_Drug", "text": "rituximab", "start": 30, "end": 31}, {"entity_id": "19717383_1_Ent17", "role": "Combination_Drug", "text": "rituximab", "start": 30, "end": 31}, {"entity_id": "19717383_1_Ent4", "role": "Treatment_Disorder", "text": "diffuse large B - cell lymphoma", "start": 37, "end": 43}]}], "entity_mentions": [{"id": "19717383_1_Ent0", "text": "a patient with AIDS", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "19717383_1_Ent1", "text": "AIDS", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19717383_1_Ent2", "text": "medical attention with pancytopenia", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "19717383_1_Ent5", "text": "48 months", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "19717383_1_Ent3", "text": "48 months postchemotherapy with etoposide , prednisone , vincristine , cyclophosphamide , doxorubicin , and rituximab ( R - EPOCH )", "entity_type": "Entity", "start": 15, "end": 36}, {"id": "19717383_1_Ent6", "text": "etoposide", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "19717383_1_Ent12", "text": "etoposide", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "19717383_1_Ent7", "text": "prednisone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19717383_1_Ent13", "text": "prednisone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19717383_1_Ent8", "text": "vincristine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "19717383_1_Ent14", "text": "vincristine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "19717383_1_Ent9", "text": "cyclophosphamide", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "19717383_1_Ent15", "text": "cyclophosphamide", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "19717383_1_Ent10", "text": "doxorubicin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "19717383_1_Ent16", "text": "doxorubicin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "19717383_1_Ent11", "text": "rituximab", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "19717383_1_Ent17", "text": "rituximab", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "19717383_1_Ent4", "text": "diffuse large B - cell lymphoma", "entity_type": "Entity", "start": 37, "end": 43}], "lang": "en"}
{"doc_id": "19725909_1", "wnd_id": "19725909_1_1", "text": "Favorable outcome of de novo hepatitis B infection after liver transplantation with lamivudine and adefovir therapy .", "tokens": ["Favorable", "outcome", "of", "de", "novo", "hepatitis", "B", "infection", "after", "liver", "transplantation", "with", "lamivudine", "and", "adefovir", "therapy", "."], "event_mentions": [{"id": "19725909_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "outcome", "start": 1, "end": 2}, "arguments": [{"entity_id": "19725909_1_Ent3", "role": "Treatment_Disorder", "text": "hepatitis B infection", "start": 5, "end": 8}, {"entity_id": "19725909_1_Ent0", "role": "Treatment", "text": "after liver transplantation with lamivudine and adefovir therapy", "start": 8, "end": 16}, {"entity_id": "19725909_1_Ent1", "role": "Treatment_Drug", "text": "lamivudine", "start": 12, "end": 13}, {"entity_id": "19725909_1_Ent4", "role": "Combination_Drug", "text": "lamivudine", "start": 12, "end": 13}, {"entity_id": "19725909_1_Ent2", "role": "Treatment_Drug", "text": "adefovir", "start": 14, "end": 15}, {"entity_id": "19725909_1_Ent5", "role": "Combination_Drug", "text": "adefovir", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "19725909_1_Ent3", "text": "hepatitis B infection", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "19725909_1_Ent0", "text": "after liver transplantation with lamivudine and adefovir therapy", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "19725909_1_Ent1", "text": "lamivudine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19725909_1_Ent4", "text": "lamivudine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19725909_1_Ent2", "text": "adefovir", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "19725909_1_Ent5", "text": "adefovir", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "19733945_1", "wnd_id": "19733945_1_1", "text": "Linezolid - associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome .", "tokens": ["Linezolid", "-", "associated", "acute", "interstitial", "nephritis", "and", "drug", "rash", "with", "eosinophilia", "and", "systemic", "symptoms", "(", "DRESS", ")", "syndrome", "."], "event_mentions": [{"id": "19733945_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "19733945_1_Ent1", "role": "Treatment", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "19733945_1_Ent2", "role": "Treatment_Drug", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "19733945_1_Ent0", "role": "Effect", "text": "acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome", "start": 3, "end": 18}]}], "entity_mentions": [{"id": "19733945_1_Ent1", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19733945_1_Ent2", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19733945_1_Ent0", "text": "acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome", "entity_type": "Entity", "start": 3, "end": 18}], "lang": "en"}
{"doc_id": "19745701_2", "wnd_id": "19745701_2_1", "text": "Reversible methotrexate - associated lymphoproliferative disorder resembling advanced gastric cancer in a patient with rheumatoid arthritis .", "tokens": ["Reversible", "methotrexate", "-", "associated", "lymphoproliferative", "disorder", "resembling", "advanced", "gastric", "cancer", "in", "a", "patient", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "19745701_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "19745701_2_Ent2", "role": "Treatment", "text": "methotrexate", "start": 1, "end": 2}, {"entity_id": "19745701_2_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 1, "end": 2}, {"entity_id": "19745701_2_Ent1", "role": "Effect", "text": "lymphoproliferative disorder", "start": 4, "end": 6}, {"entity_id": "19745701_2_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 11, "end": 16}, {"entity_id": "19745701_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "19745701_2_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19745701_2_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19745701_2_Ent1", "text": "lymphoproliferative disorder", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "19745701_2_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19745701_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "19775485_1", "wnd_id": "19775485_1_1", "text": "Are nasal decongestants safer than rhinitis ? A case of oxymetazoline - induced syncope .", "tokens": ["Are", "nasal", "decongestants", "safer", "than", "rhinitis", "?", "A", "case", "of", "oxymetazoline", "-", "induced", "syncope", "."], "event_mentions": [{"id": "19775485_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "19775485_1_Ent1", "role": "Treatment", "text": "oxymetazoline", "start": 10, "end": 11}, {"entity_id": "19775485_1_Ent2", "role": "Treatment_Drug", "text": "oxymetazoline", "start": 10, "end": 11}, {"entity_id": "19775485_1_Ent0", "role": "Effect", "text": "syncope", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "19775485_1_Ent1", "text": "oxymetazoline", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19775485_1_Ent2", "text": "oxymetazoline", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19775485_1_Ent0", "text": "syncope", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "1977935_1", "wnd_id": "1977935_1_1", "text": "Torsades de pointes occurring in association with terfenadine use .", "tokens": ["Torsades", "de", "pointes", "occurring", "in", "association", "with", "terfenadine", "use", "."], "event_mentions": [{"id": "1977935_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 5, "end": 6}, "arguments": [{"entity_id": "1977935_1_Ent0", "role": "Effect", "text": "Torsades de pointes", "start": 0, "end": 3}, {"entity_id": "1977935_1_Ent1", "role": "Treatment", "text": "terfenadine", "start": 7, "end": 8}, {"entity_id": "1977935_1_Ent2", "role": "Treatment_Drug", "text": "terfenadine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "1977935_1_Ent0", "text": "Torsades de pointes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1977935_1_Ent1", "text": "terfenadine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1977935_1_Ent2", "text": "terfenadine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "19782276_1", "wnd_id": "19782276_1_1", "text": "Fulminant fatal cardiotoxicity following cyclophosphamide therapy .", "tokens": ["Fulminant", "fatal", "cardiotoxicity", "following", "cyclophosphamide", "therapy", "."], "event_mentions": [{"id": "19782276_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "19782276_1_Ent0", "role": "Effect", "text": "Fulminant fatal cardiotoxicity", "start": 0, "end": 3}, {"entity_id": "19782276_1_Ent1", "role": "Treatment", "text": "cyclophosphamide", "start": 4, "end": 5}, {"entity_id": "19782276_1_Ent2", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "19782276_1_Ent0", "text": "Fulminant fatal cardiotoxicity", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19782276_1_Ent1", "text": "cyclophosphamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19782276_1_Ent2", "text": "cyclophosphamide", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "19782276_4", "wnd_id": "19782276_4_1", "text": "He developed congestive heart failure 5 days after administration of cyclophosphamide .", "tokens": ["He", "developed", "congestive", "heart", "failure", "5", "days", "after", "administration", "of", "cyclophosphamide", "."], "event_mentions": [{"id": "19782276_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "19782276_4_Ent0", "role": "Effect", "text": "congestive heart failure", "start": 2, "end": 5}, {"entity_id": "19782276_4_Ent2", "role": "Treatment_Time_elapsed", "text": "5 days", "start": 5, "end": 7}, {"entity_id": "19782276_4_Ent1", "role": "Treatment", "text": "5 days after administration of cyclophosphamide", "start": 5, "end": 11}, {"entity_id": "19782276_4_Ent3", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "19782276_4_Ent0", "text": "congestive heart failure", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "19782276_4_Ent2", "text": "5 days", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "19782276_4_Ent1", "text": "5 days after administration of cyclophosphamide", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "19782276_4_Ent3", "text": "cyclophosphamide", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "19789166_2", "wnd_id": "19789166_2_1", "text": "Nitrofurantoin - induced acute liver damage in pregnancy .", "tokens": ["Nitrofurantoin", "-", "induced", "acute", "liver", "damage", "in", "pregnancy", "."], "event_mentions": [{"id": "19789166_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19789166_2_Ent2", "role": "Treatment", "text": "Nitrofurantoin", "start": 0, "end": 1}, {"entity_id": "19789166_2_Ent3", "role": "Treatment_Drug", "text": "Nitrofurantoin", "start": 0, "end": 1}, {"entity_id": "19789166_2_Ent1", "role": "Effect", "text": "acute liver damage", "start": 3, "end": 6}, {"entity_id": "19789166_2_Ent0", "role": "Subject", "text": "pregnancy", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "19789166_2_Ent2", "text": "Nitrofurantoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19789166_2_Ent3", "text": "Nitrofurantoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19789166_2_Ent1", "text": "acute liver damage", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "19789166_2_Ent0", "text": "pregnancy", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "19826099_3", "wnd_id": "19826099_3_1", "text": "The Naranjo probability scale indicated a probable relationship between apnea and exposure to lamotrigine through breast - feeding in this infant .", "tokens": ["The", "Naranjo", "probability", "scale", "indicated", "a", "probable", "relationship", "between", "apnea", "and", "exposure", "to", "lamotrigine", "through", "breast", "-", "feeding", "in", "this", "infant", "."], "event_mentions": [{"id": "19826099_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "a probable relationship", "start": 5, "end": 8}, "arguments": [{"entity_id": "19826099_3_Ent2", "role": "Effect", "text": "apnea", "start": 9, "end": 10}, {"entity_id": "19826099_3_Ent4", "role": "Treatment_Drug", "text": "lamotrigine", "start": 13, "end": 14}, {"entity_id": "19826099_3_Ent3", "role": "Treatment", "text": "lamotrigine through breast - feeding", "start": 13, "end": 18}, {"entity_id": "19826099_3_Ent5", "role": "Treatment_Route", "text": "breast - feeding", "start": 15, "end": 18}, {"entity_id": "19826099_3_Ent0", "role": "Subject", "text": "in this infant", "start": 18, "end": 21}, {"entity_id": "19826099_3_Ent1", "role": "Subject_Age", "text": "infant", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "19826099_3_Ent2", "text": "apnea", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19826099_3_Ent4", "text": "lamotrigine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19826099_3_Ent3", "text": "lamotrigine through breast - feeding", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "19826099_3_Ent5", "text": "breast - feeding", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "19826099_3_Ent0", "text": "in this infant", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "19826099_3_Ent1", "text": "infant", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "19857154_1", "wnd_id": "19857154_1_1", "text": "Clinically significant adverse events from a drug interaction between quetiapine and atazanavir - ritonavir in two patients .", "tokens": ["Clinically", "significant", "adverse", "events", "from", "a", "drug", "interaction", "between", "quetiapine", "and", "atazanavir", "-", "ritonavir", "in", "two", "patients", "."], "event_mentions": [{"id": "19857154_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse events", "start": 2, "end": 4}, "arguments": [{"entity_id": "19857154_1_Ent2", "role": "Effect", "text": "Clinically significant", "start": 0, "end": 2}, {"entity_id": "19857154_1_Ent3", "role": "Treatment", "text": "interaction between quetiapine and atazanavir - ritonavir", "start": 7, "end": 14}, {"entity_id": "19857154_1_Ent4", "role": "Treatment_Drug", "text": "quetiapine", "start": 9, "end": 10}, {"entity_id": "19857154_1_Ent6", "role": "Combination_Drug", "text": "quetiapine", "start": 9, "end": 10}, {"entity_id": "19857154_1_Ent5", "role": "Treatment_Drug", "text": "atazanavir - ritonavir", "start": 11, "end": 14}, {"entity_id": "19857154_1_Ent7", "role": "Combination_Drug", "text": "atazanavir - ritonavir", "start": 11, "end": 14}, {"entity_id": "19857154_1_Ent1", "role": "Subject_Population", "text": "two", "start": 15, "end": 16}, {"entity_id": "19857154_1_Ent0", "role": "Subject", "text": "two patients", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "19857154_1_Ent2", "text": "Clinically significant", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19857154_1_Ent3", "text": "interaction between quetiapine and atazanavir - ritonavir", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "19857154_1_Ent4", "text": "quetiapine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19857154_1_Ent6", "text": "quetiapine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19857154_1_Ent5", "text": "atazanavir - ritonavir", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "19857154_1_Ent7", "text": "atazanavir - ritonavir", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "19857154_1_Ent1", "text": "two", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "19857154_1_Ent0", "text": "two patients", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "19857154_7", "wnd_id": "19857154_7_1", "text": "The second patient was a 32 - year - old woman with HIV , anxiety disorder , and a history of intravenous drug abuse who developed increased sedation and mental confusion when an atazanavir - ritonavir - based antiretroviral regimen was added to her stable antianxiety drug regimen , which included quetiapine .", "tokens": ["The", "second", "patient", "was", "a", "32", "-", "year", "-", "old", "woman", "with", "HIV", ",", "anxiety", "disorder", ",", "and", "a", "history", "of", "intravenous", "drug", "abuse", "who", "developed", "increased", "sedation", "and", "mental", "confusion", "when", "an", "atazanavir", "-", "ritonavir", "-", "based", "antiretroviral", "regimen", "was", "added", "to", "her", "stable", "antianxiety", "drug", "regimen", ",", "which", "included", "quetiapine", "."], "event_mentions": [{"id": "19857154_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 25, "end": 26}, "arguments": [{"entity_id": "19857154_7_Ent0", "role": "Subject", "text": "a 32 - year - old woman with HIV , anxiety disorder , and a history of intravenous drug abuse", "start": 4, "end": 24}, {"entity_id": "19857154_7_Ent1", "role": "Subject_Age", "text": "32 - year - old", "start": 5, "end": 10}, {"entity_id": "19857154_7_Ent2", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "19857154_7_Ent9", "role": "Treatment_Disorder", "text": "HIV", "start": 12, "end": 13}, {"entity_id": "19857154_7_Ent10", "role": "Treatment_Disorder", "text": "anxiety disorder", "start": 14, "end": 16}, {"entity_id": "19857154_7_Ent3", "role": "Subject_Disorder", "text": "intravenous drug abuse", "start": 21, "end": 24}, {"entity_id": "19857154_7_Ent4", "role": "Effect", "text": "increased sedation and mental confusion", "start": 26, "end": 31}, {"entity_id": "19857154_7_Ent7", "role": "Treatment_Drug", "text": "atazanavir", "start": 33, "end": 34}, {"entity_id": "19857154_7_Ent12", "role": "Combination_Drug", "text": "atazanavir", "start": 33, "end": 34}, {"entity_id": "19857154_7_Ent5", "role": "Treatment", "text": "atazanavir - ritonavir - based antiretroviral regimen was added to her stable antianxiety drug regimen , which included quetiapine", "start": 33, "end": 52}, {"entity_id": "19857154_7_Ent8", "role": "Treatment_Drug", "text": "ritonavir", "start": 35, "end": 36}, {"entity_id": "19857154_7_Ent11", "role": "Combination_Drug", "text": "ritonavir", "start": 35, "end": 36}, {"entity_id": "19857154_7_Ent6", "role": "Treatment_Drug", "text": "quetiapine", "start": 51, "end": 52}, {"entity_id": "19857154_7_Ent13", "role": "Combination_Drug", "text": "quetiapine", "start": 51, "end": 52}]}], "entity_mentions": [{"id": "19857154_7_Ent0", "text": "a 32 - year - old woman with HIV , anxiety disorder , and a history of intravenous drug abuse", "entity_type": "Entity", "start": 4, "end": 24}, {"id": "19857154_7_Ent1", "text": "32 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "19857154_7_Ent2", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19857154_7_Ent9", "text": "HIV", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19857154_7_Ent10", "text": "anxiety disorder", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "19857154_7_Ent3", "text": "intravenous drug abuse", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "19857154_7_Ent4", "text": "increased sedation and mental confusion", "entity_type": "Entity", "start": 26, "end": 31}, {"id": "19857154_7_Ent7", "text": "atazanavir", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "19857154_7_Ent12", "text": "atazanavir", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "19857154_7_Ent5", "text": "atazanavir - ritonavir - based antiretroviral regimen was added to her stable antianxiety drug regimen , which included quetiapine", "entity_type": "Entity", "start": 33, "end": 52}, {"id": "19857154_7_Ent8", "text": "ritonavir", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "19857154_7_Ent11", "text": "ritonavir", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "19857154_7_Ent6", "text": "quetiapine", "entity_type": "Entity", "start": 51, "end": 52}, {"id": "19857154_7_Ent13", "text": "quetiapine", "entity_type": "Entity", "start": 51, "end": 52}], "lang": "en"}
{"doc_id": "19875411_2", "wnd_id": "19875411_2_1", "text": "Severe cardiomyopathy following treatment with the tumour necrosis factor - alpha inhibitor adalimumab for Crohn 's disease .", "tokens": ["Severe", "cardiomyopathy", "following", "treatment", "with", "the", "tumour", "necrosis", "factor", "-", "alpha", "inhibitor", "adalimumab", "for", "Crohn", "'s", "disease", "."], "event_mentions": [{"id": "19875411_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "19875411_2_Ent0", "role": "Effect", "text": "cardiomyopathy", "start": 1, "end": 2}, {"entity_id": "19875411_2_Ent1", "role": "Treatment", "text": "treatment with the tumour necrosis factor - alpha inhibitor adalimumab", "start": 3, "end": 13}, {"entity_id": "19875411_2_Ent2", "role": "Treatment_Drug", "text": "adalimumab", "start": 12, "end": 13}, {"entity_id": "19875411_2_Ent3", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "19875411_2_Ent0", "text": "cardiomyopathy", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19875411_2_Ent1", "text": "treatment with the tumour necrosis factor - alpha inhibitor adalimumab", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "19875411_2_Ent2", "text": "adalimumab", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19875411_2_Ent3", "text": "Crohn 's disease", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "19897274_1", "wnd_id": "19897274_1_1", "text": "However , a recent post - marketing survey in Japan revealed that interstitial pneumonia occurred in 4 among approximately 2 000 Japanese patients treated with sorafenib .", "tokens": ["However", ",", "a", "recent", "post", "-", "marketing", "survey", "in", "Japan", "revealed", "that", "interstitial", "pneumonia", "occurred", "in", "4", "among", "approximately", "2", "000", "Japanese", "patients", "treated", "with", "sorafenib", "."], "event_mentions": [{"id": "19897274_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 14, "end": 15}, "arguments": [{"entity_id": "19897274_1_Ent3", "role": "Effect", "text": "interstitial pneumonia", "start": 12, "end": 14}, {"entity_id": "19897274_1_Ent2", "role": "Subject_Population", "text": "4 among approximately 2 000", "start": 16, "end": 21}, {"entity_id": "19897274_1_Ent0", "role": "Subject", "text": "4 among approximately 2 000 Japanese patients", "start": 16, "end": 23}, {"entity_id": "19897274_1_Ent1", "role": "Subject_Race", "text": "Japanese", "start": 21, "end": 22}, {"entity_id": "19897274_1_Ent4", "role": "Treatment", "text": "sorafenib", "start": 25, "end": 26}, {"entity_id": "19897274_1_Ent5", "role": "Treatment_Drug", "text": "sorafenib", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "19897274_1_Ent3", "text": "interstitial pneumonia", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "19897274_1_Ent2", "text": "4 among approximately 2 000", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "19897274_1_Ent0", "text": "4 among approximately 2 000 Japanese patients", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "19897274_1_Ent1", "text": "Japanese", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19897274_1_Ent4", "text": "sorafenib", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "19897274_1_Ent5", "text": "sorafenib", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "19897274_3", "wnd_id": "19897274_3_1", "text": "In this article , we describe a Japanese patient with severe interstitial pneumonia probably caused by sorafenib treatment for metastatic renal cell carcinoma .", "tokens": ["In", "this", "article", ",", "we", "describe", "a", "Japanese", "patient", "with", "severe", "interstitial", "pneumonia", "probably", "caused", "by", "sorafenib", "treatment", "for", "metastatic", "renal", "cell", "carcinoma", "."], "event_mentions": [{"id": "19897274_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 14, "end": 15}, "arguments": [{"entity_id": "19897274_3_Ent0", "role": "Subject", "text": "a Japanese patient", "start": 6, "end": 9}, {"entity_id": "19897274_3_Ent1", "role": "Subject_Race", "text": "Japanese", "start": 7, "end": 8}, {"entity_id": "19897274_3_Ent2", "role": "Effect", "text": "severe interstitial pneumonia", "start": 10, "end": 13}, {"entity_id": "19897274_3_Ent3", "role": "Treatment", "text": "sorafenib", "start": 16, "end": 17}, {"entity_id": "19897274_3_Ent5", "role": "Treatment_Drug", "text": "sorafenib", "start": 16, "end": 17}, {"entity_id": "19897274_3_Ent4", "role": "Treatment_Disorder", "text": "metastatic renal cell carcinoma", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "19897274_3_Ent0", "text": "a Japanese patient", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19897274_3_Ent1", "text": "Japanese", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19897274_3_Ent2", "text": "severe interstitial pneumonia", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "19897274_3_Ent3", "text": "sorafenib", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19897274_3_Ent5", "text": "sorafenib", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19897274_3_Ent4", "text": "metastatic renal cell carcinoma", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "19904536_13", "wnd_id": "19904536_13_1", "text": "Gemcitabine - induced pulmonary toxicity is usually a dramatic condition .", "tokens": ["Gemcitabine", "-", "induced", "pulmonary", "toxicity", "is", "usually", "a", "dramatic", "condition", "."], "event_mentions": [{"id": "19904536_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19904536_13_Ent1", "role": "Treatment", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "19904536_13_Ent2", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "19904536_13_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "19904536_13_Ent1", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19904536_13_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19904536_13_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "19904536_14", "wnd_id": "19904536_14_1", "text": "Physicians should suspect pulmonary toxicity in patients with respiratory distress after gemcitabine chemotherapy , mainly in elderly patients .", "tokens": ["Physicians", "should", "suspect", "pulmonary", "toxicity", "in", "patients", "with", "respiratory", "distress", "after", "gemcitabine", "chemotherapy", ",", "mainly", "in", "elderly", "patients", "."], "event_mentions": [{"id": "19904536_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 10, "end": 11}, "arguments": [{"entity_id": "19904536_14_Ent2", "role": "Effect", "text": "pulmonary toxicity", "start": 3, "end": 5}, {"entity_id": "19904536_14_Ent0", "role": "Subject", "text": "patients with respiratory distress", "start": 6, "end": 10}, {"entity_id": "19904536_14_Ent5", "role": "Treatment_Disorder", "text": "respiratory distress", "start": 8, "end": 10}, {"entity_id": "19904536_14_Ent4", "role": "Treatment_Drug", "text": "gemcitabine", "start": 11, "end": 12}, {"entity_id": "19904536_14_Ent3", "role": "Treatment", "text": "gemcitabine chemotherapy", "start": 11, "end": 13}, {"entity_id": "19904536_14_Ent6", "role": "Treatment_Route", "text": "chemotherapy", "start": 12, "end": 13}, {"entity_id": "19904536_14_Ent1", "role": "Subject", "text": "mainly in elderly patients", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "19904536_14_Ent2", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19904536_14_Ent0", "text": "patients with respiratory distress", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "19904536_14_Ent5", "text": "respiratory distress", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "19904536_14_Ent4", "text": "gemcitabine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19904536_14_Ent3", "text": "gemcitabine chemotherapy", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "19904536_14_Ent6", "text": "chemotherapy", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19904536_14_Ent1", "text": "mainly in elderly patients", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "19904536_15", "wnd_id": "19904536_15_1", "text": "Fatal gemcitabine - induced pulmonary toxicity in metastatic    gallbladder adenocarcinoma .", "tokens": ["Fatal", "gemcitabine", "-", "induced", "pulmonary", "toxicity", "in", "metastatic", "  ", "gallbladder", "adenocarcinoma", "."], "event_mentions": [{"id": "19904536_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "19904536_15_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 1, "end": 2}, {"entity_id": "19904536_15_Ent3", "role": "Treatment_Drug", "text": "gemcitabine", "start": 1, "end": 2}, {"entity_id": "19904536_15_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 4, "end": 6}, {"entity_id": "19904536_15_Ent2", "role": "Treatment_Disorder", "text": "metastatic    gallbladder adenocarcinoma", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "19904536_15_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19904536_15_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "19904536_15_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "19904536_15_Ent2", "text": "metastatic    gallbladder adenocarcinoma", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "19904536_2", "wnd_id": "19904536_2_1", "text": "Gemcitabine is a chemotherapy agent that may cause unpredictable side effects .", "tokens": ["Gemcitabine", "is", "a", "chemotherapy", "agent", "that", "may", "cause", "unpredictable", "side", "effects", "."], "event_mentions": [{"id": "19904536_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 7, "end": 8}, "arguments": [{"entity_id": "19904536_2_Ent1", "role": "Treatment", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "19904536_2_Ent2", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "19904536_2_Ent0", "role": "Effect", "text": "unpredictable side effects", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "19904536_2_Ent1", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19904536_2_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19904536_2_Ent0", "text": "unpredictable side effects", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "19915794_3", "wnd_id": "19915794_3_1", "text": "Torsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450 , family 3 , subfamily A polypeptide - 4 - influencing drugs during hypokalemia due to licorice .", "tokens": ["Torsades", "de", "Pointes", "induced", "by", "a", "combination", "of", "garenoxacin", "and", "disopyramide", "and", "other", "cytochrome", "P450", ",", "family", "3", ",", "subfamily", "A", "polypeptide", "-", "4", "-", "influencing", "drugs", "during", "hypokalemia", "due", "to", "licorice", "."], "event_mentions": [{"id": "19915794_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "19915794_3_Ent0", "role": "Effect", "text": "Torsades de Pointes", "start": 0, "end": 3}, {"entity_id": "19915794_3_Ent1", "role": "Treatment", "text": "a combination of garenoxacin and disopyramide and other cytochrome P450 , family 3 , subfamily A polypeptide - 4 - influencing drugs", "start": 5, "end": 27}, {"entity_id": "19915794_3_Ent2", "role": "Treatment_Drug", "text": "garenoxacin", "start": 8, "end": 9}, {"entity_id": "19915794_3_Ent5", "role": "Combination_Drug", "text": "garenoxacin", "start": 8, "end": 9}, {"entity_id": "19915794_3_Ent3", "role": "Treatment_Drug", "text": "disopyramide", "start": 10, "end": 11}, {"entity_id": "19915794_3_Ent6", "role": "Combination_Drug", "text": "disopyramide", "start": 10, "end": 11}, {"entity_id": "19915794_3_Ent4", "role": "Treatment_Drug", "text": "cytochrome P450 , family 3 , subfamily A polypeptide - 4 - influencing drugs", "start": 13, "end": 27}, {"entity_id": "19915794_3_Ent7", "role": "Combination_Drug", "text": "cytochrome P450 , family 3 , subfamily A polypeptide - 4 - influencing drugs", "start": 13, "end": 27}]}], "entity_mentions": [{"id": "19915794_3_Ent0", "text": "Torsades de Pointes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19915794_3_Ent1", "text": "a combination of garenoxacin and disopyramide and other cytochrome P450 , family 3 , subfamily A polypeptide - 4 - influencing drugs", "entity_type": "Entity", "start": 5, "end": 27}, {"id": "19915794_3_Ent2", "text": "garenoxacin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19915794_3_Ent5", "text": "garenoxacin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19915794_3_Ent3", "text": "disopyramide", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19915794_3_Ent6", "text": "disopyramide", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19915794_3_Ent4", "text": "cytochrome P450 , family 3 , subfamily A polypeptide - 4 - influencing drugs", "entity_type": "Entity", "start": 13, "end": 27}, {"id": "19915794_3_Ent7", "text": "cytochrome P450 , family 3 , subfamily A polypeptide - 4 - influencing drugs", "entity_type": "Entity", "start": 13, "end": 27}], "lang": "en"}
{"doc_id": "19915794_4", "wnd_id": "19915794_4_1", "text": "We report an 82 - year - old man who developed ventricular tachycardia and Torsades de Pointes ( TdP ) after oral administration of garenoxacin , a novel quinolone antibiotic agent that differs from the third - generation quinolones , for pneumonia .", "tokens": ["We", "report", "an", "82", "-", "year", "-", "old", "man", "who", "developed", "ventricular", "tachycardia", "and", "Torsades", "de", "Pointes", "(", "TdP", ")", "after", "oral", "administration", "of", "garenoxacin", ",", "a", "novel", "quinolone", "antibiotic", "agent", "that", "differs", "from", "the", "third", "-", "generation", "quinolones", ",", "for", "pneumonia", "."], "event_mentions": [{"id": "19915794_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 20, "end": 21}, "arguments": [{"entity_id": "19915794_4_Ent0", "role": "Subject", "text": "an 82 - year - old man", "start": 2, "end": 9}, {"entity_id": "19915794_4_Ent1", "role": "Subject_Age", "text": "82 - year - old", "start": 3, "end": 8}, {"entity_id": "19915794_4_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "19915794_4_Ent3", "role": "Effect", "text": "ventricular tachycardia and Torsades de Pointes ( TdP )", "start": 11, "end": 20}, {"entity_id": "19915794_4_Ent6", "role": "Treatment_Route", "text": "oral", "start": 21, "end": 22}, {"entity_id": "19915794_4_Ent4", "role": "Treatment", "text": "oral administration of garenoxacin", "start": 21, "end": 25}, {"entity_id": "19915794_4_Ent7", "role": "Treatment_Drug", "text": "garenoxacin", "start": 24, "end": 25}, {"entity_id": "19915794_4_Ent5", "role": "Treatment_Disorder", "text": "pneumonia", "start": 41, "end": 42}]}], "entity_mentions": [{"id": "19915794_4_Ent0", "text": "an 82 - year - old man", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "19915794_4_Ent1", "text": "82 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "19915794_4_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19915794_4_Ent3", "text": "ventricular tachycardia and Torsades de Pointes ( TdP )", "entity_type": "Entity", "start": 11, "end": 20}, {"id": "19915794_4_Ent6", "text": "oral", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19915794_4_Ent4", "text": "oral administration of garenoxacin", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "19915794_4_Ent7", "text": "garenoxacin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "19915794_4_Ent5", "text": "pneumonia", "entity_type": "Entity", "start": 41, "end": 42}], "lang": "en"}
{"doc_id": "19949685_3", "wnd_id": "19949685_3_1", "text": "Two days after administration of Kalimate enema , he had profuse hematochezia , and a sigmoidoscopy showed diffuse colonic mucosal necrosis in the rectum and sigmoid colon .", "tokens": ["Two", "days", "after", "administration", "of", "Kalimate", "enema", ",", "he", "had", "profuse", "hematochezia", ",", "and", "a", "sigmoidoscopy", "showed", "diffuse", "colonic", "mucosal", "necrosis", "in", "the", "rectum", "and", "sigmoid", "colon", "."], "event_mentions": [{"id": "19949685_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "19949685_3_Ent7", "role": "Treatment_Time_elapsed", "text": "Two days", "start": 0, "end": 2}, {"entity_id": "19949685_3_Ent4", "role": "Treatment", "text": "Two days after administration of Kalimate enema", "start": 0, "end": 7}, {"entity_id": "19949685_3_Ent6", "role": "Treatment_Drug", "text": "Kalimate", "start": 5, "end": 6}, {"entity_id": "19949685_3_Ent5", "role": "Treatment_Route", "text": "enema", "start": 6, "end": 7}, {"entity_id": "19949685_3_Ent0", "role": "Subject", "text": "he", "start": 8, "end": 9}, {"entity_id": "19949685_3_Ent1", "role": "Subject_Gender", "text": "he", "start": 8, "end": 9}, {"entity_id": "19949685_3_Ent2", "role": "Effect", "text": "profuse hematochezia", "start": 10, "end": 12}, {"entity_id": "19949685_3_Ent3", "role": "Effect", "text": "diffuse colonic mucosal necrosis in the rectum", "start": 17, "end": 24}]}], "entity_mentions": [{"id": "19949685_3_Ent7", "text": "Two days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19949685_3_Ent4", "text": "Two days after administration of Kalimate enema", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "19949685_3_Ent6", "text": "Kalimate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19949685_3_Ent5", "text": "enema", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19949685_3_Ent0", "text": "he", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19949685_3_Ent1", "text": "he", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19949685_3_Ent2", "text": "profuse hematochezia", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19949685_3_Ent3", "text": "diffuse colonic mucosal necrosis in the rectum", "entity_type": "Entity", "start": 17, "end": 24}], "lang": "en"}
{"doc_id": "19995222_2", "wnd_id": "19995222_2_1", "text": "CONCLUSIONS : These results suggest that clozapine may cause TD ; however , the prevalence is low and the severity is relatively mild , with no or mild self - reported discomfort .", "tokens": ["CONCLUSIONS", ":", "These", "results", "suggest", "that", "clozapine", "may", "cause", "TD", ";", "however", ",", "the", "prevalence", "is", "low", "and", "the", "severity", "is", "relatively", "mild", ",", "with", "no", "or", "mild", "self", "-", "reported", "discomfort", "."], "event_mentions": [{"id": "19995222_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 8, "end": 9}, "arguments": [{"entity_id": "19995222_2_Ent1", "role": "Treatment", "text": "clozapine", "start": 6, "end": 7}, {"entity_id": "19995222_2_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 6, "end": 7}, {"entity_id": "19995222_2_Ent0", "role": "Effect", "text": "TD", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19995222_2_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19995222_2_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19995222_2_Ent0", "text": "TD", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "19995222_3", "wnd_id": "19995222_3_1", "text": "However , several case reports have suggested that clozapine could also cause TD .", "tokens": ["However", ",", "several", "case", "reports", "have", "suggested", "that", "clozapine", "could", "also", "cause", "TD", "."], "event_mentions": [{"id": "19995222_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 11, "end": 12}, "arguments": [{"entity_id": "19995222_3_Ent1", "role": "Treatment", "text": "clozapine", "start": 8, "end": 9}, {"entity_id": "19995222_3_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 8, "end": 9}, {"entity_id": "19995222_3_Ent0", "role": "Effect", "text": "TD", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "19995222_3_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19995222_3_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19995222_3_Ent0", "text": "TD", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "19995222_4", "wnd_id": "19995222_4_1", "text": "OBJECTIVE : Clozapine causes few extrapyramidal symptoms and is recommended as a treatment drug for severe tardive dyskinesia ( TD ) .", "tokens": ["OBJECTIVE", ":", "Clozapine", "causes", "few", "extrapyramidal", "symptoms", "and", "is", "recommended", "as", "a", "treatment", "drug", "for", "severe", "tardive", "dyskinesia", "(", "TD", ")", "."], "event_mentions": [{"id": "19995222_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 3, "end": 4}, "arguments": [{"entity_id": "19995222_4_Ent1", "role": "Treatment", "text": "Clozapine", "start": 2, "end": 3}, {"entity_id": "19995222_4_Ent2", "role": "Treatment_Drug", "text": "Clozapine", "start": 2, "end": 3}, {"entity_id": "19995222_4_Ent0", "role": "Effect", "text": "few extrapyramidal symptoms", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "19995222_4_Ent1", "text": "Clozapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19995222_4_Ent2", "text": "Clozapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19995222_4_Ent0", "text": "few extrapyramidal symptoms", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "20020238_2", "wnd_id": "20020238_2_1", "text": "CONCLUSION : Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon .", "tokens": ["CONCLUSION", ":", "Significant", "ocular", "complications", "such", "as", "an", "irreversible", "decrease", "of", "visual", "acuity", "may", "develop", "in", "patients", "treated", "with", "pegylated", "interferon", "."], "event_mentions": [{"id": "20020238_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 17, "end": 18}, "arguments": [{"entity_id": "20020238_2_Ent1", "role": "Effect", "text": "irreversible decrease of visual acuity", "start": 8, "end": 13}, {"entity_id": "20020238_2_Ent0", "role": "Subject", "text": "patients", "start": 16, "end": 17}, {"entity_id": "20020238_2_Ent2", "role": "Treatment", "text": "pegylated interferon", "start": 19, "end": 21}, {"entity_id": "20020238_2_Ent3", "role": "Treatment_Drug", "text": "pegylated interferon", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "20020238_2_Ent1", "text": "irreversible decrease of visual acuity", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "20020238_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "20020238_2_Ent2", "text": "pegylated interferon", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "20020238_2_Ent3", "text": "pegylated interferon", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "20020238_3", "wnd_id": "20020238_3_1", "text": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin .", "tokens": ["Retinopathy", "in", "hepatitis", "C", "patients", "due", "to", "combination", "therapy", "with", "pegylated", "interferon", "and", "ribavirin", "."], "event_mentions": [{"id": "20020238_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 5, "end": 6}, "arguments": [{"entity_id": "20020238_3_Ent1", "role": "Effect", "text": "Retinopathy", "start": 0, "end": 1}, {"entity_id": "20020238_3_Ent3", "role": "Treatment_Disorder", "text": "hepatitis C", "start": 2, "end": 4}, {"entity_id": "20020238_3_Ent0", "role": "Subject", "text": "hepatitis C patients", "start": 2, "end": 5}, {"entity_id": "20020238_3_Ent4", "role": "Treatment_Drug", "text": "pegylated interferon", "start": 10, "end": 12}, {"entity_id": "20020238_3_Ent6", "role": "Combination_Drug", "text": "pegylated interferon", "start": 10, "end": 12}, {"entity_id": "20020238_3_Ent2", "role": "Treatment", "text": "pegylated interferon and ribavirin", "start": 10, "end": 14}, {"entity_id": "20020238_3_Ent5", "role": "Treatment_Drug", "text": "ribavirin", "start": 13, "end": 14}, {"entity_id": "20020238_3_Ent7", "role": "Combination_Drug", "text": "ribavirin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "20020238_3_Ent1", "text": "Retinopathy", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20020238_3_Ent3", "text": "hepatitis C", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "20020238_3_Ent0", "text": "hepatitis C patients", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "20020238_3_Ent4", "text": "pegylated interferon", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "20020238_3_Ent6", "text": "pegylated interferon", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "20020238_3_Ent2", "text": "pegylated interferon and ribavirin", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "20020238_3_Ent5", "text": "ribavirin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "20020238_3_Ent7", "text": "ribavirin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "2011096_5", "wnd_id": "2011096_5_1", "text": "Neurotoxicity can occur at any time using high - dose cytosine therapy .", "tokens": ["Neurotoxicity", "can", "occur", "at", "any", "time", "using", "high", "-", "dose", "cytosine", "therapy", "."], "event_mentions": [{"id": "2011096_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 2, "end": 3}, "arguments": [{"entity_id": "2011096_5_Ent0", "role": "Effect", "text": "Neurotoxicity", "start": 0, "end": 1}, {"entity_id": "2011096_5_Ent2", "role": "Treatment_Dosage", "text": "high - dose", "start": 7, "end": 10}, {"entity_id": "2011096_5_Ent1", "role": "Treatment", "text": "high - dose cytosine", "start": 7, "end": 11}, {"entity_id": "2011096_5_Ent3", "role": "Treatment_Drug", "text": "cytosine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "2011096_5_Ent0", "text": "Neurotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2011096_5_Ent2", "text": "high - dose", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "2011096_5_Ent1", "text": "high - dose cytosine", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "2011096_5_Ent3", "text": "cytosine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "20120657_2", "wnd_id": "20120657_2_1", "text": "We report a case of Zidovudine induced anaemia and bone marrow aplasia in a patient infected with HIV .", "tokens": ["We", "report", "a", "case", "of", "Zidovudine", "induced", "anaemia", "and", "bone", "marrow", "aplasia", "in", "a", "patient", "infected", "with", "HIV", "."], "event_mentions": [{"id": "20120657_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "20120657_2_Ent2", "role": "Treatment", "text": "Zidovudine", "start": 5, "end": 6}, {"entity_id": "20120657_2_Ent3", "role": "Treatment_Drug", "text": "Zidovudine", "start": 5, "end": 6}, {"entity_id": "20120657_2_Ent1", "role": "Effect", "text": "anaemia and bone marrow aplasia", "start": 7, "end": 12}, {"entity_id": "20120657_2_Ent0", "role": "Subject", "text": "a patient infected with HIV", "start": 13, "end": 18}, {"entity_id": "20120657_2_Ent4", "role": "Treatment_Disorder", "text": "HIV", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "20120657_2_Ent2", "text": "Zidovudine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20120657_2_Ent3", "text": "Zidovudine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20120657_2_Ent1", "text": "anaemia and bone marrow aplasia", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "20120657_2_Ent0", "text": "a patient infected with HIV", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "20120657_2_Ent4", "text": "HIV", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "2016556_1", "wnd_id": "2016556_1_1", "text": "We describe a patient who experienced chronic nausea and an episode of confusion while treated with a small , stable dose of oral morphine in the setting of mild renal insufficiency .", "tokens": ["We", "describe", "a", "patient", "who", "experienced", "chronic", "nausea", "and", "an", "episode", "of", "confusion", "while", "treated", "with", "a", "small", ",", "stable", "dose", "of", "oral", "morphine", "in", "the", "setting", "of", "mild", "renal", "insufficiency", "."], "event_mentions": [{"id": "2016556_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 5, "end": 6}, "arguments": [{"entity_id": "2016556_1_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "2016556_1_Ent2", "role": "Effect", "text": "chronic nausea and an episode of confusion", "start": 6, "end": 13}, {"entity_id": "2016556_1_Ent3", "role": "Treatment", "text": "a small , stable dose of oral morphine", "start": 16, "end": 24}, {"entity_id": "2016556_1_Ent4", "role": "Treatment_Dosage", "text": "small , stable dose", "start": 17, "end": 21}, {"entity_id": "2016556_1_Ent5", "role": "Treatment_Route", "text": "oral", "start": 22, "end": 23}, {"entity_id": "2016556_1_Ent6", "role": "Treatment_Drug", "text": "morphine", "start": 23, "end": 24}, {"entity_id": "2016556_1_Ent1", "role": "Subject_Disorder", "text": "mild renal insufficiency", "start": 28, "end": 31}]}], "entity_mentions": [{"id": "2016556_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "2016556_1_Ent2", "text": "chronic nausea and an episode of confusion", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "2016556_1_Ent3", "text": "a small , stable dose of oral morphine", "entity_type": "Entity", "start": 16, "end": 24}, {"id": "2016556_1_Ent4", "text": "small , stable dose", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "2016556_1_Ent5", "text": "oral", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "2016556_1_Ent6", "text": "morphine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "2016556_1_Ent1", "text": "mild renal insufficiency", "entity_type": "Entity", "start": 28, "end": 31}], "lang": "en"}
{"doc_id": "20178709_2", "wnd_id": "20178709_2_1", "text": "Methotrexate may rarely provoke serositis , even with low doses and after just a few weeks of therapy .", "tokens": ["Methotrexate", "may", "rarely", "provoke", "serositis", ",", "even", "with", "low", "doses", "and", "after", "just", "a", "few", "weeks", "of", "therapy", "."], "event_mentions": [{"id": "20178709_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoke", "start": 3, "end": 4}, "arguments": [{"entity_id": "20178709_2_Ent1", "role": "Treatment", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "20178709_2_Ent2", "role": "Treatment_Drug", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "20178709_2_Ent0", "role": "Effect", "text": "serositis", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "20178709_2_Ent1", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20178709_2_Ent2", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20178709_2_Ent0", "text": "serositis", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "20178709_3", "wnd_id": "20178709_3_1", "text": "We report here a rare case of pleuropericarditis due to methotrexate .", "tokens": ["We", "report", "here", "a", "rare", "case", "of", "pleuropericarditis", "due", "to", "methotrexate", "."], "event_mentions": [{"id": "20178709_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 8, "end": 9}, "arguments": [{"entity_id": "20178709_3_Ent0", "role": "Subject", "text": "a rare case", "start": 3, "end": 6}, {"entity_id": "20178709_3_Ent1", "role": "Effect", "text": "pleuropericarditis", "start": 7, "end": 8}, {"entity_id": "20178709_3_Ent2", "role": "Treatment", "text": "methotrexate", "start": 10, "end": 11}, {"entity_id": "20178709_3_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "20178709_3_Ent0", "text": "a rare case", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "20178709_3_Ent1", "text": "pleuropericarditis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "20178709_3_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "20178709_3_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "20190474_1", "wnd_id": "20190474_1_1", "text": "Acute kidney injury caused by zonisamide - induced hypersensitivity syndrome .", "tokens": ["Acute", "kidney", "injury", "caused", "by", "zonisamide", "-", "induced", "hypersensitivity", "syndrome", "."], "event_mentions": [{"id": "20190474_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "20190474_1_Ent1", "role": "Treatment", "text": "zonisamide", "start": 5, "end": 6}, {"entity_id": "20190474_1_Ent2", "role": "Treatment_Drug", "text": "zonisamide", "start": 5, "end": 6}, {"entity_id": "20190474_1_Ent0", "role": "Effect", "text": "hypersensitivity syndrome", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "20190474_1_Ent1", "text": "zonisamide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20190474_1_Ent2", "text": "zonisamide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20190474_1_Ent0", "text": "hypersensitivity syndrome", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "2022118_1", "wnd_id": "2022118_1_1", "text": "However , the use of lithium should be avoided with any patient who is purging , since it may exacerbate the loss of intracellular potassium , thereby increasing the risk of cardiac toxicity .", "tokens": ["However", ",", "the", "use", "of", "lithium", "should", "be", "avoided", "with", "any", "patient", "who", "is", "purging", ",", "since", "it", "may", "exacerbate", "the", "loss", "of", "intracellular", "potassium", ",", "thereby", "increasing", "the", "risk", "of", "cardiac", "toxicity", "."], "event_mentions": [{"id": "2022118_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exacerbate", "start": 19, "end": 20}, "arguments": [{"entity_id": "2022118_1_Ent3", "role": "Treatment", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "2022118_1_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "2022118_1_Ent0", "role": "Subject", "text": "patient who is purging", "start": 11, "end": 15}, {"entity_id": "2022118_1_Ent1", "role": "Effect", "text": "loss of intracellular potassium", "start": 21, "end": 25}, {"entity_id": "2022118_1_Ent2", "role": "Effect", "text": "increasing the risk of cardiac toxicity", "start": 27, "end": 33}]}], "entity_mentions": [{"id": "2022118_1_Ent3", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2022118_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2022118_1_Ent0", "text": "patient who is purging", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "2022118_1_Ent1", "text": "loss of intracellular potassium", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "2022118_1_Ent2", "text": "increasing the risk of cardiac toxicity", "entity_type": "Entity", "start": 27, "end": 33}], "lang": "en"}
{"doc_id": "2028358_2", "wnd_id": "2028358_2_1", "text": "Pulmonary oedema after hexoprenaline administration in preterm labour .", "tokens": ["Pulmonary", "oedema", "after", "hexoprenaline", "administration", "in", "preterm", "labour", "."], "event_mentions": [{"id": "2028358_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "2028358_2_Ent0", "role": "Effect", "text": "Pulmonary oedema", "start": 0, "end": 2}, {"entity_id": "2028358_2_Ent1", "role": "Treatment", "text": "hexoprenaline", "start": 3, "end": 4}, {"entity_id": "2028358_2_Ent3", "role": "Treatment_Drug", "text": "hexoprenaline", "start": 3, "end": 4}, {"entity_id": "2028358_2_Ent2", "role": "Treatment_Disorder", "text": "preterm labour", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "2028358_2_Ent0", "text": "Pulmonary oedema", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2028358_2_Ent1", "text": "hexoprenaline", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2028358_2_Ent3", "text": "hexoprenaline", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2028358_2_Ent2", "text": "preterm labour", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "20298401_1", "wnd_id": "20298401_1_1", "text": "Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis .", "tokens": ["Fatal", "interstitial", "lung", "disease", "after", "erlotinib", "administration", "in", "a", "patient", "with", "radiation", "fibrosis", "."], "event_mentions": [{"id": "20298401_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "20298401_1_Ent2", "role": "Effect", "text": "interstitial lung disease", "start": 1, "end": 4}, {"entity_id": "20298401_1_Ent3", "role": "Treatment", "text": "erlotinib", "start": 5, "end": 6}, {"entity_id": "20298401_1_Ent4", "role": "Treatment_Drug", "text": "erlotinib", "start": 5, "end": 6}, {"entity_id": "20298401_1_Ent0", "role": "Subject", "text": "a patient with radiation fibrosis", "start": 8, "end": 13}, {"entity_id": "20298401_1_Ent1", "role": "Subject_Disorder", "text": "radiation fibrosis", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "20298401_1_Ent2", "text": "interstitial lung disease", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "20298401_1_Ent3", "text": "erlotinib", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20298401_1_Ent4", "text": "erlotinib", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20298401_1_Ent0", "text": "a patient with radiation fibrosis", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "20298401_1_Ent1", "text": "radiation fibrosis", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "20298401_11", "wnd_id": "20298401_11_1", "text": "This case had radiation fibrosis , so we suggest that radiation fibrosis may be another contributor of the occurrence of ILD in patients taking erlotinib .", "tokens": ["This", "case", "had", "radiation", "fibrosis", ",", "so", "we", "suggest", "that", "radiation", "fibrosis", "may", "be", "another", "contributor", "of", "the", "occurrence", "of", "ILD", "in", "patients", "taking", "erlotinib", "."], "event_mentions": [{"id": "20298401_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 16, "end": 17}, "arguments": [{"entity_id": "20298401_11_Ent1", "role": "Effect", "text": "occurrence of ILD", "start": 18, "end": 21}, {"entity_id": "20298401_11_Ent0", "role": "Subject", "text": "patients", "start": 22, "end": 23}, {"entity_id": "20298401_11_Ent2", "role": "Treatment", "text": "taking erlotinib", "start": 23, "end": 25}, {"entity_id": "20298401_11_Ent3", "role": "Treatment_Drug", "text": "erlotinib", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "20298401_11_Ent1", "text": "occurrence of ILD", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "20298401_11_Ent0", "text": "patients", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "20298401_11_Ent2", "text": "taking erlotinib", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "20298401_11_Ent3", "text": "erlotinib", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "20378385_1", "wnd_id": "20378385_1_1", "text": "OBJECTIVE : 1 ) To describe a patient with rheumatoid arthritis receiving adalimumab who developed fever , pancytopenia , splenomegaly , and extreme hyperferritinemia .", "tokens": ["OBJECTIVE", ":", "1", ")", "To", "describe", "a", "patient", "with", "rheumatoid", "arthritis", "receiving", "adalimumab", "who", "developed", "fever", ",", "pancytopenia", ",", "splenomegaly", ",", "and", "extreme", "hyperferritinemia", "."], "event_mentions": [{"id": "20378385_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "20378385_1_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 6, "end": 11}, {"entity_id": "20378385_1_Ent1", "role": "Subject_Disorder", "text": "rheumatoid arthritis", "start": 9, "end": 11}, {"entity_id": "20378385_1_Ent3", "role": "Treatment", "text": "adalimumab", "start": 12, "end": 13}, {"entity_id": "20378385_1_Ent4", "role": "Treatment_Drug", "text": "adalimumab", "start": 12, "end": 13}, {"entity_id": "20378385_1_Ent2", "role": "Effect", "text": "fever , pancytopenia , splenomegaly , and extreme hyperferritinemia", "start": 15, "end": 24}]}], "entity_mentions": [{"id": "20378385_1_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "20378385_1_Ent1", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "20378385_1_Ent3", "text": "adalimumab", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "20378385_1_Ent4", "text": "adalimumab", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "20378385_1_Ent2", "text": "fever , pancytopenia , splenomegaly , and extreme hyperferritinemia", "entity_type": "Entity", "start": 15, "end": 24}], "lang": "en"}
{"doc_id": "2042691_1", "wnd_id": "2042691_1_1", "text": "Amiodarone was discontinued , and thyrotoxicosis gradually abated .", "tokens": ["Amiodarone", "was", "discontinued", ",", "and", "thyrotoxicosis", "gradually", "abated", "."], "event_mentions": [{"id": "2042691_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "was discontinued", "start": 1, "end": 3}, "arguments": [{"entity_id": "2042691_1_Ent1", "role": "Treatment", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "2042691_1_Ent2", "role": "Treatment_Drug", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "2042691_1_Ent0", "role": "Effect", "text": "thyrotoxicosis gradually abated", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "2042691_1_Ent1", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2042691_1_Ent2", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2042691_1_Ent0", "text": "thyrotoxicosis gradually abated", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "20465622_1", "wnd_id": "20465622_1_1", "text": "Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors .", "tokens": ["Severe", "aphthous", "stomatitis", "associated", "with", "oral", "calcineurin", "and", "mTOR", "inhibitors", "."], "event_mentions": [{"id": "20465622_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "20465622_1_Ent0", "role": "Effect", "text": "Severe aphthous stomatitis", "start": 0, "end": 3}, {"entity_id": "20465622_1_Ent2", "role": "Treatment_Route", "text": "oral", "start": 5, "end": 6}, {"entity_id": "20465622_1_Ent1", "role": "Treatment", "text": "oral calcineurin and mTOR inhibitors", "start": 5, "end": 10}, {"entity_id": "20465622_1_Ent4", "role": "Treatment_Drug", "text": "calcineurin", "start": 6, "end": 7}, {"entity_id": "20465622_1_Ent5", "role": "Combination_Drug", "text": "calcineurin", "start": 6, "end": 7}, {"entity_id": "20465622_1_Ent3", "role": "Treatment_Drug", "text": "mTOR inhibitors", "start": 8, "end": 10}, {"entity_id": "20465622_1_Ent6", "role": "Combination_Drug", "text": "mTOR inhibitors", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "20465622_1_Ent0", "text": "Severe aphthous stomatitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "20465622_1_Ent2", "text": "oral", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "20465622_1_Ent1", "text": "oral calcineurin and mTOR inhibitors", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "20465622_1_Ent4", "text": "calcineurin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "20465622_1_Ent5", "text": "calcineurin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "20465622_1_Ent3", "text": "mTOR inhibitors", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "20465622_1_Ent6", "text": "mTOR inhibitors", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "2051906_3", "wnd_id": "2051906_3_1", "text": "Reversible cholestasis with bile duct injury following azathioprine therapy .", "tokens": ["Reversible", "cholestasis", "with", "bile", "duct", "injury", "following", "azathioprine", "therapy", "."], "event_mentions": [{"id": "2051906_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "2051906_3_Ent0", "role": "Effect", "text": "Reversible cholestasis with bile duct injury", "start": 0, "end": 6}, {"entity_id": "2051906_3_Ent1", "role": "Treatment", "text": "azathioprine", "start": 7, "end": 8}, {"entity_id": "2051906_3_Ent2", "role": "Treatment_Drug", "text": "azathioprine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "2051906_3_Ent0", "text": "Reversible cholestasis with bile duct injury", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "2051906_3_Ent1", "text": "azathioprine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2051906_3_Ent2", "text": "azathioprine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "20628041_1", "wnd_id": "20628041_1_1", "text": "An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant - like syndrome and prolonged ICU stay .", "tokens": ["An", "interaction", "between", "levodopa", "and", "enteral", "nutrition", "resulting", "in", "neuroleptic", "malignant", "-", "like", "syndrome", "and", "prolonged", "ICU", "stay", "."], "event_mentions": [{"id": "20628041_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 7, "end": 8}, "arguments": [{"entity_id": "20628041_1_Ent2", "role": "Treatment_Drug", "text": "levodopa", "start": 3, "end": 4}, {"entity_id": "20628041_1_Ent1", "role": "Treatment", "text": "levodopa and enteral nutrition", "start": 3, "end": 7}, {"entity_id": "20628041_1_Ent0", "role": "Effect", "text": "neuroleptic malignant - like syndrome and prolonged ICU stay", "start": 9, "end": 18}]}], "entity_mentions": [{"id": "20628041_1_Ent2", "text": "levodopa", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20628041_1_Ent1", "text": "levodopa and enteral nutrition", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "20628041_1_Ent0", "text": "neuroleptic malignant - like syndrome and prolonged ICU stay", "entity_type": "Entity", "start": 9, "end": 18}], "lang": "en"}
{"doc_id": "20666169_9", "wnd_id": "20666169_9_1", "text": "We presume the cause for multiple organ failure could be the result of drug - drug interaction , atorvastatin and verapamil , as verapamil is known to increase the serum concentration of atorvastatin significantly .", "tokens": ["We", "presume", "the", "cause", "for", "multiple", "organ", "failure", "could", "be", "the", "result", "of", "drug", "-", "drug", "interaction", ",", "atorvastatin", "and", "verapamil", ",", "as", "verapamil", "is", "known", "to", "increase", "the", "serum", "concentration", "of", "atorvastatin", "significantly", "."], "event_mentions": [{"id": "20666169_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "20666169_9_Ent0", "role": "Effect", "text": "multiple organ failure", "start": 5, "end": 8}, {"entity_id": "20666169_9_Ent1", "role": "Treatment", "text": "interaction , atorvastatin and verapamil", "start": 16, "end": 21}, {"entity_id": "20666169_9_Ent2", "role": "Treatment_Drug", "text": "atorvastatin", "start": 18, "end": 19}, {"entity_id": "20666169_9_Ent4", "role": "Combination_Drug", "text": "atorvastatin", "start": 18, "end": 19}, {"entity_id": "20666169_9_Ent3", "role": "Treatment_Drug", "text": "verapamil", "start": 20, "end": 21}, {"entity_id": "20666169_9_Ent5", "role": "Combination_Drug", "text": "verapamil", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "20666169_9_Ent0", "text": "multiple organ failure", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "20666169_9_Ent1", "text": "interaction , atorvastatin and verapamil", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "20666169_9_Ent2", "text": "atorvastatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20666169_9_Ent4", "text": "atorvastatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20666169_9_Ent3", "text": "verapamil", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "20666169_9_Ent5", "text": "verapamil", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "20925534_10", "wnd_id": "20925534_10_1", "text": "In all , 51 patients had a gastrointestinal event ; the event rate was 1.1 % with omeprazole and 2.9 % with placebo at 180 days ( hazard ratio with omeprazole , 0.34 , 95 % confidence interval [ CI ] , 0.18 to 0.63 ; P<0.001 ) .", "tokens": ["In", "all", ",", "51", "patients", "had", "a", "gastrointestinal", "event", ";", "the", "event", "rate", "was", "1.1", "%", "with", "omeprazole", "and", "2.9", "%", "with", "placebo", "at", "180", "days", "(", "hazard", "ratio", "with", "omeprazole", ",", "0.34", ",", "95", "%", "confidence", "interval", "[", "CI", "]", ",", "0.18", "to", "0.63", ";", "P<0.001", ")", "."], "event_mentions": [{"id": "20925534_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 5, "end": 6}, "arguments": [{"entity_id": "20925534_10_Ent1", "role": "Subject_Population", "text": "51", "start": 3, "end": 4}, {"entity_id": "20925534_10_Ent0", "role": "Subject", "text": "51 patients", "start": 3, "end": 5}, {"entity_id": "20925534_10_Ent2", "role": "Effect", "text": "gastrointestinal event", "start": 7, "end": 9}, {"entity_id": "20925534_10_Ent3", "role": "Treatment", "text": "1.1 % with omeprazole and 2.9 % with placebo", "start": 14, "end": 23}, {"entity_id": "20925534_10_Ent4", "role": "Treatment_Drug", "text": "omeprazole", "start": 17, "end": 18}, {"entity_id": "20925534_10_Ent5", "role": "Treatment_Drug", "text": "placebo", "start": 22, "end": 23}, {"entity_id": "20925534_10_Ent6", "role": "Treatment_Time_elapsed", "text": "180 days", "start": 24, "end": 26}]}], "entity_mentions": [{"id": "20925534_10_Ent1", "text": "51", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20925534_10_Ent0", "text": "51 patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "20925534_10_Ent2", "text": "gastrointestinal event", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "20925534_10_Ent3", "text": "1.1 % with omeprazole and 2.9 % with placebo", "entity_type": "Entity", "start": 14, "end": 23}, {"id": "20925534_10_Ent4", "text": "omeprazole", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "20925534_10_Ent5", "text": "placebo", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "20925534_10_Ent6", "text": "180 days", "entity_type": "Entity", "start": 24, "end": 26}], "lang": "en"}
{"doc_id": "20925534_15", "wnd_id": "20925534_15_1", "text": "There was no apparent cardiovascular interaction between clopidogrel and omeprazole , but our results do not rule out a clinically meaningful difference in cardiovascular events due to use of a PPI .", "tokens": ["There", "was", "no", "apparent", "cardiovascular", "interaction", "between", "clopidogrel", "and", "omeprazole", ",", "but", "our", "results", "do", "not", "rule", "out", "a", "clinically", "meaningful", "difference", "in", "cardiovascular", "events", "due", "to", "use", "of", "a", "PPI", "."], "event_mentions": [{"id": "20925534_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 25, "end": 26}, "arguments": [{"entity_id": "20925534_15_Ent0", "role": "Effect", "text": "cardiovascular", "start": 23, "end": 24}, {"entity_id": "20925534_15_Ent1", "role": "Treatment", "text": "PPI", "start": 30, "end": 31}, {"entity_id": "20925534_15_Ent2", "role": "Treatment_Drug", "text": "PPI", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "20925534_15_Ent0", "text": "cardiovascular", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "20925534_15_Ent1", "text": "PPI", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "20925534_15_Ent2", "text": "PPI", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "20925534_3", "wnd_id": "20925534_3_1", "text": "Proton - pump inhibitors ( PPIs ) are believed to decrease the risk of such complications , though no randomized trial has proved this in patients receiving dual antiplatelet therapy .", "tokens": ["Proton", "-", "pump", "inhibitors", "(", "PPIs", ")", "are", "believed", "to", "decrease", "the", "risk", "of", "such", "complications", ",", "though", "no", "randomized", "trial", "has", "proved", "this", "in", "patients", "receiving", "dual", "antiplatelet", "therapy", "."], "event_mentions": [{"id": "20925534_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "believed", "start": 8, "end": 9}, "arguments": [{"entity_id": "20925534_3_Ent0", "role": "Treatment", "text": "Proton - pump inhibitors ( PPIs )", "start": 0, "end": 7}, {"entity_id": "20925534_3_Ent1", "role": "Treatment_Drug", "text": "Proton - pump inhibitors ( PPIs )", "start": 0, "end": 7}, {"entity_id": "20925534_3_Ent2", "role": "Treatment_Drug", "text": "antiplatelet", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "20925534_3_Ent0", "text": "Proton - pump inhibitors ( PPIs )", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "20925534_3_Ent1", "text": "Proton - pump inhibitors ( PPIs )", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "20925534_3_Ent2", "text": "antiplatelet", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "21045170_3", "wnd_id": "21045170_3_1", "text": "A 47 - year - old HIV - infected man with dilated cardiomyopathy and prolonged QT syndrome with an automatic implantable cardiovascular defibrillator device was prescribed subcutaneous enfuvirtide 90 mg twice daily as part of his antiretroviral regimen and oral extended - release niacin 500 mg / day for a high - density lipoprotein level of 8 mg / dL. After 1 week of concomitant therapy , the patient began experiencing extreme redness , edema , and swelling at the injection site that corresponded with the flushing sensation due to niacin .", "tokens": ["A", "47", "-", "year", "-", "old", "HIV", "-", "infected", "man", "with", "dilated", "cardiomyopathy", "and", "prolonged", "QT", "syndrome", "with", "an", "automatic", "implantable", "cardiovascular", "defibrillator", "device", "was", "prescribed", "subcutaneous", "enfuvirtide", "90", "mg", "twice", "daily", "as", "part", "of", "his", "antiretroviral", "regimen", "and", "oral", "extended", "-", "release", "niacin", "500", "mg", "/", "day", "for", "a", "high", "-", "density", "lipoprotein", "level", "of", "8", "mg", "/", "dL.", "After", "1", "week", "of", "concomitant", "therapy", ",", "the", "patient", "began", "experiencing", "extreme", "redness", ",", "edema", ",", "and", "swelling", "at", "the", "injection", "site", "that", "corresponded", "with", "the", "flushing", "sensation", "due", "to", "niacin", "."], "event_mentions": [{"id": "21045170_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experiencing", "start": 70, "end": 71}, "arguments": [{"entity_id": "21045170_3_Ent0", "role": "Subject", "text": "A 47 - year - old HIV - infected man with dilated cardiomyopathy and prolonged QT syndrome with an automatic implantable cardiovascular defibrillator device", "start": 0, "end": 24}, {"entity_id": "21045170_3_Ent3", "role": "Subject_Age", "text": "47 - year - old", "start": 1, "end": 6}, {"entity_id": "21045170_3_Ent7", "role": "Treatment_Disorder", "text": "HIV - infected", "start": 6, "end": 9}, {"entity_id": "21045170_3_Ent4", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "21045170_3_Ent1", "role": "Subject_Disorder", "text": "dilated cardiomyopathy", "start": 11, "end": 13}, {"entity_id": "21045170_3_Ent2", "role": "Subject_Disorder", "text": "prolonged QT syndrome", "start": 14, "end": 17}, {"entity_id": "21045170_3_Ent14", "role": "Treatment_Route", "text": "subcutaneous", "start": 26, "end": 27}, {"entity_id": "21045170_3_Ent6", "role": "Treatment", "text": "subcutaneous enfuvirtide 90 mg twice daily as part of his antiretroviral regimen and oral extended - release niacin 500 mg / day for a high - density lipoprotein level of 8 mg / dL.", "start": 26, "end": 60}, {"entity_id": "21045170_3_Ent12", "role": "Treatment_Drug", "text": "enfuvirtide", "start": 27, "end": 28}, {"entity_id": "21045170_3_Ent18", "role": "Combination_Drug", "text": "enfuvirtide", "start": 27, "end": 28}, {"entity_id": "21045170_3_Ent8", "role": "Treatment_Dosage", "text": "90 mg", "start": 28, "end": 30}, {"entity_id": "21045170_3_Ent10", "role": "Treatment_Freq", "text": "twice daily", "start": 30, "end": 32}, {"entity_id": "21045170_3_Ent15", "role": "Treatment_Route", "text": "oral", "start": 39, "end": 40}, {"entity_id": "21045170_3_Ent13", "role": "Treatment_Drug", "text": "niacin", "start": 43, "end": 44}, {"entity_id": "21045170_3_Ent17", "role": "Combination_Drug", "text": "niacin", "start": 43, "end": 44}, {"entity_id": "21045170_3_Ent9", "role": "Treatment_Dosage", "text": "500 mg", "start": 44, "end": 46}, {"entity_id": "21045170_3_Ent11", "role": "Treatment_Freq", "text": "day", "start": 47, "end": 48}, {"entity_id": "21045170_3_Ent16", "role": "Treatment_Time_elapsed", "text": "1 week", "start": 61, "end": 63}, {"entity_id": "21045170_3_Ent5", "role": "Effect", "text": "extreme redness , edema , and swelling at the injection site that corresponded with the flushing sensation due to niacin", "start": 71, "end": 91}]}], "entity_mentions": [{"id": "21045170_3_Ent0", "text": "A 47 - year - old HIV - infected man with dilated cardiomyopathy and prolonged QT syndrome with an automatic implantable cardiovascular defibrillator device", "entity_type": "Entity", "start": 0, "end": 24}, {"id": "21045170_3_Ent3", "text": "47 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "21045170_3_Ent7", "text": "HIV - infected", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "21045170_3_Ent4", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "21045170_3_Ent1", "text": "dilated cardiomyopathy", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "21045170_3_Ent2", "text": "prolonged QT syndrome", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "21045170_3_Ent14", "text": "subcutaneous", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "21045170_3_Ent6", "text": "subcutaneous enfuvirtide 90 mg twice daily as part of his antiretroviral regimen and oral extended - release niacin 500 mg / day for a high - density lipoprotein level of 8 mg / dL.", "entity_type": "Entity", "start": 26, "end": 60}, {"id": "21045170_3_Ent12", "text": "enfuvirtide", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "21045170_3_Ent18", "text": "enfuvirtide", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "21045170_3_Ent8", "text": "90 mg", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "21045170_3_Ent10", "text": "twice daily", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "21045170_3_Ent15", "text": "oral", "entity_type": "Entity", "start": 39, "end": 40}, {"id": "21045170_3_Ent13", "text": "niacin", "entity_type": "Entity", "start": 43, "end": 44}, {"id": "21045170_3_Ent17", "text": "niacin", "entity_type": "Entity", "start": 43, "end": 44}, {"id": "21045170_3_Ent9", "text": "500 mg", "entity_type": "Entity", "start": 44, "end": 46}, {"id": "21045170_3_Ent11", "text": "day", "entity_type": "Entity", "start": 47, "end": 48}, {"id": "21045170_3_Ent16", "text": "1 week", "entity_type": "Entity", "start": 61, "end": 63}, {"id": "21045170_3_Ent5", "text": "extreme redness , edema , and swelling at the injection site that corresponded with the flushing sensation due to niacin", "entity_type": "Entity", "start": 71, "end": 91}], "lang": "en"}
{"doc_id": "21104646_1", "wnd_id": "21104646_1_1", "text": "Abnormal dexamethasone suppression tests in a rifampicin - treated patient with suspected Cushing 's syndrome .", "tokens": ["Abnormal", "dexamethasone", "suppression", "tests", "in", "a", "rifampicin", "-", "treated", "patient", "with", "suspected", "Cushing", "'s", "syndrome", "."], "event_mentions": [{"id": "21104646_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Abnormal", "start": 0, "end": 1}, "arguments": [{"entity_id": "21104646_1_Ent1", "role": "Effect", "text": "Abnormal dexamethasone suppression tests", "start": 0, "end": 4}, {"entity_id": "21104646_1_Ent2", "role": "Treatment", "text": "rifampicin", "start": 6, "end": 7}, {"entity_id": "21104646_1_Ent4", "role": "Treatment_Drug", "text": "rifampicin", "start": 6, "end": 7}, {"entity_id": "21104646_1_Ent0", "role": "Subject", "text": "patient with suspected Cushing 's syndrome", "start": 9, "end": 15}, {"entity_id": "21104646_1_Ent3", "role": "Treatment_Disorder", "text": "Cushing 's syndrome", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "21104646_1_Ent1", "text": "Abnormal dexamethasone suppression tests", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "21104646_1_Ent2", "text": "rifampicin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21104646_1_Ent4", "text": "rifampicin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21104646_1_Ent0", "text": "patient with suspected Cushing 's syndrome", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "21104646_1_Ent3", "text": "Cushing 's syndrome", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "21350204_12", "wnd_id": "21350204_12_1", "text": "The results from the present study suggest that tissue plasminogen activator treatment appears to be safe in patients with acute ischemic stroke taking warfarin with an international normalized ratio < 1.7 and may reduce the risk of poor functional outcome .", "tokens": ["The", "results", "from", "the", "present", "study", "suggest", "that", "tissue", "plasminogen", "activator", "treatment", "appears", "to", "be", "safe", "in", "patients", "with", "acute", "ischemic", "stroke", "taking", "warfarin", "with", "an", "international", "normalized", "ratio", "<", "1.7", "and", "may", "reduce", "the", "risk", "of", "poor", "functional", "outcome", "."], "event_mentions": [{"id": "21350204_12_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "appears", "start": 12, "end": 13}, "arguments": [{"entity_id": "21350204_12_Ent5", "role": "Treatment_Drug", "text": "tissue plasminogen activator", "start": 8, "end": 11}, {"entity_id": "21350204_12_Ent7", "role": "Combination_Drug", "text": "tissue plasminogen activator", "start": 8, "end": 11}, {"entity_id": "21350204_12_Ent3", "role": "Treatment", "text": "tissue plasminogen activator treatment", "start": 8, "end": 12}, {"entity_id": "21350204_12_Ent0", "role": "Subject", "text": "patients with acute ischemic stroke", "start": 17, "end": 22}, {"entity_id": "21350204_12_Ent4", "role": "Treatment_Disorder", "text": "acute ischemic stroke", "start": 19, "end": 22}, {"entity_id": "21350204_12_Ent2", "role": "Treatment", "text": "taking warfarin with an international normalized ratio < 1.7", "start": 22, "end": 31}, {"entity_id": "21350204_12_Ent6", "role": "Treatment_Drug", "text": "warfarin", "start": 23, "end": 24}, {"entity_id": "21350204_12_Ent8", "role": "Combination_Drug", "text": "warfarin", "start": 23, "end": 24}, {"entity_id": "21350204_12_Ent1", "role": "Effect", "text": "may reduce the risk of poor functional outcome", "start": 32, "end": 40}]}], "entity_mentions": [{"id": "21350204_12_Ent5", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "21350204_12_Ent7", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "21350204_12_Ent3", "text": "tissue plasminogen activator treatment", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "21350204_12_Ent0", "text": "patients with acute ischemic stroke", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "21350204_12_Ent4", "text": "acute ischemic stroke", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "21350204_12_Ent2", "text": "taking warfarin with an international normalized ratio < 1.7", "entity_type": "Entity", "start": 22, "end": 31}, {"id": "21350204_12_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "21350204_12_Ent8", "text": "warfarin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "21350204_12_Ent1", "text": "may reduce the risk of poor functional outcome", "entity_type": "Entity", "start": 32, "end": 40}], "lang": "en"}
{"doc_id": "21417793_10", "wnd_id": "21417793_10_1", "text": "Severe symptoms associated with serotonin toxicity were shown to be uncommon in patients receiving linezolid and selected serotonin reuptake inhibitors .", "tokens": ["Severe", "symptoms", "associated", "with", "serotonin", "toxicity", "were", "shown", "to", "be", "uncommon", "in", "patients", "receiving", "linezolid", "and", "selected", "serotonin", "reuptake", "inhibitors", "."], "event_mentions": [{"id": "21417793_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 13, "end": 14}, "arguments": [{"entity_id": "21417793_10_Ent1", "role": "Effect", "text": "Severe symptoms associated with serotonin toxicity", "start": 0, "end": 6}, {"entity_id": "21417793_10_Ent3", "role": "Treatment_Drug", "text": "serotonin", "start": 4, "end": 5}, {"entity_id": "21417793_10_Ent0", "role": "Subject", "text": "patients", "start": 12, "end": 13}, {"entity_id": "21417793_10_Ent4", "role": "Treatment_Drug", "text": "linezolid", "start": 14, "end": 15}, {"entity_id": "21417793_10_Ent6", "role": "Combination_Drug", "text": "linezolid", "start": 14, "end": 15}, {"entity_id": "21417793_10_Ent2", "role": "Treatment", "text": "linezolid and selected serotonin reuptake inhibitors", "start": 14, "end": 20}, {"entity_id": "21417793_10_Ent5", "role": "Treatment_Drug", "text": "serotonin reuptake inhibitors", "start": 17, "end": 20}, {"entity_id": "21417793_10_Ent7", "role": "Combination_Drug", "text": "serotonin reuptake inhibitors", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "21417793_10_Ent1", "text": "Severe symptoms associated with serotonin toxicity", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "21417793_10_Ent3", "text": "serotonin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "21417793_10_Ent0", "text": "patients", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "21417793_10_Ent4", "text": "linezolid", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "21417793_10_Ent6", "text": "linezolid", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "21417793_10_Ent2", "text": "linezolid and selected serotonin reuptake inhibitors", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "21417793_10_Ent5", "text": "serotonin reuptake inhibitors", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "21417793_10_Ent7", "text": "serotonin reuptake inhibitors", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "21512888_7", "wnd_id": "21512888_7_1", "text": "Patient was on warfarin for a prior deep venous thrombosis .", "tokens": ["Patient", "was", "on", "warfarin", "for", "a", "prior", "deep", "venous", "thrombosis", "."], "event_mentions": [{"id": "21512888_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 4, "end": 5}, "arguments": [{"entity_id": "21512888_7_Ent0", "role": "Treatment", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "21512888_7_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "21512888_7_Ent1", "role": "Treatment_Disorder", "text": "a prior deep venous thrombosis", "start": 5, "end": 10}]}], "entity_mentions": [{"id": "21512888_7_Ent0", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21512888_7_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21512888_7_Ent1", "text": "a prior deep venous thrombosis", "entity_type": "Entity", "start": 5, "end": 10}], "lang": "en"}
{"doc_id": "21512888_8", "wnd_id": "21512888_8_1", "text": "After treatment with levetiracetam , seizures recurred and intravenous loading with valproic acid was administered , but resulted in a rapid increase in international normalized ratio ( INR ) to 7.6 .", "tokens": ["After", "treatment", "with", "levetiracetam", ",", "seizures", "recurred", "and", "intravenous", "loading", "with", "valproic", "acid", "was", "administered", ",", "but", "resulted", "in", "a", "rapid", "increase", "in", "international", "normalized", "ratio", "(", "INR", ")", "to", "7.6", "."], "event_mentions": [{"id": "21512888_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "recurred", "start": 6, "end": 7}, "arguments": [{"entity_id": "21512888_8_Ent1", "role": "Treatment", "text": "levetiracetam", "start": 3, "end": 4}, {"entity_id": "21512888_8_Ent2", "role": "Treatment_Drug", "text": "levetiracetam", "start": 3, "end": 4}, {"entity_id": "21512888_8_Ent0", "role": "Effect", "text": "seizures", "start": 5, "end": 6}]}, {"id": "21512888_8_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "administered", "start": 14, "end": 15}, "arguments": [{"entity_id": "21512888_8_Ent4", "role": "Treatment_Disorder", "text": "seizures", "start": 5, "end": 6}, {"entity_id": "21512888_8_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 8, "end": 9}, {"entity_id": "21512888_8_Ent3", "role": "Treatment", "text": "intravenous loading with valproic acid", "start": 8, "end": 13}, {"entity_id": "21512888_8_Ent6", "role": "Treatment_Drug", "text": "valproic acid", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "21512888_8_Ent1", "text": "levetiracetam", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21512888_8_Ent2", "text": "levetiracetam", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21512888_8_Ent0", "text": "seizures", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "21512888_8_Ent4", "text": "seizures", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "21512888_8_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "21512888_8_Ent3", "text": "intravenous loading with valproic acid", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "21512888_8_Ent6", "text": "valproic acid", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "21515865_1", "wnd_id": "21515865_1_1", "text": "Moxifloxacin - acetaminophen - warfarin interaction during bacille Calmette - Guerin treatment for bladder cancer .", "tokens": ["Moxifloxacin", "-", "acetaminophen", "-", "warfarin", "interaction", "during", "bacille", "Calmette", "-", "Guerin", "treatment", "for", "bladder", "cancer", "."], "event_mentions": [{"id": "21515865_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 6, "end": 7}, "arguments": [{"entity_id": "21515865_1_Ent2", "role": "Treatment_Drug", "text": "Moxifloxacin", "start": 0, "end": 1}, {"entity_id": "21515865_1_Ent9", "role": "Combination_Drug", "text": "Moxifloxacin", "start": 0, "end": 1}, {"entity_id": "21515865_1_Ent0", "role": "Treatment", "text": "Moxifloxacin - acetaminophen - warfarin interaction", "start": 0, "end": 6}, {"entity_id": "21515865_1_Ent3", "role": "Treatment_Drug", "text": "acetaminophen", "start": 2, "end": 3}, {"entity_id": "21515865_1_Ent8", "role": "Combination_Drug", "text": "acetaminophen", "start": 2, "end": 3}, {"entity_id": "21515865_1_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 4, "end": 5}, {"entity_id": "21515865_1_Ent7", "role": "Combination_Drug", "text": "warfarin", "start": 4, "end": 5}, {"entity_id": "21515865_1_Ent5", "role": "Treatment_Drug", "text": "bacille Calmette - Guerin", "start": 7, "end": 11}, {"entity_id": "21515865_1_Ent10", "role": "Combination_Drug", "text": "bacille Calmette - Guerin", "start": 7, "end": 11}, {"entity_id": "21515865_1_Ent1", "role": "Treatment", "text": "bacille Calmette - Guerin treatment", "start": 7, "end": 12}, {"entity_id": "21515865_1_Ent6", "role": "Treatment_Disorder", "text": "bladder cancer", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "21515865_1_Ent2", "text": "Moxifloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21515865_1_Ent9", "text": "Moxifloxacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21515865_1_Ent0", "text": "Moxifloxacin - acetaminophen - warfarin interaction", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "21515865_1_Ent3", "text": "acetaminophen", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "21515865_1_Ent8", "text": "acetaminophen", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "21515865_1_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "21515865_1_Ent7", "text": "warfarin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "21515865_1_Ent5", "text": "bacille Calmette - Guerin", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "21515865_1_Ent10", "text": "bacille Calmette - Guerin", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "21515865_1_Ent1", "text": "bacille Calmette - Guerin treatment", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "21515865_1_Ent6", "text": "bladder cancer", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "2161782_1", "wnd_id": "2161782_1_1", "text": "Data have been published regarding the possibility that tamoxifen may be responsible for the subsequent development of carcinoma of the corpus uteri in these patients .", "tokens": ["Data", "have", "been", "published", "regarding", "the", "possibility", "that", "tamoxifen", "may", "be", "responsible", "for", "the", "subsequent", "development", "of", "carcinoma", "of", "the", "corpus", "uteri", "in", "these", "patients", "."], "event_mentions": [{"id": "2161782_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 11, "end": 12}, "arguments": [{"entity_id": "2161782_1_Ent2", "role": "Treatment", "text": "tamoxifen", "start": 8, "end": 9}, {"entity_id": "2161782_1_Ent3", "role": "Treatment_Drug", "text": "tamoxifen", "start": 8, "end": 9}, {"entity_id": "2161782_1_Ent1", "role": "Effect", "text": "subsequent development of carcinoma of the corpus uteri", "start": 14, "end": 22}, {"entity_id": "2161782_1_Ent0", "role": "Subject", "text": "these patients", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "2161782_1_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2161782_1_Ent3", "text": "tamoxifen", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2161782_1_Ent1", "text": "subsequent development of carcinoma of the corpus uteri", "entity_type": "Entity", "start": 14, "end": 22}, {"id": "2161782_1_Ent0", "text": "these patients", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "21630612_1", "wnd_id": "21630612_1_1", "text": "Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis : a case report and review of the literature .", "tokens": ["Concomitant", "use", "of", "simvastatin", "and", "amiodarone", "resulting", "in", "severe", "rhabdomyolysis", ":", "a", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "21630612_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 6, "end": 7}, "arguments": [{"entity_id": "21630612_1_Ent2", "role": "Treatment", "text": "Concomitant use of simvastatin and amiodarone", "start": 0, "end": 6}, {"entity_id": "21630612_1_Ent3", "role": "Treatment_Drug", "text": "simvastatin", "start": 3, "end": 4}, {"entity_id": "21630612_1_Ent5", "role": "Combination_Drug", "text": "simvastatin", "start": 3, "end": 4}, {"entity_id": "21630612_1_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "21630612_1_Ent6", "role": "Combination_Drug", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "21630612_1_Ent1", "role": "Effect", "text": "rhabdomyolysis", "start": 9, "end": 10}, {"entity_id": "21630612_1_Ent0", "role": "Subject", "text": "a case", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "21630612_1_Ent2", "text": "Concomitant use of simvastatin and amiodarone", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "21630612_1_Ent3", "text": "simvastatin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21630612_1_Ent5", "text": "simvastatin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "21630612_1_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "21630612_1_Ent6", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "21630612_1_Ent1", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "21630612_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "21751542_4", "wnd_id": "21751542_4_1", "text": "Angiotensin converting enzyme blockers and their influence on the endothelial dysfunction , but the risk of hyperpotassemia are showed .", "tokens": ["Angiotensin", "converting", "enzyme", "blockers", "and", "their", "influence", "on", "the", "endothelial", "dysfunction", ",", "but", "the", "risk", "of", "hyperpotassemia", "are", "showed", "."], "event_mentions": [{"id": "21751542_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "showed", "start": 18, "end": 19}, "arguments": [{"entity_id": "21751542_4_Ent1", "role": "Treatment", "text": "Angiotensin converting enzyme blockers", "start": 0, "end": 4}, {"entity_id": "21751542_4_Ent2", "role": "Treatment_Drug", "text": "Angiotensin converting enzyme blockers", "start": 0, "end": 4}, {"entity_id": "21751542_4_Ent0", "role": "Effect", "text": "hyperpotassemia", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "21751542_4_Ent1", "text": "Angiotensin converting enzyme blockers", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "21751542_4_Ent2", "text": "Angiotensin converting enzyme blockers", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "21751542_4_Ent0", "text": "hyperpotassemia", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "21751666_1", "wnd_id": "21751666_1_1", "text": "Post - exposure prophylaxis for H1N1 with oseltamivir in renal allograft recipient -- safe and effective without any immunosuppresive drug interaction .", "tokens": ["Post", "-", "exposure", "prophylaxis", "for", "H1N1", "with", "oseltamivir", "in", "renal", "allograft", "recipient", "--", "safe", "and", "effective", "without", "any", "immunosuppresive", "drug", "interaction", "."], "event_mentions": [{"id": "21751666_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Post - exposure prophylaxis", "start": 0, "end": 4}, "arguments": [{"entity_id": "21751666_1_Ent4", "role": "Treatment_Disorder", "text": "H1N1", "start": 5, "end": 6}, {"entity_id": "21751666_1_Ent3", "role": "Treatment", "text": "oseltamivir", "start": 7, "end": 8}, {"entity_id": "21751666_1_Ent5", "role": "Treatment_Drug", "text": "oseltamivir", "start": 7, "end": 8}, {"entity_id": "21751666_1_Ent1", "role": "Subject_Disorder", "text": "renal allograft", "start": 9, "end": 11}, {"entity_id": "21751666_1_Ent0", "role": "Subject", "text": "renal allograft recipient", "start": 9, "end": 12}, {"entity_id": "21751666_1_Ent2", "role": "Effect", "text": "safe and effective without any immunosuppresive drug interaction", "start": 13, "end": 21}]}], "entity_mentions": [{"id": "21751666_1_Ent4", "text": "H1N1", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "21751666_1_Ent3", "text": "oseltamivir", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21751666_1_Ent5", "text": "oseltamivir", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21751666_1_Ent1", "text": "renal allograft", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "21751666_1_Ent0", "text": "renal allograft recipient", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "21751666_1_Ent2", "text": "safe and effective without any immunosuppresive drug interaction", "entity_type": "Entity", "start": 13, "end": 21}], "lang": "en"}
{"doc_id": "21751666_3", "wnd_id": "21751666_3_1", "text": "Prevention of infection by immunization , together with early recognition and prompt antiviral treatment are critical .", "tokens": ["Prevention", "of", "infection", "by", "immunization", ",", "together", "with", "early", "recognition", "and", "prompt", "antiviral", "treatment", "are", "critical", "."], "event_mentions": [{"id": "21751666_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Prevention", "start": 0, "end": 1}, "arguments": [{"entity_id": "21751666_3_Ent1", "role": "Treatment_Disorder", "text": "infection", "start": 2, "end": 3}, {"entity_id": "21751666_3_Ent0", "role": "Treatment", "text": "immunization , together with early recognition and prompt antiviral treatment", "start": 4, "end": 14}]}], "entity_mentions": [{"id": "21751666_3_Ent1", "text": "infection", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "21751666_3_Ent0", "text": "immunization , together with early recognition and prompt antiviral treatment", "entity_type": "Entity", "start": 4, "end": 14}], "lang": "en"}
{"doc_id": "21751692_4", "wnd_id": "21751692_4_1", "text": "EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low - dose ketamine was added to propofol .", "tokens": ["EA", "signs", "were", "observed", "in", "all", "7", "patients", "in", "association", "with", "propofol", "TIVA", "but", "did", "not", "recur", "in", "any", "of", "123", "subsequent", "anesthetics", "sessions", "during", "which", "low", "-", "dose", "ketamine", "was", "added", "to", "propofol", "."], "event_mentions": [{"id": "21751692_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 3, "end": 4}, "arguments": [{"entity_id": "21751692_4_Ent2", "role": "Effect", "text": "EA signs", "start": 0, "end": 2}, {"entity_id": "21751692_4_Ent0", "role": "Subject", "text": "all 7 patients", "start": 5, "end": 8}, {"entity_id": "21751692_4_Ent1", "role": "Subject_Population", "text": "7", "start": 6, "end": 7}, {"entity_id": "21751692_4_Ent5", "role": "Treatment_Drug", "text": "propofol", "start": 11, "end": 12}, {"entity_id": "21751692_4_Ent3", "role": "Treatment", "text": "propofol TIVA", "start": 11, "end": 13}, {"entity_id": "21751692_4_Ent8", "role": "Treatment_Route", "text": "TIVA", "start": 12, "end": 13}, {"entity_id": "21751692_4_Ent9", "role": "Treatment_Dosage", "text": "low - dose", "start": 26, "end": 29}, {"entity_id": "21751692_4_Ent4", "role": "Treatment", "text": "low - dose ketamine was added to propofol", "start": 26, "end": 34}, {"entity_id": "21751692_4_Ent6", "role": "Treatment_Drug", "text": "ketamine", "start": 29, "end": 30}, {"entity_id": "21751692_4_Ent11", "role": "Combination_Drug", "text": "ketamine", "start": 29, "end": 30}, {"entity_id": "21751692_4_Ent7", "role": "Treatment_Drug", "text": "propofol", "start": 33, "end": 34}, {"entity_id": "21751692_4_Ent10", "role": "Combination_Drug", "text": "propofol", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "21751692_4_Ent2", "text": "EA signs", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21751692_4_Ent0", "text": "all 7 patients", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "21751692_4_Ent1", "text": "7", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21751692_4_Ent5", "text": "propofol", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "21751692_4_Ent3", "text": "propofol TIVA", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "21751692_4_Ent8", "text": "TIVA", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "21751692_4_Ent9", "text": "low - dose", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "21751692_4_Ent4", "text": "low - dose ketamine was added to propofol", "entity_type": "Entity", "start": 26, "end": 34}, {"id": "21751692_4_Ent6", "text": "ketamine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "21751692_4_Ent11", "text": "ketamine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "21751692_4_Ent7", "text": "propofol", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "21751692_4_Ent10", "text": "propofol", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "21887897_2", "wnd_id": "21887897_2_1", "text": "A fatal poisoning case involving etizolam , phenobarbital , promethazine and chlorpromazine is presented .", "tokens": ["A", "fatal", "poisoning", "case", "involving", "etizolam", ",", "phenobarbital", ",", "promethazine", "and", "chlorpromazine", "is", "presented", "."], "event_mentions": [{"id": "21887897_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "involving", "start": 4, "end": 5}, "arguments": [{"entity_id": "21887897_2_Ent1", "role": "Effect", "text": "A fatal poisoning", "start": 0, "end": 3}, {"entity_id": "21887897_2_Ent0", "role": "Subject", "text": "A fatal poisoning case", "start": 0, "end": 4}, {"entity_id": "21887897_2_Ent3", "role": "Treatment_Drug", "text": "etizolam", "start": 5, "end": 6}, {"entity_id": "21887897_2_Ent2", "role": "Treatment", "text": "etizolam , phenobarbital , promethazine and chlorpromazine", "start": 5, "end": 12}, {"entity_id": "21887897_2_Ent4", "role": "Treatment_Drug", "text": "phenobarbital", "start": 7, "end": 8}, {"entity_id": "21887897_2_Ent5", "role": "Treatment_Drug", "text": "promethazine", "start": 9, "end": 10}, {"entity_id": "21887897_2_Ent6", "role": "Treatment_Drug", "text": "chlorpromazine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "21887897_2_Ent1", "text": "A fatal poisoning", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "21887897_2_Ent0", "text": "A fatal poisoning case", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "21887897_2_Ent3", "text": "etizolam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "21887897_2_Ent2", "text": "etizolam , phenobarbital , promethazine and chlorpromazine", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "21887897_2_Ent4", "text": "phenobarbital", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21887897_2_Ent5", "text": "promethazine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "21887897_2_Ent6", "text": "chlorpromazine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "2196696_2", "wnd_id": "2196696_2_1", "text": "Our patient had headache , mild fever , nausea , vomiting , rash , and eosinophilia after 3 weeks of disulfiram therapy .", "tokens": ["Our", "patient", "had", "headache", ",", "mild", "fever", ",", "nausea", ",", "vomiting", ",", "rash", ",", "and", "eosinophilia", "after", "3", "weeks", "of", "disulfiram", "therapy", "."], "event_mentions": [{"id": "2196696_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "2196696_2_Ent0", "role": "Effect", "text": "headache , mild fever , nausea , vomiting , rash , and eosinophilia", "start": 3, "end": 16}, {"entity_id": "2196696_2_Ent3", "role": "Treatment_Time_elapsed", "text": "after 3 weeks", "start": 16, "end": 19}, {"entity_id": "2196696_2_Ent1", "role": "Treatment", "text": "after 3 weeks of disulfiram", "start": 16, "end": 21}, {"entity_id": "2196696_2_Ent2", "role": "Treatment_Drug", "text": "disulfiram", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "2196696_2_Ent0", "text": "headache , mild fever , nausea , vomiting , rash , and eosinophilia", "entity_type": "Entity", "start": 3, "end": 16}, {"id": "2196696_2_Ent3", "text": "after 3 weeks", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "2196696_2_Ent1", "text": "after 3 weeks of disulfiram", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "2196696_2_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "2196696_3", "wnd_id": "2196696_3_1", "text": "We reported a case of disulfiram - induced hepatitis with unique clinical features and compared our case with others in the literature .", "tokens": ["We", "reported", "a", "case", "of", "disulfiram", "-", "induced", "hepatitis", "with", "unique", "clinical", "features", "and", "compared", "our", "case", "with", "others", "in", "the", "literature", "."], "event_mentions": [{"id": "2196696_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "2196696_3_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "2196696_3_Ent2", "role": "Treatment", "text": "disulfiram", "start": 5, "end": 6}, {"entity_id": "2196696_3_Ent3", "role": "Treatment_Drug", "text": "disulfiram", "start": 5, "end": 6}, {"entity_id": "2196696_3_Ent1", "role": "Effect", "text": "hepatitis", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "2196696_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "2196696_3_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2196696_3_Ent3", "text": "disulfiram", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2196696_3_Ent1", "text": "hepatitis", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "22010004_1", "wnd_id": "22010004_1_1", "text": "Critically elevated INR in a patient on warfarin after increase in extended - release niacin dose .", "tokens": ["Critically", "elevated", "INR", "in", "a", "patient", "on", "warfarin", "after", "increase", "in", "extended", "-", "release", "niacin", "dose", "."], "event_mentions": [{"id": "22010004_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "22010004_1_Ent1", "role": "Effect", "text": "elevated INR", "start": 1, "end": 3}, {"entity_id": "22010004_1_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "22010004_1_Ent2", "role": "Treatment", "text": "warfarin", "start": 7, "end": 8}, {"entity_id": "22010004_1_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 7, "end": 8}, {"entity_id": "22010004_1_Ent6", "role": "Treatment_Dosage", "text": "increase in", "start": 9, "end": 11}, {"entity_id": "22010004_1_Ent3", "role": "Treatment", "text": "increase in extended - release niacin dose", "start": 9, "end": 16}, {"entity_id": "22010004_1_Ent5", "role": "Treatment_Drug", "text": "niacin", "start": 14, "end": 15}, {"entity_id": "22010004_1_Ent7", "role": "Treatment_Dosage", "text": "dose", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "22010004_1_Ent1", "text": "elevated INR", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "22010004_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "22010004_1_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "22010004_1_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "22010004_1_Ent6", "text": "increase in", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "22010004_1_Ent3", "text": "increase in extended - release niacin dose", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "22010004_1_Ent5", "text": "niacin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "22010004_1_Ent7", "text": "dose", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "2212262_1", "wnd_id": "2212262_1_1", "text": "Severe heparin associated thrombocytopenia is a rare complication of heparin therapy .", "tokens": ["Severe", "heparin", "associated", "thrombocytopenia", "is", "a", "rare", "complication", "of", "heparin", "therapy", "."], "event_mentions": [{"id": "2212262_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "2212262_1_Ent1", "role": "Treatment", "text": "heparin", "start": 1, "end": 2}, {"entity_id": "2212262_1_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 1, "end": 2}, {"entity_id": "2212262_1_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "2212262_1_Ent1", "text": "heparin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2212262_1_Ent2", "text": "heparin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2212262_1_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "2241449_1", "wnd_id": "2241449_1_1", "text": "Physicians using this \" new \" drug must be aware of the potential danger of sulfonamide - induced injury to the urinary tract .", "tokens": ["Physicians", "using", "this", "\"", "new", "\"", "drug", "must", "be", "aware", "of", "the", "potential", "danger", "of", "sulfonamide", "-", "induced", "injury", "to", "the", "urinary", "tract", "."], "event_mentions": [{"id": "2241449_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 17, "end": 18}, "arguments": [{"entity_id": "2241449_1_Ent1", "role": "Treatment", "text": "sulfonamide", "start": 15, "end": 16}, {"entity_id": "2241449_1_Ent2", "role": "Treatment_Drug", "text": "sulfonamide", "start": 15, "end": 16}, {"entity_id": "2241449_1_Ent0", "role": "Effect", "text": "injury to the urinary tract", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "2241449_1_Ent1", "text": "sulfonamide", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2241449_1_Ent2", "text": "sulfonamide", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2241449_1_Ent0", "text": "injury to the urinary tract", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "2241449_2", "wnd_id": "2241449_2_1", "text": "Sulfadiazine crystalluria revisited .", "tokens": ["Sulfadiazine", "crystalluria", "revisited", "."], "event_mentions": [{"id": "2241449_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "revisited", "start": 2, "end": 3}, "arguments": [{"entity_id": "2241449_2_Ent1", "role": "Treatment", "text": "Sulfadiazine", "start": 0, "end": 1}, {"entity_id": "2241449_2_Ent2", "role": "Treatment_Drug", "text": "Sulfadiazine", "start": 0, "end": 1}, {"entity_id": "2241449_2_Ent0", "role": "Effect", "text": "crystalluria", "start": 1, "end": 2}]}], "entity_mentions": [{"id": "2241449_2_Ent1", "text": "Sulfadiazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2241449_2_Ent2", "text": "Sulfadiazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2241449_2_Ent0", "text": "crystalluria", "entity_type": "Entity", "start": 1, "end": 2}], "lang": "en"}
{"doc_id": "2250853_2", "wnd_id": "2250853_2_1", "text": "We report a case of secondary glaucoma caused by epithelial downgrowth in which filtration surgery was performed with adjunctive use of subconjunctival 5 - fluorouracil .", "tokens": ["We", "report", "a", "case", "of", "secondary", "glaucoma", "caused", "by", "epithelial", "downgrowth", "in", "which", "filtration", "surgery", "was", "performed", "with", "adjunctive", "use", "of", "subconjunctival", "5", "-", "fluorouracil", "."], "event_mentions": [{"id": "2250853_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 7, "end": 8}, "arguments": [{"entity_id": "2250853_2_Ent0", "role": "Effect", "text": "secondary glaucoma", "start": 5, "end": 7}, {"entity_id": "2250853_2_Ent1", "role": "Effect", "text": "epithelial downgrowth", "start": 9, "end": 11}, {"entity_id": "2250853_2_Ent2", "role": "Treatment", "text": "filtration surgery was performed with adjunctive use of subconjunctival 5 - fluorouracil", "start": 13, "end": 25}, {"entity_id": "2250853_2_Ent3", "role": "Treatment_Route", "text": "subconjunctival", "start": 21, "end": 22}, {"entity_id": "2250853_2_Ent4", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "2250853_2_Ent0", "text": "secondary glaucoma", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "2250853_2_Ent1", "text": "epithelial downgrowth", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "2250853_2_Ent2", "text": "filtration surgery was performed with adjunctive use of subconjunctival 5 - fluorouracil", "entity_type": "Entity", "start": 13, "end": 25}, {"id": "2250853_2_Ent3", "text": "subconjunctival", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "2250853_2_Ent4", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "22552763_4", "wnd_id": "22552763_4_1", "text": "We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate , with and without concomitant NSAID or ASA .", "tokens": ["We", "assessed", "the", "bleeding", "risk", "in", "patients", "treated", "with", "thromboprophylactic", "dabigatran", "etexilate", ",", "with", "and", "without", "concomitant", "NSAID", "or", "ASA", "."], "event_mentions": [{"id": "22552763_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 7, "end": 8}, "arguments": [{"entity_id": "22552763_4_Ent1", "role": "Effect", "text": "bleeding", "start": 3, "end": 4}, {"entity_id": "22552763_4_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "22552763_4_Ent2", "role": "Treatment", "text": "thromboprophylactic dabigatran etexilate , with and without concomitant NSAID or ASA", "start": 9, "end": 20}, {"entity_id": "22552763_4_Ent5", "role": "Treatment_Drug", "text": "dabigatran etexilate", "start": 10, "end": 12}, {"entity_id": "22552763_4_Ent6", "role": "Combination_Drug", "text": "dabigatran etexilate", "start": 10, "end": 12}, {"entity_id": "22552763_4_Ent4", "role": "Treatment_Drug", "text": "NSAID", "start": 17, "end": 18}, {"entity_id": "22552763_4_Ent7", "role": "Combination_Drug", "text": "NSAID", "start": 17, "end": 18}, {"entity_id": "22552763_4_Ent3", "role": "Treatment_Drug", "text": "ASA", "start": 19, "end": 20}, {"entity_id": "22552763_4_Ent8", "role": "Combination_Drug", "text": "ASA", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "22552763_4_Ent1", "text": "bleeding", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "22552763_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "22552763_4_Ent2", "text": "thromboprophylactic dabigatran etexilate , with and without concomitant NSAID or ASA", "entity_type": "Entity", "start": 9, "end": 20}, {"id": "22552763_4_Ent5", "text": "dabigatran etexilate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "22552763_4_Ent6", "text": "dabigatran etexilate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "22552763_4_Ent4", "text": "NSAID", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "22552763_4_Ent7", "text": "NSAID", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "22552763_4_Ent3", "text": "ASA", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "22552763_4_Ent8", "text": "ASA", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "22677303_10", "wnd_id": "22677303_10_1", "text": "In the presented case , the temporal relationship between the administration of cloxacillin and increased INR suggests that the cloxacillin was responsible for the enhanced warfarin activity .", "tokens": ["In", "the", "presented", "case", ",", "the", "temporal", "relationship", "between", "the", "administration", "of", "cloxacillin", "and", "increased", "INR", "suggests", "that", "the", "cloxacillin", "was", "responsible", "for", "the", "enhanced", "warfarin", "activity", "."], "event_mentions": [{"id": "22677303_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "administration", "start": 10, "end": 11}, "arguments": [{"entity_id": "22677303_10_Ent0", "role": "Subject", "text": "case", "start": 3, "end": 4}, {"entity_id": "22677303_10_Ent2", "role": "Effect", "text": "increased INR", "start": 14, "end": 16}, {"entity_id": "22677303_10_Ent3", "role": "Treatment", "text": "cloxacillin", "start": 19, "end": 20}, {"entity_id": "22677303_10_Ent4", "role": "Treatment_Drug", "text": "cloxacillin", "start": 19, "end": 20}, {"entity_id": "22677303_10_Ent7", "role": "Combination_Drug", "text": "cloxacillin", "start": 19, "end": 20}, {"entity_id": "22677303_10_Ent1", "role": "Effect", "text": "enhanced warfarin activity .", "start": 24, "end": 28}, {"entity_id": "22677303_10_Ent5", "role": "Treatment_Drug", "text": "warfarin", "start": 25, "end": 26}, {"entity_id": "22677303_10_Ent6", "role": "Combination_Drug", "text": "warfarin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "22677303_10_Ent0", "text": "case", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "22677303_10_Ent2", "text": "increased INR", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "22677303_10_Ent3", "text": "cloxacillin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "22677303_10_Ent4", "text": "cloxacillin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "22677303_10_Ent7", "text": "cloxacillin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "22677303_10_Ent1", "text": "enhanced warfarin activity .", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "22677303_10_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "22677303_10_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "22735246_5", "wnd_id": "22735246_5_1", "text": "This is the first reported fatality due to this drug interaction and only the second case of serotonin syndrome reported with oxcarbazepine .", "tokens": ["This", "is", "the", "first", "reported", "fatality", "due", "to", "this", "drug", "interaction", "and", "only", "the", "second", "case", "of", "serotonin", "syndrome", "reported", "with", "oxcarbazepine", "."], "event_mentions": [{"id": "22735246_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 19, "end": 20}, "arguments": [{"entity_id": "22735246_5_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 17, "end": 19}, {"entity_id": "22735246_5_Ent1", "role": "Treatment", "text": "oxcarbazepine", "start": 21, "end": 22}, {"entity_id": "22735246_5_Ent2", "role": "Treatment_Drug", "text": "oxcarbazepine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "22735246_5_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "22735246_5_Ent1", "text": "oxcarbazepine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "22735246_5_Ent2", "text": "oxcarbazepine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "228648_1", "wnd_id": "228648_1_1", "text": "Prenatal cytomegalovirus ( CMV ) infection associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus ( SLE ) .", "tokens": ["Prenatal", "cytomegalovirus", "(", "CMV", ")", "infection", "associated", "with", "severe", "brain", "damage", "was", "detected", "in", "an", "infant", "whose", "mother", "had", "been", "treated", "with", "prednisolone", "and", "azathioprine", "for", "systemic", "lupus", "erythematosus", "(", "SLE", ")", "."], "event_mentions": [{"id": "228648_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 20, "end": 21}, "arguments": [{"entity_id": "228648_1_Ent2", "role": "Effect", "text": "Prenatal cytomegalovirus ( CMV ) infection associated with severe brain damage", "start": 0, "end": 11}, {"entity_id": "228648_1_Ent0", "role": "Subject", "text": "an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus ( SLE )", "start": 14, "end": 32}, {"entity_id": "228648_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 15, "end": 16}, {"entity_id": "228648_1_Ent4", "role": "Treatment_Drug", "text": "prednisolone", "start": 22, "end": 23}, {"entity_id": "228648_1_Ent6", "role": "Combination_Drug", "text": "prednisolone", "start": 22, "end": 23}, {"entity_id": "228648_1_Ent3", "role": "Treatment", "text": "prednisolone and azathioprine", "start": 22, "end": 25}, {"entity_id": "228648_1_Ent5", "role": "Treatment_Drug", "text": "azathioprine", "start": 24, "end": 25}, {"entity_id": "228648_1_Ent7", "role": "Combination_Drug", "text": "azathioprine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "228648_1_Ent2", "text": "Prenatal cytomegalovirus ( CMV ) infection associated with severe brain damage", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "228648_1_Ent0", "text": "an infant whose mother had been treated with prednisolone and azathioprine for systemic lupus erythematosus ( SLE )", "entity_type": "Entity", "start": 14, "end": 32}, {"id": "228648_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "228648_1_Ent4", "text": "prednisolone", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "228648_1_Ent6", "text": "prednisolone", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "228648_1_Ent3", "text": "prednisolone and azathioprine", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "228648_1_Ent5", "text": "azathioprine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "228648_1_Ent7", "text": "azathioprine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "2295443_2", "wnd_id": "2295443_2_1", "text": "Delayed bowel injury is an infrequently observed complication of chromic phosphate administration .", "tokens": ["Delayed", "bowel", "injury", "is", "an", "infrequently", "observed", "complication", "of", "chromic", "phosphate", "administration", "."], "event_mentions": [{"id": "2295443_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 7, "end": 8}, "arguments": [{"entity_id": "2295443_2_Ent0", "role": "Effect", "text": "Delayed bowel injury", "start": 0, "end": 3}, {"entity_id": "2295443_2_Ent2", "role": "Treatment_Drug", "text": "chromic phosphate", "start": 9, "end": 11}, {"entity_id": "2295443_2_Ent1", "role": "Treatment", "text": "chromic phosphate administration", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "2295443_2_Ent0", "text": "Delayed bowel injury", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2295443_2_Ent2", "text": "chromic phosphate", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "2295443_2_Ent1", "text": "chromic phosphate administration", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "2295443_3", "wnd_id": "2295443_3_1", "text": "This report presents a case of colon perforation which occurred 4 months after treatment with intraperitoneal chromic phosphate for stage IB ovarian papillary serous cystadenocarcinoma .", "tokens": ["This", "report", "presents", "a", "case", "of", "colon", "perforation", "which", "occurred", "4", "months", "after", "treatment", "with", "intraperitoneal", "chromic", "phosphate", "for", "stage", "IB", "ovarian", "papillary", "serous", "cystadenocarcinoma", "."], "event_mentions": [{"id": "2295443_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 9, "end": 10}, "arguments": [{"entity_id": "2295443_3_Ent0", "role": "Effect", "text": "colon perforation", "start": 6, "end": 8}, {"entity_id": "2295443_3_Ent3", "role": "Treatment_Time_elapsed", "text": "4 months", "start": 10, "end": 12}, {"entity_id": "2295443_3_Ent4", "role": "Treatment_Route", "text": "intraperitoneal", "start": 15, "end": 16}, {"entity_id": "2295443_3_Ent1", "role": "Treatment", "text": "intraperitoneal chromic phosphate", "start": 15, "end": 18}, {"entity_id": "2295443_3_Ent2", "role": "Treatment_Drug", "text": "chromic phosphate", "start": 16, "end": 18}, {"entity_id": "2295443_3_Ent5", "role": "Treatment_Disorder", "text": "stage IB ovarian papillary serous cystadenocarcinoma", "start": 19, "end": 25}]}], "entity_mentions": [{"id": "2295443_3_Ent0", "text": "colon perforation", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "2295443_3_Ent3", "text": "4 months", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "2295443_3_Ent4", "text": "intraperitoneal", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2295443_3_Ent1", "text": "intraperitoneal chromic phosphate", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "2295443_3_Ent2", "text": "chromic phosphate", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "2295443_3_Ent5", "text": "stage IB ovarian papillary serous cystadenocarcinoma", "entity_type": "Entity", "start": 19, "end": 25}], "lang": "en"}
{"doc_id": "2299784_2", "wnd_id": "2299784_2_1", "text": "Bromide intoxication secondary to pyridostigmine bromide therapy .", "tokens": ["Bromide", "intoxication", "secondary", "to", "pyridostigmine", "bromide", "therapy", "."], "event_mentions": [{"id": "2299784_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 2, "end": 3}, "arguments": [{"entity_id": "2299784_2_Ent0", "role": "Effect", "text": "Bromide intoxication", "start": 0, "end": 2}, {"entity_id": "2299784_2_Ent1", "role": "Treatment", "text": "pyridostigmine bromide", "start": 4, "end": 6}, {"entity_id": "2299784_2_Ent2", "role": "Treatment_Drug", "text": "pyridostigmine bromide", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "2299784_2_Ent0", "text": "Bromide intoxication", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2299784_2_Ent1", "text": "pyridostigmine bromide", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2299784_2_Ent2", "text": "pyridostigmine bromide", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "2309833_1", "wnd_id": "2309833_1_1", "text": "After discontinuation of danazol the diabetes completely resolved .", "tokens": ["After", "discontinuation", "of", "danazol", "the", "diabetes", "completely", "resolved", "."], "event_mentions": [{"id": "2309833_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 7, "end": 8}, "arguments": [{"entity_id": "2309833_1_Ent0", "role": "Treatment", "text": "discontinuation of danazol", "start": 1, "end": 4}, {"entity_id": "2309833_1_Ent2", "role": "Treatment_Drug", "text": "danazol", "start": 3, "end": 4}, {"entity_id": "2309833_1_Ent1", "role": "Treatment_Disorder", "text": "diabetes", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "2309833_1_Ent0", "text": "discontinuation of danazol", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "2309833_1_Ent2", "text": "danazol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2309833_1_Ent1", "text": "diabetes", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "2320800_6", "wnd_id": "2320800_6_1", "text": "Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies .", "tokens": ["Ifosfamide", "is", "a", "known", "nephrotoxic", "drug", "with", "demonstrated", "tubulopathies", "."], "event_mentions": [{"id": "2320800_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 6, "end": 7}, "arguments": [{"entity_id": "2320800_6_Ent1", "role": "Treatment", "text": "Ifosfamide", "start": 0, "end": 1}, {"entity_id": "2320800_6_Ent2", "role": "Treatment_Drug", "text": "Ifosfamide", "start": 0, "end": 1}, {"entity_id": "2320800_6_Ent0", "role": "Effect", "text": "tubulopathies", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "2320800_6_Ent1", "text": "Ifosfamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2320800_6_Ent2", "text": "Ifosfamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2320800_6_Ent0", "text": "tubulopathies", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "23471710_1", "wnd_id": "23471710_1_1", "text": "Severe hypoglycemia from Helicobacter pylori triple - drug therapy and insulin detemir drug interaction .", "tokens": ["Severe", "hypoglycemia", "from", "Helicobacter", "pylori", "triple", "-", "drug", "therapy", "and", "insulin", "detemir", "drug", "interaction", "."], "event_mentions": [{"id": "23471710_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "23471710_1_Ent0", "role": "Effect", "text": "Severe hypoglycemia", "start": 0, "end": 2}, {"entity_id": "23471710_1_Ent2", "role": "Treatment_Drug", "text": "Helicobacter pylori triple - drug", "start": 3, "end": 8}, {"entity_id": "23471710_1_Ent5", "role": "Combination_Drug", "text": "Helicobacter pylori triple - drug", "start": 3, "end": 8}, {"entity_id": "23471710_1_Ent1", "role": "Treatment", "text": "Helicobacter pylori triple - drug therapy and insulin detemir drug interaction", "start": 3, "end": 14}, {"entity_id": "23471710_1_Ent3", "role": "Treatment_Drug", "text": "insulin detemir drug", "start": 10, "end": 13}, {"entity_id": "23471710_1_Ent4", "role": "Combination_Drug", "text": "insulin detemir drug", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "23471710_1_Ent0", "text": "Severe hypoglycemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "23471710_1_Ent2", "text": "Helicobacter pylori triple - drug", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "23471710_1_Ent5", "text": "Helicobacter pylori triple - drug", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "23471710_1_Ent1", "text": "Helicobacter pylori triple - drug therapy and insulin detemir drug interaction", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "23471710_1_Ent3", "text": "insulin detemir drug", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "23471710_1_Ent4", "text": "insulin detemir drug", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "2357706_1", "wnd_id": "2357706_1_1", "text": "Although tardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents , it was only rarely reported in association with sulpiride , a selective D2 - receptor antagonist .", "tokens": ["Although", "tardive", "dyskinesia", "is", "a", "known", "adverse", "reaction", "of", "sustained", "treatment", "with", "traditional", "neuroleptic", "agents", ",", "it", "was", "only", "rarely", "reported", "in", "association", "with", "sulpiride", ",", "a", "selective", "D2", "-", "receptor", "antagonist", "."], "event_mentions": [{"id": "2357706_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 22, "end": 23}, "arguments": [{"entity_id": "2357706_1_Ent0", "role": "Effect", "text": "tardive dyskinesia", "start": 1, "end": 3}, {"entity_id": "2357706_1_Ent1", "role": "Treatment", "text": "sulpiride", "start": 24, "end": 25}, {"entity_id": "2357706_1_Ent2", "role": "Treatment_Drug", "text": "sulpiride", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "2357706_1_Ent0", "text": "tardive dyskinesia", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "2357706_1_Ent1", "text": "sulpiride", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "2357706_1_Ent2", "text": "sulpiride", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "23624139_10", "wnd_id": "23624139_10_1", "text": "Risks and benefits of co - treatment should be carefully considered and therapeutic alternatives to NSAIDs should be recommended to patients with central DI in order to improve DDAVP safety .", "tokens": ["Risks", "and", "benefits", "of", "co", "-", "treatment", "should", "be", "carefully", "considered", "and", "therapeutic", "alternatives", "to", "NSAIDs", "should", "be", "recommended", "to", "patients", "with", "central", "DI", "in", "order", "to", "improve", "DDAVP", "safety", "."], "event_mentions": [{"id": "23624139_10_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "recommended", "start": 18, "end": 19}, "arguments": [{"entity_id": "23624139_10_Ent2", "role": "Treatment", "text": "therapeutic alternatives to NSAIDs", "start": 12, "end": 16}, {"entity_id": "23624139_10_Ent4", "role": "Treatment_Drug", "text": "NSAIDs", "start": 15, "end": 16}, {"entity_id": "23624139_10_Ent0", "role": "Subject", "text": "patients with central DI", "start": 20, "end": 24}, {"entity_id": "23624139_10_Ent3", "role": "Treatment_Disorder", "text": "central DI", "start": 22, "end": 24}, {"entity_id": "23624139_10_Ent1", "role": "Effect", "text": "in order to improve DDAVP safety", "start": 24, "end": 30}]}], "entity_mentions": [{"id": "23624139_10_Ent2", "text": "therapeutic alternatives to NSAIDs", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "23624139_10_Ent4", "text": "NSAIDs", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "23624139_10_Ent0", "text": "patients with central DI", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "23624139_10_Ent3", "text": "central DI", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "23624139_10_Ent1", "text": "in order to improve DDAVP safety", "entity_type": "Entity", "start": 24, "end": 30}], "lang": "en"}
{"doc_id": "23624139_2", "wnd_id": "23624139_2_1", "text": "Most of the clinical data on the safety profile of desmopressin ( DDAVP ) , which is an effective treatment for both polyuric conditions and bleeding disorders , originate from studies on the tailoring of drug treatment , whereas few reports exist describing severe side effects secondary to drug - drug interaction .", "tokens": ["Most", "of", "the", "clinical", "data", "on", "the", "safety", "profile", "of", "desmopressin", "(", "DDAVP", ")", ",", "which", "is", "an", "effective", "treatment", "for", "both", "polyuric", "conditions", "and", "bleeding", "disorders", ",", "originate", "from", "studies", "on", "the", "tailoring", "of", "drug", "treatment", ",", "whereas", "few", "reports", "exist", "describing", "severe", "side", "effects", "secondary", "to", "drug", "-", "drug", "interaction", "."], "event_mentions": [{"id": "23624139_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 19, "end": 20}, "arguments": [{"entity_id": "23624139_2_Ent2", "role": "Treatment_Drug", "text": "desmopressin", "start": 10, "end": 11}, {"entity_id": "23624139_2_Ent1", "role": "Treatment", "text": "desmopressin ( DDAVP )", "start": 10, "end": 14}, {"entity_id": "23624139_2_Ent0", "role": "Subject", "text": "both polyuric conditions and bleeding disorders", "start": 21, "end": 27}, {"entity_id": "23624139_2_Ent3", "role": "Treatment_Disorder", "text": "polyuric conditions", "start": 22, "end": 24}, {"entity_id": "23624139_2_Ent4", "role": "Treatment_Disorder", "text": "bleeding disorders", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "23624139_2_Ent2", "text": "desmopressin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "23624139_2_Ent1", "text": "desmopressin ( DDAVP )", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "23624139_2_Ent0", "text": "both polyuric conditions and bleeding disorders", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "23624139_2_Ent3", "text": "polyuric conditions", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "23624139_2_Ent4", "text": "bleeding disorders", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "2369419_2", "wnd_id": "2369419_2_1", "text": "Hepatitis with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking methotrexate .", "tokens": ["Hepatitis", "with", "bridging", "fibrosis", "and", "reversible", "hepatic", "insufficiency", "in", "a", "woman", "with", "rheumatoid", "arthritis", "taking", "methotrexate", "."], "event_mentions": [{"id": "2369419_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 14, "end": 15}, "arguments": [{"entity_id": "2369419_2_Ent2", "role": "Effect", "text": "Hepatitis with bridging fibrosis and reversible hepatic insufficiency", "start": 0, "end": 8}, {"entity_id": "2369419_2_Ent0", "role": "Subject", "text": "a woman with rheumatoid arthritis", "start": 9, "end": 14}, {"entity_id": "2369419_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "2369419_2_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 12, "end": 14}, {"entity_id": "2369419_2_Ent3", "role": "Treatment", "text": "methotrexate", "start": 15, "end": 16}, {"entity_id": "2369419_2_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "2369419_2_Ent2", "text": "Hepatitis with bridging fibrosis and reversible hepatic insufficiency", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "2369419_2_Ent0", "text": "a woman with rheumatoid arthritis", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "2369419_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2369419_2_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "2369419_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2369419_2_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "2369419_3", "wnd_id": "2369419_3_1", "text": "This is the third report of reversible hepatic decompensation associated with prolonged MTX therapy in patients with rheumatoid arthritis .", "tokens": ["This", "is", "the", "third", "report", "of", "reversible", "hepatic", "decompensation", "associated", "with", "prolonged", "MTX", "therapy", "in", "patients", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "2369419_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "2369419_3_Ent1", "role": "Effect", "text": "reversible hepatic decompensation", "start": 6, "end": 9}, {"entity_id": "2369419_3_Ent2", "role": "Treatment", "text": "MTX", "start": 12, "end": 13}, {"entity_id": "2369419_3_Ent4", "role": "Treatment_Drug", "text": "MTX", "start": 12, "end": 13}, {"entity_id": "2369419_3_Ent0", "role": "Subject", "text": "patients with rheumatoid arthritis", "start": 15, "end": 19}, {"entity_id": "2369419_3_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "2369419_3_Ent1", "text": "reversible hepatic decompensation", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "2369419_3_Ent2", "text": "MTX", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2369419_3_Ent4", "text": "MTX", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2369419_3_Ent0", "text": "patients with rheumatoid arthritis", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "2369419_3_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "2378415_2", "wnd_id": "2378415_2_1", "text": "A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed fatal cerebral edema and brainstem herniation after she received a single dose of intravenous methotrexate .", "tokens": ["A", "patient", "with", "intracranial", "osteosarcoma", "that", "arose", "16", "years", "after", "radiation", "therapy", "for", "hereditary", "retinoblastoma", "developed", "fatal", "cerebral", "edema", "and", "brainstem", "herniation", "after", "she", "received", "a", "single", "dose", "of", "intravenous", "methotrexate", "."], "event_mentions": [{"id": "2378415_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "2378415_2_Ent0", "role": "Subject", "text": "A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma", "start": 0, "end": 15}, {"entity_id": "2378415_2_Ent4", "role": "Treatment_Disorder", "text": "intracranial osteosarcoma", "start": 3, "end": 5}, {"entity_id": "2378415_2_Ent1", "role": "Subject_Disorder", "text": "hereditary retinoblastoma", "start": 13, "end": 15}, {"entity_id": "2378415_2_Ent2", "role": "Effect", "text": "cerebral edema and brainstem herniation", "start": 17, "end": 22}, {"entity_id": "2378415_2_Ent5", "role": "Treatment_Freq", "text": "a single dose", "start": 25, "end": 28}, {"entity_id": "2378415_2_Ent3", "role": "Treatment", "text": "a single dose of intravenous methotrexate", "start": 25, "end": 31}, {"entity_id": "2378415_2_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 29, "end": 30}, {"entity_id": "2378415_2_Ent7", "role": "Treatment_Drug", "text": "methotrexate", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "2378415_2_Ent0", "text": "A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma", "entity_type": "Entity", "start": 0, "end": 15}, {"id": "2378415_2_Ent4", "text": "intracranial osteosarcoma", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "2378415_2_Ent1", "text": "hereditary retinoblastoma", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "2378415_2_Ent2", "text": "cerebral edema and brainstem herniation", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "2378415_2_Ent5", "text": "a single dose", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "2378415_2_Ent3", "text": "a single dose of intravenous methotrexate", "entity_type": "Entity", "start": 25, "end": 31}, {"id": "2378415_2_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "2378415_2_Ent7", "text": "methotrexate", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "23970584_4", "wnd_id": "23970584_4_1", "text": "Forty - one days later , she developed severe iatrogenic Cushing 's syndrome due to the drug - drug interaction between triamcinolone and her boosted protease inhibitor therapy .", "tokens": ["Forty", "-", "one", "days", "later", ",", "she", "developed", "severe", "iatrogenic", "Cushing", "'s", "syndrome", "due", "to", "the", "drug", "-", "drug", "interaction", "between", "triamcinolone", "and", "her", "boosted", "protease", "inhibitor", "therapy", "."], "event_mentions": [{"id": "23970584_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "23970584_4_Ent2", "role": "Effect", "text": "Forty - one days later", "start": 0, "end": 5}, {"entity_id": "23970584_4_Ent0", "role": "Subject", "text": "she", "start": 6, "end": 7}, {"entity_id": "23970584_4_Ent1", "role": "Subject_Gender", "text": "she", "start": 6, "end": 7}, {"entity_id": "23970584_4_Ent3", "role": "Effect", "text": "severe iatrogenic Cushing 's syndrome", "start": 8, "end": 13}, {"entity_id": "23970584_4_Ent5", "role": "Treatment_Drug", "text": "triamcinolone", "start": 21, "end": 22}, {"entity_id": "23970584_4_Ent7", "role": "Combination_Drug", "text": "triamcinolone", "start": 21, "end": 22}, {"entity_id": "23970584_4_Ent4", "role": "Treatment", "text": "triamcinolone and her boosted protease inhibitor", "start": 21, "end": 27}, {"entity_id": "23970584_4_Ent6", "role": "Treatment_Drug", "text": "protease inhibitor", "start": 25, "end": 27}, {"entity_id": "23970584_4_Ent8", "role": "Combination_Drug", "text": "protease inhibitor", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "23970584_4_Ent2", "text": "Forty - one days later", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "23970584_4_Ent0", "text": "she", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "23970584_4_Ent1", "text": "she", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "23970584_4_Ent3", "text": "severe iatrogenic Cushing 's syndrome", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "23970584_4_Ent5", "text": "triamcinolone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "23970584_4_Ent7", "text": "triamcinolone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "23970584_4_Ent4", "text": "triamcinolone and her boosted protease inhibitor", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "23970584_4_Ent6", "text": "protease inhibitor", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "23970584_4_Ent8", "text": "protease inhibitor", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "23970584_6", "wnd_id": "23970584_6_1", "text": "Shortly after commencing the drug , the patient developed a severe adverse drug reaction manifesting as Drug Reaction ( or Rash ) with Eosinophilia and Systemic Symptoms ( DRESS ) syndrome .", "tokens": ["Shortly", "after", "commencing", "the", "drug", ",", "the", "patient", "developed", "a", "severe", "adverse", "drug", "reaction", "manifesting", "as", "Drug", "Reaction", "(", "or", "Rash", ")", "with", "Eosinophilia", "and", "Systemic", "Symptoms", "(", "DRESS", ")", "syndrome", "."], "event_mentions": [{"id": "23970584_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "23970584_6_Ent3", "role": "Treatment_Time_elapsed", "text": "Shortly after", "start": 0, "end": 2}, {"entity_id": "23970584_6_Ent2", "role": "Treatment", "text": "Shortly after commencing the drug", "start": 0, "end": 5}, {"entity_id": "23970584_6_Ent0", "role": "Subject", "text": "the patient", "start": 6, "end": 8}, {"entity_id": "23970584_6_Ent1", "role": "Effect", "text": "severe adverse drug reaction manifesting as Drug Reaction ( or Rash ) with Eosinophilia and Systemic Symptoms ( DRESS ) syndrome", "start": 10, "end": 31}]}], "entity_mentions": [{"id": "23970584_6_Ent3", "text": "Shortly after", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "23970584_6_Ent2", "text": "Shortly after commencing the drug", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "23970584_6_Ent0", "text": "the patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "23970584_6_Ent1", "text": "severe adverse drug reaction manifesting as Drug Reaction ( or Rash ) with Eosinophilia and Systemic Symptoms ( DRESS ) syndrome", "entity_type": "Entity", "start": 10, "end": 31}], "lang": "en"}
{"doc_id": "24163322_7", "wnd_id": "24163322_7_1", "text": "Bismuth subsalicylate 30 mL every 4 hours was prescribed for diarrhea .", "tokens": ["Bismuth", "subsalicylate", "30", "mL", "every", "4", "hours", "was", "prescribed", "for", "diarrhea", "."], "event_mentions": [{"id": "24163322_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prescribed", "start": 8, "end": 9}, "arguments": [{"entity_id": "24163322_7_Ent1", "role": "Treatment_Drug", "text": "Bismuth subsalicylate", "start": 0, "end": 2}, {"entity_id": "24163322_7_Ent0", "role": "Treatment", "text": "Bismuth subsalicylate 30 mL every 4 hours", "start": 0, "end": 7}, {"entity_id": "24163322_7_Ent2", "role": "Treatment_Dosage", "text": "30 mL", "start": 2, "end": 4}, {"entity_id": "24163322_7_Ent3", "role": "Treatment_Freq", "text": "every 4 hours", "start": 4, "end": 7}, {"entity_id": "24163322_7_Ent4", "role": "Treatment_Disorder", "text": "diarrhea", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "24163322_7_Ent1", "text": "Bismuth subsalicylate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "24163322_7_Ent0", "text": "Bismuth subsalicylate 30 mL every 4 hours", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "24163322_7_Ent2", "text": "30 mL", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "24163322_7_Ent3", "text": "every 4 hours", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "24163322_7_Ent4", "text": "diarrhea", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "24163322_8", "wnd_id": "24163322_8_1", "text": "Within 3 days after starting bismuth subsalicylate therapy , the patient 's INR increased from 2.56 to 3.54 and minor bleeding was noted from the patient 's tracheostomy site .", "tokens": ["Within", "3", "days", "after", "starting", "bismuth", "subsalicylate", "therapy", ",", "the", "patient", "'s", "INR", "increased", "from", "2.56", "to", "3.54", "and", "minor", "bleeding", "was", "noted", "from", "the", "patient", "'s", "tracheostomy", "site", "."], "event_mentions": [{"id": "24163322_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "noted", "start": 22, "end": 23}, "arguments": [{"entity_id": "24163322_8_Ent2", "role": "Treatment", "text": "Within 3 days after starting bismuth subsalicylate therapy", "start": 0, "end": 8}, {"entity_id": "24163322_8_Ent3", "role": "Treatment_Duration", "text": "3 days", "start": 1, "end": 3}, {"entity_id": "24163322_8_Ent4", "role": "Treatment_Drug", "text": "bismuth subsalicylate", "start": 5, "end": 7}, {"entity_id": "24163322_8_Ent0", "role": "Subject", "text": "the patient", "start": 9, "end": 11}, {"entity_id": "24163322_8_Ent1", "role": "Effect", "text": "INR increased from 2.56 to 3.54 and minor bleeding was noted from the patient 's tracheostomy site", "start": 12, "end": 29}]}], "entity_mentions": [{"id": "24163322_8_Ent2", "text": "Within 3 days after starting bismuth subsalicylate therapy", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "24163322_8_Ent3", "text": "3 days", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "24163322_8_Ent4", "text": "bismuth subsalicylate", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "24163322_8_Ent0", "text": "the patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "24163322_8_Ent1", "text": "INR increased from 2.56 to 3.54 and minor bleeding was noted from the patient 's tracheostomy site", "entity_type": "Entity", "start": 12, "end": 29}], "lang": "en"}
{"doc_id": "2417800_3", "wnd_id": "2417800_3_1", "text": "Bleomycin pneumonitis potentiated by oxygen administration .", "tokens": ["Bleomycin", "pneumonitis", "potentiated", "by", "oxygen", "administration", "."], "event_mentions": [{"id": "2417800_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 3, "end": 4}, "arguments": [{"entity_id": "2417800_3_Ent0", "role": "Effect", "text": "Bleomycin pneumonitis", "start": 0, "end": 2}, {"entity_id": "2417800_3_Ent2", "role": "Treatment_Drug", "text": "oxygen", "start": 4, "end": 5}, {"entity_id": "2417800_3_Ent1", "role": "Treatment", "text": "oxygen administration", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "2417800_3_Ent0", "text": "Bleomycin pneumonitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2417800_3_Ent2", "text": "oxygen", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2417800_3_Ent1", "text": "oxygen administration", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "2417800_4", "wnd_id": "2417800_4_1", "text": "Oxygen potentiation of bleomycin - induced pulmonary toxicity is discussed .", "tokens": ["Oxygen", "potentiation", "of", "bleomycin", "-", "induced", "pulmonary", "toxicity", "is", "discussed", "."], "event_mentions": [{"id": "2417800_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "2417800_4_Ent2", "role": "Treatment_Drug", "text": "Oxygen", "start": 0, "end": 1}, {"entity_id": "2417800_4_Ent5", "role": "Combination_Drug", "text": "Oxygen", "start": 0, "end": 1}, {"entity_id": "2417800_4_Ent1", "role": "Treatment", "text": "Oxygen potentiation of bleomycin", "start": 0, "end": 4}, {"entity_id": "2417800_4_Ent3", "role": "Treatment_Drug", "text": "bleomycin", "start": 3, "end": 4}, {"entity_id": "2417800_4_Ent4", "role": "Combination_Drug", "text": "bleomycin", "start": 3, "end": 4}, {"entity_id": "2417800_4_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "2417800_4_Ent2", "text": "Oxygen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2417800_4_Ent5", "text": "Oxygen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2417800_4_Ent1", "text": "Oxygen potentiation of bleomycin", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "2417800_4_Ent3", "text": "bleomycin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2417800_4_Ent4", "text": "bleomycin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2417800_4_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "24477376_4", "wnd_id": "24477376_4_1", "text": "The patient was previously on phenytoin and was initiated on ticagrelor for antiplatelet therapy following stent placement .", "tokens": ["The", "patient", "was", "previously", "on", "phenytoin", "and", "was", "initiated", "on", "ticagrelor", "for", "antiplatelet", "therapy", "following", "stent", "placement", "."], "event_mentions": [{"id": "24477376_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 11, "end": 12}, "arguments": [{"entity_id": "24477376_4_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "24477376_4_Ent1", "role": "Treatment", "text": "previously on phenytoin", "start": 3, "end": 6}, {"entity_id": "24477376_4_Ent5", "role": "Treatment_Drug", "text": "phenytoin", "start": 5, "end": 6}, {"entity_id": "24477376_4_Ent2", "role": "Treatment", "text": "initiated on ticagrelor", "start": 8, "end": 11}, {"entity_id": "24477376_4_Ent6", "role": "Treatment_Drug", "text": "ticagrelor", "start": 10, "end": 11}, {"entity_id": "24477376_4_Ent4", "role": "Treatment_Disorder", "text": "antiplatelet therapy", "start": 12, "end": 14}, {"entity_id": "24477376_4_Ent3", "role": "Treatment", "text": "following stent placement", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "24477376_4_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "24477376_4_Ent1", "text": "previously on phenytoin", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "24477376_4_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "24477376_4_Ent2", "text": "initiated on ticagrelor", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "24477376_4_Ent6", "text": "ticagrelor", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "24477376_4_Ent4", "text": "antiplatelet therapy", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "24477376_4_Ent3", "text": "following stent placement", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "24661191_4", "wnd_id": "24661191_4_1", "text": "We report a case of a 29 - year - old liver transplant patient who suffered liver injury most likely induced by drug interaction between capecitabine and warfarin .", "tokens": ["We", "report", "a", "case", "of", "a", "29", "-", "year", "-", "old", "liver", "transplant", "patient", "who", "suffered", "liver", "injury", "most", "likely", "induced", "by", "drug", "interaction", "between", "capecitabine", "and", "warfarin", "."], "event_mentions": [{"id": "24661191_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 20, "end": 21}, "arguments": [{"entity_id": "24661191_4_Ent0", "role": "Subject", "text": "a 29 - year - old liver transplant patient", "start": 5, "end": 14}, {"entity_id": "24661191_4_Ent1", "role": "Subject_Age", "text": "29 - year - old", "start": 6, "end": 11}, {"entity_id": "24661191_4_Ent2", "role": "Subject_Disorder", "text": "liver transplant", "start": 11, "end": 13}, {"entity_id": "24661191_4_Ent3", "role": "Effect", "text": "liver injury", "start": 16, "end": 18}, {"entity_id": "24661191_4_Ent4", "role": "Treatment", "text": "drug interaction between capecitabine and warfarin", "start": 22, "end": 28}, {"entity_id": "24661191_4_Ent5", "role": "Treatment_Drug", "text": "capecitabine", "start": 25, "end": 26}, {"entity_id": "24661191_4_Ent7", "role": "Combination_Drug", "text": "capecitabine", "start": 25, "end": 26}, {"entity_id": "24661191_4_Ent6", "role": "Treatment_Drug", "text": "warfarin", "start": 27, "end": 28}, {"entity_id": "24661191_4_Ent8", "role": "Combination_Drug", "text": "warfarin", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "24661191_4_Ent0", "text": "a 29 - year - old liver transplant patient", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "24661191_4_Ent1", "text": "29 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "24661191_4_Ent2", "text": "liver transplant", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "24661191_4_Ent3", "text": "liver injury", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "24661191_4_Ent4", "text": "drug interaction between capecitabine and warfarin", "entity_type": "Entity", "start": 22, "end": 28}, {"id": "24661191_4_Ent5", "text": "capecitabine", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "24661191_4_Ent7", "text": "capecitabine", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "24661191_4_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "24661191_4_Ent8", "text": "warfarin", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "24661191_5", "wnd_id": "24661191_5_1", "text": "Vitamin K1 caused skin rash possibly because of the distribution and metabolism characteristic of the drug in this patient .", "tokens": ["Vitamin", "K1", "caused", "skin", "rash", "possibly", "because", "of", "the", "distribution", "and", "metabolism", "characteristic", "of", "the", "drug", "in", "this", "patient", "."], "event_mentions": [{"id": "24661191_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 2, "end": 3}, "arguments": [{"entity_id": "24661191_5_Ent1", "role": "Treatment", "text": "Vitamin K1", "start": 0, "end": 2}, {"entity_id": "24661191_5_Ent2", "role": "Treatment_Drug", "text": "Vitamin K1", "start": 0, "end": 2}, {"entity_id": "24661191_5_Ent0", "role": "Effect", "text": "skin rash", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "24661191_5_Ent1", "text": "Vitamin K1", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "24661191_5_Ent2", "text": "Vitamin K1", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "24661191_5_Ent0", "text": "skin rash", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "24755135_3", "wnd_id": "24755135_3_1", "text": "Study 202 was an open - label , add - on study in patients with partial or generalized epilepsy treated with valproic acid ( VPA ) , carbamazepine ( CBZ ) , phenytoin ( PHT ) , or topiramate ( TPM ) as monotherapy .", "tokens": ["Study", "202", "was", "an", "open", "-", "label", ",", "add", "-", "on", "study", "in", "patients", "with", "partial", "or", "generalized", "epilepsy", "treated", "with", "valproic", "acid", "(", "VPA", ")", ",", "carbamazepine", "(", "CBZ", ")", ",", "phenytoin", "(", "PHT", ")", ",", "or", "topiramate", "(", "TPM", ")", "as", "monotherapy", "."], "event_mentions": [{"id": "24755135_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 19, "end": 20}, "arguments": [{"entity_id": "24755135_3_Ent0", "role": "Subject", "text": "patients with partial or generalized epilepsy", "start": 13, "end": 19}, {"entity_id": "24755135_3_Ent2", "role": "Treatment_Drug", "text": "valproic acid", "start": 21, "end": 23}, {"entity_id": "24755135_3_Ent6", "role": "Combination_Drug", "text": "valproic acid", "start": 21, "end": 23}, {"entity_id": "24755135_3_Ent1", "role": "Treatment", "text": "valproic acid ( VPA ) , carbamazepine ( CBZ ) , phenytoin ( PHT ) , or topiramate ( TPM ) as monotherapy", "start": 21, "end": 44}, {"entity_id": "24755135_3_Ent3", "role": "Treatment_Drug", "text": "carbamazepine", "start": 27, "end": 28}, {"entity_id": "24755135_3_Ent7", "role": "Combination_Drug", "text": "carbamazepine", "start": 27, "end": 28}, {"entity_id": "24755135_3_Ent4", "role": "Treatment_Drug", "text": "phenytoin", "start": 32, "end": 33}, {"entity_id": "24755135_3_Ent8", "role": "Combination_Drug", "text": "phenytoin", "start": 32, "end": 33}, {"entity_id": "24755135_3_Ent5", "role": "Treatment_Drug", "text": "topiramate", "start": 38, "end": 39}, {"entity_id": "24755135_3_Ent9", "role": "Combination_Drug", "text": "topiramate", "start": 38, "end": 39}]}], "entity_mentions": [{"id": "24755135_3_Ent0", "text": "patients with partial or generalized epilepsy", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "24755135_3_Ent2", "text": "valproic acid", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "24755135_3_Ent6", "text": "valproic acid", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "24755135_3_Ent1", "text": "valproic acid ( VPA ) , carbamazepine ( CBZ ) , phenytoin ( PHT ) , or topiramate ( TPM ) as monotherapy", "entity_type": "Entity", "start": 21, "end": 44}, {"id": "24755135_3_Ent3", "text": "carbamazepine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "24755135_3_Ent7", "text": "carbamazepine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "24755135_3_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "24755135_3_Ent8", "text": "phenytoin", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "24755135_3_Ent5", "text": "topiramate", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "24755135_3_Ent9", "text": "topiramate", "entity_type": "Entity", "start": 38, "end": 39}], "lang": "en"}
{"doc_id": "2483959_1", "wnd_id": "2483959_1_1", "text": "A typical case of dextran - 40 associated acute renal failure is presented .", "tokens": ["A", "typical", "case", "of", "dextran", "-", "40", "associated", "acute", "renal", "failure", "is", "presented", "."], "event_mentions": [{"id": "2483959_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "2483959_1_Ent1", "role": "Treatment", "text": "dextran - 40", "start": 4, "end": 7}, {"entity_id": "2483959_1_Ent2", "role": "Treatment_Drug", "text": "dextran - 40", "start": 4, "end": 7}, {"entity_id": "2483959_1_Ent0", "role": "Effect", "text": "acute renal failure", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "2483959_1_Ent1", "text": "dextran - 40", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "2483959_1_Ent2", "text": "dextran - 40", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "2483959_1_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "2483959_2", "wnd_id": "2483959_2_1", "text": "Renal failure associated with the use of dextran - 40 .", "tokens": ["Renal", "failure", "associated", "with", "the", "use", "of", "dextran", "-", "40", "."], "event_mentions": [{"id": "2483959_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "2483959_2_Ent0", "role": "Effect", "text": "Renal failure", "start": 0, "end": 2}, {"entity_id": "2483959_2_Ent1", "role": "Treatment", "text": "dextran - 40", "start": 7, "end": 10}, {"entity_id": "2483959_2_Ent2", "role": "Treatment_Drug", "text": "dextran - 40", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "2483959_2_Ent0", "text": "Renal failure", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2483959_2_Ent1", "text": "dextran - 40", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "2483959_2_Ent2", "text": "dextran - 40", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "2483959_3", "wnd_id": "2483959_3_1", "text": "Several possible explanations of the mechanism of renal failure associated with the use of dextran - 40 are discussed .", "tokens": ["Several", "possible", "explanations", "of", "the", "mechanism", "of", "renal", "failure", "associated", "with", "the", "use", "of", "dextran", "-", "40", "are", "discussed", "."], "event_mentions": [{"id": "2483959_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "2483959_3_Ent0", "role": "Effect", "text": "renal failure", "start": 7, "end": 9}, {"entity_id": "2483959_3_Ent1", "role": "Treatment", "text": "dextran - 40", "start": 14, "end": 17}, {"entity_id": "2483959_3_Ent2", "role": "Treatment_Drug", "text": "dextran - 40", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "2483959_3_Ent0", "text": "renal failure", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "2483959_3_Ent1", "text": "dextran - 40", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "2483959_3_Ent2", "text": "dextran - 40", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "24846936_1", "wnd_id": "24846936_1_1", "text": "Fatal methylene blue associated serotonin toxicity .", "tokens": ["Fatal", "methylene", "blue", "associated", "serotonin", "toxicity", "."], "event_mentions": [{"id": "24846936_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "24846936_1_Ent1", "role": "Treatment", "text": "methylene blue", "start": 1, "end": 3}, {"entity_id": "24846936_1_Ent2", "role": "Treatment_Drug", "text": "methylene blue", "start": 1, "end": 3}, {"entity_id": "24846936_1_Ent0", "role": "Effect", "text": "serotonin toxicity", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "24846936_1_Ent1", "text": "methylene blue", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "24846936_1_Ent2", "text": "methylene blue", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "24846936_1_Ent0", "text": "serotonin toxicity", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "25204404_2", "wnd_id": "25204404_2_1", "text": "Abiraterone acetate , an androgen biosynthesis inhibitor , prolongs survival in men with metastatic castration - resistant prostate cancer ( mCRPC ) in the pre - and post - chemotherapy setting as demonstrated by the pivotal phase III studies COU - AA - 301 and COU - AA - 302 .", "tokens": ["Abiraterone", "acetate", ",", "an", "androgen", "biosynthesis", "inhibitor", ",", "prolongs", "survival", "in", "men", "with", "metastatic", "castration", "-", "resistant", "prostate", "cancer", "(", "mCRPC", ")", "in", "the", "pre", "-", "and", "post", "-", "chemotherapy", "setting", "as", "demonstrated", "by", "the", "pivotal", "phase", "III", "studies", "COU", "-", "AA", "-", "301", "and", "COU", "-", "AA", "-", "302", "."], "event_mentions": [{"id": "25204404_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prolongs survival", "start": 8, "end": 10}, "arguments": [{"entity_id": "25204404_2_Ent3", "role": "Treatment_Drug", "text": "Abiraterone acetate", "start": 0, "end": 2}, {"entity_id": "25204404_2_Ent2", "role": "Treatment", "text": "Abiraterone acetate , an androgen biosynthesis inhibitor", "start": 0, "end": 7}, {"entity_id": "25204404_2_Ent1", "role": "Subject_Gender", "text": "men", "start": 11, "end": 12}, {"entity_id": "25204404_2_Ent0", "role": "Subject", "text": "men with metastatic castration - resistant prostate cancer ( mCRPC )", "start": 11, "end": 22}, {"entity_id": "25204404_2_Ent4", "role": "Treatment_Disorder", "text": "metastatic castration - resistant prostate cancer", "start": 13, "end": 19}]}], "entity_mentions": [{"id": "25204404_2_Ent3", "text": "Abiraterone acetate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "25204404_2_Ent2", "text": "Abiraterone acetate , an androgen biosynthesis inhibitor", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "25204404_2_Ent1", "text": "men", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "25204404_2_Ent0", "text": "men with metastatic castration - resistant prostate cancer ( mCRPC )", "entity_type": "Entity", "start": 11, "end": 22}, {"id": "25204404_2_Ent4", "text": "metastatic castration - resistant prostate cancer", "entity_type": "Entity", "start": 13, "end": 19}], "lang": "en"}
{"doc_id": "2549018_6", "wnd_id": "2549018_6_1", "text": "Three patients who had experienced neuroleptic - induced akathisia in the past reported that the symptoms of fluoxetine - induced akathisia were identical , although somewhat milder .", "tokens": ["Three", "patients", "who", "had", "experienced", "neuroleptic", "-", "induced", "akathisia", "in", "the", "past", "reported", "that", "the", "symptoms", "of", "fluoxetine", "-", "induced", "akathisia", "were", "identical", ",", "although", "somewhat", "milder", "."], "event_mentions": [{"id": "2549018_6_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "2549018_6_Ent8", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "2549018_6_Ent6", "role": "Subject", "text": "Three patients", "start": 0, "end": 2}, {"entity_id": "2549018_6_Ent10", "role": "Treatment", "text": "neuroleptic", "start": 5, "end": 6}, {"entity_id": "2549018_6_Ent11", "role": "Treatment_Drug", "text": "neuroleptic", "start": 5, "end": 6}, {"entity_id": "2549018_6_Ent7", "role": "Subject_Disorder", "text": "neuroleptic - induced akathisia", "start": 5, "end": 9}, {"entity_id": "2549018_6_Ent9", "role": "Effect", "text": "akathisia", "start": 8, "end": 9}]}, {"id": "2549018_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 19, "end": 20}, "arguments": [{"entity_id": "2549018_6_Ent2", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "2549018_6_Ent0", "role": "Subject", "text": "Three patients", "start": 0, "end": 2}, {"entity_id": "2549018_6_Ent1", "role": "Subject_Disorder", "text": "neuroleptic - induced akathisia", "start": 5, "end": 9}, {"entity_id": "2549018_6_Ent4", "role": "Treatment", "text": "fluoxetine", "start": 17, "end": 18}, {"entity_id": "2549018_6_Ent5", "role": "Treatment_Drug", "text": "fluoxetine", "start": 17, "end": 18}, {"entity_id": "2549018_6_Ent3", "role": "Effect", "text": "akathisia", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "2549018_6_Ent2", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2549018_6_Ent8", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2549018_6_Ent0", "text": "Three patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2549018_6_Ent6", "text": "Three patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2549018_6_Ent10", "text": "neuroleptic", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2549018_6_Ent11", "text": "neuroleptic", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2549018_6_Ent1", "text": "neuroleptic - induced akathisia", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "2549018_6_Ent7", "text": "neuroleptic - induced akathisia", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "2549018_6_Ent9", "text": "akathisia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2549018_6_Ent4", "text": "fluoxetine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2549018_6_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2549018_6_Ent3", "text": "akathisia", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "25515435_8", "wnd_id": "25515435_8_1", "text": "A liver biopsy in 2012 revealed marked fibrosis , leading the patient to start hepatitis C treatment with peginterferon alfa - 2a , ribavirin and boceprevir .", "tokens": ["A", "liver", "biopsy", "in", "2012", "revealed", "marked", "fibrosis", ",", "leading", "the", "patient", "to", "start", "hepatitis", "C", "treatment", "with", "peginterferon", "alfa", "-", "2a", ",", "ribavirin", "and", "boceprevir", "."], "event_mentions": [{"id": "25515435_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 16, "end": 17}, "arguments": [{"entity_id": "25515435_8_Ent2", "role": "Treatment_Disorder", "text": "fibrosis", "start": 7, "end": 8}, {"entity_id": "25515435_8_Ent0", "role": "Subject", "text": "fibrosis , leading the patient", "start": 7, "end": 12}, {"entity_id": "25515435_8_Ent3", "role": "Treatment_Drug", "text": "peginterferon alfa - 2a", "start": 18, "end": 22}, {"entity_id": "25515435_8_Ent8", "role": "Combination_Drug", "text": "peginterferon alfa - 2a", "start": 18, "end": 22}, {"entity_id": "25515435_8_Ent1", "role": "Treatment", "text": "peginterferon alfa - 2a , ribavirin and boceprevir", "start": 18, "end": 26}, {"entity_id": "25515435_8_Ent4", "role": "Treatment_Drug", "text": "ribavirin", "start": 23, "end": 24}, {"entity_id": "25515435_8_Ent6", "role": "Combination_Drug", "text": "ribavirin", "start": 23, "end": 24}, {"entity_id": "25515435_8_Ent5", "role": "Treatment_Drug", "text": "boceprevir", "start": 25, "end": 26}, {"entity_id": "25515435_8_Ent7", "role": "Combination_Drug", "text": "boceprevir", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "25515435_8_Ent2", "text": "fibrosis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "25515435_8_Ent0", "text": "fibrosis , leading the patient", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "25515435_8_Ent3", "text": "peginterferon alfa - 2a", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "25515435_8_Ent8", "text": "peginterferon alfa - 2a", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "25515435_8_Ent1", "text": "peginterferon alfa - 2a , ribavirin and boceprevir", "entity_type": "Entity", "start": 18, "end": 26}, {"id": "25515435_8_Ent4", "text": "ribavirin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "25515435_8_Ent6", "text": "ribavirin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "25515435_8_Ent5", "text": "boceprevir", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "25515435_8_Ent7", "text": "boceprevir", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "25538343_2", "wnd_id": "25538343_2_1", "text": "Hyponatremia is a known adverse effect of duloxetine , and it can lead to potentially life - threatening complications .", "tokens": ["Hyponatremia", "is", "a", "known", "adverse", "effect", "of", "duloxetine", ",", "and", "it", "can", "lead", "to", "potentially", "life", "-", "threatening", "complications", "."], "event_mentions": [{"id": "25538343_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse", "start": 4, "end": 5}, "arguments": [{"entity_id": "25538343_2_Ent0", "role": "Effect", "text": "Hyponatremia", "start": 0, "end": 1}, {"entity_id": "25538343_2_Ent2", "role": "Treatment", "text": "duloxetine", "start": 7, "end": 8}, {"entity_id": "25538343_2_Ent3", "role": "Treatment_Drug", "text": "duloxetine", "start": 7, "end": 8}, {"entity_id": "25538343_2_Ent1", "role": "Effect", "text": "potentially life - threatening complications", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "25538343_2_Ent0", "text": "Hyponatremia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25538343_2_Ent2", "text": "duloxetine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "25538343_2_Ent3", "text": "duloxetine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "25538343_2_Ent1", "text": "potentially life - threatening complications", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "25538343_3", "wnd_id": "25538343_3_1", "text": "Administration of thiazide diuretics also has been the cause of hyponatremia .", "tokens": ["Administration", "of", "thiazide", "diuretics", "also", "has", "been", "the", "cause", "of", "hyponatremia", "."], "event_mentions": [{"id": "25538343_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 8, "end": 9}, "arguments": [{"entity_id": "25538343_3_Ent1", "role": "Treatment", "text": "thiazide diuretics", "start": 2, "end": 4}, {"entity_id": "25538343_3_Ent2", "role": "Treatment_Drug", "text": "thiazide diuretics", "start": 2, "end": 4}, {"entity_id": "25538343_3_Ent0", "role": "Effect", "text": "hyponatremia", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "25538343_3_Ent1", "text": "thiazide diuretics", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "25538343_3_Ent2", "text": "thiazide diuretics", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "25538343_3_Ent0", "text": "hyponatremia", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "25538343_4", "wnd_id": "25538343_4_1", "text": "We report a case of duloxetine - induced hyponatremia in an elderly patient treated with thiazide diuretics .", "tokens": ["We", "report", "a", "case", "of", "duloxetine", "-", "induced", "hyponatremia", "in", "an", "elderly", "patient", "treated", "with", "thiazide", "diuretics", "."], "event_mentions": [{"id": "25538343_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "25538343_4_Ent3", "role": "Treatment", "text": "duloxetine", "start": 5, "end": 6}, {"entity_id": "25538343_4_Ent5", "role": "Treatment_Drug", "text": "duloxetine", "start": 5, "end": 6}, {"entity_id": "25538343_4_Ent8", "role": "Combination_Drug", "text": "duloxetine", "start": 5, "end": 6}, {"entity_id": "25538343_4_Ent2", "role": "Effect", "text": "hyponatremia", "start": 8, "end": 9}, {"entity_id": "25538343_4_Ent0", "role": "Subject", "text": "an elderly patient", "start": 10, "end": 13}, {"entity_id": "25538343_4_Ent1", "role": "Subject_Age", "text": "elderly", "start": 11, "end": 12}, {"entity_id": "25538343_4_Ent4", "role": "Treatment", "text": "thiazide diuretics", "start": 15, "end": 17}, {"entity_id": "25538343_4_Ent6", "role": "Treatment_Drug", "text": "thiazide diuretics", "start": 15, "end": 17}, {"entity_id": "25538343_4_Ent7", "role": "Combination_Drug", "text": "thiazide diuretics", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "25538343_4_Ent3", "text": "duloxetine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "25538343_4_Ent5", "text": "duloxetine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "25538343_4_Ent8", "text": "duloxetine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "25538343_4_Ent2", "text": "hyponatremia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "25538343_4_Ent0", "text": "an elderly patient", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "25538343_4_Ent1", "text": "elderly", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "25538343_4_Ent4", "text": "thiazide diuretics", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "25538343_4_Ent6", "text": "thiazide diuretics", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "25538343_4_Ent7", "text": "thiazide diuretics", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "25540831_7", "wnd_id": "25540831_7_1", "text": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics .", "tokens": ["Most", "physicians", "are", "aware", "of", "serotonin", "syndrome", "secondary", "to", "antidepressants", "but", "do", "not", "think", "about", "other", "classes", "of", "medications", "such", "as", "analgesics", "."], "event_mentions": [{"id": "25540831_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 7, "end": 8}, "arguments": [{"entity_id": "25540831_7_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 5, "end": 7}, {"entity_id": "25540831_7_Ent1", "role": "Treatment", "text": "antidepressants", "start": 9, "end": 10}, {"entity_id": "25540831_7_Ent2", "role": "Treatment_Drug", "text": "antidepressants", "start": 9, "end": 10}, {"entity_id": "25540831_7_Ent3", "role": "Treatment_Drug", "text": "analgesics", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "25540831_7_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "25540831_7_Ent1", "text": "antidepressants", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "25540831_7_Ent2", "text": "antidepressants", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "25540831_7_Ent3", "text": "analgesics", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "2554727_5", "wnd_id": "2554727_5_1", "text": "Peripheral nerve dysfunction is a potentially serious complication of high - dose cytosine arabinoside .", "tokens": ["Peripheral", "nerve", "dysfunction", "is", "a", "potentially", "serious", "complication", "of", "high", "-", "dose", "cytosine", "arabinoside", "."], "event_mentions": [{"id": "2554727_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 8, "end": 9}, "arguments": [{"entity_id": "2554727_5_Ent0", "role": "Effect", "text": "Peripheral nerve dysfunction", "start": 0, "end": 3}, {"entity_id": "2554727_5_Ent3", "role": "Treatment_Dosage", "text": "high - dose", "start": 9, "end": 12}, {"entity_id": "2554727_5_Ent1", "role": "Treatment", "text": "cytosine arabinoside", "start": 12, "end": 14}, {"entity_id": "2554727_5_Ent2", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "2554727_5_Ent0", "text": "Peripheral nerve dysfunction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2554727_5_Ent3", "text": "high - dose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "2554727_5_Ent1", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "2554727_5_Ent2", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "25671244_4", "wnd_id": "25671244_4_1", "text": "( Case 1 ) A 29 - year - old woman with overdose of metaxalone presented to the emergency department with altered mental status , seizure - like activity , hyperthermia , rigidity in the lower extremities , myoclonus , and hyperreflexia .", "tokens": ["(", "Case", "1", ")", "A", "29", "-", "year", "-", "old", "woman", "with", "overdose", "of", "metaxalone", "presented", "to", "the", "emergency", "department", "with", "altered", "mental", "status", ",", "seizure", "-", "like", "activity", ",", "hyperthermia", ",", "rigidity", "in", "the", "lower", "extremities", ",", "myoclonus", ",", "and", "hyperreflexia", "."], "event_mentions": [{"id": "25671244_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 15, "end": 16}, "arguments": [{"entity_id": "25671244_4_Ent0", "role": "Subject", "text": "A 29 - year - old woman", "start": 4, "end": 11}, {"entity_id": "25671244_4_Ent1", "role": "Subject_Age", "text": "29 - year - old", "start": 5, "end": 10}, {"entity_id": "25671244_4_Ent2", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "25671244_4_Ent6", "role": "Treatment_Dosage", "text": "overdose", "start": 12, "end": 13}, {"entity_id": "25671244_4_Ent4", "role": "Treatment", "text": "metaxalone", "start": 14, "end": 15}, {"entity_id": "25671244_4_Ent5", "role": "Treatment_Drug", "text": "metaxalone", "start": 14, "end": 15}, {"entity_id": "25671244_4_Ent3", "role": "Effect", "text": "altered mental status , seizure - like activity , hyperthermia , rigidity in the lower extremities , myoclonus , and hyperreflexia", "start": 21, "end": 42}]}], "entity_mentions": [{"id": "25671244_4_Ent0", "text": "A 29 - year - old woman", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "25671244_4_Ent1", "text": "29 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "25671244_4_Ent2", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "25671244_4_Ent6", "text": "overdose", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "25671244_4_Ent4", "text": "metaxalone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "25671244_4_Ent5", "text": "metaxalone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "25671244_4_Ent3", "text": "altered mental status , seizure - like activity , hyperthermia , rigidity in the lower extremities , myoclonus , and hyperreflexia", "entity_type": "Entity", "start": 21, "end": 42}], "lang": "en"}
{"doc_id": "25957434_2", "wnd_id": "25957434_2_1", "text": "The spectrum of cutaneous eruptions associated with dihydropyridines is extensive , varying from exanthemas to severe adverse events .", "tokens": ["The", "spectrum", "of", "cutaneous", "eruptions", "associated", "with", "dihydropyridines", "is", "extensive", ",", "varying", "from", "exanthemas", "to", "severe", "adverse", "events", "."], "event_mentions": [{"id": "25957434_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "25957434_2_Ent0", "role": "Effect", "text": "cutaneous eruptions", "start": 3, "end": 5}, {"entity_id": "25957434_2_Ent2", "role": "Treatment", "text": "dihydropyridines", "start": 7, "end": 8}, {"entity_id": "25957434_2_Ent3", "role": "Treatment_Drug", "text": "dihydropyridines", "start": 7, "end": 8}, {"entity_id": "25957434_2_Ent1", "role": "Effect", "text": "exanthemas", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "25957434_2_Ent0", "text": "cutaneous eruptions", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "25957434_2_Ent2", "text": "dihydropyridines", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "25957434_2_Ent3", "text": "dihydropyridines", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "25957434_2_Ent1", "text": "exanthemas", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "2621382_3", "wnd_id": "2621382_3_1", "text": "Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of clofazimine , showed discoloration of nail plate , subungual hyperkeratosis and onycholysis .", "tokens": ["Two", "cases", "of", "lepromatous", "leprosy", "with", "erythema", "nodosum", "leprosum", "who", "were", "on", "high", "doses", "of", "clofazimine", ",", "showed", "discoloration", "of", "nail", "plate", ",", "subungual", "hyperkeratosis", "and", "onycholysis", "."], "event_mentions": [{"id": "2621382_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "showed", "start": 17, "end": 18}, "arguments": [{"entity_id": "2621382_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "2621382_3_Ent0", "role": "Subject", "text": "Two cases of lepromatous leprosy with erythema nodosum leprosum", "start": 0, "end": 9}, {"entity_id": "2621382_3_Ent4", "role": "Treatment_Disorder", "text": "lepromatous leprosy with erythema nodosum leprosum", "start": 3, "end": 9}, {"entity_id": "2621382_3_Ent6", "role": "Treatment_Dosage", "text": "high doses", "start": 12, "end": 14}, {"entity_id": "2621382_3_Ent3", "role": "Treatment", "text": "high doses of clofazimine", "start": 12, "end": 16}, {"entity_id": "2621382_3_Ent5", "role": "Treatment_Drug", "text": "clofazimine", "start": 15, "end": 16}, {"entity_id": "2621382_3_Ent2", "role": "Effect", "text": "discoloration of nail plate , subungual hyperkeratosis and onycholysis", "start": 18, "end": 27}]}], "entity_mentions": [{"id": "2621382_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2621382_3_Ent0", "text": "Two cases of lepromatous leprosy with erythema nodosum leprosum", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "2621382_3_Ent4", "text": "lepromatous leprosy with erythema nodosum leprosum", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "2621382_3_Ent6", "text": "high doses", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "2621382_3_Ent3", "text": "high doses of clofazimine", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "2621382_3_Ent5", "text": "clofazimine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2621382_3_Ent2", "text": "discoloration of nail plate , subungual hyperkeratosis and onycholysis", "entity_type": "Entity", "start": 18, "end": 27}], "lang": "en"}
{"doc_id": "2719905_2", "wnd_id": "2719905_2_1", "text": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome .", "tokens": ["We", "report", "a", "case", "of", "long", "lasting", "respiratory", "depression", "after", "intravenous", "administration", "of", "morphine", "to", "a", "7", "year", "old", "girl", "with", "haemolytic", "uraemic", "syndrome", "."], "event_mentions": [{"id": "2719905_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "2719905_2_Ent4", "role": "Effect", "text": "a case of long lasting respiratory depression", "start": 2, "end": 9}, {"entity_id": "2719905_2_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 10, "end": 11}, {"entity_id": "2719905_2_Ent5", "role": "Treatment", "text": "intravenous administration of morphine", "start": 10, "end": 14}, {"entity_id": "2719905_2_Ent7", "role": "Treatment_Drug", "text": "morphine", "start": 13, "end": 14}, {"entity_id": "2719905_2_Ent0", "role": "Subject", "text": "a 7 year old girl with haemolytic uraemic syndrome", "start": 15, "end": 24}, {"entity_id": "2719905_2_Ent1", "role": "Subject_Age", "text": "7 year old", "start": 16, "end": 19}, {"entity_id": "2719905_2_Ent2", "role": "Subject_Gender", "text": "girl", "start": 19, "end": 20}, {"entity_id": "2719905_2_Ent3", "role": "Subject_Disorder", "text": "haemolytic uraemic syndrome", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "2719905_2_Ent4", "text": "a case of long lasting respiratory depression", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "2719905_2_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2719905_2_Ent5", "text": "intravenous administration of morphine", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "2719905_2_Ent7", "text": "morphine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "2719905_2_Ent0", "text": "a 7 year old girl with haemolytic uraemic syndrome", "entity_type": "Entity", "start": 15, "end": 24}, {"id": "2719905_2_Ent1", "text": "7 year old", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "2719905_2_Ent2", "text": "girl", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "2719905_2_Ent3", "text": "haemolytic uraemic syndrome", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "2728526_2", "wnd_id": "2728526_2_1", "text": "Rifampin can be associated with severe adverse effects such as hepatitis , acute renal failure , hemolytic anemia , and thrombocytopenia .", "tokens": ["Rifampin", "can", "be", "associated", "with", "severe", "adverse", "effects", "such", "as", "hepatitis", ",", "acute", "renal", "failure", ",", "hemolytic", "anemia", ",", "and", "thrombocytopenia", "."], "event_mentions": [{"id": "2728526_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "2728526_2_Ent1", "role": "Treatment", "text": "Rifampin", "start": 0, "end": 1}, {"entity_id": "2728526_2_Ent2", "role": "Treatment_Drug", "text": "Rifampin", "start": 0, "end": 1}, {"entity_id": "2728526_2_Ent0", "role": "Effect", "text": "hepatitis , acute renal failure , hemolytic anemia , and thrombocytopenia", "start": 10, "end": 21}]}], "entity_mentions": [{"id": "2728526_2_Ent1", "text": "Rifampin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2728526_2_Ent2", "text": "Rifampin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2728526_2_Ent0", "text": "hepatitis , acute renal failure , hemolytic anemia , and thrombocytopenia", "entity_type": "Entity", "start": 10, "end": 21}], "lang": "en"}
{"doc_id": "2796025_1", "wnd_id": "2796025_1_1", "text": "Panic anxiety after abrupt discontinuation of mianserin .", "tokens": ["Panic", "anxiety", "after", "abrupt", "discontinuation", "of", "mianserin", "."], "event_mentions": [{"id": "2796025_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "2796025_1_Ent0", "role": "Effect", "text": "Panic anxiety", "start": 0, "end": 2}, {"entity_id": "2796025_1_Ent1", "role": "Treatment", "text": "abrupt discontinuation of mianserin", "start": 3, "end": 7}, {"entity_id": "2796025_1_Ent2", "role": "Treatment_Drug", "text": "mianserin", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "2796025_1_Ent0", "text": "Panic anxiety", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2796025_1_Ent1", "text": "abrupt discontinuation of mianserin", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "2796025_1_Ent2", "text": "mianserin", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "2796025_2", "wnd_id": "2796025_2_1", "text": "This panic anxiety was not relieved by taking etizolam and flunitrazepam again , but subsided rapidly by the re - administration of mianserin 30 mg / day , and because of that the depressive symptom also disappeared .", "tokens": ["This", "panic", "anxiety", "was", "not", "relieved", "by", "taking", "etizolam", "and", "flunitrazepam", "again", ",", "but", "subsided", "rapidly", "by", "the", "re", "-", "administration", "of", "mianserin", "30", "mg", "/", "day", ",", "and", "because", "of", "that", "the", "depressive", "symptom", "also", "disappeared", "."], "event_mentions": [{"id": "2796025_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "subsided", "start": 14, "end": 15}, "arguments": [{"entity_id": "2796025_2_Ent3", "role": "Treatment_Disorder", "text": "panic anxiety", "start": 1, "end": 3}, {"entity_id": "2796025_2_Ent6", "role": "Treatment_Drug", "text": "etizolam", "start": 8, "end": 9}, {"entity_id": "2796025_2_Ent9", "role": "Combination_Drug", "text": "etizolam", "start": 8, "end": 9}, {"entity_id": "2796025_2_Ent1", "role": "Treatment", "text": "etizolam and flunitrazepam", "start": 8, "end": 11}, {"entity_id": "2796025_2_Ent5", "role": "Treatment_Drug", "text": "flunitrazepam", "start": 10, "end": 11}, {"entity_id": "2796025_2_Ent10", "role": "Combination_Drug", "text": "flunitrazepam", "start": 10, "end": 11}, {"entity_id": "2796025_2_Ent7", "role": "Treatment_Drug", "text": "mianserin", "start": 22, "end": 23}, {"entity_id": "2796025_2_Ent11", "role": "Combination_Drug", "text": "mianserin", "start": 22, "end": 23}, {"entity_id": "2796025_2_Ent2", "role": "Treatment", "text": "mianserin 30 mg / day", "start": 22, "end": 27}, {"entity_id": "2796025_2_Ent8", "role": "Treatment_Dosage", "text": "30 mg / day", "start": 23, "end": 27}, {"entity_id": "2796025_2_Ent0", "role": "Effect", "text": "because of that the depressive symptom also disappeared", "start": 29, "end": 37}, {"entity_id": "2796025_2_Ent4", "role": "Treatment_Disorder", "text": "depressive symptom", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "2796025_2_Ent3", "text": "panic anxiety", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "2796025_2_Ent6", "text": "etizolam", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2796025_2_Ent9", "text": "etizolam", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2796025_2_Ent1", "text": "etizolam and flunitrazepam", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "2796025_2_Ent5", "text": "flunitrazepam", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2796025_2_Ent10", "text": "flunitrazepam", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2796025_2_Ent7", "text": "mianserin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "2796025_2_Ent11", "text": "mianserin", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "2796025_2_Ent2", "text": "mianserin 30 mg / day", "entity_type": "Entity", "start": 22, "end": 27}, {"id": "2796025_2_Ent8", "text": "30 mg / day", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "2796025_2_Ent0", "text": "because of that the depressive symptom also disappeared", "entity_type": "Entity", "start": 29, "end": 37}, {"id": "2796025_2_Ent4", "text": "depressive symptom", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "2830062_2", "wnd_id": "2830062_2_1", "text": "Two patients with adrenal carcinoma treated with 2,2 - bis ( 2 - chlorophenyl - 4 - chlorophenyl) - 1,1 - dichloroethane ( o , p' - DDD ) as adjuvant therapy were studied .", "tokens": ["Two", "patients", "with", "adrenal", "carcinoma", "treated", "with", "2,2", "-", "bis", "(", "2", "-", "chlorophenyl", "-", "4", "-", "chlorophenyl)", "-", "1,1", "-", "dichloroethane", "(", "o", ",", "p'", "-", "DDD", ")", "as", "adjuvant", "therapy", "were", "studied", "."], "event_mentions": [{"id": "2830062_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 5, "end": 6}, "arguments": [{"entity_id": "2830062_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "2830062_2_Ent0", "role": "Subject", "text": "Two patients with adrenal carcinoma", "start": 0, "end": 5}, {"entity_id": "2830062_2_Ent4", "role": "Treatment_Disorder", "text": "adrenal carcinoma", "start": 3, "end": 5}, {"entity_id": "2830062_2_Ent3", "role": "Treatment_Drug", "text": "2,2 - bis ( 2 - chlorophenyl - 4 - chlorophenyl) - 1,1 - dichloroethane", "start": 7, "end": 22}, {"entity_id": "2830062_2_Ent2", "role": "Treatment", "text": "2,2 - bis ( 2 - chlorophenyl - 4 - chlorophenyl) - 1,1 - dichloroethane ( o , p' - DDD ) as adjuvant therapy", "start": 7, "end": 32}]}], "entity_mentions": [{"id": "2830062_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2830062_2_Ent0", "text": "Two patients with adrenal carcinoma", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "2830062_2_Ent4", "text": "adrenal carcinoma", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "2830062_2_Ent3", "text": "2,2 - bis ( 2 - chlorophenyl - 4 - chlorophenyl) - 1,1 - dichloroethane", "entity_type": "Entity", "start": 7, "end": 22}, {"id": "2830062_2_Ent2", "text": "2,2 - bis ( 2 - chlorophenyl - 4 - chlorophenyl) - 1,1 - dichloroethane ( o , p' - DDD ) as adjuvant therapy", "entity_type": "Entity", "start": 7, "end": 32}], "lang": "en"}
{"doc_id": "2875665_2", "wnd_id": "2875665_2_1", "text": "Administration of amantadine was associated with psychotic decompensations in two schizophrenic patients being maintained on concomitant neuroleptic medication .", "tokens": ["Administration", "of", "amantadine", "was", "associated", "with", "psychotic", "decompensations", "in", "two", "schizophrenic", "patients", "being", "maintained", "on", "concomitant", "neuroleptic", "medication", "."], "event_mentions": [{"id": "2875665_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "2875665_2_Ent5", "role": "Treatment", "text": "amantadine", "start": 2, "end": 3}, {"entity_id": "2875665_2_Ent6", "role": "Treatment_Drug", "text": "amantadine", "start": 2, "end": 3}, {"entity_id": "2875665_2_Ent9", "role": "Combination_Drug", "text": "amantadine", "start": 2, "end": 3}, {"entity_id": "2875665_2_Ent3", "role": "Effect", "text": "psychotic decompensations", "start": 6, "end": 8}, {"entity_id": "2875665_2_Ent1", "role": "Subject_Population", "text": "two", "start": 9, "end": 10}, {"entity_id": "2875665_2_Ent0", "role": "Subject", "text": "two schizophrenic patients", "start": 9, "end": 12}, {"entity_id": "2875665_2_Ent2", "role": "Subject_Disorder", "text": "schizophrenic", "start": 10, "end": 11}, {"entity_id": "2875665_2_Ent4", "role": "Treatment", "text": "concomitant neuroleptic medication", "start": 15, "end": 18}, {"entity_id": "2875665_2_Ent7", "role": "Treatment_Drug", "text": "neuroleptic", "start": 16, "end": 17}, {"entity_id": "2875665_2_Ent8", "role": "Combination_Drug", "text": "neuroleptic", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "2875665_2_Ent5", "text": "amantadine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "2875665_2_Ent6", "text": "amantadine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "2875665_2_Ent9", "text": "amantadine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "2875665_2_Ent3", "text": "psychotic decompensations", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "2875665_2_Ent1", "text": "two", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2875665_2_Ent0", "text": "two schizophrenic patients", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "2875665_2_Ent2", "text": "schizophrenic", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2875665_2_Ent4", "text": "concomitant neuroleptic medication", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "2875665_2_Ent7", "text": "neuroleptic", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "2875665_2_Ent8", "text": "neuroleptic", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "2924444_5", "wnd_id": "2924444_5_1", "text": "Electrocardiographic findings and laboratory data indicated a diagnosis of acute myocardial infarction due to the L - thyroxine therapy .", "tokens": ["Electrocardiographic", "findings", "and", "laboratory", "data", "indicated", "a", "diagnosis", "of", "acute", "myocardial", "infarction", "due", "to", "the", "L", "-", "thyroxine", "therapy", "."], "event_mentions": [{"id": "2924444_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 12, "end": 14}, "arguments": [{"entity_id": "2924444_5_Ent0", "role": "Effect", "text": "acute myocardial infarction", "start": 9, "end": 12}, {"entity_id": "2924444_5_Ent1", "role": "Treatment", "text": "the L - thyroxine therapy .", "start": 14, "end": 20}, {"entity_id": "2924444_5_Ent2", "role": "Treatment_Drug", "text": "L - thyroxine", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "2924444_5_Ent0", "text": "acute myocardial infarction", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "2924444_5_Ent1", "text": "the L - thyroxine therapy .", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "2924444_5_Ent2", "text": "L - thyroxine", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "2931445_2", "wnd_id": "2931445_2_1", "text": "A study of in vitro reactivity to L - T4 , as assessed by peripheral blood lymphocyte transformation , was carried out in a patient with Hashimoto 's disease who developed leukopenia during treatment with L - T4 .", "tokens": ["A", "study", "of", "in", "vitro", "reactivity", "to", "L", "-", "T4", ",", "as", "assessed", "by", "peripheral", "blood", "lymphocyte", "transformation", ",", "was", "carried", "out", "in", "a", "patient", "with", "Hashimoto", "'s", "disease", "who", "developed", "leukopenia", "during", "treatment", "with", "L", "-", "T4", "."], "event_mentions": [{"id": "2931445_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 30, "end": 31}, "arguments": [{"entity_id": "2931445_2_Ent0", "role": "Subject", "text": "a patient with Hashimoto 's disease", "start": 23, "end": 29}, {"entity_id": "2931445_2_Ent3", "role": "Treatment_Disorder", "text": "Hashimoto 's disease", "start": 26, "end": 29}, {"entity_id": "2931445_2_Ent1", "role": "Effect", "text": "leukopenia", "start": 31, "end": 32}, {"entity_id": "2931445_2_Ent2", "role": "Treatment", "text": "L - T4", "start": 35, "end": 38}, {"entity_id": "2931445_2_Ent4", "role": "Treatment_Drug", "text": "L - T4", "start": 35, "end": 38}]}], "entity_mentions": [{"id": "2931445_2_Ent0", "text": "a patient with Hashimoto 's disease", "entity_type": "Entity", "start": 23, "end": 29}, {"id": "2931445_2_Ent3", "text": "Hashimoto 's disease", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "2931445_2_Ent1", "text": "leukopenia", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "2931445_2_Ent2", "text": "L - T4", "entity_type": "Entity", "start": 35, "end": 38}, {"id": "2931445_2_Ent4", "text": "L - T4", "entity_type": "Entity", "start": 35, "end": 38}], "lang": "en"}
{"doc_id": "2931445_3", "wnd_id": "2931445_3_1", "text": "L - T4 stimulated lymphocyte transformation in this patient .", "tokens": ["L", "-", "T4", "stimulated", "lymphocyte", "transformation", "in", "this", "patient", "."], "event_mentions": [{"id": "2931445_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "stimulated", "start": 3, "end": 4}, "arguments": [{"entity_id": "2931445_3_Ent2", "role": "Treatment", "text": "L - T4", "start": 0, "end": 3}, {"entity_id": "2931445_3_Ent3", "role": "Treatment_Drug", "text": "L - T4", "start": 0, "end": 3}, {"entity_id": "2931445_3_Ent1", "role": "Effect", "text": "lymphocyte transformation", "start": 4, "end": 6}, {"entity_id": "2931445_3_Ent0", "role": "Subject", "text": "this patient", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "2931445_3_Ent2", "text": "L - T4", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2931445_3_Ent3", "text": "L - T4", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2931445_3_Ent1", "text": "lymphocyte transformation", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2931445_3_Ent0", "text": "this patient", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "2935070_2", "wnd_id": "2935070_2_1", "text": "However , there are few reports in the literature of ampicillin as a cause of acute interstitial nephritis .", "tokens": ["However", ",", "there", "are", "few", "reports", "in", "the", "literature", "of", "ampicillin", "as", "a", "cause", "of", "acute", "interstitial", "nephritis", "."], "event_mentions": [{"id": "2935070_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 13, "end": 14}, "arguments": [{"entity_id": "2935070_2_Ent1", "role": "Treatment", "text": "ampicillin", "start": 10, "end": 11}, {"entity_id": "2935070_2_Ent2", "role": "Treatment_Drug", "text": "ampicillin", "start": 10, "end": 11}, {"entity_id": "2935070_2_Ent0", "role": "Effect", "text": "acute interstitial nephritis", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "2935070_2_Ent1", "text": "ampicillin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2935070_2_Ent2", "text": "ampicillin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2935070_2_Ent0", "text": "acute interstitial nephritis", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "2937155_1", "wnd_id": "2937155_1_1", "text": "A patient receiving vancomycin for a serious staphylococcal infection had a lupus - like syndrome characterized by a malar rash , pain and erythema of the cartilage of both ears , and tender erythematous and hemorrhagic lesions of the finger tips .", "tokens": ["A", "patient", "receiving", "vancomycin", "for", "a", "serious", "staphylococcal", "infection", "had", "a", "lupus", "-", "like", "syndrome", "characterized", "by", "a", "malar", "rash", ",", "pain", "and", "erythema", "of", "the", "cartilage", "of", "both", "ears", ",", "and", "tender", "erythematous", "and", "hemorrhagic", "lesions", "of", "the", "finger", "tips", "."], "event_mentions": [{"id": "2937155_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 9, "end": 10}, "arguments": [{"entity_id": "2937155_1_Ent1", "role": "Treatment", "text": "vancomycin", "start": 3, "end": 4}, {"entity_id": "2937155_1_Ent2", "role": "Treatment_Drug", "text": "vancomycin", "start": 3, "end": 4}, {"entity_id": "2937155_1_Ent3", "role": "Treatment_Disorder", "text": "serious staphylococcal infection", "start": 6, "end": 9}, {"entity_id": "2937155_1_Ent0", "role": "Effect", "text": "a lupus - like syndrome characterized by a malar rash , pain and erythema of the cartilage of both ears , and tender erythematous and hemorrhagic lesions of the finger tips", "start": 10, "end": 41}]}], "entity_mentions": [{"id": "2937155_1_Ent1", "text": "vancomycin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2937155_1_Ent2", "text": "vancomycin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2937155_1_Ent3", "text": "serious staphylococcal infection", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "2937155_1_Ent0", "text": "a lupus - like syndrome characterized by a malar rash , pain and erythema of the cartilage of both ears , and tender erythematous and hemorrhagic lesions of the finger tips", "entity_type": "Entity", "start": 10, "end": 41}], "lang": "en"}
{"doc_id": "2956288_1", "wnd_id": "2956288_1_1", "text": "Ethambutol is frequently used in the treatment of tuberculosis , and , although optic neuropathies have been reported with the use of ethambutol , this adverse side effect has been considered to be rare and generally reversible with discontinuation of the medication .", "tokens": ["Ethambutol", "is", "frequently", "used", "in", "the", "treatment", "of", "tuberculosis", ",", "and", ",", "although", "optic", "neuropathies", "have", "been", "reported", "with", "the", "use", "of", "ethambutol", ",", "this", "adverse", "side", "effect", "has", "been", "considered", "to", "be", "rare", "and", "generally", "reversible", "with", "discontinuation", "of", "the", "medication", "."], "event_mentions": [{"id": "2956288_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 3, "end": 4}, "arguments": [{"entity_id": "2956288_1_Ent0", "role": "Treatment", "text": "Ethambutol", "start": 0, "end": 1}, {"entity_id": "2956288_1_Ent2", "role": "Treatment_Drug", "text": "Ethambutol", "start": 0, "end": 1}, {"entity_id": "2956288_1_Ent1", "role": "Treatment_Disorder", "text": "tuberculosis", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "2956288_1_Ent0", "text": "Ethambutol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2956288_1_Ent2", "text": "Ethambutol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2956288_1_Ent1", "text": "tuberculosis", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "2956288_3", "wnd_id": "2956288_3_1", "text": "Optic neuropathy in ethambutol - treated renal tuberculosis .", "tokens": ["Optic", "neuropathy", "in", "ethambutol", "-", "treated", "renal", "tuberculosis", "."], "event_mentions": [{"id": "2956288_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 5, "end": 6}, "arguments": [{"entity_id": "2956288_3_Ent0", "role": "Effect", "text": "Optic neuropathy", "start": 0, "end": 2}, {"entity_id": "2956288_3_Ent1", "role": "Treatment", "text": "ethambutol", "start": 3, "end": 4}, {"entity_id": "2956288_3_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 3, "end": 4}, {"entity_id": "2956288_3_Ent3", "role": "Treatment_Disorder", "text": "renal tuberculosis", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "2956288_3_Ent0", "text": "Optic neuropathy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2956288_3_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2956288_3_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2956288_3_Ent3", "text": "renal tuberculosis", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "3003260_1", "wnd_id": "3003260_1_1", "text": "A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five - drug antiemetic regimen for cisplatin - associated nausea .", "tokens": ["A", "young", "diamond", "dealer", "developed", "visual", "impairment", "attributed", "to", "bilateral", "posterior", "subcapsular", "cataracts", "following", "only", "four", "courses", "of", "intermittent", "Decadron", "used", "as", "part", "of", "a", "five", "-", "drug", "antiemetic", "regimen", "for", "cisplatin", "-", "associated", "nausea", "."], "event_mentions": [{"id": "3003260_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 13, "end": 14}, "arguments": [{"entity_id": "3003260_1_Ent0", "role": "Subject", "text": "A young diamond dealer", "start": 0, "end": 4}, {"entity_id": "3003260_1_Ent1", "role": "Subject_Age", "text": "young", "start": 1, "end": 2}, {"entity_id": "3003260_1_Ent2", "role": "Effect", "text": "visual impairment attributed to bilateral posterior subcapsular cataracts", "start": 5, "end": 13}, {"entity_id": "3003260_1_Ent3", "role": "Treatment", "text": "only four courses of intermittent Decadron used as part of a five - drug antiemetic regimen", "start": 14, "end": 30}, {"entity_id": "3003260_1_Ent7", "role": "Treatment_Dosage", "text": "four courses", "start": 15, "end": 17}, {"entity_id": "3003260_1_Ent5", "role": "Treatment_Drug", "text": "Decadron", "start": 19, "end": 20}, {"entity_id": "3003260_1_Ent8", "role": "Combination_Drug", "text": "Decadron", "start": 19, "end": 20}, {"entity_id": "3003260_1_Ent6", "role": "Treatment_Drug", "text": "five - drug antiemetic regimen", "start": 25, "end": 30}, {"entity_id": "3003260_1_Ent9", "role": "Combination_Drug", "text": "five - drug antiemetic regimen", "start": 25, "end": 30}, {"entity_id": "3003260_1_Ent4", "role": "Treatment_Disorder", "text": "cisplatin - associated nausea", "start": 31, "end": 35}]}], "entity_mentions": [{"id": "3003260_1_Ent0", "text": "A young diamond dealer", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3003260_1_Ent1", "text": "young", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3003260_1_Ent2", "text": "visual impairment attributed to bilateral posterior subcapsular cataracts", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "3003260_1_Ent3", "text": "only four courses of intermittent Decadron used as part of a five - drug antiemetic regimen", "entity_type": "Entity", "start": 14, "end": 30}, {"id": "3003260_1_Ent7", "text": "four courses", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "3003260_1_Ent5", "text": "Decadron", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3003260_1_Ent8", "text": "Decadron", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3003260_1_Ent6", "text": "five - drug antiemetic regimen", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "3003260_1_Ent9", "text": "five - drug antiemetic regimen", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "3003260_1_Ent4", "text": "cisplatin - associated nausea", "entity_type": "Entity", "start": 31, "end": 35}], "lang": "en"}
{"doc_id": "3003260_2", "wnd_id": "3003260_2_1", "text": "Cataracts induced by intermittent Decadron used as an antiemetic .", "tokens": ["Cataracts", "induced", "by", "intermittent", "Decadron", "used", "as", "an", "antiemetic", "."], "event_mentions": [{"id": "3003260_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "3003260_2_Ent0", "role": "Effect", "text": "Cataracts", "start": 0, "end": 1}, {"entity_id": "3003260_2_Ent1", "role": "Treatment", "text": "Decadron", "start": 4, "end": 5}, {"entity_id": "3003260_2_Ent2", "role": "Treatment_Drug", "text": "Decadron", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "3003260_2_Ent0", "text": "Cataracts", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3003260_2_Ent1", "text": "Decadron", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3003260_2_Ent2", "text": "Decadron", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "3030084_1", "wnd_id": "3030084_1_1", "text": "Transient phenytoin induced IgA deficiency and permanent IgE increase .", "tokens": ["Transient", "phenytoin", "induced", "IgA", "deficiency", "and", "permanent", "IgE", "increase", "."], "event_mentions": [{"id": "3030084_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3030084_1_Ent1", "role": "Treatment", "text": "phenytoin", "start": 1, "end": 2}, {"entity_id": "3030084_1_Ent2", "role": "Treatment_Drug", "text": "phenytoin", "start": 1, "end": 2}, {"entity_id": "3030084_1_Ent0", "role": "Effect", "text": "IgA deficiency and permanent IgE increase", "start": 3, "end": 9}]}], "entity_mentions": [{"id": "3030084_1_Ent1", "text": "phenytoin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3030084_1_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3030084_1_Ent0", "text": "IgA deficiency and permanent IgE increase", "entity_type": "Entity", "start": 3, "end": 9}], "lang": "en"}
{"doc_id": "3067748_1", "wnd_id": "3067748_1_1", "text": "Adrenaline dacryolith : detection by ultrasound examination of the nasolacrimal duct .", "tokens": ["Adrenaline", "dacryolith", ":", "detection", "by", "ultrasound", "examination", "of", "the", "nasolacrimal", "duct", "."], "event_mentions": [{"id": "3067748_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Adrenaline dacryolith", "start": 0, "end": 2}, "arguments": [{"entity_id": "3067748_1_Ent1", "role": "Treatment", "text": "Adrenaline", "start": 0, "end": 1}, {"entity_id": "3067748_1_Ent2", "role": "Treatment_Drug", "text": "Adrenaline", "start": 0, "end": 1}, {"entity_id": "3067748_1_Ent0", "role": "Effect", "text": "dacryolith", "start": 1, "end": 2}, {"entity_id": "3067748_1_Ent3", "role": "Treatment_Route", "text": "nasolacrimal duct", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "3067748_1_Ent1", "text": "Adrenaline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3067748_1_Ent2", "text": "Adrenaline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3067748_1_Ent0", "text": "dacryolith", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3067748_1_Ent3", "text": "nasolacrimal duct", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "3101617_1", "wnd_id": "3101617_1_1", "text": "Co - trimoxazole red cell aplasia in leukaemia .", "tokens": ["Co", "-", "trimoxazole", "red", "cell", "aplasia", "in", "leukaemia", "."], "event_mentions": [{"id": "3101617_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 6, "end": 7}, "arguments": [{"entity_id": "3101617_1_Ent1", "role": "Treatment", "text": "Co - trimoxazole", "start": 0, "end": 3}, {"entity_id": "3101617_1_Ent3", "role": "Treatment_Drug", "text": "Co - trimoxazole", "start": 0, "end": 3}, {"entity_id": "3101617_1_Ent0", "role": "Effect", "text": "red cell aplasia", "start": 3, "end": 6}, {"entity_id": "3101617_1_Ent2", "role": "Treatment_Disorder", "text": "leukaemia", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "3101617_1_Ent1", "text": "Co - trimoxazole", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3101617_1_Ent3", "text": "Co - trimoxazole", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3101617_1_Ent0", "text": "red cell aplasia", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3101617_1_Ent2", "text": "leukaemia", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "3124393_2", "wnd_id": "3124393_2_1", "text": "Calcification and ossification of the spinal arachnoid after intrathecal administration of Depo - Medrol .", "tokens": ["Calcification", "and", "ossification", "of", "the", "spinal", "arachnoid", "after", "intrathecal", "administration", "of", "Depo", "-", "Medrol", "."], "event_mentions": [{"id": "3124393_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "3124393_2_Ent0", "role": "Effect", "text": "Calcification and ossification of the spinal arachnoid", "start": 0, "end": 7}, {"entity_id": "3124393_2_Ent2", "role": "Treatment_Route", "text": "intrathecal", "start": 8, "end": 9}, {"entity_id": "3124393_2_Ent1", "role": "Treatment", "text": "intrathecal administration of Depo - Medrol", "start": 8, "end": 14}, {"entity_id": "3124393_2_Ent3", "role": "Treatment_Drug", "text": "Depo - Medrol", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "3124393_2_Ent0", "text": "Calcification and ossification of the spinal arachnoid", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "3124393_2_Ent2", "text": "intrathecal", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3124393_2_Ent1", "text": "intrathecal administration of Depo - Medrol", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "3124393_2_Ent3", "text": "Depo - Medrol", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "3143551_2", "wnd_id": "3143551_2_1", "text": "A mentally retarded 23 - year - old woman with myoclonic astatic epilepsy developed an abnormal posture of extreme forward flexion , called camptocormia , during valproate monotherapy .", "tokens": ["A", "mentally", "retarded", "23", "-", "year", "-", "old", "woman", "with", "myoclonic", "astatic", "epilepsy", "developed", "an", "abnormal", "posture", "of", "extreme", "forward", "flexion", ",", "called", "camptocormia", ",", "during", "valproate", "monotherapy", "."], "event_mentions": [{"id": "3143551_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 25, "end": 26}, "arguments": [{"entity_id": "3143551_2_Ent0", "role": "Subject", "text": "A mentally retarded 23 - year - old woman with myoclonic astatic epilepsy", "start": 0, "end": 13}, {"entity_id": "3143551_2_Ent1", "role": "Subject_Disorder", "text": "mentally retarded", "start": 1, "end": 3}, {"entity_id": "3143551_2_Ent2", "role": "Subject_Age", "text": "23 - year - old", "start": 3, "end": 8}, {"entity_id": "3143551_2_Ent6", "role": "Treatment_Disorder", "text": "myoclonic astatic epilepsy", "start": 10, "end": 13}, {"entity_id": "3143551_2_Ent3", "role": "Effect", "text": "abnormal posture of extreme forward flexion , called camptocormia ,", "start": 15, "end": 25}, {"entity_id": "3143551_2_Ent4", "role": "Treatment", "text": "valproate", "start": 26, "end": 27}, {"entity_id": "3143551_2_Ent5", "role": "Treatment_Drug", "text": "valproate", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "3143551_2_Ent0", "text": "A mentally retarded 23 - year - old woman with myoclonic astatic epilepsy", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "3143551_2_Ent1", "text": "mentally retarded", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "3143551_2_Ent2", "text": "23 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "3143551_2_Ent6", "text": "myoclonic astatic epilepsy", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "3143551_2_Ent3", "text": "abnormal posture of extreme forward flexion , called camptocormia ,", "entity_type": "Entity", "start": 15, "end": 25}, {"id": "3143551_2_Ent4", "text": "valproate", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "3143551_2_Ent5", "text": "valproate", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "3143551_5", "wnd_id": "3143551_5_1", "text": "Hepatopathy subsided after the cessation of carbamazepine and lynestrenol .", "tokens": ["Hepatopathy", "subsided", "after", "the", "cessation", "of", "carbamazepine", "and", "lynestrenol", "."], "event_mentions": [{"id": "3143551_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "3143551_5_Ent0", "role": "Effect", "text": "Hepatopathy subsided", "start": 0, "end": 2}, {"entity_id": "3143551_5_Ent3", "role": "Treatment_Dosage", "text": "cessation", "start": 4, "end": 5}, {"entity_id": "3143551_5_Ent1", "role": "Treatment", "text": "carbamazepine", "start": 6, "end": 7}, {"entity_id": "3143551_5_Ent4", "role": "Treatment_Drug", "text": "carbamazepine", "start": 6, "end": 7}, {"entity_id": "3143551_5_Ent7", "role": "Combination_Drug", "text": "carbamazepine", "start": 6, "end": 7}, {"entity_id": "3143551_5_Ent2", "role": "Treatment", "text": "lynestrenol", "start": 8, "end": 9}, {"entity_id": "3143551_5_Ent5", "role": "Treatment_Drug", "text": "lynestrenol", "start": 8, "end": 9}, {"entity_id": "3143551_5_Ent6", "role": "Combination_Drug", "text": "lynestrenol", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "3143551_5_Ent0", "text": "Hepatopathy subsided", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3143551_5_Ent3", "text": "cessation", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3143551_5_Ent1", "text": "carbamazepine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3143551_5_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3143551_5_Ent7", "text": "carbamazepine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3143551_5_Ent2", "text": "lynestrenol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3143551_5_Ent5", "text": "lynestrenol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3143551_5_Ent6", "text": "lynestrenol", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "3149484_2", "wnd_id": "3149484_2_1", "text": "Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures .", "tokens": ["Paradoxical", "precipitation", "of", "tonic", "seizures", "by", "lorazepam", "in", "a", "child", "with", "atypical", "absence", "seizures", "."], "event_mentions": [{"id": "3149484_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitation", "start": 1, "end": 2}, "arguments": [{"entity_id": "3149484_2_Ent2", "role": "Effect", "text": "Paradoxical precipitation of tonic seizures", "start": 0, "end": 5}, {"entity_id": "3149484_2_Ent3", "role": "Treatment", "text": "lorazepam", "start": 6, "end": 7}, {"entity_id": "3149484_2_Ent5", "role": "Treatment_Drug", "text": "lorazepam", "start": 6, "end": 7}, {"entity_id": "3149484_2_Ent1", "role": "Subject_Age", "text": "child", "start": 9, "end": 10}, {"entity_id": "3149484_2_Ent0", "role": "Subject", "text": "child with atypical absence seizures", "start": 9, "end": 14}, {"entity_id": "3149484_2_Ent4", "role": "Treatment_Disorder", "text": "absence seizures", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "3149484_2_Ent2", "text": "Paradoxical precipitation of tonic seizures", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "3149484_2_Ent3", "text": "lorazepam", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3149484_2_Ent5", "text": "lorazepam", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3149484_2_Ent1", "text": "child", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3149484_2_Ent0", "text": "child with atypical absence seizures", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "3149484_2_Ent4", "text": "absence seizures", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "3174043_2", "wnd_id": "3174043_2_1", "text": "Niacin maculopathy .", "tokens": ["Niacin", "maculopathy", "."], "event_mentions": [{"id": "3174043_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "maculopathy", "start": 1, "end": 2}, "arguments": [{"entity_id": "3174043_2_Ent1", "role": "Treatment", "text": "Niacin", "start": 0, "end": 1}, {"entity_id": "3174043_2_Ent2", "role": "Treatment_Drug", "text": "Niacin", "start": 0, "end": 1}, {"entity_id": "3174043_2_Ent0", "role": "Effect", "text": "maculopathy", "start": 1, "end": 2}]}], "entity_mentions": [{"id": "3174043_2_Ent1", "text": "Niacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3174043_2_Ent2", "text": "Niacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3174043_2_Ent0", "text": "maculopathy", "entity_type": "Entity", "start": 1, "end": 2}], "lang": "en"}
{"doc_id": "3195622_3", "wnd_id": "3195622_3_1", "text": "Case report : dapsone hypersensitivity syndrome associated with treatment of the bite of a brown recluse spider .", "tokens": ["Case", "report", ":", "dapsone", "hypersensitivity", "syndrome", "associated", "with", "treatment", "of", "the", "bite", "of", "a", "brown", "recluse", "spider", "."], "event_mentions": [{"id": "3195622_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "3195622_3_Ent1", "role": "Treatment", "text": "dapsone", "start": 3, "end": 4}, {"entity_id": "3195622_3_Ent2", "role": "Treatment_Drug", "text": "dapsone", "start": 3, "end": 4}, {"entity_id": "3195622_3_Ent0", "role": "Effect", "text": "hypersensitivity syndrome", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "3195622_3_Ent1", "text": "dapsone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3195622_3_Ent2", "text": "dapsone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3195622_3_Ent0", "text": "hypersensitivity syndrome", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "3200786_3", "wnd_id": "3200786_3_1", "text": "We report the case of a patient with the acquired immunodeficiency syndrome treated with rifampicin who had a ' normal ' screening test for adrenal insufficiency , yet had clinical evidence of adrenal failure .", "tokens": ["We", "report", "the", "case", "of", "a", "patient", "with", "the", "acquired", "immunodeficiency", "syndrome", "treated", "with", "rifampicin", "who", "had", "a", "'", "normal", "'", "screening", "test", "for", "adrenal", "insufficiency", ",", "yet", "had", "clinical", "evidence", "of", "adrenal", "failure", "."], "event_mentions": [{"id": "3200786_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 28, "end": 29}, "arguments": [{"entity_id": "3200786_3_Ent0", "role": "Subject", "text": "a patient with the acquired immunodeficiency syndrome", "start": 5, "end": 12}, {"entity_id": "3200786_3_Ent4", "role": "Treatment_Disorder", "text": "acquired immunodeficiency syndrome", "start": 9, "end": 12}, {"entity_id": "3200786_3_Ent2", "role": "Treatment", "text": "rifampicin", "start": 14, "end": 15}, {"entity_id": "3200786_3_Ent3", "role": "Treatment_Drug", "text": "rifampicin", "start": 14, "end": 15}, {"entity_id": "3200786_3_Ent1", "role": "Effect", "text": "adrenal failure", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "3200786_3_Ent0", "text": "a patient with the acquired immunodeficiency syndrome", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "3200786_3_Ent4", "text": "acquired immunodeficiency syndrome", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "3200786_3_Ent2", "text": "rifampicin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3200786_3_Ent3", "text": "rifampicin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3200786_3_Ent1", "text": "adrenal failure", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "3211830_1", "wnd_id": "3211830_1_1", "text": "Two cases of widespread cutaneous vasculitis are described in association with diltiazem , a recently introduced calcium antagonist .", "tokens": ["Two", "cases", "of", "widespread", "cutaneous", "vasculitis", "are", "described", "in", "association", "with", "diltiazem", ",", "a", "recently", "introduced", "calcium", "antagonist", "."], "event_mentions": [{"id": "3211830_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 9, "end": 10}, "arguments": [{"entity_id": "3211830_1_Ent0", "role": "Effect", "text": "widespread cutaneous vasculitis", "start": 3, "end": 6}, {"entity_id": "3211830_1_Ent2", "role": "Treatment_Drug", "text": "diltiazem", "start": 11, "end": 12}, {"entity_id": "3211830_1_Ent1", "role": "Treatment", "text": "diltiazem , a recently introduced calcium antagonist", "start": 11, "end": 18}]}], "entity_mentions": [{"id": "3211830_1_Ent0", "text": "widespread cutaneous vasculitis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3211830_1_Ent2", "text": "diltiazem", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3211830_1_Ent1", "text": "diltiazem , a recently introduced calcium antagonist", "entity_type": "Entity", "start": 11, "end": 18}], "lang": "en"}
{"doc_id": "3211830_2", "wnd_id": "3211830_2_1", "text": "Widespread cutaneous vasculitis associated with diltiazem .", "tokens": ["Widespread", "cutaneous", "vasculitis", "associated", "with", "diltiazem", "."], "event_mentions": [{"id": "3211830_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "3211830_2_Ent0", "role": "Effect", "text": "cutaneous vasculitis", "start": 1, "end": 3}, {"entity_id": "3211830_2_Ent1", "role": "Treatment", "text": "diltiazem", "start": 5, "end": 6}, {"entity_id": "3211830_2_Ent2", "role": "Treatment_Drug", "text": "diltiazem", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "3211830_2_Ent0", "text": "cutaneous vasculitis", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "3211830_2_Ent1", "text": "diltiazem", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3211830_2_Ent2", "text": "diltiazem", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "3242521_1", "wnd_id": "3242521_1_1", "text": "Intraventricular nafcillin - induced seizures in a neonate .", "tokens": ["Intraventricular", "nafcillin", "-", "induced", "seizures", "in", "a", "neonate", "."], "event_mentions": [{"id": "3242521_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "3242521_1_Ent2", "role": "Effect", "text": "Intraventricular", "start": 0, "end": 1}, {"entity_id": "3242521_1_Ent4", "role": "Treatment", "text": "nafcillin", "start": 1, "end": 2}, {"entity_id": "3242521_1_Ent5", "role": "Treatment_Drug", "text": "nafcillin", "start": 1, "end": 2}, {"entity_id": "3242521_1_Ent3", "role": "Effect", "text": "seizures", "start": 4, "end": 5}, {"entity_id": "3242521_1_Ent0", "role": "Subject", "text": "a neonate", "start": 6, "end": 8}, {"entity_id": "3242521_1_Ent1", "role": "Subject_Age", "text": "neonate", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "3242521_1_Ent2", "text": "Intraventricular", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3242521_1_Ent4", "text": "nafcillin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3242521_1_Ent5", "text": "nafcillin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3242521_1_Ent3", "text": "seizures", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3242521_1_Ent0", "text": "a neonate", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "3242521_1_Ent1", "text": "neonate", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "3259776_2", "wnd_id": "3259776_2_1", "text": "Thrombo - embolic complication after streptokinase therapy of pulmonary emboli .", "tokens": ["Thrombo", "-", "embolic", "complication", "after", "streptokinase", "therapy", "of", "pulmonary", "emboli", "."], "event_mentions": [{"id": "3259776_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "3259776_2_Ent0", "role": "Effect", "text": "Thrombo - embolic complication", "start": 0, "end": 4}, {"entity_id": "3259776_2_Ent1", "role": "Treatment", "text": "streptokinase", "start": 5, "end": 6}, {"entity_id": "3259776_2_Ent2", "role": "Treatment_Drug", "text": "streptokinase", "start": 5, "end": 6}, {"entity_id": "3259776_2_Ent3", "role": "Treatment_Disorder", "text": "pulmonary emboli .", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "3259776_2_Ent0", "text": "Thrombo - embolic complication", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3259776_2_Ent1", "text": "streptokinase", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3259776_2_Ent2", "text": "streptokinase", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3259776_2_Ent3", "text": "pulmonary emboli .", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "3301251_2", "wnd_id": "3301251_2_1", "text": "Hepatotoxicity associated with choline magnesium trisalicylate : case report and review of salicylate - induced hepatotoxicity .", "tokens": ["Hepatotoxicity", "associated", "with", "choline", "magnesium", "trisalicylate", ":", "case", "report", "and", "review", "of", "salicylate", "-", "induced", "hepatotoxicity", "."], "event_mentions": [{"id": "3301251_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "3301251_2_Ent1", "role": "Effect", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "3301251_2_Ent2", "role": "Treatment", "text": "choline magnesium trisalicylate", "start": 3, "end": 6}, {"entity_id": "3301251_2_Ent3", "role": "Treatment_Drug", "text": "choline magnesium trisalicylate", "start": 3, "end": 6}, {"entity_id": "3301251_2_Ent0", "role": "Subject", "text": "case", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "3301251_2_Ent1", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3301251_2_Ent2", "text": "choline magnesium trisalicylate", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3301251_2_Ent3", "text": "choline magnesium trisalicylate", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3301251_2_Ent0", "text": "case", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "3310776_1", "wnd_id": "3310776_1_1", "text": "A 51 - yr - old nonsmoking male patient without any history of previous allergies , asthma , hay fever , or urticaria developed attacks of asthma when captopril was added to the nadolol and dyazide treatment for his high blood pressure .", "tokens": ["A", "51", "-", "yr", "-", "old", "nonsmoking", "male", "patient", "without", "any", "history", "of", "previous", "allergies", ",", "asthma", ",", "hay", "fever", ",", "or", "urticaria", "developed", "attacks", "of", "asthma", "when", "captopril", "was", "added", "to", "the", "nadolol", "and", "dyazide", "treatment", "for", "his", "high", "blood", "pressure", "."], "event_mentions": [{"id": "3310776_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 23, "end": 24}, "arguments": [{"entity_id": "3310776_1_Ent0", "role": "Subject", "text": "A 51 - yr - old nonsmoking male patient without any history of previous allergies , asthma , hay fever , or urticaria", "start": 0, "end": 23}, {"entity_id": "3310776_1_Ent1", "role": "Subject_Age", "text": "51 - yr - old", "start": 1, "end": 6}, {"entity_id": "3310776_1_Ent2", "role": "Subject_Gender", "text": "male", "start": 7, "end": 8}, {"entity_id": "3310776_1_Ent3", "role": "Effect", "text": "attacks of asthma", "start": 24, "end": 27}, {"entity_id": "3310776_1_Ent6", "role": "Treatment_Drug", "text": "captopril", "start": 28, "end": 29}, {"entity_id": "3310776_1_Ent9", "role": "Combination_Drug", "text": "captopril", "start": 28, "end": 29}, {"entity_id": "3310776_1_Ent4", "role": "Treatment", "text": "captopril was added to the nadolol and dyazide", "start": 28, "end": 36}, {"entity_id": "3310776_1_Ent7", "role": "Treatment_Drug", "text": "nadolol", "start": 33, "end": 34}, {"entity_id": "3310776_1_Ent10", "role": "Combination_Drug", "text": "nadolol", "start": 33, "end": 34}, {"entity_id": "3310776_1_Ent8", "role": "Treatment_Drug", "text": "dyazide", "start": 35, "end": 36}, {"entity_id": "3310776_1_Ent11", "role": "Combination_Drug", "text": "dyazide", "start": 35, "end": 36}, {"entity_id": "3310776_1_Ent5", "role": "Treatment_Disorder", "text": "high blood pressure", "start": 39, "end": 42}]}], "entity_mentions": [{"id": "3310776_1_Ent0", "text": "A 51 - yr - old nonsmoking male patient without any history of previous allergies , asthma , hay fever , or urticaria", "entity_type": "Entity", "start": 0, "end": 23}, {"id": "3310776_1_Ent1", "text": "51 - yr - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "3310776_1_Ent2", "text": "male", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3310776_1_Ent3", "text": "attacks of asthma", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "3310776_1_Ent6", "text": "captopril", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "3310776_1_Ent9", "text": "captopril", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "3310776_1_Ent4", "text": "captopril was added to the nadolol and dyazide", "entity_type": "Entity", "start": 28, "end": 36}, {"id": "3310776_1_Ent7", "text": "nadolol", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "3310776_1_Ent10", "text": "nadolol", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "3310776_1_Ent8", "text": "dyazide", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "3310776_1_Ent11", "text": "dyazide", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "3310776_1_Ent5", "text": "high blood pressure", "entity_type": "Entity", "start": 39, "end": 42}], "lang": "en"}
{"doc_id": "331881_1", "wnd_id": "331881_1_1", "text": "Deposits of plasma proteins in the skin during treatment with carbamazepine and diphenylhydantoin .", "tokens": ["Deposits", "of", "plasma", "proteins", "in", "the", "skin", "during", "treatment", "with", "carbamazepine", "and", "diphenylhydantoin", "."], "event_mentions": [{"id": "331881_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 8, "end": 9}, "arguments": [{"entity_id": "331881_1_Ent0", "role": "Effect", "text": "Deposits of plasma proteins in the skin", "start": 0, "end": 7}, {"entity_id": "331881_1_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 10, "end": 11}, {"entity_id": "331881_1_Ent4", "role": "Combination_Drug", "text": "carbamazepine", "start": 10, "end": 11}, {"entity_id": "331881_1_Ent1", "role": "Treatment", "text": "carbamazepine and diphenylhydantoin", "start": 10, "end": 13}, {"entity_id": "331881_1_Ent3", "role": "Treatment_Drug", "text": "diphenylhydantoin", "start": 12, "end": 13}, {"entity_id": "331881_1_Ent5", "role": "Combination_Drug", "text": "diphenylhydantoin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "331881_1_Ent0", "text": "Deposits of plasma proteins in the skin", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "331881_1_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "331881_1_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "331881_1_Ent1", "text": "carbamazepine and diphenylhydantoin", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "331881_1_Ent3", "text": "diphenylhydantoin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "331881_1_Ent5", "text": "diphenylhydantoin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "3379435_2", "wnd_id": "3379435_2_1", "text": "Reye - like syndrome following treatment with the pantothenic acid antagonist , calcium hopantenate .", "tokens": ["Reye", "-", "like", "syndrome", "following", "treatment", "with", "the", "pantothenic", "acid", "antagonist", ",", "calcium", "hopantenate", "."], "event_mentions": [{"id": "3379435_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 4, "end": 5}, "arguments": [{"entity_id": "3379435_2_Ent0", "role": "Effect", "text": "Reye - like syndrome", "start": 0, "end": 4}, {"entity_id": "3379435_2_Ent1", "role": "Treatment", "text": "calcium hopantenate", "start": 12, "end": 14}, {"entity_id": "3379435_2_Ent2", "role": "Treatment_Drug", "text": "calcium hopantenate", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "3379435_2_Ent0", "text": "Reye - like syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3379435_2_Ent1", "text": "calcium hopantenate", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "3379435_2_Ent2", "text": "calcium hopantenate", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "3379435_3", "wnd_id": "3379435_3_1", "text": "Three senile patients developed fatal acute encephalopathy while receiving calcium hopantenate .", "tokens": ["Three", "senile", "patients", "developed", "fatal", "acute", "encephalopathy", "while", "receiving", "calcium", "hopantenate", "."], "event_mentions": [{"id": "3379435_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "3379435_3_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "3379435_3_Ent0", "role": "Subject", "text": "Three senile patients", "start": 0, "end": 3}, {"entity_id": "3379435_3_Ent2", "role": "Subject_Age", "text": "senile", "start": 1, "end": 2}, {"entity_id": "3379435_3_Ent3", "role": "Effect", "text": "encephalopathy", "start": 6, "end": 7}, {"entity_id": "3379435_3_Ent4", "role": "Treatment", "text": "calcium hopantenate", "start": 9, "end": 11}, {"entity_id": "3379435_3_Ent5", "role": "Treatment_Drug", "text": "calcium hopantenate", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "3379435_3_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3379435_3_Ent0", "text": "Three senile patients", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3379435_3_Ent2", "text": "senile", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3379435_3_Ent3", "text": "encephalopathy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3379435_3_Ent4", "text": "calcium hopantenate", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "3379435_3_Ent5", "text": "calcium hopantenate", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "3397227_1", "wnd_id": "3397227_1_1", "text": "Anhedonic ejaculation with desipramine .", "tokens": ["Anhedonic", "ejaculation", "with", "desipramine", "."], "event_mentions": [{"id": "3397227_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "3397227_1_Ent0", "role": "Effect", "text": "Anhedonic ejaculation", "start": 0, "end": 2}, {"entity_id": "3397227_1_Ent1", "role": "Treatment", "text": "desipramine", "start": 3, "end": 4}, {"entity_id": "3397227_1_Ent2", "role": "Treatment_Drug", "text": "desipramine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "3397227_1_Ent0", "text": "Anhedonic ejaculation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3397227_1_Ent1", "text": "desipramine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3397227_1_Ent2", "text": "desipramine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "3405528_2", "wnd_id": "3405528_2_1", "text": "Halothane hepatitis and prompt resolution with methionine therapy : case report .", "tokens": ["Halothane", "hepatitis", "and", "prompt", "resolution", "with", "methionine", "therapy", ":", "case", "report", "."], "event_mentions": [{"id": "3405528_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolution", "start": 4, "end": 5}, "arguments": [{"entity_id": "3405528_2_Ent2", "role": "Treatment_Disorder", "text": "Halothane hepatitis", "start": 0, "end": 2}, {"entity_id": "3405528_2_Ent1", "role": "Treatment", "text": "methionine", "start": 6, "end": 7}, {"entity_id": "3405528_2_Ent3", "role": "Treatment_Drug", "text": "methionine", "start": 6, "end": 7}, {"entity_id": "3405528_2_Ent0", "role": "Subject", "text": "case", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "3405528_2_Ent2", "text": "Halothane hepatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3405528_2_Ent1", "text": "methionine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3405528_2_Ent3", "text": "methionine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3405528_2_Ent0", "text": "case", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "3410226_2", "wnd_id": "3410226_2_1", "text": "We report a 46 - yr - old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide .", "tokens": ["We", "report", "a", "46", "-", "yr", "-", "old", "woman", "with", "ovarian", "carcinoma", "who", "developed", "porphyria", "cutanea", "tarda", "while", "undergoing", "treatment", "with", "cisplatin", "and", "cyclophosphamide", "."], "event_mentions": [{"id": "3410226_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "3410226_2_Ent0", "role": "Subject", "text": "a 46 - yr - old woman with ovarian carcinoma", "start": 2, "end": 12}, {"entity_id": "3410226_2_Ent1", "role": "Subject_Age", "text": "46 - yr - old", "start": 3, "end": 8}, {"entity_id": "3410226_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "3410226_2_Ent7", "role": "Treatment_Disorder", "text": "ovarian carcinoma", "start": 10, "end": 12}, {"entity_id": "3410226_2_Ent3", "role": "Effect", "text": "porphyria cutanea tarda", "start": 14, "end": 17}, {"entity_id": "3410226_2_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 21, "end": 22}, {"entity_id": "3410226_2_Ent8", "role": "Combination_Drug", "text": "cisplatin", "start": 21, "end": 22}, {"entity_id": "3410226_2_Ent4", "role": "Treatment", "text": "cisplatin and cyclophosphamide", "start": 21, "end": 24}, {"entity_id": "3410226_2_Ent6", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 23, "end": 24}, {"entity_id": "3410226_2_Ent9", "role": "Combination_Drug", "text": "cyclophosphamide", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "3410226_2_Ent0", "text": "a 46 - yr - old woman with ovarian carcinoma", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "3410226_2_Ent1", "text": "46 - yr - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "3410226_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3410226_2_Ent7", "text": "ovarian carcinoma", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "3410226_2_Ent3", "text": "porphyria cutanea tarda", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "3410226_2_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "3410226_2_Ent8", "text": "cisplatin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "3410226_2_Ent4", "text": "cisplatin and cyclophosphamide", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "3410226_2_Ent6", "text": "cyclophosphamide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "3410226_2_Ent9", "text": "cyclophosphamide", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "3430507_6", "wnd_id": "3430507_6_1", "text": "A 56 - year - old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis after 27 months of D - penicillamine therapy and a cumulative dose of 1,200 g.", "tokens": ["A", "56", "-", "year", "-", "old", "woman", "with", "scleroderma", "developed", "rapidly", "progressive", "glomerulonephritis", "with", "epithelial", "crescents", "associated", "with", "hemoptysis", "after", "27", "months", "of", "D", "-", "penicillamine", "therapy", "and", "a", "cumulative", "dose", "of", "1,200", "g."], "event_mentions": [{"id": "3430507_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "3430507_6_Ent0", "role": "Subject", "text": "A 56 - year - old woman with scleroderma", "start": 0, "end": 9}, {"entity_id": "3430507_6_Ent1", "role": "Subject_Age", "text": "56 - year - old", "start": 1, "end": 6}, {"entity_id": "3430507_6_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "3430507_6_Ent5", "role": "Treatment_Disorder", "text": "scleroderma", "start": 8, "end": 9}, {"entity_id": "3430507_6_Ent3", "role": "Effect", "text": "rapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis", "start": 10, "end": 19}, {"entity_id": "3430507_6_Ent6", "role": "Treatment_Time_elapsed", "text": "27 months", "start": 20, "end": 22}, {"entity_id": "3430507_6_Ent4", "role": "Treatment", "text": "27 months of D - penicillamine therapy and a cumulative dose of 1,200 g.", "start": 20, "end": 34}, {"entity_id": "3430507_6_Ent7", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 23, "end": 26}, {"entity_id": "3430507_6_Ent8", "role": "Treatment_Dosage", "text": "1,200 g.", "start": 32, "end": 34}]}], "entity_mentions": [{"id": "3430507_6_Ent0", "text": "A 56 - year - old woman with scleroderma", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "3430507_6_Ent1", "text": "56 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "3430507_6_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3430507_6_Ent5", "text": "scleroderma", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3430507_6_Ent3", "text": "rapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "3430507_6_Ent6", "text": "27 months", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "3430507_6_Ent4", "text": "27 months of D - penicillamine therapy and a cumulative dose of 1,200 g.", "entity_type": "Entity", "start": 20, "end": 34}, {"id": "3430507_6_Ent7", "text": "D - penicillamine", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "3430507_6_Ent8", "text": "1,200 g.", "entity_type": "Entity", "start": 32, "end": 34}], "lang": "en"}
{"doc_id": "3438585_1", "wnd_id": "3438585_1_1", "text": "Gold - induced pneumonitis .", "tokens": ["Gold", "-", "induced", "pneumonitis", "."], "event_mentions": [{"id": "3438585_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3438585_1_Ent1", "role": "Treatment", "text": "Gold", "start": 0, "end": 1}, {"entity_id": "3438585_1_Ent2", "role": "Treatment_Drug", "text": "Gold", "start": 0, "end": 1}, {"entity_id": "3438585_1_Ent0", "role": "Effect", "text": "pneumonitis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "3438585_1_Ent1", "text": "Gold", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3438585_1_Ent2", "text": "Gold", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3438585_1_Ent0", "text": "pneumonitis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "3438585_6", "wnd_id": "3438585_6_1", "text": "This case supports the view that in gold - induced pneumonitis a prolonged treatment with corticosteroids may be necessary , as lung function continued to improve .", "tokens": ["This", "case", "supports", "the", "view", "that", "in", "gold", "-", "induced", "pneumonitis", "a", "prolonged", "treatment", "with", "corticosteroids", "may", "be", "necessary", ",", "as", "lung", "function", "continued", "to", "improve", "."], "event_mentions": [{"id": "3438585_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "as", "start": 20, "end": 21}, "arguments": [{"entity_id": "3438585_6_Ent1", "role": "Treatment_Disorder", "text": "in gold - induced pneumonitis", "start": 6, "end": 11}, {"entity_id": "3438585_6_Ent2", "role": "Treatment_Drug", "text": "gold", "start": 7, "end": 8}, {"entity_id": "3438585_6_Ent0", "role": "Treatment", "text": "a prolonged treatment with corticosteroids", "start": 11, "end": 16}, {"entity_id": "3438585_6_Ent3", "role": "Treatment_Drug", "text": "corticosteroids", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "3438585_6_Ent1", "text": "in gold - induced pneumonitis", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "3438585_6_Ent2", "text": "gold", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3438585_6_Ent0", "text": "a prolonged treatment with corticosteroids", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "3438585_6_Ent3", "text": "corticosteroids", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "3449312_1", "wnd_id": "3449312_1_1", "text": "Gold - induced aplastic anemia .", "tokens": ["Gold", "-", "induced", "aplastic", "anemia", "."], "event_mentions": [{"id": "3449312_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3449312_1_Ent1", "role": "Treatment", "text": "Gold", "start": 0, "end": 1}, {"entity_id": "3449312_1_Ent2", "role": "Treatment_Drug", "text": "Gold", "start": 0, "end": 1}, {"entity_id": "3449312_1_Ent0", "role": "Effect", "text": "aplastic anemia", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "3449312_1_Ent1", "text": "Gold", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3449312_1_Ent2", "text": "Gold", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3449312_1_Ent0", "text": "aplastic anemia", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "3449312_2", "wnd_id": "3449312_2_1", "text": "Three patients receiving gold salt treatment for rheumatoid arthritis developed severe aplastic anemia .", "tokens": ["Three", "patients", "receiving", "gold", "salt", "treatment", "for", "rheumatoid", "arthritis", "developed", "severe", "aplastic", "anemia", "."], "event_mentions": [{"id": "3449312_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "3449312_2_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "3449312_2_Ent0", "role": "Subject", "text": "Three patients", "start": 0, "end": 2}, {"entity_id": "3449312_2_Ent3", "role": "Treatment", "text": "gold salt", "start": 3, "end": 5}, {"entity_id": "3449312_2_Ent5", "role": "Treatment_Drug", "text": "gold salt", "start": 3, "end": 5}, {"entity_id": "3449312_2_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 7, "end": 9}, {"entity_id": "3449312_2_Ent2", "role": "Effect", "text": "severe aplastic anemia", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "3449312_2_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3449312_2_Ent0", "text": "Three patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3449312_2_Ent3", "text": "gold salt", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3449312_2_Ent5", "text": "gold salt", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3449312_2_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "3449312_2_Ent2", "text": "severe aplastic anemia", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "3470173_4", "wnd_id": "3470173_4_1", "text": "The neurotoxicity seen with HDARAC is dose - related and has occurred in up to 60 percent of treated patients .", "tokens": ["The", "neurotoxicity", "seen", "with", "HDARAC", "is", "dose", "-", "related", "and", "has", "occurred", "in", "up", "to", "60", "percent", "of", "treated", "patients", "."], "event_mentions": [{"id": "3470173_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 8, "end": 9}, "arguments": [{"entity_id": "3470173_4_Ent2", "role": "Effect", "text": "neurotoxicity", "start": 1, "end": 2}, {"entity_id": "3470173_4_Ent3", "role": "Treatment", "text": "HDARAC", "start": 4, "end": 5}, {"entity_id": "3470173_4_Ent4", "role": "Treatment_Drug", "text": "HDARAC", "start": 4, "end": 5}, {"entity_id": "3470173_4_Ent1", "role": "Subject_Population", "text": "60 percent", "start": 15, "end": 17}, {"entity_id": "3470173_4_Ent0", "role": "Subject", "text": "60 percent of treated patients", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "3470173_4_Ent2", "text": "neurotoxicity", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3470173_4_Ent3", "text": "HDARAC", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3470173_4_Ent4", "text": "HDARAC", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3470173_4_Ent1", "text": "60 percent", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "3470173_4_Ent0", "text": "60 percent of treated patients", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "3508194_1", "wnd_id": "3508194_1_1", "text": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion .", "tokens": ["Transient", "leucopenia", "and", "thrombocytopenia", "associated", "with", "sodium", "nitroprusside", "infusion", "."], "event_mentions": [{"id": "3508194_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "3508194_1_Ent0", "role": "Effect", "text": "Transient leucopenia and thrombocytopenia", "start": 0, "end": 4}, {"entity_id": "3508194_1_Ent3", "role": "Treatment_Drug", "text": "sodium nitroprusside", "start": 6, "end": 8}, {"entity_id": "3508194_1_Ent1", "role": "Treatment", "text": "sodium nitroprusside infusion", "start": 6, "end": 9}, {"entity_id": "3508194_1_Ent2", "role": "Treatment_Route", "text": "infusion", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "3508194_1_Ent0", "text": "Transient leucopenia and thrombocytopenia", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3508194_1_Ent3", "text": "sodium nitroprusside", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "3508194_1_Ent1", "text": "sodium nitroprusside infusion", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "3508194_1_Ent2", "text": "infusion", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "3528096_1", "wnd_id": "3528096_1_1", "text": "Administration of excessive insulin induced hypoglycemia within 4 to 8 hours , followed by rebound hyperglycemia .", "tokens": ["Administration", "of", "excessive", "insulin", "induced", "hypoglycemia", "within", "4", "to", "8", "hours", ",", "followed", "by", "rebound", "hyperglycemia", "."], "event_mentions": [{"id": "3528096_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "3528096_1_Ent2", "role": "Treatment", "text": "Administration of excessive insulin", "start": 0, "end": 4}, {"entity_id": "3528096_1_Ent4", "role": "Treatment_Dosage", "text": "excessive", "start": 2, "end": 3}, {"entity_id": "3528096_1_Ent3", "role": "Treatment_Drug", "text": "insulin", "start": 3, "end": 4}, {"entity_id": "3528096_1_Ent0", "role": "Effect", "text": "hypoglycemia", "start": 5, "end": 6}, {"entity_id": "3528096_1_Ent5", "role": "Treatment_Duration", "text": "4 to 8 hours", "start": 7, "end": 11}, {"entity_id": "3528096_1_Ent1", "role": "Effect", "text": "rebound hyperglycemia", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "3528096_1_Ent2", "text": "Administration of excessive insulin", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3528096_1_Ent4", "text": "excessive", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "3528096_1_Ent3", "text": "insulin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3528096_1_Ent0", "text": "hypoglycemia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3528096_1_Ent5", "text": "4 to 8 hours", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "3528096_1_Ent1", "text": "rebound hyperglycemia", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "354311_2", "wnd_id": "354311_2_1", "text": "Metastatic osteomyelitis following BCG vaccination .", "tokens": ["Metastatic", "osteomyelitis", "following", "BCG", "vaccination", "."], "event_mentions": [{"id": "354311_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "354311_2_Ent0", "role": "Effect", "text": "Metastatic osteomyelitis", "start": 0, "end": 2}, {"entity_id": "354311_2_Ent1", "role": "Treatment", "text": "BCG vaccination", "start": 3, "end": 5}, {"entity_id": "354311_2_Ent2", "role": "Treatment_Drug", "text": "BCG vaccination", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "354311_2_Ent0", "text": "Metastatic osteomyelitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "354311_2_Ent1", "text": "BCG vaccination", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "354311_2_Ent2", "text": "BCG vaccination", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "3569037_2", "wnd_id": "3569037_2_1", "text": "Hypersensitivity reaction following chloramphenicol administration in a patient with typhoid fever .", "tokens": ["Hypersensitivity", "reaction", "following", "chloramphenicol", "administration", "in", "a", "patient", "with", "typhoid", "fever", "."], "event_mentions": [{"id": "3569037_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "3569037_2_Ent1", "role": "Effect", "text": "Hypersensitivity reaction", "start": 0, "end": 2}, {"entity_id": "3569037_2_Ent2", "role": "Treatment", "text": "chloramphenicol", "start": 3, "end": 4}, {"entity_id": "3569037_2_Ent3", "role": "Treatment_Drug", "text": "chloramphenicol", "start": 3, "end": 4}, {"entity_id": "3569037_2_Ent0", "role": "Subject", "text": "a patient with typhoid fever", "start": 6, "end": 11}, {"entity_id": "3569037_2_Ent4", "role": "Treatment_Disorder", "text": "typhoid fever", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "3569037_2_Ent1", "text": "Hypersensitivity reaction", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3569037_2_Ent2", "text": "chloramphenicol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3569037_2_Ent3", "text": "chloramphenicol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3569037_2_Ent0", "text": "a patient with typhoid fever", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "3569037_2_Ent4", "text": "typhoid fever", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "3569037_3", "wnd_id": "3569037_3_1", "text": "Hypersensitivity reactions due to chloramphenicol are rarely reported in the literature .", "tokens": ["Hypersensitivity", "reactions", "due", "to", "chloramphenicol", "are", "rarely", "reported", "in", "the", "literature", "."], "event_mentions": [{"id": "3569037_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "3569037_3_Ent0", "role": "Effect", "text": "Hypersensitivity reactions", "start": 0, "end": 2}, {"entity_id": "3569037_3_Ent1", "role": "Treatment", "text": "chloramphenicol", "start": 4, "end": 5}, {"entity_id": "3569037_3_Ent2", "role": "Treatment_Drug", "text": "chloramphenicol", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "3569037_3_Ent0", "text": "Hypersensitivity reactions", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3569037_3_Ent1", "text": "chloramphenicol", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3569037_3_Ent2", "text": "chloramphenicol", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "3586163_3", "wnd_id": "3586163_3_1", "text": "We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic cyclophosphamide therapy for nonHodgkin 's lymphoma .", "tokens": ["We", "report", "an", "unusual", "case", "of", "simultaneous", "transitional", "cell", "carcinoma", "of", "the", "renal", "pelvis", "and", "distal", "ureter", "without", "transitional", "cell", "carcinoma", "of", "the", "bladder", "occurring", "after", "chronic", "cyclophosphamide", "therapy", "for", "nonHodgkin", "'s", "lymphoma", "."], "event_mentions": [{"id": "3586163_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 25, "end": 26}, "arguments": [{"entity_id": "3586163_3_Ent0", "role": "Effect", "text": "simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder", "start": 6, "end": 24}, {"entity_id": "3586163_3_Ent4", "role": "Treatment_Duration", "text": "chronic", "start": 26, "end": 27}, {"entity_id": "3586163_3_Ent1", "role": "Treatment", "text": "chronic cyclophosphamide therapy", "start": 26, "end": 29}, {"entity_id": "3586163_3_Ent2", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 27, "end": 28}, {"entity_id": "3586163_3_Ent3", "role": "Treatment_Disorder", "text": "nonHodgkin 's lymphoma", "start": 30, "end": 33}]}], "entity_mentions": [{"id": "3586163_3_Ent0", "text": "simultaneous transitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder", "entity_type": "Entity", "start": 6, "end": 24}, {"id": "3586163_3_Ent4", "text": "chronic", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "3586163_3_Ent1", "text": "chronic cyclophosphamide therapy", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "3586163_3_Ent2", "text": "cyclophosphamide", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "3586163_3_Ent3", "text": "nonHodgkin 's lymphoma", "entity_type": "Entity", "start": 30, "end": 33}], "lang": "en"}
{"doc_id": "3612639_2", "wnd_id": "3612639_2_1", "text": "Pulmonary edema occurred 24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous terbutaline therapy .", "tokens": ["Pulmonary", "edema", "occurred", "24", "hours", "after", "intravenous", "ritodrine", "therapy", "and", "10", "hours", "after", "subcutaneous", "terbutaline", "therapy", "."], "event_mentions": [{"id": "3612639_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 2, "end": 3}, "arguments": [{"entity_id": "3612639_2_Ent0", "role": "Effect", "text": "Pulmonary edema", "start": 0, "end": 2}, {"entity_id": "3612639_2_Ent2", "role": "Treatment_Time_elapsed", "text": "24 hours", "start": 3, "end": 5}, {"entity_id": "3612639_2_Ent1", "role": "Treatment", "text": "24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous terbutaline therapy", "start": 3, "end": 16}, {"entity_id": "3612639_2_Ent4", "role": "Treatment_Route", "text": "intravenous", "start": 6, "end": 7}, {"entity_id": "3612639_2_Ent6", "role": "Treatment_Drug", "text": "ritodrine", "start": 7, "end": 8}, {"entity_id": "3612639_2_Ent8", "role": "Combination_Drug", "text": "ritodrine", "start": 7, "end": 8}, {"entity_id": "3612639_2_Ent3", "role": "Treatment_Time_elapsed", "text": "10 hours", "start": 10, "end": 12}, {"entity_id": "3612639_2_Ent5", "role": "Treatment_Route", "text": "subcutaneous", "start": 13, "end": 14}, {"entity_id": "3612639_2_Ent7", "role": "Treatment_Drug", "text": "terbutaline", "start": 14, "end": 15}, {"entity_id": "3612639_2_Ent9", "role": "Combination_Drug", "text": "terbutaline", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "3612639_2_Ent0", "text": "Pulmonary edema", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3612639_2_Ent2", "text": "24 hours", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3612639_2_Ent1", "text": "24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous terbutaline therapy", "entity_type": "Entity", "start": 3, "end": 16}, {"id": "3612639_2_Ent4", "text": "intravenous", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3612639_2_Ent6", "text": "ritodrine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3612639_2_Ent8", "text": "ritodrine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3612639_2_Ent3", "text": "10 hours", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "3612639_2_Ent5", "text": "subcutaneous", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "3612639_2_Ent7", "text": "terbutaline", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3612639_2_Ent9", "text": "terbutaline", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "3620420_1", "wnd_id": "3620420_1_1", "text": "Cyclosporin therapy in Mooren 's ulcer .", "tokens": ["Cyclosporin", "therapy", "in", "Mooren", "'s", "ulcer", "."], "event_mentions": [{"id": "3620420_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapy", "start": 1, "end": 2}, "arguments": [{"entity_id": "3620420_1_Ent0", "role": "Treatment", "text": "Cyclosporin", "start": 0, "end": 1}, {"entity_id": "3620420_1_Ent2", "role": "Treatment_Drug", "text": "Cyclosporin", "start": 0, "end": 1}, {"entity_id": "3620420_1_Ent1", "role": "Treatment_Disorder", "text": "Mooren 's ulcer", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "3620420_1_Ent0", "text": "Cyclosporin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3620420_1_Ent2", "text": "Cyclosporin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3620420_1_Ent1", "text": "Mooren 's ulcer", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "3677571_4", "wnd_id": "3677571_4_1", "text": "She was receiving phenytoin sodium 300 mg / day ; carbamazepine 200 mg four times daily had been discontinued four days before admission because of leukopenia .", "tokens": ["She", "was", "receiving", "phenytoin", "sodium", "300", "mg", "/", "day", ";", "carbamazepine", "200", "mg", "four", "times", "daily", "had", "been", "discontinued", "four", "days", "before", "admission", "because", "of", "leukopenia", "."], "event_mentions": [{"id": "3677571_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "because", "start": 23, "end": 24}, "arguments": [{"entity_id": "3677571_4_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 10, "end": 11}, {"entity_id": "3677571_4_Ent1", "role": "Treatment", "text": "carbamazepine 200 mg four times daily", "start": 10, "end": 16}, {"entity_id": "3677571_4_Ent3", "role": "Treatment_Dosage", "text": "200 mg", "start": 11, "end": 13}, {"entity_id": "3677571_4_Ent4", "role": "Treatment_Freq", "text": "four times daily", "start": 13, "end": 16}, {"entity_id": "3677571_4_Ent0", "role": "Effect", "text": "leukopenia", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "3677571_4_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3677571_4_Ent1", "text": "carbamazepine 200 mg four times daily", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "3677571_4_Ent3", "text": "200 mg", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "3677571_4_Ent4", "text": "four times daily", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "3677571_4_Ent0", "text": "leukopenia", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "3677571_8", "wnd_id": "3677571_8_1", "text": "Seizures were treated with diazepam .", "tokens": ["Seizures", "were", "treated", "with", "diazepam", "."], "event_mentions": [{"id": "3677571_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 2, "end": 3}, "arguments": [{"entity_id": "3677571_8_Ent1", "role": "Treatment_Disorder", "text": "Seizures", "start": 0, "end": 1}, {"entity_id": "3677571_8_Ent0", "role": "Treatment", "text": "diazepam", "start": 4, "end": 5}, {"entity_id": "3677571_8_Ent2", "role": "Treatment_Drug", "text": "diazepam", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "3677571_8_Ent1", "text": "Seizures", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3677571_8_Ent0", "text": "diazepam", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3677571_8_Ent2", "text": "diazepam", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "3680913_1", "wnd_id": "3680913_1_1", "text": "It was restarted 6 weeks later , and 10 weeks after that , the patient presented with fulminant hepatic failure , which resolved rapidly after cessation of nicotinic acid therapy .", "tokens": ["It", "was", "restarted", "6", "weeks", "later", ",", "and", "10", "weeks", "after", "that", ",", "the", "patient", "presented", "with", "fulminant", "hepatic", "failure", ",", "which", "resolved", "rapidly", "after", "cessation", "of", "nicotinic", "acid", "therapy", "."], "event_mentions": [{"id": "3680913_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 15, "end": 16}, "arguments": [{"entity_id": "3680913_1_Ent2", "role": "Treatment", "text": "10 weeks after", "start": 8, "end": 11}, {"entity_id": "3680913_1_Ent4", "role": "Treatment_Time_elapsed", "text": "10 weeks after", "start": 8, "end": 11}, {"entity_id": "3680913_1_Ent0", "role": "Subject", "text": "the patient", "start": 13, "end": 15}, {"entity_id": "3680913_1_Ent1", "role": "Effect", "text": "fulminant hepatic failure", "start": 17, "end": 20}, {"entity_id": "3680913_1_Ent3", "role": "Treatment", "text": "nicotinic acid", "start": 27, "end": 29}, {"entity_id": "3680913_1_Ent5", "role": "Treatment_Drug", "text": "nicotinic acid", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "3680913_1_Ent2", "text": "10 weeks after", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "3680913_1_Ent4", "text": "10 weeks after", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "3680913_1_Ent0", "text": "the patient", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "3680913_1_Ent1", "text": "fulminant hepatic failure", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "3680913_1_Ent3", "text": "nicotinic acid", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "3680913_1_Ent5", "text": "nicotinic acid", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "3732375_2", "wnd_id": "3732375_2_1", "text": "A case is reported of theophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine .", "tokens": ["A", "case", "is", "reported", "of", "theophylline", "intoxication", "due", "to", "a", "dramatic", "decrease", "in", "theophylline", "clearance", "following", "concomitant", "administration", "of", "viloxazine", "."], "event_mentions": [{"id": "3732375_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 7, "end": 8}, "arguments": [{"entity_id": "3732375_2_Ent0", "role": "Effect", "text": "theophylline intoxication", "start": 5, "end": 7}, {"entity_id": "3732375_2_Ent2", "role": "Treatment_Drug", "text": "theophylline", "start": 13, "end": 14}, {"entity_id": "3732375_2_Ent5", "role": "Combination_Drug", "text": "theophylline", "start": 13, "end": 14}, {"entity_id": "3732375_2_Ent1", "role": "Treatment", "text": "concomitant administration of viloxazine", "start": 16, "end": 20}, {"entity_id": "3732375_2_Ent3", "role": "Treatment_Drug", "text": "viloxazine", "start": 19, "end": 20}, {"entity_id": "3732375_2_Ent4", "role": "Combination_Drug", "text": "viloxazine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "3732375_2_Ent0", "text": "theophylline intoxication", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3732375_2_Ent2", "text": "theophylline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "3732375_2_Ent5", "text": "theophylline", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "3732375_2_Ent1", "text": "concomitant administration of viloxazine", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "3732375_2_Ent3", "text": "viloxazine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3732375_2_Ent4", "text": "viloxazine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "3753891_1", "wnd_id": "3753891_1_1", "text": "Acute myocardial necrosis during administration of amsacrine .", "tokens": ["Acute", "myocardial", "necrosis", "during", "administration", "of", "amsacrine", "."], "event_mentions": [{"id": "3753891_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "3753891_1_Ent0", "role": "Effect", "text": "Acute myocardial necrosis", "start": 0, "end": 3}, {"entity_id": "3753891_1_Ent1", "role": "Treatment", "text": "amsacrine", "start": 6, "end": 7}, {"entity_id": "3753891_1_Ent2", "role": "Treatment_Drug", "text": "amsacrine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "3753891_1_Ent0", "text": "Acute myocardial necrosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3753891_1_Ent1", "text": "amsacrine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3753891_1_Ent2", "text": "amsacrine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "3753891_3", "wnd_id": "3753891_3_1", "text": "The authors report a case of focal myocardial necrosis , presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug , amsacrine , in a patient without coronary artery disease .", "tokens": ["The", "authors", "report", "a", "case", "of", "focal", "myocardial", "necrosis", ",", "presenting", "clinically", "as", "an", "acute", "myocardial", "infarction", "during", "the", "administration", "of", "the", "antineoplastic", "drug", ",", "amsacrine", ",", "in", "a", "patient", "without", "coronary", "artery", "disease", "."], "event_mentions": [{"id": "3753891_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 17, "end": 18}, "arguments": [{"entity_id": "3753891_3_Ent1", "role": "Effect", "text": "focal myocardial necrosis , presenting clinically as an acute myocardial infarction", "start": 6, "end": 17}, {"entity_id": "3753891_3_Ent2", "role": "Treatment", "text": "amsacrine", "start": 25, "end": 26}, {"entity_id": "3753891_3_Ent3", "role": "Treatment_Drug", "text": "amsacrine", "start": 25, "end": 26}, {"entity_id": "3753891_3_Ent0", "role": "Subject", "text": "a patient without coronary artery disease", "start": 28, "end": 34}]}], "entity_mentions": [{"id": "3753891_3_Ent1", "text": "focal myocardial necrosis , presenting clinically as an acute myocardial infarction", "entity_type": "Entity", "start": 6, "end": 17}, {"id": "3753891_3_Ent2", "text": "amsacrine", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "3753891_3_Ent3", "text": "amsacrine", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "3753891_3_Ent0", "text": "a patient without coronary artery disease", "entity_type": "Entity", "start": 28, "end": 34}], "lang": "en"}
{"doc_id": "3790438_1", "wnd_id": "3790438_1_1", "text": "Generalized pustular psoriasis precipitated by trazodone in the treatment of depression .", "tokens": ["Generalized", "pustular", "psoriasis", "precipitated", "by", "trazodone", "in", "the", "treatment", "of", "depression", "."], "event_mentions": [{"id": "3790438_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitated", "start": 3, "end": 4}, "arguments": [{"entity_id": "3790438_1_Ent0", "role": "Effect", "text": "Generalized pustular psoriasis", "start": 0, "end": 3}, {"entity_id": "3790438_1_Ent1", "role": "Treatment", "text": "trazodone", "start": 5, "end": 6}, {"entity_id": "3790438_1_Ent3", "role": "Treatment_Drug", "text": "trazodone", "start": 5, "end": 6}, {"entity_id": "3790438_1_Ent2", "role": "Treatment_Disorder", "text": "depression", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "3790438_1_Ent0", "text": "Generalized pustular psoriasis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3790438_1_Ent1", "text": "trazodone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3790438_1_Ent3", "text": "trazodone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3790438_1_Ent2", "text": "depression", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "3790438_2", "wnd_id": "3790438_2_1", "text": "We report a patient in whom the anti - depressant trazodone hydrochloride ( Molipaxin , Roussel ) , a serotonin antagonist , provoked generalized pustular psoriasis ( GPP ) .", "tokens": ["We", "report", "a", "patient", "in", "whom", "the", "anti", "-", "depressant", "trazodone", "hydrochloride", "(", "Molipaxin", ",", "Roussel", ")", ",", "a", "serotonin", "antagonist", ",", "provoked", "generalized", "pustular", "psoriasis", "(", "GPP", ")", "."], "event_mentions": [{"id": "3790438_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoked", "start": 22, "end": 23}, "arguments": [{"entity_id": "3790438_2_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "3790438_2_Ent3", "role": "Treatment_Drug", "text": "trazodone hydrochloride", "start": 10, "end": 12}, {"entity_id": "3790438_2_Ent2", "role": "Treatment", "text": "trazodone hydrochloride ( Molipaxin , Roussel )", "start": 10, "end": 17}, {"entity_id": "3790438_2_Ent1", "role": "Effect", "text": "generalized pustular psoriasis ( GPP )", "start": 23, "end": 29}]}], "entity_mentions": [{"id": "3790438_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "3790438_2_Ent3", "text": "trazodone hydrochloride", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "3790438_2_Ent2", "text": "trazodone hydrochloride ( Molipaxin , Roussel )", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "3790438_2_Ent1", "text": "generalized pustular psoriasis ( GPP )", "entity_type": "Entity", "start": 23, "end": 29}], "lang": "en"}
{"doc_id": "3797173_1", "wnd_id": "3797173_1_1", "text": "Intravenous verapamil therapy in babies may cause apnea , hypotension , and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; quinidine may be related to the death ; children with \" familial seizure disorders \" may in fact have the long QT interval syndrome .", "tokens": ["Intravenous", "verapamil", "therapy", "in", "babies", "may", "cause", "apnea", ",", "hypotension", ",", "and", "bradycardia", ";", "continued", "episodes", "of", "atrial", "flutter", "in", "a", "child", "may", "cause", "sudden", "death", ";", "quinidine", "may", "be", "related", "to", "the", "death", ";", "children", "with", "\"", "familial", "seizure", "disorders", "\"", "may", "in", "fact", "have", "the", "long", "QT", "interval", "syndrome", "."], "event_mentions": [{"id": "3797173_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 6, "end": 7}, "arguments": [{"entity_id": "3797173_1_Ent4", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "3797173_1_Ent3", "role": "Treatment", "text": "Intravenous verapamil", "start": 0, "end": 2}, {"entity_id": "3797173_1_Ent5", "role": "Treatment_Drug", "text": "verapamil", "start": 1, "end": 2}, {"entity_id": "3797173_1_Ent0", "role": "Subject", "text": "babies", "start": 4, "end": 5}, {"entity_id": "3797173_1_Ent1", "role": "Subject_Age", "text": "babies", "start": 4, "end": 5}, {"entity_id": "3797173_1_Ent2", "role": "Effect", "text": "apnea , hypotension , and bradycardia", "start": 7, "end": 13}]}, {"id": "3797173_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 30, "end": 31}, "arguments": [{"entity_id": "3797173_1_Ent7", "role": "Treatment", "text": "quinidine", "start": 27, "end": 28}, {"entity_id": "3797173_1_Ent8", "role": "Treatment_Drug", "text": "quinidine", "start": 27, "end": 28}, {"entity_id": "3797173_1_Ent6", "role": "Effect", "text": "death", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "3797173_1_Ent4", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3797173_1_Ent3", "text": "Intravenous verapamil", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3797173_1_Ent5", "text": "verapamil", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3797173_1_Ent0", "text": "babies", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3797173_1_Ent1", "text": "babies", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3797173_1_Ent2", "text": "apnea , hypotension , and bradycardia", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "3797173_1_Ent7", "text": "quinidine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "3797173_1_Ent8", "text": "quinidine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "3797173_1_Ent6", "text": "death", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "3804181_3", "wnd_id": "3804181_3_1", "text": "The main clinical features of this 58 - year - old female patient were laboratory evidence of leucopenia and cholestasis , and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis , demonstrated 20 days after the initiation of antithyroid therapy with 20 mg methimazole daily .", "tokens": ["The", "main", "clinical", "features", "of", "this", "58", "-", "year", "-", "old", "female", "patient", "were", "laboratory", "evidence", "of", "leucopenia", "and", "cholestasis", ",", "and", "biopsy", "features", "of", "fatty", "liver", "parenchyma", "degeneration", "with", "granulocytic", "portal", "infiltration", "and", "bile", "stasis", ",", "demonstrated", "20", "days", "after", "the", "initiation", "of", "antithyroid", "therapy", "with", "20", "mg", "methimazole", "daily", "."], "event_mentions": [{"id": "3804181_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "demonstrated", "start": 37, "end": 38}, "arguments": [{"entity_id": "3804181_3_Ent0", "role": "Subject", "text": "this 58 - year - old female", "start": 5, "end": 12}, {"entity_id": "3804181_3_Ent1", "role": "Subject_Age", "text": "58 - year - old", "start": 6, "end": 11}, {"entity_id": "3804181_3_Ent2", "role": "Subject_Gender", "text": "female", "start": 11, "end": 12}, {"entity_id": "3804181_3_Ent3", "role": "Effect", "text": "leucopenia and cholestasis , and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis", "start": 17, "end": 36}, {"entity_id": "3804181_3_Ent5", "role": "Treatment_Time_elapsed", "text": "20 days after", "start": 38, "end": 41}, {"entity_id": "3804181_3_Ent4", "role": "Treatment", "text": "antithyroid therapy with 20 mg methimazole daily", "start": 44, "end": 51}, {"entity_id": "3804181_3_Ent7", "role": "Treatment_Dosage", "text": "20 mg", "start": 47, "end": 49}, {"entity_id": "3804181_3_Ent6", "role": "Treatment_Drug", "text": "methimazole", "start": 49, "end": 50}, {"entity_id": "3804181_3_Ent8", "role": "Treatment_Freq", "text": "daily", "start": 50, "end": 51}]}], "entity_mentions": [{"id": "3804181_3_Ent0", "text": "this 58 - year - old female", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "3804181_3_Ent1", "text": "58 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "3804181_3_Ent2", "text": "female", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3804181_3_Ent3", "text": "leucopenia and cholestasis , and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis", "entity_type": "Entity", "start": 17, "end": 36}, {"id": "3804181_3_Ent5", "text": "20 days after", "entity_type": "Entity", "start": 38, "end": 41}, {"id": "3804181_3_Ent4", "text": "antithyroid therapy with 20 mg methimazole daily", "entity_type": "Entity", "start": 44, "end": 51}, {"id": "3804181_3_Ent7", "text": "20 mg", "entity_type": "Entity", "start": 47, "end": 49}, {"id": "3804181_3_Ent6", "text": "methimazole", "entity_type": "Entity", "start": 49, "end": 50}, {"id": "3804181_3_Ent8", "text": "daily", "entity_type": "Entity", "start": 50, "end": 51}], "lang": "en"}
{"doc_id": "3815268_1", "wnd_id": "3815268_1_1", "text": "A 57 - year - old woman developed pulmonary sarcoidosis during therapy with interferon beta for advanced renal cell carcinoma metastatic to mediastinal lymph nodes .", "tokens": ["A", "57", "-", "year", "-", "old", "woman", "developed", "pulmonary", "sarcoidosis", "during", "therapy", "with", "interferon", "beta", "for", "advanced", "renal", "cell", "carcinoma", "metastatic", "to", "mediastinal", "lymph", "nodes", "."], "event_mentions": [{"id": "3815268_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "3815268_1_Ent1", "role": "Subject_Age", "text": "57 - year - old", "start": 1, "end": 6}, {"entity_id": "3815268_1_Ent0", "role": "Subject", "text": "57 - year - old woman", "start": 1, "end": 7}, {"entity_id": "3815268_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "3815268_1_Ent3", "role": "Effect", "text": "pulmonary sarcoidosis", "start": 8, "end": 10}, {"entity_id": "3815268_1_Ent6", "role": "Treatment_Drug", "text": "interferon beta", "start": 13, "end": 15}, {"entity_id": "3815268_1_Ent4", "role": "Treatment", "text": "interferon beta for advanced renal cell carcinoma metastatic to mediastinal lymph nodes", "start": 13, "end": 25}, {"entity_id": "3815268_1_Ent5", "role": "Treatment_Disorder", "text": "advanced renal cell carcinoma metastatic to mediastinal lymph nodes", "start": 16, "end": 25}]}], "entity_mentions": [{"id": "3815268_1_Ent1", "text": "57 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "3815268_1_Ent0", "text": "57 - year - old woman", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "3815268_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3815268_1_Ent3", "text": "pulmonary sarcoidosis", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "3815268_1_Ent6", "text": "interferon beta", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "3815268_1_Ent4", "text": "interferon beta for advanced renal cell carcinoma metastatic to mediastinal lymph nodes", "entity_type": "Entity", "start": 13, "end": 25}, {"id": "3815268_1_Ent5", "text": "advanced renal cell carcinoma metastatic to mediastinal lymph nodes", "entity_type": "Entity", "start": 16, "end": 25}], "lang": "en"}
{"doc_id": "3873709_2", "wnd_id": "3873709_2_1", "text": "Pseudomembranous colitis readily occurs in at least certain population groups receiving trimethoprim - sulfamethoxazole .", "tokens": ["Pseudomembranous", "colitis", "readily", "occurs", "in", "at", "least", "certain", "population", "groups", "receiving", "trimethoprim", "-", "sulfamethoxazole", "."], "event_mentions": [{"id": "3873709_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurs", "start": 3, "end": 4}, "arguments": [{"entity_id": "3873709_2_Ent1", "role": "Effect", "text": "Pseudomembranous colitis", "start": 0, "end": 2}, {"entity_id": "3873709_2_Ent0", "role": "Subject", "text": "certain population groups", "start": 7, "end": 10}, {"entity_id": "3873709_2_Ent3", "role": "Treatment_Drug", "text": "trimethoprim", "start": 11, "end": 12}, {"entity_id": "3873709_2_Ent6", "role": "Combination_Drug", "text": "trimethoprim", "start": 11, "end": 12}, {"entity_id": "3873709_2_Ent2", "role": "Treatment", "text": "trimethoprim - sulfamethoxazole", "start": 11, "end": 14}, {"entity_id": "3873709_2_Ent4", "role": "Treatment_Drug", "text": "sulfamethoxazole", "start": 13, "end": 14}, {"entity_id": "3873709_2_Ent5", "role": "Combination_Drug", "text": "sulfamethoxazole", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "3873709_2_Ent1", "text": "Pseudomembranous colitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3873709_2_Ent0", "text": "certain population groups", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "3873709_2_Ent3", "text": "trimethoprim", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3873709_2_Ent6", "text": "trimethoprim", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3873709_2_Ent2", "text": "trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "3873709_2_Ent4", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "3873709_2_Ent5", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "3878320_2", "wnd_id": "3878320_2_1", "text": "The condition should be suspected in patients who develop unexplained abdominal pain or collapse following vasopressin treatment .", "tokens": ["The", "condition", "should", "be", "suspected", "in", "patients", "who", "develop", "unexplained", "abdominal", "pain", "or", "collapse", "following", "vasopressin", "treatment", "."], "event_mentions": [{"id": "3878320_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 8, "end": 9}, "arguments": [{"entity_id": "3878320_2_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "3878320_2_Ent1", "role": "Effect", "text": "unexplained abdominal pain or collapse", "start": 9, "end": 14}, {"entity_id": "3878320_2_Ent2", "role": "Treatment", "text": "vasopressin", "start": 15, "end": 16}, {"entity_id": "3878320_2_Ent3", "role": "Treatment_Drug", "text": "vasopressin", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "3878320_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3878320_2_Ent1", "text": "unexplained abdominal pain or collapse", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "3878320_2_Ent2", "text": "vasopressin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "3878320_2_Ent3", "text": "vasopressin", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "3892171_4", "wnd_id": "3892171_4_1", "text": "Although adverse reactions to protamine are reported infrequently and are usually mild , we recently observed the first fatal case of type I anaphylaxis resulting from protamine .", "tokens": ["Although", "adverse", "reactions", "to", "protamine", "are", "reported", "infrequently", "and", "are", "usually", "mild", ",", "we", "recently", "observed", "the", "first", "fatal", "case", "of", "type", "I", "anaphylaxis", "resulting", "from", "protamine", "."], "event_mentions": [{"id": "3892171_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 24, "end": 25}, "arguments": [{"entity_id": "3892171_4_Ent0", "role": "Effect", "text": "fatal case of type I anaphylaxis", "start": 18, "end": 24}, {"entity_id": "3892171_4_Ent1", "role": "Treatment", "text": "protamine", "start": 26, "end": 27}, {"entity_id": "3892171_4_Ent2", "role": "Treatment_Drug", "text": "protamine", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "3892171_4_Ent0", "text": "fatal case of type I anaphylaxis", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "3892171_4_Ent1", "text": "protamine", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "3892171_4_Ent2", "text": "protamine", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "3926849_1", "wnd_id": "3926849_1_1", "text": "Administration of intravenous nitroglycerin in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance .", "tokens": ["Administration", "of", "intravenous", "nitroglycerin", "in", "a", "patient", "with", "idiopathic", "pulmonary", "hypertension", "resulted", "in", "an", "increase", "in", "pulmonary", "artery", "pressure", "associated", "with", "a", "decrease", "in", "blood", "flow", "that", "is", "best", "explained", "by", "an", "increase", "in", "pulmonary", "vascular", "resistance", "."], "event_mentions": [{"id": "3926849_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Administration", "start": 0, "end": 1}, "arguments": [{"entity_id": "3926849_1_Ent4", "role": "Treatment_Route", "text": "intravenous", "start": 2, "end": 3}, {"entity_id": "3926849_1_Ent2", "role": "Treatment", "text": "intravenous nitroglycerin", "start": 2, "end": 4}, {"entity_id": "3926849_1_Ent5", "role": "Treatment_Drug", "text": "nitroglycerin", "start": 3, "end": 4}, {"entity_id": "3926849_1_Ent0", "role": "Subject", "text": "a patient with idiopathic pulmonary hypertension", "start": 5, "end": 11}, {"entity_id": "3926849_1_Ent3", "role": "Treatment_Disorder", "text": "idiopathic pulmonary hypertension", "start": 8, "end": 11}, {"entity_id": "3926849_1_Ent1", "role": "Effect", "text": "increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance", "start": 14, "end": 37}]}], "entity_mentions": [{"id": "3926849_1_Ent4", "text": "intravenous", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "3926849_1_Ent2", "text": "intravenous nitroglycerin", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "3926849_1_Ent5", "text": "nitroglycerin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3926849_1_Ent0", "text": "a patient with idiopathic pulmonary hypertension", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "3926849_1_Ent3", "text": "idiopathic pulmonary hypertension", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "3926849_1_Ent1", "text": "increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance", "entity_type": "Entity", "start": 14, "end": 37}], "lang": "en"}
{"doc_id": "3926849_2", "wnd_id": "3926849_2_1", "text": "Paradoxical pulmonary vasoconstriction induced by nitroglycerin in idiopathic pulmonary hypertension .", "tokens": ["Paradoxical", "pulmonary", "vasoconstriction", "induced", "by", "nitroglycerin", "in", "idiopathic", "pulmonary", "hypertension", "."], "event_mentions": [{"id": "3926849_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "3926849_2_Ent0", "role": "Effect", "text": "Paradoxical pulmonary vasoconstriction", "start": 0, "end": 3}, {"entity_id": "3926849_2_Ent1", "role": "Treatment", "text": "nitroglycerin", "start": 5, "end": 6}, {"entity_id": "3926849_2_Ent2", "role": "Treatment_Drug", "text": "nitroglycerin", "start": 5, "end": 6}, {"entity_id": "3926849_2_Ent3", "role": "Treatment_Disorder", "text": "idiopathic pulmonary hypertension", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "3926849_2_Ent0", "text": "Paradoxical pulmonary vasoconstriction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3926849_2_Ent1", "text": "nitroglycerin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3926849_2_Ent2", "text": "nitroglycerin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3926849_2_Ent3", "text": "idiopathic pulmonary hypertension", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "3941210_1", "wnd_id": "3941210_1_1", "text": "Atrioventricular block complicating amiodarone - induced hypothyroidism in a patient with pre - excitation and rate - dependent bilateral bundle branch block .", "tokens": ["Atrioventricular", "block", "complicating", "amiodarone", "-", "induced", "hypothyroidism", "in", "a", "patient", "with", "pre", "-", "excitation", "and", "rate", "-", "dependent", "bilateral", "bundle", "branch", "block", "."], "event_mentions": [{"id": "3941210_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "3941210_1_Ent3", "role": "Subject_Disorder", "text": "Atrioventricular block", "start": 0, "end": 2}, {"entity_id": "3941210_1_Ent5", "role": "Treatment", "text": "amiodarone", "start": 3, "end": 4}, {"entity_id": "3941210_1_Ent6", "role": "Treatment_Drug", "text": "amiodarone", "start": 3, "end": 4}, {"entity_id": "3941210_1_Ent4", "role": "Effect", "text": "hypothyroidism", "start": 6, "end": 7}, {"entity_id": "3941210_1_Ent0", "role": "Subject", "text": "a patient with pre - excitation and rate - dependent bilateral bundle branch block", "start": 8, "end": 22}, {"entity_id": "3941210_1_Ent1", "role": "Subject_Disorder", "text": "pre - excitation", "start": 11, "end": 14}, {"entity_id": "3941210_1_Ent2", "role": "Subject_Disorder", "text": "rate - dependent bilateral bundle branch block", "start": 15, "end": 22}]}], "entity_mentions": [{"id": "3941210_1_Ent3", "text": "Atrioventricular block", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3941210_1_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3941210_1_Ent6", "text": "amiodarone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3941210_1_Ent4", "text": "hypothyroidism", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3941210_1_Ent0", "text": "a patient with pre - excitation and rate - dependent bilateral bundle branch block", "entity_type": "Entity", "start": 8, "end": 22}, {"id": "3941210_1_Ent1", "text": "pre - excitation", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "3941210_1_Ent2", "text": "rate - dependent bilateral bundle branch block", "entity_type": "Entity", "start": 15, "end": 22}], "lang": "en"}
{"doc_id": "3967536_1", "wnd_id": "3967536_1_1", "text": "Hypotension and sinus arrest with nifedipine in pulmonary hypertension .", "tokens": ["Hypotension", "and", "sinus", "arrest", "with", "nifedipine", "in", "pulmonary", "hypertension", "."], "event_mentions": [{"id": "3967536_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 4, "end": 5}, "arguments": [{"entity_id": "3967536_1_Ent0", "role": "Effect", "text": "Hypotension and sinus arrest", "start": 0, "end": 4}, {"entity_id": "3967536_1_Ent1", "role": "Treatment", "text": "nifedipine", "start": 5, "end": 6}, {"entity_id": "3967536_1_Ent2", "role": "Treatment_Drug", "text": "nifedipine", "start": 5, "end": 6}, {"entity_id": "3967536_1_Ent3", "role": "Treatment_Disorder", "text": "pulmonary hypertension", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "3967536_1_Ent0", "text": "Hypotension and sinus arrest", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3967536_1_Ent1", "text": "nifedipine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3967536_1_Ent2", "text": "nifedipine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3967536_1_Ent3", "text": "pulmonary hypertension", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "3967572_5", "wnd_id": "3967572_5_1", "text": "With combined use , clinicians should be aware , when phenytoin is added , of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations .", "tokens": ["With", "combined", "use", ",", "clinicians", "should", "be", "aware", ",", "when", "phenytoin", "is", "added", ",", "of", "the", "potential", "for", "reexacerbation", "of", "pulmonary", "symptomatology", "due", "to", "lowered", "serum", "theophylline", "concentrations", "."], "event_mentions": [{"id": "3967572_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 22, "end": 23}, "arguments": [{"entity_id": "3967572_5_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 10, "end": 11}, {"entity_id": "3967572_5_Ent5", "role": "Combination_Drug", "text": "phenytoin", "start": 10, "end": 11}, {"entity_id": "3967572_5_Ent1", "role": "Treatment", "text": "phenytoin is added", "start": 10, "end": 13}, {"entity_id": "3967572_5_Ent0", "role": "Effect", "text": "reexacerbation of pulmonary symptomatology", "start": 18, "end": 22}, {"entity_id": "3967572_5_Ent2", "role": "Treatment", "text": "theophylline", "start": 26, "end": 27}, {"entity_id": "3967572_5_Ent4", "role": "Treatment_Drug", "text": "theophylline", "start": 26, "end": 27}, {"entity_id": "3967572_5_Ent6", "role": "Combination_Drug", "text": "theophylline", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "3967572_5_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3967572_5_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3967572_5_Ent1", "text": "phenytoin is added", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "3967572_5_Ent0", "text": "reexacerbation of pulmonary symptomatology", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "3967572_5_Ent2", "text": "theophylline", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "3967572_5_Ent4", "text": "theophylline", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "3967572_5_Ent6", "text": "theophylline", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "3970339_1", "wnd_id": "3970339_1_1", "text": "A patient presented with a painful , oedematous , cyanosed hand having injected a solution of diamorphine and methylphenidate into his radial artery .", "tokens": ["A", "patient", "presented", "with", "a", "painful", ",", "oedematous", ",", "cyanosed", "hand", "having", "injected", "a", "solution", "of", "diamorphine", "and", "methylphenidate", "into", "his", "radial", "artery", "."], "event_mentions": [{"id": "3970339_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 2, "end": 3}, "arguments": [{"entity_id": "3970339_1_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "3970339_1_Ent1", "role": "Effect", "text": "painful , oedematous , cyanosed hand", "start": 5, "end": 11}, {"entity_id": "3970339_1_Ent3", "role": "Treatment_Route", "text": "injected", "start": 12, "end": 13}, {"entity_id": "3970339_1_Ent2", "role": "Treatment", "text": "injected a solution of diamorphine and methylphenidate into his radial artery", "start": 12, "end": 23}, {"entity_id": "3970339_1_Ent5", "role": "Treatment_Drug", "text": "diamorphine", "start": 16, "end": 17}, {"entity_id": "3970339_1_Ent7", "role": "Combination_Drug", "text": "diamorphine", "start": 16, "end": 17}, {"entity_id": "3970339_1_Ent6", "role": "Treatment_Drug", "text": "methylphenidate", "start": 18, "end": 19}, {"entity_id": "3970339_1_Ent8", "role": "Combination_Drug", "text": "methylphenidate", "start": 18, "end": 19}, {"entity_id": "3970339_1_Ent4", "role": "Treatment_Route", "text": "into his radial artery", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "3970339_1_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3970339_1_Ent1", "text": "painful , oedematous , cyanosed hand", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "3970339_1_Ent3", "text": "injected", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "3970339_1_Ent2", "text": "injected a solution of diamorphine and methylphenidate into his radial artery", "entity_type": "Entity", "start": 12, "end": 23}, {"id": "3970339_1_Ent5", "text": "diamorphine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "3970339_1_Ent7", "text": "diamorphine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "3970339_1_Ent6", "text": "methylphenidate", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "3970339_1_Ent8", "text": "methylphenidate", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "3970339_1_Ent4", "text": "into his radial artery", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "3970339_2", "wnd_id": "3970339_2_1", "text": "Ischaemia following selfadministered intra - arterial injection of methylphenidate and diamorphine .", "tokens": ["Ischaemia", "following", "selfadministered", "intra", "-", "arterial", "injection", "of", "methylphenidate", "and", "diamorphine", "."], "event_mentions": [{"id": "3970339_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 1, "end": 2}, "arguments": [{"entity_id": "3970339_2_Ent0", "role": "Effect", "text": "Ischaemia", "start": 0, "end": 1}, {"entity_id": "3970339_2_Ent1", "role": "Treatment", "text": "selfadministered intra - arterial injection of methylphenidate and diamorphine", "start": 2, "end": 11}, {"entity_id": "3970339_2_Ent4", "role": "Treatment_Route", "text": "intra - arterial injection", "start": 3, "end": 7}, {"entity_id": "3970339_2_Ent2", "role": "Treatment_Drug", "text": "methylphenidate", "start": 8, "end": 9}, {"entity_id": "3970339_2_Ent5", "role": "Combination_Drug", "text": "methylphenidate", "start": 8, "end": 9}, {"entity_id": "3970339_2_Ent3", "role": "Treatment_Drug", "text": "diamorphine", "start": 10, "end": 11}, {"entity_id": "3970339_2_Ent6", "role": "Combination_Drug", "text": "diamorphine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "3970339_2_Ent0", "text": "Ischaemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3970339_2_Ent1", "text": "selfadministered intra - arterial injection of methylphenidate and diamorphine", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "3970339_2_Ent4", "text": "intra - arterial injection", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "3970339_2_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3970339_2_Ent5", "text": "methylphenidate", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3970339_2_Ent3", "text": "diamorphine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3970339_2_Ent6", "text": "diamorphine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "4004433_2", "wnd_id": "4004433_2_1", "text": "Our findings suggest that hyperkalemia can develop with the use of low - dose heparin , within seven days of initiating heparin therapy , and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication .", "tokens": ["Our", "findings", "suggest", "that", "hyperkalemia", "can", "develop", "with", "the", "use", "of", "low", "-", "dose", "heparin", ",", "within", "seven", "days", "of", "initiating", "heparin", "therapy", ",", "and", "that", "patients", "with", "diabetes", "mellitus", "or", "chronic", "renal", "insufficiency", "are", "especially", "predisposed", "to", "this", "complication", "."], "event_mentions": [{"id": "4004433_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 6, "end": 7}, "arguments": [{"entity_id": "4004433_2_Ent3", "role": "Effect", "text": "hyperkalemia", "start": 4, "end": 5}, {"entity_id": "4004433_2_Ent5", "role": "Treatment_Dosage", "text": "low - dose", "start": 11, "end": 14}, {"entity_id": "4004433_2_Ent4", "role": "Treatment", "text": "low - dose heparin , within seven days of initiating heparin therapy", "start": 11, "end": 23}, {"entity_id": "4004433_2_Ent6", "role": "Treatment_Drug", "text": "heparin", "start": 14, "end": 15}, {"entity_id": "4004433_2_Ent7", "role": "Treatment_Time_elapsed", "text": "within seven days", "start": 16, "end": 19}, {"entity_id": "4004433_2_Ent0", "role": "Subject", "text": "patients with diabetes mellitus or chronic renal insufficiency", "start": 26, "end": 34}, {"entity_id": "4004433_2_Ent1", "role": "Subject_Disorder", "text": "diabetes mellitus", "start": 28, "end": 30}, {"entity_id": "4004433_2_Ent2", "role": "Subject_Disorder", "text": "chronic renal insufficiency", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "4004433_2_Ent3", "text": "hyperkalemia", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "4004433_2_Ent5", "text": "low - dose", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "4004433_2_Ent4", "text": "low - dose heparin , within seven days of initiating heparin therapy", "entity_type": "Entity", "start": 11, "end": 23}, {"id": "4004433_2_Ent6", "text": "heparin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "4004433_2_Ent7", "text": "within seven days", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "4004433_2_Ent0", "text": "patients with diabetes mellitus or chronic renal insufficiency", "entity_type": "Entity", "start": 26, "end": 34}, {"id": "4004433_2_Ent1", "text": "diabetes mellitus", "entity_type": "Entity", "start": 28, "end": 30}, {"id": "4004433_2_Ent2", "text": "chronic renal insufficiency", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "4018433_1", "wnd_id": "4018433_1_1", "text": "A case of pyridoxine - dependent seizures is reported .", "tokens": ["A", "case", "of", "pyridoxine", "-", "dependent", "seizures", "is", "reported", "."], "event_mentions": [{"id": "4018433_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "dependent", "start": 5, "end": 6}, "arguments": [{"entity_id": "4018433_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "4018433_1_Ent2", "role": "Treatment", "text": "pyridoxine", "start": 3, "end": 4}, {"entity_id": "4018433_1_Ent3", "role": "Treatment_Drug", "text": "pyridoxine", "start": 3, "end": 4}, {"entity_id": "4018433_1_Ent1", "role": "Effect", "text": "seizures", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "4018433_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "4018433_1_Ent2", "text": "pyridoxine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "4018433_1_Ent3", "text": "pyridoxine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "4018433_1_Ent1", "text": "seizures", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "4036917_3", "wnd_id": "4036917_3_1", "text": "These findings support previous studies that showed that the use of aspirin during the antecedent illness may be a risk factor for the development of RS .", "tokens": ["These", "findings", "support", "previous", "studies", "that", "showed", "that", "the", "use", "of", "aspirin", "during", "the", "antecedent", "illness", "may", "be", "a", "risk", "factor", "for", "the", "development", "of", "RS", "."], "event_mentions": [{"id": "4036917_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 23, "end": 24}, "arguments": [{"entity_id": "4036917_3_Ent1", "role": "Treatment", "text": "aspirin", "start": 11, "end": 12}, {"entity_id": "4036917_3_Ent3", "role": "Treatment_Drug", "text": "aspirin", "start": 11, "end": 12}, {"entity_id": "4036917_3_Ent2", "role": "Treatment_Disorder", "text": "the antecedent illness", "start": 13, "end": 16}, {"entity_id": "4036917_3_Ent0", "role": "Effect", "text": "RS", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "4036917_3_Ent1", "text": "aspirin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4036917_3_Ent3", "text": "aspirin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4036917_3_Ent2", "text": "the antecedent illness", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "4036917_3_Ent0", "text": "RS", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "4051280_1", "wnd_id": "4051280_1_1", "text": "IV propranolol was used as the initial treatment for his hyperadrenergic state , resulting in a decrease in heart rate but a paroxsymal increase in blood pressure .", "tokens": ["IV", "propranolol", "was", "used", "as", "the", "initial", "treatment", "for", "his", "hyperadrenergic", "state", ",", "resulting", "in", "a", "decrease", "in", "heart", "rate", "but", "a", "paroxsymal", "increase", "in", "blood", "pressure", "."], "event_mentions": [{"id": "4051280_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 13, "end": 14}, "arguments": [{"entity_id": "4051280_1_Ent6", "role": "Treatment_Route", "text": "IV", "start": 0, "end": 1}, {"entity_id": "4051280_1_Ent3", "role": "Treatment", "text": "IV propranolol", "start": 0, "end": 2}, {"entity_id": "4051280_1_Ent4", "role": "Treatment_Drug", "text": "propranolol", "start": 1, "end": 2}, {"entity_id": "4051280_1_Ent1", "role": "Subject_Gender", "text": "his", "start": 9, "end": 10}, {"entity_id": "4051280_1_Ent0", "role": "Subject", "text": "his hyperadrenergic state", "start": 9, "end": 12}, {"entity_id": "4051280_1_Ent5", "role": "Treatment_Disorder", "text": "hyperadrenergic state", "start": 10, "end": 12}, {"entity_id": "4051280_1_Ent2", "role": "Effect", "text": "decrease in heart rate but a paroxsymal increase in blood pressure", "start": 16, "end": 27}]}], "entity_mentions": [{"id": "4051280_1_Ent6", "text": "IV", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4051280_1_Ent3", "text": "IV propranolol", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "4051280_1_Ent4", "text": "propranolol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "4051280_1_Ent1", "text": "his", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "4051280_1_Ent0", "text": "his hyperadrenergic state", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "4051280_1_Ent5", "text": "hyperadrenergic state", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "4051280_1_Ent2", "text": "decrease in heart rate but a paroxsymal increase in blood pressure", "entity_type": "Entity", "start": 16, "end": 27}], "lang": "en"}
{"doc_id": "4054170_3", "wnd_id": "4054170_3_1", "text": "EEG abnormalities were observed in two of the nine children during chlorambucil therapy .", "tokens": ["EEG", "abnormalities", "were", "observed", "in", "two", "of", "the", "nine", "children", "during", "chlorambucil", "therapy", "."], "event_mentions": [{"id": "4054170_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 3, "end": 4}, "arguments": [{"entity_id": "4054170_3_Ent3", "role": "Effect", "text": "EEG abnormalities", "start": 0, "end": 2}, {"entity_id": "4054170_3_Ent1", "role": "Subject_Population", "text": "two of the nine", "start": 5, "end": 9}, {"entity_id": "4054170_3_Ent0", "role": "Subject", "text": "two of the nine children", "start": 5, "end": 10}, {"entity_id": "4054170_3_Ent2", "role": "Subject_Age", "text": "children", "start": 9, "end": 10}, {"entity_id": "4054170_3_Ent4", "role": "Treatment", "text": "chlorambucil", "start": 11, "end": 12}, {"entity_id": "4054170_3_Ent5", "role": "Treatment_Drug", "text": "chlorambucil", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "4054170_3_Ent3", "text": "EEG abnormalities", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "4054170_3_Ent1", "text": "two of the nine", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "4054170_3_Ent0", "text": "two of the nine children", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "4054170_3_Ent2", "text": "children", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "4054170_3_Ent4", "text": "chlorambucil", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4054170_3_Ent5", "text": "chlorambucil", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "4066620_1", "wnd_id": "4066620_1_1", "text": "A 65 - year - old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following high doses of trazodone for treatment of an acute depression .", "tokens": ["A", "65", "-", "year", "-", "old", "woman", "with", "bipolar", "disorder", "and", "complicated", "cardiovascular", "disease", "who", "was", "on", "maintenance", "lithium", "therapy", "developed", "a", "movement", "disorder", "following", "high", "doses", "of", "trazodone", "for", "treatment", "of", "an", "acute", "depression", "."], "event_mentions": [{"id": "4066620_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 24, "end": 25}, "arguments": [{"entity_id": "4066620_1_Ent0", "role": "Subject", "text": "A 65 - year - old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy", "start": 0, "end": 20}, {"entity_id": "4066620_1_Ent1", "role": "Subject_Age", "text": "65 - year - old", "start": 1, "end": 6}, {"entity_id": "4066620_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "4066620_1_Ent3", "role": "Subject_Disorder", "text": "bipolar disorder", "start": 8, "end": 10}, {"entity_id": "4066620_1_Ent4", "role": "Subject_Disorder", "text": "cardiovascular disease", "start": 12, "end": 14}, {"entity_id": "4066620_1_Ent8", "role": "Treatment_Drug", "text": "lithium", "start": 18, "end": 19}, {"entity_id": "4066620_1_Ent11", "role": "Combination_Drug", "text": "lithium", "start": 18, "end": 19}, {"entity_id": "4066620_1_Ent5", "role": "Effect", "text": "a movement disorder", "start": 21, "end": 24}, {"entity_id": "4066620_1_Ent9", "role": "Treatment_Dosage", "text": "high doses", "start": 25, "end": 27}, {"entity_id": "4066620_1_Ent6", "role": "Treatment", "text": "high doses of trazodone", "start": 25, "end": 29}, {"entity_id": "4066620_1_Ent7", "role": "Treatment_Drug", "text": "trazodone", "start": 28, "end": 29}, {"entity_id": "4066620_1_Ent12", "role": "Combination_Drug", "text": "trazodone", "start": 28, "end": 29}, {"entity_id": "4066620_1_Ent10", "role": "Treatment_Disorder", "text": "acute depression", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "4066620_1_Ent0", "text": "A 65 - year - old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy", "entity_type": "Entity", "start": 0, "end": 20}, {"id": "4066620_1_Ent1", "text": "65 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "4066620_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "4066620_1_Ent3", "text": "bipolar disorder", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "4066620_1_Ent4", "text": "cardiovascular disease", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "4066620_1_Ent8", "text": "lithium", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "4066620_1_Ent11", "text": "lithium", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "4066620_1_Ent5", "text": "a movement disorder", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "4066620_1_Ent9", "text": "high doses", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "4066620_1_Ent6", "text": "high doses of trazodone", "entity_type": "Entity", "start": 25, "end": 29}, {"id": "4066620_1_Ent7", "text": "trazodone", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "4066620_1_Ent12", "text": "trazodone", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "4066620_1_Ent10", "text": "acute depression", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "4066622_2", "wnd_id": "4066622_2_1", "text": "The calcium channel blockers are a group of drugs that have recently become available for the treatment of angina .", "tokens": ["The", "calcium", "channel", "blockers", "are", "a", "group", "of", "drugs", "that", "have", "recently", "become", "available", "for", "the", "treatment", "of", "angina", "."], "event_mentions": [{"id": "4066622_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 16, "end": 17}, "arguments": [{"entity_id": "4066622_2_Ent0", "role": "Treatment", "text": "calcium channel blockers", "start": 1, "end": 4}, {"entity_id": "4066622_2_Ent2", "role": "Treatment_Drug", "text": "calcium channel blockers", "start": 1, "end": 4}, {"entity_id": "4066622_2_Ent1", "role": "Treatment_Disorder", "text": "angina", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "4066622_2_Ent0", "text": "calcium channel blockers", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "4066622_2_Ent2", "text": "calcium channel blockers", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "4066622_2_Ent1", "text": "angina", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "4082283_1", "wnd_id": "4082283_1_1", "text": "Rifampicin - induced renal failure .", "tokens": ["Rifampicin", "-", "induced", "renal", "failure", "."], "event_mentions": [{"id": "4082283_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "4082283_1_Ent1", "role": "Treatment", "text": "Rifampicin", "start": 0, "end": 1}, {"entity_id": "4082283_1_Ent2", "role": "Treatment_Drug", "text": "Rifampicin", "start": 0, "end": 1}, {"entity_id": "4082283_1_Ent0", "role": "Effect", "text": "renal failure", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "4082283_1_Ent1", "text": "Rifampicin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4082283_1_Ent2", "text": "Rifampicin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4082283_1_Ent0", "text": "renal failure", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "4082283_3", "wnd_id": "4082283_3_1", "text": "The following is a report of 2 cases of rifampicin - induced renal insufficiency .", "tokens": ["The", "following", "is", "a", "report", "of", "2", "cases", "of", "rifampicin", "-", "induced", "renal", "insufficiency", "."], "event_mentions": [{"id": "4082283_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "4082283_3_Ent1", "role": "Treatment", "text": "rifampicin", "start": 9, "end": 10}, {"entity_id": "4082283_3_Ent2", "role": "Treatment_Drug", "text": "rifampicin", "start": 9, "end": 10}, {"entity_id": "4082283_3_Ent0", "role": "Effect", "text": "renal insufficiency", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "4082283_3_Ent1", "text": "rifampicin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "4082283_3_Ent2", "text": "rifampicin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "4082283_3_Ent0", "text": "renal insufficiency", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "412488_7", "wnd_id": "412488_7_1", "text": "These findings are consistent with an immune - complex form of glomerulopathy in which gold is neither the antigen nor a hapten in the glomerular deposits , and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by gold therapy may be a causative factor in the renal disease associated with gold therapy in rheumatoid arthritis .", "tokens": ["These", "findings", "are", "consistent", "with", "an", "immune", "-", "complex", "form", "of", "glomerulopathy", "in", "which", "gold", "is", "neither", "the", "antigen", "nor", "a", "hapten", "in", "the", "glomerular", "deposits", ",", "and", "they", "suggest", "the", "hypothesis", "that", "antibodies", "to", "tubular", "epithelial", "antigens", "induced", "by", "gold", "therapy", "may", "be", "a", "causative", "factor", "in", "the", "renal", "disease", "associated", "with", "gold", "therapy", "in", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "412488_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 51, "end": 52}, "arguments": [{"entity_id": "412488_7_Ent0", "role": "Effect", "text": "renal disease", "start": 49, "end": 51}, {"entity_id": "412488_7_Ent2", "role": "Treatment_Drug", "text": "gold", "start": 53, "end": 54}, {"entity_id": "412488_7_Ent1", "role": "Treatment", "text": "gold therapy in rheumatoid arthritis", "start": 53, "end": 58}, {"entity_id": "412488_7_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 56, "end": 58}]}], "entity_mentions": [{"id": "412488_7_Ent0", "text": "renal disease", "entity_type": "Entity", "start": 49, "end": 51}, {"id": "412488_7_Ent2", "text": "gold", "entity_type": "Entity", "start": 53, "end": 54}, {"id": "412488_7_Ent1", "text": "gold therapy in rheumatoid arthritis", "entity_type": "Entity", "start": 53, "end": 58}, {"id": "412488_7_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 56, "end": 58}], "lang": "en"}
{"doc_id": "417679_1", "wnd_id": "417679_1_1", "text": "Four cases of fat embolism are described in infants receiving prolonged intravenous infusion of fat ( Intralipid 20 % ) .", "tokens": ["Four", "cases", "of", "fat", "embolism", "are", "described", "in", "infants", "receiving", "prolonged", "intravenous", "infusion", "of", "fat", "(", "Intralipid", "20", "%", ")", "."], "event_mentions": [{"id": "417679_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 9, "end": 10}, "arguments": [{"entity_id": "417679_1_Ent3", "role": "Subject_Age", "text": "Four", "start": 0, "end": 1}, {"entity_id": "417679_1_Ent0", "role": "Subject", "text": "Four cases", "start": 0, "end": 2}, {"entity_id": "417679_1_Ent4", "role": "Effect", "text": "fat embolism", "start": 3, "end": 5}, {"entity_id": "417679_1_Ent1", "role": "Subject", "text": "infants", "start": 8, "end": 9}, {"entity_id": "417679_1_Ent2", "role": "Subject_Age", "text": "infants", "start": 8, "end": 9}, {"entity_id": "417679_1_Ent5", "role": "Treatment", "text": "prolonged intravenous infusion of fat ( Intralipid 20 % )", "start": 10, "end": 20}, {"entity_id": "417679_1_Ent6", "role": "Treatment_Route", "text": "intravenous infusion", "start": 11, "end": 13}, {"entity_id": "417679_1_Ent7", "role": "Treatment_Drug", "text": "Intralipid", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "417679_1_Ent3", "text": "Four", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "417679_1_Ent0", "text": "Four cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "417679_1_Ent4", "text": "fat embolism", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "417679_1_Ent1", "text": "infants", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "417679_1_Ent2", "text": "infants", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "417679_1_Ent5", "text": "prolonged intravenous infusion of fat ( Intralipid 20 % )", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "417679_1_Ent6", "text": "intravenous infusion", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "417679_1_Ent7", "text": "Intralipid", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "426502_2", "wnd_id": "426502_2_1", "text": "Inappropriate antidiuretic hormone following adenine arabinoside administration .", "tokens": ["Inappropriate", "antidiuretic", "hormone", "following", "adenine", "arabinoside", "administration", "."], "event_mentions": [{"id": "426502_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "426502_2_Ent0", "role": "Effect", "text": "Inappropriate antidiuretic hormone", "start": 0, "end": 3}, {"entity_id": "426502_2_Ent1", "role": "Treatment", "text": "adenine arabinoside", "start": 4, "end": 6}, {"entity_id": "426502_2_Ent2", "role": "Treatment_Drug", "text": "adenine arabinoside", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "426502_2_Ent0", "text": "Inappropriate antidiuretic hormone", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "426502_2_Ent1", "text": "adenine arabinoside", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "426502_2_Ent2", "text": "adenine arabinoside", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "440873_1", "wnd_id": "440873_1_1", "text": "Dystonia associated with carbamazepine administration : experience in brain - damaged children .", "tokens": ["Dystonia", "associated", "with", "carbamazepine", "administration", ":", "experience", "in", "brain", "-", "damaged", "children", "."], "event_mentions": [{"id": "440873_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 1, "end": 3}, "arguments": [{"entity_id": "440873_1_Ent3", "role": "Effect", "text": "Dystonia", "start": 0, "end": 1}, {"entity_id": "440873_1_Ent5", "role": "Treatment_Drug", "text": "carbamazepine", "start": 3, "end": 4}, {"entity_id": "440873_1_Ent4", "role": "Treatment", "text": "carbamazepine administration", "start": 3, "end": 5}, {"entity_id": "440873_1_Ent1", "role": "Subject_Disorder", "text": "brain - damaged", "start": 8, "end": 11}, {"entity_id": "440873_1_Ent0", "role": "Subject", "text": "brain - damaged children", "start": 8, "end": 12}, {"entity_id": "440873_1_Ent2", "role": "Subject_Age", "text": "children", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "440873_1_Ent3", "text": "Dystonia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "440873_1_Ent5", "text": "carbamazepine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "440873_1_Ent4", "text": "carbamazepine administration", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "440873_1_Ent1", "text": "brain - damaged", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "440873_1_Ent0", "text": "brain - damaged children", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "440873_1_Ent2", "text": "children", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "440873_2", "wnd_id": "440873_2_1", "text": "In one child , a second course of carbamazepine resulted in a return of the dystonia .", "tokens": ["In", "one", "child", ",", "a", "second", "course", "of", "carbamazepine", "resulted", "in", "a", "return", "of", "the", "dystonia", "."], "event_mentions": [{"id": "440873_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 9, "end": 10}, "arguments": [{"entity_id": "440873_2_Ent1", "role": "Subject_Population", "text": "one", "start": 1, "end": 2}, {"entity_id": "440873_2_Ent0", "role": "Subject", "text": "one child", "start": 1, "end": 3}, {"entity_id": "440873_2_Ent2", "role": "Subject_Age", "text": "child", "start": 2, "end": 3}, {"entity_id": "440873_2_Ent4", "role": "Treatment", "text": "a second course of carbamazepine", "start": 4, "end": 9}, {"entity_id": "440873_2_Ent5", "role": "Treatment_Duration", "text": "second course", "start": 5, "end": 7}, {"entity_id": "440873_2_Ent6", "role": "Treatment_Drug", "text": "carbamazepine", "start": 8, "end": 9}, {"entity_id": "440873_2_Ent3", "role": "Effect", "text": "a return of the dystonia", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "440873_2_Ent1", "text": "one", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "440873_2_Ent0", "text": "one child", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "440873_2_Ent2", "text": "child", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "440873_2_Ent4", "text": "a second course of carbamazepine", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "440873_2_Ent5", "text": "second course", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "440873_2_Ent6", "text": "carbamazepine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "440873_2_Ent3", "text": "a return of the dystonia", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "448845_2", "wnd_id": "448845_2_1", "text": "Carbonic anhydrase inhibitors used in the treatment of glaucoma , seizure disorders , and hypertension are rarely associated with blood dyscrasias .", "tokens": ["Carbonic", "anhydrase", "inhibitors", "used", "in", "the", "treatment", "of", "glaucoma", ",", "seizure", "disorders", ",", "and", "hypertension", "are", "rarely", "associated", "with", "blood", "dyscrasias", "."], "event_mentions": [{"id": "448845_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "rarely associated", "start": 16, "end": 18}, "arguments": [{"entity_id": "448845_2_Ent1", "role": "Treatment", "text": "Carbonic anhydrase inhibitors", "start": 0, "end": 3}, {"entity_id": "448845_2_Ent2", "role": "Treatment_Drug", "text": "Carbonic anhydrase inhibitors", "start": 0, "end": 3}, {"entity_id": "448845_2_Ent3", "role": "Treatment_Disorder", "text": "glaucoma , seizure disorders , and hypertension", "start": 8, "end": 15}, {"entity_id": "448845_2_Ent0", "role": "Effect", "text": "blood dyscrasias", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "448845_2_Ent1", "text": "Carbonic anhydrase inhibitors", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "448845_2_Ent2", "text": "Carbonic anhydrase inhibitors", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "448845_2_Ent3", "text": "glaucoma , seizure disorders , and hypertension", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "448845_2_Ent0", "text": "blood dyscrasias", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "515777_2", "wnd_id": "515777_2_1", "text": "Two patients developed diabetic coma when taking a combination of a thiazide diuretic and propranolol .", "tokens": ["Two", "patients", "developed", "diabetic", "coma", "when", "taking", "a", "combination", "of", "a", "thiazide", "diuretic", "and", "propranolol", "."], "event_mentions": [{"id": "515777_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "515777_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "515777_2_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "515777_2_Ent2", "role": "Effect", "text": "diabetic coma", "start": 3, "end": 5}, {"entity_id": "515777_2_Ent3", "role": "Treatment", "text": "a combination of a thiazide diuretic and propranolol", "start": 7, "end": 15}, {"entity_id": "515777_2_Ent4", "role": "Treatment_Drug", "text": "thiazide", "start": 11, "end": 12}, {"entity_id": "515777_2_Ent6", "role": "Combination_Drug", "text": "thiazide", "start": 11, "end": 12}, {"entity_id": "515777_2_Ent5", "role": "Treatment_Drug", "text": "propranolol", "start": 14, "end": 15}, {"entity_id": "515777_2_Ent7", "role": "Combination_Drug", "text": "propranolol", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "515777_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "515777_2_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "515777_2_Ent2", "text": "diabetic coma", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "515777_2_Ent3", "text": "a combination of a thiazide diuretic and propranolol", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "515777_2_Ent4", "text": "thiazide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "515777_2_Ent6", "text": "thiazide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "515777_2_Ent5", "text": "propranolol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "515777_2_Ent7", "text": "propranolol", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "527355_2", "wnd_id": "527355_2_1", "text": "Severe acidosis from acetazolamide in a diabetic patient .", "tokens": ["Severe", "acidosis", "from", "acetazolamide", "in", "a", "diabetic", "patient", "."], "event_mentions": [{"id": "527355_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "527355_2_Ent2", "role": "Effect", "text": "Severe acidosis", "start": 0, "end": 2}, {"entity_id": "527355_2_Ent3", "role": "Treatment", "text": "acetazolamide", "start": 3, "end": 4}, {"entity_id": "527355_2_Ent4", "role": "Treatment_Drug", "text": "acetazolamide", "start": 3, "end": 4}, {"entity_id": "527355_2_Ent0", "role": "Subject", "text": "a diabetic patient", "start": 5, "end": 8}, {"entity_id": "527355_2_Ent1", "role": "Subject_Disorder", "text": "diabetic", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "527355_2_Ent2", "text": "Severe acidosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "527355_2_Ent3", "text": "acetazolamide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "527355_2_Ent4", "text": "acetazolamide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "527355_2_Ent0", "text": "a diabetic patient", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "527355_2_Ent1", "text": "diabetic", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "536461_1", "wnd_id": "536461_1_1", "text": "Five cases of clindamycin - associated pseudomembranous colitis in leukaemic patients are reported .", "tokens": ["Five", "cases", "of", "clindamycin", "-", "associated", "pseudomembranous", "colitis", "in", "leukaemic", "patients", "are", "reported", "."], "event_mentions": [{"id": "536461_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "536461_1_Ent3", "role": "Treatment", "text": "clindamycin", "start": 3, "end": 4}, {"entity_id": "536461_1_Ent4", "role": "Treatment_Drug", "text": "clindamycin", "start": 3, "end": 4}, {"entity_id": "536461_1_Ent2", "role": "Effect", "text": "pseudomembranous colitis", "start": 6, "end": 8}, {"entity_id": "536461_1_Ent1", "role": "Subject_Disorder", "text": "leukaemic", "start": 9, "end": 10}, {"entity_id": "536461_1_Ent0", "role": "Subject", "text": "leukaemic patients", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "536461_1_Ent3", "text": "clindamycin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "536461_1_Ent4", "text": "clindamycin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "536461_1_Ent2", "text": "pseudomembranous colitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "536461_1_Ent1", "text": "leukaemic", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "536461_1_Ent0", "text": "leukaemic patients", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "576675_2", "wnd_id": "576675_2_1", "text": "Edema associated with ibuprofen therapy .", "tokens": ["Edema", "associated", "with", "ibuprofen", "therapy", "."], "event_mentions": [{"id": "576675_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "576675_2_Ent0", "role": "Effect", "text": "Edema", "start": 0, "end": 1}, {"entity_id": "576675_2_Ent1", "role": "Treatment", "text": "ibuprofen", "start": 3, "end": 4}, {"entity_id": "576675_2_Ent2", "role": "Treatment_Drug", "text": "ibuprofen", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "576675_2_Ent0", "text": "Edema", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "576675_2_Ent1", "text": "ibuprofen", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "576675_2_Ent2", "text": "ibuprofen", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "578255_1", "wnd_id": "578255_1_1", "text": "Allopurinol - associated hand and foot deformities in chronic tophaceous gout .", "tokens": ["Allopurinol", "-", "associated", "hand", "and", "foot", "deformities", "in", "chronic", "tophaceous", "gout", "."], "event_mentions": [{"id": "578255_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "578255_1_Ent1", "role": "Treatment", "text": "Allopurinol", "start": 0, "end": 1}, {"entity_id": "578255_1_Ent2", "role": "Treatment_Drug", "text": "Allopurinol", "start": 0, "end": 1}, {"entity_id": "578255_1_Ent0", "role": "Effect", "text": "hand and foot deformities", "start": 3, "end": 7}, {"entity_id": "578255_1_Ent3", "role": "Treatment_Disorder", "text": "chronic tophaceous gout", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "578255_1_Ent1", "text": "Allopurinol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "578255_1_Ent2", "text": "Allopurinol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "578255_1_Ent0", "text": "hand and foot deformities", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "578255_1_Ent3", "text": "chronic tophaceous gout", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "582099_1", "wnd_id": "582099_1_1", "text": "A patient with coccidioidal meningitis was treated with intrathecally administered amphotericin B , and an acute toxic delirium with EEG abnormalities developed .", "tokens": ["A", "patient", "with", "coccidioidal", "meningitis", "was", "treated", "with", "intrathecally", "administered", "amphotericin", "B", ",", "and", "an", "acute", "toxic", "delirium", "with", "EEG", "abnormalities", "developed", "."], "event_mentions": [{"id": "582099_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated with", "start": 6, "end": 8}, "arguments": [{"entity_id": "582099_1_Ent0", "role": "Subject", "text": "A patient with coccidioidal meningitis", "start": 0, "end": 5}, {"entity_id": "582099_1_Ent3", "role": "Treatment_Disorder", "text": "coccidioidal meningitis", "start": 3, "end": 5}, {"entity_id": "582099_1_Ent5", "role": "Treatment_Route", "text": "intrathecally", "start": 8, "end": 9}, {"entity_id": "582099_1_Ent2", "role": "Treatment", "text": "intrathecally administered amphotericin B", "start": 8, "end": 12}, {"entity_id": "582099_1_Ent4", "role": "Treatment_Drug", "text": "amphotericin B", "start": 10, "end": 12}, {"entity_id": "582099_1_Ent1", "role": "Effect", "text": "an acute toxic delirium with EEG abnormalities", "start": 14, "end": 21}]}], "entity_mentions": [{"id": "582099_1_Ent0", "text": "A patient with coccidioidal meningitis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "582099_1_Ent3", "text": "coccidioidal meningitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "582099_1_Ent5", "text": "intrathecally", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "582099_1_Ent2", "text": "intrathecally administered amphotericin B", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "582099_1_Ent4", "text": "amphotericin B", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "582099_1_Ent1", "text": "an acute toxic delirium with EEG abnormalities", "entity_type": "Entity", "start": 14, "end": 21}], "lang": "en"}
{"doc_id": "58443_1", "wnd_id": "58443_1_1", "text": "In keeping with findings in the literature , the aortic wall in this case was damaged by secondary changes following irradiation and Bleomycin treatment .", "tokens": ["In", "keeping", "with", "findings", "in", "the", "literature", ",", "the", "aortic", "wall", "in", "this", "case", "was", "damaged", "by", "secondary", "changes", "following", "irradiation", "and", "Bleomycin", "treatment", "."], "event_mentions": [{"id": "58443_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 19, "end": 20}, "arguments": [{"entity_id": "58443_1_Ent0", "role": "Effect", "text": "aortic wall in this case was damaged", "start": 9, "end": 16}, {"entity_id": "58443_1_Ent1", "role": "Treatment", "text": "irradiation and Bleomycin treatment .", "start": 20, "end": 25}, {"entity_id": "58443_1_Ent2", "role": "Treatment_Drug", "text": "Bleomycin", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "58443_1_Ent0", "text": "aortic wall in this case was damaged", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "58443_1_Ent1", "text": "irradiation and Bleomycin treatment .", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "58443_1_Ent2", "text": "Bleomycin", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "6108450_1", "wnd_id": "6108450_1_1", "text": "Reversal of ergotamine - induced arteriospasm by mechanical intra - arterial dilatation .", "tokens": ["Reversal", "of", "ergotamine", "-", "induced", "arteriospasm", "by", "mechanical", "intra", "-", "arterial", "dilatation", "."], "event_mentions": [{"id": "6108450_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "6108450_1_Ent1", "role": "Treatment", "text": "ergotamine", "start": 2, "end": 3}, {"entity_id": "6108450_1_Ent2", "role": "Treatment_Drug", "text": "ergotamine", "start": 2, "end": 3}, {"entity_id": "6108450_1_Ent0", "role": "Effect", "text": "arteriospasm", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "6108450_1_Ent1", "text": "ergotamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "6108450_1_Ent2", "text": "ergotamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "6108450_1_Ent0", "text": "arteriospasm", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "6149250_3", "wnd_id": "6149250_3_1", "text": "One of the patients had a dexamethasone dependent brain metastatic condition .", "tokens": ["One", "of", "the", "patients", "had", "a", "dexamethasone", "dependent", "brain", "metastatic", "condition", "."], "event_mentions": [{"id": "6149250_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 4, "end": 5}, "arguments": [{"entity_id": "6149250_3_Ent1", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "6149250_3_Ent0", "role": "Subject", "text": "One of the patients", "start": 0, "end": 4}, {"entity_id": "6149250_3_Ent3", "role": "Treatment", "text": "dexamethasone", "start": 6, "end": 7}, {"entity_id": "6149250_3_Ent4", "role": "Treatment_Drug", "text": "dexamethasone", "start": 6, "end": 7}, {"entity_id": "6149250_3_Ent2", "role": "Effect", "text": "brain metastatic condition", "start": 8, "end": 11}, {"entity_id": "6149250_3_Ent5", "role": "Treatment_Disorder", "text": "brain metastatic condition", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "6149250_3_Ent1", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6149250_3_Ent0", "text": "One of the patients", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "6149250_3_Ent3", "text": "dexamethasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6149250_3_Ent4", "text": "dexamethasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6149250_3_Ent2", "text": "brain metastatic condition", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "6149250_3_Ent5", "text": "brain metastatic condition", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "6149250_4", "wnd_id": "6149250_4_1", "text": "The second patient suffered from high blood pressure , which was controlled with beta - blocker drugs .", "tokens": ["The", "second", "patient", "suffered", "from", "high", "blood", "pressure", ",", "which", "was", "controlled", "with", "beta", "-", "blocker", "drugs", "."], "event_mentions": [{"id": "6149250_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "controlled", "start": 11, "end": 12}, "arguments": [{"entity_id": "6149250_4_Ent0", "role": "Subject", "text": "The second patient suffered from high blood pressure", "start": 0, "end": 8}, {"entity_id": "6149250_4_Ent2", "role": "Treatment_Disorder", "text": "high blood pressure", "start": 5, "end": 8}, {"entity_id": "6149250_4_Ent1", "role": "Treatment", "text": "beta - blocker drugs", "start": 13, "end": 17}, {"entity_id": "6149250_4_Ent3", "role": "Treatment_Drug", "text": "beta - blocker drugs", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "6149250_4_Ent0", "text": "The second patient suffered from high blood pressure", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "6149250_4_Ent2", "text": "high blood pressure", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6149250_4_Ent1", "text": "beta - blocker drugs", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "6149250_4_Ent3", "text": "beta - blocker drugs", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "6159523_2", "wnd_id": "6159523_2_1", "text": "Two patients with extrinsic asthma and coexistent insulin - dependent diabetes mellitus sustained an anaphylactoid reaction after the intravenous administration of 50 % solution of dextrose .", "tokens": ["Two", "patients", "with", "extrinsic", "asthma", "and", "coexistent", "insulin", "-", "dependent", "diabetes", "mellitus", "sustained", "an", "anaphylactoid", "reaction", "after", "the", "intravenous", "administration", "of", "50", "%", "solution", "of", "dextrose", "."], "event_mentions": [{"id": "6159523_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "6159523_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "6159523_2_Ent0", "role": "Subject", "text": "Two patients with extrinsic asthma and coexistent insulin - dependent diabetes mellitus", "start": 0, "end": 12}, {"entity_id": "6159523_2_Ent2", "role": "Subject_Disorder", "text": "extrinsic asthma", "start": 3, "end": 5}, {"entity_id": "6159523_2_Ent3", "role": "Subject_Disorder", "text": "insulin - dependent diabetes mellitus", "start": 7, "end": 12}, {"entity_id": "6159523_2_Ent4", "role": "Effect", "text": "anaphylactoid reaction", "start": 14, "end": 16}, {"entity_id": "6159523_2_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 18, "end": 19}, {"entity_id": "6159523_2_Ent5", "role": "Treatment", "text": "intravenous administration of 50 % solution of dextrose", "start": 18, "end": 26}, {"entity_id": "6159523_2_Ent7", "role": "Treatment_Drug", "text": "dextrose", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "6159523_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6159523_2_Ent0", "text": "Two patients with extrinsic asthma and coexistent insulin - dependent diabetes mellitus", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "6159523_2_Ent2", "text": "extrinsic asthma", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "6159523_2_Ent3", "text": "insulin - dependent diabetes mellitus", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "6159523_2_Ent4", "text": "anaphylactoid reaction", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "6159523_2_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "6159523_2_Ent5", "text": "intravenous administration of 50 % solution of dextrose", "entity_type": "Entity", "start": 18, "end": 26}, {"id": "6159523_2_Ent7", "text": "dextrose", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "6197014_1", "wnd_id": "6197014_1_1", "text": "Salicylate hepato toxicity in rheumatic fever .", "tokens": ["Salicylate", "hepato", "toxicity", "in", "rheumatic", "fever", "."], "event_mentions": [{"id": "6197014_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 2, "end": 3}, "arguments": [{"entity_id": "6197014_1_Ent1", "role": "Treatment", "text": "Salicylate", "start": 0, "end": 1}, {"entity_id": "6197014_1_Ent3", "role": "Treatment_Drug", "text": "Salicylate", "start": 0, "end": 1}, {"entity_id": "6197014_1_Ent0", "role": "Effect", "text": "hepato toxicity", "start": 1, "end": 3}, {"entity_id": "6197014_1_Ent2", "role": "Treatment_Disorder", "text": "rheumatic fever", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "6197014_1_Ent1", "text": "Salicylate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6197014_1_Ent3", "text": "Salicylate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6197014_1_Ent0", "text": "hepato toxicity", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "6197014_1_Ent2", "text": "rheumatic fever", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "6199475_1", "wnd_id": "6199475_1_1", "text": "A 36 - year - old man being treated with cisplatinum , vinblastine , and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia , encephalopathy , and a partial nondominant parietal lobe syndrome .", "tokens": ["A", "36", "-", "year", "-", "old", "man", "being", "treated", "with", "cisplatinum", ",", "vinblastine", ",", "and", "bleomycin", "for", "testicular", "carcinoma", "developed", "a", "dense", "left", "homonymous", "hemianopsia", ",", "encephalopathy", ",", "and", "a", "partial", "nondominant", "parietal", "lobe", "syndrome", "."], "event_mentions": [{"id": "6199475_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "6199475_1_Ent0", "role": "Subject", "text": "A 36 - year - old man", "start": 0, "end": 7}, {"entity_id": "6199475_1_Ent2", "role": "Subject_Age", "text": "36 - year - old", "start": 1, "end": 6}, {"entity_id": "6199475_1_Ent3", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "6199475_1_Ent7", "role": "Treatment_Drug", "text": "cisplatinum", "start": 10, "end": 11}, {"entity_id": "6199475_1_Ent10", "role": "Combination_Drug", "text": "cisplatinum", "start": 10, "end": 11}, {"entity_id": "6199475_1_Ent5", "role": "Treatment", "text": "cisplatinum , vinblastine , and bleomycin", "start": 10, "end": 16}, {"entity_id": "6199475_1_Ent8", "role": "Treatment_Drug", "text": "vinblastine", "start": 12, "end": 13}, {"entity_id": "6199475_1_Ent11", "role": "Combination_Drug", "text": "vinblastine", "start": 12, "end": 13}, {"entity_id": "6199475_1_Ent9", "role": "Treatment_Drug", "text": "bleomycin", "start": 15, "end": 16}, {"entity_id": "6199475_1_Ent12", "role": "Combination_Drug", "text": "bleomycin", "start": 15, "end": 16}, {"entity_id": "6199475_1_Ent1", "role": "Subject", "text": "testicular carcinoma", "start": 17, "end": 19}, {"entity_id": "6199475_1_Ent6", "role": "Treatment_Disorder", "text": "testicular carcinoma", "start": 17, "end": 19}, {"entity_id": "6199475_1_Ent4", "role": "Effect", "text": "dense left homonymous hemianopsia , encephalopathy , and a partial nondominant parietal lobe syndrome", "start": 21, "end": 35}]}], "entity_mentions": [{"id": "6199475_1_Ent0", "text": "A 36 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "6199475_1_Ent2", "text": "36 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6199475_1_Ent3", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6199475_1_Ent7", "text": "cisplatinum", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6199475_1_Ent10", "text": "cisplatinum", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6199475_1_Ent5", "text": "cisplatinum , vinblastine , and bleomycin", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "6199475_1_Ent8", "text": "vinblastine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6199475_1_Ent11", "text": "vinblastine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6199475_1_Ent9", "text": "bleomycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6199475_1_Ent12", "text": "bleomycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6199475_1_Ent1", "text": "testicular carcinoma", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "6199475_1_Ent6", "text": "testicular carcinoma", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "6199475_1_Ent4", "text": "dense left homonymous hemianopsia , encephalopathy , and a partial nondominant parietal lobe syndrome", "entity_type": "Entity", "start": 21, "end": 35}], "lang": "en"}
{"doc_id": "6236730_1", "wnd_id": "6236730_1_1", "text": "A patient developed transient , acute myopia while on isotretinoin ( Accutane ) therapy for acne .", "tokens": ["A", "patient", "developed", "transient", ",", "acute", "myopia", "while", "on", "isotretinoin", "(", "Accutane", ")", "therapy", "for", "acne", "."], "event_mentions": [{"id": "6236730_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "6236730_1_Ent1", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "6236730_1_Ent2", "role": "Effect", "text": "transient , acute myopia", "start": 3, "end": 7}, {"entity_id": "6236730_1_Ent5", "role": "Treatment_Drug", "text": "isotretinoin", "start": 9, "end": 10}, {"entity_id": "6236730_1_Ent3", "role": "Treatment", "text": "isotretinoin ( Accutane )", "start": 9, "end": 13}, {"entity_id": "6236730_1_Ent0", "role": "Subject", "text": "acne", "start": 15, "end": 16}, {"entity_id": "6236730_1_Ent4", "role": "Treatment_Disorder", "text": "acne", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "6236730_1_Ent1", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6236730_1_Ent2", "text": "transient , acute myopia", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "6236730_1_Ent5", "text": "isotretinoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6236730_1_Ent3", "text": "isotretinoin ( Accutane )", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "6236730_1_Ent0", "text": "acne", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6236730_1_Ent4", "text": "acne", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "6239881_1", "wnd_id": "6239881_1_1", "text": "Allergic contact dermatitis to compound tincture of benzoin .", "tokens": ["Allergic", "contact", "dermatitis", "to", "compound", "tincture", "of", "benzoin", "."], "event_mentions": [{"id": "6239881_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 3, "end": 4}, "arguments": [{"entity_id": "6239881_1_Ent0", "role": "Effect", "text": "Allergic contact dermatitis", "start": 0, "end": 3}, {"entity_id": "6239881_1_Ent1", "role": "Treatment", "text": "compound tincture of benzoin", "start": 4, "end": 8}, {"entity_id": "6239881_1_Ent2", "role": "Treatment_Drug", "text": "benzoin", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "6239881_1_Ent0", "text": "Allergic contact dermatitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6239881_1_Ent1", "text": "compound tincture of benzoin", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "6239881_1_Ent2", "text": "benzoin", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "6239881_2", "wnd_id": "6239881_2_1", "text": "Nineteen cases of allergic contact dermatitis to compound tincture of benzoin are described .", "tokens": ["Nineteen", "cases", "of", "allergic", "contact", "dermatitis", "to", "compound", "tincture", "of", "benzoin", "are", "described", "."], "event_mentions": [{"id": "6239881_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "described", "start": 12, "end": 13}, "arguments": [{"entity_id": "6239881_2_Ent1", "role": "Subject_Population", "text": "Nineteen", "start": 0, "end": 1}, {"entity_id": "6239881_2_Ent0", "role": "Subject", "text": "Nineteen cases", "start": 0, "end": 2}, {"entity_id": "6239881_2_Ent2", "role": "Effect", "text": "allergic contact dermatitis", "start": 3, "end": 6}, {"entity_id": "6239881_2_Ent3", "role": "Treatment", "text": "compound tincture of benzoin", "start": 7, "end": 11}, {"entity_id": "6239881_2_Ent4", "role": "Treatment_Drug", "text": "benzoin", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "6239881_2_Ent1", "text": "Nineteen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6239881_2_Ent0", "text": "Nineteen cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6239881_2_Ent2", "text": "allergic contact dermatitis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6239881_2_Ent3", "text": "compound tincture of benzoin", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "6239881_2_Ent4", "text": "benzoin", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "6251941_2", "wnd_id": "6251941_2_1", "text": "Three cases of gold - related neuropathy are reported .", "tokens": ["Three", "cases", "of", "gold", "-", "related", "neuropathy", "are", "reported", "."], "event_mentions": [{"id": "6251941_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 5, "end": 6}, "arguments": [{"entity_id": "6251941_2_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "6251941_2_Ent0", "role": "Subject", "text": "Three cases", "start": 0, "end": 2}, {"entity_id": "6251941_2_Ent3", "role": "Treatment", "text": "gold", "start": 3, "end": 4}, {"entity_id": "6251941_2_Ent4", "role": "Treatment_Drug", "text": "gold", "start": 3, "end": 4}, {"entity_id": "6251941_2_Ent2", "role": "Effect", "text": "neuropathy", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6251941_2_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6251941_2_Ent0", "text": "Three cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6251941_2_Ent3", "text": "gold", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6251941_2_Ent4", "text": "gold", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6251941_2_Ent2", "text": "neuropathy", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6303138_1", "wnd_id": "6303138_1_1", "text": "Marked sinus tachycardia resulting from the synergistic effects of marijuana and nortriptyline .", "tokens": ["Marked", "sinus", "tachycardia", "resulting", "from", "the", "synergistic", "effects", "of", "marijuana", "and", "nortriptyline", "."], "event_mentions": [{"id": "6303138_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 3, "end": 4}, "arguments": [{"entity_id": "6303138_1_Ent0", "role": "Effect", "text": "Marked sinus tachycardia", "start": 0, "end": 3}, {"entity_id": "6303138_1_Ent2", "role": "Treatment_Drug", "text": "marijuana", "start": 9, "end": 10}, {"entity_id": "6303138_1_Ent4", "role": "Combination_Drug", "text": "marijuana", "start": 9, "end": 10}, {"entity_id": "6303138_1_Ent1", "role": "Treatment", "text": "marijuana and nortriptyline", "start": 9, "end": 12}, {"entity_id": "6303138_1_Ent3", "role": "Treatment_Drug", "text": "nortriptyline", "start": 11, "end": 12}, {"entity_id": "6303138_1_Ent5", "role": "Combination_Drug", "text": "nortriptyline", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6303138_1_Ent0", "text": "Marked sinus tachycardia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6303138_1_Ent2", "text": "marijuana", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6303138_1_Ent4", "text": "marijuana", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6303138_1_Ent1", "text": "marijuana and nortriptyline", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "6303138_1_Ent3", "text": "nortriptyline", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6303138_1_Ent5", "text": "nortriptyline", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "6311654_3", "wnd_id": "6311654_3_1", "text": "In six cases CT scans did not return to their original state after ACTH therapy .", "tokens": ["In", "six", "cases", "CT", "scans", "did", "not", "return", "to", "their", "original", "state", "after", "ACTH", "therapy", "."], "event_mentions": [{"id": "6311654_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "6311654_3_Ent1", "role": "Subject_Population", "text": "six", "start": 1, "end": 2}, {"entity_id": "6311654_3_Ent0", "role": "Subject", "text": "six cases", "start": 1, "end": 3}, {"entity_id": "6311654_3_Ent2", "role": "Effect", "text": "CT scans did not return to their original state", "start": 3, "end": 12}, {"entity_id": "6311654_3_Ent3", "role": "Treatment", "text": "ACTH", "start": 13, "end": 14}, {"entity_id": "6311654_3_Ent4", "role": "Treatment_Drug", "text": "ACTH", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "6311654_3_Ent1", "text": "six", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6311654_3_Ent0", "text": "six cases", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "6311654_3_Ent2", "text": "CT scans did not return to their original state", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "6311654_3_Ent3", "text": "ACTH", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6311654_3_Ent4", "text": "ACTH", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "633424_1", "wnd_id": "633424_1_1", "text": "Acute leukopenia associated with silver sulfadiazine therapy .", "tokens": ["Acute", "leukopenia", "associated", "with", "silver", "sulfadiazine", "therapy", "."], "event_mentions": [{"id": "633424_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "633424_1_Ent0", "role": "Effect", "text": "Acute leukopenia", "start": 0, "end": 2}, {"entity_id": "633424_1_Ent1", "role": "Treatment", "text": "silver sulfadiazine", "start": 4, "end": 6}, {"entity_id": "633424_1_Ent2", "role": "Treatment_Drug", "text": "silver sulfadiazine", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "633424_1_Ent0", "text": "Acute leukopenia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "633424_1_Ent1", "text": "silver sulfadiazine", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "633424_1_Ent2", "text": "silver sulfadiazine", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "6340463_4", "wnd_id": "6340463_4_1", "text": "Patients from endemic areas referred to transplant centers may be at high risk for disseminated histoplasmosis when treated with long - term prednisone for graft - versus - host disease .", "tokens": ["Patients", "from", "endemic", "areas", "referred", "to", "transplant", "centers", "may", "be", "at", "high", "risk", "for", "disseminated", "histoplasmosis", "when", "treated", "with", "long", "-", "term", "prednisone", "for", "graft", "-", "versus", "-", "host", "disease", "."], "event_mentions": [{"id": "6340463_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 18, "end": 19}, "arguments": [{"entity_id": "6340463_4_Ent0", "role": "Subject", "text": "Patients", "start": 0, "end": 1}, {"entity_id": "6340463_4_Ent1", "role": "Effect", "text": "disseminated histoplasmosis", "start": 14, "end": 16}, {"entity_id": "6340463_4_Ent2", "role": "Treatment", "text": "long - term prednisone", "start": 19, "end": 23}, {"entity_id": "6340463_4_Ent3", "role": "Treatment_Drug", "text": "prednisone", "start": 22, "end": 23}, {"entity_id": "6340463_4_Ent4", "role": "Treatment_Disorder", "text": "graft - versus - host disease .", "start": 24, "end": 31}]}], "entity_mentions": [{"id": "6340463_4_Ent0", "text": "Patients", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6340463_4_Ent1", "text": "disseminated histoplasmosis", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "6340463_4_Ent2", "text": "long - term prednisone", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "6340463_4_Ent3", "text": "prednisone", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "6340463_4_Ent4", "text": "graft - versus - host disease .", "entity_type": "Entity", "start": 24, "end": 31}], "lang": "en"}
{"doc_id": "6408978_1", "wnd_id": "6408978_1_1", "text": "Intravenous diazepam exacerbated the seizures .", "tokens": ["Intravenous", "diazepam", "exacerbated", "the", "seizures", "."], "event_mentions": [{"id": "6408978_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exacerbated", "start": 2, "end": 3}, "arguments": [{"entity_id": "6408978_1_Ent2", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "6408978_1_Ent1", "role": "Treatment", "text": "Intravenous diazepam", "start": 0, "end": 2}, {"entity_id": "6408978_1_Ent3", "role": "Treatment_Drug", "text": "diazepam", "start": 1, "end": 2}, {"entity_id": "6408978_1_Ent0", "role": "Effect", "text": "seizures", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "6408978_1_Ent2", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6408978_1_Ent1", "text": "Intravenous diazepam", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6408978_1_Ent3", "text": "diazepam", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6408978_1_Ent0", "text": "seizures", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "6414095_4", "wnd_id": "6414095_4_1", "text": "The episode appeared to have been precipitated by toxicity due to ingestion of a large amount of phenytoin .", "tokens": ["The", "episode", "appeared", "to", "have", "been", "precipitated", "by", "toxicity", "due", "to", "ingestion", "of", "a", "large", "amount", "of", "phenytoin", "."], "event_mentions": [{"id": "6414095_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 9, "end": 10}, "arguments": [{"entity_id": "6414095_4_Ent0", "role": "Effect", "text": "The episode appeared to have been precipitated by toxicity", "start": 0, "end": 9}, {"entity_id": "6414095_4_Ent2", "role": "Treatment_Route", "text": "ingestion", "start": 11, "end": 12}, {"entity_id": "6414095_4_Ent1", "role": "Treatment", "text": "a large amount of phenytoin .", "start": 13, "end": 19}, {"entity_id": "6414095_4_Ent4", "role": "Treatment_Dosage", "text": "large amount", "start": 14, "end": 16}, {"entity_id": "6414095_4_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "6414095_4_Ent0", "text": "The episode appeared to have been precipitated by toxicity", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "6414095_4_Ent2", "text": "ingestion", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6414095_4_Ent1", "text": "a large amount of phenytoin .", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "6414095_4_Ent4", "text": "large amount", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "6414095_4_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "6453500_1", "wnd_id": "6453500_1_1", "text": "A reversible toxic liver damage was observed in a non - alcoholic woman treated with disulfiram .", "tokens": ["A", "reversible", "toxic", "liver", "damage", "was", "observed", "in", "a", "non", "-", "alcoholic", "woman", "treated", "with", "disulfiram", "."], "event_mentions": [{"id": "6453500_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "damage", "start": 4, "end": 5}, "arguments": [{"entity_id": "6453500_1_Ent3", "role": "Effect", "text": "reversible toxic liver damage", "start": 1, "end": 5}, {"entity_id": "6453500_1_Ent0", "role": "Subject", "text": "a non - alcoholic woman", "start": 8, "end": 13}, {"entity_id": "6453500_1_Ent1", "role": "Subject_Disorder", "text": "non - alcoholic", "start": 9, "end": 12}, {"entity_id": "6453500_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 12, "end": 13}, {"entity_id": "6453500_1_Ent4", "role": "Treatment", "text": "disulfiram", "start": 15, "end": 16}, {"entity_id": "6453500_1_Ent5", "role": "Treatment_Drug", "text": "disulfiram", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "6453500_1_Ent3", "text": "reversible toxic liver damage", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "6453500_1_Ent0", "text": "a non - alcoholic woman", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "6453500_1_Ent1", "text": "non - alcoholic", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "6453500_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6453500_1_Ent4", "text": "disulfiram", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6453500_1_Ent5", "text": "disulfiram", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "6453500_2", "wnd_id": "6453500_2_1", "text": "Toxic hepatitis induced by disulfiram in a non - alcoholic .", "tokens": ["Toxic", "hepatitis", "induced", "by", "disulfiram", "in", "a", "non", "-", "alcoholic", "."], "event_mentions": [{"id": "6453500_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "6453500_2_Ent1", "role": "Effect", "text": "Toxic hepatitis", "start": 0, "end": 2}, {"entity_id": "6453500_2_Ent2", "role": "Treatment", "text": "disulfiram", "start": 4, "end": 5}, {"entity_id": "6453500_2_Ent3", "role": "Treatment_Drug", "text": "disulfiram", "start": 4, "end": 5}, {"entity_id": "6453500_2_Ent0", "role": "Subject", "text": "a non - alcoholic", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "6453500_2_Ent1", "text": "Toxic hepatitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6453500_2_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6453500_2_Ent3", "text": "disulfiram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6453500_2_Ent0", "text": "a non - alcoholic", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "6484655_1", "wnd_id": "6484655_1_1", "text": "Although they had complex medical problems , the high serum concentrations of ampicillin at the time of seizures without their recurrence after discontinuing the antibiotic suggest that the seizures were related to the ampicillin therapy .", "tokens": ["Although", "they", "had", "complex", "medical", "problems", ",", "the", "high", "serum", "concentrations", "of", "ampicillin", "at", "the", "time", "of", "seizures", "without", "their", "recurrence", "after", "discontinuing", "the", "antibiotic", "suggest", "that", "the", "seizures", "were", "related", "to", "the", "ampicillin", "therapy", "."], "event_mentions": [{"id": "6484655_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 30, "end": 31}, "arguments": [{"entity_id": "6484655_1_Ent0", "role": "Effect", "text": "seizures", "start": 28, "end": 29}, {"entity_id": "6484655_1_Ent2", "role": "Treatment_Drug", "text": "ampicillin", "start": 33, "end": 34}, {"entity_id": "6484655_1_Ent1", "role": "Treatment", "text": "ampicillin therapy", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "6484655_1_Ent0", "text": "seizures", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "6484655_1_Ent2", "text": "ampicillin", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "6484655_1_Ent1", "text": "ampicillin therapy", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "6498095_2", "wnd_id": "6498095_2_1", "text": "Pemphigus foliaceus induced by rifampicin .", "tokens": ["Pemphigus", "foliaceus", "induced", "by", "rifampicin", "."], "event_mentions": [{"id": "6498095_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "6498095_2_Ent0", "role": "Effect", "text": "Pemphigus foliaceus", "start": 0, "end": 2}, {"entity_id": "6498095_2_Ent1", "role": "Treatment", "text": "rifampicin", "start": 4, "end": 5}, {"entity_id": "6498095_2_Ent2", "role": "Treatment_Drug", "text": "rifampicin", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "6498095_2_Ent0", "text": "Pemphigus foliaceus", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6498095_2_Ent1", "text": "rifampicin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6498095_2_Ent2", "text": "rifampicin", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "6507240_4", "wnd_id": "6507240_4_1", "text": "One patient developed severe hyponatremia with serum Na+ of 108 mEq / L when hydrochlorothiazide was given to control hypertension .", "tokens": ["One", "patient", "developed", "severe", "hyponatremia", "with", "serum", "Na+", "of", "108", "mEq", "/", "L", "when", "hydrochlorothiazide", "was", "given", "to", "control", "hypertension", "."], "event_mentions": [{"id": "6507240_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "6507240_4_Ent1", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "6507240_4_Ent0", "role": "Subject", "text": "One patient", "start": 0, "end": 2}, {"entity_id": "6507240_4_Ent2", "role": "Effect", "text": "severe hyponatremia with serum Na+ of 108 mEq / L", "start": 3, "end": 13}, {"entity_id": "6507240_4_Ent3", "role": "Treatment", "text": "hydrochlorothiazide", "start": 14, "end": 15}, {"entity_id": "6507240_4_Ent5", "role": "Treatment_Drug", "text": "hydrochlorothiazide", "start": 14, "end": 15}, {"entity_id": "6507240_4_Ent4", "role": "Treatment_Disorder", "text": "hypertension", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "6507240_4_Ent1", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6507240_4_Ent0", "text": "One patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6507240_4_Ent2", "text": "severe hyponatremia with serum Na+ of 108 mEq / L", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "6507240_4_Ent3", "text": "hydrochlorothiazide", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6507240_4_Ent5", "text": "hydrochlorothiazide", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6507240_4_Ent4", "text": "hypertension", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "6572542_2", "wnd_id": "6572542_2_1", "text": "Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia .", "tokens": ["Pulmonary", "fibrosis", "subsequent", "to", "high", "doses", "of", "CCNU", "for", "chronic", "myeloid", "leukemia", "."], "event_mentions": [{"id": "6572542_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "subsequent", "start": 2, "end": 3}, "arguments": [{"entity_id": "6572542_2_Ent0", "role": "Effect", "text": "Pulmonary fibrosis", "start": 0, "end": 2}, {"entity_id": "6572542_2_Ent3", "role": "Treatment_Dosage", "text": "high doses", "start": 4, "end": 6}, {"entity_id": "6572542_2_Ent1", "role": "Treatment", "text": "high doses of CCNU", "start": 4, "end": 8}, {"entity_id": "6572542_2_Ent4", "role": "Treatment_Drug", "text": "CCNU", "start": 7, "end": 8}, {"entity_id": "6572542_2_Ent2", "role": "Treatment_Disorder", "text": "chronic myeloid leukemia", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "6572542_2_Ent0", "text": "Pulmonary fibrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6572542_2_Ent3", "text": "high doses", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "6572542_2_Ent1", "text": "high doses of CCNU", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "6572542_2_Ent4", "text": "CCNU", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6572542_2_Ent2", "text": "chronic myeloid leukemia", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "6578007_1", "wnd_id": "6578007_1_1", "text": "Additive pulmonary toxicity with melphalan and busulfan therapy .", "tokens": ["Additive", "pulmonary", "toxicity", "with", "melphalan", "and", "busulfan", "therapy", "."], "event_mentions": [{"id": "6578007_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 3, "end": 4}, "arguments": [{"entity_id": "6578007_1_Ent0", "role": "Effect", "text": "Additive pulmonary toxicity", "start": 0, "end": 3}, {"entity_id": "6578007_1_Ent2", "role": "Treatment_Drug", "text": "melphalan", "start": 4, "end": 5}, {"entity_id": "6578007_1_Ent4", "role": "Combination_Drug", "text": "melphalan", "start": 4, "end": 5}, {"entity_id": "6578007_1_Ent1", "role": "Treatment", "text": "melphalan and busulfan therapy", "start": 4, "end": 8}, {"entity_id": "6578007_1_Ent3", "role": "Treatment_Drug", "text": "busulfan", "start": 6, "end": 7}, {"entity_id": "6578007_1_Ent5", "role": "Combination_Drug", "text": "busulfan", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6578007_1_Ent0", "text": "Additive pulmonary toxicity", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6578007_1_Ent2", "text": "melphalan", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6578007_1_Ent4", "text": "melphalan", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6578007_1_Ent1", "text": "melphalan and busulfan therapy", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "6578007_1_Ent3", "text": "busulfan", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6578007_1_Ent5", "text": "busulfan", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6597713_2", "wnd_id": "6597713_2_1", "text": "Cholestyramine induced hyperchloremic metabolic acidosis .", "tokens": ["Cholestyramine", "induced", "hyperchloremic", "metabolic", "acidosis", "."], "event_mentions": [{"id": "6597713_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "6597713_2_Ent1", "role": "Treatment", "text": "Cholestyramine", "start": 0, "end": 1}, {"entity_id": "6597713_2_Ent2", "role": "Treatment_Drug", "text": "Cholestyramine", "start": 0, "end": 1}, {"entity_id": "6597713_2_Ent0", "role": "Effect", "text": "hyperchloremic metabolic acidosis .", "start": 2, "end": 6}]}], "entity_mentions": [{"id": "6597713_2_Ent1", "text": "Cholestyramine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6597713_2_Ent2", "text": "Cholestyramine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6597713_2_Ent0", "text": "hyperchloremic metabolic acidosis .", "entity_type": "Entity", "start": 2, "end": 6}], "lang": "en"}
{"doc_id": "6614033_2", "wnd_id": "6614033_2_1", "text": "Amphotericin B nephrotoxicity in humans decreased by salt repletion .", "tokens": ["Amphotericin", "B", "nephrotoxicity", "in", "humans", "decreased", "by", "salt", "repletion", "."], "event_mentions": [{"id": "6614033_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "decreased", "start": 5, "end": 6}, "arguments": [{"entity_id": "6614033_2_Ent1", "role": "Effect", "text": "Amphotericin B nephrotoxicity in humans decreased", "start": 0, "end": 6}, {"entity_id": "6614033_2_Ent0", "role": "Subject", "text": "humans", "start": 4, "end": 5}, {"entity_id": "6614033_2_Ent3", "role": "Treatment_Drug", "text": "salt", "start": 7, "end": 8}, {"entity_id": "6614033_2_Ent2", "role": "Treatment", "text": "salt repletion", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "6614033_2_Ent1", "text": "Amphotericin B nephrotoxicity in humans decreased", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "6614033_2_Ent0", "text": "humans", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6614033_2_Ent3", "text": "salt", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6614033_2_Ent2", "text": "salt repletion", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "6618859_1", "wnd_id": "6618859_1_1", "text": "Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered .", "tokens": ["Gynecomastia", "developed", "in", "two", "epileptic", "patients", "some", "months", "after", "the", "addition", "of", "oral", "fluoresone", "750", "mg", "daily", "to", "the", "phenobarbital", "and", "phenytoin", "already", "being", "administered", "."], "event_mentions": [{"id": "6618859_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "6618859_1_Ent2", "role": "Effect", "text": "Gynecomastia", "start": 0, "end": 1}, {"entity_id": "6618859_1_Ent1", "role": "Subject_Population", "text": "two", "start": 3, "end": 4}, {"entity_id": "6618859_1_Ent0", "role": "Subject", "text": "two epileptic patients", "start": 3, "end": 6}, {"entity_id": "6618859_1_Ent10", "role": "Treatment_Disorder", "text": "epileptic", "start": 4, "end": 5}, {"entity_id": "6618859_1_Ent11", "role": "Treatment_Time_elapsed", "text": "some months after", "start": 6, "end": 9}, {"entity_id": "6618859_1_Ent3", "role": "Treatment", "text": "some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered", "start": 6, "end": 25}, {"entity_id": "6618859_1_Ent4", "role": "Treatment_Route", "text": "oral", "start": 12, "end": 13}, {"entity_id": "6618859_1_Ent5", "role": "Treatment_Drug", "text": "fluoresone", "start": 13, "end": 14}, {"entity_id": "6618859_1_Ent12", "role": "Combination_Drug", "text": "fluoresone", "start": 13, "end": 14}, {"entity_id": "6618859_1_Ent8", "role": "Treatment_Dosage", "text": "750 mg", "start": 14, "end": 16}, {"entity_id": "6618859_1_Ent9", "role": "Treatment_Freq", "text": "daily", "start": 16, "end": 17}, {"entity_id": "6618859_1_Ent6", "role": "Treatment_Drug", "text": "phenobarbital", "start": 19, "end": 20}, {"entity_id": "6618859_1_Ent13", "role": "Combination_Drug", "text": "phenobarbital", "start": 19, "end": 20}, {"entity_id": "6618859_1_Ent7", "role": "Treatment_Drug", "text": "phenytoin", "start": 21, "end": 22}, {"entity_id": "6618859_1_Ent14", "role": "Combination_Drug", "text": "phenytoin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "6618859_1_Ent2", "text": "Gynecomastia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6618859_1_Ent1", "text": "two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6618859_1_Ent0", "text": "two epileptic patients", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6618859_1_Ent10", "text": "epileptic", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6618859_1_Ent11", "text": "some months after", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "6618859_1_Ent3", "text": "some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and phenytoin already being administered", "entity_type": "Entity", "start": 6, "end": 25}, {"id": "6618859_1_Ent4", "text": "oral", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6618859_1_Ent5", "text": "fluoresone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6618859_1_Ent12", "text": "fluoresone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6618859_1_Ent8", "text": "750 mg", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "6618859_1_Ent9", "text": "daily", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "6618859_1_Ent6", "text": "phenobarbital", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "6618859_1_Ent13", "text": "phenobarbital", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "6618859_1_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6618859_1_Ent14", "text": "phenytoin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "6625005_1", "wnd_id": "6625005_1_1", "text": "Case report of withdrawal dyskinesia associated with amoxapine .", "tokens": ["Case", "report", "of", "withdrawal", "dyskinesia", "associated", "with", "amoxapine", "."], "event_mentions": [{"id": "6625005_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "6625005_1_Ent0", "role": "Subject", "text": "Case", "start": 0, "end": 1}, {"entity_id": "6625005_1_Ent1", "role": "Effect", "text": "withdrawal dyskinesia", "start": 3, "end": 5}, {"entity_id": "6625005_1_Ent2", "role": "Treatment", "text": "amoxapine", "start": 7, "end": 8}, {"entity_id": "6625005_1_Ent3", "role": "Treatment_Drug", "text": "amoxapine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "6625005_1_Ent0", "text": "Case", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6625005_1_Ent1", "text": "withdrawal dyskinesia", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "6625005_1_Ent2", "text": "amoxapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6625005_1_Ent3", "text": "amoxapine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "6625005_3", "wnd_id": "6625005_3_1", "text": "The authors describe a case of oral - facial dyskinesia that occurred after discontinuation of amoxapine , and antidepressant which may also have neuroleptic effects .", "tokens": ["The", "authors", "describe", "a", "case", "of", "oral", "-", "facial", "dyskinesia", "that", "occurred", "after", "discontinuation", "of", "amoxapine", ",", "and", "antidepressant", "which", "may", "also", "have", "neuroleptic", "effects", "."], "event_mentions": [{"id": "6625005_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 11, "end": 12}, "arguments": [{"entity_id": "6625005_3_Ent0", "role": "Effect", "text": "oral - facial dyskinesia", "start": 6, "end": 10}, {"entity_id": "6625005_3_Ent1", "role": "Treatment", "text": "discontinuation of amoxapine , and antidepressant which may also have neuroleptic effects", "start": 13, "end": 25}, {"entity_id": "6625005_3_Ent3", "role": "Treatment_Drug", "text": "amoxapine", "start": 15, "end": 16}, {"entity_id": "6625005_3_Ent2", "role": "Treatment_Drug", "text": "antidepressant", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "6625005_3_Ent0", "text": "oral - facial dyskinesia", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "6625005_3_Ent1", "text": "discontinuation of amoxapine , and antidepressant which may also have neuroleptic effects", "entity_type": "Entity", "start": 13, "end": 25}, {"id": "6625005_3_Ent3", "text": "amoxapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "6625005_3_Ent2", "text": "antidepressant", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "6651138_1", "wnd_id": "6651138_1_1", "text": "A 58 - year - old woman developed unilateral acute angle - closure glaucoma four days after the application of a patch of transdermal scopolamine delivery system ( TRANSDERM - V ) .", "tokens": ["A", "58", "-", "year", "-", "old", "woman", "developed", "unilateral", "acute", "angle", "-", "closure", "glaucoma", "four", "days", "after", "the", "application", "of", "a", "patch", "of", "transdermal", "scopolamine", "delivery", "system", "(", "TRANSDERM", "-", "V", ")", "."], "event_mentions": [{"id": "6651138_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "6651138_1_Ent0", "role": "Subject", "text": "A 58 - year - old woman", "start": 0, "end": 7}, {"entity_id": "6651138_1_Ent1", "role": "Subject_Age", "text": "58 - year - old", "start": 1, "end": 6}, {"entity_id": "6651138_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "6651138_1_Ent3", "role": "Effect", "text": "unilateral acute angle - closure glaucoma", "start": 8, "end": 14}, {"entity_id": "6651138_1_Ent7", "role": "Treatment_Time_elapsed", "text": "four days", "start": 14, "end": 16}, {"entity_id": "6651138_1_Ent4", "role": "Treatment", "text": "four days after the application of a patch of transdermal scopolamine delivery system ( TRANSDERM - V )", "start": 14, "end": 32}, {"entity_id": "6651138_1_Ent5", "role": "Treatment_Route", "text": "patch", "start": 21, "end": 22}, {"entity_id": "6651138_1_Ent6", "role": "Treatment_Drug", "text": "scopolamine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "6651138_1_Ent0", "text": "A 58 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "6651138_1_Ent1", "text": "58 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6651138_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6651138_1_Ent3", "text": "unilateral acute angle - closure glaucoma", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "6651138_1_Ent7", "text": "four days", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "6651138_1_Ent4", "text": "four days after the application of a patch of transdermal scopolamine delivery system ( TRANSDERM - V )", "entity_type": "Entity", "start": 14, "end": 32}, {"id": "6651138_1_Ent5", "text": "patch", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6651138_1_Ent6", "text": "scopolamine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "6692713_2", "wnd_id": "6692713_2_1", "text": "Possible recurrence of amiodarone pulmonary toxicity following corticosteroid therapy .", "tokens": ["Possible", "recurrence", "of", "amiodarone", "pulmonary", "toxicity", "following", "corticosteroid", "therapy", "."], "event_mentions": [{"id": "6692713_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "6692713_2_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 3, "end": 4}, {"entity_id": "6692713_2_Ent0", "role": "Effect", "text": "amiodarone pulmonary toxicity", "start": 3, "end": 6}, {"entity_id": "6692713_2_Ent1", "role": "Treatment", "text": "corticosteroid", "start": 7, "end": 8}, {"entity_id": "6692713_2_Ent3", "role": "Treatment_Drug", "text": "corticosteroid", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "6692713_2_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6692713_2_Ent0", "text": "amiodarone pulmonary toxicity", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "6692713_2_Ent1", "text": "corticosteroid", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6692713_2_Ent3", "text": "corticosteroid", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "6725214_1", "wnd_id": "6725214_1_1", "text": "A case of priapism associated with trazodone is described .", "tokens": ["A", "case", "of", "priapism", "associated", "with", "trazodone", "is", "described", "."], "event_mentions": [{"id": "6725214_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "6725214_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "6725214_1_Ent1", "role": "Effect", "text": "priapism", "start": 3, "end": 4}, {"entity_id": "6725214_1_Ent2", "role": "Treatment", "text": "trazodone", "start": 6, "end": 7}, {"entity_id": "6725214_1_Ent3", "role": "Treatment_Drug", "text": "trazodone", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6725214_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6725214_1_Ent1", "text": "priapism", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6725214_1_Ent2", "text": "trazodone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6725214_1_Ent3", "text": "trazodone", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6731466_6", "wnd_id": "6731466_6_1", "text": "This observation adds another dimension to the previously reported renal complications of nonsteroidal anti - inflammatory agents , especially zomepirac .", "tokens": ["This", "observation", "adds", "another", "dimension", "to", "the", "previously", "reported", "renal", "complications", "of", "nonsteroidal", "anti", "-", "inflammatory", "agents", ",", "especially", "zomepirac", "."], "event_mentions": [{"id": "6731466_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 8, "end": 9}, "arguments": [{"entity_id": "6731466_6_Ent0", "role": "Effect", "text": "renal complications", "start": 9, "end": 11}, {"entity_id": "6731466_6_Ent2", "role": "Treatment_Drug", "text": "nonsteroidal anti - inflammatory", "start": 12, "end": 16}, {"entity_id": "6731466_6_Ent1", "role": "Treatment", "text": "nonsteroidal anti - inflammatory agents , especially zomepirac", "start": 12, "end": 20}, {"entity_id": "6731466_6_Ent3", "role": "Treatment_Drug", "text": "zomepirac", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "6731466_6_Ent0", "text": "renal complications", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "6731466_6_Ent2", "text": "nonsteroidal anti - inflammatory", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "6731466_6_Ent1", "text": "nonsteroidal anti - inflammatory agents , especially zomepirac", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "6731466_6_Ent3", "text": "zomepirac", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "6733633_1", "wnd_id": "6733633_1_1", "text": "Cimetidine - induced fever .", "tokens": ["Cimetidine", "-", "induced", "fever", "."], "event_mentions": [{"id": "6733633_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "6733633_1_Ent1", "role": "Treatment", "text": "Cimetidine", "start": 0, "end": 1}, {"entity_id": "6733633_1_Ent2", "role": "Treatment_Drug", "text": "Cimetidine", "start": 0, "end": 1}, {"entity_id": "6733633_1_Ent0", "role": "Effect", "text": "fever", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "6733633_1_Ent1", "text": "Cimetidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6733633_1_Ent2", "text": "Cimetidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6733633_1_Ent0", "text": "fever", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "6738830_1", "wnd_id": "6738830_1_1", "text": "A 56 - year - old male parkinsonian patient developed a unique behavioral change following the oral administration of cinepazide , a cerebral vasodilator .", "tokens": ["A", "56", "-", "year", "-", "old", "male", "parkinsonian", "patient", "developed", "a", "unique", "behavioral", "change", "following", "the", "oral", "administration", "of", "cinepazide", ",", "a", "cerebral", "vasodilator", "."], "event_mentions": [{"id": "6738830_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "6738830_1_Ent0", "role": "Subject", "text": "A 56 - year - old male parkinsonian patient", "start": 0, "end": 9}, {"entity_id": "6738830_1_Ent1", "role": "Subject_Age", "text": "56 - year - old", "start": 1, "end": 6}, {"entity_id": "6738830_1_Ent2", "role": "Subject_Gender", "text": "male", "start": 6, "end": 7}, {"entity_id": "6738830_1_Ent3", "role": "Subject_Disorder", "text": "parkinsonian", "start": 7, "end": 8}, {"entity_id": "6738830_1_Ent4", "role": "Effect", "text": "a unique behavioral change", "start": 10, "end": 14}, {"entity_id": "6738830_1_Ent5", "role": "Treatment", "text": "the oral administration of cinepazide , a cerebral vasodilator", "start": 15, "end": 24}, {"entity_id": "6738830_1_Ent7", "role": "Treatment_Route", "text": "oral administration", "start": 16, "end": 18}, {"entity_id": "6738830_1_Ent6", "role": "Treatment_Drug", "text": "cinepazide", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "6738830_1_Ent0", "text": "A 56 - year - old male parkinsonian patient", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "6738830_1_Ent1", "text": "56 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6738830_1_Ent2", "text": "male", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6738830_1_Ent3", "text": "parkinsonian", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6738830_1_Ent4", "text": "a unique behavioral change", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "6738830_1_Ent5", "text": "the oral administration of cinepazide , a cerebral vasodilator", "entity_type": "Entity", "start": 15, "end": 24}, {"id": "6738830_1_Ent7", "text": "oral administration", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "6738830_1_Ent6", "text": "cinepazide", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "6788011_3", "wnd_id": "6788011_3_1", "text": "Gold - salt therapy may result in damage to proximal tubules that leak renal tubular antigens , which in turn complex with autoantibody and produce an autoimmune membranous nephropathy .", "tokens": ["Gold", "-", "salt", "therapy", "may", "result", "in", "damage", "to", "proximal", "tubules", "that", "leak", "renal", "tubular", "antigens", ",", "which", "in", "turn", "complex", "with", "autoantibody", "and", "produce", "an", "autoimmune", "membranous", "nephropathy", "."], "event_mentions": [{"id": "6788011_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 5, "end": 6}, "arguments": [{"entity_id": "6788011_3_Ent1", "role": "Treatment", "text": "Gold - salt", "start": 0, "end": 3}, {"entity_id": "6788011_3_Ent2", "role": "Treatment_Drug", "text": "Gold - salt", "start": 0, "end": 3}, {"entity_id": "6788011_3_Ent0", "role": "Effect", "text": "damage to proximal tubules", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "6788011_3_Ent1", "text": "Gold - salt", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6788011_3_Ent2", "text": "Gold - salt", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6788011_3_Ent0", "text": "damage to proximal tubules", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "6788011_4", "wnd_id": "6788011_4_1", "text": "The nephrotic syndrome developed in a patient receiving therapy with gold for rheumatoid arthritis .", "tokens": ["The", "nephrotic", "syndrome", "developed", "in", "a", "patient", "receiving", "therapy", "with", "gold", "for", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "6788011_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "6788011_4_Ent1", "role": "Effect", "text": "nephrotic syndrome", "start": 1, "end": 3}, {"entity_id": "6788011_4_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "6788011_4_Ent2", "role": "Treatment", "text": "therapy with gold", "start": 8, "end": 11}, {"entity_id": "6788011_4_Ent4", "role": "Treatment_Drug", "text": "gold", "start": 10, "end": 11}, {"entity_id": "6788011_4_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "6788011_4_Ent1", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "6788011_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "6788011_4_Ent2", "text": "therapy with gold", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "6788011_4_Ent4", "text": "gold", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6788011_4_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "6794018_2", "wnd_id": "6794018_2_1", "text": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy .", "tokens": ["Intrahepatic", "cholestasis", "and", "cutaneous", "bullae", "associated", "with", "glibenclamide", "therapy", "."], "event_mentions": [{"id": "6794018_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "6794018_2_Ent0", "role": "Effect", "text": "Intrahepatic cholestasis and cutaneous bullae", "start": 0, "end": 5}, {"entity_id": "6794018_2_Ent2", "role": "Treatment_Drug", "text": "glibenclamide", "start": 7, "end": 8}, {"entity_id": "6794018_2_Ent1", "role": "Treatment", "text": "glibenclamide therapy", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "6794018_2_Ent0", "text": "Intrahepatic cholestasis and cutaneous bullae", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "6794018_2_Ent2", "text": "glibenclamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6794018_2_Ent1", "text": "glibenclamide therapy", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "6833205_1", "wnd_id": "6833205_1_1", "text": "A case of SIADH associated with desipramine treatment in an elderly depressed woman is described .", "tokens": ["A", "case", "of", "SIADH", "associated", "with", "desipramine", "treatment", "in", "an", "elderly", "depressed", "woman", "is", "described", "."], "event_mentions": [{"id": "6833205_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "6833205_1_Ent3", "role": "Effect", "text": "SIADH", "start": 3, "end": 4}, {"entity_id": "6833205_1_Ent6", "role": "Treatment_Drug", "text": "desipramine", "start": 6, "end": 7}, {"entity_id": "6833205_1_Ent4", "role": "Treatment", "text": "desipramine treatment", "start": 6, "end": 8}, {"entity_id": "6833205_1_Ent0", "role": "Subject", "text": "an elderly depressed woman", "start": 9, "end": 13}, {"entity_id": "6833205_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 10, "end": 11}, {"entity_id": "6833205_1_Ent5", "role": "Treatment_Disorder", "text": "depressed", "start": 11, "end": 12}, {"entity_id": "6833205_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "6833205_1_Ent3", "text": "SIADH", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6833205_1_Ent6", "text": "desipramine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6833205_1_Ent4", "text": "desipramine treatment", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "6833205_1_Ent0", "text": "an elderly depressed woman", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "6833205_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6833205_1_Ent5", "text": "depressed", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6833205_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "6833205_2", "wnd_id": "6833205_2_1", "text": "Desipramine - associated SIADH in an elderly woman : case report .", "tokens": ["Desipramine", "-", "associated", "SIADH", "in", "an", "elderly", "woman", ":", "case", "report", "."], "event_mentions": [{"id": "6833205_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "6833205_2_Ent4", "role": "Treatment", "text": "Desipramine", "start": 0, "end": 1}, {"entity_id": "6833205_2_Ent5", "role": "Treatment_Drug", "text": "Desipramine", "start": 0, "end": 1}, {"entity_id": "6833205_2_Ent3", "role": "Effect", "text": "SIADH", "start": 3, "end": 4}, {"entity_id": "6833205_2_Ent0", "role": "Subject", "text": "an elderly woman", "start": 5, "end": 8}, {"entity_id": "6833205_2_Ent1", "role": "Subject_Age", "text": "elderly", "start": 6, "end": 7}, {"entity_id": "6833205_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "6833205_2_Ent4", "text": "Desipramine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6833205_2_Ent5", "text": "Desipramine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6833205_2_Ent3", "text": "SIADH", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6833205_2_Ent0", "text": "an elderly woman", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6833205_2_Ent1", "text": "elderly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6833205_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "6837655_1", "wnd_id": "6837655_1_1", "text": "Prior reports have emphasized the tubular and interstitial lesions associated with intermittent or discontinuous rifampin therapy for tuberculosis .", "tokens": ["Prior", "reports", "have", "emphasized", "the", "tubular", "and", "interstitial", "lesions", "associated", "with", "intermittent", "or", "discontinuous", "rifampin", "therapy", "for", "tuberculosis", "."], "event_mentions": [{"id": "6837655_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "6837655_1_Ent0", "role": "Effect", "text": "tubular and interstitial lesions", "start": 5, "end": 9}, {"entity_id": "6837655_1_Ent1", "role": "Treatment", "text": "intermittent or discontinuous rifampin therapy", "start": 11, "end": 16}, {"entity_id": "6837655_1_Ent2", "role": "Treatment_Drug", "text": "rifampin", "start": 14, "end": 15}, {"entity_id": "6837655_1_Ent3", "role": "Treatment_Disorder", "text": "tuberculosis", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "6837655_1_Ent0", "text": "tubular and interstitial lesions", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "6837655_1_Ent1", "text": "intermittent or discontinuous rifampin therapy", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "6837655_1_Ent2", "text": "rifampin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6837655_1_Ent3", "text": "tuberculosis", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "6865827_1", "wnd_id": "6865827_1_1", "text": "A 45 - year - old woman with thyrotoxicosis developed agranulocytosis after treatment with propylthiouracil .", "tokens": ["A", "45", "-", "year", "-", "old", "woman", "with", "thyrotoxicosis", "developed", "agranulocytosis", "after", "treatment", "with", "propylthiouracil", "."], "event_mentions": [{"id": "6865827_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "6865827_1_Ent0", "role": "Subject", "text": "A 45 - year - old woman with thyrotoxicosis", "start": 0, "end": 9}, {"entity_id": "6865827_1_Ent1", "role": "Subject_Age", "text": "45 - year - old", "start": 1, "end": 6}, {"entity_id": "6865827_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "6865827_1_Ent5", "role": "Treatment_Disorder", "text": "thyrotoxicosis", "start": 8, "end": 9}, {"entity_id": "6865827_1_Ent3", "role": "Effect", "text": "agranulocytosis", "start": 10, "end": 11}, {"entity_id": "6865827_1_Ent4", "role": "Treatment", "text": "propylthiouracil", "start": 14, "end": 15}, {"entity_id": "6865827_1_Ent6", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "6865827_1_Ent0", "text": "A 45 - year - old woman with thyrotoxicosis", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "6865827_1_Ent1", "text": "45 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6865827_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6865827_1_Ent5", "text": "thyrotoxicosis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6865827_1_Ent3", "text": "agranulocytosis", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6865827_1_Ent4", "text": "propylthiouracil", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6865827_1_Ent6", "text": "propylthiouracil", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "6865827_3", "wnd_id": "6865827_3_1", "text": "This is , to the best of our knowledge , the first report of a case in which agranulocytosis followed treatment with both propylthiouracil and methimazole in the same patient .", "tokens": ["This", "is", ",", "to", "the", "best", "of", "our", "knowledge", ",", "the", "first", "report", "of", "a", "case", "in", "which", "agranulocytosis", "followed", "treatment", "with", "both", "propylthiouracil", "and", "methimazole", "in", "the", "same", "patient", "."], "event_mentions": [{"id": "6865827_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "followed", "start": 19, "end": 20}, "arguments": [{"entity_id": "6865827_3_Ent1", "role": "Effect", "text": "agranulocytosis", "start": 18, "end": 19}, {"entity_id": "6865827_3_Ent2", "role": "Treatment", "text": "both propylthiouracil and methimazole", "start": 22, "end": 26}, {"entity_id": "6865827_3_Ent4", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 23, "end": 24}, {"entity_id": "6865827_3_Ent5", "role": "Combination_Drug", "text": "propylthiouracil", "start": 23, "end": 24}, {"entity_id": "6865827_3_Ent3", "role": "Treatment_Drug", "text": "methimazole", "start": 25, "end": 26}, {"entity_id": "6865827_3_Ent6", "role": "Combination_Drug", "text": "methimazole", "start": 25, "end": 26}, {"entity_id": "6865827_3_Ent0", "role": "Subject", "text": "the same patient", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "6865827_3_Ent1", "text": "agranulocytosis", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "6865827_3_Ent2", "text": "both propylthiouracil and methimazole", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "6865827_3_Ent4", "text": "propylthiouracil", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "6865827_3_Ent5", "text": "propylthiouracil", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "6865827_3_Ent3", "text": "methimazole", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "6865827_3_Ent6", "text": "methimazole", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "6865827_3_Ent0", "text": "the same patient", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "6873616_2", "wnd_id": "6873616_2_1", "text": "Intrahepatic cholestasis and sicca complex after thiabendazole .", "tokens": ["Intrahepatic", "cholestasis", "and", "sicca", "complex", "after", "thiabendazole", "."], "event_mentions": [{"id": "6873616_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "6873616_2_Ent0", "role": "Effect", "text": "Intrahepatic cholestasis and sicca complex", "start": 0, "end": 5}, {"entity_id": "6873616_2_Ent1", "role": "Treatment", "text": "thiabendazole", "start": 6, "end": 7}, {"entity_id": "6873616_2_Ent2", "role": "Treatment_Drug", "text": "thiabendazole", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6873616_2_Ent0", "text": "Intrahepatic cholestasis and sicca complex", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "6873616_2_Ent1", "text": "thiabendazole", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6873616_2_Ent2", "text": "thiabendazole", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6933231_1", "wnd_id": "6933231_1_1", "text": "Intracranial hemorrhage and focal seizures secondary to use of L - asparaginase during induction therapy of acute lymphocytic leukemia .", "tokens": ["Intracranial", "hemorrhage", "and", "focal", "seizures", "secondary", "to", "use", "of", "L", "-", "asparaginase", "during", "induction", "therapy", "of", "acute", "lymphocytic", "leukemia", "."], "event_mentions": [{"id": "6933231_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 5, "end": 7}, "arguments": [{"entity_id": "6933231_1_Ent0", "role": "Effect", "text": "Intracranial hemorrhage and focal seizures", "start": 0, "end": 5}, {"entity_id": "6933231_1_Ent1", "role": "Treatment", "text": "L - asparaginase", "start": 9, "end": 12}, {"entity_id": "6933231_1_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "6933231_1_Ent0", "text": "Intracranial hemorrhage and focal seizures", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "6933231_1_Ent1", "text": "L - asparaginase", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "6933231_1_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "6987607_1", "wnd_id": "6987607_1_1", "text": "However , the amount of prednisone required to maintain normotension resulted in Cushingoid features and has been discontinued .", "tokens": ["However", ",", "the", "amount", "of", "prednisone", "required", "to", "maintain", "normotension", "resulted", "in", "Cushingoid", "features", "and", "has", "been", "discontinued", "."], "event_mentions": [{"id": "6987607_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted in", "start": 10, "end": 12}, "arguments": [{"entity_id": "6987607_1_Ent1", "role": "Treatment", "text": "prednisone", "start": 5, "end": 6}, {"entity_id": "6987607_1_Ent3", "role": "Treatment_Drug", "text": "prednisone", "start": 5, "end": 6}, {"entity_id": "6987607_1_Ent2", "role": "Treatment", "text": "to maintain normotension", "start": 7, "end": 10}, {"entity_id": "6987607_1_Ent0", "role": "Effect", "text": "Cushingoid features", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "6987607_1_Ent1", "text": "prednisone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6987607_1_Ent3", "text": "prednisone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6987607_1_Ent2", "text": "to maintain normotension", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "6987607_1_Ent0", "text": "Cushingoid features", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "6998294_2", "wnd_id": "6998294_2_1", "text": "Disopyramide ( Norpace) - induced hypoglycemia .", "tokens": ["Disopyramide", "(", "Norpace)", "-", "induced", "hypoglycemia", "."], "event_mentions": [{"id": "6998294_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "6998294_2_Ent2", "role": "Treatment_Drug", "text": "Disopyramide", "start": 0, "end": 1}, {"entity_id": "6998294_2_Ent1", "role": "Treatment", "text": "Disopyramide ( Norpace)", "start": 0, "end": 3}, {"entity_id": "6998294_2_Ent0", "role": "Effect", "text": "hypoglycemia", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "6998294_2_Ent2", "text": "Disopyramide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6998294_2_Ent1", "text": "Disopyramide ( Norpace)", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6998294_2_Ent0", "text": "hypoglycemia", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "7035691_1", "wnd_id": "7035691_1_1", "text": "Transient anuria following administration of angiotensin I - converting enzyme inhibitor ( SQ 14225 ) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation .", "tokens": ["Transient", "anuria", "following", "administration", "of", "angiotensin", "I", "-", "converting", "enzyme", "inhibitor", "(", "SQ", "14225", ")", "in", "a", "patient", "with", "renal", "artery", "stenosis", "of", "the", "solitary", "kidney", "successfully", "treated", "with", "renal", "autotransplantation", "."], "event_mentions": [{"id": "7035691_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "7035691_1_Ent1", "role": "Effect", "text": "Transient anuria", "start": 0, "end": 2}, {"entity_id": "7035691_1_Ent4", "role": "Treatment_Drug", "text": "angiotensin I - converting enzyme inhibitor", "start": 5, "end": 11}, {"entity_id": "7035691_1_Ent2", "role": "Treatment", "text": "angiotensin I - converting enzyme inhibitor ( SQ 14225 )", "start": 5, "end": 15}, {"entity_id": "7035691_1_Ent0", "role": "Subject", "text": "a patient with renal artery stenosis of the solitary kidney", "start": 16, "end": 26}, {"entity_id": "7035691_1_Ent3", "role": "Treatment_Disorder", "text": "renal artery stenosis of the solitary kidney", "start": 19, "end": 26}]}, {"id": "7035691_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 27, "end": 28}, "arguments": [{"entity_id": "7035691_1_Ent7", "role": "Treatment_Disorder", "text": "Transient anuria", "start": 0, "end": 2}, {"entity_id": "7035691_1_Ent5", "role": "Subject", "text": "a patient with renal artery stenosis of the solitary kidney", "start": 16, "end": 26}, {"entity_id": "7035691_1_Ent6", "role": "Treatment", "text": "renal autotransplantation", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "7035691_1_Ent1", "text": "Transient anuria", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7035691_1_Ent7", "text": "Transient anuria", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7035691_1_Ent4", "text": "angiotensin I - converting enzyme inhibitor", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "7035691_1_Ent2", "text": "angiotensin I - converting enzyme inhibitor ( SQ 14225 )", "entity_type": "Entity", "start": 5, "end": 15}, {"id": "7035691_1_Ent0", "text": "a patient with renal artery stenosis of the solitary kidney", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "7035691_1_Ent5", "text": "a patient with renal artery stenosis of the solitary kidney", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "7035691_1_Ent3", "text": "renal artery stenosis of the solitary kidney", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "7035691_1_Ent6", "text": "renal autotransplantation", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "7035691_3", "wnd_id": "7035691_3_1", "text": "Although inhibition of the angiotensin - converting enzyme is considered to be efficient treatment for hypertension associated with chronic renal failure , care should be taken when captopril is administered initially to a patient with decreased renal function , under the conditions of sodium and water depletion .", "tokens": ["Although", "inhibition", "of", "the", "angiotensin", "-", "converting", "enzyme", "is", "considered", "to", "be", "efficient", "treatment", "for", "hypertension", "associated", "with", "chronic", "renal", "failure", ",", "care", "should", "be", "taken", "when", "captopril", "is", "administered", "initially", "to", "a", "patient", "with", "decreased", "renal", "function", ",", "under", "the", "conditions", "of", "sodium", "and", "water", "depletion", "."], "event_mentions": [{"id": "7035691_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 13, "end": 14}, "arguments": [{"entity_id": "7035691_3_Ent3", "role": "Treatment_Disorder", "text": "hypertension associated with chronic renal failure", "start": 15, "end": 21}, {"entity_id": "7035691_3_Ent2", "role": "Treatment", "text": "captopril", "start": 27, "end": 28}, {"entity_id": "7035691_3_Ent4", "role": "Treatment_Drug", "text": "captopril", "start": 27, "end": 28}, {"entity_id": "7035691_3_Ent0", "role": "Subject", "text": "a patient with decreased renal function", "start": 32, "end": 38}, {"entity_id": "7035691_3_Ent1", "role": "Subject_Disorder", "text": "decreased renal function", "start": 35, "end": 38}]}], "entity_mentions": [{"id": "7035691_3_Ent3", "text": "hypertension associated with chronic renal failure", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "7035691_3_Ent2", "text": "captopril", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "7035691_3_Ent4", "text": "captopril", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "7035691_3_Ent0", "text": "a patient with decreased renal function", "entity_type": "Entity", "start": 32, "end": 38}, {"id": "7035691_3_Ent1", "text": "decreased renal function", "entity_type": "Entity", "start": 35, "end": 38}], "lang": "en"}
{"doc_id": "7056119_4", "wnd_id": "7056119_4_1", "text": "Because of a recurrence of paroxysmal atrial fibrillation , the dose of the drug was increased to 1.4 g / day ; 24 hours later AVT with syncope developed but responded promptly to atropine .", "tokens": ["Because", "of", "a", "recurrence", "of", "paroxysmal", "atrial", "fibrillation", ",", "the", "dose", "of", "the", "drug", "was", "increased", "to", "1.4", "g", "/", "day", ";", "24", "hours", "later", "AVT", "with", "syncope", "developed", "but", "responded", "promptly", "to", "atropine", "."], "event_mentions": [{"id": "7056119_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 28, "end": 29}, "arguments": [{"entity_id": "7056119_4_Ent0", "role": "Subject", "text": "paroxysmal atrial fibrillation", "start": 5, "end": 8}, {"entity_id": "7056119_4_Ent1", "role": "Subject_Disorder", "text": "paroxysmal atrial fibrillation", "start": 5, "end": 8}, {"entity_id": "7056119_4_Ent3", "role": "Treatment", "text": "the dose of the drug was increased to 1.4 g / day", "start": 9, "end": 21}, {"entity_id": "7056119_4_Ent6", "role": "Treatment_Drug", "text": "the drug", "start": 12, "end": 14}, {"entity_id": "7056119_4_Ent5", "role": "Treatment_Dosage", "text": "1.4 g / day", "start": 17, "end": 21}, {"entity_id": "7056119_4_Ent4", "role": "Treatment_Time_elapsed", "text": "24 hours", "start": 22, "end": 24}, {"entity_id": "7056119_4_Ent2", "role": "Effect", "text": "AVT with syncope", "start": 25, "end": 28}]}, {"id": "7056119_4_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "responded", "start": 30, "end": 31}, "arguments": [{"entity_id": "7056119_4_Ent8", "role": "Treatment_Disorder", "text": "AVT with syncope", "start": 25, "end": 28}, {"entity_id": "7056119_4_Ent7", "role": "Treatment", "text": "atropine", "start": 33, "end": 34}, {"entity_id": "7056119_4_Ent9", "role": "Treatment_Drug", "text": "atropine", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "7056119_4_Ent0", "text": "paroxysmal atrial fibrillation", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7056119_4_Ent1", "text": "paroxysmal atrial fibrillation", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7056119_4_Ent3", "text": "the dose of the drug was increased to 1.4 g / day", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "7056119_4_Ent6", "text": "the drug", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "7056119_4_Ent5", "text": "1.4 g / day", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "7056119_4_Ent4", "text": "24 hours", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "7056119_4_Ent2", "text": "AVT with syncope", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "7056119_4_Ent8", "text": "AVT with syncope", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "7056119_4_Ent7", "text": "atropine", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "7056119_4_Ent9", "text": "atropine", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "7067510_1", "wnd_id": "7067510_1_1", "text": "Although the existence of an acute pericarditis or an acute myocarditis as possible causes of the ST elevation can not be fully ruled out , the sudden onset , prominent magnitude , and brief duration of the ST elevation are perhaps more indicative of an acute ischemic event , possibly related to a transient coronary vasoconstriction induced by the dopamine infusion .", "tokens": ["Although", "the", "existence", "of", "an", "acute", "pericarditis", "or", "an", "acute", "myocarditis", "as", "possible", "causes", "of", "the", "ST", "elevation", "can", "not", "be", "fully", "ruled", "out", ",", "the", "sudden", "onset", ",", "prominent", "magnitude", ",", "and", "brief", "duration", "of", "the", "ST", "elevation", "are", "perhaps", "more", "indicative", "of", "an", "acute", "ischemic", "event", ",", "possibly", "related", "to", "a", "transient", "coronary", "vasoconstriction", "induced", "by", "the", "dopamine", "infusion", "."], "event_mentions": [{"id": "7067510_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 56, "end": 57}, "arguments": [{"entity_id": "7067510_1_Ent0", "role": "Effect", "text": "transient coronary vasoconstriction", "start": 53, "end": 56}, {"entity_id": "7067510_1_Ent1", "role": "Treatment", "text": "dopamine", "start": 59, "end": 60}, {"entity_id": "7067510_1_Ent2", "role": "Treatment_Drug", "text": "dopamine", "start": 59, "end": 60}]}], "entity_mentions": [{"id": "7067510_1_Ent0", "text": "transient coronary vasoconstriction", "entity_type": "Entity", "start": 53, "end": 56}, {"id": "7067510_1_Ent1", "text": "dopamine", "entity_type": "Entity", "start": 59, "end": 60}, {"id": "7067510_1_Ent2", "text": "dopamine", "entity_type": "Entity", "start": 59, "end": 60}], "lang": "en"}
{"doc_id": "7098384_1", "wnd_id": "7098384_1_1", "text": "A 66 - year - old mand suffering from severe coronary heart disease took digoxin with suicidal intent an was treated for the ensuing complete atrioventricular block with digoxin - specific antibody fragments .", "tokens": ["A", "66", "-", "year", "-", "old", "mand", "suffering", "from", "severe", "coronary", "heart", "disease", "took", "digoxin", "with", "suicidal", "intent", "an", "was", "treated", "for", "the", "ensuing", "complete", "atrioventricular", "block", "with", "digoxin", "-", "specific", "antibody", "fragments", "."], "event_mentions": [{"id": "7098384_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "took", "start": 13, "end": 14}, "arguments": [{"entity_id": "7098384_1_Ent0", "role": "Subject", "text": "A 66 - year - old mand suffering from severe coronary heart disease", "start": 0, "end": 13}, {"entity_id": "7098384_1_Ent1", "role": "Subject_Age", "text": "66 - year - old", "start": 1, "end": 6}, {"entity_id": "7098384_1_Ent2", "role": "Subject_Gender", "text": "mand", "start": 6, "end": 7}, {"entity_id": "7098384_1_Ent3", "role": "Subject_Disorder", "text": "coronary heart disease", "start": 10, "end": 13}, {"entity_id": "7098384_1_Ent5", "role": "Treatment", "text": "digoxin", "start": 14, "end": 15}, {"entity_id": "7098384_1_Ent6", "role": "Treatment_Drug", "text": "digoxin", "start": 14, "end": 15}, {"entity_id": "7098384_1_Ent4", "role": "Effect", "text": "complete atrioventricular block", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "7098384_1_Ent0", "text": "A 66 - year - old mand suffering from severe coronary heart disease", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "7098384_1_Ent1", "text": "66 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "7098384_1_Ent2", "text": "mand", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7098384_1_Ent3", "text": "coronary heart disease", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "7098384_1_Ent5", "text": "digoxin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "7098384_1_Ent6", "text": "digoxin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "7098384_1_Ent4", "text": "complete atrioventricular block", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "7117795_3", "wnd_id": "7117795_3_1", "text": "Ulcerating enteritis associated with flucytosine therapy .", "tokens": ["Ulcerating", "enteritis", "associated", "with", "flucytosine", "therapy", "."], "event_mentions": [{"id": "7117795_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated with", "start": 2, "end": 4}, "arguments": [{"entity_id": "7117795_3_Ent0", "role": "Effect", "text": "Ulcerating enteritis", "start": 0, "end": 2}, {"entity_id": "7117795_3_Ent2", "role": "Treatment_Drug", "text": "flucytosine", "start": 4, "end": 5}, {"entity_id": "7117795_3_Ent1", "role": "Treatment", "text": "flucytosine therapy", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "7117795_3_Ent0", "text": "Ulcerating enteritis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7117795_3_Ent2", "text": "flucytosine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7117795_3_Ent1", "text": "flucytosine therapy", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "7174620_1", "wnd_id": "7174620_1_1", "text": "Nine delirious patients suffering from lithium intoxication were examined with the Mini - Mental State Exam ( MMS ) to describe the clinical course of the disorder .", "tokens": ["Nine", "delirious", "patients", "suffering", "from", "lithium", "intoxication", "were", "examined", "with", "the", "Mini", "-", "Mental", "State", "Exam", "(", "MMS", ")", "to", "describe", "the", "clinical", "course", "of", "the", "disorder", "."], "event_mentions": [{"id": "7174620_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffering from", "start": 3, "end": 5}, "arguments": [{"entity_id": "7174620_1_Ent1", "role": "Subject_Population", "text": "Nine", "start": 0, "end": 1}, {"entity_id": "7174620_1_Ent0", "role": "Subject", "text": "Nine delirious patients", "start": 0, "end": 3}, {"entity_id": "7174620_1_Ent2", "role": "Subject_Disorder", "text": "delirious", "start": 1, "end": 2}, {"entity_id": "7174620_1_Ent4", "role": "Treatment", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "7174620_1_Ent5", "role": "Treatment_Drug", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "7174620_1_Ent3", "role": "Effect", "text": "lithium intoxication", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "7174620_1_Ent1", "text": "Nine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7174620_1_Ent0", "text": "Nine delirious patients", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7174620_1_Ent2", "text": "delirious", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7174620_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7174620_1_Ent5", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7174620_1_Ent3", "text": "lithium intoxication", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "71813_1", "wnd_id": "71813_1_1", "text": "A 58 - year - old man with rheumatoid arthritis developed lichen planus during treatment with gold .", "tokens": ["A", "58", "-", "year", "-", "old", "man", "with", "rheumatoid", "arthritis", "developed", "lichen", "planus", "during", "treatment", "with", "gold", "."], "event_mentions": [{"id": "71813_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "71813_1_Ent0", "role": "Subject", "text": "A 58 - year - old man with rheumatoid arthritis", "start": 0, "end": 10}, {"entity_id": "71813_1_Ent1", "role": "Subject_Age", "text": "58 - year - old", "start": 1, "end": 6}, {"entity_id": "71813_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "71813_1_Ent6", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 8, "end": 10}, {"entity_id": "71813_1_Ent3", "role": "Effect", "text": "lichen planus during", "start": 11, "end": 14}, {"entity_id": "71813_1_Ent4", "role": "Treatment", "text": "treatment with gold", "start": 14, "end": 17}, {"entity_id": "71813_1_Ent5", "role": "Treatment_Drug", "text": "gold", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "71813_1_Ent0", "text": "A 58 - year - old man with rheumatoid arthritis", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "71813_1_Ent1", "text": "58 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "71813_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "71813_1_Ent6", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "71813_1_Ent3", "text": "lichen planus during", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "71813_1_Ent4", "text": "treatment with gold", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "71813_1_Ent5", "text": "gold", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "71813_3", "wnd_id": "71813_3_1", "text": "Lichen planus and acne provoked by gold .", "tokens": ["Lichen", "planus", "and", "acne", "provoked", "by", "gold", "."], "event_mentions": [{"id": "71813_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoked", "start": 4, "end": 5}, "arguments": [{"entity_id": "71813_3_Ent0", "role": "Effect", "text": "Lichen planus and acne", "start": 0, "end": 4}, {"entity_id": "71813_3_Ent1", "role": "Treatment", "text": "gold", "start": 6, "end": 7}, {"entity_id": "71813_3_Ent2", "role": "Treatment_Drug", "text": "gold", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "71813_3_Ent0", "text": "Lichen planus and acne", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "71813_3_Ent1", "text": "gold", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "71813_3_Ent2", "text": "gold", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "7212107_2", "wnd_id": "7212107_2_1", "text": "These results indicate that lithium may cause biochemical hyperparathyroidism .", "tokens": ["These", "results", "indicate", "that", "lithium", "may", "cause", "biochemical", "hyperparathyroidism", "."], "event_mentions": [{"id": "7212107_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "may", "start": 5, "end": 6}, "arguments": [{"entity_id": "7212107_2_Ent1", "role": "Treatment", "text": "lithium", "start": 4, "end": 5}, {"entity_id": "7212107_2_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 4, "end": 5}, {"entity_id": "7212107_2_Ent0", "role": "Effect", "text": "biochemical hyperparathyroidism", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "7212107_2_Ent1", "text": "lithium", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7212107_2_Ent2", "text": "lithium", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7212107_2_Ent0", "text": "biochemical hyperparathyroidism", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "7235792_2", "wnd_id": "7235792_2_1", "text": "In the first patient , two episodes of ventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering bretylium .", "tokens": ["In", "the", "first", "patient", ",", "two", "episodes", "of", "ventricular", "tachycardia", "requiring", "cardioversion", "occurred", "in", "close", "temporal", "sequence", "with", "administering", "bretylium", "."], "event_mentions": [{"id": "7235792_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 12, "end": 13}, "arguments": [{"entity_id": "7235792_2_Ent0", "role": "Subject", "text": "first patient", "start": 2, "end": 4}, {"entity_id": "7235792_2_Ent1", "role": "Effect", "text": "two episodes of ventricular tachycardia requiring cardioversion", "start": 5, "end": 12}, {"entity_id": "7235792_2_Ent3", "role": "Treatment_Time_elapsed", "text": "close temporal sequence", "start": 14, "end": 17}, {"entity_id": "7235792_2_Ent2", "role": "Treatment", "text": "close temporal sequence with administering bretylium", "start": 14, "end": 20}, {"entity_id": "7235792_2_Ent4", "role": "Treatment_Drug", "text": "bretylium", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "7235792_2_Ent0", "text": "first patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7235792_2_Ent1", "text": "two episodes of ventricular tachycardia requiring cardioversion", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "7235792_2_Ent3", "text": "close temporal sequence", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "7235792_2_Ent2", "text": "close temporal sequence with administering bretylium", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "7235792_2_Ent4", "text": "bretylium", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "7304798_1", "wnd_id": "7304798_1_1", "text": "Induction of rapid mood cycling during L - dopa treatment in a bipolar patient .", "tokens": ["Induction", "of", "rapid", "mood", "cycling", "during", "L", "-", "dopa", "treatment", "in", "a", "bipolar", "patient", "."], "event_mentions": [{"id": "7304798_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 5, "end": 6}, "arguments": [{"entity_id": "7304798_1_Ent1", "role": "Effect", "text": "rapid mood cycling", "start": 2, "end": 5}, {"entity_id": "7304798_1_Ent2", "role": "Treatment", "text": "L - dopa", "start": 6, "end": 9}, {"entity_id": "7304798_1_Ent3", "role": "Treatment_Drug", "text": "L - dopa", "start": 6, "end": 9}, {"entity_id": "7304798_1_Ent0", "role": "Subject", "text": "a bipolar patient", "start": 11, "end": 14}, {"entity_id": "7304798_1_Ent4", "role": "Treatment_Disorder", "text": "bipolar", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "7304798_1_Ent1", "text": "rapid mood cycling", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "7304798_1_Ent2", "text": "L - dopa", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "7304798_1_Ent3", "text": "L - dopa", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "7304798_1_Ent0", "text": "a bipolar patient", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "7304798_1_Ent4", "text": "bipolar", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "7321956_1", "wnd_id": "7321956_1_1", "text": "Liver disease induced by perhexiline maleate .", "tokens": ["Liver", "disease", "induced", "by", "perhexiline", "maleate", "."], "event_mentions": [{"id": "7321956_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced by", "start": 2, "end": 4}, "arguments": [{"entity_id": "7321956_1_Ent0", "role": "Effect", "text": "Liver disease", "start": 0, "end": 2}, {"entity_id": "7321956_1_Ent1", "role": "Treatment", "text": "perhexiline maleate", "start": 4, "end": 6}, {"entity_id": "7321956_1_Ent2", "role": "Treatment_Drug", "text": "perhexiline maleate", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "7321956_1_Ent0", "text": "Liver disease", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7321956_1_Ent1", "text": "perhexiline maleate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7321956_1_Ent2", "text": "perhexiline maleate", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "7369302_3", "wnd_id": "7369302_3_1", "text": "Total blindness with a transient tonic pupillary response , denervation supersensitivity , and abnormal visual - evoked potentials developed in a 54 - year - old man after the use of quinine sulfate for leg cramps .", "tokens": ["Total", "blindness", "with", "a", "transient", "tonic", "pupillary", "response", ",", "denervation", "supersensitivity", ",", "and", "abnormal", "visual", "-", "evoked", "potentials", "developed", "in", "a", "54", "-", "year", "-", "old", "man", "after", "the", "use", "of", "quinine", "sulfate", "for", "leg", "cramps", "."], "event_mentions": [{"id": "7369302_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 27, "end": 28}, "arguments": [{"entity_id": "7369302_3_Ent3", "role": "Effect", "text": "Total blindness with a transient tonic pupillary response , denervation supersensitivity , and abnormal visual - evoked", "start": 0, "end": 17}, {"entity_id": "7369302_3_Ent0", "role": "Subject", "text": "a 54 - year - old man", "start": 20, "end": 27}, {"entity_id": "7369302_3_Ent1", "role": "Subject_Age", "text": "54 - year - old", "start": 21, "end": 26}, {"entity_id": "7369302_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 26, "end": 27}, {"entity_id": "7369302_3_Ent4", "role": "Treatment", "text": "quinine sulfate", "start": 31, "end": 33}, {"entity_id": "7369302_3_Ent6", "role": "Treatment_Drug", "text": "quinine sulfate", "start": 31, "end": 33}, {"entity_id": "7369302_3_Ent5", "role": "Treatment_Disorder", "text": "leg cramps", "start": 34, "end": 36}]}], "entity_mentions": [{"id": "7369302_3_Ent3", "text": "Total blindness with a transient tonic pupillary response , denervation supersensitivity , and abnormal visual - evoked", "entity_type": "Entity", "start": 0, "end": 17}, {"id": "7369302_3_Ent0", "text": "a 54 - year - old man", "entity_type": "Entity", "start": 20, "end": 27}, {"id": "7369302_3_Ent1", "text": "54 - year - old", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "7369302_3_Ent2", "text": "man", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "7369302_3_Ent4", "text": "quinine sulfate", "entity_type": "Entity", "start": 31, "end": 33}, {"id": "7369302_3_Ent6", "text": "quinine sulfate", "entity_type": "Entity", "start": 31, "end": 33}, {"id": "7369302_3_Ent5", "text": "leg cramps", "entity_type": "Entity", "start": 34, "end": 36}], "lang": "en"}
{"doc_id": "7387219_2", "wnd_id": "7387219_2_1", "text": "These cases and a review of the literature suggested that hepatotoxicity , though rare , should be added to the list of adverse reactions to D - penicillamine .", "tokens": ["These", "cases", "and", "a", "review", "of", "the", "literature", "suggested", "that", "hepatotoxicity", ",", "though", "rare", ",", "should", "be", "added", "to", "the", "list", "of", "adverse", "reactions", "to", "D", "-", "penicillamine", "."], "event_mentions": [{"id": "7387219_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse", "start": 22, "end": 23}, "arguments": [{"entity_id": "7387219_2_Ent0", "role": "Subject", "text": "These cases", "start": 0, "end": 2}, {"entity_id": "7387219_2_Ent1", "role": "Effect", "text": "hepatotoxicity", "start": 10, "end": 11}, {"entity_id": "7387219_2_Ent2", "role": "Treatment", "text": "D - penicillamine", "start": 25, "end": 28}, {"entity_id": "7387219_2_Ent3", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 25, "end": 28}]}], "entity_mentions": [{"id": "7387219_2_Ent0", "text": "These cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7387219_2_Ent1", "text": "hepatotoxicity", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7387219_2_Ent2", "text": "D - penicillamine", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "7387219_2_Ent3", "text": "D - penicillamine", "entity_type": "Entity", "start": 25, "end": 28}], "lang": "en"}
{"doc_id": "7408538_2", "wnd_id": "7408538_2_1", "text": "Unusual pigmentary changes associated with 5 - fluorouracil therapy .", "tokens": ["Unusual", "pigmentary", "changes", "associated", "with", "5", "-", "fluorouracil", "therapy", "."], "event_mentions": [{"id": "7408538_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "7408538_2_Ent0", "role": "Effect", "text": "Unusual pigmentary changes", "start": 0, "end": 3}, {"entity_id": "7408538_2_Ent1", "role": "Treatment", "text": "5 - fluorouracil", "start": 5, "end": 8}, {"entity_id": "7408538_2_Ent2", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "7408538_2_Ent0", "text": "Unusual pigmentary changes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7408538_2_Ent1", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7408538_2_Ent2", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "7416268_3", "wnd_id": "7416268_3_1", "text": "Although useful in the management of chronic alcoholism , disulfiram is being increasingly associated with a wide spectrum of side effects and untoward medical sequelae , which now include catatonia .", "tokens": ["Although", "useful", "in", "the", "management", "of", "chronic", "alcoholism", ",", "disulfiram", "is", "being", "increasingly", "associated", "with", "a", "wide", "spectrum", "of", "side", "effects", "and", "untoward", "medical", "sequelae", ",", "which", "now", "include", "catatonia", "."], "event_mentions": [{"id": "7416268_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "7416268_3_Ent3", "role": "Treatment_Disorder", "text": "chronic alcoholism", "start": 6, "end": 8}, {"entity_id": "7416268_3_Ent1", "role": "Treatment", "text": "disulfiram", "start": 9, "end": 10}, {"entity_id": "7416268_3_Ent2", "role": "Treatment_Drug", "text": "disulfiram", "start": 9, "end": 10}, {"entity_id": "7416268_3_Ent0", "role": "Effect", "text": "a wide spectrum of side effects and untoward medical sequelae , which now include catatonia", "start": 15, "end": 30}]}], "entity_mentions": [{"id": "7416268_3_Ent3", "text": "chronic alcoholism", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7416268_3_Ent1", "text": "disulfiram", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7416268_3_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7416268_3_Ent0", "text": "a wide spectrum of side effects and untoward medical sequelae , which now include catatonia", "entity_type": "Entity", "start": 15, "end": 30}], "lang": "en"}
{"doc_id": "7436161_2", "wnd_id": "7436161_2_1", "text": "Seven patients with hematologic malignancies who were treated with miconazole for either suspected or proven fungal infections developed eight episodes of major adverse cardiorespiratory and anaphylactic reactions .", "tokens": ["Seven", "patients", "with", "hematologic", "malignancies", "who", "were", "treated", "with", "miconazole", "for", "either", "suspected", "or", "proven", "fungal", "infections", "developed", "eight", "episodes", "of", "major", "adverse", "cardiorespiratory", "and", "anaphylactic", "reactions", "."], "event_mentions": [{"id": "7436161_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "7436161_2_Ent1", "role": "Subject_Population", "text": "Seven", "start": 0, "end": 1}, {"entity_id": "7436161_2_Ent0", "role": "Subject", "text": "Seven patients with hematologic malignancies", "start": 0, "end": 5}, {"entity_id": "7436161_2_Ent2", "role": "Subject_Disorder", "text": "hematologic malignancies", "start": 3, "end": 5}, {"entity_id": "7436161_2_Ent4", "role": "Treatment", "text": "miconazole", "start": 9, "end": 10}, {"entity_id": "7436161_2_Ent5", "role": "Treatment_Drug", "text": "miconazole", "start": 9, "end": 10}, {"entity_id": "7436161_2_Ent6", "role": "Treatment_Disorder", "text": "fungal infections", "start": 15, "end": 17}, {"entity_id": "7436161_2_Ent3", "role": "Effect", "text": "eight episodes of major adverse cardiorespiratory and anaphylactic reactions", "start": 18, "end": 27}]}], "entity_mentions": [{"id": "7436161_2_Ent1", "text": "Seven", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7436161_2_Ent0", "text": "Seven patients with hematologic malignancies", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7436161_2_Ent2", "text": "hematologic malignancies", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7436161_2_Ent4", "text": "miconazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7436161_2_Ent5", "text": "miconazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7436161_2_Ent6", "text": "fungal infections", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "7436161_2_Ent3", "text": "eight episodes of major adverse cardiorespiratory and anaphylactic reactions", "entity_type": "Entity", "start": 18, "end": 27}], "lang": "en"}
{"doc_id": "7448830_1", "wnd_id": "7448830_1_1", "text": "Hepatotoxicity of hycanthone in patients with metastatic breast cancer .", "tokens": ["Hepatotoxicity", "of", "hycanthone", "in", "patients", "with", "metastatic", "breast", "cancer", "."], "event_mentions": [{"id": "7448830_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 1, "end": 2}, "arguments": [{"entity_id": "7448830_1_Ent1", "role": "Effect", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "7448830_1_Ent2", "role": "Treatment", "text": "hycanthone", "start": 2, "end": 3}, {"entity_id": "7448830_1_Ent4", "role": "Treatment_Drug", "text": "hycanthone", "start": 2, "end": 3}, {"entity_id": "7448830_1_Ent0", "role": "Subject", "text": "patients with metastatic breast cancer", "start": 4, "end": 9}, {"entity_id": "7448830_1_Ent3", "role": "Treatment_Disorder", "text": "metastatic breast cancer", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "7448830_1_Ent1", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7448830_1_Ent2", "text": "hycanthone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7448830_1_Ent4", "text": "hycanthone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7448830_1_Ent0", "text": "patients with metastatic breast cancer", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "7448830_1_Ent3", "text": "metastatic breast cancer", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "7459812_2", "wnd_id": "7459812_2_1", "text": "Following several of these courses of therapy , respiratory distress occurred 9 to 12 days after the chlorambucil was given .", "tokens": ["Following", "several", "of", "these", "courses", "of", "therapy", ",", "respiratory", "distress", "occurred", "9", "to", "12", "days", "after", "the", "chlorambucil", "was", "given", "."], "event_mentions": [{"id": "7459812_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 15, "end": 16}, "arguments": [{"entity_id": "7459812_2_Ent0", "role": "Effect", "text": "respiratory distress", "start": 8, "end": 10}, {"entity_id": "7459812_2_Ent2", "role": "Treatment_Time_elapsed", "text": "9 to 12 days", "start": 11, "end": 15}, {"entity_id": "7459812_2_Ent1", "role": "Treatment", "text": "the chlorambucil", "start": 16, "end": 18}, {"entity_id": "7459812_2_Ent3", "role": "Treatment_Drug", "text": "chlorambucil", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "7459812_2_Ent0", "text": "respiratory distress", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7459812_2_Ent2", "text": "9 to 12 days", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "7459812_2_Ent1", "text": "the chlorambucil", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "7459812_2_Ent3", "text": "chlorambucil", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "7474364_1", "wnd_id": "7474364_1_1", "text": "A 71 - year - old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained - release procainamide ( 750 mg / day ) .", "tokens": ["A", "71", "-", "year", "-", "old", "man", "with", "paroxysmal", "atrial", "fibrillation", "who", "had", "a", "previous", "anterior", "myocardial", "infarction", "exhibited", "granulocytopenia", "8", "days", "following", "the", "administration", "of", "oral", "sustained", "-", "release", "procainamide", "(", "750", "mg", "/", "day", ")", "."], "event_mentions": [{"id": "7474364_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exhibited", "start": 18, "end": 19}, "arguments": [{"entity_id": "7474364_1_Ent0", "role": "Subject", "text": "A 71 - year - old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction", "start": 0, "end": 18}, {"entity_id": "7474364_1_Ent1", "role": "Subject_Age", "text": "71 - year - old", "start": 1, "end": 6}, {"entity_id": "7474364_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "7474364_1_Ent10", "role": "Treatment_Disorder", "text": "paroxysmal atrial fibrillation", "start": 8, "end": 11}, {"entity_id": "7474364_1_Ent3", "role": "Subject_Disorder", "text": "anterior myocardial infarction", "start": 15, "end": 18}, {"entity_id": "7474364_1_Ent4", "role": "Effect", "text": "granulocytopenia", "start": 19, "end": 20}, {"entity_id": "7474364_1_Ent6", "role": "Treatment_Time_elapsed", "text": "8 days", "start": 20, "end": 22}, {"entity_id": "7474364_1_Ent8", "role": "Treatment_Route", "text": "oral", "start": 26, "end": 27}, {"entity_id": "7474364_1_Ent5", "role": "Treatment", "text": "oral sustained - release procainamide ( 750 mg / day )", "start": 26, "end": 37}, {"entity_id": "7474364_1_Ent7", "role": "Treatment_Drug", "text": "sustained - release procainamide", "start": 27, "end": 31}, {"entity_id": "7474364_1_Ent9", "role": "Treatment_Dosage", "text": "750 mg / day", "start": 32, "end": 36}]}], "entity_mentions": [{"id": "7474364_1_Ent0", "text": "A 71 - year - old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction", "entity_type": "Entity", "start": 0, "end": 18}, {"id": "7474364_1_Ent1", "text": "71 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "7474364_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7474364_1_Ent10", "text": "paroxysmal atrial fibrillation", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "7474364_1_Ent3", "text": "anterior myocardial infarction", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "7474364_1_Ent4", "text": "granulocytopenia", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "7474364_1_Ent6", "text": "8 days", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "7474364_1_Ent8", "text": "oral", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "7474364_1_Ent5", "text": "oral sustained - release procainamide ( 750 mg / day )", "entity_type": "Entity", "start": 26, "end": 37}, {"id": "7474364_1_Ent7", "text": "sustained - release procainamide", "entity_type": "Entity", "start": 27, "end": 31}, {"id": "7474364_1_Ent9", "text": "750 mg / day", "entity_type": "Entity", "start": 32, "end": 36}], "lang": "en"}
{"doc_id": "7538828_8", "wnd_id": "7538828_8_1", "text": "Development of an extensive skin rash following a single dose of MTX may be an early warning sign for life - threatening bone marrow aplasia .", "tokens": ["Development", "of", "an", "extensive", "skin", "rash", "following", "a", "single", "dose", "of", "MTX", "may", "be", "an", "early", "warning", "sign", "for", "life", "-", "threatening", "bone", "marrow", "aplasia", "."], "event_mentions": [{"id": "7538828_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "7538828_8_Ent0", "role": "Effect", "text": "extensive skin rash", "start": 3, "end": 6}, {"entity_id": "7538828_8_Ent1", "role": "Treatment", "text": "MTX", "start": 11, "end": 12}, {"entity_id": "7538828_8_Ent2", "role": "Treatment_Drug", "text": "MTX", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "7538828_8_Ent0", "text": "extensive skin rash", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "7538828_8_Ent1", "text": "MTX", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7538828_8_Ent2", "text": "MTX", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "7545251_1", "wnd_id": "7545251_1_1", "text": "Chlormadinone acetate withdrawal syndrome under combined androgen blockade for advanced prostate cancer .", "tokens": ["Chlormadinone", "acetate", "withdrawal", "syndrome", "under", "combined", "androgen", "blockade", "for", "advanced", "prostate", "cancer", "."], "event_mentions": [{"id": "7545251_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "under", "start": 4, "end": 5}, "arguments": [{"entity_id": "7545251_1_Ent0", "role": "Treatment", "text": "Chlormadinone acetate", "start": 0, "end": 2}, {"entity_id": "7545251_1_Ent3", "role": "Treatment_Drug", "text": "Chlormadinone acetate", "start": 0, "end": 2}, {"entity_id": "7545251_1_Ent6", "role": "Combination_Drug", "text": "Chlormadinone acetate", "start": 0, "end": 2}, {"entity_id": "7545251_1_Ent1", "role": "Treatment", "text": "androgen blockade", "start": 6, "end": 8}, {"entity_id": "7545251_1_Ent4", "role": "Treatment_Drug", "text": "androgen blockade", "start": 6, "end": 8}, {"entity_id": "7545251_1_Ent5", "role": "Combination_Drug", "text": "androgen blockade", "start": 6, "end": 8}, {"entity_id": "7545251_1_Ent2", "role": "Treatment_Disorder", "text": "advanced prostate cancer", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "7545251_1_Ent0", "text": "Chlormadinone acetate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7545251_1_Ent3", "text": "Chlormadinone acetate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7545251_1_Ent6", "text": "Chlormadinone acetate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7545251_1_Ent1", "text": "androgen blockade", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7545251_1_Ent4", "text": "androgen blockade", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7545251_1_Ent5", "text": "androgen blockade", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7545251_1_Ent2", "text": "advanced prostate cancer", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "7577414_2", "wnd_id": "7577414_2_1", "text": "To our knowledge , this is the first case of griseofulvin - exacerbated lupus in which nephrotic syndrome has been observed .", "tokens": ["To", "our", "knowledge", ",", "this", "is", "the", "first", "case", "of", "griseofulvin", "-", "exacerbated", "lupus", "in", "which", "nephrotic", "syndrome", "has", "been", "observed", "."], "event_mentions": [{"id": "7577414_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exacerbated", "start": 12, "end": 13}, "arguments": [{"entity_id": "7577414_2_Ent0", "role": "Subject", "text": "the first case", "start": 6, "end": 9}, {"entity_id": "7577414_2_Ent3", "role": "Treatment", "text": "griseofulvin", "start": 10, "end": 11}, {"entity_id": "7577414_2_Ent4", "role": "Treatment_Drug", "text": "griseofulvin", "start": 10, "end": 11}, {"entity_id": "7577414_2_Ent1", "role": "Effect", "text": "lupus", "start": 13, "end": 14}, {"entity_id": "7577414_2_Ent2", "role": "Effect", "text": "nephrotic syndrome", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "7577414_2_Ent0", "text": "the first case", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "7577414_2_Ent3", "text": "griseofulvin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7577414_2_Ent4", "text": "griseofulvin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7577414_2_Ent1", "text": "lupus", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7577414_2_Ent2", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "7639655_2", "wnd_id": "7639655_2_1", "text": "CONCLUSION : Anterior ischemic optic neuropathy may complicate treatment with interferon alfa .", "tokens": ["CONCLUSION", ":", "Anterior", "ischemic", "optic", "neuropathy", "may", "complicate", "treatment", "with", "interferon", "alfa", "."], "event_mentions": [{"id": "7639655_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicate", "start": 7, "end": 8}, "arguments": [{"entity_id": "7639655_2_Ent0", "role": "Effect", "text": "Anterior ischemic optic neuropathy", "start": 2, "end": 6}, {"entity_id": "7639655_2_Ent1", "role": "Treatment", "text": "interferon alfa", "start": 10, "end": 12}, {"entity_id": "7639655_2_Ent2", "role": "Treatment_Drug", "text": "interferon alfa", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "7639655_2_Ent0", "text": "Anterior ischemic optic neuropathy", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "7639655_2_Ent1", "text": "interferon alfa", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7639655_2_Ent2", "text": "interferon alfa", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "7653281_2", "wnd_id": "7653281_2_1", "text": "Little has been studied of the adverse effects of the exposure of the liver to the interaction of ethanol with its congeners and acetaldehyde , coexisting in the contents of alcoholic beverages .", "tokens": ["Little", "has", "been", "studied", "of", "the", "adverse", "effects", "of", "the", "exposure", "of", "the", "liver", "to", "the", "interaction", "of", "ethanol", "with", "its", "congeners", "and", "acetaldehyde", ",", "coexisting", "in", "the", "contents", "of", "alcoholic", "beverages", "."], "event_mentions": [{"id": "7653281_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "interaction", "start": 16, "end": 17}, "arguments": [{"entity_id": "7653281_2_Ent0", "role": "Effect", "text": "adverse effects of the exposure of the liver", "start": 6, "end": 14}, {"entity_id": "7653281_2_Ent3", "role": "Treatment_Drug", "text": "ethanol", "start": 18, "end": 19}, {"entity_id": "7653281_2_Ent4", "role": "Combination_Drug", "text": "ethanol", "start": 18, "end": 19}, {"entity_id": "7653281_2_Ent1", "role": "Treatment", "text": "ethanol with its congeners and acetaldehyde", "start": 18, "end": 24}, {"entity_id": "7653281_2_Ent2", "role": "Treatment_Drug", "text": "acetaldehyde", "start": 23, "end": 24}, {"entity_id": "7653281_2_Ent5", "role": "Combination_Drug", "text": "acetaldehyde", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "7653281_2_Ent0", "text": "adverse effects of the exposure of the liver", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "7653281_2_Ent3", "text": "ethanol", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "7653281_2_Ent4", "text": "ethanol", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "7653281_2_Ent1", "text": "ethanol with its congeners and acetaldehyde", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "7653281_2_Ent2", "text": "acetaldehyde", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "7653281_2_Ent5", "text": "acetaldehyde", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "7663030_1", "wnd_id": "7663030_1_1", "text": "Probable propafenone - induced transient global amnesia .", "tokens": ["Probable", "propafenone", "-", "induced", "transient", "global", "amnesia", "."], "event_mentions": [{"id": "7663030_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "7663030_1_Ent1", "role": "Treatment", "text": "propafenone", "start": 1, "end": 2}, {"entity_id": "7663030_1_Ent2", "role": "Treatment_Drug", "text": "propafenone", "start": 1, "end": 2}, {"entity_id": "7663030_1_Ent0", "role": "Effect", "text": "transient global amnesia", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "7663030_1_Ent1", "text": "propafenone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7663030_1_Ent2", "text": "propafenone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7663030_1_Ent0", "text": "transient global amnesia", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "7663030_12", "wnd_id": "7663030_12_1", "text": "Propafenone 's distribution , clearance , and structural similarity to propranolol contribute to its central nervous system effects .", "tokens": ["Propafenone", "'s", "distribution", ",", "clearance", ",", "and", "structural", "similarity", "to", "propranolol", "contribute", "to", "its", "central", "nervous", "system", "effects", "."], "event_mentions": [{"id": "7663030_12_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "contribute", "start": 11, "end": 12}, "arguments": [{"entity_id": "7663030_12_Ent1", "role": "Treatment", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "7663030_12_Ent3", "role": "Treatment_Drug", "text": "Propafenone", "start": 0, "end": 1}, {"entity_id": "7663030_12_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 10, "end": 11}, {"entity_id": "7663030_12_Ent0", "role": "Effect", "text": "central nervous system effects", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "7663030_12_Ent1", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7663030_12_Ent3", "text": "Propafenone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7663030_12_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7663030_12_Ent0", "text": "central nervous system effects", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "7668127_3", "wnd_id": "7668127_3_1", "text": "To the best of our knowledge no comparable case and no discussion of possible complications of aspirin prophylaxis in patients with brain tumours have been published .", "tokens": ["To", "the", "best", "of", "our", "knowledge", "no", "comparable", "case", "and", "no", "discussion", "of", "possible", "complications", "of", "aspirin", "prophylaxis", "in", "patients", "with", "brain", "tumours", "have", "been", "published", "."], "event_mentions": [{"id": "7668127_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complications", "start": 14, "end": 15}, "arguments": [{"entity_id": "7668127_3_Ent3", "role": "Treatment_Drug", "text": "aspirin", "start": 16, "end": 17}, {"entity_id": "7668127_3_Ent2", "role": "Treatment", "text": "aspirin prophylaxis", "start": 16, "end": 18}, {"entity_id": "7668127_3_Ent0", "role": "Subject", "text": "patients with brain tumours", "start": 19, "end": 23}, {"entity_id": "7668127_3_Ent1", "role": "Subject_Disorder", "text": "brain tumours", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "7668127_3_Ent3", "text": "aspirin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "7668127_3_Ent2", "text": "aspirin prophylaxis", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "7668127_3_Ent0", "text": "patients with brain tumours", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "7668127_3_Ent1", "text": "brain tumours", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "7685228_1", "wnd_id": "7685228_1_1", "text": "Reversal of gold - induced neutropenia with granulocyte colony - stimulating factor ( G - CSF ) .", "tokens": ["Reversal", "of", "gold", "-", "induced", "neutropenia", "with", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", "."], "event_mentions": [{"id": "7685228_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "7685228_1_Ent2", "role": "Treatment", "text": "gold", "start": 2, "end": 3}, {"entity_id": "7685228_1_Ent4", "role": "Treatment_Drug", "text": "gold", "start": 2, "end": 3}, {"entity_id": "7685228_1_Ent1", "role": "Effect", "text": "neutropenia", "start": 5, "end": 6}, {"entity_id": "7685228_1_Ent0", "role": "Subject", "text": "granulocyte colony - stimulating factor", "start": 7, "end": 12}, {"entity_id": "7685228_1_Ent3", "role": "Treatment", "text": "granulocyte colony - stimulating factor ( G - CSF )", "start": 7, "end": 17}]}], "entity_mentions": [{"id": "7685228_1_Ent2", "text": "gold", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7685228_1_Ent4", "text": "gold", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7685228_1_Ent1", "text": "neutropenia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7685228_1_Ent0", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "7685228_1_Ent3", "text": "granulocyte colony - stimulating factor ( G - CSF )", "entity_type": "Entity", "start": 7, "end": 17}], "lang": "en"}
{"doc_id": "7712052_6", "wnd_id": "7712052_6_1", "text": "These findings should lead to further study of the role of lithium in the treatment of this symptom complex in patients with PTSD .", "tokens": ["These", "findings", "should", "lead", "to", "further", "study", "of", "the", "role", "of", "lithium", "in", "the", "treatment", "of", "this", "symptom", "complex", "in", "patients", "with", "PTSD", "."], "event_mentions": [{"id": "7712052_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 14, "end": 15}, "arguments": [{"entity_id": "7712052_6_Ent1", "role": "Treatment", "text": "lithium", "start": 11, "end": 12}, {"entity_id": "7712052_6_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 11, "end": 12}, {"entity_id": "7712052_6_Ent0", "role": "Subject", "text": "patients with PTSD", "start": 20, "end": 23}, {"entity_id": "7712052_6_Ent3", "role": "Treatment_Disorder", "text": "PTSD", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "7712052_6_Ent1", "text": "lithium", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7712052_6_Ent2", "text": "lithium", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7712052_6_Ent0", "text": "patients with PTSD", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "7712052_6_Ent3", "text": "PTSD", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "7718983_5", "wnd_id": "7718983_5_1", "text": "We report a case of Graves ' hyperthyroidism induced by long - term interferon ( IFN ) therapy .", "tokens": ["We", "report", "a", "case", "of", "Graves", "'", "hyperthyroidism", "induced", "by", "long", "-", "term", "interferon", "(", "IFN", ")", "therapy", "."], "event_mentions": [{"id": "7718983_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "7718983_5_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "7718983_5_Ent1", "role": "Effect", "text": "Graves ' hyperthyroidism", "start": 5, "end": 8}, {"entity_id": "7718983_5_Ent3", "role": "Treatment_Time_elapsed", "text": "long - term", "start": 10, "end": 13}, {"entity_id": "7718983_5_Ent2", "role": "Treatment", "text": "long - term interferon ( IFN ) therapy", "start": 10, "end": 18}, {"entity_id": "7718983_5_Ent4", "role": "Treatment_Drug", "text": "interferon", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "7718983_5_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7718983_5_Ent1", "text": "Graves ' hyperthyroidism", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7718983_5_Ent3", "text": "long - term", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "7718983_5_Ent2", "text": "long - term interferon ( IFN ) therapy", "entity_type": "Entity", "start": 10, "end": 18}, {"id": "7718983_5_Ent4", "text": "interferon", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "7720517_2", "wnd_id": "7720517_2_1", "text": "Budesonide is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis .", "tokens": ["Budesonide", "is", "a", "synthetic", "glucocorticosteroid", "that", "is", "commonly", "used", "in", "topical", "treatment", "of", "asthma", "and", "rhinitis", "."], "event_mentions": [{"id": "7720517_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used in", "start": 8, "end": 10}, "arguments": [{"entity_id": "7720517_2_Ent0", "role": "Treatment", "text": "Budesonide", "start": 0, "end": 1}, {"entity_id": "7720517_2_Ent2", "role": "Treatment_Drug", "text": "Budesonide", "start": 0, "end": 1}, {"entity_id": "7720517_2_Ent1", "role": "Treatment_Disorder", "text": "asthma and rhinitis .", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "7720517_2_Ent0", "text": "Budesonide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7720517_2_Ent2", "text": "Budesonide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7720517_2_Ent1", "text": "asthma and rhinitis .", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "7724306_2", "wnd_id": "7724306_2_1", "text": "Acute isoniazid neurotoxicity in an urban hospital .", "tokens": ["Acute", "isoniazid", "neurotoxicity", "in", "an", "urban", "hospital", "."], "event_mentions": [{"id": "7724306_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "7724306_2_Ent0", "role": "Effect", "text": "Acute", "start": 0, "end": 1}, {"entity_id": "7724306_2_Ent2", "role": "Treatment", "text": "isoniazid", "start": 1, "end": 2}, {"entity_id": "7724306_2_Ent3", "role": "Treatment_Drug", "text": "isoniazid", "start": 1, "end": 2}, {"entity_id": "7724306_2_Ent1", "role": "Effect", "text": "neurotoxicity", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "7724306_2_Ent0", "text": "Acute", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7724306_2_Ent2", "text": "isoniazid", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7724306_2_Ent3", "text": "isoniazid", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7724306_2_Ent1", "text": "neurotoxicity", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "7748076_2", "wnd_id": "7748076_2_1", "text": "OBJECTIVE : To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "finding", "of", "squamous", "metaplasia", "within", "endometrial", "glands", "occurring", "as", "a", "result", "of", "progestin", "therapy", "of", "hyperplasia", "."], "event_mentions": [{"id": "7748076_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "as a result of", "start": 13, "end": 17}, "arguments": [{"entity_id": "7748076_2_Ent0", "role": "Effect", "text": "squamous metaplasia within endometrial glands", "start": 7, "end": 12}, {"entity_id": "7748076_2_Ent3", "role": "Treatment_Drug", "text": "progestin", "start": 17, "end": 18}, {"entity_id": "7748076_2_Ent1", "role": "Treatment", "text": "progestin therapy", "start": 17, "end": 19}, {"entity_id": "7748076_2_Ent2", "role": "Treatment_Disorder", "text": "hyperplasia", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "7748076_2_Ent0", "text": "squamous metaplasia within endometrial glands", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "7748076_2_Ent3", "text": "progestin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "7748076_2_Ent1", "text": "progestin therapy", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "7748076_2_Ent2", "text": "hyperplasia", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "7752014_3", "wnd_id": "7752014_3_1", "text": "Fever caused by the use of furosemide was proved ; the fever resolved after discontinuation of this medication and recurred after its reintroduction .", "tokens": ["Fever", "caused", "by", "the", "use", "of", "furosemide", "was", "proved", ";", "the", "fever", "resolved", "after", "discontinuation", "of", "this", "medication", "and", "recurred", "after", "its", "reintroduction", "."], "event_mentions": [{"id": "7752014_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 1, "end": 2}, "arguments": [{"entity_id": "7752014_3_Ent0", "role": "Effect", "text": "Fever", "start": 0, "end": 1}, {"entity_id": "7752014_3_Ent1", "role": "Treatment", "text": "furosemide", "start": 6, "end": 7}, {"entity_id": "7752014_3_Ent2", "role": "Treatment_Drug", "text": "furosemide", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "7752014_3_Ent0", "text": "Fever", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7752014_3_Ent1", "text": "furosemide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7752014_3_Ent2", "text": "furosemide", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "7761316_1", "wnd_id": "7761316_1_1", "text": "Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .", "tokens": ["Musculoskeletal", "complaints", "were", "the", "presenting", "symptoms", "in", "four", "of", "44", "children", "(", "9", "%", ")", "treated", "for", "relapsed", "Wilms", "'", "tumors", "with", "ifosfamide", ",", "a", "derivative", "of", "cyclophosphamide", "."], "event_mentions": [{"id": "7761316_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 21, "end": 22}, "arguments": [{"entity_id": "7761316_1_Ent3", "role": "Effect", "text": "Musculoskeletal complaints", "start": 0, "end": 2}, {"entity_id": "7761316_1_Ent1", "role": "Subject_Population", "text": "four of 44", "start": 7, "end": 10}, {"entity_id": "7761316_1_Ent0", "role": "Subject", "text": "four of 44 children ( 9 % )", "start": 7, "end": 15}, {"entity_id": "7761316_1_Ent2", "role": "Subject_Age", "text": "children", "start": 10, "end": 11}, {"entity_id": "7761316_1_Ent5", "role": "Treatment_Disorder", "text": "relapsed Wilms ' tumors", "start": 17, "end": 21}, {"entity_id": "7761316_1_Ent4", "role": "Treatment", "text": "ifosfamide", "start": 22, "end": 23}, {"entity_id": "7761316_1_Ent6", "role": "Treatment_Drug", "text": "ifosfamide", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "7761316_1_Ent3", "text": "Musculoskeletal complaints", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7761316_1_Ent1", "text": "four of 44", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "7761316_1_Ent0", "text": "four of 44 children ( 9 % )", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "7761316_1_Ent2", "text": "children", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7761316_1_Ent5", "text": "relapsed Wilms ' tumors", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "7761316_1_Ent4", "text": "ifosfamide", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "7761316_1_Ent6", "text": "ifosfamide", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "7779233_2", "wnd_id": "7779233_2_1", "text": "This case study describes an atypical case of refractory , sodium warfarin - induced necrotizing fasciitis and myonecrosis .", "tokens": ["This", "case", "study", "describes", "an", "atypical", "case", "of", "refractory", ",", "sodium", "warfarin", "-", "induced", "necrotizing", "fasciitis", "and", "myonecrosis", "."], "event_mentions": [{"id": "7779233_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "7779233_2_Ent1", "role": "Treatment", "text": "sodium warfarin", "start": 10, "end": 12}, {"entity_id": "7779233_2_Ent2", "role": "Treatment_Drug", "text": "sodium warfarin", "start": 10, "end": 12}, {"entity_id": "7779233_2_Ent0", "role": "Effect", "text": "necrotizing fasciitis and myonecrosis", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "7779233_2_Ent1", "text": "sodium warfarin", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7779233_2_Ent2", "text": "sodium warfarin", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7779233_2_Ent0", "text": "necrotizing fasciitis and myonecrosis", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "7781845_2", "wnd_id": "7781845_2_1", "text": "Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .", "tokens": ["Quinine", "and", "its", "isomer", "quinidine", "are", "well", "-", "known", "causes", "of", "iatrogenic", "hypoglycaemia", ",", "due", "to", "excessive", "insulin", "secretion", "."], "event_mentions": [{"id": "7781845_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 9, "end": 10}, "arguments": [{"entity_id": "7781845_2_Ent2", "role": "Treatment_Drug", "text": "Quinine", "start": 0, "end": 1}, {"entity_id": "7781845_2_Ent1", "role": "Treatment", "text": "Quinine and its isomer quinidine", "start": 0, "end": 5}, {"entity_id": "7781845_2_Ent0", "role": "Effect", "text": "iatrogenic hypoglycaemia , due to excessive insulin secretion", "start": 11, "end": 19}]}], "entity_mentions": [{"id": "7781845_2_Ent2", "text": "Quinine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7781845_2_Ent1", "text": "Quinine and its isomer quinidine", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7781845_2_Ent0", "text": "iatrogenic hypoglycaemia , due to excessive insulin secretion", "entity_type": "Entity", "start": 11, "end": 19}], "lang": "en"}
{"doc_id": "7783891_2", "wnd_id": "7783891_2_1", "text": "Cardiac arrest following use of sumatriptan .", "tokens": ["Cardiac", "arrest", "following", "use", "of", "sumatriptan", "."], "event_mentions": [{"id": "7783891_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "7783891_2_Ent0", "role": "Effect", "text": "Cardiac arrest", "start": 0, "end": 2}, {"entity_id": "7783891_2_Ent1", "role": "Treatment", "text": "sumatriptan", "start": 5, "end": 6}, {"entity_id": "7783891_2_Ent2", "role": "Treatment_Drug", "text": "sumatriptan", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "7783891_2_Ent0", "text": "Cardiac arrest", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7783891_2_Ent1", "text": "sumatriptan", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7783891_2_Ent2", "text": "sumatriptan", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "7787496_1", "wnd_id": "7787496_1_1", "text": "Sotalol - induced bradycardia reversed by glucagon .", "tokens": ["Sotalol", "-", "induced", "bradycardia", "reversed", "by", "glucagon", "."], "event_mentions": [{"id": "7787496_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "7787496_1_Ent4", "role": "Treatment", "text": "Sotalol", "start": 0, "end": 1}, {"entity_id": "7787496_1_Ent5", "role": "Treatment_Drug", "text": "Sotalol", "start": 0, "end": 1}, {"entity_id": "7787496_1_Ent3", "role": "Effect", "text": "bradycardia", "start": 3, "end": 4}]}, {"id": "7787496_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reversed", "start": 4, "end": 5}, "arguments": [{"entity_id": "7787496_1_Ent1", "role": "Treatment_Disorder", "text": "Sotalol - induced bradycardia", "start": 0, "end": 4}, {"entity_id": "7787496_1_Ent0", "role": "Treatment", "text": "glucagon", "start": 6, "end": 7}, {"entity_id": "7787496_1_Ent2", "role": "Treatment_Drug", "text": "glucagon", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "7787496_1_Ent4", "text": "Sotalol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7787496_1_Ent5", "text": "Sotalol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7787496_1_Ent1", "text": "Sotalol - induced bradycardia", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7787496_1_Ent3", "text": "bradycardia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7787496_1_Ent0", "text": "glucagon", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7787496_1_Ent2", "text": "glucagon", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "7814182_2", "wnd_id": "7814182_2_1", "text": "We present a case in which dipyridamole induced high - grade atrioventricular ( AV ) block that responded promptly to intravenous aminophylline but not to atropine .", "tokens": ["We", "present", "a", "case", "in", "which", "dipyridamole", "induced", "high", "-", "grade", "atrioventricular", "(", "AV", ")", "block", "that", "responded", "promptly", "to", "intravenous", "aminophylline", "but", "not", "to", "atropine", "."], "event_mentions": [{"id": "7814182_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "7814182_2_Ent1", "role": "Treatment", "text": "dipyridamole", "start": 6, "end": 7}, {"entity_id": "7814182_2_Ent2", "role": "Treatment_Drug", "text": "dipyridamole", "start": 6, "end": 7}, {"entity_id": "7814182_2_Ent0", "role": "Effect", "text": "high - grade atrioventricular ( AV ) block", "start": 8, "end": 16}]}, {"id": "7814182_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "responded", "start": 17, "end": 18}, "arguments": [{"entity_id": "7814182_2_Ent6", "role": "Treatment_Disorder", "text": "dipyridamole induced high - grade atrioventricular ( AV ) block", "start": 6, "end": 16}, {"entity_id": "7814182_2_Ent4", "role": "Treatment_Drug", "text": "intravenous aminophylline", "start": 20, "end": 22}, {"entity_id": "7814182_2_Ent3", "role": "Treatment", "text": "intravenous aminophylline but not to atropine", "start": 20, "end": 26}, {"entity_id": "7814182_2_Ent5", "role": "Treatment_Drug", "text": "atropine", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "7814182_2_Ent1", "text": "dipyridamole", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7814182_2_Ent2", "text": "dipyridamole", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7814182_2_Ent6", "text": "dipyridamole induced high - grade atrioventricular ( AV ) block", "entity_type": "Entity", "start": 6, "end": 16}, {"id": "7814182_2_Ent0", "text": "high - grade atrioventricular ( AV ) block", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "7814182_2_Ent4", "text": "intravenous aminophylline", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "7814182_2_Ent3", "text": "intravenous aminophylline but not to atropine", "entity_type": "Entity", "start": 20, "end": 26}, {"id": "7814182_2_Ent5", "text": "atropine", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "7831179_2", "wnd_id": "7831179_2_1", "text": "There is a dose - effect relationship between doxorubicin and the incidence of symptomatic cardiac failure .", "tokens": ["There", "is", "a", "dose", "-", "effect", "relationship", "between", "doxorubicin", "and", "the", "incidence", "of", "symptomatic", "cardiac", "failure", "."], "event_mentions": [{"id": "7831179_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 6, "end": 7}, "arguments": [{"entity_id": "7831179_2_Ent1", "role": "Treatment", "text": "doxorubicin", "start": 8, "end": 9}, {"entity_id": "7831179_2_Ent2", "role": "Treatment_Drug", "text": "doxorubicin", "start": 8, "end": 9}, {"entity_id": "7831179_2_Ent0", "role": "Effect", "text": "symptomatic cardiac failure", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "7831179_2_Ent1", "text": "doxorubicin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7831179_2_Ent2", "text": "doxorubicin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7831179_2_Ent0", "text": "symptomatic cardiac failure", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "7865488_2", "wnd_id": "7865488_2_1", "text": "However , EO - induced noncardiogenic pulmonary edema has not been reported in human .", "tokens": ["However", ",", "EO", "-", "induced", "noncardiogenic", "pulmonary", "edema", "has", "not", "been", "reported", "in", "human", "."], "event_mentions": [{"id": "7865488_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "7865488_2_Ent2", "role": "Treatment", "text": "EO", "start": 2, "end": 3}, {"entity_id": "7865488_2_Ent3", "role": "Treatment_Drug", "text": "EO", "start": 2, "end": 3}, {"entity_id": "7865488_2_Ent1", "role": "Effect", "text": "noncardiogenic pulmonary edema", "start": 5, "end": 8}, {"entity_id": "7865488_2_Ent0", "role": "Subject", "text": "human", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "7865488_2_Ent2", "text": "EO", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7865488_2_Ent3", "text": "EO", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7865488_2_Ent1", "text": "noncardiogenic pulmonary edema", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7865488_2_Ent0", "text": "human", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "788666_2", "wnd_id": "788666_2_1", "text": "Gentamicin - associated acute renal failure .", "tokens": ["Gentamicin", "-", "associated", "acute", "renal", "failure", "."], "event_mentions": [{"id": "788666_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "788666_2_Ent1", "role": "Treatment", "text": "Gentamicin", "start": 0, "end": 1}, {"entity_id": "788666_2_Ent2", "role": "Treatment_Drug", "text": "Gentamicin", "start": 0, "end": 1}, {"entity_id": "788666_2_Ent0", "role": "Effect", "text": "acute renal failure", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "788666_2_Ent1", "text": "Gentamicin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "788666_2_Ent2", "text": "Gentamicin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "788666_2_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "7887138_1", "wnd_id": "7887138_1_1", "text": "A 15 - year follow - up of phenytoin - induced unilateral gingival hyperplasia : a case report .", "tokens": ["A", "15", "-", "year", "follow", "-", "up", "of", "phenytoin", "-", "induced", "unilateral", "gingival", "hyperplasia", ":", "a", "case", "report", "."], "event_mentions": [{"id": "7887138_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "7887138_1_Ent3", "role": "Treatment_Time_elapsed", "text": "15 - year", "start": 1, "end": 4}, {"entity_id": "7887138_1_Ent1", "role": "Treatment", "text": "phenytoin", "start": 8, "end": 9}, {"entity_id": "7887138_1_Ent2", "role": "Treatment_Drug", "text": "phenytoin", "start": 8, "end": 9}, {"entity_id": "7887138_1_Ent0", "role": "Effect", "text": "unilateral gingival hyperplasia", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "7887138_1_Ent3", "text": "15 - year", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "7887138_1_Ent1", "text": "phenytoin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7887138_1_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7887138_1_Ent0", "text": "unilateral gingival hyperplasia", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "7900744_5", "wnd_id": "7900744_5_1", "text": "The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism(s ) of mannitol nephrotoxicity are discussed .", "tokens": ["The", "literature", "is", "also", "reviewed", "for", "ARF", "associated", "with", "mannitol", "infusion", "in", "patients", "who", "received", "dialysis", "and", "those", "who", "did", "not", "receive", "dialysis", ";", "and", "the", "possible", "mechanism(s", ")", "of", "mannitol", "nephrotoxicity", "are", "discussed", "."], "event_mentions": [{"id": "7900744_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "7900744_5_Ent1", "role": "Effect", "text": "ARF", "start": 6, "end": 7}, {"entity_id": "7900744_5_Ent3", "role": "Treatment_Drug", "text": "mannitol", "start": 9, "end": 10}, {"entity_id": "7900744_5_Ent2", "role": "Treatment", "text": "mannitol infusion", "start": 9, "end": 11}, {"entity_id": "7900744_5_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 10, "end": 11}, {"entity_id": "7900744_5_Ent0", "role": "Subject", "text": "patients", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "7900744_5_Ent1", "text": "ARF", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7900744_5_Ent3", "text": "mannitol", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7900744_5_Ent2", "text": "mannitol infusion", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "7900744_5_Ent4", "text": "infusion", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7900744_5_Ent0", "text": "patients", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "7900744_6", "wnd_id": "7900744_6_1", "text": "This is a report of a case of anuric ARF after high - dose mannitol infusion for treatment of narrow - angle glaucoma that readily responded to acute hemodialysis .", "tokens": ["This", "is", "a", "report", "of", "a", "case", "of", "anuric", "ARF", "after", "high", "-", "dose", "mannitol", "infusion", "for", "treatment", "of", "narrow", "-", "angle", "glaucoma", "that", "readily", "responded", "to", "acute", "hemodialysis", "."], "event_mentions": [{"id": "7900744_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 10, "end": 11}, "arguments": [{"entity_id": "7900744_6_Ent0", "role": "Subject", "text": "a case", "start": 5, "end": 7}, {"entity_id": "7900744_6_Ent1", "role": "Effect", "text": "anuric ARF", "start": 8, "end": 10}, {"entity_id": "7900744_6_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 11, "end": 14}, {"entity_id": "7900744_6_Ent2", "role": "Treatment", "text": "high - dose mannitol infusion", "start": 11, "end": 16}, {"entity_id": "7900744_6_Ent3", "role": "Treatment_Drug", "text": "mannitol", "start": 14, "end": 15}, {"entity_id": "7900744_6_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 15, "end": 16}, {"entity_id": "7900744_6_Ent6", "role": "Treatment_Disorder", "text": "narrow - angle glaucoma", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "7900744_6_Ent0", "text": "a case", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "7900744_6_Ent1", "text": "anuric ARF", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7900744_6_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "7900744_6_Ent2", "text": "high - dose mannitol infusion", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "7900744_6_Ent3", "text": "mannitol", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "7900744_6_Ent4", "text": "infusion", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7900744_6_Ent6", "text": "narrow - angle glaucoma", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "7962394_2", "wnd_id": "7962394_2_1", "text": "Additionally , danazol produces hepatocellular damage in approximately 10 % of women .", "tokens": ["Additionally", ",", "danazol", "produces", "hepatocellular", "damage", "in", "approximately", "10", "%", "of", "women", "."], "event_mentions": [{"id": "7962394_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produces", "start": 3, "end": 4}, "arguments": [{"entity_id": "7962394_2_Ent4", "role": "Treatment", "text": "danazol", "start": 2, "end": 3}, {"entity_id": "7962394_2_Ent5", "role": "Treatment_Drug", "text": "danazol", "start": 2, "end": 3}, {"entity_id": "7962394_2_Ent3", "role": "Effect", "text": "hepatocellular damage", "start": 4, "end": 6}, {"entity_id": "7962394_2_Ent1", "role": "Subject_Population", "text": "10 %", "start": 8, "end": 10}, {"entity_id": "7962394_2_Ent0", "role": "Subject", "text": "10 % of women", "start": 8, "end": 12}, {"entity_id": "7962394_2_Ent2", "role": "Subject_Gender", "text": "women", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "7962394_2_Ent4", "text": "danazol", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7962394_2_Ent5", "text": "danazol", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7962394_2_Ent3", "text": "hepatocellular damage", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7962394_2_Ent1", "text": "10 %", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "7962394_2_Ent0", "text": "10 % of women", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "7962394_2_Ent2", "text": "women", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "7973922_2", "wnd_id": "7973922_2_1", "text": "Acyclovir produces neurologic symptoms that resemble extension of viral infection into the central nervous system .", "tokens": ["Acyclovir", "produces", "neurologic", "symptoms", "that", "resemble", "extension", "of", "viral", "infection", "into", "the", "central", "nervous", "system", "."], "event_mentions": [{"id": "7973922_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produces", "start": 1, "end": 2}, "arguments": [{"entity_id": "7973922_2_Ent1", "role": "Treatment", "text": "Acyclovir", "start": 0, "end": 1}, {"entity_id": "7973922_2_Ent2", "role": "Treatment_Drug", "text": "Acyclovir", "start": 0, "end": 1}, {"entity_id": "7973922_2_Ent0", "role": "Effect", "text": "neurologic symptoms", "start": 2, "end": 4}]}], "entity_mentions": [{"id": "7973922_2_Ent1", "text": "Acyclovir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7973922_2_Ent2", "text": "Acyclovir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7973922_2_Ent0", "text": "neurologic symptoms", "entity_type": "Entity", "start": 2, "end": 4}], "lang": "en"}
{"doc_id": "7986915_2", "wnd_id": "7986915_2_1", "text": "We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .", "tokens": ["We", "describe", "a", "patient", "with", "a", "liver", "abscess", "due", "to", "Entamoeba", "histolytica", ",", "in", "whom", "metronidazole", "therapy", "(", "total", "dose", ",", "21", "g", "over", "14", "days", ")", "was", "complicated", "by", "reversible", "deafness", ",", "tinnitus", ",", "and", "ataxia", "and", "who", "relapsed", "5", "months", "later", "with", "a", "splenic", "abscess", "."], "event_mentions": [{"id": "7986915_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicated", "start": 28, "end": 29}, "arguments": [{"entity_id": "7986915_2_Ent0", "role": "Subject", "text": "a patient with a liver abscess due to Entamoeba histolytica", "start": 2, "end": 12}, {"entity_id": "7986915_2_Ent6", "role": "Treatment_Disorder", "text": "liver abscess", "start": 6, "end": 8}, {"entity_id": "7986915_2_Ent7", "role": "Treatment_Disorder", "text": "Entamoeba histolytica", "start": 10, "end": 12}, {"entity_id": "7986915_2_Ent3", "role": "Treatment_Drug", "text": "metronidazole", "start": 15, "end": 16}, {"entity_id": "7986915_2_Ent2", "role": "Treatment", "text": "metronidazole therapy ( total dose , 21 g over 14 days )", "start": 15, "end": 27}, {"entity_id": "7986915_2_Ent4", "role": "Treatment_Dosage", "text": "21 g", "start": 21, "end": 23}, {"entity_id": "7986915_2_Ent5", "role": "Treatment_Duration", "text": "14 days", "start": 24, "end": 26}, {"entity_id": "7986915_2_Ent1", "role": "Effect", "text": "reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess", "start": 30, "end": 47}]}], "entity_mentions": [{"id": "7986915_2_Ent0", "text": "a patient with a liver abscess due to Entamoeba histolytica", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "7986915_2_Ent6", "text": "liver abscess", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "7986915_2_Ent7", "text": "Entamoeba histolytica", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7986915_2_Ent3", "text": "metronidazole", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7986915_2_Ent2", "text": "metronidazole therapy ( total dose , 21 g over 14 days )", "entity_type": "Entity", "start": 15, "end": 27}, {"id": "7986915_2_Ent4", "text": "21 g", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "7986915_2_Ent5", "text": "14 days", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "7986915_2_Ent1", "text": "reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess", "entity_type": "Entity", "start": 30, "end": 47}], "lang": "en"}
{"doc_id": "7995508_2", "wnd_id": "7995508_2_1", "text": "We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .", "tokens": ["We", "report", "a", "cae", "of", "paranoid", "psychosis", "following", "use", "of", "a", "decongestant", "containing", "PPA", "and", "summarize", "the", "case", "report", "literature", "of", "psychiatric", "adverse", "effects", "to", "PPA", "in", "which", "doses", "were", "known", "and", "stated", "to", "be", "within", "recommended", "guidelines", "."], "event_mentions": [{"id": "7995508_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 7, "end": 8}, "arguments": [{"entity_id": "7995508_2_Ent0", "role": "Subject", "text": "a cae", "start": 2, "end": 4}, {"entity_id": "7995508_2_Ent1", "role": "Effect", "text": "paranoid psychosis", "start": 5, "end": 7}, {"entity_id": "7995508_2_Ent2", "role": "Treatment", "text": "decongestant containing PPA", "start": 11, "end": 14}, {"entity_id": "7995508_2_Ent3", "role": "Treatment_Drug", "text": "PPA", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "7995508_2_Ent0", "text": "a cae", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7995508_2_Ent1", "text": "paranoid psychosis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "7995508_2_Ent2", "text": "decongestant containing PPA", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "7995508_2_Ent3", "text": "PPA", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "8038468_2", "wnd_id": "8038468_2_1", "text": "However , prolongation of 5 - FU half - life and an increase in INR have been reported with the concurrent use of 5 - FU and warfarin .", "tokens": ["However", ",", "prolongation", "of", "5", "-", "FU", "half", "-", "life", "and", "an", "increase", "in", "INR", "have", "been", "reported", "with", "the", "concurrent", "use", "of", "5", "-", "FU", "and", "warfarin", "."], "event_mentions": [{"id": "8038468_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 17, "end": 18}, "arguments": [{"entity_id": "8038468_2_Ent0", "role": "Effect", "text": "prolongation of 5 - FU half - life and an increase in INR", "start": 2, "end": 15}, {"entity_id": "8038468_2_Ent1", "role": "Treatment", "text": "the concurrent use of 5 - FU and warfarin", "start": 19, "end": 28}, {"entity_id": "8038468_2_Ent3", "role": "Treatment_Drug", "text": "5 - FU", "start": 23, "end": 26}, {"entity_id": "8038468_2_Ent4", "role": "Combination_Drug", "text": "5 - FU", "start": 23, "end": 26}, {"entity_id": "8038468_2_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 27, "end": 28}, {"entity_id": "8038468_2_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "8038468_2_Ent0", "text": "prolongation of 5 - FU half - life and an increase in INR", "entity_type": "Entity", "start": 2, "end": 15}, {"id": "8038468_2_Ent1", "text": "the concurrent use of 5 - FU and warfarin", "entity_type": "Entity", "start": 19, "end": 28}, {"id": "8038468_2_Ent3", "text": "5 - FU", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "8038468_2_Ent4", "text": "5 - FU", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "8038468_2_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "8038468_2_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "8053440_1", "wnd_id": "8053440_1_1", "text": "Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .", "tokens": ["Cholestatic", "liver", "disease", "with", "ductopenia", "(", "vanishing", "bile", "duct", "syndrome", ")", "after", "administration", "of", "clindamycin", "and", "trimethoprim", "-", "sulfamethoxazole", "."], "event_mentions": [{"id": "8053440_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "8053440_1_Ent0", "role": "Effect", "text": "Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome )", "start": 0, "end": 11}, {"entity_id": "8053440_1_Ent2", "role": "Treatment_Drug", "text": "clindamycin", "start": 14, "end": 15}, {"entity_id": "8053440_1_Ent5", "role": "Combination_Drug", "text": "clindamycin", "start": 14, "end": 15}, {"entity_id": "8053440_1_Ent1", "role": "Treatment", "text": "clindamycin and trimethoprim - sulfamethoxazole", "start": 14, "end": 19}, {"entity_id": "8053440_1_Ent3", "role": "Treatment_Drug", "text": "trimethoprim", "start": 16, "end": 17}, {"entity_id": "8053440_1_Ent7", "role": "Combination_Drug", "text": "trimethoprim", "start": 16, "end": 17}, {"entity_id": "8053440_1_Ent4", "role": "Treatment_Drug", "text": "sulfamethoxazole", "start": 18, "end": 19}, {"entity_id": "8053440_1_Ent6", "role": "Combination_Drug", "text": "sulfamethoxazole", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "8053440_1_Ent0", "text": "Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome )", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "8053440_1_Ent2", "text": "clindamycin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8053440_1_Ent5", "text": "clindamycin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8053440_1_Ent1", "text": "clindamycin and trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "8053440_1_Ent3", "text": "trimethoprim", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8053440_1_Ent7", "text": "trimethoprim", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8053440_1_Ent4", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "8053440_1_Ent6", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "8071504_7", "wnd_id": "8071504_7_1", "text": "RESULTS : Ethambutol , and to a lesser extent isoniazid , are both implicated in the development of visually related side effects .", "tokens": ["RESULTS", ":", "Ethambutol", ",", "and", "to", "a", "lesser", "extent", "isoniazid", ",", "are", "both", "implicated", "in", "the", "development", "of", "visually", "related", "side", "effects", "."], "event_mentions": [{"id": "8071504_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 16, "end": 17}, "arguments": [{"entity_id": "8071504_7_Ent1", "role": "Treatment", "text": "Ethambutol", "start": 2, "end": 3}, {"entity_id": "8071504_7_Ent4", "role": "Treatment_Drug", "text": "Ethambutol", "start": 2, "end": 3}, {"entity_id": "8071504_7_Ent5", "role": "Combination_Drug", "text": "Ethambutol", "start": 2, "end": 3}, {"entity_id": "8071504_7_Ent2", "role": "Treatment", "text": "isoniazid", "start": 9, "end": 10}, {"entity_id": "8071504_7_Ent3", "role": "Treatment_Drug", "text": "isoniazid", "start": 9, "end": 10}, {"entity_id": "8071504_7_Ent6", "role": "Combination_Drug", "text": "isoniazid", "start": 9, "end": 10}, {"entity_id": "8071504_7_Ent0", "role": "Effect", "text": "visually related side effects", "start": 18, "end": 22}]}], "entity_mentions": [{"id": "8071504_7_Ent1", "text": "Ethambutol", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8071504_7_Ent4", "text": "Ethambutol", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8071504_7_Ent5", "text": "Ethambutol", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8071504_7_Ent2", "text": "isoniazid", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8071504_7_Ent3", "text": "isoniazid", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8071504_7_Ent6", "text": "isoniazid", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8071504_7_Ent0", "text": "visually related side effects", "entity_type": "Entity", "start": 18, "end": 22}], "lang": "en"}
{"doc_id": "812008_2", "wnd_id": "812008_2_1", "text": "Significant clinical improvement of the porphyria followed withdrawal of the diphenylhydantoin .", "tokens": ["Significant", "clinical", "improvement", "of", "the", "porphyria", "followed", "withdrawal", "of", "the", "diphenylhydantoin", "."], "event_mentions": [{"id": "812008_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improvement", "start": 2, "end": 3}, "arguments": [{"entity_id": "812008_2_Ent1", "role": "Treatment_Disorder", "text": "porphyria", "start": 5, "end": 6}, {"entity_id": "812008_2_Ent0", "role": "Treatment", "text": "withdrawal of the diphenylhydantoin", "start": 7, "end": 11}, {"entity_id": "812008_2_Ent2", "role": "Treatment_Drug", "text": "diphenylhydantoin", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "812008_2_Ent1", "text": "porphyria", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "812008_2_Ent0", "text": "withdrawal of the diphenylhydantoin", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "812008_2_Ent2", "text": "diphenylhydantoin", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "8140860_2", "wnd_id": "8140860_2_1", "text": "We present the case of a woman undergoing treatment with acenocoumarol for deep vein thrombosis , who maintained an international normalized ratio ( INR ) of between 2.5 and 4 for 2 months .", "tokens": ["We", "present", "the", "case", "of", "a", "woman", "undergoing", "treatment", "with", "acenocoumarol", "for", "deep", "vein", "thrombosis", ",", "who", "maintained", "an", "international", "normalized", "ratio", "(", "INR", ")", "of", "between", "2.5", "and", "4", "for", "2", "months", "."], "event_mentions": [{"id": "8140860_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 8, "end": 9}, "arguments": [{"entity_id": "8140860_2_Ent0", "role": "Subject", "text": "a woman", "start": 5, "end": 7}, {"entity_id": "8140860_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "8140860_2_Ent2", "role": "Treatment", "text": "acenocoumarol", "start": 10, "end": 11}, {"entity_id": "8140860_2_Ent3", "role": "Treatment_Drug", "text": "acenocoumarol", "start": 10, "end": 11}, {"entity_id": "8140860_2_Ent4", "role": "Treatment_Disorder", "text": "deep vein thrombosis", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "8140860_2_Ent0", "text": "a woman", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8140860_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8140860_2_Ent2", "text": "acenocoumarol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8140860_2_Ent3", "text": "acenocoumarol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8140860_2_Ent4", "text": "deep vein thrombosis", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "8145359_2", "wnd_id": "8145359_2_1", "text": "The association of phenothiazine overdose and respiratory distress syndrome merits consideration .", "tokens": ["The", "association", "of", "phenothiazine", "overdose", "and", "respiratory", "distress", "syndrome", "merits", "consideration", "."], "event_mentions": [{"id": "8145359_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 1, "end": 2}, "arguments": [{"entity_id": "8145359_2_Ent2", "role": "Treatment_Drug", "text": "phenothiazine", "start": 3, "end": 4}, {"entity_id": "8145359_2_Ent1", "role": "Treatment", "text": "phenothiazine overdose", "start": 3, "end": 5}, {"entity_id": "8145359_2_Ent3", "role": "Treatment_Dosage", "text": "overdose", "start": 4, "end": 5}, {"entity_id": "8145359_2_Ent0", "role": "Effect", "text": "respiratory distress syndrome", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "8145359_2_Ent2", "text": "phenothiazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8145359_2_Ent1", "text": "phenothiazine overdose", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8145359_2_Ent3", "text": "overdose", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8145359_2_Ent0", "text": "respiratory distress syndrome", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "8162401_2", "wnd_id": "8162401_2_1", "text": "Seizures associated with fluoxetine therapy are uncommon .", "tokens": ["Seizures", "associated", "with", "fluoxetine", "therapy", "are", "uncommon", "."], "event_mentions": [{"id": "8162401_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "8162401_2_Ent0", "role": "Effect", "text": "Seizures", "start": 0, "end": 1}, {"entity_id": "8162401_2_Ent2", "role": "Treatment_Drug", "text": "fluoxetine", "start": 3, "end": 4}, {"entity_id": "8162401_2_Ent1", "role": "Treatment", "text": "fluoxetine therapy", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "8162401_2_Ent0", "text": "Seizures", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8162401_2_Ent2", "text": "fluoxetine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8162401_2_Ent1", "text": "fluoxetine therapy", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "8186884_3", "wnd_id": "8186884_3_1", "text": "The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of , or idiosyncratic response to , procainamide .", "tokens": ["The", "failure", "of", "therapy", "with", "disopyramide", "and", "mexiletine", "to", "reproduce", "this", "observation", "suggests", "either", "a", "previously", "unreported", "electrophysiologic", "effect", "of", ",", "or", "idiosyncratic", "response", "to", ",", "procainamide", "."], "event_mentions": [{"id": "8186884_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "response", "start": 23, "end": 24}, "arguments": [{"entity_id": "8186884_3_Ent0", "role": "Effect", "text": "electrophysiologic effect", "start": 17, "end": 19}, {"entity_id": "8186884_3_Ent1", "role": "Treatment", "text": "procainamide", "start": 26, "end": 27}, {"entity_id": "8186884_3_Ent2", "role": "Treatment_Drug", "text": "procainamide", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "8186884_3_Ent0", "text": "electrophysiologic effect", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "8186884_3_Ent1", "text": "procainamide", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "8186884_3_Ent2", "text": "procainamide", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "8192712_1", "wnd_id": "8192712_1_1", "text": "Based on our experience and on previously published data , serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status .", "tokens": ["Based", "on", "our", "experience", "and", "on", "previously", "published", "data", ",", "serum", "ammonia", "levels", "appear", "to", "be", "indicated", "in", "all", "ED", "patients", "on", "valproic", "acid", "therapy", "who", "present", "with", "altered", "mental", "status", "."], "event_mentions": [{"id": "8192712_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "present", "start": 26, "end": 27}, "arguments": [{"entity_id": "8192712_1_Ent0", "role": "Subject", "text": "all ED patients", "start": 18, "end": 21}, {"entity_id": "8192712_1_Ent3", "role": "Treatment_Disorder", "text": "ED", "start": 19, "end": 20}, {"entity_id": "8192712_1_Ent4", "role": "Treatment_Drug", "text": "valproic acid", "start": 22, "end": 24}, {"entity_id": "8192712_1_Ent2", "role": "Treatment", "text": "valproic acid therapy", "start": 22, "end": 25}, {"entity_id": "8192712_1_Ent1", "role": "Effect", "text": "altered mental status", "start": 28, "end": 31}]}], "entity_mentions": [{"id": "8192712_1_Ent0", "text": "all ED patients", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "8192712_1_Ent3", "text": "ED", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8192712_1_Ent4", "text": "valproic acid", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "8192712_1_Ent2", "text": "valproic acid therapy", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "8192712_1_Ent1", "text": "altered mental status", "entity_type": "Entity", "start": 28, "end": 31}], "lang": "en"}
{"doc_id": "8222875_1", "wnd_id": "8222875_1_1", "text": "Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .", "tokens": ["Mitomycin", "C", "(", "MMC", ")", "is", "an", "alkylating", "agent", "that", "has", "been", "recently", "associated", "with", "the", "hemolytic", "-", "uremic", "syndrome", "(", "HUS", ")", "."], "event_mentions": [{"id": "8222875_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "8222875_1_Ent2", "role": "Treatment_Drug", "text": "Mitomycin C", "start": 0, "end": 2}, {"entity_id": "8222875_1_Ent1", "role": "Treatment", "text": "Mitomycin C ( MMC )", "start": 0, "end": 5}, {"entity_id": "8222875_1_Ent0", "role": "Effect", "text": "the hemolytic - uremic syndrome ( HUS )", "start": 15, "end": 23}]}], "entity_mentions": [{"id": "8222875_1_Ent2", "text": "Mitomycin C", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8222875_1_Ent1", "text": "Mitomycin C ( MMC )", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8222875_1_Ent0", "text": "the hemolytic - uremic syndrome ( HUS )", "entity_type": "Entity", "start": 15, "end": 23}], "lang": "en"}
{"doc_id": "8239963_1", "wnd_id": "8239963_1_1", "text": "Clonidine - induced bradycardia in patients with spinal cord injury .", "tokens": ["Clonidine", "-", "induced", "bradycardia", "in", "patients", "with", "spinal", "cord", "injury", "."], "event_mentions": [{"id": "8239963_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8239963_1_Ent2", "role": "Treatment", "text": "Clonidine", "start": 0, "end": 1}, {"entity_id": "8239963_1_Ent4", "role": "Treatment_Drug", "text": "Clonidine", "start": 0, "end": 1}, {"entity_id": "8239963_1_Ent1", "role": "Effect", "text": "bradycardia", "start": 3, "end": 4}, {"entity_id": "8239963_1_Ent0", "role": "Subject", "text": "patients with spinal cord injury", "start": 5, "end": 10}, {"entity_id": "8239963_1_Ent3", "role": "Treatment_Disorder", "text": "spinal cord injury", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "8239963_1_Ent2", "text": "Clonidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8239963_1_Ent4", "text": "Clonidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8239963_1_Ent1", "text": "bradycardia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8239963_1_Ent0", "text": "patients with spinal cord injury", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "8239963_1_Ent3", "text": "spinal cord injury", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "8244201_1", "wnd_id": "8244201_1_1", "text": "A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .", "tokens": ["A", "high", "dose", "of", "cotrimoxazole", "induced", "hyperkalaemia", "with", "the", "elevation", "of", "serum", "creatinine", "and", "blood", "urea", ",", "and", "increased", "urinary", "N", "-", "acetyl", "glucosaminase", "after", "several", "days", "of", "the", "drug", "administration", "in", "these", "patients", ";", "one", "patient", "became", "unconscious", "."], "event_mentions": [{"id": "8244201_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "8244201_1_Ent2", "role": "Treatment", "text": "A high dose of cotrimoxazole", "start": 0, "end": 5}, {"entity_id": "8244201_1_Ent4", "role": "Treatment_Dosage", "text": "high dose", "start": 1, "end": 3}, {"entity_id": "8244201_1_Ent5", "role": "Treatment_Drug", "text": "cotrimoxazole", "start": 4, "end": 5}, {"entity_id": "8244201_1_Ent1", "role": "Effect", "text": "hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase", "start": 6, "end": 24}, {"entity_id": "8244201_1_Ent3", "role": "Treatment", "text": "after several days of the drug administration", "start": 24, "end": 31}, {"entity_id": "8244201_1_Ent6", "role": "Treatment_Time_elapsed", "text": "several days", "start": 25, "end": 27}, {"entity_id": "8244201_1_Ent0", "role": "Subject", "text": "these patients", "start": 32, "end": 34}]}, {"id": "8244201_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "became", "start": 37, "end": 38}, "arguments": [{"entity_id": "8244201_1_Ent10", "role": "Treatment", "text": "A high dose of cotrimoxazole", "start": 0, "end": 5}, {"entity_id": "8244201_1_Ent12", "role": "Treatment_Dosage", "text": "high dose", "start": 1, "end": 3}, {"entity_id": "8244201_1_Ent13", "role": "Treatment_Drug", "text": "cotrimoxazole", "start": 4, "end": 5}, {"entity_id": "8244201_1_Ent11", "role": "Treatment", "text": "after several days of the drug administration", "start": 24, "end": 31}, {"entity_id": "8244201_1_Ent14", "role": "Treatment_Time_elapsed", "text": "several days", "start": 25, "end": 27}, {"entity_id": "8244201_1_Ent8", "role": "Subject_Population", "text": "one", "start": 35, "end": 36}, {"entity_id": "8244201_1_Ent7", "role": "Subject", "text": "one patient", "start": 35, "end": 37}, {"entity_id": "8244201_1_Ent9", "role": "Effect", "text": "unconscious", "start": 38, "end": 39}]}], "entity_mentions": [{"id": "8244201_1_Ent2", "text": "A high dose of cotrimoxazole", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8244201_1_Ent10", "text": "A high dose of cotrimoxazole", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8244201_1_Ent4", "text": "high dose", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8244201_1_Ent12", "text": "high dose", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8244201_1_Ent5", "text": "cotrimoxazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8244201_1_Ent13", "text": "cotrimoxazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8244201_1_Ent1", "text": "hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase", "entity_type": "Entity", "start": 6, "end": 24}, {"id": "8244201_1_Ent3", "text": "after several days of the drug administration", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "8244201_1_Ent11", "text": "after several days of the drug administration", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "8244201_1_Ent6", "text": "several days", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "8244201_1_Ent14", "text": "several days", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "8244201_1_Ent0", "text": "these patients", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "8244201_1_Ent8", "text": "one", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "8244201_1_Ent7", "text": "one patient", "entity_type": "Entity", "start": 35, "end": 37}, {"id": "8244201_1_Ent9", "text": "unconscious", "entity_type": "Entity", "start": 38, "end": 39}], "lang": "en"}
{"doc_id": "8250714_2", "wnd_id": "8250714_2_1", "text": "Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency .", "tokens": ["Neurologic", "degeneration", "associated", "with", "nitrous", "oxide", "anesthesia", "in", "patients", "with", "vitamin", "B12", "deficiency", "."], "event_mentions": [{"id": "8250714_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "8250714_2_Ent2", "role": "Effect", "text": "Neurologic degeneration", "start": 0, "end": 2}, {"entity_id": "8250714_2_Ent4", "role": "Treatment_Drug", "text": "nitrous oxide", "start": 4, "end": 6}, {"entity_id": "8250714_2_Ent3", "role": "Treatment", "text": "nitrous oxide anesthesia", "start": 4, "end": 7}, {"entity_id": "8250714_2_Ent0", "role": "Subject", "text": "patients with vitamin B12 deficiency", "start": 8, "end": 13}, {"entity_id": "8250714_2_Ent1", "role": "Subject_Disorder", "text": "vitamin B12 deficiency", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "8250714_2_Ent2", "text": "Neurologic degeneration", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8250714_2_Ent4", "text": "nitrous oxide", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8250714_2_Ent3", "text": "nitrous oxide anesthesia", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8250714_2_Ent0", "text": "patients with vitamin B12 deficiency", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "8250714_2_Ent1", "text": "vitamin B12 deficiency", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "8266863_1", "wnd_id": "8266863_1_1", "text": "Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .", "tokens": ["Four", "days", "after", "the", "initial", "injection", "of", "3.6", "mg", "of", "goserelin", "acetate", ",", "severe", "dyspnea", "developed", "due", "to", "worsening", "pleuritis", "carcinomatosa", ",", "which", "was", "considered", "as", "a", "flare", "-", "up", "."], "event_mentions": [{"id": "8266863_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "8266863_1_Ent3", "role": "Treatment_Route", "text": "injection", "start": 5, "end": 6}, {"entity_id": "8266863_1_Ent2", "role": "Treatment", "text": "injection of 3.6 mg of goserelin acetate", "start": 5, "end": 12}, {"entity_id": "8266863_1_Ent4", "role": "Treatment_Dosage", "text": "3.6 mg", "start": 7, "end": 9}, {"entity_id": "8266863_1_Ent5", "role": "Treatment_Drug", "text": "goserelin acetate", "start": 10, "end": 12}, {"entity_id": "8266863_1_Ent0", "role": "Effect", "text": "severe dyspnea", "start": 13, "end": 15}, {"entity_id": "8266863_1_Ent1", "role": "Effect", "text": "worsening pleuritis carcinomatosa", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "8266863_1_Ent3", "text": "injection", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8266863_1_Ent2", "text": "injection of 3.6 mg of goserelin acetate", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "8266863_1_Ent4", "text": "3.6 mg", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "8266863_1_Ent5", "text": "goserelin acetate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "8266863_1_Ent0", "text": "severe dyspnea", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8266863_1_Ent1", "text": "worsening pleuritis carcinomatosa", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "8308951_2", "wnd_id": "8308951_2_1", "text": "A case of intercerebral hematoma due to warfarin - induced coagulopathy is presented .", "tokens": ["A", "case", "of", "intercerebral", "hematoma", "due", "to", "warfarin", "-", "induced", "coagulopathy", "is", "presented", "."], "event_mentions": [{"id": "8308951_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "8308951_2_Ent1", "role": "Effect", "text": "intercerebral hematoma", "start": 3, "end": 5}, {"entity_id": "8308951_2_Ent2", "role": "Treatment", "text": "warfarin", "start": 7, "end": 8}, {"entity_id": "8308951_2_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 7, "end": 8}, {"entity_id": "8308951_2_Ent0", "role": "Effect", "text": "coagulopathy", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "8308951_2_Ent1", "text": "intercerebral hematoma", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8308951_2_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8308951_2_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8308951_2_Ent0", "text": "coagulopathy", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "8308951_4", "wnd_id": "8308951_4_1", "text": "Percutaneous absorption of warfarin causing coagulopathy , reported three times in the past , is a significant risk if protective measures , such as gloves , are not used .", "tokens": ["Percutaneous", "absorption", "of", "warfarin", "causing", "coagulopathy", ",", "reported", "three", "times", "in", "the", "past", ",", "is", "a", "significant", "risk", "if", "protective", "measures", ",", "such", "as", "gloves", ",", "are", "not", "used", "."], "event_mentions": [{"id": "8308951_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 4, "end": 5}, "arguments": [{"entity_id": "8308951_4_Ent3", "role": "Treatment_Route", "text": "Percutaneous absorption", "start": 0, "end": 2}, {"entity_id": "8308951_4_Ent1", "role": "Treatment", "text": "Percutaneous absorption of warfarin", "start": 0, "end": 4}, {"entity_id": "8308951_4_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 3, "end": 4}, {"entity_id": "8308951_4_Ent0", "role": "Effect", "text": "coagulopathy", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "8308951_4_Ent3", "text": "Percutaneous absorption", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8308951_4_Ent1", "text": "Percutaneous absorption of warfarin", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8308951_4_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8308951_4_Ent0", "text": "coagulopathy", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "8313300_8", "wnd_id": "8313300_8_1", "text": "Regression of thyrotoxic ophthalmopathy following lithium withdrawal .", "tokens": ["Regression", "of", "thyrotoxic", "ophthalmopathy", "following", "lithium", "withdrawal", "."], "event_mentions": [{"id": "8313300_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Regression", "start": 0, "end": 1}, "arguments": [{"entity_id": "8313300_8_Ent2", "role": "Treatment_Disorder", "text": "thyrotoxic ophthalmopathy", "start": 2, "end": 4}, {"entity_id": "8313300_8_Ent1", "role": "Treatment_Drug", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "8313300_8_Ent0", "role": "Treatment", "text": "lithium withdrawal", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "8313300_8_Ent2", "text": "thyrotoxic ophthalmopathy", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8313300_8_Ent1", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8313300_8_Ent0", "text": "lithium withdrawal", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "8313300_9", "wnd_id": "8313300_9_1", "text": "The exophthalmos improved dramatically within 72 hours of the withdrawal of lithium .", "tokens": ["The", "exophthalmos", "improved", "dramatically", "within", "72", "hours", "of", "the", "withdrawal", "of", "lithium", "."], "event_mentions": [{"id": "8313300_9_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improved", "start": 2, "end": 3}, "arguments": [{"entity_id": "8313300_9_Ent1", "role": "Treatment_Disorder", "text": "exophthalmos", "start": 1, "end": 2}, {"entity_id": "8313300_9_Ent3", "role": "Treatment_Time_elapsed", "text": "within 72 hours", "start": 4, "end": 7}, {"entity_id": "8313300_9_Ent0", "role": "Treatment", "text": "within 72 hours of the withdrawal of lithium", "start": 4, "end": 12}, {"entity_id": "8313300_9_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8313300_9_Ent1", "text": "exophthalmos", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8313300_9_Ent3", "text": "within 72 hours", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8313300_9_Ent0", "text": "within 72 hours of the withdrawal of lithium", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "8313300_9_Ent2", "text": "lithium", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8329789_1", "wnd_id": "8329789_1_1", "text": "Amphotericin B overdose in pediatric patients with associated cardiac arrest .", "tokens": ["Amphotericin", "B", "overdose", "in", "pediatric", "patients", "with", "associated", "cardiac", "arrest", "."], "event_mentions": [{"id": "8329789_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "8329789_1_Ent4", "role": "Treatment_Drug", "text": "Amphotericin B", "start": 0, "end": 2}, {"entity_id": "8329789_1_Ent3", "role": "Treatment", "text": "Amphotericin B overdose", "start": 0, "end": 3}, {"entity_id": "8329789_1_Ent5", "role": "Treatment_Dosage", "text": "overdose", "start": 2, "end": 3}, {"entity_id": "8329789_1_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 4, "end": 5}, {"entity_id": "8329789_1_Ent0", "role": "Subject", "text": "pediatric patients", "start": 4, "end": 6}, {"entity_id": "8329789_1_Ent2", "role": "Effect", "text": "cardiac arrest", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "8329789_1_Ent4", "text": "Amphotericin B", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8329789_1_Ent3", "text": "Amphotericin B overdose", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8329789_1_Ent5", "text": "overdose", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8329789_1_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8329789_1_Ent0", "text": "pediatric patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8329789_1_Ent2", "text": "cardiac arrest", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "8329789_9", "wnd_id": "8329789_9_1", "text": "CONCLUSIONS : Amphotericin B overdose can be fatal in children and infants .", "tokens": ["CONCLUSIONS", ":", "Amphotericin", "B", "overdose", "can", "be", "fatal", "in", "children", "and", "infants", "."], "event_mentions": [{"id": "8329789_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "be", "start": 6, "end": 7}, "arguments": [{"entity_id": "8329789_9_Ent4", "role": "Treatment_Drug", "text": "Amphotericin B", "start": 2, "end": 4}, {"entity_id": "8329789_9_Ent3", "role": "Treatment", "text": "Amphotericin B overdose", "start": 2, "end": 5}, {"entity_id": "8329789_9_Ent5", "role": "Treatment_Dosage", "text": "overdose", "start": 4, "end": 5}, {"entity_id": "8329789_9_Ent1", "role": "Subject_Age", "text": "children", "start": 9, "end": 10}, {"entity_id": "8329789_9_Ent0", "role": "Subject", "text": "children and infants", "start": 9, "end": 12}, {"entity_id": "8329789_9_Ent2", "role": "Subject_Age", "text": "infants", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8329789_9_Ent4", "text": "Amphotericin B", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8329789_9_Ent3", "text": "Amphotericin B overdose", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "8329789_9_Ent5", "text": "overdose", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8329789_9_Ent1", "text": "children", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8329789_9_Ent0", "text": "children and infants", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8329789_9_Ent2", "text": "infants", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8363533_1", "wnd_id": "8363533_1_1", "text": "Albeit rare among Western patients , such lithium - associated thyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese .", "tokens": ["Albeit", "rare", "among", "Western", "patients", ",", "such", "lithium", "-", "associated", "thyroid", "dysfunctions", "appeared", "to", "be", "more", "likely", "to", "occur", "in", "Hong", "Kong", "Chinese", "."], "event_mentions": [{"id": "8363533_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "8363533_1_Ent3", "role": "Treatment", "text": "lithium", "start": 7, "end": 8}, {"entity_id": "8363533_1_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 7, "end": 8}, {"entity_id": "8363533_1_Ent2", "role": "Effect", "text": "thyroid dysfunctions", "start": 10, "end": 12}, {"entity_id": "8363533_1_Ent0", "role": "Subject", "text": "Hong Kong Chinese", "start": 20, "end": 23}, {"entity_id": "8363533_1_Ent1", "role": "Subject_Race", "text": "Hong Kong Chinese", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "8363533_1_Ent3", "text": "lithium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8363533_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8363533_1_Ent2", "text": "thyroid dysfunctions", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "8363533_1_Ent0", "text": "Hong Kong Chinese", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "8363533_1_Ent1", "text": "Hong Kong Chinese", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "8363533_2", "wnd_id": "8363533_2_1", "text": "Four Chinese female patients who suffered from manic - depressive disorder and underlying autoimmune thyroiditis developed transient episodes of thyrotoxicosis during maintenance lithium therapy .", "tokens": ["Four", "Chinese", "female", "patients", "who", "suffered", "from", "manic", "-", "depressive", "disorder", "and", "underlying", "autoimmune", "thyroiditis", "developed", "transient", "episodes", "of", "thyrotoxicosis", "during", "maintenance", "lithium", "therapy", "."], "event_mentions": [{"id": "8363533_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 20, "end": 21}, "arguments": [{"entity_id": "8363533_2_Ent1", "role": "Subject_Population", "text": "Four", "start": 0, "end": 1}, {"entity_id": "8363533_2_Ent0", "role": "Subject", "text": "Four Chinese female patients who suffered from manic - depressive disorder and underlying autoimmune thyroiditis", "start": 0, "end": 15}, {"entity_id": "8363533_2_Ent2", "role": "Subject_Race", "text": "Chinese", "start": 1, "end": 2}, {"entity_id": "8363533_2_Ent3", "role": "Subject_Gender", "text": "female", "start": 2, "end": 3}, {"entity_id": "8363533_2_Ent7", "role": "Treatment_Disorder", "text": "manic - depressive disorder", "start": 7, "end": 11}, {"entity_id": "8363533_2_Ent4", "role": "Subject_Disorder", "text": "underlying autoimmune thyroiditis", "start": 12, "end": 15}, {"entity_id": "8363533_2_Ent5", "role": "Effect", "text": "transient episodes of thyrotoxicosis", "start": 16, "end": 20}, {"entity_id": "8363533_2_Ent6", "role": "Treatment", "text": "maintenance lithium therapy", "start": 21, "end": 24}, {"entity_id": "8363533_2_Ent8", "role": "Treatment_Drug", "text": "lithium", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "8363533_2_Ent1", "text": "Four", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8363533_2_Ent0", "text": "Four Chinese female patients who suffered from manic - depressive disorder and underlying autoimmune thyroiditis", "entity_type": "Entity", "start": 0, "end": 15}, {"id": "8363533_2_Ent2", "text": "Chinese", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8363533_2_Ent3", "text": "female", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8363533_2_Ent7", "text": "manic - depressive disorder", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "8363533_2_Ent4", "text": "underlying autoimmune thyroiditis", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "8363533_2_Ent5", "text": "transient episodes of thyrotoxicosis", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "8363533_2_Ent6", "text": "maintenance lithium therapy", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "8363533_2_Ent8", "text": "lithium", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "8384030_5", "wnd_id": "8384030_5_1", "text": "The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .", "tokens": ["The", "patient", "experienced", "muscle", "twitches", ",", "tremulousness", ",", "and", "anxiety", "on", "day", "17", "of", "foscarnet", "therapy", "."], "event_mentions": [{"id": "8384030_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8384030_5_Ent0", "role": "Subject", "text": "patient", "start": 1, "end": 2}, {"entity_id": "8384030_5_Ent1", "role": "Effect", "text": "muscle twitches , tremulousness , and anxiety", "start": 3, "end": 10}, {"entity_id": "8384030_5_Ent4", "role": "Treatment_Time_elapsed", "text": "on day 17", "start": 10, "end": 13}, {"entity_id": "8384030_5_Ent3", "role": "Treatment_Drug", "text": "foscarnet", "start": 14, "end": 15}, {"entity_id": "8384030_5_Ent2", "role": "Treatment", "text": "foscarnet therapy", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "8384030_5_Ent0", "text": "patient", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8384030_5_Ent1", "text": "muscle twitches , tremulousness , and anxiety", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "8384030_5_Ent4", "text": "on day 17", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "8384030_5_Ent3", "text": "foscarnet", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8384030_5_Ent2", "text": "foscarnet therapy", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "8404753_1", "wnd_id": "8404753_1_1", "text": "Carbamazepine - induced tics .", "tokens": ["Carbamazepine", "-", "induced", "tics", "."], "event_mentions": [{"id": "8404753_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8404753_1_Ent1", "role": "Treatment", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "8404753_1_Ent2", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "8404753_1_Ent0", "role": "Effect", "text": "tics", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "8404753_1_Ent1", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8404753_1_Ent2", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8404753_1_Ent0", "text": "tics", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "8430717_1", "wnd_id": "8430717_1_1", "text": "Acyclovir - induced neurotoxicity : concentration - side effect relationship in acyclovir overdose .", "tokens": ["Acyclovir", "-", "induced", "neurotoxicity", ":", "concentration", "-", "side", "effect", "relationship", "in", "acyclovir", "overdose", "."], "event_mentions": [{"id": "8430717_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8430717_1_Ent1", "role": "Treatment", "text": "Acyclovir", "start": 0, "end": 1}, {"entity_id": "8430717_1_Ent2", "role": "Treatment_Drug", "text": "Acyclovir", "start": 0, "end": 1}, {"entity_id": "8430717_1_Ent0", "role": "Effect", "text": "neurotoxicity", "start": 3, "end": 4}, {"entity_id": "8430717_1_Ent3", "role": "Treatment_Dosage", "text": "overdose", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "8430717_1_Ent1", "text": "Acyclovir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8430717_1_Ent2", "text": "Acyclovir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8430717_1_Ent0", "text": "neurotoxicity", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8430717_1_Ent3", "text": "overdose", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "8442800_2", "wnd_id": "8442800_2_1", "text": "Disulfiram has been used effectively to deter alcohol consumption in patients with a history of alcohol abuse .", "tokens": ["Disulfiram", "has", "been", "used", "effectively", "to", "deter", "alcohol", "consumption", "in", "patients", "with", "a", "history", "of", "alcohol", "abuse", "."], "event_mentions": [{"id": "8442800_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 3, "end": 4}, "arguments": [{"entity_id": "8442800_2_Ent1", "role": "Treatment", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "8442800_2_Ent2", "role": "Treatment_Drug", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "8442800_2_Ent0", "role": "Subject", "text": "patients with a history of alcohol abuse", "start": 10, "end": 17}, {"entity_id": "8442800_2_Ent3", "role": "Treatment_Disorder", "text": "history of alcohol abuse", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "8442800_2_Ent1", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8442800_2_Ent2", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8442800_2_Ent0", "text": "patients with a history of alcohol abuse", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "8442800_2_Ent3", "text": "history of alcohol abuse", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "8467620_2", "wnd_id": "8467620_2_1", "text": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases , but coincidence can not be excluded .", "tokens": ["The", "mild", "immunosuppression", "that", "occurs", "with", "methotrexate", "therapy", "probably", "places", "patients", "with", "rheumatoid", "arthritis", "at", "added", "risk", "of", "developing", "lymphoproliferative", "diseases", ",", "but", "coincidence", "can", "not", "be", "excluded", "."], "event_mentions": [{"id": "8467620_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 18, "end": 19}, "arguments": [{"entity_id": "8467620_2_Ent1", "role": "Effect", "text": "mild immunosuppression", "start": 1, "end": 3}, {"entity_id": "8467620_2_Ent3", "role": "Treatment", "text": "methotrexate", "start": 6, "end": 7}, {"entity_id": "8467620_2_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 6, "end": 7}, {"entity_id": "8467620_2_Ent0", "role": "Subject", "text": "patients with rheumatoid arthritis", "start": 10, "end": 14}, {"entity_id": "8467620_2_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 12, "end": 14}, {"entity_id": "8467620_2_Ent2", "role": "Effect", "text": "lymphoproliferative diseases", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "8467620_2_Ent1", "text": "mild immunosuppression", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8467620_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8467620_2_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8467620_2_Ent0", "text": "patients with rheumatoid arthritis", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "8467620_2_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "8467620_2_Ent2", "text": "lymphoproliferative diseases", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "8496127_1", "wnd_id": "8496127_1_1", "text": "Acute dystonic reaction with low - dose pimozide .", "tokens": ["Acute", "dystonic", "reaction", "with", "low", "-", "dose", "pimozide", "."], "event_mentions": [{"id": "8496127_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 3, "end": 4}, "arguments": [{"entity_id": "8496127_1_Ent0", "role": "Effect", "text": "Acute dystonic reaction", "start": 0, "end": 3}, {"entity_id": "8496127_1_Ent2", "role": "Treatment_Dosage", "text": "low - dose", "start": 4, "end": 7}, {"entity_id": "8496127_1_Ent1", "role": "Treatment", "text": "low - dose pimozide", "start": 4, "end": 8}, {"entity_id": "8496127_1_Ent3", "role": "Treatment_Drug", "text": "pimozide", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "8496127_1_Ent0", "text": "Acute dystonic reaction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8496127_1_Ent2", "text": "low - dose", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8496127_1_Ent1", "text": "low - dose pimozide", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "8496127_1_Ent3", "text": "pimozide", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "8523340_1", "wnd_id": "8523340_1_1", "text": "All developed mucocutaneous side effects within 20 weeks of beginning i m gold therapy , at a time when RA had improved markedly compared to pretreatment status .", "tokens": ["All", "developed", "mucocutaneous", "side", "effects", "within", "20", "weeks", "of", "beginning", "i", "m", "gold", "therapy", ",", "at", "a", "time", "when", "RA", "had", "improved", "markedly", "compared", "to", "pretreatment", "status", "."], "event_mentions": [{"id": "8523340_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "beginning", "start": 9, "end": 10}, "arguments": [{"entity_id": "8523340_1_Ent0", "role": "Effect", "text": "mucocutaneous side effects", "start": 2, "end": 5}, {"entity_id": "8523340_1_Ent4", "role": "Treatment_Time_elapsed", "text": "within 20 weeks", "start": 5, "end": 8}, {"entity_id": "8523340_1_Ent3", "role": "Treatment_Route", "text": "i m", "start": 10, "end": 12}, {"entity_id": "8523340_1_Ent1", "role": "Treatment", "text": "i m gold therapy", "start": 10, "end": 14}, {"entity_id": "8523340_1_Ent2", "role": "Treatment_Drug", "text": "gold", "start": 12, "end": 13}, {"entity_id": "8523340_1_Ent5", "role": "Treatment_Disorder", "text": "RA", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "8523340_1_Ent0", "text": "mucocutaneous side effects", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "8523340_1_Ent4", "text": "within 20 weeks", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8523340_1_Ent3", "text": "i m", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "8523340_1_Ent1", "text": "i m gold therapy", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "8523340_1_Ent2", "text": "gold", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8523340_1_Ent5", "text": "RA", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "8530331_6", "wnd_id": "8530331_6_1", "text": "Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .", "tokens": ["Two", "of", "the", "five", "patients", "who", "worsened", "motorically", "also", "developed", "encephalopathy", "during", "risperidone", "treatment", ";", "the", "encephalopathy", "resolved", "when", "the", "patients", "were", "switched", "to", "clozapine", "treatment", "."], "event_mentions": [{"id": "8530331_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "8530331_6_Ent1", "role": "Subject_Population", "text": "Two of the five", "start": 0, "end": 4}, {"entity_id": "8530331_6_Ent0", "role": "Subject", "text": "Two of the five patients who worsened motorically", "start": 0, "end": 8}, {"entity_id": "8530331_6_Ent2", "role": "Subject_Disorder", "text": "worsened motorically", "start": 6, "end": 8}, {"entity_id": "8530331_6_Ent3", "role": "Effect", "text": "encephalopathy", "start": 10, "end": 11}, {"entity_id": "8530331_6_Ent5", "role": "Treatment_Drug", "text": "risperidone", "start": 12, "end": 13}, {"entity_id": "8530331_6_Ent4", "role": "Treatment", "text": "risperidone treatment", "start": 12, "end": 14}]}, {"id": "8530331_6_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 17, "end": 18}, "arguments": [{"entity_id": "8530331_6_Ent7", "role": "Subject_Population", "text": "Two of the five", "start": 0, "end": 4}, {"entity_id": "8530331_6_Ent6", "role": "Subject", "text": "Two of the five patients who worsened motorically", "start": 0, "end": 8}, {"entity_id": "8530331_6_Ent8", "role": "Subject_Disorder", "text": "worsened motorically", "start": 6, "end": 8}, {"entity_id": "8530331_6_Ent10", "role": "Treatment_Disorder", "text": "encephalopathy", "start": 16, "end": 17}, {"entity_id": "8530331_6_Ent9", "role": "Treatment", "text": "switched to clozapine treatment", "start": 22, "end": 26}, {"entity_id": "8530331_6_Ent11", "role": "Treatment_Drug", "text": "clozapine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "8530331_6_Ent1", "text": "Two of the five", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8530331_6_Ent7", "text": "Two of the five", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8530331_6_Ent0", "text": "Two of the five patients who worsened motorically", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "8530331_6_Ent6", "text": "Two of the five patients who worsened motorically", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "8530331_6_Ent2", "text": "worsened motorically", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8530331_6_Ent8", "text": "worsened motorically", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8530331_6_Ent3", "text": "encephalopathy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8530331_6_Ent5", "text": "risperidone", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8530331_6_Ent4", "text": "risperidone treatment", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "8530331_6_Ent10", "text": "encephalopathy", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8530331_6_Ent9", "text": "switched to clozapine treatment", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "8530331_6_Ent11", "text": "clozapine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "8551001_2", "wnd_id": "8551001_2_1", "text": "Azathioprine - induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis .", "tokens": ["Azathioprine", "-", "induced", "myelosuppression", "due", "to", "thiopurine", "methyltransferase", "deficiency", "in", "a", "patient", "with", "autoimmune", "hepatitis", "."], "event_mentions": [{"id": "8551001_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8551001_2_Ent2", "role": "Treatment", "text": "Azathioprine", "start": 0, "end": 1}, {"entity_id": "8551001_2_Ent5", "role": "Treatment_Drug", "text": "Azathioprine", "start": 0, "end": 1}, {"entity_id": "8551001_2_Ent1", "role": "Effect", "text": "myelosuppression", "start": 3, "end": 4}, {"entity_id": "8551001_2_Ent3", "role": "Treatment_Disorder", "text": "thiopurine methyltransferase deficiency", "start": 6, "end": 9}, {"entity_id": "8551001_2_Ent0", "role": "Subject", "text": "a patient with autoimmune hepatitis", "start": 10, "end": 15}, {"entity_id": "8551001_2_Ent4", "role": "Treatment_Disorder", "text": "autoimmune hepatitis", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "8551001_2_Ent2", "text": "Azathioprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8551001_2_Ent5", "text": "Azathioprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8551001_2_Ent1", "text": "myelosuppression", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8551001_2_Ent3", "text": "thiopurine methyltransferase deficiency", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8551001_2_Ent0", "text": "a patient with autoimmune hepatitis", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "8551001_2_Ent4", "text": "autoimmune hepatitis", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "8551001_5", "wnd_id": "8551001_5_1", "text": "We describe the first documented case of azathioprine - induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease .", "tokens": ["We", "describe", "the", "first", "documented", "case", "of", "azathioprine", "-", "induced", "severe", "myelosuppression", "due", "to", "thiopurine", "methyltransferase", "deficiency", "in", "autoimmune", "liver", "disease", "."], "event_mentions": [{"id": "8551001_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "8551001_5_Ent1", "role": "Treatment", "text": "azathioprine", "start": 7, "end": 8}, {"entity_id": "8551001_5_Ent2", "role": "Treatment_Drug", "text": "azathioprine", "start": 7, "end": 8}, {"entity_id": "8551001_5_Ent0", "role": "Effect", "text": "severe myelosuppression", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "8551001_5_Ent1", "text": "azathioprine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8551001_5_Ent2", "text": "azathioprine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8551001_5_Ent0", "text": "severe myelosuppression", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "8586895_1", "wnd_id": "8586895_1_1", "text": "However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .", "tokens": ["However", ",", "in", "1993", ",", "a", "clinical", "study", "involving", "400", "patients", "on", "the", "Thai", "-", "Burmese", "border", "revealed", "cardiac", "effects", "of", "antimalarial", "treatment", "with", "halofantrine", ",", "including", "one", "sudden", "death", "after", "the", "treatment", "."], "event_mentions": [{"id": "8586895_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "effects", "start": 19, "end": 20}, "arguments": [{"entity_id": "8586895_1_Ent1", "role": "Subject_Population", "text": "400", "start": 9, "end": 10}, {"entity_id": "8586895_1_Ent0", "role": "Subject", "text": "400 patients on the Thai - Burmese border", "start": 9, "end": 17}, {"entity_id": "8586895_1_Ent2", "role": "Effect", "text": "cardiac effects", "start": 18, "end": 20}, {"entity_id": "8586895_1_Ent6", "role": "Treatment_Drug", "text": "antimalarial treatment", "start": 21, "end": 23}, {"entity_id": "8586895_1_Ent8", "role": "Combination_Drug", "text": "antimalarial treatment", "start": 21, "end": 23}, {"entity_id": "8586895_1_Ent4", "role": "Treatment", "text": "halofantrine", "start": 24, "end": 25}, {"entity_id": "8586895_1_Ent5", "role": "Treatment_Drug", "text": "halofantrine", "start": 24, "end": 25}, {"entity_id": "8586895_1_Ent7", "role": "Combination_Drug", "text": "halofantrine", "start": 24, "end": 25}, {"entity_id": "8586895_1_Ent3", "role": "Effect", "text": "sudden death", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "8586895_1_Ent1", "text": "400", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8586895_1_Ent0", "text": "400 patients on the Thai - Burmese border", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "8586895_1_Ent2", "text": "cardiac effects", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "8586895_1_Ent6", "text": "antimalarial treatment", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "8586895_1_Ent8", "text": "antimalarial treatment", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "8586895_1_Ent4", "text": "halofantrine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "8586895_1_Ent5", "text": "halofantrine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "8586895_1_Ent7", "text": "halofantrine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "8586895_1_Ent3", "text": "sudden death", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "8586895_3", "wnd_id": "8586895_3_1", "text": "Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine .", "tokens": ["Prolongation", "of", "the", "QT", "interval", "observed", "in", "a", "Japanese", "patient", "with", "vivax", "malaria", "following", "treatment", "with", "halofantrine", "."], "event_mentions": [{"id": "8586895_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 13, "end": 14}, "arguments": [{"entity_id": "8586895_3_Ent2", "role": "Effect", "text": "Prolongation of the QT interval", "start": 0, "end": 5}, {"entity_id": "8586895_3_Ent0", "role": "Subject", "text": "a Japanese patient with vivax malaria", "start": 7, "end": 13}, {"entity_id": "8586895_3_Ent1", "role": "Subject_Race", "text": "Japanese", "start": 8, "end": 9}, {"entity_id": "8586895_3_Ent4", "role": "Treatment_Disorder", "text": "vivax malaria", "start": 11, "end": 13}, {"entity_id": "8586895_3_Ent3", "role": "Treatment", "text": "halofantrine", "start": 16, "end": 17}, {"entity_id": "8586895_3_Ent5", "role": "Treatment_Drug", "text": "halofantrine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "8586895_3_Ent2", "text": "Prolongation of the QT interval", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8586895_3_Ent0", "text": "a Japanese patient with vivax malaria", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "8586895_3_Ent1", "text": "Japanese", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8586895_3_Ent4", "text": "vivax malaria", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "8586895_3_Ent3", "text": "halofantrine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8586895_3_Ent5", "text": "halofantrine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "8586895_4", "wnd_id": "8586895_4_1", "text": "The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .", "tokens": ["The", "pharmaceutical", "company", "producing", "Halfan", "has", "reported", "8", "cardiac", "arrests", ",", "leading", "to", "6", "deaths", ",", "when", "a", "higher", "dose", "than", "recommended", "was", "used", ",", "there", "was", "recent", "or", "concomitant", "treatment", "with", "mefloquine", ",", "there", "was", "pre", "-", "existing", "prolongation", "of", "the", "QT", "interval", "or", "the", "patient", "had", "a", "thiamine", "deficiency", "."], "event_mentions": [{"id": "8586895_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 6, "end": 7}, "arguments": [{"entity_id": "8586895_4_Ent2", "role": "Treatment", "text": "Halfan", "start": 4, "end": 5}, {"entity_id": "8586895_4_Ent4", "role": "Treatment_Drug", "text": "Halfan", "start": 4, "end": 5}, {"entity_id": "8586895_4_Ent0", "role": "Effect", "text": "8 cardiac arrests", "start": 7, "end": 10}, {"entity_id": "8586895_4_Ent1", "role": "Effect", "text": "6 deaths", "start": 13, "end": 15}, {"entity_id": "8586895_4_Ent3", "role": "Treatment", "text": "when a higher dose than recommended was used", "start": 16, "end": 24}, {"entity_id": "8586895_4_Ent6", "role": "Treatment_Dosage", "text": "a higher dose than recommended", "start": 17, "end": 22}, {"entity_id": "8586895_4_Ent5", "role": "Treatment_Drug", "text": "mefloquine", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "8586895_4_Ent2", "text": "Halfan", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8586895_4_Ent4", "text": "Halfan", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8586895_4_Ent0", "text": "8 cardiac arrests", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "8586895_4_Ent1", "text": "6 deaths", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8586895_4_Ent3", "text": "when a higher dose than recommended was used", "entity_type": "Entity", "start": 16, "end": 24}, {"id": "8586895_4_Ent6", "text": "a higher dose than recommended", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "8586895_4_Ent5", "text": "mefloquine", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "8589490_2", "wnd_id": "8589490_2_1", "text": "Pigmentary aberrations are well known side effects of cytostatic chemotherapeutic agents .", "tokens": ["Pigmentary", "aberrations", "are", "well", "known", "side", "effects", "of", "cytostatic", "chemotherapeutic", "agents", "."], "event_mentions": [{"id": "8589490_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 5, "end": 7}, "arguments": [{"entity_id": "8589490_2_Ent0", "role": "Effect", "text": "Pigmentary aberrations", "start": 0, "end": 2}, {"entity_id": "8589490_2_Ent1", "role": "Treatment", "text": "cytostatic chemotherapeutic agents", "start": 8, "end": 11}, {"entity_id": "8589490_2_Ent2", "role": "Treatment_Drug", "text": "cytostatic chemotherapeutic agents", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "8589490_2_Ent0", "text": "Pigmentary aberrations", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8589490_2_Ent1", "text": "cytostatic chemotherapeutic agents", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8589490_2_Ent2", "text": "cytostatic chemotherapeutic agents", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "8610807_1", "wnd_id": "8610807_1_1", "text": "Choroidal hemorrhage associated with systemic tissue plasminogen activator .", "tokens": ["Choroidal", "hemorrhage", "associated", "with", "systemic", "tissue", "plasminogen", "activator", "."], "event_mentions": [{"id": "8610807_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "8610807_1_Ent0", "role": "Effect", "text": "Choroidal hemorrhage", "start": 0, "end": 2}, {"entity_id": "8610807_1_Ent1", "role": "Treatment", "text": "systemic tissue plasminogen activator", "start": 4, "end": 8}, {"entity_id": "8610807_1_Ent2", "role": "Treatment_Drug", "text": "systemic tissue plasminogen activator", "start": 4, "end": 8}]}], "entity_mentions": [{"id": "8610807_1_Ent0", "text": "Choroidal hemorrhage", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8610807_1_Ent1", "text": "systemic tissue plasminogen activator", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "8610807_1_Ent2", "text": "systemic tissue plasminogen activator", "entity_type": "Entity", "start": 4, "end": 8}], "lang": "en"}
{"doc_id": "8610807_2", "wnd_id": "8610807_2_1", "text": "CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .", "tokens": ["CONCLUSION", ":", "The", "administration", "of", "tissue", "plasminogen", "activator", "was", "responsible", "for", "the", "large", "extent", "of", "hemorrhage", "and", "should", "be", "considered", "in", "the", "differential", "diagnosis", "of", "hemorrhagic", "choroidal", "detachment", "."], "event_mentions": [{"id": "8610807_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 9, "end": 10}, "arguments": [{"entity_id": "8610807_2_Ent1", "role": "Treatment", "text": "tissue plasminogen activator", "start": 5, "end": 8}, {"entity_id": "8610807_2_Ent2", "role": "Treatment_Drug", "text": "tissue plasminogen activator", "start": 5, "end": 8}, {"entity_id": "8610807_2_Ent0", "role": "Effect", "text": "large extent of hemorrhage", "start": 12, "end": 16}]}], "entity_mentions": [{"id": "8610807_2_Ent1", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8610807_2_Ent2", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8610807_2_Ent0", "text": "large extent of hemorrhage", "entity_type": "Entity", "start": 12, "end": 16}], "lang": "en"}
{"doc_id": "8627446_1", "wnd_id": "8627446_1_1", "text": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis .", "tokens": ["Accelerated", "nodulosis", "during", "methotrexate", "therapy", "for", "juvenile", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "8627446_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "8627446_1_Ent0", "role": "Effect", "text": "Accelerated nodulosis", "start": 0, "end": 2}, {"entity_id": "8627446_1_Ent1", "role": "Treatment", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "8627446_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "8627446_1_Ent3", "role": "Treatment_Disorder", "text": "juvenile rheumatoid arthritis", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "8627446_1_Ent0", "text": "Accelerated nodulosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8627446_1_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8627446_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8627446_1_Ent3", "text": "juvenile rheumatoid arthritis", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "8641617_1", "wnd_id": "8641617_1_1", "text": "Although both patients recovered from the colitis after the administration of vancomycin , the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with cisplatin .", "tokens": ["Although", "both", "patients", "recovered", "from", "the", "colitis", "after", "the", "administration", "of", "vancomycin", ",", "the", "first", "case", "demonstrated", "a", "relapse", "of", "the", "colitis", "after", "receiving", "a", "subsequent", "course", "of", "the", "same", "chemotherapy", "with", "cisplatin", "."], "event_mentions": [{"id": "8641617_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "recovered", "start": 3, "end": 4}, "arguments": [{"entity_id": "8641617_1_Ent1", "role": "Subject_Population", "text": "both", "start": 1, "end": 2}, {"entity_id": "8641617_1_Ent0", "role": "Subject", "text": "both patients", "start": 1, "end": 3}, {"entity_id": "8641617_1_Ent3", "role": "Treatment_Disorder", "text": "colitis", "start": 6, "end": 7}, {"entity_id": "8641617_1_Ent2", "role": "Treatment", "text": "vancomycin", "start": 11, "end": 12}, {"entity_id": "8641617_1_Ent4", "role": "Treatment_Drug", "text": "vancomycin", "start": 11, "end": 12}]}, {"id": "8641617_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 23, "end": 24}, "arguments": [{"entity_id": "8641617_1_Ent5", "role": "Effect", "text": "a relapse of the colitis", "start": 17, "end": 22}, {"entity_id": "8641617_1_Ent6", "role": "Treatment", "text": "a subsequent course of the same chemotherapy with cisplatin", "start": 24, "end": 33}, {"entity_id": "8641617_1_Ent8", "role": "Treatment_Route", "text": "chemotherapy", "start": 30, "end": 31}, {"entity_id": "8641617_1_Ent7", "role": "Treatment_Drug", "text": "cisplatin", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "8641617_1_Ent1", "text": "both", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8641617_1_Ent0", "text": "both patients", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8641617_1_Ent3", "text": "colitis", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8641617_1_Ent2", "text": "vancomycin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8641617_1_Ent4", "text": "vancomycin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8641617_1_Ent5", "text": "a relapse of the colitis", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "8641617_1_Ent6", "text": "a subsequent course of the same chemotherapy with cisplatin", "entity_type": "Entity", "start": 24, "end": 33}, {"id": "8641617_1_Ent8", "text": "chemotherapy", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "8641617_1_Ent7", "text": "cisplatin", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "8645078_4", "wnd_id": "8645078_4_1", "text": "Patients treated with captopril who develop \" atypical cholangitis \" should be suspected of having captopril - associated liver damage .", "tokens": ["Patients", "treated", "with", "captopril", "who", "develop", "\"", "atypical", "cholangitis", "\"", "should", "be", "suspected", "of", "having", "captopril", "-", "associated", "liver", "damage", "."], "event_mentions": [{"id": "8645078_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 17, "end": 18}, "arguments": [{"entity_id": "8645078_4_Ent0", "role": "Subject", "text": "Patients", "start": 0, "end": 1}, {"entity_id": "8645078_4_Ent4", "role": "Treatment_Drug", "text": "captopril", "start": 3, "end": 4}, {"entity_id": "8645078_4_Ent1", "role": "Effect", "text": "atypical cholangitis", "start": 7, "end": 9}, {"entity_id": "8645078_4_Ent3", "role": "Treatment", "text": "captopril", "start": 15, "end": 16}, {"entity_id": "8645078_4_Ent5", "role": "Treatment_Drug", "text": "captopril", "start": 15, "end": 16}, {"entity_id": "8645078_4_Ent2", "role": "Effect", "text": "liver damage", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "8645078_4_Ent0", "text": "Patients", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8645078_4_Ent4", "text": "captopril", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8645078_4_Ent1", "text": "atypical cholangitis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "8645078_4_Ent3", "text": "captopril", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "8645078_4_Ent5", "text": "captopril", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "8645078_4_Ent2", "text": "liver damage", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "8672829_2", "wnd_id": "8672829_2_1", "text": "CONCLUSIONS : There was a temporal relationship between the onset of nonconvulsive status epilepticus and initiation of ifosfamide infusion .", "tokens": ["CONCLUSIONS", ":", "There", "was", "a", "temporal", "relationship", "between", "the", "onset", "of", "nonconvulsive", "status", "epilepticus", "and", "initiation", "of", "ifosfamide", "infusion", "."], "event_mentions": [{"id": "8672829_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 6, "end": 7}, "arguments": [{"entity_id": "8672829_2_Ent0", "role": "Effect", "text": "onset of nonconvulsive status epilepticus", "start": 9, "end": 14}, {"entity_id": "8672829_2_Ent1", "role": "Treatment", "text": "initiation of ifosfamide infusion", "start": 15, "end": 19}, {"entity_id": "8672829_2_Ent2", "role": "Treatment_Drug", "text": "ifosfamide", "start": 17, "end": 18}, {"entity_id": "8672829_2_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "8672829_2_Ent0", "text": "onset of nonconvulsive status epilepticus", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "8672829_2_Ent1", "text": "initiation of ifosfamide infusion", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "8672829_2_Ent2", "text": "ifosfamide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8672829_2_Ent3", "text": "infusion", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "8672829_6", "wnd_id": "8672829_6_1", "text": "This represents the first report of nonconvulsive status epilepticus induced by ifosfamide .", "tokens": ["This", "represents", "the", "first", "report", "of", "nonconvulsive", "status", "epilepticus", "induced", "by", "ifosfamide", "."], "event_mentions": [{"id": "8672829_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "8672829_6_Ent0", "role": "Effect", "text": "nonconvulsive status epilepticus", "start": 6, "end": 9}, {"entity_id": "8672829_6_Ent1", "role": "Treatment", "text": "ifosfamide", "start": 11, "end": 12}, {"entity_id": "8672829_6_Ent2", "role": "Treatment_Drug", "text": "ifosfamide", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8672829_6_Ent0", "text": "nonconvulsive status epilepticus", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8672829_6_Ent1", "text": "ifosfamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8672829_6_Ent2", "text": "ifosfamide", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8691927_3", "wnd_id": "8691927_3_1", "text": "Growth and adrenal suppression in asthmatic children treated with high - dose fluticasone propionate .", "tokens": ["Growth", "and", "adrenal", "suppression", "in", "asthmatic", "children", "treated", "with", "high", "-", "dose", "fluticasone", "propionate", "."], "event_mentions": [{"id": "8691927_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 4, "end": 5}, "arguments": [{"entity_id": "8691927_3_Ent2", "role": "Effect", "text": "Growth and adrenal suppression", "start": 0, "end": 4}, {"entity_id": "8691927_3_Ent6", "role": "Treatment_Disorder", "text": "asthmatic", "start": 5, "end": 6}, {"entity_id": "8691927_3_Ent0", "role": "Subject", "text": "asthmatic children", "start": 5, "end": 7}, {"entity_id": "8691927_3_Ent1", "role": "Subject_Age", "text": "children", "start": 6, "end": 7}, {"entity_id": "8691927_3_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 9, "end": 12}, {"entity_id": "8691927_3_Ent3", "role": "Treatment", "text": "high - dose fluticasone propionate", "start": 9, "end": 14}, {"entity_id": "8691927_3_Ent4", "role": "Treatment_Drug", "text": "fluticasone propionate", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "8691927_3_Ent2", "text": "Growth and adrenal suppression", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8691927_3_Ent6", "text": "asthmatic", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8691927_3_Ent0", "text": "asthmatic children", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8691927_3_Ent1", "text": "children", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8691927_3_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8691927_3_Ent3", "text": "high - dose fluticasone propionate", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "8691927_3_Ent4", "text": "fluticasone propionate", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "8696525_1", "wnd_id": "8696525_1_1", "text": "Metipranolol associated granulomatous anterior uveitis : not so uncommon as thought .", "tokens": ["Metipranolol", "associated", "granulomatous", "anterior", "uveitis", ":", "not", "so", "uncommon", "as", "thought", "."], "event_mentions": [{"id": "8696525_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "8696525_1_Ent1", "role": "Treatment", "text": "Metipranolol", "start": 0, "end": 1}, {"entity_id": "8696525_1_Ent2", "role": "Treatment_Drug", "text": "Metipranolol", "start": 0, "end": 1}, {"entity_id": "8696525_1_Ent0", "role": "Effect", "text": "granulomatous anterior uveitis", "start": 2, "end": 5}]}], "entity_mentions": [{"id": "8696525_1_Ent1", "text": "Metipranolol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8696525_1_Ent2", "text": "Metipranolol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8696525_1_Ent0", "text": "granulomatous anterior uveitis", "entity_type": "Entity", "start": 2, "end": 5}], "lang": "en"}
{"doc_id": "8739289_6", "wnd_id": "8739289_6_1", "text": "Potential mechanisms regarding the pathophysiology of lithium - associated CDI are discussed .", "tokens": ["Potential", "mechanisms", "regarding", "the", "pathophysiology", "of", "lithium", "-", "associated", "CDI", "are", "discussed", "."], "event_mentions": [{"id": "8739289_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "8739289_6_Ent1", "role": "Treatment", "text": "lithium", "start": 6, "end": 7}, {"entity_id": "8739289_6_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 6, "end": 7}, {"entity_id": "8739289_6_Ent0", "role": "Effect", "text": "CDI", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8739289_6_Ent1", "text": "lithium", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8739289_6_Ent2", "text": "lithium", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8739289_6_Ent0", "text": "CDI", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "879939_2", "wnd_id": "879939_2_1", "text": "Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .", "tokens": ["Severe", "osteomalacia", "was", "present", "in", "two", "epileptic", "patients", "who", "were", "under", "long", "-", "term", "treatment", "with", "congeners", "of", "phenytoin", ",", "phenobarbital", ",", "and", "acetazolamide", "."], "event_mentions": [{"id": "879939_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "present", "start": 3, "end": 4}, "arguments": [{"entity_id": "879939_2_Ent2", "role": "Effect", "text": "osteomalacia", "start": 1, "end": 2}, {"entity_id": "879939_2_Ent1", "role": "Subject_Population", "text": "two", "start": 5, "end": 6}, {"entity_id": "879939_2_Ent0", "role": "Subject", "text": "two epileptic patients", "start": 5, "end": 8}, {"entity_id": "879939_2_Ent4", "role": "Treatment_Disorder", "text": "epileptic", "start": 6, "end": 7}, {"entity_id": "879939_2_Ent3", "role": "Treatment", "text": "long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide", "start": 11, "end": 24}, {"entity_id": "879939_2_Ent5", "role": "Treatment_Drug", "text": "phenytoin", "start": 18, "end": 19}, {"entity_id": "879939_2_Ent8", "role": "Combination_Drug", "text": "phenytoin", "start": 18, "end": 19}, {"entity_id": "879939_2_Ent6", "role": "Treatment_Drug", "text": "phenobarbital", "start": 20, "end": 21}, {"entity_id": "879939_2_Ent9", "role": "Combination_Drug", "text": "phenobarbital", "start": 20, "end": 21}, {"entity_id": "879939_2_Ent7", "role": "Treatment_Drug", "text": "acetazolamide", "start": 23, "end": 24}, {"entity_id": "879939_2_Ent10", "role": "Combination_Drug", "text": "acetazolamide", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "879939_2_Ent2", "text": "osteomalacia", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "879939_2_Ent1", "text": "two", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "879939_2_Ent0", "text": "two epileptic patients", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "879939_2_Ent4", "text": "epileptic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "879939_2_Ent3", "text": "long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide", "entity_type": "Entity", "start": 11, "end": 24}, {"id": "879939_2_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "879939_2_Ent8", "text": "phenytoin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "879939_2_Ent6", "text": "phenobarbital", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "879939_2_Ent9", "text": "phenobarbital", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "879939_2_Ent7", "text": "acetazolamide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "879939_2_Ent10", "text": "acetazolamide", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "879939_5", "wnd_id": "879939_5_1", "text": "Acetazolamide may have accelerated the development of osteomalacia by several mechanisms , including increased renal calcium excretion .", "tokens": ["Acetazolamide", "may", "have", "accelerated", "the", "development", "of", "osteomalacia", "by", "several", "mechanisms", ",", "including", "increased", "renal", "calcium", "excretion", "."], "event_mentions": [{"id": "879939_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "accelerated", "start": 3, "end": 4}, "arguments": [{"entity_id": "879939_5_Ent1", "role": "Treatment", "text": "Acetazolamide", "start": 0, "end": 1}, {"entity_id": "879939_5_Ent2", "role": "Treatment_Drug", "text": "Acetazolamide", "start": 0, "end": 1}, {"entity_id": "879939_5_Ent0", "role": "Effect", "text": "osteomalacia", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "879939_5_Ent1", "text": "Acetazolamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "879939_5_Ent2", "text": "Acetazolamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "879939_5_Ent0", "text": "osteomalacia", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "8828999_4", "wnd_id": "8828999_4_1", "text": "Several cases of lithium - induced Creutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had \" therapeutic \" lithium serum levels .", "tokens": ["Several", "cases", "of", "lithium", "-", "induced", "Creutzfeldt", "-", "Jakob", "syndrome", "have", "been", "reported", "to", "date", ";", "all", "of", "them", "were", "elderly", "patients", "and", "a", "half", "had", "\"", "therapeutic", "\"", "lithium", "serum", "levels", "."], "event_mentions": [{"id": "8828999_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "8828999_4_Ent3", "role": "Treatment", "text": "lithium", "start": 3, "end": 4}, {"entity_id": "8828999_4_Ent5", "role": "Treatment_Drug", "text": "lithium", "start": 3, "end": 4}, {"entity_id": "8828999_4_Ent2", "role": "Effect", "text": "Creutzfeldt - Jakob syndrome", "start": 6, "end": 10}, {"entity_id": "8828999_4_Ent1", "role": "Subject_Age", "text": "elderly", "start": 20, "end": 21}, {"entity_id": "8828999_4_Ent0", "role": "Subject", "text": "elderly patients", "start": 20, "end": 22}, {"entity_id": "8828999_4_Ent4", "role": "Treatment", "text": "\" therapeutic \" lithium serum levels", "start": 26, "end": 32}, {"entity_id": "8828999_4_Ent6", "role": "Treatment_Drug", "text": "lithium", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "8828999_4_Ent3", "text": "lithium", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8828999_4_Ent5", "text": "lithium", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8828999_4_Ent2", "text": "Creutzfeldt - Jakob syndrome", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "8828999_4_Ent1", "text": "elderly", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8828999_4_Ent0", "text": "elderly patients", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "8828999_4_Ent4", "text": "\" therapeutic \" lithium serum levels", "entity_type": "Entity", "start": 26, "end": 32}, {"id": "8828999_4_Ent6", "text": "lithium", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "8832451_2", "wnd_id": "8832451_2_1", "text": "The occurrence of neuromuscular blockade and the resulting potentiation of muscle relaxants during magnesium sulfate ( MgSO4 ) administration is well known .", "tokens": ["The", "occurrence", "of", "neuromuscular", "blockade", "and", "the", "resulting", "potentiation", "of", "muscle", "relaxants", "during", "magnesium", "sulfate", "(", "MgSO4", ")", "administration", "is", "well", "known", "."], "event_mentions": [{"id": "8832451_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 12, "end": 13}, "arguments": [{"entity_id": "8832451_2_Ent0", "role": "Effect", "text": "neuromuscular blockade", "start": 3, "end": 5}, {"entity_id": "8832451_2_Ent1", "role": "Effect", "text": "potentiation of muscle relaxants", "start": 8, "end": 12}, {"entity_id": "8832451_2_Ent2", "role": "Treatment", "text": "magnesium sulfate", "start": 13, "end": 15}, {"entity_id": "8832451_2_Ent3", "role": "Treatment_Drug", "text": "magnesium sulfate ( MgSO4 )", "start": 13, "end": 18}]}], "entity_mentions": [{"id": "8832451_2_Ent0", "text": "neuromuscular blockade", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8832451_2_Ent1", "text": "potentiation of muscle relaxants", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "8832451_2_Ent2", "text": "magnesium sulfate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8832451_2_Ent3", "text": "magnesium sulfate ( MgSO4 )", "entity_type": "Entity", "start": 13, "end": 18}], "lang": "en"}
{"doc_id": "8832451_3", "wnd_id": "8832451_3_1", "text": "We also describe a new , noninvasive method to assess magnesium - induced neuromuscular block when curariform muscle relaxant was given simultaneously .", "tokens": ["We", "also", "describe", "a", "new", ",", "noninvasive", "method", "to", "assess", "magnesium", "-", "induced", "neuromuscular", "block", "when", "curariform", "muscle", "relaxant", "was", "given", "simultaneously", "."], "event_mentions": [{"id": "8832451_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "8832451_3_Ent2", "role": "Treatment_Drug", "text": "magnesium", "start": 10, "end": 11}, {"entity_id": "8832451_3_Ent4", "role": "Combination_Drug", "text": "magnesium", "start": 10, "end": 11}, {"entity_id": "8832451_3_Ent0", "role": "Effect", "text": "neuromuscular block", "start": 13, "end": 15}, {"entity_id": "8832451_3_Ent3", "role": "Treatment_Drug", "text": "curariform muscle relaxant", "start": 16, "end": 19}, {"entity_id": "8832451_3_Ent5", "role": "Combination_Drug", "text": "curariform muscle relaxant", "start": 16, "end": 19}, {"entity_id": "8832451_3_Ent1", "role": "Treatment", "text": "curariform muscle relaxant was given simultaneously", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "8832451_3_Ent2", "text": "magnesium", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8832451_3_Ent4", "text": "magnesium", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8832451_3_Ent0", "text": "neuromuscular block", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8832451_3_Ent3", "text": "curariform muscle relaxant", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "8832451_3_Ent5", "text": "curariform muscle relaxant", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "8832451_3_Ent1", "text": "curariform muscle relaxant was given simultaneously", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "8840640_2", "wnd_id": "8840640_2_1", "text": "Metabolic acidosis induced by cetrimide - chlorhexidine solution in hydatid cyst surgery .", "tokens": ["Metabolic", "acidosis", "induced", "by", "cetrimide", "-", "chlorhexidine", "solution", "in", "hydatid", "cyst", "surgery", "."], "event_mentions": [{"id": "8840640_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8840640_2_Ent0", "role": "Effect", "text": "Metabolic acidosis", "start": 0, "end": 2}, {"entity_id": "8840640_2_Ent3", "role": "Treatment_Drug", "text": "cetrimide", "start": 4, "end": 5}, {"entity_id": "8840640_2_Ent7", "role": "Combination_Drug", "text": "cetrimide", "start": 4, "end": 5}, {"entity_id": "8840640_2_Ent1", "role": "Treatment", "text": "cetrimide - chlorhexidine solution", "start": 4, "end": 8}, {"entity_id": "8840640_2_Ent4", "role": "Treatment_Drug", "text": "chlorhexidine", "start": 6, "end": 7}, {"entity_id": "8840640_2_Ent6", "role": "Combination_Drug", "text": "chlorhexidine", "start": 6, "end": 7}, {"entity_id": "8840640_2_Ent5", "role": "Treatment_Route", "text": "solution", "start": 7, "end": 8}, {"entity_id": "8840640_2_Ent2", "role": "Treatment_Disorder", "text": "hydatid cyst", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "8840640_2_Ent0", "text": "Metabolic acidosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8840640_2_Ent3", "text": "cetrimide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8840640_2_Ent7", "text": "cetrimide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8840640_2_Ent1", "text": "cetrimide - chlorhexidine solution", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "8840640_2_Ent4", "text": "chlorhexidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8840640_2_Ent6", "text": "chlorhexidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8840640_2_Ent5", "text": "solution", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8840640_2_Ent2", "text": "hydatid cyst", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "8850251_4", "wnd_id": "8850251_4_1", "text": "Mequitazine seemed to play a part similar to chlorpromazine , and absence of mequitazine - induced photosensitivity may be due to a relatively low dosage of the drug .", "tokens": ["Mequitazine", "seemed", "to", "play", "a", "part", "similar", "to", "chlorpromazine", ",", "and", "absence", "of", "mequitazine", "-", "induced", "photosensitivity", "may", "be", "due", "to", "a", "relatively", "low", "dosage", "of", "the", "drug", "."], "event_mentions": [{"id": "8850251_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "8850251_4_Ent1", "role": "Treatment", "text": "mequitazine", "start": 13, "end": 14}, {"entity_id": "8850251_4_Ent3", "role": "Treatment_Drug", "text": "mequitazine", "start": 13, "end": 14}, {"entity_id": "8850251_4_Ent0", "role": "Effect", "text": "photosensitivity", "start": 16, "end": 17}, {"entity_id": "8850251_4_Ent2", "role": "Treatment", "text": "due to a relatively low dosage of the drug", "start": 19, "end": 28}, {"entity_id": "8850251_4_Ent4", "role": "Treatment_Dosage", "text": "low dosage", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "8850251_4_Ent1", "text": "mequitazine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8850251_4_Ent3", "text": "mequitazine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8850251_4_Ent0", "text": "photosensitivity", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8850251_4_Ent2", "text": "due to a relatively low dosage of the drug", "entity_type": "Entity", "start": 19, "end": 28}, {"id": "8850251_4_Ent4", "text": "low dosage", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "8876616_2", "wnd_id": "8876616_2_1", "text": "We report the case of a 74 - year - old female patient who received the antide - pressant amitriptyline because of a major depression .", "tokens": ["We", "report", "the", "case", "of", "a", "74", "-", "year", "-", "old", "female", "patient", "who", "received", "the", "antide", "-", "pressant", "amitriptyline", "because", "of", "a", "major", "depression", "."], "event_mentions": [{"id": "8876616_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 14, "end": 15}, "arguments": [{"entity_id": "8876616_2_Ent0", "role": "Subject", "text": "a 74 - year - old female patient", "start": 5, "end": 13}, {"entity_id": "8876616_2_Ent2", "role": "Subject_Age", "text": "74 - year - old", "start": 6, "end": 11}, {"entity_id": "8876616_2_Ent3", "role": "Subject_Gender", "text": "female", "start": 11, "end": 12}, {"entity_id": "8876616_2_Ent4", "role": "Treatment", "text": "antide - pressant amitriptyline", "start": 16, "end": 20}, {"entity_id": "8876616_2_Ent6", "role": "Treatment_Drug", "text": "amitriptyline", "start": 19, "end": 20}, {"entity_id": "8876616_2_Ent1", "role": "Subject", "text": "a major depression", "start": 22, "end": 25}, {"entity_id": "8876616_2_Ent5", "role": "Treatment_Disorder", "text": "major depression", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "8876616_2_Ent0", "text": "a 74 - year - old female patient", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "8876616_2_Ent2", "text": "74 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "8876616_2_Ent3", "text": "female", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8876616_2_Ent4", "text": "antide - pressant amitriptyline", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "8876616_2_Ent6", "text": "amitriptyline", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8876616_2_Ent1", "text": "a major depression", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "8876616_2_Ent5", "text": "major depression", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "889156_4", "wnd_id": "889156_4_1", "text": "A more serious development of adrenal insufficiency may occur upon the improper replacement of systemic steroids .", "tokens": ["A", "more", "serious", "development", "of", "adrenal", "insufficiency", "may", "occur", "upon", "the", "improper", "replacement", "of", "systemic", "steroids", "."], "event_mentions": [{"id": "889156_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "replacement", "start": 12, "end": 13}, "arguments": [{"entity_id": "889156_4_Ent0", "role": "Effect", "text": "development of adrenal insufficiency", "start": 3, "end": 7}, {"entity_id": "889156_4_Ent1", "role": "Treatment", "text": "systemic steroids", "start": 14, "end": 16}, {"entity_id": "889156_4_Ent2", "role": "Treatment_Drug", "text": "steroids", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "889156_4_Ent0", "text": "development of adrenal insufficiency", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "889156_4_Ent1", "text": "systemic steroids", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "889156_4_Ent2", "text": "steroids", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "8891729_3", "wnd_id": "8891729_3_1", "text": "The occurrence of severe AIHA in CLL patients treated with fludarabine has been reported by several authors .", "tokens": ["The", "occurrence", "of", "severe", "AIHA", "in", "CLL", "patients", "treated", "with", "fludarabine", "has", "been", "reported", "by", "several", "authors", "."], "event_mentions": [{"id": "8891729_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 8, "end": 9}, "arguments": [{"entity_id": "8891729_3_Ent1", "role": "Effect", "text": "severe AIHA", "start": 3, "end": 5}, {"entity_id": "8891729_3_Ent3", "role": "Treatment_Disorder", "text": "CLL", "start": 6, "end": 7}, {"entity_id": "8891729_3_Ent0", "role": "Subject", "text": "CLL patients", "start": 6, "end": 8}, {"entity_id": "8891729_3_Ent2", "role": "Treatment", "text": "fludarabine", "start": 10, "end": 11}, {"entity_id": "8891729_3_Ent4", "role": "Treatment_Drug", "text": "fludarabine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "8891729_3_Ent1", "text": "severe AIHA", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8891729_3_Ent3", "text": "CLL", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8891729_3_Ent0", "text": "CLL patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8891729_3_Ent2", "text": "fludarabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8891729_3_Ent4", "text": "fludarabine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "8903300_3", "wnd_id": "8903300_3_1", "text": "This pattern is suggestive of renal toxicity due to tobramycin .", "tokens": ["This", "pattern", "is", "suggestive", "of", "renal", "toxicity", "due", "to", "tobramycin", "."], "event_mentions": [{"id": "8903300_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 7, "end": 9}, "arguments": [{"entity_id": "8903300_3_Ent0", "role": "Effect", "text": "renal toxicity", "start": 5, "end": 7}, {"entity_id": "8903300_3_Ent1", "role": "Treatment", "text": "tobramycin", "start": 9, "end": 10}, {"entity_id": "8903300_3_Ent2", "role": "Treatment_Drug", "text": "tobramycin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8903300_3_Ent0", "text": "renal toxicity", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8903300_3_Ent1", "text": "tobramycin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8903300_3_Ent2", "text": "tobramycin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "8908396_3", "wnd_id": "8908396_3_1", "text": "OBJECTIVE : To test the hypothesis that tumor necrosis factor ( TNF) - alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin - induced lipoatrophies of a diabetic patient who presented extensive lesions .", "tokens": ["OBJECTIVE", ":", "To", "test", "the", "hypothesis", "that", "tumor", "necrosis", "factor", "(", "TNF)", "-", "alpha", "may", "mediate", "the", "loss", "and", "the", "dedifferentiation", "of", "subcutaneous", "fat", "tissue", "in", "the", "insulin", "-", "induced", "lipoatrophies", "of", "a", "diabetic", "patient", "who", "presented", "extensive", "lesions", "."], "event_mentions": [{"id": "8908396_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 29, "end": 30}, "arguments": [{"entity_id": "8908396_3_Ent1", "role": "Treatment", "text": "insulin", "start": 27, "end": 28}, {"entity_id": "8908396_3_Ent2", "role": "Treatment_Drug", "text": "insulin", "start": 27, "end": 28}, {"entity_id": "8908396_3_Ent0", "role": "Effect", "text": "lipoatrophies", "start": 30, "end": 31}, {"entity_id": "8908396_3_Ent3", "role": "Treatment_Disorder", "text": "diabetic", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "8908396_3_Ent1", "text": "insulin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "8908396_3_Ent2", "text": "insulin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "8908396_3_Ent0", "text": "lipoatrophies", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "8908396_3_Ent3", "text": "diabetic", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "8912599_8", "wnd_id": "8912599_8_1", "text": "Well - known signs of methotrexate toxicity include bone marrow suppression and oral and gastrointestinal ulceration .", "tokens": ["Well", "-", "known", "signs", "of", "methotrexate", "toxicity", "include", "bone", "marrow", "suppression", "and", "oral", "and", "gastrointestinal", "ulceration", "."], "event_mentions": [{"id": "8912599_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "signs", "start": 3, "end": 4}, "arguments": [{"entity_id": "8912599_8_Ent1", "role": "Treatment", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "8912599_8_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "8912599_8_Ent0", "role": "Effect", "text": "bone marrow suppression and oral and gastrointestinal ulceration", "start": 8, "end": 16}]}], "entity_mentions": [{"id": "8912599_8_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8912599_8_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8912599_8_Ent0", "text": "bone marrow suppression and oral and gastrointestinal ulceration", "entity_type": "Entity", "start": 8, "end": 16}], "lang": "en"}
{"doc_id": "8921647_4", "wnd_id": "8921647_4_1", "text": "Hypoxemia improved during continuous tolazoline infusion , but gastrointestinal bleeding occurred .", "tokens": ["Hypoxemia", "improved", "during", "continuous", "tolazoline", "infusion", ",", "but", "gastrointestinal", "bleeding", "occurred", "."], "event_mentions": [{"id": "8921647_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 10, "end": 11}, "arguments": [{"entity_id": "8921647_4_Ent2", "role": "Treatment_Disorder", "text": "Hypoxemia", "start": 0, "end": 1}, {"entity_id": "8921647_4_Ent1", "role": "Treatment", "text": "Hypoxemia improved during continuous tolazoline infusion", "start": 0, "end": 6}, {"entity_id": "8921647_4_Ent3", "role": "Treatment_Drug", "text": "tolazoline", "start": 4, "end": 5}, {"entity_id": "8921647_4_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 5, "end": 6}, {"entity_id": "8921647_4_Ent0", "role": "Effect", "text": "gastrointestinal bleeding", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "8921647_4_Ent2", "text": "Hypoxemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8921647_4_Ent1", "text": "Hypoxemia improved during continuous tolazoline infusion", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "8921647_4_Ent3", "text": "tolazoline", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8921647_4_Ent4", "text": "infusion", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8921647_4_Ent0", "text": "gastrointestinal bleeding", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "8936932_1", "wnd_id": "8936932_1_1", "text": "Acute esmolol toxicity may be self - limiting because of its extremely short half - life .", "tokens": ["Acute", "esmolol", "toxicity", "may", "be", "self", "-", "limiting", "because", "of", "its", "extremely", "short", "half", "-", "life", "."], "event_mentions": [{"id": "8936932_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "be", "start": 4, "end": 5}, "arguments": [{"entity_id": "8936932_1_Ent1", "role": "Treatment", "text": "esmolol", "start": 1, "end": 2}, {"entity_id": "8936932_1_Ent2", "role": "Treatment_Drug", "text": "esmolol", "start": 1, "end": 2}, {"entity_id": "8936932_1_Ent0", "role": "Effect", "text": "toxicity", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "8936932_1_Ent1", "text": "esmolol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8936932_1_Ent2", "text": "esmolol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8936932_1_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "8942269_2", "wnd_id": "8942269_2_1", "text": "His impaired memory was found to be due to the atenolol he was on and he made a complete recovery on withdrawing the beta - blocker .", "tokens": ["His", "impaired", "memory", "was", "found", "to", "be", "due", "to", "the", "atenolol", "he", "was", "on", "and", "he", "made", "a", "complete", "recovery", "on", "withdrawing", "the", "beta", "-", "blocker", "."], "event_mentions": [{"id": "8942269_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 7, "end": 8}, "arguments": [{"entity_id": "8942269_2_Ent2", "role": "Effect", "text": "impaired memory", "start": 1, "end": 3}, {"entity_id": "8942269_2_Ent3", "role": "Treatment", "text": "atenolol", "start": 10, "end": 11}, {"entity_id": "8942269_2_Ent4", "role": "Treatment_Drug", "text": "atenolol", "start": 10, "end": 11}, {"entity_id": "8942269_2_Ent0", "role": "Subject", "text": "he", "start": 11, "end": 12}, {"entity_id": "8942269_2_Ent1", "role": "Subject_Gender", "text": "he", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8942269_2_Ent2", "text": "impaired memory", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8942269_2_Ent3", "text": "atenolol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8942269_2_Ent4", "text": "atenolol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8942269_2_Ent0", "text": "he", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8942269_2_Ent1", "text": "he", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8996514_2", "wnd_id": "8996514_2_1", "text": "Large cerebral infarction during praziquantel therapy in neurocysticercosis .", "tokens": ["Large", "cerebral", "infarction", "during", "praziquantel", "therapy", "in", "neurocysticercosis", "."], "event_mentions": [{"id": "8996514_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "8996514_2_Ent0", "role": "Effect", "text": "Large cerebral infarction", "start": 0, "end": 3}, {"entity_id": "8996514_2_Ent1", "role": "Treatment", "text": "praziquantel", "start": 4, "end": 5}, {"entity_id": "8996514_2_Ent2", "role": "Treatment_Drug", "text": "praziquantel", "start": 4, "end": 5}, {"entity_id": "8996514_2_Ent3", "role": "Treatment_Disorder", "text": "neurocysticercosis", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "8996514_2_Ent0", "text": "Large cerebral infarction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8996514_2_Ent1", "text": "praziquantel", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8996514_2_Ent2", "text": "praziquantel", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8996514_2_Ent3", "text": "neurocysticercosis", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "9007910_1", "wnd_id": "9007910_1_1", "text": "Dihydropyrimidine dehydrogenase deficiency : a pharmacogenetic defect causing severe adverse reactions to 5 - fluorouracil - based chemotherapy .", "tokens": ["Dihydropyrimidine", "dehydrogenase", "deficiency", ":", "a", "pharmacogenetic", "defect", "causing", "severe", "adverse", "reactions", "to", "5", "-", "fluorouracil", "-", "based", "chemotherapy", "."], "event_mentions": [{"id": "9007910_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 11, "end": 12}, "arguments": [{"entity_id": "9007910_1_Ent2", "role": "Treatment_Disorder", "text": "Dihydropyrimidine dehydrogenase deficiency", "start": 0, "end": 3}, {"entity_id": "9007910_1_Ent0", "role": "Effect", "text": "severe adverse reactions", "start": 8, "end": 11}, {"entity_id": "9007910_1_Ent3", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 12, "end": 15}, {"entity_id": "9007910_1_Ent1", "role": "Treatment", "text": "5 - fluorouracil - based chemotherapy", "start": 12, "end": 18}, {"entity_id": "9007910_1_Ent4", "role": "Treatment_Route", "text": "chemotherapy", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "9007910_1_Ent2", "text": "Dihydropyrimidine dehydrogenase deficiency", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9007910_1_Ent0", "text": "severe adverse reactions", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "9007910_1_Ent3", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "9007910_1_Ent1", "text": "5 - fluorouracil - based chemotherapy", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "9007910_1_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "9007910_2", "wnd_id": "9007910_2_1", "text": "PURPOSE / OBJECTIVES : To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase ( DPD ) deficiency , which predisposes patients with cancer to potentially lethal adverse reactions following 5 - fluorouracil ( 5 - FU) - based chemotherapy .", "tokens": ["PURPOSE", "/", "OBJECTIVES", ":", "To", "describe", "the", "pharmacogenetic", "syndrome", "of", "dihydropyrimidine", "dehydrogenase", "(", "DPD", ")", "deficiency", ",", "which", "predisposes", "patients", "with", "cancer", "to", "potentially", "lethal", "adverse", "reactions", "following", "5", "-", "fluorouracil", "(", "5", "-", "FU)", "-", "based", "chemotherapy", "."], "event_mentions": [{"id": "9007910_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "predisposes", "start": 18, "end": 19}, "arguments": [{"entity_id": "9007910_2_Ent0", "role": "Subject", "text": "dihydropyrimidine dehydrogenase ( DPD ) deficiency", "start": 10, "end": 16}, {"entity_id": "9007910_2_Ent1", "role": "Subject_Disorder", "text": "dihydropyrimidine dehydrogenase ( DPD ) deficiency", "start": 10, "end": 16}, {"entity_id": "9007910_2_Ent4", "role": "Treatment_Disorder", "text": "cancer", "start": 21, "end": 22}, {"entity_id": "9007910_2_Ent2", "role": "Effect", "text": "lethal adverse reactions", "start": 24, "end": 27}, {"entity_id": "9007910_2_Ent5", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 28, "end": 31}, {"entity_id": "9007910_2_Ent3", "role": "Treatment", "text": "5 - fluorouracil ( 5 - FU) - based chemotherapy", "start": 28, "end": 38}, {"entity_id": "9007910_2_Ent6", "role": "Treatment_Route", "text": "chemotherapy", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "9007910_2_Ent0", "text": "dihydropyrimidine dehydrogenase ( DPD ) deficiency", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "9007910_2_Ent1", "text": "dihydropyrimidine dehydrogenase ( DPD ) deficiency", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "9007910_2_Ent4", "text": "cancer", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "9007910_2_Ent2", "text": "lethal adverse reactions", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "9007910_2_Ent5", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 28, "end": 31}, {"id": "9007910_2_Ent3", "text": "5 - fluorouracil ( 5 - FU) - based chemotherapy", "entity_type": "Entity", "start": 28, "end": 38}, {"id": "9007910_2_Ent6", "text": "chemotherapy", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "9007910_8", "wnd_id": "9007910_8_1", "text": "IMPLICATIONS FOR NURSING PRACTICE : Nurses must understand the pharmacology , mechanism of action , clinical presentation , potentially lethal risks , and traumatic psychosocial stresses experienced by DPD - deficient patients with cancer receiving 5 - FU therapy in order to develop timely interventions and alternative plans of care .", "tokens": ["IMPLICATIONS", "FOR", "NURSING", "PRACTICE", ":", "Nurses", "must", "understand", "the", "pharmacology", ",", "mechanism", "of", "action", ",", "clinical", "presentation", ",", "potentially", "lethal", "risks", ",", "and", "traumatic", "psychosocial", "stresses", "experienced", "by", "DPD", "-", "deficient", "patients", "with", "cancer", "receiving", "5", "-", "FU", "therapy", "in", "order", "to", "develop", "timely", "interventions", "and", "alternative", "plans", "of", "care", "."], "event_mentions": [{"id": "9007910_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 34, "end": 35}, "arguments": [{"entity_id": "9007910_8_Ent1", "role": "Subject_Disorder", "text": "DPD - deficient", "start": 28, "end": 31}, {"entity_id": "9007910_8_Ent0", "role": "Subject", "text": "DPD - deficient patients with cancer", "start": 28, "end": 34}, {"entity_id": "9007910_8_Ent4", "role": "Treatment_Disorder", "text": "cancer", "start": 33, "end": 34}, {"entity_id": "9007910_8_Ent3", "role": "Treatment_Drug", "text": "5 - FU", "start": 35, "end": 38}, {"entity_id": "9007910_8_Ent2", "role": "Treatment", "text": "5 - FU therapy", "start": 35, "end": 39}]}], "entity_mentions": [{"id": "9007910_8_Ent1", "text": "DPD - deficient", "entity_type": "Entity", "start": 28, "end": 31}, {"id": "9007910_8_Ent0", "text": "DPD - deficient patients with cancer", "entity_type": "Entity", "start": 28, "end": 34}, {"id": "9007910_8_Ent4", "text": "cancer", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "9007910_8_Ent3", "text": "5 - FU", "entity_type": "Entity", "start": 35, "end": 38}, {"id": "9007910_8_Ent2", "text": "5 - FU therapy", "entity_type": "Entity", "start": 35, "end": 39}], "lang": "en"}
{"doc_id": "9022114_2", "wnd_id": "9022114_2_1", "text": "CONCLUSION : The findings in these two patients suggest that colchicine may delay corneal wound healing .", "tokens": ["CONCLUSION", ":", "The", "findings", "in", "these", "two", "patients", "suggest", "that", "colchicine", "may", "delay", "corneal", "wound", "healing", "."], "event_mentions": [{"id": "9022114_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "delay", "start": 12, "end": 13}, "arguments": [{"entity_id": "9022114_2_Ent1", "role": "Subject_Population", "text": "two", "start": 6, "end": 7}, {"entity_id": "9022114_2_Ent0", "role": "Subject", "text": "two patients", "start": 6, "end": 8}, {"entity_id": "9022114_2_Ent3", "role": "Treatment", "text": "colchicine", "start": 10, "end": 11}, {"entity_id": "9022114_2_Ent4", "role": "Treatment_Drug", "text": "colchicine", "start": 10, "end": 11}, {"entity_id": "9022114_2_Ent2", "role": "Effect", "text": "delay corneal wound healing", "start": 12, "end": 16}, {"entity_id": "9022114_2_Ent5", "role": "Treatment_Disorder", "text": "corneal wound", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "9022114_2_Ent1", "text": "two", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9022114_2_Ent0", "text": "two patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9022114_2_Ent3", "text": "colchicine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9022114_2_Ent4", "text": "colchicine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9022114_2_Ent2", "text": "delay corneal wound healing", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "9022114_2_Ent5", "text": "corneal wound", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "9103523_2", "wnd_id": "9103523_2_1", "text": "The volatile anesthetic halothane undergoes substantial biotransformation generating metabolites that mediate hepatotoxicity .", "tokens": ["The", "volatile", "anesthetic", "halothane", "undergoes", "substantial", "biotransformation", "generating", "metabolites", "that", "mediate", "hepatotoxicity", "."], "event_mentions": [{"id": "9103523_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "mediate", "start": 10, "end": 11}, "arguments": [{"entity_id": "9103523_2_Ent3", "role": "Treatment_Route", "text": "volatile", "start": 1, "end": 2}, {"entity_id": "9103523_2_Ent1", "role": "Treatment", "text": "volatile anesthetic halothane", "start": 1, "end": 4}, {"entity_id": "9103523_2_Ent2", "role": "Treatment_Drug", "text": "halothane", "start": 3, "end": 4}, {"entity_id": "9103523_2_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9103523_2_Ent3", "text": "volatile", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9103523_2_Ent1", "text": "volatile anesthetic halothane", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "9103523_2_Ent2", "text": "halothane", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9103523_2_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9161656_1", "wnd_id": "9161656_1_1", "text": "Acute asthma associated with sustained - release verapamil .", "tokens": ["Acute", "asthma", "associated", "with", "sustained", "-", "release", "verapamil", "."], "event_mentions": [{"id": "9161656_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "9161656_1_Ent0", "role": "Effect", "text": "Acute asthma", "start": 0, "end": 2}, {"entity_id": "9161656_1_Ent1", "role": "Treatment", "text": "sustained - release verapamil", "start": 4, "end": 8}, {"entity_id": "9161656_1_Ent2", "role": "Treatment_Drug", "text": "sustained - release verapamil", "start": 4, "end": 8}]}], "entity_mentions": [{"id": "9161656_1_Ent0", "text": "Acute asthma", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9161656_1_Ent1", "text": "sustained - release verapamil", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "9161656_1_Ent2", "text": "sustained - release verapamil", "entity_type": "Entity", "start": 4, "end": 8}], "lang": "en"}
{"doc_id": "9161656_16", "wnd_id": "9161656_16_1", "text": "She continued taking verapamil for 6 months , then , on her own , stopped all medications including the sustained - release verapamil , and her asthma symptoms disappeared .", "tokens": ["She", "continued", "taking", "verapamil", "for", "6", "months", ",", "then", ",", "on", "her", "own", ",", "stopped", "all", "medications", "including", "the", "sustained", "-", "release", "verapamil", ",", "and", "her", "asthma", "symptoms", "disappeared", "."], "event_mentions": [{"id": "9161656_16_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "disappeared", "start": 28, "end": 29}, "arguments": [{"entity_id": "9161656_16_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "9161656_16_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "9161656_16_Ent2", "role": "Treatment", "text": "continued taking verapamil for 6 months , then , on her own , stopped all medications including the sustained - release verapamil", "start": 1, "end": 23}, {"entity_id": "9161656_16_Ent4", "role": "Treatment_Drug", "text": "verapamil", "start": 3, "end": 4}, {"entity_id": "9161656_16_Ent5", "role": "Treatment_Duration", "text": "for 6 months", "start": 4, "end": 7}, {"entity_id": "9161656_16_Ent3", "role": "Treatment_Disorder", "text": "asthma", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "9161656_16_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9161656_16_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9161656_16_Ent2", "text": "continued taking verapamil for 6 months , then , on her own , stopped all medications including the sustained - release verapamil", "entity_type": "Entity", "start": 1, "end": 23}, {"id": "9161656_16_Ent4", "text": "verapamil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9161656_16_Ent5", "text": "for 6 months", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "9161656_16_Ent3", "text": "asthma", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "9161656_5", "wnd_id": "9161656_5_1", "text": "Antiasthmatic medications were prescribed , but the asthma symptoms did not improve .", "tokens": ["Antiasthmatic", "medications", "were", "prescribed", ",", "but", "the", "asthma", "symptoms", "did", "not", "improve", "."], "event_mentions": [{"id": "9161656_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improve", "start": 11, "end": 12}, "arguments": [{"entity_id": "9161656_5_Ent2", "role": "Treatment_Drug", "text": "Antiasthmatic medications", "start": 0, "end": 2}, {"entity_id": "9161656_5_Ent0", "role": "Treatment", "text": "Antiasthmatic medications were prescribed", "start": 0, "end": 4}, {"entity_id": "9161656_5_Ent1", "role": "Treatment_Disorder", "text": "asthma", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "9161656_5_Ent2", "text": "Antiasthmatic medications", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9161656_5_Ent0", "text": "Antiasthmatic medications were prescribed", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9161656_5_Ent1", "text": "asthma", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "9161656_8", "wnd_id": "9161656_8_1", "text": "The asthma resolved within 24 hours following three albuterol inhalations .", "tokens": ["The", "asthma", "resolved", "within", "24", "hours", "following", "three", "albuterol", "inhalations", "."], "event_mentions": [{"id": "9161656_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 2, "end": 3}, "arguments": [{"entity_id": "9161656_8_Ent1", "role": "Treatment_Disorder", "text": "asthma", "start": 1, "end": 2}, {"entity_id": "9161656_8_Ent4", "role": "Treatment_Time_elapsed", "text": "within 24 hours", "start": 3, "end": 6}, {"entity_id": "9161656_8_Ent2", "role": "Treatment_Dosage", "text": "three", "start": 7, "end": 8}, {"entity_id": "9161656_8_Ent0", "role": "Treatment", "text": "three albuterol inhalations", "start": 7, "end": 10}, {"entity_id": "9161656_8_Ent3", "role": "Treatment_Drug", "text": "albuterol", "start": 8, "end": 9}, {"entity_id": "9161656_8_Ent5", "role": "Treatment_Route", "text": "inhalations", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "9161656_8_Ent1", "text": "asthma", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9161656_8_Ent4", "text": "within 24 hours", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "9161656_8_Ent2", "text": "three", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9161656_8_Ent0", "text": "three albuterol inhalations", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "9161656_8_Ent3", "text": "albuterol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9161656_8_Ent5", "text": "inhalations", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "9169264_3", "wnd_id": "9169264_3_1", "text": "The case of a patient with infectious mononucleosis treated with cephalexin who later showed a rash is presented and the previous literature is reviewed .", "tokens": ["The", "case", "of", "a", "patient", "with", "infectious", "mononucleosis", "treated", "with", "cephalexin", "who", "later", "showed", "a", "rash", "is", "presented", "and", "the", "previous", "literature", "is", "reviewed", "."], "event_mentions": [{"id": "9169264_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "showed", "start": 13, "end": 14}, "arguments": [{"entity_id": "9169264_3_Ent0", "role": "Subject", "text": "a patient with infectious mononucleosis", "start": 3, "end": 8}, {"entity_id": "9169264_3_Ent4", "role": "Treatment_Disorder", "text": "infectious mononucleosis", "start": 6, "end": 8}, {"entity_id": "9169264_3_Ent2", "role": "Treatment", "text": "cephalexin", "start": 10, "end": 11}, {"entity_id": "9169264_3_Ent3", "role": "Treatment_Drug", "text": "cephalexin", "start": 10, "end": 11}, {"entity_id": "9169264_3_Ent1", "role": "Effect", "text": "rash", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "9169264_3_Ent0", "text": "a patient with infectious mononucleosis", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "9169264_3_Ent4", "text": "infectious mononucleosis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9169264_3_Ent2", "text": "cephalexin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9169264_3_Ent3", "text": "cephalexin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9169264_3_Ent1", "text": "rash", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "9211543_1", "wnd_id": "9211543_1_1", "text": "Bleomycin and cyclophosphamide toxicity simulating metastatic nodules to the lungs in childhood cancer .", "tokens": ["Bleomycin", "and", "cyclophosphamide", "toxicity", "simulating", "metastatic", "nodules", "to", "the", "lungs", "in", "childhood", "cancer", "."], "event_mentions": [{"id": "9211543_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "simulating", "start": 4, "end": 5}, "arguments": [{"entity_id": "9211543_1_Ent5", "role": "Treatment_Drug", "text": "Bleomycin", "start": 0, "end": 1}, {"entity_id": "9211543_1_Ent8", "role": "Combination_Drug", "text": "Bleomycin", "start": 0, "end": 1}, {"entity_id": "9211543_1_Ent3", "role": "Treatment", "text": "Bleomycin and cyclophosphamide toxicity", "start": 0, "end": 4}, {"entity_id": "9211543_1_Ent6", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 2, "end": 3}, {"entity_id": "9211543_1_Ent7", "role": "Combination_Drug", "text": "cyclophosphamide", "start": 2, "end": 3}, {"entity_id": "9211543_1_Ent2", "role": "Effect", "text": "metastatic nodules to the lungs", "start": 5, "end": 10}, {"entity_id": "9211543_1_Ent1", "role": "Subject_Age", "text": "childhood", "start": 11, "end": 12}, {"entity_id": "9211543_1_Ent0", "role": "Subject", "text": "childhood cancer", "start": 11, "end": 13}, {"entity_id": "9211543_1_Ent4", "role": "Treatment_Disorder", "text": "cancer", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "9211543_1_Ent5", "text": "Bleomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9211543_1_Ent8", "text": "Bleomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9211543_1_Ent3", "text": "Bleomycin and cyclophosphamide toxicity", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9211543_1_Ent6", "text": "cyclophosphamide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9211543_1_Ent7", "text": "cyclophosphamide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9211543_1_Ent2", "text": "metastatic nodules to the lungs", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "9211543_1_Ent1", "text": "childhood", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9211543_1_Ent0", "text": "childhood cancer", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "9211543_1_Ent4", "text": "cancer", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "921427_1", "wnd_id": "921427_1_1", "text": "An elderly man with procainamide hydrochloride - induced lupus syndrome had a circulating anticoagulant against factor XI and a biologic false - positive ( BFP ) test result for syphilis .", "tokens": ["An", "elderly", "man", "with", "procainamide", "hydrochloride", "-", "induced", "lupus", "syndrome", "had", "a", "circulating", "anticoagulant", "against", "factor", "XI", "and", "a", "biologic", "false", "-", "positive", "(", "BFP", ")", "test", "result", "for", "syphilis", "."], "event_mentions": [{"id": "921427_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "921427_1_Ent0", "role": "Subject", "text": "An elderly man", "start": 0, "end": 3}, {"entity_id": "921427_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 1, "end": 2}, {"entity_id": "921427_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 2, "end": 3}, {"entity_id": "921427_1_Ent4", "role": "Treatment", "text": "procainamide hydrochloride", "start": 4, "end": 6}, {"entity_id": "921427_1_Ent5", "role": "Treatment_Drug", "text": "procainamide hydrochloride", "start": 4, "end": 6}, {"entity_id": "921427_1_Ent3", "role": "Effect", "text": "lupus", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "921427_1_Ent0", "text": "An elderly man", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "921427_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "921427_1_Ent2", "text": "man", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "921427_1_Ent4", "text": "procainamide hydrochloride", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "921427_1_Ent5", "text": "procainamide hydrochloride", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "921427_1_Ent3", "text": "lupus", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "9220046_4", "wnd_id": "9220046_4_1", "text": "Erythromycin is a macrolide antibiotic that may increase the risk of lovastatin - induced rhabdomyolysis .", "tokens": ["Erythromycin", "is", "a", "macrolide", "antibiotic", "that", "may", "increase", "the", "risk", "of", "lovastatin", "-", "induced", "rhabdomyolysis", "."], "event_mentions": [{"id": "9220046_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "9220046_4_Ent1", "role": "Treatment", "text": "Erythromycin", "start": 0, "end": 1}, {"entity_id": "9220046_4_Ent2", "role": "Treatment_Drug", "text": "Erythromycin", "start": 0, "end": 1}, {"entity_id": "9220046_4_Ent5", "role": "Combination_Drug", "text": "Erythromycin", "start": 0, "end": 1}, {"entity_id": "9220046_4_Ent0", "role": "Effect", "text": "increase the risk of lovastatin - induced rhabdomyolysis", "start": 7, "end": 15}, {"entity_id": "9220046_4_Ent3", "role": "Treatment_Drug", "text": "lovastatin", "start": 11, "end": 12}, {"entity_id": "9220046_4_Ent4", "role": "Combination_Drug", "text": "lovastatin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9220046_4_Ent1", "text": "Erythromycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9220046_4_Ent2", "text": "Erythromycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9220046_4_Ent5", "text": "Erythromycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9220046_4_Ent0", "text": "increase the risk of lovastatin - induced rhabdomyolysis", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "9220046_4_Ent3", "text": "lovastatin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9220046_4_Ent4", "text": "lovastatin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9220046_7", "wnd_id": "9220046_7_1", "text": "To our knowledge , these cases are the first published reports of lovastatin - induced rhabdomyolysis associated with azithromycin and clarithromycin .", "tokens": ["To", "our", "knowledge", ",", "these", "cases", "are", "the", "first", "published", "reports", "of", "lovastatin", "-", "induced", "rhabdomyolysis", "associated", "with", "azithromycin", "and", "clarithromycin", "."], "event_mentions": [{"id": "9220046_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "9220046_7_Ent1", "role": "Treatment", "text": "lovastatin", "start": 12, "end": 13}, {"entity_id": "9220046_7_Ent3", "role": "Treatment_Drug", "text": "lovastatin", "start": 12, "end": 13}, {"entity_id": "9220046_7_Ent8", "role": "Combination_Drug", "text": "lovastatin", "start": 12, "end": 13}, {"entity_id": "9220046_7_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 15, "end": 16}, {"entity_id": "9220046_7_Ent2", "role": "Treatment", "text": "associated with azithromycin and clarithromycin", "start": 16, "end": 21}, {"entity_id": "9220046_7_Ent4", "role": "Treatment_Drug", "text": "azithromycin", "start": 18, "end": 19}, {"entity_id": "9220046_7_Ent6", "role": "Combination_Drug", "text": "azithromycin", "start": 18, "end": 19}, {"entity_id": "9220046_7_Ent5", "role": "Treatment_Drug", "text": "clarithromycin", "start": 20, "end": 21}, {"entity_id": "9220046_7_Ent7", "role": "Combination_Drug", "text": "clarithromycin", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "9220046_7_Ent1", "text": "lovastatin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9220046_7_Ent3", "text": "lovastatin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9220046_7_Ent8", "text": "lovastatin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9220046_7_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9220046_7_Ent2", "text": "associated with azithromycin and clarithromycin", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "9220046_7_Ent4", "text": "azithromycin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9220046_7_Ent6", "text": "azithromycin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9220046_7_Ent5", "text": "clarithromycin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "9220046_7_Ent7", "text": "clarithromycin", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "9232614_1", "wnd_id": "9232614_1_1", "text": "Acute leukaemia during tamoxifen therapy .", "tokens": ["Acute", "leukaemia", "during", "tamoxifen", "therapy", "."], "event_mentions": [{"id": "9232614_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "9232614_1_Ent0", "role": "Effect", "text": "Acute leukaemia", "start": 0, "end": 2}, {"entity_id": "9232614_1_Ent2", "role": "Treatment_Drug", "text": "tamoxifen", "start": 3, "end": 4}, {"entity_id": "9232614_1_Ent1", "role": "Treatment", "text": "tamoxifen therapy", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "9232614_1_Ent0", "text": "Acute leukaemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9232614_1_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9232614_1_Ent1", "text": "tamoxifen therapy", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "9247841_4", "wnd_id": "9247841_4_1", "text": "We report 3 patients who developed cutaneous vasculitis which is a rare and serious side - effect during antithyroid drug therapy .", "tokens": ["We", "report", "3", "patients", "who", "developed", "cutaneous", "vasculitis", "which", "is", "a", "rare", "and", "serious", "side", "-", "effect", "during", "antithyroid", "drug", "therapy", "."], "event_mentions": [{"id": "9247841_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "9247841_4_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "9247841_4_Ent0", "role": "Subject", "text": "3 patients", "start": 2, "end": 4}, {"entity_id": "9247841_4_Ent2", "role": "Effect", "text": "cutaneous vasculitis", "start": 6, "end": 8}, {"entity_id": "9247841_4_Ent3", "role": "Treatment", "text": "during antithyroid drug therapy", "start": 17, "end": 21}, {"entity_id": "9247841_4_Ent4", "role": "Treatment_Drug", "text": "antithyroid", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "9247841_4_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9247841_4_Ent0", "text": "3 patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9247841_4_Ent2", "text": "cutaneous vasculitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9247841_4_Ent3", "text": "during antithyroid drug therapy", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "9247841_4_Ent4", "text": "antithyroid", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "9253492_1", "wnd_id": "9253492_1_1", "text": "A 2 - year - old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled heat stroke during the administration of zonisamide .", "tokens": ["A", "2", "-", "year", "-", "old", "mentally", "retarded", "boy", "with", "frontal", "lobe", "epilepsy", "presented", "with", "an", "episode", "that", "resembled", "heat", "stroke", "during", "the", "administration", "of", "zonisamide", "."], "event_mentions": [{"id": "9253492_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 21, "end": 22}, "arguments": [{"entity_id": "9253492_1_Ent0", "role": "Subject", "text": "A 2 - year - old mentally retarded boy with frontal lobe epilepsy", "start": 0, "end": 13}, {"entity_id": "9253492_1_Ent1", "role": "Subject_Age", "text": "2 - year - old", "start": 1, "end": 6}, {"entity_id": "9253492_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 8, "end": 9}, {"entity_id": "9253492_1_Ent6", "role": "Treatment_Disorder", "text": "frontal lobe epilepsy", "start": 10, "end": 13}, {"entity_id": "9253492_1_Ent3", "role": "Effect", "text": "an episode that resembled heat stroke", "start": 15, "end": 21}, {"entity_id": "9253492_1_Ent4", "role": "Treatment", "text": "zonisamide", "start": 25, "end": 26}, {"entity_id": "9253492_1_Ent5", "role": "Treatment_Drug", "text": "zonisamide", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "9253492_1_Ent0", "text": "A 2 - year - old mentally retarded boy with frontal lobe epilepsy", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "9253492_1_Ent1", "text": "2 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9253492_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9253492_1_Ent6", "text": "frontal lobe epilepsy", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "9253492_1_Ent3", "text": "an episode that resembled heat stroke", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "9253492_1_Ent4", "text": "zonisamide", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "9253492_1_Ent5", "text": "zonisamide", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "9256906_2", "wnd_id": "9256906_2_1", "text": "Acute renal failure should be recognized as a potential complication of suramin treatment .", "tokens": ["Acute", "renal", "failure", "should", "be", "recognized", "as", "a", "potential", "complication", "of", "suramin", "treatment", "."], "event_mentions": [{"id": "9256906_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 9, "end": 10}, "arguments": [{"entity_id": "9256906_2_Ent0", "role": "Effect", "text": "Acute renal failure", "start": 0, "end": 3}, {"entity_id": "9256906_2_Ent2", "role": "Treatment_Drug", "text": "suramin", "start": 11, "end": 12}, {"entity_id": "9256906_2_Ent1", "role": "Treatment", "text": "suramin treatment", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "9256906_2_Ent0", "text": "Acute renal failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9256906_2_Ent2", "text": "suramin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9256906_2_Ent1", "text": "suramin treatment", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "9260733_1", "wnd_id": "9260733_1_1", "text": "Clozapine induced polyserositis .", "tokens": ["Clozapine", "induced", "polyserositis", "."], "event_mentions": [{"id": "9260733_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "9260733_1_Ent1", "role": "Treatment", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "9260733_1_Ent2", "role": "Treatment_Drug", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "9260733_1_Ent0", "role": "Effect", "text": "polyserositis", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "9260733_1_Ent1", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9260733_1_Ent2", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9260733_1_Ent0", "text": "polyserositis", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "9311175_2", "wnd_id": "9311175_2_1", "text": "Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to cisplatin : one , involving intrahepatic artery infusion , manifested general erythema , dyspnea , and hypotension ; the other , involving intravenous infusion , manifested abdominal pain , general erythema , and fever .", "tokens": ["Two", "patients", "with", "ovarian", "cancer", "who", "had", "received", "multiple", "courses", "of", "cisplatin", "without", "complications", "experienced", "hypersensitivity", "reactions", "to", "cisplatin", ":", "one", ",", "involving", "intrahepatic", "artery", "infusion", ",", "manifested", "general", "erythema", ",", "dyspnea", ",", "and", "hypotension", ";", "the", "other", ",", "involving", "intravenous", "infusion", ",", "manifested", "abdominal", "pain", ",", "general", "erythema", ",", "and", "fever", "."], "event_mentions": [{"id": "9311175_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reactions", "start": 16, "end": 17}, "arguments": [{"entity_id": "9311175_2_Ent5", "role": "Treatment_Disorder", "text": "ovarian cancer", "start": 3, "end": 5}, {"entity_id": "9311175_2_Ent2", "role": "Treatment", "text": "cisplatin", "start": 18, "end": 19}, {"entity_id": "9311175_2_Ent4", "role": "Treatment_Drug", "text": "cisplatin", "start": 18, "end": 19}, {"entity_id": "9311175_2_Ent0", "role": "Subject", "text": "one", "start": 20, "end": 21}, {"entity_id": "9311175_2_Ent3", "role": "Treatment", "text": "involving intrahepatic artery infusion", "start": 22, "end": 26}, {"entity_id": "9311175_2_Ent6", "role": "Treatment_Route", "text": "intrahepatic artery infusion", "start": 23, "end": 26}, {"entity_id": "9311175_2_Ent1", "role": "Effect", "text": "manifested general erythema , dyspnea , and hypotension", "start": 27, "end": 35}]}, {"id": "9311175_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "reactions", "start": 16, "end": 17}, "arguments": [{"entity_id": "9311175_2_Ent9", "role": "Treatment", "text": "cisplatin", "start": 18, "end": 19}, {"entity_id": "9311175_2_Ent11", "role": "Treatment_Drug", "text": "cisplatin", "start": 18, "end": 19}, {"entity_id": "9311175_2_Ent7", "role": "Subject", "text": "the other", "start": 36, "end": 38}, {"entity_id": "9311175_2_Ent10", "role": "Treatment", "text": "involving intravenous infusion", "start": 39, "end": 42}, {"entity_id": "9311175_2_Ent12", "role": "Treatment_Route", "text": "intravenous infusion", "start": 40, "end": 42}, {"entity_id": "9311175_2_Ent8", "role": "Effect", "text": "manifested abdominal pain , general erythema , and fever", "start": 43, "end": 52}]}], "entity_mentions": [{"id": "9311175_2_Ent5", "text": "ovarian cancer", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9311175_2_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9311175_2_Ent4", "text": "cisplatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9311175_2_Ent9", "text": "cisplatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9311175_2_Ent11", "text": "cisplatin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9311175_2_Ent0", "text": "one", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "9311175_2_Ent3", "text": "involving intrahepatic artery infusion", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "9311175_2_Ent6", "text": "intrahepatic artery infusion", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "9311175_2_Ent1", "text": "manifested general erythema , dyspnea , and hypotension", "entity_type": "Entity", "start": 27, "end": 35}, {"id": "9311175_2_Ent7", "text": "the other", "entity_type": "Entity", "start": 36, "end": 38}, {"id": "9311175_2_Ent10", "text": "involving intravenous infusion", "entity_type": "Entity", "start": 39, "end": 42}, {"id": "9311175_2_Ent12", "text": "intravenous infusion", "entity_type": "Entity", "start": 40, "end": 42}, {"id": "9311175_2_Ent8", "text": "manifested abdominal pain , general erythema , and fever", "entity_type": "Entity", "start": 43, "end": 52}], "lang": "en"}
{"doc_id": "9337441_14", "wnd_id": "9337441_14_1", "text": "To our knowledge , this case report represents only the third description of laxative - induced TEN .", "tokens": ["To", "our", "knowledge", ",", "this", "case", "report", "represents", "only", "the", "third", "description", "of", "laxative", "-", "induced", "TEN", "."], "event_mentions": [{"id": "9337441_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "9337441_14_Ent1", "role": "Treatment", "text": "laxative", "start": 13, "end": 14}, {"entity_id": "9337441_14_Ent2", "role": "Treatment_Drug", "text": "laxative", "start": 13, "end": 14}, {"entity_id": "9337441_14_Ent0", "role": "Effect", "text": "TEN", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "9337441_14_Ent1", "text": "laxative", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9337441_14_Ent2", "text": "laxative", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9337441_14_Ent0", "text": "TEN", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "9337441_18", "wnd_id": "9337441_18_1", "text": "Clinicians should include phenolphthalein in their list of possible causes of drug - induced TEN .", "tokens": ["Clinicians", "should", "include", "phenolphthalein", "in", "their", "list", "of", "possible", "causes", "of", "drug", "-", "induced", "TEN", "."], "event_mentions": [{"id": "9337441_18_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 13, "end": 14}, "arguments": [{"entity_id": "9337441_18_Ent1", "role": "Treatment", "text": "phenolphthalein", "start": 3, "end": 4}, {"entity_id": "9337441_18_Ent2", "role": "Treatment_Drug", "text": "phenolphthalein", "start": 3, "end": 4}, {"entity_id": "9337441_18_Ent0", "role": "Effect", "text": "TEN", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "9337441_18_Ent1", "text": "phenolphthalein", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9337441_18_Ent2", "text": "phenolphthalein", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9337441_18_Ent0", "text": "TEN", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "9347384_1", "wnd_id": "9347384_1_1", "text": "Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients .", "tokens": ["Carbamazepine", "toxicity", "induced", "by", "clarithromycin", "coadministration", "in", "psychiatric", "patients", "."], "event_mentions": [{"id": "9347384_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9347384_1_Ent5", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "9347384_1_Ent7", "role": "Combination_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "9347384_1_Ent2", "role": "Effect", "text": "Carbamazepine toxicity", "start": 0, "end": 2}, {"entity_id": "9347384_1_Ent3", "role": "Treatment", "text": "clarithromycin", "start": 4, "end": 5}, {"entity_id": "9347384_1_Ent4", "role": "Treatment_Drug", "text": "clarithromycin", "start": 4, "end": 5}, {"entity_id": "9347384_1_Ent6", "role": "Combination_Drug", "text": "clarithromycin", "start": 4, "end": 5}, {"entity_id": "9347384_1_Ent1", "role": "Subject_Disorder", "text": "psychiatric", "start": 7, "end": 8}, {"entity_id": "9347384_1_Ent0", "role": "Subject", "text": "psychiatric patients", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "9347384_1_Ent5", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9347384_1_Ent7", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9347384_1_Ent2", "text": "Carbamazepine toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9347384_1_Ent3", "text": "clarithromycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9347384_1_Ent4", "text": "clarithromycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9347384_1_Ent6", "text": "clarithromycin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9347384_1_Ent1", "text": "psychiatric", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9347384_1_Ent0", "text": "psychiatric patients", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "9352164_2", "wnd_id": "9352164_2_1", "text": "As far as we know , this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication .", "tokens": ["As", "far", "as", "we", "know", ",", "this", "is", "the", "first", "case", "report", "of", "acute", "hemorrhagic", "gastritis", "associated", "with", "AZ", "intoxication", "."], "event_mentions": [{"id": "9352164_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 16, "end": 17}, "arguments": [{"entity_id": "9352164_2_Ent0", "role": "Effect", "text": "acute hemorrhagic gastritis", "start": 13, "end": 16}, {"entity_id": "9352164_2_Ent2", "role": "Treatment", "text": "AZ", "start": 18, "end": 19}, {"entity_id": "9352164_2_Ent3", "role": "Treatment_Drug", "text": "AZ", "start": 18, "end": 19}, {"entity_id": "9352164_2_Ent1", "role": "Effect", "text": "AZ intoxication", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "9352164_2_Ent0", "text": "acute hemorrhagic gastritis", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "9352164_2_Ent2", "text": "AZ", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9352164_2_Ent3", "text": "AZ", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9352164_2_Ent1", "text": "AZ intoxication", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "9352164_3", "wnd_id": "9352164_3_1", "text": "She was thus diagnosed as having AZ intoxication .", "tokens": ["She", "was", "thus", "diagnosed", "as", "having", "AZ", "intoxication", "."], "event_mentions": [{"id": "9352164_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "having", "start": 5, "end": 6}, "arguments": [{"entity_id": "9352164_3_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "9352164_3_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "9352164_3_Ent3", "role": "Treatment", "text": "AZ", "start": 6, "end": 7}, {"entity_id": "9352164_3_Ent4", "role": "Treatment_Drug", "text": "AZ", "start": 6, "end": 7}, {"entity_id": "9352164_3_Ent2", "role": "Effect", "text": "AZ intoxication", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "9352164_3_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9352164_3_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9352164_3_Ent3", "text": "AZ", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9352164_3_Ent4", "text": "AZ", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9352164_3_Ent2", "text": "AZ intoxication", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "9366852_2", "wnd_id": "9366852_2_1", "text": "Skin necrosis is a rare complication of subcutaneous heparin therapy that usually occurs at injection sites .", "tokens": ["Skin", "necrosis", "is", "a", "rare", "complication", "of", "subcutaneous", "heparin", "therapy", "that", "usually", "occurs", "at", "injection", "sites", "."], "event_mentions": [{"id": "9366852_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 5, "end": 6}, "arguments": [{"entity_id": "9366852_2_Ent0", "role": "Effect", "text": "Skin necrosis", "start": 0, "end": 2}, {"entity_id": "9366852_2_Ent3", "role": "Treatment_Route", "text": "subcutaneous", "start": 7, "end": 8}, {"entity_id": "9366852_2_Ent1", "role": "Treatment", "text": "subcutaneous heparin therapy", "start": 7, "end": 10}, {"entity_id": "9366852_2_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "9366852_2_Ent0", "text": "Skin necrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9366852_2_Ent3", "text": "subcutaneous", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9366852_2_Ent1", "text": "subcutaneous heparin therapy", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "9366852_2_Ent2", "text": "heparin", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "937377_1", "wnd_id": "937377_1_1", "text": "Finally , reserpine toxicity , in particular central nervous system ( CNS ) disturbances , was reported more frequently in patients also receiving barbiturates , suggesting additive CNS effects .", "tokens": ["Finally", ",", "reserpine", "toxicity", ",", "in", "particular", "central", "nervous", "system", "(", "CNS", ")", "disturbances", ",", "was", "reported", "more", "frequently", "in", "patients", "also", "receiving", "barbiturates", ",", "suggesting", "additive", "CNS", "effects", "."], "event_mentions": [{"id": "937377_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 16, "end": 17}, "arguments": [{"entity_id": "937377_1_Ent2", "role": "Treatment", "text": "reserpine", "start": 2, "end": 3}, {"entity_id": "937377_1_Ent5", "role": "Treatment_Drug", "text": "reserpine", "start": 2, "end": 3}, {"entity_id": "937377_1_Ent7", "role": "Combination_Drug", "text": "reserpine", "start": 2, "end": 3}, {"entity_id": "937377_1_Ent0", "role": "Effect", "text": "reserpine toxicity , in particular central nervous system ( CNS ) disturbances", "start": 2, "end": 14}, {"entity_id": "937377_1_Ent3", "role": "Treatment", "text": "also receiving barbiturates ,", "start": 21, "end": 25}, {"entity_id": "937377_1_Ent4", "role": "Treatment_Drug", "text": "barbiturates", "start": 23, "end": 24}, {"entity_id": "937377_1_Ent6", "role": "Combination_Drug", "text": "barbiturates", "start": 23, "end": 24}, {"entity_id": "937377_1_Ent1", "role": "Effect", "text": "additive CNS effects", "start": 26, "end": 29}]}], "entity_mentions": [{"id": "937377_1_Ent2", "text": "reserpine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "937377_1_Ent5", "text": "reserpine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "937377_1_Ent7", "text": "reserpine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "937377_1_Ent0", "text": "reserpine toxicity , in particular central nervous system ( CNS ) disturbances", "entity_type": "Entity", "start": 2, "end": 14}, {"id": "937377_1_Ent3", "text": "also receiving barbiturates ,", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "937377_1_Ent4", "text": "barbiturates", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "937377_1_Ent6", "text": "barbiturates", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "937377_1_Ent1", "text": "additive CNS effects", "entity_type": "Entity", "start": 26, "end": 29}], "lang": "en"}
{"doc_id": "9407188_1", "wnd_id": "9407188_1_1", "text": "Early ritonavir - induced maculopapular eruption .", "tokens": ["Early", "ritonavir", "-", "induced", "maculopapular", "eruption", "."], "event_mentions": [{"id": "9407188_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "9407188_1_Ent1", "role": "Treatment", "text": "ritonavir", "start": 1, "end": 2}, {"entity_id": "9407188_1_Ent2", "role": "Treatment_Drug", "text": "ritonavir", "start": 1, "end": 2}, {"entity_id": "9407188_1_Ent0", "role": "Effect", "text": "maculopapular eruption", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "9407188_1_Ent1", "text": "ritonavir", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9407188_1_Ent2", "text": "ritonavir", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9407188_1_Ent0", "text": "maculopapular eruption", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "9433539_1", "wnd_id": "9433539_1_1", "text": "A case is reported of an elderly woman who developed febrile agranulocytosis several weeks after commencing ticlopidine but who had a favorable outcome after cessation of that drug and treatment with filgastrim .", "tokens": ["A", "case", "is", "reported", "of", "an", "elderly", "woman", "who", "developed", "febrile", "agranulocytosis", "several", "weeks", "after", "commencing", "ticlopidine", "but", "who", "had", "a", "favorable", "outcome", "after", "cessation", "of", "that", "drug", "and", "treatment", "with", "filgastrim", "."], "event_mentions": [{"id": "9433539_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "9433539_1_Ent0", "role": "Subject", "text": "an elderly woman", "start": 5, "end": 8}, {"entity_id": "9433539_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 6, "end": 7}, {"entity_id": "9433539_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "9433539_1_Ent3", "role": "Effect", "text": "febrile agranulocytosis", "start": 10, "end": 12}, {"entity_id": "9433539_1_Ent5", "role": "Treatment_Time_elapsed", "text": "several weeks", "start": 12, "end": 14}, {"entity_id": "9433539_1_Ent4", "role": "Treatment", "text": "several weeks after commencing ticlopidine", "start": 12, "end": 17}, {"entity_id": "9433539_1_Ent6", "role": "Treatment_Drug", "text": "ticlopidine", "start": 16, "end": 17}]}, {"id": "9433539_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "after", "start": 23, "end": 24}, "arguments": [{"entity_id": "9433539_1_Ent7", "role": "Subject", "text": "an elderly woman", "start": 5, "end": 8}, {"entity_id": "9433539_1_Ent8", "role": "Subject_Age", "text": "elderly", "start": 6, "end": 7}, {"entity_id": "9433539_1_Ent9", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "9433539_1_Ent12", "role": "Treatment_Disorder", "text": "febrile agranulocytosis", "start": 10, "end": 12}, {"entity_id": "9433539_1_Ent10", "role": "Effect", "text": "a favorable outcome", "start": 20, "end": 23}, {"entity_id": "9433539_1_Ent11", "role": "Treatment", "text": "cessation of that drug and treatment with filgastrim", "start": 24, "end": 32}, {"entity_id": "9433539_1_Ent13", "role": "Treatment_Drug", "text": "filgastrim", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "9433539_1_Ent0", "text": "an elderly woman", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "9433539_1_Ent7", "text": "an elderly woman", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "9433539_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9433539_1_Ent8", "text": "elderly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9433539_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9433539_1_Ent9", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9433539_1_Ent3", "text": "febrile agranulocytosis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9433539_1_Ent12", "text": "febrile agranulocytosis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9433539_1_Ent5", "text": "several weeks", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "9433539_1_Ent4", "text": "several weeks after commencing ticlopidine", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "9433539_1_Ent6", "text": "ticlopidine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9433539_1_Ent10", "text": "a favorable outcome", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "9433539_1_Ent11", "text": "cessation of that drug and treatment with filgastrim", "entity_type": "Entity", "start": 24, "end": 32}, {"id": "9433539_1_Ent13", "text": "filgastrim", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "9433539_3", "wnd_id": "9433539_3_1", "text": "Ticlopidine is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with severe bone marrow suppression , typically aplastic anemia .", "tokens": ["Ticlopidine", "is", "an", "oral", "antiplatelet", "agent", "frequently", "utilized", "in", "the", "treatment", "of", "cerebrovascular", "disease", "and", "is", "rarely", "associated", "with", "severe", "bone", "marrow", "suppression", ",", "typically", "aplastic", "anemia", "."], "event_mentions": [{"id": "9433539_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 17, "end": 18}, "arguments": [{"entity_id": "9433539_3_Ent3", "role": "Treatment_Drug", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "9433539_3_Ent1", "role": "Treatment", "text": "Ticlopidine is an oral antiplatelet agent", "start": 0, "end": 6}, {"entity_id": "9433539_3_Ent4", "role": "Treatment_Route", "text": "oral", "start": 3, "end": 4}, {"entity_id": "9433539_3_Ent2", "role": "Treatment_Disorder", "text": "cerebrovascular disease", "start": 12, "end": 14}, {"entity_id": "9433539_3_Ent0", "role": "Effect", "text": "severe bone marrow suppression , typically aplastic anemia", "start": 19, "end": 27}]}], "entity_mentions": [{"id": "9433539_3_Ent3", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9433539_3_Ent1", "text": "Ticlopidine is an oral antiplatelet agent", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "9433539_3_Ent4", "text": "oral", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9433539_3_Ent2", "text": "cerebrovascular disease", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "9433539_3_Ent0", "text": "severe bone marrow suppression , typically aplastic anemia", "entity_type": "Entity", "start": 19, "end": 27}], "lang": "en"}
{"doc_id": "9443627_1", "wnd_id": "9443627_1_1", "text": "Hemodialysis was also shown to reverse ifosfamide - related neurotoxicity .", "tokens": ["Hemodialysis", "was", "also", "shown", "to", "reverse", "ifosfamide", "-", "related", "neurotoxicity", "."], "event_mentions": [{"id": "9443627_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reverse", "start": 5, "end": 6}, "arguments": [{"entity_id": "9443627_1_Ent3", "role": "Treatment", "text": "Hemodialysis", "start": 0, "end": 1}, {"entity_id": "9443627_1_Ent4", "role": "Treatment_Drug", "text": "Hemodialysis", "start": 0, "end": 1}, {"entity_id": "9443627_1_Ent5", "role": "Treatment_Disorder", "text": "ifosfamide - related neurotoxicity .", "start": 6, "end": 11}]}, {"id": "9443627_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 8, "end": 9}, "arguments": [{"entity_id": "9443627_1_Ent1", "role": "Treatment", "text": "ifosfamide", "start": 6, "end": 7}, {"entity_id": "9443627_1_Ent2", "role": "Treatment_Drug", "text": "ifosfamide", "start": 6, "end": 7}, {"entity_id": "9443627_1_Ent0", "role": "Effect", "text": "neurotoxicity", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "9443627_1_Ent3", "text": "Hemodialysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9443627_1_Ent4", "text": "Hemodialysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9443627_1_Ent1", "text": "ifosfamide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9443627_1_Ent2", "text": "ifosfamide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9443627_1_Ent5", "text": "ifosfamide - related neurotoxicity .", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "9443627_1_Ent0", "text": "neurotoxicity", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "946400_1", "wnd_id": "946400_1_1", "text": "A 55 - year - old woman developed symptoms suggestive of hepatitis 12 weeks after first receiving methyldopa for hypertension .", "tokens": ["A", "55", "-", "year", "-", "old", "woman", "developed", "symptoms", "suggestive", "of", "hepatitis", "12", "weeks", "after", "first", "receiving", "methyldopa", "for", "hypertension", "."], "event_mentions": [{"id": "946400_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "946400_1_Ent0", "role": "Subject", "text": "A 55 - year - old woman", "start": 0, "end": 7}, {"entity_id": "946400_1_Ent1", "role": "Subject_Age", "text": "55 - year - old", "start": 1, "end": 6}, {"entity_id": "946400_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "946400_1_Ent3", "role": "Effect", "text": "hepatitis", "start": 11, "end": 12}, {"entity_id": "946400_1_Ent6", "role": "Treatment_Time_elapsed", "text": "12 weeks", "start": 12, "end": 14}, {"entity_id": "946400_1_Ent4", "role": "Treatment", "text": "methyldopa", "start": 17, "end": 18}, {"entity_id": "946400_1_Ent7", "role": "Treatment_Drug", "text": "methyldopa", "start": 17, "end": 18}, {"entity_id": "946400_1_Ent5", "role": "Treatment_Disorder", "text": "hypertension", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "946400_1_Ent0", "text": "A 55 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "946400_1_Ent1", "text": "55 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "946400_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "946400_1_Ent3", "text": "hepatitis", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "946400_1_Ent6", "text": "12 weeks", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "946400_1_Ent4", "text": "methyldopa", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "946400_1_Ent7", "text": "methyldopa", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "946400_1_Ent5", "text": "hypertension", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "9491301_3", "wnd_id": "9491301_3_1", "text": "Stroke is an infrequent but recognized complication of heroin addiction .", "tokens": ["Stroke", "is", "an", "infrequent", "but", "recognized", "complication", "of", "heroin", "addiction", "."], "event_mentions": [{"id": "9491301_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 6, "end": 7}, "arguments": [{"entity_id": "9491301_3_Ent0", "role": "Effect", "text": "Stroke", "start": 0, "end": 1}, {"entity_id": "9491301_3_Ent2", "role": "Treatment_Drug", "text": "heroin", "start": 8, "end": 9}, {"entity_id": "9491301_3_Ent1", "role": "Treatment", "text": "heroin addiction", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "9491301_3_Ent0", "text": "Stroke", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9491301_3_Ent2", "text": "heroin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9491301_3_Ent1", "text": "heroin addiction", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "9494448_1", "wnd_id": "9494448_1_1", "text": "A MEDLINE search identified all the reported cases of hypersensitivity reactions to cyclosporine .", "tokens": ["A", "MEDLINE", "search", "identified", "all", "the", "reported", "cases", "of", "hypersensitivity", "reactions", "to", "cyclosporine", "."], "event_mentions": [{"id": "9494448_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reactions", "start": 10, "end": 11}, "arguments": [{"entity_id": "9494448_1_Ent0", "role": "Effect", "text": "hypersensitivity reactions", "start": 9, "end": 11}, {"entity_id": "9494448_1_Ent1", "role": "Treatment", "text": "cyclosporine", "start": 12, "end": 13}, {"entity_id": "9494448_1_Ent2", "role": "Treatment_Drug", "text": "cyclosporine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "9494448_1_Ent0", "text": "hypersensitivity reactions", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9494448_1_Ent1", "text": "cyclosporine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9494448_1_Ent2", "text": "cyclosporine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "9494448_8", "wnd_id": "9494448_8_1", "text": "The literature search revealed 22 cases of hypersensitivity reaction to cyclosporine .", "tokens": ["The", "literature", "search", "revealed", "22", "cases", "of", "hypersensitivity", "reaction", "to", "cyclosporine", "."], "event_mentions": [{"id": "9494448_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 9, "end": 10}, "arguments": [{"entity_id": "9494448_8_Ent1", "role": "Subject_Population", "text": "22", "start": 4, "end": 5}, {"entity_id": "9494448_8_Ent0", "role": "Subject", "text": "22 cases", "start": 4, "end": 6}, {"entity_id": "9494448_8_Ent2", "role": "Effect", "text": "hypersensitivity reaction", "start": 7, "end": 9}, {"entity_id": "9494448_8_Ent3", "role": "Treatment", "text": "cyclosporine", "start": 10, "end": 11}, {"entity_id": "9494448_8_Ent4", "role": "Treatment_Drug", "text": "cyclosporine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "9494448_8_Ent1", "text": "22", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9494448_8_Ent0", "text": "22 cases", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9494448_8_Ent2", "text": "hypersensitivity reaction", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9494448_8_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9494448_8_Ent4", "text": "cyclosporine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "9527943_1", "wnd_id": "9527943_1_1", "text": "Effect of beta - blockade on symptomatic dexamethasone - induced hypertrophic obstructive cardiomyopathy in premature infants : three case reports and literature review .", "tokens": ["Effect", "of", "beta", "-", "blockade", "on", "symptomatic", "dexamethasone", "-", "induced", "hypertrophic", "obstructive", "cardiomyopathy", "in", "premature", "infants", ":", "three", "case", "reports", "and", "literature", "review", "."], "event_mentions": [{"id": "9527943_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Effect", "start": 0, "end": 1}, "arguments": [{"entity_id": "9527943_1_Ent9", "role": "Treatment", "text": "beta - blockade", "start": 2, "end": 5}, {"entity_id": "9527943_1_Ent11", "role": "Treatment_Drug", "text": "beta - blockade", "start": 2, "end": 5}, {"entity_id": "9527943_1_Ent10", "role": "Treatment_Disorder", "text": "symptomatic dexamethasone - induced hypertrophic obstructive cardiomyopathy", "start": 6, "end": 13}, {"entity_id": "9527943_1_Ent7", "role": "Subject_Disorder", "text": "premature", "start": 14, "end": 15}, {"entity_id": "9527943_1_Ent6", "role": "Subject", "text": "premature infants", "start": 14, "end": 16}, {"entity_id": "9527943_1_Ent8", "role": "Subject_Age", "text": "infants", "start": 15, "end": 16}]}, {"id": "9527943_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "9527943_1_Ent4", "role": "Treatment", "text": "dexamethasone", "start": 7, "end": 8}, {"entity_id": "9527943_1_Ent5", "role": "Treatment_Drug", "text": "dexamethasone", "start": 7, "end": 8}, {"entity_id": "9527943_1_Ent3", "role": "Effect", "text": "hypertrophic obstructive cardiomyopathy", "start": 10, "end": 13}, {"entity_id": "9527943_1_Ent1", "role": "Subject_Disorder", "text": "premature", "start": 14, "end": 15}, {"entity_id": "9527943_1_Ent0", "role": "Subject", "text": "premature infants", "start": 14, "end": 16}, {"entity_id": "9527943_1_Ent2", "role": "Subject_Age", "text": "infants", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "9527943_1_Ent9", "text": "beta - blockade", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "9527943_1_Ent11", "text": "beta - blockade", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "9527943_1_Ent10", "text": "symptomatic dexamethasone - induced hypertrophic obstructive cardiomyopathy", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "9527943_1_Ent4", "text": "dexamethasone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9527943_1_Ent5", "text": "dexamethasone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9527943_1_Ent3", "text": "hypertrophic obstructive cardiomyopathy", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "9527943_1_Ent1", "text": "premature", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9527943_1_Ent7", "text": "premature", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9527943_1_Ent0", "text": "premature infants", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "9527943_1_Ent6", "text": "premature infants", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "9527943_1_Ent2", "text": "infants", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9527943_1_Ent8", "text": "infants", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "9527943_2", "wnd_id": "9527943_2_1", "text": "One patient had a lower average heart rate and two patients had lower average mean blood pressure values during propranolol treatment , none of which was clinically significant .", "tokens": ["One", "patient", "had", "a", "lower", "average", "heart", "rate", "and", "two", "patients", "had", "lower", "average", "mean", "blood", "pressure", "values", "during", "propranolol", "treatment", ",", "none", "of", "which", "was", "clinically", "significant", "."], "event_mentions": [{"id": "9527943_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 18, "end": 19}, "arguments": [{"entity_id": "9527943_2_Ent1", "role": "Subject_Population", "text": "two", "start": 9, "end": 10}, {"entity_id": "9527943_2_Ent0", "role": "Subject", "text": "two patients", "start": 9, "end": 11}, {"entity_id": "9527943_2_Ent2", "role": "Effect", "text": "lower average mean blood pressure values", "start": 12, "end": 18}, {"entity_id": "9527943_2_Ent3", "role": "Treatment", "text": "propranolol", "start": 19, "end": 20}, {"entity_id": "9527943_2_Ent4", "role": "Treatment_Drug", "text": "propranolol", "start": 19, "end": 20}]}, {"id": "9527943_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 18, "end": 19}, "arguments": [{"entity_id": "9527943_2_Ent6", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "9527943_2_Ent5", "role": "Subject", "text": "One patient", "start": 0, "end": 2}, {"entity_id": "9527943_2_Ent7", "role": "Effect", "text": "lower average heart rate", "start": 4, "end": 8}, {"entity_id": "9527943_2_Ent8", "role": "Treatment", "text": "propranolol", "start": 19, "end": 20}, {"entity_id": "9527943_2_Ent9", "role": "Treatment_Drug", "text": "propranolol", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "9527943_2_Ent6", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9527943_2_Ent5", "text": "One patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9527943_2_Ent7", "text": "lower average heart rate", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "9527943_2_Ent1", "text": "two", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9527943_2_Ent0", "text": "two patients", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9527943_2_Ent2", "text": "lower average mean blood pressure values", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "9527943_2_Ent3", "text": "propranolol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9527943_2_Ent4", "text": "propranolol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9527943_2_Ent8", "text": "propranolol", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9527943_2_Ent9", "text": "propranolol", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "9554064_1", "wnd_id": "9554064_1_1", "text": "Methanol toxicity can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies .", "tokens": ["Methanol", "toxicity", "can", "cause", "severe", "central", "nervous", "system", "insult", "in", "which", "a", "characteristic", "pattern", "of", "bilateral", "putaminal", "injury", "is", "noted", "on", "brain", "imaging", "studies", "."], "event_mentions": [{"id": "9554064_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "9554064_1_Ent2", "role": "Treatment_Drug", "text": "Methanol", "start": 0, "end": 1}, {"entity_id": "9554064_1_Ent1", "role": "Treatment", "text": "Methanol toxicity", "start": 0, "end": 2}, {"entity_id": "9554064_1_Ent0", "role": "Effect", "text": "central nervous system insult", "start": 5, "end": 9}]}], "entity_mentions": [{"id": "9554064_1_Ent2", "text": "Methanol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9554064_1_Ent1", "text": "Methanol toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9554064_1_Ent0", "text": "central nervous system insult", "entity_type": "Entity", "start": 5, "end": 9}], "lang": "en"}
{"doc_id": "961329_2", "wnd_id": "961329_2_1", "text": "Suxamethonium apnoea terminated with commercial serumcholinesterase .", "tokens": ["Suxamethonium", "apnoea", "terminated", "with", "commercial", "serumcholinesterase", "."], "event_mentions": [{"id": "961329_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "terminated", "start": 2, "end": 3}, "arguments": [{"entity_id": "961329_2_Ent0", "role": "Effect", "text": "Suxamethonium apnoea", "start": 0, "end": 2}, {"entity_id": "961329_2_Ent1", "role": "Treatment", "text": "commercial serumcholinesterase", "start": 4, "end": 6}, {"entity_id": "961329_2_Ent2", "role": "Treatment_Drug", "text": "commercial serumcholinesterase", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "961329_2_Ent0", "text": "Suxamethonium apnoea", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "961329_2_Ent1", "text": "commercial serumcholinesterase", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "961329_2_Ent2", "text": "commercial serumcholinesterase", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "9634122_1", "wnd_id": "9634122_1_1", "text": "Flutamide withdrawal syndrome is characterized by a decrease in prostate - specific antigen ( PSA ) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate .", "tokens": ["Flutamide", "withdrawal", "syndrome", "is", "characterized", "by", "a", "decrease", "in", "prostate", "-", "specific", "antigen", "(", "PSA", ")", "after", "flutamide", "withdrawal", "in", "a", "subset", "of", "patients", "with", "progressing", "metastatic", "carcinoma", "of", "the", "prostate", "."], "event_mentions": [{"id": "9634122_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "withdrawal", "start": 18, "end": 19}, "arguments": [{"entity_id": "9634122_1_Ent1", "role": "Effect", "text": "decrease in prostate - specific antigen ( PSA )", "start": 7, "end": 16}, {"entity_id": "9634122_1_Ent2", "role": "Treatment", "text": "flutamide", "start": 17, "end": 18}, {"entity_id": "9634122_1_Ent4", "role": "Treatment_Drug", "text": "flutamide", "start": 17, "end": 18}, {"entity_id": "9634122_1_Ent0", "role": "Subject", "text": "subset of patients with progressing metastatic carcinoma of the prostate", "start": 21, "end": 31}, {"entity_id": "9634122_1_Ent3", "role": "Treatment_Disorder", "text": "progressing metastatic carcinoma of the prostate", "start": 25, "end": 31}]}], "entity_mentions": [{"id": "9634122_1_Ent1", "text": "decrease in prostate - specific antigen ( PSA )", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "9634122_1_Ent2", "text": "flutamide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9634122_1_Ent4", "text": "flutamide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9634122_1_Ent0", "text": "subset of patients with progressing metastatic carcinoma of the prostate", "entity_type": "Entity", "start": 21, "end": 31}, {"id": "9634122_1_Ent3", "text": "progressing metastatic carcinoma of the prostate", "entity_type": "Entity", "start": 25, "end": 31}], "lang": "en"}
{"doc_id": "9634122_4", "wnd_id": "9634122_4_1", "text": "We describe a patient with androgen - independent prostate cancer in whom PSA continued to decrease for a period of 15 months after flutamide withdrawal .", "tokens": ["We", "describe", "a", "patient", "with", "androgen", "-", "independent", "prostate", "cancer", "in", "whom", "PSA", "continued", "to", "decrease", "for", "a", "period", "of", "15", "months", "after", "flutamide", "withdrawal", "."], "event_mentions": [{"id": "9634122_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 22, "end": 23}, "arguments": [{"entity_id": "9634122_4_Ent0", "role": "Subject", "text": "a patient with androgen - independent prostate cancer", "start": 2, "end": 10}, {"entity_id": "9634122_4_Ent4", "role": "Treatment_Disorder", "text": "androgen - independent prostate cancer", "start": 5, "end": 10}, {"entity_id": "9634122_4_Ent1", "role": "Effect", "text": "PSA continued to decrease for a period of 15 months", "start": 12, "end": 22}, {"entity_id": "9634122_4_Ent3", "role": "Treatment_Drug", "text": "flutamide", "start": 23, "end": 24}, {"entity_id": "9634122_4_Ent2", "role": "Treatment", "text": "flutamide withdrawal", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "9634122_4_Ent0", "text": "a patient with androgen - independent prostate cancer", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "9634122_4_Ent4", "text": "androgen - independent prostate cancer", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "9634122_4_Ent1", "text": "PSA continued to decrease for a period of 15 months", "entity_type": "Entity", "start": 12, "end": 22}, {"id": "9634122_4_Ent3", "text": "flutamide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "9634122_4_Ent2", "text": "flutamide withdrawal", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "9651465_3", "wnd_id": "9651465_3_1", "text": "The vomiting occurred on switching to different pancreatic enzymes preparations , ie , Creon 10 , Viokase , and Pancrease MT 16 .", "tokens": ["The", "vomiting", "occurred", "on", "switching", "to", "different", "pancreatic", "enzymes", "preparations", ",", "ie", ",", "Creon", "10", ",", "Viokase", ",", "and", "Pancrease", "MT", "16", "."], "event_mentions": [{"id": "9651465_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "switching", "start": 4, "end": 5}, "arguments": [{"entity_id": "9651465_3_Ent0", "role": "Effect", "text": "vomiting", "start": 1, "end": 2}, {"entity_id": "9651465_3_Ent1", "role": "Treatment", "text": "different pancreatic enzymes preparations , ie , Creon 10 , Viokase , and Pancrease MT 16", "start": 6, "end": 22}, {"entity_id": "9651465_3_Ent2", "role": "Treatment_Drug", "text": "Creon 10", "start": 13, "end": 15}, {"entity_id": "9651465_3_Ent3", "role": "Treatment_Drug", "text": "Viokase", "start": 16, "end": 17}, {"entity_id": "9651465_3_Ent4", "role": "Treatment_Drug", "text": "Pancrease MT 16", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "9651465_3_Ent0", "text": "vomiting", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9651465_3_Ent1", "text": "different pancreatic enzymes preparations , ie , Creon 10 , Viokase , and Pancrease MT 16", "entity_type": "Entity", "start": 6, "end": 22}, {"id": "9651465_3_Ent2", "text": "Creon 10", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "9651465_3_Ent3", "text": "Viokase", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9651465_3_Ent4", "text": "Pancrease MT 16", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "9671138_1", "wnd_id": "9671138_1_1", "text": "CD4 T - lymphocyte depletion , myelosuppression , and subsequent severe infections are the major side effects of fludarabine phosphate therapy .", "tokens": ["CD4", "T", "-", "lymphocyte", "depletion", ",", "myelosuppression", ",", "and", "subsequent", "severe", "infections", "are", "the", "major", "side", "effects", "of", "fludarabine", "phosphate", "therapy", "."], "event_mentions": [{"id": "9671138_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 17, "end": 18}, "arguments": [{"entity_id": "9671138_1_Ent0", "role": "Effect", "text": "CD4 T - lymphocyte depletion , myelosuppression , and subsequent severe infections", "start": 0, "end": 12}, {"entity_id": "9671138_1_Ent1", "role": "Treatment", "text": "fludarabine phosphate", "start": 18, "end": 20}, {"entity_id": "9671138_1_Ent2", "role": "Treatment_Drug", "text": "fludarabine phosphate", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "9671138_1_Ent0", "text": "CD4 T - lymphocyte depletion , myelosuppression , and subsequent severe infections", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "9671138_1_Ent1", "text": "fludarabine phosphate", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "9671138_1_Ent2", "text": "fludarabine phosphate", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "9681092_1", "wnd_id": "9681092_1_1", "text": "Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction .", "tokens": ["Torsade", "de", "pointes", "resulting", "from", "the", "addition", "of", "droperidol", "to", "an", "existing", "cytochrome", "P450", "drug", "interaction", "."], "event_mentions": [{"id": "9681092_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 3, "end": 4}, "arguments": [{"entity_id": "9681092_1_Ent0", "role": "Effect", "text": "Torsade de pointes", "start": 0, "end": 3}, {"entity_id": "9681092_1_Ent1", "role": "Treatment", "text": "droperidol", "start": 8, "end": 9}, {"entity_id": "9681092_1_Ent3", "role": "Treatment_Drug", "text": "droperidol", "start": 8, "end": 9}, {"entity_id": "9681092_1_Ent2", "role": "Treatment", "text": "cytochrome P450", "start": 12, "end": 14}, {"entity_id": "9681092_1_Ent4", "role": "Treatment_Drug", "text": "cytochrome P450", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "9681092_1_Ent0", "text": "Torsade de pointes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9681092_1_Ent1", "text": "droperidol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9681092_1_Ent3", "text": "droperidol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9681092_1_Ent2", "text": "cytochrome P450", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "9681092_1_Ent4", "text": "cytochrome P450", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "9681092_10", "wnd_id": "9681092_10_1", "text": "The combination of cyclobenzaprine and fluoxetine resulted in significant QT prolongation in our patient that progressed to torsade de pointes after preoperative droperidol administration .", "tokens": ["The", "combination", "of", "cyclobenzaprine", "and", "fluoxetine", "resulted", "in", "significant", "QT", "prolongation", "in", "our", "patient", "that", "progressed", "to", "torsade", "de", "pointes", "after", "preoperative", "droperidol", "administration", "."], "event_mentions": [{"id": "9681092_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 6, "end": 7}, "arguments": [{"entity_id": "9681092_10_Ent3", "role": "Treatment", "text": "The combination of cyclobenzaprine and fluoxetine", "start": 0, "end": 6}, {"entity_id": "9681092_10_Ent5", "role": "Treatment_Drug", "text": "cyclobenzaprine", "start": 3, "end": 4}, {"entity_id": "9681092_10_Ent9", "role": "Combination_Drug", "text": "cyclobenzaprine", "start": 3, "end": 4}, {"entity_id": "9681092_10_Ent6", "role": "Treatment_Drug", "text": "fluoxetine", "start": 5, "end": 6}, {"entity_id": "9681092_10_Ent10", "role": "Combination_Drug", "text": "fluoxetine", "start": 5, "end": 6}, {"entity_id": "9681092_10_Ent1", "role": "Effect", "text": "significant QT prolongation", "start": 8, "end": 11}, {"entity_id": "9681092_10_Ent0", "role": "Subject", "text": "our patient", "start": 12, "end": 14}, {"entity_id": "9681092_10_Ent2", "role": "Effect", "text": "progressed to torsade de pointes", "start": 15, "end": 20}, {"entity_id": "9681092_10_Ent8", "role": "Treatment_Time_elapsed", "text": "preoperative", "start": 21, "end": 22}, {"entity_id": "9681092_10_Ent4", "role": "Treatment", "text": "preoperative droperidol administration", "start": 21, "end": 24}, {"entity_id": "9681092_10_Ent7", "role": "Treatment_Drug", "text": "droperidol", "start": 22, "end": 23}, {"entity_id": "9681092_10_Ent11", "role": "Combination_Drug", "text": "droperidol", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "9681092_10_Ent3", "text": "The combination of cyclobenzaprine and fluoxetine", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "9681092_10_Ent5", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9681092_10_Ent9", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9681092_10_Ent6", "text": "fluoxetine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9681092_10_Ent10", "text": "fluoxetine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9681092_10_Ent1", "text": "significant QT prolongation", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "9681092_10_Ent0", "text": "our patient", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "9681092_10_Ent2", "text": "progressed to torsade de pointes", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "9681092_10_Ent8", "text": "preoperative", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "9681092_10_Ent4", "text": "preoperative droperidol administration", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "9681092_10_Ent7", "text": "droperidol", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "9681092_10_Ent11", "text": "droperidol", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "9681211_1", "wnd_id": "9681211_1_1", "text": "Although this G - CSF - driven leucocytosis was alarming it did not appear to have adversely affected the patient 's prognosis .", "tokens": ["Although", "this", "G", "-", "CSF", "-", "driven", "leucocytosis", "was", "alarming", "it", "did", "not", "appear", "to", "have", "adversely", "affected", "the", "patient", "'s", "prognosis", "."], "event_mentions": [{"id": "9681211_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "driven", "start": 6, "end": 7}, "arguments": [{"entity_id": "9681211_1_Ent1", "role": "Treatment", "text": "G - CSF", "start": 2, "end": 5}, {"entity_id": "9681211_1_Ent2", "role": "Treatment_Drug", "text": "G - CSF", "start": 2, "end": 5}, {"entity_id": "9681211_1_Ent0", "role": "Effect", "text": "leucocytosis", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "9681211_1_Ent1", "text": "G - CSF", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "9681211_1_Ent2", "text": "G - CSF", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "9681211_1_Ent0", "text": "leucocytosis", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "968449_1", "wnd_id": "968449_1_1", "text": "Chromosome abnormalities after chlorambucil therapy of polycythaemia vera .", "tokens": ["Chromosome", "abnormalities", "after", "chlorambucil", "therapy", "of", "polycythaemia", "vera", "."], "event_mentions": [{"id": "968449_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "968449_1_Ent0", "role": "Effect", "text": "Chromosome abnormalities", "start": 0, "end": 2}, {"entity_id": "968449_1_Ent2", "role": "Treatment_Drug", "text": "chlorambucil", "start": 3, "end": 4}, {"entity_id": "968449_1_Ent1", "role": "Treatment", "text": "chlorambucil therapy", "start": 3, "end": 5}, {"entity_id": "968449_1_Ent3", "role": "Treatment_Disorder", "text": "polycythaemia vera", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "968449_1_Ent0", "text": "Chromosome abnormalities", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "968449_1_Ent2", "text": "chlorambucil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "968449_1_Ent1", "text": "chlorambucil therapy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "968449_1_Ent3", "text": "polycythaemia vera", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "9704170_2", "wnd_id": "9704170_2_1", "text": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium - activated K+ channels .", "tokens": ["Clozapine", "is", "speculated", "to", "cause", "rhabdomyolysis", "in", "patients", "with", "defective", "calcium", "-", "activated", "K+", "channels", "."], "event_mentions": [{"id": "9704170_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "9704170_2_Ent3", "role": "Treatment", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "9704170_2_Ent4", "role": "Treatment_Drug", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "9704170_2_Ent2", "role": "Effect", "text": "rhabdomyolysis", "start": 5, "end": 6}, {"entity_id": "9704170_2_Ent0", "role": "Subject", "text": "patients with defective calcium - activated K+ channels", "start": 7, "end": 15}, {"entity_id": "9704170_2_Ent1", "role": "Subject_Disorder", "text": "defective calcium - activated K+ channels", "start": 9, "end": 15}]}], "entity_mentions": [{"id": "9704170_2_Ent3", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9704170_2_Ent4", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9704170_2_Ent2", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9704170_2_Ent0", "text": "patients with defective calcium - activated K+ channels", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "9704170_2_Ent1", "text": "defective calcium - activated K+ channels", "entity_type": "Entity", "start": 9, "end": 15}], "lang": "en"}
{"doc_id": "9704170_3", "wnd_id": "9704170_3_1", "text": "Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium - dependent potassium permeability of cell membranes .", "tokens": ["Rhabdomyolysis", "associated", "with", "clozapine", "treatment", "in", "a", "patient", "with", "decreased", "calcium", "-", "dependent", "potassium", "permeability", "of", "cell", "membranes", "."], "event_mentions": [{"id": "9704170_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "9704170_3_Ent2", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "9704170_3_Ent3", "role": "Treatment", "text": "clozapine", "start": 3, "end": 4}, {"entity_id": "9704170_3_Ent4", "role": "Treatment_Drug", "text": "clozapine", "start": 3, "end": 4}, {"entity_id": "9704170_3_Ent0", "role": "Subject", "text": "a patient with decreased calcium - dependent potassium permeability of cell membranes", "start": 6, "end": 18}, {"entity_id": "9704170_3_Ent1", "role": "Subject_Disorder", "text": "decreased calcium - dependent potassium permeability of cell membranes", "start": 9, "end": 18}]}], "entity_mentions": [{"id": "9704170_3_Ent2", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9704170_3_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9704170_3_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9704170_3_Ent0", "text": "a patient with decreased calcium - dependent potassium permeability of cell membranes", "entity_type": "Entity", "start": 6, "end": 18}, {"id": "9704170_3_Ent1", "text": "decreased calcium - dependent potassium permeability of cell membranes", "entity_type": "Entity", "start": 9, "end": 18}], "lang": "en"}
{"doc_id": "9719245_1", "wnd_id": "9719245_1_1", "text": "Excluding other causes , Pentasa - associated pancytopenia was considered .", "tokens": ["Excluding", "other", "causes", ",", "Pentasa", "-", "associated", "pancytopenia", "was", "considered", "."], "event_mentions": [{"id": "9719245_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "9719245_1_Ent1", "role": "Treatment", "text": "Pentasa", "start": 4, "end": 5}, {"entity_id": "9719245_1_Ent2", "role": "Treatment_Drug", "text": "Pentasa", "start": 4, "end": 5}, {"entity_id": "9719245_1_Ent0", "role": "Effect", "text": "pancytopenia", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "9719245_1_Ent1", "text": "Pentasa", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9719245_1_Ent2", "text": "Pentasa", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9719245_1_Ent0", "text": "pancytopenia", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "9725786_1", "wnd_id": "9725786_1_1", "text": "We describe a renal transplant recipient maintained on cyclosporine and prednisone developing Nocardia Asteroides brain abscess .", "tokens": ["We", "describe", "a", "renal", "transplant", "recipient", "maintained", "on", "cyclosporine", "and", "prednisone", "developing", "Nocardia", "Asteroides", "brain", "abscess", "."], "event_mentions": [{"id": "9725786_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 11, "end": 12}, "arguments": [{"entity_id": "9725786_1_Ent0", "role": "Subject", "text": "a renal transplant recipient", "start": 2, "end": 6}, {"entity_id": "9725786_1_Ent5", "role": "Treatment_Disorder", "text": "renal transplant recipient", "start": 3, "end": 6}, {"entity_id": "9725786_1_Ent2", "role": "Treatment", "text": "maintained on cyclosporine and prednisone", "start": 6, "end": 11}, {"entity_id": "9725786_1_Ent3", "role": "Treatment_Drug", "text": "cyclosporine", "start": 8, "end": 9}, {"entity_id": "9725786_1_Ent7", "role": "Combination_Drug", "text": "cyclosporine", "start": 8, "end": 9}, {"entity_id": "9725786_1_Ent4", "role": "Treatment_Drug", "text": "prednisone", "start": 10, "end": 11}, {"entity_id": "9725786_1_Ent6", "role": "Combination_Drug", "text": "prednisone", "start": 10, "end": 11}, {"entity_id": "9725786_1_Ent1", "role": "Effect", "text": "Nocardia Asteroides brain abscess", "start": 12, "end": 16}]}], "entity_mentions": [{"id": "9725786_1_Ent0", "text": "a renal transplant recipient", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "9725786_1_Ent5", "text": "renal transplant recipient", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "9725786_1_Ent2", "text": "maintained on cyclosporine and prednisone", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "9725786_1_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9725786_1_Ent7", "text": "cyclosporine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9725786_1_Ent4", "text": "prednisone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9725786_1_Ent6", "text": "prednisone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9725786_1_Ent1", "text": "Nocardia Asteroides brain abscess", "entity_type": "Entity", "start": 12, "end": 16}], "lang": "en"}
{"doc_id": "9726762_2", "wnd_id": "9726762_2_1", "text": "The following describes a patient on a stable regimen of warfarin who developed severe hypoprothrombinemia and bleeding 4 weeks after starting gemfibrozil .", "tokens": ["The", "following", "describes", "a", "patient", "on", "a", "stable", "regimen", "of", "warfarin", "who", "developed", "severe", "hypoprothrombinemia", "and", "bleeding", "4", "weeks", "after", "starting", "gemfibrozil", "."], "event_mentions": [{"id": "9726762_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "9726762_2_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "9726762_2_Ent2", "role": "Treatment", "text": "on a stable regimen of warfarin", "start": 5, "end": 11}, {"entity_id": "9726762_2_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 10, "end": 11}, {"entity_id": "9726762_2_Ent1", "role": "Effect", "text": "hypoprothrombinemia and bleeding", "start": 14, "end": 17}, {"entity_id": "9726762_2_Ent6", "role": "Treatment_Time_elapsed", "text": "4 weeks", "start": 17, "end": 19}, {"entity_id": "9726762_2_Ent3", "role": "Treatment", "text": "4 weeks after starting gemfibrozil", "start": 17, "end": 22}, {"entity_id": "9726762_2_Ent5", "role": "Treatment_Drug", "text": "gemfibrozil", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "9726762_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "9726762_2_Ent2", "text": "on a stable regimen of warfarin", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "9726762_2_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9726762_2_Ent1", "text": "hypoprothrombinemia and bleeding", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "9726762_2_Ent6", "text": "4 weeks", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "9726762_2_Ent3", "text": "4 weeks after starting gemfibrozil", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "9726762_2_Ent5", "text": "gemfibrozil", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "9726762_4", "wnd_id": "9726762_4_1", "text": "This interaction may be overlooked by clinicians , which may result in a serious bleeding risk for patients on warfarin .", "tokens": ["This", "interaction", "may", "be", "overlooked", "by", "clinicians", ",", "which", "may", "result", "in", "a", "serious", "bleeding", "risk", "for", "patients", "on", "warfarin", "."], "event_mentions": [{"id": "9726762_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result in", "start": 10, "end": 12}, "arguments": [{"entity_id": "9726762_4_Ent1", "role": "Effect", "text": "serious bleeding risk", "start": 13, "end": 16}, {"entity_id": "9726762_4_Ent0", "role": "Subject", "text": "patients", "start": 17, "end": 18}, {"entity_id": "9726762_4_Ent2", "role": "Treatment", "text": "warfarin", "start": 19, "end": 20}, {"entity_id": "9726762_4_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "9726762_4_Ent1", "text": "serious bleeding risk", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "9726762_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9726762_4_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9726762_4_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "9733234_1", "wnd_id": "9733234_1_1", "text": "Young children undergoing cisplatin chemotherapy are known to be at risk for progressive sensorineural hearing loss .", "tokens": ["Young", "children", "undergoing", "cisplatin", "chemotherapy", "are", "known", "to", "be", "at", "risk", "for", "progressive", "sensorineural", "hearing", "loss", "."], "event_mentions": [{"id": "9733234_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 10, "end": 11}, "arguments": [{"entity_id": "9733234_1_Ent1", "role": "Subject_Age", "text": "Young", "start": 0, "end": 1}, {"entity_id": "9733234_1_Ent0", "role": "Subject", "text": "Young children", "start": 0, "end": 2}, {"entity_id": "9733234_1_Ent2", "role": "Subject_Age", "text": "children", "start": 1, "end": 2}, {"entity_id": "9733234_1_Ent4", "role": "Treatment", "text": "undergoing cisplatin chemotherapy", "start": 2, "end": 5}, {"entity_id": "9733234_1_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 3, "end": 4}, {"entity_id": "9733234_1_Ent6", "role": "Treatment_Route", "text": "chemotherapy", "start": 4, "end": 5}, {"entity_id": "9733234_1_Ent3", "role": "Effect", "text": "progressive sensorineural hearing loss", "start": 12, "end": 16}]}], "entity_mentions": [{"id": "9733234_1_Ent1", "text": "Young", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9733234_1_Ent0", "text": "Young children", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9733234_1_Ent2", "text": "children", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9733234_1_Ent4", "text": "undergoing cisplatin chemotherapy", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "9733234_1_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9733234_1_Ent6", "text": "chemotherapy", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9733234_1_Ent3", "text": "progressive sensorineural hearing loss", "entity_type": "Entity", "start": 12, "end": 16}], "lang": "en"}
{"doc_id": "9737132_2", "wnd_id": "9737132_2_1", "text": "Caution in longterm usage and early recognition of pentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug - induced fibrous myopathy and localized neuropathy .", "tokens": ["Caution", "in", "longterm", "usage", "and", "early", "recognition", "of", "pentazocine", "toxicity", "as", "a", "neuromuscular", "complication", "are", "important", "in", "order", "to", "prevent", "irreversible", "drug", "-", "induced", "fibrous", "myopathy", "and", "localized", "neuropathy", "."], "event_mentions": [{"id": "9737132_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 13, "end": 14}, "arguments": [{"entity_id": "9737132_2_Ent1", "role": "Treatment", "text": "pentazocine", "start": 8, "end": 9}, {"entity_id": "9737132_2_Ent2", "role": "Treatment_Drug", "text": "pentazocine", "start": 8, "end": 9}, {"entity_id": "9737132_2_Ent0", "role": "Effect", "text": "toxicity", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "9737132_2_Ent1", "text": "pentazocine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9737132_2_Ent2", "text": "pentazocine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9737132_2_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "9754850_2", "wnd_id": "9754850_2_1", "text": "Like other atypical neuroleptics olanzapine is considered to show a reduced prevalence of extrapyramidal side effects when compared to classical neuroleptic drugs .", "tokens": ["Like", "other", "atypical", "neuroleptics", "olanzapine", "is", "considered", "to", "show", "a", "reduced", "prevalence", "of", "extrapyramidal", "side", "effects", "when", "compared", "to", "classical", "neuroleptic", "drugs", "."], "event_mentions": [{"id": "9754850_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "show", "start": 8, "end": 9}, "arguments": [{"entity_id": "9754850_2_Ent1", "role": "Treatment", "text": "olanzapine", "start": 4, "end": 5}, {"entity_id": "9754850_2_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 4, "end": 5}, {"entity_id": "9754850_2_Ent0", "role": "Effect", "text": "reduced prevalence of extrapyramidal side effects", "start": 10, "end": 16}, {"entity_id": "9754850_2_Ent3", "role": "Treatment_Drug", "text": "neuroleptic drugs .", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "9754850_2_Ent1", "text": "olanzapine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9754850_2_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9754850_2_Ent0", "text": "reduced prevalence of extrapyramidal side effects", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "9754850_2_Ent3", "text": "neuroleptic drugs .", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "9754850_3", "wnd_id": "9754850_3_1", "text": "One should therefore be aware of possible extrapyramidal side effects with olanzapine that are reduced compared to classical neuroleptic drugs but not completely eliminated .", "tokens": ["One", "should", "therefore", "be", "aware", "of", "possible", "extrapyramidal", "side", "effects", "with", "olanzapine", "that", "are", "reduced", "compared", "to", "classical", "neuroleptic", "drugs", "but", "not", "completely", "eliminated", "."], "event_mentions": [{"id": "9754850_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 10, "end": 11}, "arguments": [{"entity_id": "9754850_3_Ent0", "role": "Effect", "text": "extrapyramidal side effects", "start": 7, "end": 10}, {"entity_id": "9754850_3_Ent1", "role": "Treatment", "text": "olanzapine", "start": 11, "end": 12}, {"entity_id": "9754850_3_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9754850_3_Ent0", "text": "extrapyramidal side effects", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "9754850_3_Ent1", "text": "olanzapine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9754850_3_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9792602_2", "wnd_id": "9792602_2_1", "text": "Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast .", "tokens": ["Tubulointerstitial", "nephritis", "induced", "by", "the", "leukotriene", "receptor", "antagonist", "pranlukast", "."], "event_mentions": [{"id": "9792602_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9792602_2_Ent0", "role": "Effect", "text": "Tubulointerstitial nephritis", "start": 0, "end": 2}, {"entity_id": "9792602_2_Ent1", "role": "Treatment", "text": "pranlukast", "start": 8, "end": 9}, {"entity_id": "9792602_2_Ent2", "role": "Treatment_Drug", "text": "pranlukast", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "9792602_2_Ent0", "text": "Tubulointerstitial nephritis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9792602_2_Ent1", "text": "pranlukast", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9792602_2_Ent2", "text": "pranlukast", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "9796135_3", "wnd_id": "9796135_3_1", "text": "In a postural challenge test after administration of isosorbide dinitrate ( 5 mg ) , blood pressure decreased from 120/67 to 65/35 mmHg , followed by syncope with a sudden decrease in pulse rate from 85 to 60 beats / min .", "tokens": ["In", "a", "postural", "challenge", "test", "after", "administration", "of", "isosorbide", "dinitrate", "(", "5", "mg", ")", ",", "blood", "pressure", "decreased", "from", "120/67", "to", "65/35", "mmHg", ",", "followed", "by", "syncope", "with", "a", "sudden", "decrease", "in", "pulse", "rate", "from", "85", "to", "60", "beats", "/", "min", "."], "event_mentions": [{"id": "9796135_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "9796135_3_Ent3", "role": "Treatment", "text": "administration of isosorbide dinitrate ( 5 mg )", "start": 6, "end": 14}, {"entity_id": "9796135_3_Ent4", "role": "Treatment_Drug", "text": "isosorbide dinitrate", "start": 8, "end": 10}, {"entity_id": "9796135_3_Ent5", "role": "Treatment_Dosage", "text": "5 mg", "start": 11, "end": 13}, {"entity_id": "9796135_3_Ent0", "role": "Effect", "text": "blood pressure decreased", "start": 15, "end": 18}, {"entity_id": "9796135_3_Ent1", "role": "Effect", "text": "syncope", "start": 26, "end": 27}, {"entity_id": "9796135_3_Ent2", "role": "Effect", "text": "a sudden decrease in pulse rate", "start": 28, "end": 34}]}], "entity_mentions": [{"id": "9796135_3_Ent3", "text": "administration of isosorbide dinitrate ( 5 mg )", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "9796135_3_Ent4", "text": "isosorbide dinitrate", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9796135_3_Ent5", "text": "5 mg", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "9796135_3_Ent0", "text": "blood pressure decreased", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "9796135_3_Ent1", "text": "syncope", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "9796135_3_Ent2", "text": "a sudden decrease in pulse rate", "entity_type": "Entity", "start": 28, "end": 34}], "lang": "en"}
{"doc_id": "9804082_2", "wnd_id": "9804082_2_1", "text": "We observed 3 diabetic patients with intolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha - glucosidase inhibitor , voglibose .", "tokens": ["We", "observed", "3", "diabetic", "patients", "with", "intolerable", "dizziness", "followed", "by", "nausea", "and", "vomiting", "immediately", "after", "an", "initial", "administration", "of", "the", "alpha", "-", "glucosidase", "inhibitor", ",", "voglibose", "."], "event_mentions": [{"id": "9804082_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 14, "end": 15}, "arguments": [{"entity_id": "9804082_2_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "9804082_2_Ent0", "role": "Subject", "text": "3 diabetic patients", "start": 2, "end": 5}, {"entity_id": "9804082_2_Ent4", "role": "Treatment_Disorder", "text": "diabetic", "start": 3, "end": 4}, {"entity_id": "9804082_2_Ent2", "role": "Effect", "text": "intolerable dizziness followed by nausea and vomiting", "start": 6, "end": 13}, {"entity_id": "9804082_2_Ent3", "role": "Treatment", "text": "an initial administration of the alpha - glucosidase inhibitor , voglibose", "start": 15, "end": 26}, {"entity_id": "9804082_2_Ent5", "role": "Treatment_Drug", "text": "voglibose", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "9804082_2_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9804082_2_Ent0", "text": "3 diabetic patients", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "9804082_2_Ent4", "text": "diabetic", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9804082_2_Ent2", "text": "intolerable dizziness followed by nausea and vomiting", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "9804082_2_Ent3", "text": "an initial administration of the alpha - glucosidase inhibitor , voglibose", "entity_type": "Entity", "start": 15, "end": 26}, {"id": "9804082_2_Ent5", "text": "voglibose", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "9824032_1", "wnd_id": "9824032_1_1", "text": "Dental and gingival pain as side effects of niacin therapy .", "tokens": ["Dental", "and", "gingival", "pain", "as", "side", "effects", "of", "niacin", "therapy", "."], "event_mentions": [{"id": "9824032_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 5, "end": 7}, "arguments": [{"entity_id": "9824032_1_Ent0", "role": "Effect", "text": "Dental and gingival pain", "start": 0, "end": 4}, {"entity_id": "9824032_1_Ent1", "role": "Treatment", "text": "niacin", "start": 8, "end": 9}, {"entity_id": "9824032_1_Ent2", "role": "Treatment_Drug", "text": "niacin", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "9824032_1_Ent0", "text": "Dental and gingival pain", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9824032_1_Ent1", "text": "niacin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9824032_1_Ent2", "text": "niacin", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "9824032_3", "wnd_id": "9824032_3_1", "text": "Two 65 - year - old white men with coronary heart disease , given niacin therapy for dyslipidemia for 5 months , developed intense dental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of niacin treatment .", "tokens": ["Two", "65", "-", "year", "-", "old", "white", "men", "with", "coronary", "heart", "disease", ",", "given", "niacin", "therapy", "for", "dyslipidemia", "for", "5", "months", ",", "developed", "intense", "dental", "and", "gingival", "pain", "that", "was", "associated", "with", "increases", "in", "dose", "and", "that", "was", "relieved", "with", "discontinuance", "of", "niacin", "treatment", "."], "event_mentions": [{"id": "9824032_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 22, "end": 23}, "arguments": [{"entity_id": "9824032_3_Ent2", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "9824032_3_Ent0", "role": "Subject", "text": "Two 65 - year - old white men with coronary heart disease", "start": 0, "end": 12}, {"entity_id": "9824032_3_Ent3", "role": "Subject_Age", "text": "65 - year - old", "start": 1, "end": 6}, {"entity_id": "9824032_3_Ent4", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "9824032_3_Ent5", "role": "Subject_Gender", "text": "men", "start": 7, "end": 8}, {"entity_id": "9824032_3_Ent1", "role": "Subject_Disorder", "text": "coronary heart disease", "start": 9, "end": 12}, {"entity_id": "9824032_3_Ent10", "role": "Treatment_Drug", "text": "niacin", "start": 14, "end": 15}, {"entity_id": "9824032_3_Ent7", "role": "Treatment", "text": "niacin therapy for dyslipidemia for 5 months", "start": 14, "end": 21}, {"entity_id": "9824032_3_Ent9", "role": "Treatment_Disorder", "text": "dyslipidemia", "start": 17, "end": 18}, {"entity_id": "9824032_3_Ent12", "role": "Treatment_Duration", "text": "5 months", "start": 19, "end": 21}, {"entity_id": "9824032_3_Ent6", "role": "Effect", "text": "intense dental and gingival pain", "start": 23, "end": 28}, {"entity_id": "9824032_3_Ent8", "role": "Treatment", "text": "increases in dose", "start": 32, "end": 35}, {"entity_id": "9824032_3_Ent11", "role": "Treatment_Dosage", "text": "increases in dose", "start": 32, "end": 35}]}], "entity_mentions": [{"id": "9824032_3_Ent2", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9824032_3_Ent0", "text": "Two 65 - year - old white men with coronary heart disease", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "9824032_3_Ent3", "text": "65 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9824032_3_Ent4", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9824032_3_Ent5", "text": "men", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9824032_3_Ent1", "text": "coronary heart disease", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "9824032_3_Ent10", "text": "niacin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9824032_3_Ent7", "text": "niacin therapy for dyslipidemia for 5 months", "entity_type": "Entity", "start": 14, "end": 21}, {"id": "9824032_3_Ent9", "text": "dyslipidemia", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9824032_3_Ent12", "text": "5 months", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "9824032_3_Ent6", "text": "intense dental and gingival pain", "entity_type": "Entity", "start": 23, "end": 28}, {"id": "9824032_3_Ent8", "text": "increases in dose", "entity_type": "Entity", "start": 32, "end": 35}, {"id": "9824032_3_Ent11", "text": "increases in dose", "entity_type": "Entity", "start": 32, "end": 35}], "lang": "en"}
{"doc_id": "9846036_4", "wnd_id": "9846036_4_1", "text": "Clozapine , an atypical antipsychotic , can be toxic at doses 4 times a moderate dose .", "tokens": ["Clozapine", ",", "an", "atypical", "antipsychotic", ",", "can", "be", "toxic", "at", "doses", "4", "times", "a", "moderate", "dose", "."], "event_mentions": [{"id": "9846036_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "be", "start": 7, "end": 8}, "arguments": [{"entity_id": "9846036_4_Ent2", "role": "Treatment", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "9846036_4_Ent4", "role": "Treatment_Drug", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "9846036_4_Ent0", "role": "Effect", "text": "toxic", "start": 8, "end": 9}, {"entity_id": "9846036_4_Ent1", "role": "Treatment", "text": "doses 4 times a moderate dose", "start": 10, "end": 16}, {"entity_id": "9846036_4_Ent3", "role": "Treatment_Dosage", "text": "4 times a moderate dose", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "9846036_4_Ent2", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9846036_4_Ent4", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9846036_4_Ent0", "text": "toxic", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "9846036_4_Ent1", "text": "doses 4 times a moderate dose", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "9846036_4_Ent3", "text": "4 times a moderate dose", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "9847899_1", "wnd_id": "9847899_1_1", "text": "As this relapse coincided with development of a strong delayed - type hypersensitivity response to tuberculin and improved after treatment with the anti - inflammatory agent oxpentifylline , it was probably caused by restoration of pathogen - specific cellular immunity .", "tokens": ["As", "this", "relapse", "coincided", "with", "development", "of", "a", "strong", "delayed", "-", "type", "hypersensitivity", "response", "to", "tuberculin", "and", "improved", "after", "treatment", "with", "the", "anti", "-", "inflammatory", "agent", "oxpentifylline", ",", "it", "was", "probably", "caused", "by", "restoration", "of", "pathogen", "-", "specific", "cellular", "immunity", "."], "event_mentions": [{"id": "9847899_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 5, "end": 6}, "arguments": [{"entity_id": "9847899_1_Ent0", "role": "Effect", "text": "a strong delayed - type hypersensitivity response", "start": 7, "end": 14}, {"entity_id": "9847899_1_Ent1", "role": "Treatment", "text": "tuberculin", "start": 15, "end": 16}, {"entity_id": "9847899_1_Ent2", "role": "Treatment_Drug", "text": "tuberculin", "start": 15, "end": 16}]}, {"id": "9847899_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improved", "start": 17, "end": 18}, "arguments": [{"entity_id": "9847899_1_Ent4", "role": "Treatment_Disorder", "text": "this relapse", "start": 1, "end": 3}, {"entity_id": "9847899_1_Ent3", "role": "Treatment", "text": "anti - inflammatory agent oxpentifylline", "start": 22, "end": 27}, {"entity_id": "9847899_1_Ent5", "role": "Treatment_Drug", "text": "oxpentifylline", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "9847899_1_Ent4", "text": "this relapse", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "9847899_1_Ent0", "text": "a strong delayed - type hypersensitivity response", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "9847899_1_Ent1", "text": "tuberculin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9847899_1_Ent2", "text": "tuberculin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9847899_1_Ent3", "text": "anti - inflammatory agent oxpentifylline", "entity_type": "Entity", "start": 22, "end": 27}, {"id": "9847899_1_Ent5", "text": "oxpentifylline", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "9865241_4", "wnd_id": "9865241_4_1", "text": "The use of pamidronate for hypercalcemia secondary to acute vitamin D intoxication .", "tokens": ["The", "use", "of", "pamidronate", "for", "hypercalcemia", "secondary", "to", "acute", "vitamin", "D", "intoxication", "."], "event_mentions": [{"id": "9865241_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 4, "end": 5}, "arguments": [{"entity_id": "9865241_4_Ent0", "role": "Treatment", "text": "pamidronate", "start": 3, "end": 4}, {"entity_id": "9865241_4_Ent2", "role": "Treatment_Drug", "text": "pamidronate", "start": 3, "end": 4}, {"entity_id": "9865241_4_Ent1", "role": "Treatment_Disorder", "text": "hypercalcemia secondary to acute vitamin D intoxication", "start": 5, "end": 12}]}, {"id": "9865241_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 6, "end": 7}, "arguments": [{"entity_id": "9865241_4_Ent3", "role": "Effect", "text": "hypercalcemia", "start": 5, "end": 6}, {"entity_id": "9865241_4_Ent4", "role": "Treatment", "text": "vitamin D", "start": 9, "end": 11}, {"entity_id": "9865241_4_Ent5", "role": "Treatment_Drug", "text": "vitamin D", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9865241_4_Ent0", "text": "pamidronate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9865241_4_Ent2", "text": "pamidronate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9865241_4_Ent3", "text": "hypercalcemia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9865241_4_Ent1", "text": "hypercalcemia secondary to acute vitamin D intoxication", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "9865241_4_Ent4", "text": "vitamin D", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9865241_4_Ent5", "text": "vitamin D", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9870779_1", "wnd_id": "9870779_1_1", "text": "A 40 - year - old man with a long standing history of rheumatoid arthritis was treated with MTX over a 6 month period and developed an overwhelming hepatic necrosis .", "tokens": ["A", "40", "-", "year", "-", "old", "man", "with", "a", "long", "standing", "history", "of", "rheumatoid", "arthritis", "was", "treated", "with", "MTX", "over", "a", "6", "month", "period", "and", "developed", "an", "overwhelming", "hepatic", "necrosis", "."], "event_mentions": [{"id": "9870779_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 25, "end": 26}, "arguments": [{"entity_id": "9870779_1_Ent0", "role": "Subject", "text": "A 40 - year - old man with a long standing history of rheumatoid arthritis", "start": 0, "end": 15}, {"entity_id": "9870779_1_Ent1", "role": "Subject_Age", "text": "40 - year - old", "start": 1, "end": 6}, {"entity_id": "9870779_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "9870779_1_Ent7", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 13, "end": 15}, {"entity_id": "9870779_1_Ent6", "role": "Treatment_Drug", "text": "MTX", "start": 18, "end": 19}, {"entity_id": "9870779_1_Ent4", "role": "Treatment", "text": "MTX over a 6 month period", "start": 18, "end": 24}, {"entity_id": "9870779_1_Ent5", "role": "Treatment_Time_elapsed", "text": "6 month", "start": 21, "end": 23}, {"entity_id": "9870779_1_Ent3", "role": "Effect", "text": "an overwhelming hepatic necrosis", "start": 26, "end": 30}]}], "entity_mentions": [{"id": "9870779_1_Ent0", "text": "A 40 - year - old man with a long standing history of rheumatoid arthritis", "entity_type": "Entity", "start": 0, "end": 15}, {"id": "9870779_1_Ent1", "text": "40 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "9870779_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9870779_1_Ent7", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "9870779_1_Ent6", "text": "MTX", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9870779_1_Ent4", "text": "MTX over a 6 month period", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "9870779_1_Ent5", "text": "6 month", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "9870779_1_Ent3", "text": "an overwhelming hepatic necrosis", "entity_type": "Entity", "start": 26, "end": 30}], "lang": "en"}
{"doc_id": "9876809_2", "wnd_id": "9876809_2_1", "text": "To report a probable case of ticlopidine - induced phenytoin toxicity .", "tokens": ["To", "report", "a", "probable", "case", "of", "ticlopidine", "-", "induced", "phenytoin", "toxicity", "."], "event_mentions": [{"id": "9876809_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "9876809_2_Ent0", "role": "Subject", "text": "a probable case", "start": 2, "end": 5}, {"entity_id": "9876809_2_Ent3", "role": "Treatment", "text": "ticlopidine", "start": 6, "end": 7}, {"entity_id": "9876809_2_Ent4", "role": "Treatment_Drug", "text": "ticlopidine", "start": 6, "end": 7}, {"entity_id": "9876809_2_Ent6", "role": "Combination_Drug", "text": "ticlopidine", "start": 6, "end": 7}, {"entity_id": "9876809_2_Ent2", "role": "Treatment", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "9876809_2_Ent5", "role": "Treatment_Drug", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "9876809_2_Ent7", "role": "Combination_Drug", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "9876809_2_Ent1", "role": "Effect", "text": "phenytoin toxicity", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9876809_2_Ent0", "text": "a probable case", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "9876809_2_Ent3", "text": "ticlopidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9876809_2_Ent4", "text": "ticlopidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9876809_2_Ent6", "text": "ticlopidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9876809_2_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9876809_2_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9876809_2_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9876809_2_Ent1", "text": "phenytoin toxicity", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9883483_3", "wnd_id": "9883483_3_1", "text": "We report on a 56 - year - old female who exhibited drug refractory paroxysmal atrial fibrillation , in which marked prolongation of the QT interval and T wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral pirmenol therapy .", "tokens": ["We", "report", "on", "a", "56", "-", "year", "-", "old", "female", "who", "exhibited", "drug", "refractory", "paroxysmal", "atrial", "fibrillation", ",", "in", "which", "marked", "prolongation", "of", "the", "QT", "interval", "and", "T", "wave", "inversion", "on", "electrocardiogram", "was", "demonstrated", "reproducibly", "shortly", "after", "the", "administration", "of", "oral", "pirmenol", "therapy", "."], "event_mentions": [{"id": "9883483_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 36, "end": 37}, "arguments": [{"entity_id": "9883483_3_Ent0", "role": "Subject", "text": "a 56 - year - old female", "start": 3, "end": 10}, {"entity_id": "9883483_3_Ent1", "role": "Subject_Age", "text": "56 - year - old", "start": 4, "end": 9}, {"entity_id": "9883483_3_Ent2", "role": "Subject_Gender", "text": "female", "start": 9, "end": 10}, {"entity_id": "9883483_3_Ent3", "role": "Effect", "text": "drug refractory paroxysmal atrial fibrillation , in which marked prolongation of the QT interval and T wave inversion", "start": 12, "end": 30}, {"entity_id": "9883483_3_Ent6", "role": "Treatment_Route", "text": "oral", "start": 40, "end": 41}, {"entity_id": "9883483_3_Ent4", "role": "Treatment", "text": "pirmenol", "start": 41, "end": 42}, {"entity_id": "9883483_3_Ent5", "role": "Treatment_Drug", "text": "pirmenol", "start": 41, "end": 42}]}], "entity_mentions": [{"id": "9883483_3_Ent0", "text": "a 56 - year - old female", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "9883483_3_Ent1", "text": "56 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "9883483_3_Ent2", "text": "female", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9883483_3_Ent3", "text": "drug refractory paroxysmal atrial fibrillation , in which marked prolongation of the QT interval and T wave inversion", "entity_type": "Entity", "start": 12, "end": 30}, {"id": "9883483_3_Ent6", "text": "oral", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "9883483_3_Ent4", "text": "pirmenol", "entity_type": "Entity", "start": 41, "end": 42}, {"id": "9883483_3_Ent5", "text": "pirmenol", "entity_type": "Entity", "start": 41, "end": 42}], "lang": "en"}
{"doc_id": "9892272_3", "wnd_id": "9892272_3_1", "text": "The authors report a case of a patient who received alteplase for acute myocardial infarction and developed spontaneous subfascial hematoma without any evidence of direct trauma .", "tokens": ["The", "authors", "report", "a", "case", "of", "a", "patient", "who", "received", "alteplase", "for", "acute", "myocardial", "infarction", "and", "developed", "spontaneous", "subfascial", "hematoma", "without", "any", "evidence", "of", "direct", "trauma", "."], "event_mentions": [{"id": "9892272_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "9892272_3_Ent0", "role": "Subject", "text": "a case of a patient", "start": 3, "end": 8}, {"entity_id": "9892272_3_Ent2", "role": "Treatment", "text": "alteplase", "start": 10, "end": 11}, {"entity_id": "9892272_3_Ent4", "role": "Treatment_Drug", "text": "alteplase", "start": 10, "end": 11}, {"entity_id": "9892272_3_Ent3", "role": "Treatment_Disorder", "text": "acute myocardial infarction", "start": 12, "end": 15}, {"entity_id": "9892272_3_Ent1", "role": "Effect", "text": "spontaneous subfascial hematoma without any evidence of direct trauma", "start": 17, "end": 26}]}], "entity_mentions": [{"id": "9892272_3_Ent0", "text": "a case of a patient", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "9892272_3_Ent2", "text": "alteplase", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9892272_3_Ent4", "text": "alteplase", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9892272_3_Ent3", "text": "acute myocardial infarction", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "9892272_3_Ent1", "text": "spontaneous subfascial hematoma without any evidence of direct trauma", "entity_type": "Entity", "start": 17, "end": 26}], "lang": "en"}
{"doc_id": "9920368_1", "wnd_id": "9920368_1_1", "text": "Amiodarone - induced thyrotoxicosis associated with thyrotropin receptor antibody .", "tokens": ["Amiodarone", "-", "induced", "thyrotoxicosis", "associated", "with", "thyrotropin", "receptor", "antibody", "."], "event_mentions": [{"id": "9920368_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9920368_1_Ent1", "role": "Treatment", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "9920368_1_Ent2", "role": "Treatment_Drug", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "9920368_1_Ent0", "role": "Effect", "text": "thyrotoxicosis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "9920368_1_Ent1", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9920368_1_Ent2", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9920368_1_Ent0", "text": "thyrotoxicosis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "9925865_2", "wnd_id": "9925865_2_1", "text": "In patients with swallowing dysfunction and pneumonia , a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred .", "tokens": ["In", "patients", "with", "swallowing", "dysfunction", "and", "pneumonia", ",", "a", "history", "of", "mineral", "oil", "use", "should", "be", "obtained", "and", "a", "diagnosis", "of", "ELP", "should", "be", "considered", "in", "the", "differential", "diagnoses", "if", "mineral", "oil", "use", "has", "occurred", "."], "event_mentions": [{"id": "9925865_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "considered", "start": 24, "end": 25}, "arguments": [{"entity_id": "9925865_2_Ent0", "role": "Subject", "text": "In patients with swallowing dysfunction and pneumonia", "start": 0, "end": 7}, {"entity_id": "9925865_2_Ent2", "role": "Treatment", "text": "a history of mineral oil use", "start": 8, "end": 14}, {"entity_id": "9925865_2_Ent3", "role": "Treatment_Drug", "text": "mineral oil", "start": 11, "end": 13}, {"entity_id": "9925865_2_Ent1", "role": "Effect", "text": "ELP", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "9925865_2_Ent0", "text": "In patients with swallowing dysfunction and pneumonia", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9925865_2_Ent2", "text": "a history of mineral oil use", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "9925865_2_Ent3", "text": "mineral oil", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "9925865_2_Ent1", "text": "ELP", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "9925865_3", "wnd_id": "9925865_3_1", "text": "Lipoid pneumonia : a silent complication of mineral oil aspiration .", "tokens": ["Lipoid", "pneumonia", ":", "a", "silent", "complication", "of", "mineral", "oil", "aspiration", "."], "event_mentions": [{"id": "9925865_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 6, "end": 7}, "arguments": [{"entity_id": "9925865_3_Ent0", "role": "Effect", "text": "Lipoid pneumonia", "start": 0, "end": 2}, {"entity_id": "9925865_3_Ent2", "role": "Treatment_Drug", "text": "mineral oil", "start": 7, "end": 9}, {"entity_id": "9925865_3_Ent1", "role": "Treatment", "text": "mineral oil aspiration", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "9925865_3_Ent0", "text": "Lipoid pneumonia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9925865_3_Ent2", "text": "mineral oil", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9925865_3_Ent1", "text": "mineral oil aspiration", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "9934637_1", "wnd_id": "9934637_1_1", "text": "An unusual cause of burn injury : unsupervised use of drugs that contain psoralens .", "tokens": ["An", "unusual", "cause", "of", "burn", "injury", ":", "unsupervised", "use", "of", "drugs", "that", "contain", "psoralens", "."], "event_mentions": [{"id": "9934637_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 2, "end": 3}, "arguments": [{"entity_id": "9934637_1_Ent0", "role": "Effect", "text": "burn injury", "start": 4, "end": 6}, {"entity_id": "9934637_1_Ent1", "role": "Treatment", "text": "use of drugs that contain psoralens .", "start": 8, "end": 15}, {"entity_id": "9934637_1_Ent2", "role": "Treatment_Drug", "text": "psoralens", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "9934637_1_Ent0", "text": "burn injury", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9934637_1_Ent1", "text": "use of drugs that contain psoralens .", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "9934637_1_Ent2", "text": "psoralens", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "9934637_3", "wnd_id": "9934637_3_1", "text": "In this article , we present the case of a vitiligo patient who was admitted to our facility with an intense burn after the topical use of 8 - methoxypsoralen solution as a suntanning agent .", "tokens": ["In", "this", "article", ",", "we", "present", "the", "case", "of", "a", "vitiligo", "patient", "who", "was", "admitted", "to", "our", "facility", "with", "an", "intense", "burn", "after", "the", "topical", "use", "of", "8", "-", "methoxypsoralen", "solution", "as", "a", "suntanning", "agent", "."], "event_mentions": [{"id": "9934637_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 22, "end": 23}, "arguments": [{"entity_id": "9934637_3_Ent0", "role": "Subject", "text": "a vitiligo patient", "start": 9, "end": 12}, {"entity_id": "9934637_3_Ent1", "role": "Subject_Disorder", "text": "vitiligo", "start": 10, "end": 11}, {"entity_id": "9934637_3_Ent2", "role": "Effect", "text": "intense burn", "start": 20, "end": 22}, {"entity_id": "9934637_3_Ent5", "role": "Treatment_Route", "text": "topical", "start": 24, "end": 25}, {"entity_id": "9934637_3_Ent3", "role": "Treatment", "text": "topical use of 8 - methoxypsoralen solution as a suntanning agent", "start": 24, "end": 35}, {"entity_id": "9934637_3_Ent4", "role": "Treatment_Drug", "text": "8 - methoxypsoralen", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "9934637_3_Ent0", "text": "a vitiligo patient", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "9934637_3_Ent1", "text": "vitiligo", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9934637_3_Ent2", "text": "intense burn", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "9934637_3_Ent5", "text": "topical", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "9934637_3_Ent3", "text": "topical use of 8 - methoxypsoralen solution as a suntanning agent", "entity_type": "Entity", "start": 24, "end": 35}, {"id": "9934637_3_Ent4", "text": "8 - methoxypsoralen", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "9972383_1", "wnd_id": "9972383_1_1", "text": "CONCLUSIONS : Metoclopramide may cause reversible nonthrombocytopenic vascular - type palpable purpura .", "tokens": ["CONCLUSIONS", ":", "Metoclopramide", "may", "cause", "reversible", "nonthrombocytopenic", "vascular", "-", "type", "palpable", "purpura", "."], "event_mentions": [{"id": "9972383_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "9972383_1_Ent1", "role": "Treatment", "text": "Metoclopramide", "start": 2, "end": 3}, {"entity_id": "9972383_1_Ent2", "role": "Treatment_Drug", "text": "Metoclopramide", "start": 2, "end": 3}, {"entity_id": "9972383_1_Ent0", "role": "Effect", "text": "reversible nonthrombocytopenic vascular - type palpable purpura", "start": 5, "end": 12}]}], "entity_mentions": [{"id": "9972383_1_Ent1", "text": "Metoclopramide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9972383_1_Ent2", "text": "Metoclopramide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9972383_1_Ent0", "text": "reversible nonthrombocytopenic vascular - type palpable purpura", "entity_type": "Entity", "start": 5, "end": 12}], "lang": "en"}
{"doc_id": "9988365_1", "wnd_id": "9988365_1_1", "text": "Eosinophilia caused by clozapine was observed in challenge , preceded by a faster neutrophil production and consecutive decrease ( z = 2.27 , p = 0.01 ) .", "tokens": ["Eosinophilia", "caused", "by", "clozapine", "was", "observed", "in", "challenge", ",", "preceded", "by", "a", "faster", "neutrophil", "production", "and", "consecutive", "decrease", "(", "z", "=", "2.27", ",", "p", "=", "0.01", ")", "."], "event_mentions": [{"id": "9988365_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 1, "end": 2}, "arguments": [{"entity_id": "9988365_1_Ent0", "role": "Effect", "text": "Eosinophilia", "start": 0, "end": 1}, {"entity_id": "9988365_1_Ent2", "role": "Treatment", "text": "clozapine", "start": 3, "end": 4}, {"entity_id": "9988365_1_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 3, "end": 4}, {"entity_id": "9988365_1_Ent1", "role": "Effect", "text": "preceded by a faster neutrophil production and consecutive decrease ( z = 2.27 , p = 0.01 )", "start": 9, "end": 27}]}], "entity_mentions": [{"id": "9988365_1_Ent0", "text": "Eosinophilia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9988365_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9988365_1_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9988365_1_Ent1", "text": "preceded by a faster neutrophil production and consecutive decrease ( z = 2.27 , p = 0.01 )", "entity_type": "Entity", "start": 9, "end": 27}], "lang": "en"}
{"doc_id": "9988365_2", "wnd_id": "9988365_2_1", "text": "Eosinophilia has been encountered from 0.2 to 61.7 % in clozapine - treated patients , mostly with a transient course and spontaneous remission .", "tokens": ["Eosinophilia", "has", "been", "encountered", "from", "0.2", "to", "61.7", "%", "in", "clozapine", "-", "treated", "patients", ",", "mostly", "with", "a", "transient", "course", "and", "spontaneous", "remission", "."], "event_mentions": [{"id": "9988365_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "encountered", "start": 3, "end": 4}, "arguments": [{"entity_id": "9988365_2_Ent1", "role": "Effect", "text": "Eosinophilia", "start": 0, "end": 1}, {"entity_id": "9988365_2_Ent2", "role": "Treatment", "text": "clozapine", "start": 10, "end": 11}, {"entity_id": "9988365_2_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 10, "end": 11}, {"entity_id": "9988365_2_Ent0", "role": "Subject", "text": "patients", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "9988365_2_Ent1", "text": "Eosinophilia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9988365_2_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9988365_2_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9988365_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
